Page 1 Extracted Terms:
**Key heart‑disease related terms**

- Acute Coronary Syndromes (ACS)  
- ST‑Elevation Myocardial Infarction (STEMI)  
- Non‑ST‑Elevation Acute Coronary Syndromes (NST‑ACS)  
- Coronary Artery Disease (CAD)  
- Primary Percutaneous Coronary Intervention (PCI)  
- Dual Antiplatelet Therapy (DAPT)  
- Coronary Artery Revascularization  
- Myocardial Infarction (MI)  
- Coronary Angiography  
- Cardiac Catheterization  
- ACS Management Guideline  
- Revascularization Therapy  
- Cardiovascular Interventions  
- Emergency Cardiovascular Care  
- Cardiovascular Angioplasty  

These terms capture the core concepts and clinical interventions discussed in the guideline text.

Page 2 Extracted Terms:
- Acute Coronary Syndrome (ACS)  
- Coronary Artery Disease (CAD)  
- Myocardial Infarction (MI)  
- ST‑Segment Elevation Myocardial Infarction (STEMI)  
- Non‑ST‑Segment Elevation Myocardial Infarction (NSTEMI/NSTE‑ACS)  
- Unstable Angina  
- Coronary Syndromes  
- Fibrinolytic Therapy (Fibrinolytic Agents)  
- Percutaneous Coronary Intervention (PCI)  
- Primary PCI (PPCI)  
- Urgent Coronary Artery Bypass Grafting (CABG)  
- Antiplatelet Therapy  
- Aspirin (acetylsalicylic acid)  
- P2Y12 Inhibitors (oral and intravenous)  
- Glycoprotein IIb/IIIa Inhibitors  
- Parenteral Anticoagulation (heparin, enoxaparin, etc.)  
- Anticoagulants (general)  
- Beta‑Blocker Therapy  
- Renin‑Angiotensin‑Aldosterone System (RAAS) Inhibitors (ACE inhibitors, ARBs, aldosterone antagonists)  
- Lipid Management (statins, LDL‑c reduction)  
- Oxygen Therapy  
- Analgesics (morphine, etc.)  
- Cardiogenic Shock  
- Risk Stratification Tools (e.g., TIMI, GRACE scores)  
- Prehospital Assessment and Management  
- Emergency Medical Services (EMS)  
- Regional STEMI Care Systems  
- Intravenous Glycoprotein IIb/IIIa Inhibition  
- Intravenous P2Y12 Inhibition  
- Use of Aspiration Thrombectomy  
- Use of Intracoronary Imaging (IVUS, OCT)  
- Vascular Access Approach for PCI (radial vs femoral)  
- Routine Invasive vs Selective Invasive Approach in NSTE‑ACS  
- Multivessel Coronary Disease Management in ACS  
- Revascularization Strategies in Cardiogenic Shock  

These terms capture the core heart‑disease concepts and therapeutic approaches outlined in the guideline.

Page 3 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- ST‑segment elevation ACS (STEMI)  
- Non‑ST‑segment elevation ACS (NSTEMI)  
- Cardiogenic Shock  
- Mechanical complications of ACS  
- Electrical complications of ACS  
- Sudden cardiac death  
- Pericarditis after myocardial infarction (MI)  
- Left ventricular (LV) thrombus after MI  
- Cardiac Intensive Care Unit (CICU)  
- Dual Antiplatelet Therapy (DAPT)  
- Aspirin  
- P2Y12 inhibitor  
- Ticagrelor  
- Prasugrel  
- Clopidogrel  
- Triple antiplatelet therapy  
- Proton pump inhibitor (PPI)  
- Bleeding risk management in ACS  
- Long‑term anticoagulation in ACS  
- High‑intensity statin therapy  
- Low‑density lipoprotein (LDL) cholesterol  
- Ezetimibe  
- Evolocumab  
- Alirocumab  
- Inclisiran  
- Bempedoic acid  
- Lipid‑lowering agents  
- SGLT‑2 inhibitors  
- GLP‑1 receptor agonists  
- Chronic colchicine therapy  
- Immunization (vaccine recommendations)  
- Invasive strategy (angiography, revascularization)  
- Percutaneous Coronary Intervention (PCI)  
- Radial access approach (radial artery)  
- Femoral access approach  
- Intracoronary imaging  
- Risk stratification (ischemic risk, bleeding risk)  
- Coronary artery disease (CAD)  
- Revascularization (stenting, CABG)  
- Mechanical circulatory support (MCS)  
- Anemia management in ACS  
- Telemetry monitoring  
- Length of hospital stay  
- Non‑invasive diagnostic testing before discharge  
- Discharge planning  
- Patient education  
- Post‑discharge follow‑up  
- Cardiac rehabilitation  
- Secondary prevention strategies  
- Evidence gaps and future research directions  


Page 4 Extracted Terms:
**Key Heart‑Disease–Related Terms Extracted**

- Complete revascularization  
- ST‑segment elevation myocardial infarction (STEMI)  
- Non‑ST‑segment elevation acute coronary syndrome (NSTE‑ACS)  
- Coronary artery bypass graft (CABG)  
- Multivessel percutaneous coronary intervention (PCI)  
- Cardiogenic shock  
- Microaxial flow pump (intra‑aortic balloon pump, V‑AX, Impella, etc.)  
- Red blood cell transfusion  
- Hemoglobin level (10 g/dL target)  
- Secondary prevention (post‑discharge care)  
- Fasting lipid panel  
- Lipid‑lowering therapy (statins, PCSK9 inhibitors, etc.)  
- Cardiac rehabilitation (in‑person & home‑based programs)  
- Cardiovascular disease (CVD)  
- Cardiovascular health  
- Clinical practice guidelines  
- American College of Cardiology (ACC)  
- American Heart Association (AHA)  
- Revascularization strategy  
- Culprit vessel  
- Non‑infarct‑related arteries  
- Bleeding complications  
- Limb ischemia  
- Renal failure  
- Vascular access  
- Weaning of mechanical support  
- Clinical judgment  
- Shared decision‑making  
- Patient engagement  

These terms capture the central concepts, interventions, and policy references relevant to heart disease within the guideline excerpt.

Page 5 Extracted Terms:
Acute coronary syndrome  
Angina, unstable  
Anticoagulants  
Aspirin  
Atrial fibrillation  
Cardiovascular diseases  
Coronary artery disease (CAD)  
Coronary syndrome  
Emergency medical services  
Fibrinolytic agents  
Major adverse cardiovascular events (MACE)  
Morphine  
Myocardial infarction  
Non–ST-elevation myocardial infarction (NSTEMI)  
Percutaneous coronary intervention (PCI)  
Prehospital  
Revascularization  
Risk  
ST-elevation myocardial infarction (STEMI)  
Time factors  
Treatment outcome  
Guideline-directed medical therapy  
Clinical evaluation  
Diagnostic testing  
Pharmacological treatments  
Procedural treatments  
Cardiovascular community  
Heart disease

Page 6 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- ST‑Elevation Myocardial Infarction (STEMI)  
- Non‑ST‑Elevation Acute Coronary Syndromes (NSTE‑ACS)  
- Primary Percutaneous Coronary Intervention (PCI)  
- Coronary Artery Revascularization  
- Dual Antiplatelet Therapy (DAPT)  
- Coronary Artery Disease (CAD)  
- Acute Myocardial Infarction (AMI)  
- Myocardial Infarction (MI)  
- Recurrent MI  
- Secondary Prevention  
- Guideline‑Recommended Medications  
- Guideline‑Directed Medical Therapy  
- Coronary Revascularization  
- Cardiac Imaging  
- Interventional Cardiology  
- Cardiovascular Surgery  
- Critical‑Care Cardiology  
- Cardiovascular Risk Factors  
- Racial and Sex Disparities in ACS Care  

(Each term is a key concept pertaining to heart disease extracted from the guideline text.)

Page 7 Extracted Terms:
- Acute Coronary Syndromes  
- Acute Myocardial Infarction  
- Coronary Artery Disease  
- Coronary Artery Revascularization  
- Chronic Coronary Disease  
- Myocardial Infarction (non‑obstructive)  
- Invasive Management of Acute Myocardial Infarction  
- Invasive Management of Acute MI Complicated by Cardiogenic Shock  
- Cardiogenic Shock  
- Classification of Cardiogenic Shock  
- SHOCK Stage Classification  
- Mechanical Complications of Acute Myocardial Infarction  
- Diagnosis and Management of Chest Pain  
- Cardiac Catheterization Laboratory Management of Out‑of‑Hospital Cardiac Arrest  
- Management of Heart Failure  
- Atrial Fibrillation Management  
- Left Ventricular Thrombus Management  
- Cardiac Rehabilitation  
- Blood Cholesterol Management  
- Hypertension (High Blood Pressure) Management  
- Stroke Prevention in Stroke and Transient Ischemic Attack  
- Prevention of Cardiovascular Disease  
- Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults  
- Diagnosis and Management of Atrial Fibrillation  
- Management of Patients with Chronic Coronary Disease  
- Invasive Management of Acute MI with Cardiogenic Shock (specific to acute MI)

Page 8 Extracted Terms:
- ACEi – Angiotensin‑converting enzyme inhibitor
- ACS – Acute coronary syndromes
- AF – Atrial fibrillation
- AMI – Acute myocardial infarction
- ARB – Angiotensin receptor blocker
- ASCVD – Atherosclerotic cardiovascular disease
- CABG – Coronary artery bypass grafting
- CAD – Coronary artery disease
- CCD – Chronic coronary disease
- CDP – Clinical decision pathway
- CICU – Cardiac intensive care unit
- CR – Cardiac rehabilitation
- cTn – Cardiac troponin
- CVD – Cardiovascular disease
- DAPT – Dual antiplatelet therapy
- DOAC – Direct oral anticoagulant
- ECG – Electrocardiogram
- FDA – U.S. Food and Drug Administration
- FFR – Fractional flow reserve

Page 9 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- Unstable angina  
- Non‑ST‑segment elevation myocardial infarction (NSTEMI)  
- ST‑segment elevation myocardial infarction (STEMI)  
- Myocardial infarction (MI)  
- Myocardial ischemia  
- Coronary artery  
- Plaque rupture  
- Plaque erosion  
- Atherosclerosis  
- Thrombosis  
- Coagulation cascade  
- Myonecrosis  
- First medical contact (FMC)  
- Glucagon‑like peptide‑1 (GLP‑1)  
- Heart failure (HF)  
- High‑sensitivity cardiac troponin (hs‑cTn)  
- Intra‑aortic balloon pump (IABP)  
- Implantable cardioverter‑defibrillator (ICD)  
- Intravascular ultrasound (IVUS)  
- Low‑density lipoprotein (LDL)  
- Low‑density lipoprotein cholesterol (LDL‑C)  
- Left ventricle (LV)  
- Left ventricular ejection fraction (LVEF)  
- Major adverse cardiovascular event (MACE)  
- Mechanical circulatory support (MCS)  
- Myocardial infarction with non‑obstructive coronary artery disease (MINOCA)  
- Multivessel disease (MVD)  
- Non‑ST‑segment elevation acute coronary syndrome (NSTE‑ACS)  
- Optical coherence tomography (OCT)  
- Odds ratio (OR)  
- Percutaneous coronary intervention (PCI)  
- Proprotein convertase subtilisin/kexin type 9 (PCSK9)  
- Primary percutaneous coronary intervention (PPCI)  
- Proton pump inhibitor (PPI)  
- Quality of life (QOL)  
- Randomized controlled trial (RCT)  
- Return of spontaneous circulation (ROSC)  
- Sodium‑glucose cotransporter‑2 (SGLT‑2)  
- Unfractionated heparin (UFH)  
- Veno‑arterial extracorporeal membrane oxygenation (VA‑ECMO)  
- Coronary artery spasm  
- Coronary embolism  
- Coronary artery dissection  
- Epicardial vessel  
- Plaque contents exposure  
- Plaque instability  
- Thrombus formation  
- Intrinsic flow compromise in myocardium  
- Atherosclerotic plaque instability  
- Coagulation cascade activation  
- Myocardial necrosis (myonecrosis)

Page 10 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- Myocardial ischemia  
- Cardiovascular complications  
- Recurrent cardiovascular events  
- Acute inflammatory milieu  
- Stable coronary disease  
- Chronic coronary disease (CCD)  
- 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Chronic Coronary Disease Guideline  
- 12‑lead ECG  
- STEMI (ST‑segment elevation myocardial infarction)  
- NSTE‑ACS (non‑ST‑segment elevation acute coronary syndrome)  
- Primary percutaneous coronary intervention (PPCI)  
- PCI‑capable hospital  
- Emergency medical services (EMS)  
- First medical contact (FMC)  
- Time to reperfusion  
- Cardiac catheterization team  
- Arrhythmias  
- Cardiac arrest  
- Vital signs  
- Electrocardiographic interpretation for suspected ACS  
- Ischemic changes on ECG  
- ST‑segment depression ≥0.5 mm in ≥2 contiguous leads  
- T‑wave inversion >1 mm in ≥2 contiguous leads  
- ST‑segment elevation ≥1 mm in ≥2 contiguous leads (J‑point)  
- R wave prominence or R/S ratio >1  
- Left ventricular hypertrophy (LVH)  
- Left bundle branch block (LBBB / LBBB)  
- Brugada syndrome  
- Right ventricular pacing  
- Takotsubo syndrome (stress‑cardiomyopathy)  
- Early repolarization pattern  
- Posterior leads (V7–V9)  
- Left circumflex occlusion  
- Acute myocardial infarction (AMI)  
- J‑point definition  
- V2–V3 lead criteria (male/female thresholds)  
- Acute pericarditis  
- STEMI equivalent conditions  
- Prehospital assessment and management of suspected ACS  
- Primary PCI triage strategy  
- STEMI recognition and activation protocol  
- ECG serial monitoring for nondiagnostic STEMI  
- Critical time metrics: FMC‑to‑first‑device ≤90 min  
- Early advance notification to PCI‑capable hospital  
- EMS transport for suspected ACS  
- Structured prehospital history and physical examination  
- Hemodynamic monitoring during transport  
- Early reperfusion strategy  
- Emergency department (ED) triage for ACS  
- Clinical suspicion of ACS  
- Persistent chest pain symptoms  
- Dynamic ST‑segment changes  
- Coronary artery disease (CAD)  
- Coronary artery occlusion  
- Cardiac catheterization procedure  
- Reperfusion therapy  
- Cardiovascular event prevention  
- Post‑acute management of ACS  
- Medication therapy for stable coronary disease  
- Extended therapy beyond one year post‑ACS  
- Acute coronary event classification (STEMI vs. NSTE‑ACS)  
- ECG interpretation criteria (ST‑depression, ST‑elevation, T‑wave changes)  
- ECG lead placement for posterior ischemia  
- Age‑ and sex‑based ST‑elevation thresholds  
- Cardiac ischemia diagnosis and management guidelines  

*(List includes core clinical, diagnostic, therapeutic, and guideline‑related terms pertinent to heart disease found in the provided text.)

Page 11 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- ST‑segment elevation myocardial infarction (STEMI)  
- Non‑ST‑segment elevation myocardial infarction (NSTEMI)  
- ST‑segment elevation (STEMI criteria)  
- 12‑lead electrocardiogram (ECG)  
- Electrocardiographic tracings  
- Coronary reperfusion  
- Percutaneous coronary intervention (PCI)  
- Primary PCI (PPCI)  
- PCI‑capable facility  
- Cardiogenic shock  
- Heart failure (HF)  
- Ventricular arrhythmias  
- Prehospital setting  
- Emergency medical services (EMS) personnel (paramedics)  
- Cardiac complications  
- Triage to PCI‑capable facility  



Page 12 Extracted Terms:
- Acute Coronary Syndrome (ACS)  
- ST‑segment elevation myocardial infarction (STEMI)  
- Non‑ST‑segment elevation ACS (NSTE‑ACS)  
- Electrocardiogram (ECG)  
- ST‑segment elevation  
- Posterior STEMI  
- Pre‑hospital ECG  
- Primary percutaneous coronary intervention (PPCI or PPCI)  
- Coronary reperfusion  
- First‑medical‑contact (FMC)  
- PCI‑capable hospital  
- Catheterization laboratory activation  
- Single‑call transfer protocol  
- ED bypass to catheterization laboratory  
- Acute myocardial infarction (AMI)  
- Type 1 myocardial infarction (Type 1 MI)  
- Type 2 myocardial infarction (Type 2 MI)  
- Type 3 myocardial infarction (Type 3 MI)  
- Type 4a peri‑PCI myocardial infarction (PCI MI)  
- Type 4b post‑PCI myocardial infarction (stent‑related MI)  
- Type 4c post‑PCI myocardial infarction (stent restenosis)  
- Type 5 peri‑coronary artery bypass grafting myocardial infarction (CABG MI)  
- Myocardial infarction with non‑obstructive coronary arteries (MINOCA)  
- Spontaneous coronary artery dissection (SCAD)  
- Infarct‑related artery  
- Reperfusion time  
- Time‑to‑device  
- Coronary artery bypass grafting (CABG)  
- Percutaneous coronary intervention (PCI)

Page 13 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- ST‑segment Elevation Myocardial Infarction (STEMI)  
- Non–ST‑segment Elevation ACS (NSTE‑ACS)  
- Myocardial Infarction (MI)  
- Acute Myocardial Infarction (AMI)  
- Cardiac Troponin (cTn)  
- High‑Sensitivity Cardiac Troponin (hs‑cTn)  
- 12‑lead Electrocardiogram (ECG)  
- Serial ECG monitoring  
- Chest pain  
- Cardiogenic shock  
- Hemodynamic instability  
- Mechanical complications (of the heart)  
- Cardiac catheterization  
- Fibrinolytic therapy  
- Reperfusion therapy  
- Posterior STEMI  
- Right ventricular involvement  
- Major Adverse Cardiovascular Events (MACE)

Page 14 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- ST‑segment elevation myocardial infarction (STEMI)  
- Non‑ST‑segment elevation myocardial infarction (NSTEMI)  
- Cardiac troponin (cTn)  
- High‑sensitivity cardiac troponin (hs‑cTn)  
- Clinical decision pathway (CDP)  
- Risk categories: low, intermediate, high risk  
- Class of Recommendation  
- Chest pain  
- AHA/ACC/Multisociety guideline  
- 2025 Acute Coronary Syndromes Guideline  
- 2021 Chest Pain Guideline

Page 15 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- ST‑segment–elevation myocardial infarction (STEMI)  
- Non–ST‑segment–elevation myocardial infarction (NSTEMI)  
- Unstable angina  
- Acute coronary event  
- Myocardial ischemia  
- Cardiac injury  
- High‑sensitivity cardiac troponin (hs‑cTn)  
- Cardiac troponin (cTn) assay  
- 99th percentile upper reference limit  
- Delta hs‑cTn (change in troponin)  
- Cardiac Diagnostic Pathway (CDP)  
- Serial troponin testing (0, 1–2 h)  
- ST‑segment deviation  
- Killip class (II–IV)  
- Pulmonary congestion (clinical, CXR, lung US)  
- Heart failure (HF)  
- Major Adverse Cardiac Events (MACE)  
- Myocardial infarction (MI)  
- Coronary artery disease (CAD)  
- Coronary stenosis (≥50 %)  
- Creatine kinase‑myocardial band (CK‑MB)  
- B‑type natriuretic peptide (BNP)  
- N‑terminal pro‑BNP (NT‑proBNP)  
- International guidelines (e.g., Circulation ACS guideline)  
- Global Registry of Acute Coronary Events (GRACE) risk score  
- Thrombolysis In Myocardial Infarction (TIMI) risk score  
- Aspirin use (pre‑hospital/within 7 days)  
- Time to treatment (>4 h)  
- Invasive vs. selective invasive strategy (routine invasive approach)  
- Left bundle branch block (LBBB)  
- High‑negative predictive value (>99.5 %)  
- Diagnostic thresholds for hs‑cTn  
- Cardiovascular event risk assessment  
- Revascularization (urgent/refractory)  

These terms capture the key heart‑disease concepts discussed in the text.

Page 16 Extracted Terms:
**Key terms related to heart disease**

- Acute Coronary Syndromes (ACS)  
- Acute Myocardial Infarction (AMI)  
- ST‑Elevation Myocardial Infarction (STEMI)  
- Non‑STEMI (NSTEMI)  
- B‑type Natriuretic Peptide (BNP)  
- Cardiogenic Shock  
- Cardiac Arrest  
- Primary Percutaneous Coronary Intervention (PPCI)  
- Percutaneous Coronary Intervention (PCI)  
- Coronary Angiography  
- Mechanical Circulatory Support (MCS)  
  - (Sub‑types: Intra‑Aortic Balloon Pump, Impella, ECMO – commonly referenced in MCS)  
- Shock Severity Scales (risk‑stratification tools for cardiogenic shock)  
- Major Adverse Cardiac Events (MACE)  
- Heart Failure (HF)  
- Electrocardiogram (ECG) / Electrocardiographic changes (ST‑segment elevation)  
- Return of Spontaneous Circulation (ROSC)  
- Shockable Rhythm (ventricular fibrillation, ventricular tachycardia)  
- Non‑shockable Rhythm (asystole, pulseless electrical activity)  
- Advanced Reperfusion Strategies (e.g., ARREST trial, CARES registry)  

These terms encapsulate the central concepts, diagnostic markers, management strategies, and outcome metrics discussed in the guideline excerpts.

Page 17 Extracted Terms:
**Key heart‑disease‑related terms extracted from the guideline text**

- Acute Coronary Syndromes (ACS)  
- ST‑Elevation Myocardial Infarction (STEMI)  
- Non‑ST‑Elevation ACS (NSTE‑ACS)  
- Primary Percutaneous Coronary Intervention (PPCI)  
- Emergency coronary angiography  
- Delayed coronary angiography  
- Cardiac arrest (post‑CPR, comatose)  
- Hemodynamic stability  
- Neurologic recovery / prognosis  
- Hypoxia (oxygen saturation < 90 %)  
- Supplemental oxygen therapy  
- Oxygen saturation (SpO₂)  
- Angina / chest pain  
- Myocardial oxygen supply  
- Vasoconstriction  
- Oxidative stress  
- Myocardial injury  
- Infarct size  
- Short‑term mortality  
- Long‑term mortality  
- Re‑hospitalization with MI  
- U‑shaped oxygenation–mortality relationship  
- AVOID (Air Versus Oxygen in STEMI) trial  
- DETO2X‑AMI (Efficacy and Outcome Study of Supplemental Oxygen Treatment in MI) trial  
- Analgesic therapies in ACS  
- Nitrates  
- Opiate medications  
- Routine vs. conservative oxygen administration  
- Clinical benefit (or lack thereof)  
- Cardiovascular outcomes  

These terms capture the core clinical concepts, interventions, outcomes, and study references addressed in the guideline excerpt.

Page 18 Extracted Terms:
**Key heart‑disease terms extracted from the guidelines**

- Acute Coronary Syndromes (ACS)  
- Angina / Anginal pain  
- Antiplatelet therapy  
- Antiplatelet therapy in patients on anticoagulation post‑discharge  
- Aspirin  
- Aspirin desensitization (for hypersensitivity)  
- Aspirin hypersensitivity  
- Aspirin loading dose (162–325 mg)  
- Aspirin maintenance dose (75–100 mg/day)  
- Aspirin discontinuation strategy  
- Atherothrombotic events  
- Baseline management strategy (invasive or non‑invasive)  
- Bleeding risk (minor and gastrointestinal bleeding)  
- Calcium channel blockers (mentioned in context of anti‑ischemic therapy)  
- Coronary artery disease (CAD)  
- Coronary events (MI, stroke)  
- Dual Antiplatelet Therapy (DAPT)  
- Dual antiplatelet therapy in ACS  
- Dual antiplatelet therapy discontinuation (P2Y12 inhibitor discontinuation)  
- Dual antiplatelet therapy in the first 12 months post‑discharge  
- Dual antiplatelet therapy during hospitalization (oral P2Y12 inhibitors)  
- Drug interactions with opiates and oral P2Y12 inhibitors  
- End points: mortality, MACE (major adverse cardiovascular events)  
- Gastric / intestinal absorption of P2Y12 inhibitors  
- Glycoprotein IIb/IIIa inhibitors (in the broader guideline context)  
- Myocardial infarction (MI)  
- Non‑aspirin non‑steroidal anti‑inflammatory drugs (NSAIDs) – their impact on MACE risk  
- Oral P2Y12 inhibitors (clopidogrel, ticagrelor, prasugrel, etc.)  
- PCI (Percutaneous Coronary Intervention)  
- Post‑discharge antiplatelet therapy  
- Right ventricular infarction (RV infarction)  
- Stroke (as a cardiovascular event)  
- Titrated intravenous (IV) nitrates (e.g., nitroglycerin)  
- Vascular death  
- Vascular events (including MI and stroke)  
- Vascular death after AMI  
- Non‑invasive management of ACS  
- Invasive strategy for ACS (including PCI)  
- Pharmacodynamics of oral antiplatelet therapy  
- Pharmacologic delay of P2Y12 inhibitor effects by opioids (morphine, fentanyl)  

*These terms capture the clinical concepts, therapies, and outcomes discussed in the extracted guideline text that are directly relevant to heart disease management.*

Page 19 Extracted Terms:
Acute Coronary Syndromes (ACS)  
ST‑segment elevation myocardial infarction (STEMI)  
Non–ST‑segment elevation acute coronary syndromes (NSTE‑ACS)  
Atherosclerotic cardiovascular disease (ASCVD)  
Myocardial infarction (MI)  
Major adverse cardiovascular events (MACE)  
Platelet‑activating factor P2Y12 receptor inhibitors  
Clopidogrel  
Prasugrel  
Ticagrelor  
Aspirin (low‑dose, 81 mg, 75‑100 mg)  
High‑dose aspirin (162‑325 mg)  
Loading dose (aspirin, clopidogrel, prasugrel, ticagrelor)  
Maintenance dose (aspirin, clopidogrel, prasugrel, ticagrelor)  
Percutaneous coronary intervention (PCI)  
Primary percutaneous coronary intervention (PPCI)  
Fibrinolytic therapy  
Stent thrombosis  
Platelet aggregation  
Bleeding risk (major bleeding, increased risk of bleeding)  
Net clinical outcomes (stroke, transient ischemic attack)  
Antiplatelet therapy (dual antiplatelet therapy, DAPT)  
Coronary artery revascularization  
Chronic coronary disease guidelines  
Guideline recommendations  
Evidence grade (COR, LOE)

Page 20 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- ST‑segment Elevation Myocardial Infarction (STEMI)  
- Non‑ST‑segment Elevation ACS (NSTE‑ACS)  
- Myocardial Infarction (MI)  
- Percutaneous Coronary Intervention (PCI)  
- Coronary Artery Bypass Grafting (CABG)  
- Dual Antiplatelet Therapy (DAPT)  
- Coronary Artery Disease (CAD)  
- Coronary Thrombosis / Stent Thrombosis  
- Major Adverse Cardiac Events (MACE)  
- Bleeding Risk / Bleeding Complications  
- Net Clinical Benefit (MACE + Bleeding)  
- Oral P2Y12 Inhibitors  
- Clopidogrel  
- Prasugrel  
- Ticagrelor  
- Aspirin (ASA)  
- Platelet Activation / Inhibition  
- Transient Dyspnea  
- Pharmacodynamic Variability  
- Hyporesponder Status  
- Fibrinolytic Therapy  
- Transient Ischemic Attack (TIA)  
- Stroke  
- Body Weight Threshold (<60 kg)  
- Age Threshold (≥75 years)  
- Platelet Inhibition Loading Dose  
- Metabolic Transformation (liver biotransformation)  
- Drug Potency (clopidogrel vs prasugrel vs ticagrelor)  
- DAPT Strategy Guidelines (Section 11.1)  
- Clinical Trial: TRITON‑TIMI 38  
- Clinical Trial: PLATO  
- Clinical Trial: TRITON‑TIMI 38, PLATO, and other RCTs mentioned  
- Net Harm (prasugrel vs clopidogrel in certain subgroups)  
- DAPT Duration after CABG  
- DAPT Duration in the first 12 months post‑discharge  
- Platelet Inhibition Variability in Clopidogrel  
- Risk of Bleeding in P2Y12 Inhibitor Therapy  
- Primary Prevention of STEMI/PCR  
- Secondary Prevention after ACS  

These terms capture the diseases, treatments, risk factors, clinical outcomes, and guideline recommendations discussed in the provided text.

Page 21 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- Non‑ST‑Elevation ACS (NSTE‑ACS)  
- ST‑Elevation Myocardial Infarction (STEMI)  
- Myocardial Infarction (MI)  
- Cardiovascular death  
- Stroke  
- Stent thrombosis  
- Percutaneous Coronary Intervention (PCI)  
- Coronary artery bypass grafting (CABG)  
- Invasive strategy  
- Elective CABG  
- Urgent CABG  
- Major Adverse Cardiac Events (MACE)  
- Ischemic events  
- Bleeding (including non‑CABG major bleeding and life‑threatening bleeds)  
- Clopidogrel (P2Y12 inhibitor, prodrug)  
- Prasugrel (P2Y12 inhibitor)  
- Ticagrelor (P2Y12 inhibitor)  
- P2Y12 inhibitor therapy  
- Vascular death  
- Coronary anatomy  
- Coronary angiography  
- Pretreatment (loading dose)  
- Cytochrome P450 enzyme system (metabolism of clopidogrel)  
- CURE trial (Clopidogrel in Unstable Angina to Prevent Recurrent Events)  
- PLATO trial (P2Y12 inhibitor study of ticagrelor vs. clopidogrel)  
- TRITON‑TIMI 38 trial (pragmatic comparison of prasugrel and clopidogrel)  
- Open‑label trial (comparative efficacy of prasugrel vs. ticagrelor)  
- Meta‑analysis of clopidogrel in ACS undergoing PCI  

Page 22 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- ST‑Elevation Myocardial Infarction (STEMI)  
- Non‑STEMI Acute Coronary Syndromes (NSTE‑ACS)  
- Percutaneous Coronary Intervention (PCI)  
- Primary PCI (PPCI)  
- Coronary Reperfusion / Revascularization  
- Stent Thrombosis  
- Major Adverse Cardiac Events (MACE)  
- Cardiovascular Death  
- Myocardial Infarction (MI)  
- Stroke  
- Bleeding (minor & major)  
- Antiplatelet Therapy  
- P2Y12 Inhibitors  
- Clopidogrel  
- Prasugrel  
- Ticagrelor  
- Cangrelor (intravenous P2Y12 antagonist)  
- Fibrinolytic Therapy  
- CABG (Coronary Artery Bypass Grafting)  
- Loading Dose (300 mg then 75 mg daily)  
- Intravenous vs Oral P2Y12 inhibition  
- Preloading / Pre‑administration of P2Y12 inhibitors  
- Pre‑hospital ticagrelor  
- TRITON‑TIMI 38 trial  
- PLATO trial  
- CLARITY‑TIMI 28 trial  
- COMMIT trial  
- Intravenous cangrelor trials (RCTs 1–3)  
- Meta‑analysis on clopidogrel pretreatment  
- Registry data on preloading efficacy  
- Transition strategy from intravenous to oral P2Y12 inhibition  
- Clinical endpoints: death, reinfarction, stroke, ischemic events, bleeding.

Page 23 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- ST‑Segment Elevation Myocardial Infarction (STEMI)  
- Non‑ST‑Segment Elevation Acute Coronary Syndrome (NSTE‑ACS)  
- Percutaneous Coronary Intervention (PCI)  
- Coronary Revascularization  
- Cangrelor  
- Clopidogrel  
- Prasugrel  
- Ticagrelor  
- P‑2Y12 inhibitors  
- Glycoprotein IIb/IIIa inhibitors  
- Abciximab  
- Eptifibatide  
- Tirofiban  
- Glycoprotein IIb/IIIa receptor  
- Intravenous glycoprotein IIb/IIIa inhibitors  
- Intracoronary glycoprotein IIb/IIIa inhibitors  
- Large thrombus burden  
- No‑reflow  
- Slow flow  
- Stent thrombosis  
- Intraprocedural ischemic events  
- Infarct size  
- Drug‑eluting stents  
- Coronary thrombus resolution  
- Peri‑procedural ischemic events  
- Ischemia‑driven revascularization  
- Bleeding risk (in context of glycoprotein inhibitors)  
- Intravenous bolus  
- Intravenous infusion  
- Loading dose  
- Adjunctive therapy  
- Rescue or bail‑out therapy  
- Upstream administration  
- Clinical guideline recommendations (e.g., 2025 ACS Guideline, 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization)

Page 24 Extracted Terms:
- Acute Coronary Syndrome (ACS)  
- Non–ST‑Segment Elevation ACS (NSTE‑ACS)  
- ST‑Elevation Myocardial Infarction (STEMI)  
- Percutaneous Coronary Intervention (PCI)  
- Coronary Angiography  
- Glycoprotein IIb/IIIa Inhibitor  
- Eptifibatide  
- Clopidogrel  
- Bleeding Complications  
- Ischemic Events  
- Parenteral Anticoagulation  
- Unfractionated Heparin (UFH)  
- Enoxaparin  
- Fondaparinux  
- Bivalirudin  
- Fibrinolytic Therapy  
- Catheter Thrombosis  
- Major Adverse Cardiac Events (MACE)  
- Atherothrombosis  
- Thrombin Generation  
- Platelet Aggregation  
- Heparin‑Induced Thrombocytopenia (HIT)  
- Argatroban  
- Low‑Molecular‑Weight Heparin (LMWH)  
- Coronary Artery Revascularization  
- Coronary Plaque Rupture  
- Plaque Erosion  
- Type‑1 Myocardial Infarction (MI)  
- Stress Cardiomyopathy  
- Myocarditis  
- EARLY‑ACS Trial (Early Glycoprotein IIb/IIIa Inhibition in Non‑ST‑Elevation ACS)

Page 25 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- Non‑ST‑elevation Acute Coronary Syndromes (NSTE‑ACS)  
- ST‑elevation Myocardial Infarction (STEMI)  
- Myocardial Infarction (MI)  
- Unstable Angina  
- Coronary Revascularization  
- Percutaneous Coronary Intervention (PCI)  
- Coronary Artery Bypass Grafting (CABG)  
- Dual Antiplatelet Therapy (DAPT)  
- Aspirin  
- Heparin (unfractionated heparin, UFH)  
- Heparin‑induced Thrombocytopenia (HIT)  
- Low‑molecular‑weight Heparin (LMWH) – e.g., enoxaparin  
- Fondaparinux  
- Bivalirudin  
- Antithrombin  
- Factor Xa  
- Thrombin  
- Activated Clotting Time (ACT)  
- Activated Partial Thromboplastin Time (aPTT)  
- Catheter Thrombosis  
- Ischemic Events  
- Major Bleeding  
- Bleeding Academic Research Consortium (BARC)  
- Creatinine Clearance (CrCl) (relevant to drug dosing in cardiovascular therapy)

Page 26 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- ST‑Elevation Myocardial Infarction (STEMI)  
- Non‑ST‑Elevation Acute Coronary Syndrome (NSTE‑ACS)  
- Primary Percutaneous Coronary Intervention (PPCI)  
- Percutaneous Coronary Intervention (PCI)  
- Unfractionated Heparin (UFH)  
- Low‑molecular‑weight heparin (Enoxaparin)  
- Bivalirudin  
- Fondaparinux  
- Glycoprotein IIb/IIIa inhibitors  
- Stent thrombosis  
- Major bleeding  
- Major Adverse Cardiovascular Events (MACE)  
- Ischemic outcomes  
- Mortality / Death  
- Recurrent acute coronary syndromes (ACS)  
- Urgent revascularization  
- Catheter thrombosis  
- Coronary complications  
- Fibrinolytic therapy  
- Thrombolytic agents (streptokinase, tissue plasminogen activator)  
- Heparin infusion  
- Subcutaneous enoxaparin injections  
- ExTRACT‑TIMI 25 trial  
- GUSTO trial  
- ASSENT‑3 trial  
- ACUITY trial  
- MATRIX trial  
- OASIS‑5 trial  
- OASIS‑6 trial  
- Meta‑analysis of ACS trials

Page 27 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- Myocardial Infarction (MI)  
- Major Adverse Cardiovascular Events (MACE)  
- Low‑Density Lipoprotein Cholesterol (LDL‑C)  
- High‑intensity statin therapy  
- Moderate‑intensity statin therapy  
- Statin intolerance  
- Non‑statin lipid‑lowering therapy  
- Ezetimibe  
- Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitors  
- Monoclonal antibodies to PCSK9  
- Bempedoic acid  
- Inclisiran  
- Coronary Artery Disease (CAD)  
- Cardiovascular death  
- Ischemic stroke  
- ASCVD (Atherosclerotic Cardiovascular Disease) event rates  
- LDL‑cholesterol target levels  
- Lipid profile measurement  
- Lipid management post‑ACS  
- Cholesterol Treatment Trialists (CTT) meta‑analysis  
- A to Z (Aggrastat to Zocor) study  
- PROVE IT‑TIMI 22 trial  
- IMPROVE IT trial  

Page 28 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- Non‑ST‑Elevation Myocardial Infarction (NSTEMI)  
- Acute Myocardial Infarction (AMI)  
- Atherosclerotic Cardiovascular Disease (ASCVD)  
- Cardiovascular Disease (CVD)  
- Low‑Density Lipoprotein Cholesterol (LDL‑C)  
- Major Adverse Cardiovascular Events (MACE)  
- Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)  
- Niemann‑Pick C1‑Like 1 protein (NPC1L1)  
- Evolocumab (PCSK9 monoclonal antibody)  
- Alirocumab (PCSK9 monoclonal antibody)  
- Inclisiran (small interfering RNA PCSK9 inhibitor)  
- Bempedoic Acid (ATP‑citrate lyase inhibitor)  
- Ezetimibe (NPC1L1 cholesterol‑absorption inhibitor)  
- Statin therapy (high‑dose; statin‑related adverse effects)  
- Intracoronary imaging (plaque assessment & regression)  
- Plaque regression / plaque components  
- Injection‑site reaction (adverse effect of PCSK9 therapies)  
- Elevated liver‑function tests (adverse effect of ezetimibe)  
- Gout and gallstones (adverse effect of bempedoic acid)  
- Muscle‑related adverse effects (increased with concomitant statins)  
- FDA approval status (regulatory context for cardiovascular drugs)

Page 29 Extracted Terms:
- Acute Coronary Syndrome (ACS)  
- Acute Coronary Syndromes  
- Statin intolerance  
- Statin-associated muscle symptoms  
- Ezetimibe  
- PCSK9 inhibitors (monoclonal antibodies)  
- Inclisiran  
- Bempedoic acid (ATP citrate lyase inhibitor)  
- Bempedoic acid + ezetimibe combination therapy  
- Major Adverse Cardiovascular Events (MACE)  
- Atherosclerotic Cardiovascular Disease (ASCVD)  
- Low‑density lipoprotein cholesterol (LDL‑C)  
- Hyperlipidemia  
- High‑intensity statin therapy  
- Moderate‑intensity statin therapy  
- Low‑intensity statin therapy  
- Atorvastatin (40‑80 mg)  
- Rosuvastatin (20‑40 mg)  
- Atorvastatin (10‑20 mg)  
- Rosuvastatin (5‑10 mg)  
- Simvastatin (20‑40 mg; 10 mg)  
- Pravastatin (40‑80 mg; 10‑20 mg)  
- Lovastatin (40 mg; 20 mg)  
- Fluvastatin XL (80 mg)  
- Fluvastatin (40 mg BID; 20‑40 mg)  
- Pitavastatin (1‑4 mg)  
- IMPROVE IT trial  
- FOURIER trial  
- ODYSSEY OUTCOMES trial  
- CLEAR Outcomes trial  
- Neurocognitive events  
- Hemorrhagic stroke  
- Polyvascular disease  
- Coronary disease  
- Diabetes mellitus (as a cardiovascular risk factor)  
- Elevated cardiovascular biomarkers  
- Secondary cardiovascular prevention  
- Cardiovascular outcomes research  
- Niemann‑Pick C1‑Like 1 protein (NPC1L1)  
- Statin‑intolerant patient management strategies  
- LDL‑C lowering efficacy (≥50 %, 30‑49 %, <30 %)

Page 30 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- ST‑Segment Elevation Myocardial Infarction (STEMI)  
- Non‑ST‑Segment Elevation Acute Coronary Syndrome / NSTEMI (NSTE‑ACS)  
- Early initiation of oral beta‑blocker therapy  
- Beta‑blockers (e.g., metoprolol, carvedilol)  
- Myocardial oxygen demand reduction (via heart rate, blood pressure, contractility)  
- Left ventricular ejection fraction (LVEF) < 40 %  
- Stabilized heart failure (HF)  
- Post‑myocardial infarction (post‑MI) patients  
- Pre‑reperfusion era trials  
- Killip class II‑IV acute heart failure  
- Low cardiac output state / cardiogenic shock risk  
- PR interval > 0.24 ms  
- Second‑ or third‑degree heart block (without pacemaker)  
- Severe bradycardia  
- Active bronchospasm  
- Randomized controlled trials (RCTs)  
- COMMIT trial (Clopidogrel and Metoprolol in Myocardial Infarction)  
- Metoprolol high‑dose IV/PO therapy  
- Intravenous beta‑blocker use prior to reperfusion  
- Carvedilol in STEMI with PCI  
- Major adverse cardiovascular events (MACE)  
- Renin‑Angiotensin‑Aldosterone System (RAAS) inhibitors  
- Angiotensin‑converting enzyme inhibitor (ACE‑i)  
- Angiotensin receptor blocker (ARB)  
- Mineralocorticoid receptor antagonist  
- All‑cause death  
- High‑risk ACS (LVEF ≤ 40 %, hypertension, diabetes mellitus, anterior STEMI)  
- Coronary revascularization (PCI/CABG)  
- Clinical benefit of long‑term beta‑blocker therapy post‑discharge  
- Optimal beta‑blocker duration in preserved LVEF patients.

Page 31 Extracted Terms:
**Key heart‑disease terms extracted from the guideline text**

- Acute Coronary Syndromes  
- Acute Myocardial Infarction (AMI)  
- ST‑Elevation Myocardial Infarction (STEMI)  
- Heart Failure (HF)  
- Left Ventricular Systolic Dysfunction  
- Left Ventricular Ejection Fraction (LVEF)  
- Angiotensin‑Converting Enzyme Inhibitor (ACEi)  
- Angiotensin Receptor Blocker (ARB)  
- Mineralocorticoid Receptor Antagonist  
- Eplerenone  
- Sacubitril‑Valsartan  
- Major Adverse Cardiovascular Events (MACE)  
- All‑cause death  
- Cardiovascular death  
- Hypotensive events  
- Hyperkalemia  
- Chronic kidney disease  
- Survival benefit  
- Natriuretic peptides  
- Beta blocker  
- Percutaneous Coronary Intervention (PCI)  
- Reperfusion therapy  
- Regional STEMI care  
- Prehospital STEMI care  
- Hospital‑based STEMI care  
- Total ischemic time  
- Cardiac surgical care  
- Advanced care modalities  
- 30‑day mortality  
- Non‑fatal cardiac failure  

These terms capture the principal diagnoses, therapeutic agents, clinical outcomes, and care‐system concepts discussed in the guideline excerpt.

Page 32 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- ST‑Segment Elevation Myocardial Infarction (STEMI)  
- Reperfusion  
- First Medical Contact (FMC)  
- Percutaneous Coronary Intervention (PCI)  
- Primary Percutaneous Coronary Intervention (PPCI)  
- Cardiac Catheterization Laboratory  
- Emergency Medical Services (EMS)  
- Emergency Department (ED)  
- Electrocardiogram (ECG)  
- Ischemic Symptoms  
- Heart Attack  
- STEMI Performance Measures  
- Class of Recommendation  
- Cardiac Catheterization Center  
- FMC‑to‑Device Time  
- STEMI Care System Pathway  



Page 33 Extracted Terms:
**Key Heart‑Disease Terms Extracted**

- Acute Coronary Syndromes (ACS)  
- ST‑Elevation Myocardial Infarction (STEMI)  
- Emergency Medical Services (EMS)  
- Primary Percutaneous Coronary Intervention (PPCI / PPCI)  
- Percutaneous Coronary Intervention (PCI)  
- Coronary Artery Bypass Grafting (CABG)  
- Cardiogenic shock  
- Hemodynamic instability  
- Infarct‑related artery  
- Myocardial salvage  
- First medical contact (FMC) to device activation time  
- Ischemic symptoms  
- Ongoing ischemia  
- Life‑threatening arrhythmia  
- Fibrinolytic therapy  
- TIMI 3 epicardial flow grade  
- Radial vascular access  
- Femoral vascular access  
- Intracranial hemorrhage  
- Acute kidney injury  
- Recurrent ischemia  
- Reinfarction  
- Emergency revascularization  
- SHOCK trial (Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock)  
- AHA Mission: Lifeline program  
- STEMI care system (regional STEMI system of care)  
- Emergency revascularization strategy  
- Early death reduction  
- Clinical outcomes (survival, infarct size, reperfusion success)  
- Data collection and sharing in STEMI care  
- Transfer time to PCI‑capable hospital  
- AHA/AACC/SCAI Guidelines for Coronary Artery Revascularization  
- Coronary artery disease (implied context)

Page 34 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- ST‑Elevation Myocardial Infarction (STEMI)  
- Primary Percutaneous Coronary Intervention (PPCI) / PCI  
- Coronary Artery Bypass Grafting (CABG)  
- Cardio‑gic Shock  
- Left Ventricular Ejection Fraction (LVEF)  
- Major Adverse Cardiac Events (MACE)  
- Myocardial Infarction (MI)  
- Fibrinolytic Therapy  
- First Medical Contact (FMC)  
- Reperfusion Strategy  
- Non‑PCI‑Capable Hospital  
- Intravenous Thrombolysis  
- In‑hospital Mortality  
- Ongoing Ischemia  
- Infarct Size  
- Multivessel Coronary Artery Disease (CAD)  
- Mechanical Complications (e.g., mechanical valve failure, ventricular rupture)  
- Outcomes: Mortality at 30 days, 6 months, 1 year, 6 years  
- Clinical Trials / Studies:  
  - FITT‑STEMI trial  
  - Occluded Artery Trial (OAT)  
  - DECOPI (Desobstruction Coronaire en Post‑Infarctus)  
  - 2025 Acute Coronary Syndromes Guideline  
  - 2021 ACC/AHA/SCAI Guideline for Coronary Artery Re‑vascularization  
- Guidelines:  
  - "Revascularization in ACS With Cardiogenic Shock"  
  - "Mechanical Complications"  
  - "Management of Multivessel CAD in STEMI"

Page 35 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- ST‑segment Elevation Myocardial Infarction (STEMI)  
- Non‑STEMI (implied as other ACS presentations)  
- Percutaneous Coronary Intervention (PCI)  
- Primary Percutaneous Coronary Intervention (PPCI)  
- Fibrinolytic therapy  
- Myocardial Infarction (MI)  
- Coronary reperfusion  
- Reperfusion modality  
- Major Adverse Cardiac Events (MACE)  
- Hemodynamic instability  
- Infarct size  
- Large infarct territory  
- Hemorrhagic stroke  
- Major noncerebral bleeding  
- Congestive heart failure (CHF)  
- Shock  
- Reinfarction  
- Late presenters (12‑24 hours after symptom onset)  
- Pre‑hospital fibrinolysis  
- Pharmaco‑invasive approach (fibrinolysis followed by PCI)  
- TIMI (not explicitly mentioned, but related to reperfusion)  
- STREAM trial (Strategic Reperfusion Early After Myocardial Infarction)  
- Time to first medical contact (FMC)  
- Time from FMC to device activation (≤120 minutes threshold)  
- Time from symptom onset (≤12 hours window)  
- Time‑dependent reduction in mortality and morbidity  
- Tenecteplase  
- Alteplase  
- Reteplase  
- Fibrin‑specific fibrinolytic agents  
- Non‑fibrin‑specific agents  
- Patency rates  
- Immunogenicity  
- Recurrent MACE  
- Non‑PCI‑capable hospital  
- PCI‑capable hospital  
- Reperfusion strategy  
- Recurrent morbidity and mortality rates  
- Early presenters (≤3 hours after symptom onset)  
- Large anterior infarction  
- Low bleeding risk  
- Large area of myocardium at risk  
- Revascularization  
- Coronary artery disease (implied)  
- Reperfusion delay  
- Transfer delays  
- Reperfusion benefit  
- Clinical benefit  
- Morbidity and mortality rates  
- Recurrent myocardial infarction  
- Recurrent cardiac events  

(Note: Each entry represents a key term or concept related to heart disease and its management as extracted from the guideline text.)

Page 36 Extracted Terms:
- Acute Coronary Syndromes  
- ST‑segment Elevation Myocardial Infarction (STEMI)  
- Myocardial Infarction (MI)  
- Fibrinolytic Therapy  
- Alteplase (tPA)  
- Tenecteplase (TNK‑tPA)  
- Reteplase (rPA)  
- Coronary Angiography  
- Percutaneous Coronary Intervention (PCI)  
- Rescue PCI  
- Reperfusion  
- Failed Reperfusion  
- Re‑occlusion  
- Coronary Revascularization  
- Intracranial Hemorrhage (as a contraindication to fibrinolysis)  
- ST‑segment Elevation (definition criteria)  
- Hemodynamic Instability  
- Electrical Instability  
- Ischemic Stroke (relevant contraindication)  
- Antiplatelet Therapy  
- Anticoagulant Therapy  
- Catheterization  
- Transfer to PCI‑capable Center  
- Parenteral Anticoagulation  
- Oral P2Y12 Inhibitors  
- Fibrin‑Specific Fibrinolytic Agents  
- ST‑segment Elevation Resolution Criteria  
- Cardiogenic Shock (implied by hemodynamic instability)  
- Aortic Dissection (contraindication but relevant to cardiac care)

Page 37 Extracted Terms:
- Acute coronary syndromes (ACS)  
- Non‑ST‑segment elevation acute coronary syndrome (NSTE‑ACS)  
- ST‑segment elevation myocardial infarction (STEMI)  
- Coronary angiography  
- Percutaneous coronary intervention (PCI)  
- Fibrinolytic therapy (fibrinolysis)  
- Reperfusion  
- Recurrent ischemic events  
- Major adverse cardiovascular events (MACE)  
- Myocardial infarction (MI) / reinfarction  
- Heart failure (HF)  
- Early invasive strategy  
- Routine invasive strategy  
- Selective invasive strategy  
- Pharmaco‑invasive strategy  
- Revascularization  
- Hemodynamic instability  
- Electrical instability  
- Refractory angina  
- Early transfer to specialized center  
- Femoral artery access  
- Radial artery access  
- Glycoprotein IIb/IIIa inhibitors  
- Antiplatelet therapy  
- Anticoagulant therapy  
- Blowing (major/minor) bleeding  
- Stroke  
- Death  
- Intermediate, high, and low risk of ischemic events  
- Clinical trials, meta‑analyses, network meta‑analysis (study designs)  
- Composite primary endpoints (death, reinfarction, stroke, HF)  
- Timing of angiography (≤24 hours, >24 hours, immediate)  
- Recurrent coronary artery stenosis or suboptimal flow  
- Treatment arms (rescue PCI, conservative care, repeat fibrinolytic therapy)  
- Era of reperfusion therapy (fibrinolysis‑only, pharmaco‑invasive, PPCI)  
- Outcomes: mortality, reduced MACE, bleeding rates, rehospitalisation.

Page 38 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- Non‑ST‑segment Elevation Acute Coronary Syndromes (NSTE‑ACS)  
- Coronary Artery Disease (CAD)  
- Myocardial Infarction (MI)  
- Recurrent MI  
- Recurrent Ischemia  
- Major Adverse Cardiovascular Events (MACE)  
- Coronary Revascularization  
- Percutaneous Coronary Intervention (PCI)  
- Coronary Artery Bypass Grafting (CABG)  
- Coronary Angiography  
- Invasive Approach (Routine Invasive Strategy)  
- Selective Invasive Approach  
- Non‑invasive Risk Stratification  
- Non‑invasive Stress Testing  
- Coronary CT Angiography (CCTA)  
- Cardiac Computed Tomography (CT) Angiography  
- Cardiac Biomarkers  
- High‑Sensitivity Cardiac Troponin (hs‑cTn)  
- Hematology‑Guided Antiplatelet Therapies  
- Drug‑Eluting Stents (DES)  
- Radial Approach for Coronary Angiography  
- Acute Coronary Syndrome Guidelines  
- Myocardial Infarction with Non‑Obstructive Coronary Artery Disease (MINOCA)  
- Non‑obstructive Coronary Artery Disease  
- AHA Scientific Statement  
- Hospital Discharge in ACS management  
- Recurrent Ischemic Symptoms  
- Non‑invasive Testing Prior to Discharge  
- Invasive Coronary Angiography Prior to Discharge  
- Class of Recommendation (for guideline tiers)

Page 39 Extracted Terms:
Acute Coronary Syndromes (ACS)  
Non‑ST‑Elevation Acute Coronary Syndromes (NSTE‑ACS)  
NSTEMI (Non‑ST‑Elevation Myocardial Infarction)  
Unstable Angina  
Coronary Angiography  
Routine Invasive Strategy  
Selective Invasive Approach  
Revascularization  
Percutaneous Coronary Intervention (PCI)  
Coronary Artery Bypass Grafting (CABG)  
Myocardial Infarction (MI)  
Major Adverse Cardiovascular Events (MACE)  
GRACE Risk Score  
TIMI Risk Score  
Cardiac Biomarkers  
CK‑MB (Creatine Kinase MB)  
Troponin (conventional, older generation)  
High‑Sensitivity Cardiac Troponin (hs‑cTn)  
Coronary CT Angiography  
Noninvasive Stress Testing  
Refractory or Recurrent Angina  
Hemodynamic Instability  
Electrical Instability  
Acute Pulmonary Edema  
Heart Failure (HF)  
Mitral Regurgitation  
PCI‑Capable Hospital  
Dual Antiplatelet Therapy (DAPT)  
Bleeding Risk  
Thrombocytopenia (platelet count <50 × 10⁹/L)  
Advanced Kidney Disease (non‑dialysis)  
Acute Renal Failure  
Limited Life Expectancy (<1‑2 years)  
Advanced Dementia  
Coronary Anatomy precluding PCI/CABG  
Patient Preference  
Emergency Invasive Strategy (<2 hours from admission)  
Timing of Intervention (Early vs Delayed)  
TIMACS Trial (Timing of Intervention in Acute Coronary Syndromes)  
VERDICT Trial (Very Early vs Deferred Invasive Evaluation)  
GRACE Risk Score >140  
Diabetes  
Age >75 years  
Steep Rise in Cardiac Biomarkers (ongoing ischemia)

Page 40 Extracted Terms:
**Key terms related to heart disease (from the excerpt provided):**

1. Acute Coronary Syndromes (ACS)  
2. Non–ST‑segment elevation acute coronary syndromes (NSTE‑ACS)  
3. Percutaneous Coronary Intervention (PCI)  
4. Transradial access / radial approach  
5. Transfemoral access / femoral approach  
6. Radial artery  
7. Femoral artery  
8. Coronary artery bypass graft (CABG)  
9. Bypass conduit (radial artery, ulnar artery, distal radial artery)  
10. Mechanical circulatory support (MCS)  
11. Ultrasound guidance (for vascular access)  
12. Bleeding complications  
13. Vascular complications  
14. Mortality / death  
15. Hemorrhage / bleeding risk  
16. Global Registry of Acute Coronary Events (GRACE) score  
17. Heart failure (HF)  
18. Troponin (Tn)  
19. Thrombolysis in Myocardial Infarction (TIMI)  
20. Ventricular fibrillation (VF)  
21. Ventricular tachycardia (VT)  
22. ACC/AHA/SCAI Guideline  
23. Cardiovascular Surgical Team  
24. Heart Team approach  
25. CATHETERIZATION LABORATORY recommendations  
26. Evidence Table / Level of Evidence (LOE)  
27. Class of Recommendation (COR)  
28. Meta‑analysis (individual patient data)  
29. Clinical, anatomical, or technical reasons (affecting access choice)  

These terms capture the key concepts and entities related to the management and complications of heart disease discussed in the text.

Page 41 Extracted Terms:
- Acute Coronary Syndrome (ACS)  
- ST‑Elevation Myocardial Infarction (STEMI)  
- Percutaneous Coronary Intervention (PCI)  
- Transradial approach  
- Transfemoral approach  
- Radial access  
- Femoral access  
- Major bleeding  
- Vascular complications  
- MACE (Major Adverse Cardiovascular Events)  
- Net adverse clinical events  
- Coronary artery revascularization  
- Aspiration thrombectomy  
- Myocardial infarction (MI) size  
- Left ventricular (LV) function  
- Coronary patency  
- Coronary thrombus  
- Balloon angioplasty  
- Stent deployment  
- Stent malapposition  
- Coronary dissections  
- Intravascular ultrasound (IVUS)  
- Optical coherence tomography (OCT)  
- Coronary stent implantation  
- Left main artery lesions  
- Complex lesions  
- Recurrent myocardial infarction  
- Target vessel revascularization  
- Stent thrombosis  
- Heart failure (HF)  
- Stroke / transient ischemic attack  
- Thrombus burden  
- No‑reflow phenomenon

Page 42 Extracted Terms:
**Key heart‑disease terms extracted from the guideline text**

- Acute Coronary Syndromes (ACS)  
- Coronary artery disease (CAD)  
- Multivessel coronary artery disease (MVD)  
- ST‑segment–elevation myocardial infarction (STEMI)  
- Percutaneous coronary intervention (PCI)  
- Coronary artery bypass grafting (CABG)  
- Left main coronary artery disease  
- Target vessel failure  
- Cardiac death  
- Target vessel myocardial infarction (MI)  
- Ischemia‑driven target vessel revascularization  
- Target lesion revascularization  
- Stent thrombosis (definite or probable)  
- Major adverse cardiac events (MACE)  
- Minimum stent area (MSA)  
- Malapposition  
- Underexpansion  
- Tissue protrusion  
- Edge disease / edge dissection  
- Optical coherence tomography (OCT)  
- Intravascular ultrasound (IVUS)  
- Intracoronary imaging guidance  
- Angiographic guidance  
- Intracoronary imaging (general)  
- Calcification extent  
- Lipid presence  
- Thrombus formation  
- Fibroatheroma  
- Plaque rupture  
- Plaque burden  
- Plaque length  
- External elastic lamina diameter  
- Coronary artery diameter stenosis severity  
- Cardiogenic shock  
- Renal failure (associated risk in PCI)

These terms represent the core concepts, diagnostic features, interventions, and outcomes discussed in the provided guideline excerpt.

Page 43 Extracted Terms:
**Key terms related to heart disease extracted from the guideline text:**

- Acute Coronary Syndromes (ACS)  
- ST‑elevation myocardial infarction (STEMI)  
- Major adverse cardiovascular events (MACE)  
- Myocardial infarction (MI)  
- Recurrent MI  
- Recurrent ischemia  
- Cardiac mortality (cardiovascular death)  
- Angina (refractory angina)  
- Angina‑related quality of life (QOL)  
- Coronary artery disease (CAD)  
- Multivessel coronary artery disease (MVD)  
- Complete revascularization (CR)  
- Culprit artery only revascularization  
- Staged percutaneous coronary intervention (PCI)  
- Immediate (single‑procedure) multivessel PCI  
- Physiology‑guided PCI  
- Fractional flow reserve (FFR)  
- Angiography‑guided PCI  
- Coronary artery bypass grafting (CABG)  
- Left main coronary artery disease  
- Left anterior descending (LAD) artery disease  
- Chronic total occlusion (CTO)  
- Diabetes mellitus (as a CAD risk factor)  
- Bleeding risk from dual antiplatelet therapy (DAPT)  
- Ischemia‑driven revascularization  
- Unplanned revascularization  
- Cerebrovascular events  
- Heart failure (HF)  
- Re‑infarction (reinfarction)  
- Hospitalization for heart failure  
- Network meta‑analysis

These terms capture the core concepts, interventions, clinical outcomes, and patient subgroups addressed in the 2025 Acute Coronary Syndromes Guideline.

Page 44 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- ST‑segment Elevation Myocardial Infarction (STEMI)  
- Non‑ST‑segment Elevation Acute Coronary Syndromes (NSTE‑ACS)  
- Cardiogenic shock  
- Multivessel Percutaneous Coronary Intervention (PCI)  
- Culprit lesion PCI / culprit‑only PCI  
- Non‑culprit lesion PCI  
- Complete revascularization  
- Staged multivessel PCI  
- Coronary Artery Disease (CAD)  
- Multivessel Disease (MVD)  
- Left Main Coronary Artery stenosis  
- Left Anterior Descending (LAD) artery disease  
- Complex CAD (including left‑main, 3‑vessel, diffuse disease)  
- Diabetes mellitus with coronary involvement  
- Left Ventricular (LV) dysfunction / severe LV dysfunction  
- Major Adverse Cardiovascular Events (MACE)  
- Coronary Artery Bypass Grafting (CABG)  
- Coronary Artery Bypass Grafting (CABG) vs PCI decision  
- Heart Team approach  
- Physiological assessment (e.g., fractional flow reserve) of non‑culprit stenosis  
- Renal replacement therapy / kidney failure in PCI context  
- CULPRIT‑SHOCK trial  
- Right/Left coronary artery involvement  
- Coronary artery bypass grafting (CABG) surgery  
- Percutaneous Coronary Intervention (PCI)  
- Angiographic assessment  
- Clinical outcomes (death, renal outcomes, rehospitalization)  

These terms capture the key heart‑disease concepts and procedures discussed in the guideline excerpt.

Page 45 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- ST‑segment Elevation Myocardial Infarction (STEMI)  
- Non–ST‑segment Elevation Acute Coronary Syndromes (NSTE‑ACS)  
- Coronary Artery Bypass Grafting (CABG)  
- Percutaneous Coronary Intervention (PCI)  
- Multivessel Disease (MVD)  
- Major Adverse Cardiac Events (MACE)  
- Functional Assessment in Elderly MI Patients With Multivessel Disease (FIRE trial)  
- Single Staged Versus Multistaged PCI in Multivessel NSTEMI Patients (SMILE trial)  
- BIOVASC trial  
- Fractional Flow Reserve (FFR)  
- Fractional Flow Reserve Versus Angiography for Multivessel Evaluation (FAME trial)  
- Fractional Flow Reserve vs. Angiography‑Guided Strategy for Management of Non‑Infarction Related Artery Stenosis in Patients with Acute Myocardial Infarction (FRAME‑AMI trial)  
- Fractional Flow Reserve Versus Angiographically Guided Management to Optimise Outcomes in Unstable Coronary Syndromes (FAMOUS‑NSTEMI trial)  
- Cardiogenic Shock  
- CULPRIT‑SHOCK trial  
- Culprit Lesion Only PCI vs. Multivessel PCI  
- Angiography‑guided PCI  
- Culprit‑only PCI  
- Emergency revascularization  
- Hemodynamic instability  
- Renal replacement therapy  
- Survival benefit with revascularization  
- Risk of death or renal failure with multivessel PCI  
- Stent deployment  
- Revascularization procedures  
- Coronary artery revascularization (clinical guideline context)  
- Angiographic assessment of stenosis (≥50 %)  
- Minimum vessel diameter (>2.5 mm)  
- Drug‑eluting stents (implicit in PCI)

Page 46 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- Myocardial infarction (MI)  
- ST‑segment elevation myocardial infarction (STEMI)  
- Non‑ST‑segment elevation myocardial infarction (NSTEMI)  
- Cardiogenic shock  
- Revascularization  
- Percutaneous coronary intervention (PCI)  
- Coronary artery bypass grafting (CABG)  
- Multivessel PCI  
- Culprit lesion  
- Non‑culprit lesion  
- Microaxial intravascular flow pump (microaxial pump)  
- Intra‑aortic balloon pump (IABP)  
- Venoarterial extracorporeal membrane oxygenation (VA‑ECMO)  
- Mechanical circulatory support (MCS)  
- Hemodynamic stabilization  
- Bridge to surgery  
- Shock (SHOCK) trial  
- CULPRIT‑SHOCK trial  
- FITT‑STEMI trial  
- Primary percutaneous coronary intervention (PPCI)  
- Renal replacement therapy (as outcome endpoint)

Page 47 Extracted Terms:
- Acute Coronary Syndrome (ACS)  
- Acute Myocardial Infarction (AMI)  
- ST‑Segment Elevation Myocardial Infarction (STEMI)  
- Cardiogenic shock  
- DanGer‑SHOCK trial  
- SCAI shock stages (C, D, E)  
- Microaxial flow pump (MCP)  
- Mechanical circulatory support (MCS) devices  
- Intra‑aortic balloon pump (IABP)  
- Veno‑arterial extracorporeal membrane oxygenation (VA‑ECMO)  
- Extracorporeal Life Support (ECLS)  
- ECMO‑CS trial  
- ECLS‑SHOCK trial  
- IABP‑SHOCK II trial  
- Ventricular septal rupture (VSR)  
- Mechanical complications of AMI  
- Bridge to surgery  
- Early revascularization  
- Percutaneous coronary intervention (PCI)  
- End‑organ hypoperfusion  
- Arterial lactate (≥2.5 mmol/L)  
- Central venous oxygen saturation (SvO₂ < 55 %)  
- PaO₂ (oxygen partial pressure)  
- LVEF (left ventricular ejection fraction) < 45 %  
- Hypotension (SBP < 100 mm Hg)  
- Renal replacement therapy  
- Limb ischemia  
- Major bleeding  
- Peripheral vascular complications  
- In‑hospital mortality  
- 30‑day mortality  
- All‑cause mortality  
- Absolute risk reduction  
- Hazard ratio (HR)  
- Odds ratio (OR)  
- Glasgow Coma Scale score < 8  
- Right ventricular failure  
- Overt right ventricular failure  
- Large‑bore access  
- Clinical guidelines (2025 Acute Coronary Syndromes Guideline)

Page 48 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- Myocardial Infarction (MI / AMI)  
- Cardiogenic Shock  
- Mechanical Complications of ACS  
- Ventricular Septal Rupture  
- Mitral Valve Insufficiency (due to papillary muscle infarction)  
- Free Wall Rupture  
- Heart Failure (HF)  
- Sudden Cardiac Death  
- Intra‑Aortic Balloon Pump (IABP)  
- Veno‑Arterial Extracorporeal Membrane Oxygenation (VA‑ECMO)  
- Extracorporeal Life Support (ECLS)  
- Mechanical Circulatory Support (MCS)  
- Temporary MCS Devices  
- Reperfusion Therapy  
- Cardiac Surgical Expertise  
- Cardiac Intensive Care Unit (CICU)  
- Shock Teams  
- Cardiac Transplantation  
- Durable Left Ventricular Assist Device (LVAD)  
- Percutaneous Structural Intervention  
- Acute Mitral Regurgitation  
- Heart Team Approach  
- Early Corrective Surgery  
- Delayed Surgery (post‑AMI)  
- End‑Organ Injury  
- Hemodynamic Stabilization  
- Left‑to‑Right Shunting  
- Multidisciplinary Care  
- Peri‑operative Mortality  

These terms capture the key concepts related to heart disease and its management discussed in the guideline excerpt.

Page 49 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- Myocardial infarction (MI)  
- Left ventricular ejection fraction (LVEF)  
- Implantable cardioverter‑defibrillator (ICD)  
- Ventricular arrhythmias  
- Sudden cardiac death (SCD)  
- Atrial fibrillation (AF)  
- Atrial flutter  
- Second‑degree atrioventricular block, Mobitz type II  
- High‑grade atrioventricular block  
- Alternating bundle‑branch block  
- Third‑degree atrioventricular block (infranodal)  
- Permanent pacing  
- Temporary wearable cardioverter‑defibrillator  
- Arrhythmic complications  
- Heart failure (HF)  
- Coronary revascularization  
- Percutaneous coronary intervention (PCI)  
- Fibrinolytic therapy  
- Antiarrhythmic therapy  
- Electrophysiologic interventions  
- Mechanical complications of acute myocardial infarction (e.g., rupture, pseudo‑aneurysm)  
- Left atrium (LA)  
- Left ventricle (LV)  
- Mitral regurgitation (MR)  
- National/American Heart Association (AHA), American College of Cardiology (ACC), Heart Rhythm Society (HRS) guideline documents  
- MADIT II (Multicenter Automatic Defibrillator Implantation Trial)  
- Evidence‑based guideline terminology (e.g., “recommended”, “reasonable”)

Page 50 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- Prophylactic implantable cardioverter‑defibrillator (ICD) implantation  
- Left Ventricular Ejection Fraction (LVEF)  
- New York Heart Association (NYHA) functional class  
- Ventricular tachycardia (VT)  
- Ventricular fibrillation (VF)  
- Myocardial infarction (MI)  
- Coronary Artery Bypass Grafting (CABG)  
- Sudden cardiac death  
- Beta‑blocker therapy  
- Antiarrhythmic drug therapy  
- Radiofrequency catheter ablation  
- Wearable cardioverter‑defibrillator (WCD)  
- ST‑elevation myocardial infarction (STEMI)  
- High‑degree atrioventricular (AV) block  
- Cardiogenic shock  
- Pericarditis after myocardial infarction  
- Inducible ventricular arrhythmia  
- Temporary pacemaker insertion  
- Permanent pacemaker insertion  
- Defibrillator in Acute Myocardial Infarction Trial (DINAMIT)  
- VEST trial (Vest Prevention of Early Sudden Death)  
- Ventricular arrhythmias occurring >48 hours post‑reperfusion  
- Non‑arrhythmic deaths following ICD implantation or MI  
- LVEF thresholds (≤ 35 % and ≤ 40 %) predictive of ICD benefit

Page 51 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- Myocardial Infarction (MI)  
- Dressler’s syndrome  
- Pericarditis (acute & late)  
- Pericardial effusion  
- High‑dose aspirin therapy  
- Colchicine therapy  
- Glucocorticoids  
- Non‑steroidal anti‑inflammatory drugs (NSAIDs)  
- Left ventricular (LV) thrombus  
- ST‑segment elevation myocardial infarction (STEMI)  
- Anterior STEMI  
- Left ventricular ejection fraction (LVEF)  
- LV aneurysm  
- Left anterior descending (LAD) artery  
- Echocardiogram (transthoracic echo)  
- Cardiac magnetic resonance imaging (MRI)  
- Dual antiplatelet therapy (DAPT)  
- Anticoagulation (warfarin, DOAC, vitamin K antagonists)  
- Direct oral anticoagulants (DOACs)  
- Vitamin K antagonist  
- Cardiac intensive care unit (CICU)  
- Cardiogenic shock  
- Arrhythmias (torsades, VT/VF)  
- Reperfusion therapy (PCI, thrombolysis)  
- Angina (ongoing)  
- Hemodynamic instability  
- Stroke (thromboembolic complication)  
- Systemic embolization  
- Bleeding risk  
- Thromboembolic risk  
- ECG findings (PR‑segment depression, concave ST elevation, dynamic T‑wave changes)  
- Friction pericardial rub  
- Pleuritic chest pain  
- Residual thrombus monitoring  
- Anticoagulant duration (3 months, prolonged)  
- Imaging for LV thrombus detection  
- Clinical risk assessment for anticoagulation  
- Pericarditis diagnostic criteria  
- Clinical management of pericarditis (aspirin dose, colchicine dosing)

Page 52 Extracted Terms:
**Key heart‑disease terms extracted from the guideline text**

- Acute Coronary Syndromes (ACS)  
- Myocardial infarction (MI)  
- ST‑elevation myocardial infarction (STEMI)  
- Non‑ST elevation myocardial infarction (NSTEMI)  
- Cardiac intensive care unit (CICU)  
- Hemodynamic instability  
- Uncontrolled arrhythmias  
- Heart failure (HF)  
- Cardiogenic shock  
- Angina  
- Ischemic symptoms  
- Cardiac catheterization  
- Telemetry monitoring  
- Intermediate care unit  
- ACTION ICU risk score  
- Signs / symptoms of heart failure  
- Heart rate  
- Systolic blood pressure (SBP)  
- Troponin  
- Serum creatinine  
- Prior revascularization  
- Chronic lung disease  
- ST‑segment depression  
- Age > 70 years  
- Anemia  
- Blood transfusion  
- Hemoglobin level (≥ 10 g/dL, < 7–8 g/dL)  
- Cardiovascular events  
- Restrictive transfusion strategy  
- Liberal transfusion strategy  
- Myocardial Ischemia and Transfusion (MINT) trial  
- End‑stage renal disease (ESRD)  
- Cardiac surgery  
- Percutaneous coronary intervention (PCI)  
- Cardiac death  
- Recurrent myocardial infarction  

These terms capture the clinical concepts, procedures, scoring systems, and outcomes discussed in the guideline excerpt.

Page 53 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- Myocardial Infarction (MI)  
- ST‑Segment Elevation Myocardial Infarction (STEMI)  
- Non‑ST‑Segment Elevation Acute Coronary Syndrome (NSTE‑ACS)  
- Percutaneous Coronary Intervention (PCI)  
- Primary Percutaneous Coronary Intervention (PPCI)  
- Left Ventricular Ejection Fraction (LVEF)  
- Left Ventricular (LV) function  
- Left Ventricular dysfunction  
- Left Ventricular thrombus  
- Ventricular wall motion abnormalities  
- Mechanical complications of MI (e.g., LV free‑wall rupture, papillary muscle rupture)  
- Valvular dysfunction (e.g., mitral regurgitation)  
- Killip class  
- TIMI Flow Grade  
- Zwolle score  
- Troponin (troponin‑negative)  
- Acute kidney injury (AKI)  
- Heart failure (HF)  
- Implantable Cardioverter‑Defibrillator (ICD)  
- Telemetry monitoring  
- Continuous ST‑segment monitoring  
- Transthoracic echocardiography (TTE)  
- Cardiac magnetic resonance imaging (CMR)  
- Left ventriculography  
- Myocardial perfusion imaging  
- Revascularization (e.g., coronary revascularization)  
- Clinical risk stratification  
- Early discharge strategy  
- Same‑day discharge  
- Post‑discharge prescription medications  
- Follow‑up after discharge  
- Intermediate care unit (ICU)  

(Note: Terms are listed in bullet format for clarity.)

Page 54 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- Coronary heart disease (CHD)  
- Myocardial infarction (MI, sometimes referred to as AMI)  
- Cardiac rehabilitation (CR) – center‑based and home‑based  
- Secondary prevention of cardiovascular disease (CVD)  
- Functional status  
- Quality of life (QOL)  
- Readmission (30‑day readmission)  
- Hospital discharge planning  
- Transition from hospital to home  
- Hospital‑to‑Home Initiative  
- AMI Toolkit  
- Digital health interventions (for transition of care)  
- Risk factor modification (e.g., smoking cessation, physical activity, healthy diet)  
- Medication adherence and optimization  
- Health and nutrition education  
- Psychological support (depression & anxiety screening)  
- Life’s Essential 8 (AHA lifestyle recommendations)  
- Cardiovascular mortality  
- All‑cause death  
- All‑cause hospitalization  
- Under‑utilization of cardiac rehabilitation  
- Intensive care unit (ICU) services (as a readmission risk factor)  
- Chronic coronary disease  
- American Heart Association (AHA) recommendations  
- Cardiovascular disease (CVD)  
- Coronary artery disease (sometimes used interchangeably with CHD)  
- Cardiovascular risk factors (hyperlipidemia, hypertension, diabetes, etc.)  
- Patient education (symptom monitoring, return to daily routine, psychosocial considerations)  
- Multicomponent integrated care (combination of quality improvement strategies)  

These terms capture the principal clinical concepts, interventions, and outcomes discussed in the guideline text regarding heart disease.

Page 55 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- Myocardial infarction (MI / AMI)  
- Coronary heart disease (CHD)  
- Cardiac rehabilitation (CR)  
- Exercise‑based CR programs  
- Home‑based CR programs  
- Center‑based CR programs  
- Hybrid CR models  
- Digital health tools  
- Remote monitoring  
- Risk factor education and counseling  
- Lifestyle management (dietary counseling, smoking cessation, weight control)  
- Risk factor control (lipids, blood pressure, diabetes)  
- Psychological interventions  
- Re‑infarction risk reduction  
- Cardiovascular mortality  
- Cardiovascular death  
- Recurrent myocardial infarction  
- Rehospitalization  
- Quality of life (QOL)  
- Ischemic symptoms assessment  
- Bleeding risk assessment (medication or procedural)  
- Diagnostic testing (repeat echocardiogram, staged PCI)  
- Influenza vaccination status  
- Medication reconciliation  
- Sublingual nitroglycerin prescribing  
- Primary prevention (secondary prevention)  
- Self‑care education and adherence  
- Social determinants of health (medication access, CR attendance barriers)  

These terms capture the key concepts related to heart disease discussed in the guideline text.

Page 56 Extracted Terms:
- Acute Coronary Syndromes  
- Dual Antiplatelet Therapy (DAPT)  
- Aspirin  
- P2Y12 inhibitor  
- Ticagrelor  
- Clopidogrel  
- Prasugrel  
- Monotherapy  
- Gastrointestinal bleeding  
- Proton Pump Inhibitor (PPI)  
- Percutaneous Coronary Intervention (PCI)  
- Cardiac Rehabilitation  
- Major Adverse Cardiovascular Events (MACE)  
- Oral Anticoagulants  
- Bleeding risk  
- High bleeding risk  
- High gastrointestinal bleeding risk  
- De‑escalation of DAPT  

Page 57 Extracted Terms:
- Acute coronary syndrome (ACS)  
- ST‑elevation myocardial infarction (STEMI)  
- Non‑ST‑elevation acute coronary syndrome (NSTE‑ACS)  
- Unstable angina  
- Dual antiplatelet therapy (DAPT)  
- Aspirin  
- Oral P2Y12 inhibitor  
- Ticagrelor  
- Prasugrel  
- Clopidogrel  
- Ticagrelor monotherapy  
- Clopidogrel monotherapy  
- Aspirin monotherapy  
- De‑escalation strategy (switching P2Y12 inhibitors)  
- Percutaneous coronary intervention (PCI)  
- Coronary artery bypass grafting (CABG)  
- Major adverse cardiovascular events (MACE)  
- Bleeding risk  
- Thrombotic risk  
- Gastrointestinal bleeding  
- Proton pump inhibitor (PPI)  
- Antiplatelet therapy  
- Antithrombotic therapy  
- Platelet inhibition / pharmacodynamic response  
- High bleeding risk  
- High thrombotic risk  
- Early thrombotic events  
- Late thrombotic events  
- Ischemic events / ischemic efficacy  
- Net clinical benefit / harm  
- Shorter DAPT strategy  
- Prothrombotic state  
- CURE trial (Clopidogrel in Unstable Angina to Prevent Recurrent Events)

Page 58 Extracted Terms:
**Key heart‑disease–related terms identified in the text**

- Acute coronary syndromes (ACS)  
- Dual antiplatelet therapy (DAPT)  
- Single antiplatelet therapy (SAPT)  
- Oral anticoagulant (OAC)  
- Percutaneous coronary intervention (PCI)  
- Drug‑eluting stent (DES)  
- Bioresorbable polymer‑coated stent  
- Clopidogrel  
- Ticagrelor  
- Prasugrel  
- P2Y12 inhibitor  
- Platelet function assays  
- Genotyping (CYP2C19 polymorphisms)  
- Proton‑pump inhibitor (PPI) therapy  
- Omeprazole  
- Gastric/ gastrointestinal bleeding  
- Ischemic events (myocardial infarction, stroke)  
- High bleeding risk  
- Guided de‑escalation of DAPT  
- Unguided de‑escalation of DAPT  
- De‑escalation strategy (switching to clopidogrel)  
- Antiplatelet efficacy  
- Bleeding risk reduction  
- Management of high bleeding risk patients (MASTER DAPT trial)  

These terms capture the core concepts related to cardiovascular disease management, antiplatelet therapy, procedural interventions, and associated risks discussed in the excerpt.

Page 59 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- ST‑elevation myocardial infarction (STEMI)  
- Myocardial infarction (MI)  
- Dual antiplatelet therapy (DAPT)  
- Triple antithrombotic therapy  
- Aspirin  
- P2Y12 inhibitors (e.g., clopidogrel, ticagrelor)  
- Clopidogrel  
- Ticagrelor  
- Oral anticoagulant (OAC)  
- Direct oral anticoagulant (DOAC)  
- Vitamin K antagonist (e.g., warfarin)  
- Percutaneous coronary intervention (PCI)  
- High bleeding risk  
- Major bleeding  
- Minor bleeding  
- Major adverse cardiovascular events (MACE)  
- Ischemic events  
- Chronic kidney disease (CKD)  
- Estimated glomerular filtration rate (eGFR)  
- Hemoglobin level  
- Platelet count (thrombocytopenia)  
- Intracranial hemorrhage (ICH)  
- Nonsteroidal anti‑inflammatory drugs (NSAIDs)  
- Steroids  
- Active malignancy  
- Brain arteriovenous malformation  
- Ischemic stroke  
- Anticoagulation therapy  
- Aspirin discontinuation (1–4 weeks post‑ACS)  
- Antiplatelet therapy guidelines  
- Academic Research Consortium (ARC) high‑bleeding‑risk criteria  
- Age ≥ 75 years  
- Long‑term oral anticoagulation  
- Renal function (CKD stages)  
- Major/minor bleeding criteria  
- Non‑deferrable major surgery on DAPT  
- Recent major surgery or trauma (within 30 days)

Page 60 Extracted Terms:
**Key heart‑disease–related terms extracted from the text**

- Acute Coronary Syndromes (ACS)  
- Percutaneous Coronary Intervention (PCI)  
- Dual Antiplatelet Therapy (DAPT)  
- Aspirin  
- P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor)  
- Oral anticoagulant  
- Low‑intensity vs. high‑intensity anticoagulation  
- Atrial fibrillation (AF)  
- Stent thrombosis  
- Myocardial infarction (MI)  
- Coronary revascularization  
- Lipid‑lowering therapy  
- Statin intolerance (requiring ≥2 statins)  
- Low‑density lipoprotein cholesterol (LDL‑C)  
- LDL‑C target levels  
- Major Adverse Cardiovascular Events (MACE)  
- Cardiovascular events (stroke, death, MI, stent thrombosis)  
- High‑potency (high‑intensity) statin  
- LDL‑C lowering strategy (rapid, intensive)  
- Lipid management guidelines  
- Early follow‑up and lipid testing  
- PALM (Provider Assessment of Lipid Management) registry  
- AUGUSTUS trial (antithrombotic therapy after ACS/PCI in AF)  

These terms capture the principal clinical concepts, therapies, outcomes, and guideline recommendations relevant to heart disease discussed in the passage.

Page 61 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- Myocardial infarction (MI)  
- Heart failure (HF)  
- Left ventricular (LV) systolic function  
- Atherosclerotic cardiovascular disease (ASCVD)  
- Coronary artery disease (CAD)  
- Major adverse cardiovascular events (MACE)  
- Cardiovascular death  
- Resuscitated cardiac arrest  
- Stroke (ischemic)  
- Urgent coronary revascularization  
- Angina  
- Coronary revascularization procedures  
- Coronary artery bypass graft (CABG)  
- Lipid‑lowering therapy  
- Aspirin therapy  
- Statin therapy  
- Glucagon‑like peptide‑1 (GLP‑1) receptor agonists  
- Sodium‑glucose co‑transporter‑2 (SGLT‑2) inhibitors  
- Empagliflozin  
- Dapagliflozin  
- Canagliflozin  
- Ertugliflozin  
- Colchicine  
- Anti‑inflammatory therapy  
- High‑sensitivity C‑reactive protein (hs‑CRP)  
- Plaque volume  
- Non‑cardiovascular death  
- Acute kidney injury  
- Hypovolemia  
- Urinary tract infection  
- Genital mycotic infection  
- Ketoacidosis (perioperative)

Page 62 Extracted Terms:
**Heart‑Disease–Related Terms**

- Acute Coronary Syndrome (ACS)  
- Myocardial infarction (MI)  
- Coronary artery disease / coronary heart disease  
- ST‑segment elevation (ST‑elevation)  
- ST‑segment–elevation myocardial infarction (STEMI)  
- Cardiac arrest  
- Revascularization (e.g., percutaneous coronary intervention – PCI)  
- Primary PCI  
- Fibrinolysis / fibrinolytic therapy  
- Coronary angiography / coronary catheterization  
- Invasive risk stratification  
- Telemetry monitoring  
- Life‑threatening arrhythmias  
- Atrioventricular (AV) block  
- Atrial fibrillation (AF)  
- Ischemia / severe recurrent ischemia  
- Rehospitalization for ischemia  
- Reperfusion therapy  
- Stent thrombosis  
- Major adverse cardiovascular events (MACE)  
- Cardiovascular death  
- Non‑fatal MI  
- Immunization for cardiovascular risk reduction (e.g., influenza vaccine, pneumococcal vaccine)  
- FLUVACS (Flu Vaccination in Acute Coronary Syndromes) study  
- Cardiovascular morbidity and mortality  
- ASCVD (atherosclerotic cardiovascular disease)  
- Risk scores for death/recurrent MI prediction  
- Telemetry duration in ACS management  
- Preloading of oral P2Y12 inhibitors (loading dose prior to angiography)  
- Pulmonary complications (COVID‑19, pneumococcal pneumonia) as cardiovascular event risk enhancers  
- Colchicine use post‑MI (ongoing trials)  

These terms capture the core clinical concepts, interventions, outcomes, and risk factors discussed in the guideline excerpt.

Page 63 Extracted Terms:
- Acute Coronary Syndrome (ACS)  
- ST‑Elevation Myocardial Infarction (STEMI)  
- Non‑ST‑Elevation ACS (NSTE‑ACS)  
- Non‑ST‑Elevation Myocardial Infarction (NSTEMI)  
- Multivessel Disease (MVD)  
- Percutaneous Coronary Intervention (PCI)  
- Culprit‑Only PCI  
- Multivessel PCI  
- Coronary Artery Bypass Graft (CABG)  
- Coronary Angiography  
- Cardiogenic Shock  
- Mechanical Circulatory Support (MCS)  
- Microaxial Flow Pump  
- Chronic Coronary Syndrome (CCS)  
- Left Ventricular Thrombus  
- Antiplatelet Therapy  
- Clopidogrel  
- P2Y12 Inhibitors (oral & parenteral)  
- Beta Blockers  
- Sacubitril‑Valsartan  
- Non‑statin Lipid‑Lowering Therapies  
- PCSK9 Inhibitors  
- GLP‑1 Receptor Agonists  
- Aspirin  
- Direct Oral Anticoagulants (DOACs)  
- Colchicine  
- Post‑MI Pericarditis  
- Cardiac Rehabilitation (CR) – home‐based vs facility‐based  
- Residual Unrevascularized Coronary Artery Disease (CAD)  
- Vascular Complications  
- Bleeding Risk  
- Major Adverse Cardiac Events (MACE)  
- Long‑Term Secondary Prevention  
- Diabetes  
- Overweight/Obesity

Page 64 Extracted Terms:
**Key heart‑disease related terms extracted from the text**

- Acute Coronary Syndromes (ACS)  
- ST‑elevation myocardial infarction (STEMI)  
- Non‑ST‑elevation acute coronary syndromes  
- Primary percutaneous coronary intervention (PCI)  
- Coronary artery revascularization  
- Coronary artery disease (CAD)  
- Dual antiplatelet therapy (DAPT)  
- Cardiovascular disease  
- Heart disease  
- 2013 ACCF/AHA guideline for the management of ST‑elevation myocardial infarction  
- 2014 AHA/ACC guideline for the management of patients with non‑ST‑elevation acute coronary syndromes  
- 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy  
- 2021 ACC/AHA/SCAI guideline for coronary artery revascularization  
- ACC/AHA clinical practice guidelines  
- American College of Cardiology (ACC)  
- American Heart Association (AHA)  
- SCAI (Society for Cardiovascular Angiography and Interventions)  
- Myocardial infarction  
- Coronary artery disease management  
- Cardiovascular disease and comorbid conditions  
- Heart disease and stroke statistics (circulation data)

Page 65 Extracted Terms:
Acute Coronary Syndromes (ACS)  
Myocardial infarction (MI)  
ST‑segment–elevation myocardial infarction (STEMI)  
Non‑ST‑segment–elevation ACS (NSTE‑ACS)  
Acute coronary syndrome  
Coronary artery disease (CAD)  
Coronary heart disease  
Percutaneous coronary intervention (PCI)  
Coronary stent  
Cardiogenic shock  
Left ventricular thrombus  
Chronic coronary disease  
Atrial fibrillation (AF)  
Heart failure (HF)  
Heart failure with reduced ejection fraction (HFrEF)  
Heart failure with preserved ejection fraction (HFpEF)  
Cardiac rehabilitation  
Chest pain evaluation  
Mechanical complications of MI (e.g., ventricular septal defect, free‑wall rupture)  
Catheterization laboratory management for cardiac arrest  
Out‑of‑hospital cardiac arrest  
Stroke prevention  
Transient ischemic attack (TIA)  
Hypertension  
Elevated blood pressure  
Dyslipidemia / high‑cholesterol / lipid management  
Statins (including high‑intensity statin therapy)  
Low‑density lipoprotein cholesterol (LDL‑C) goals  
Cardiovascular risk factors (e.g., diabetes, smoking)  
Sex, gender, and ethnicity disparities in cardiovascular care  
Racial and ethnic differences in heart disease outcomes  
Sex differences in symptom presentation and treatment of MI  
Pre‑vention and control of hypertension  
Management of patients with left ventricular thrombus  
Guidelines for blood cholesterol management (ACC/AHA)  
Guidelines for prevention, detection, and management of high blood pressure (ACC/AHA)  
Guidelines for primary prevention of cardiovascular disease (ACC/AHA)  
Guidelines for evaluation and diagnosis of chest pain (ACC/AHA)  
Guidelines for prevention of stroke in patients with stroke/TIA (ACC/AHA)  
Guidelines for management of heart failure (ACC/AHA/HFSA)  
Guidelines for management of chronic coronary disease (ACC/AHA)  
Guidelines for diagnosis and management of atrial fibrillation (ACC/AHA)  
Guidelines for home‑based cardiac rehabilitation (ACC/AHA)  
Consensus statements on cardiogenic shock classification (SCAI)  
Consensus updates on cardiogenic shock stages (SCAI)  
Safety and effectiveness of antithrombotic therapy in coronary artery disease  
Evaluation of out‑of‑hospital cardiac arrest patients in the catheterization laboratory  
Out‑of‑hospital cardiac arrest management guidelines  
Management of patients at risk for and with left ventricular thrombus (ACC/AHA)  
Non‑obstructive coronary artery disease (MINOCA)  
Sex‑specific criteria for myocardial infarction diagnosis  
Statin use disparities in post‑MI patients  
Guidelines for prevention of acute coronary syndrome.

Page 66 Extracted Terms:
- Acute Coronary Syndrome (ACS)  
- Myocardial Infarction (MI)  
- ST‑Elevation Myocardial Infarction (STEMI)  
- Non‑ST‑Elevation Acute Coronary Syndrome (NSTE‑ACS)  
- Coronary Artery Disease (CAD)  
- Chronic Coronary Disease  
- Chest Pain (diagnostic evaluation)  
- Prehospital 12‑lead Electrocardiography (ECG)  
- Cardiac Arrest (during transport or self‑transport)  
- Primary Percutaneous Coronary Intervention (PCI)  
- Fibrinolytic (Thrombolytic) Therapy  
- Mechanical Reperfusion  
- Spontaneous Coronary Artery Dissection (SCAD)  
- Type 2 Myocardial Infarction  
- Acute Non‑Ischemic Myocardial Injury  
- Cardiovascular Risk (post‑MI)  
- Left Bundle‑Branch Block (LBBB)  
- STEMI Equivalent (e.g., LBBB‑equivalent ECG)  
- Electrocardiogram (ECG) Interpretation  
- ST‑Segment Elevation (in ECG)  
- Door‑to‑Balloon Time  
- Emergency Medical Services (EMS) Transport  
- Prehospital Notification/Advance Notification  
- Regionalization of STEMI Care  
- Cath Lab Preactivation  
- Reperfusion Timing Metrics  
- Prehospital Serial ECGs  
- Chest Pain Evaluation Guidelines  
- STEMI Receiving Center (SRC) Networks  

These terms capture the core heart‑disease concepts addressed in the guideline excerpts.

Page 67 Extracted Terms:
- Acute Coronary Syndrome (ACS)  
- Acute Chest Pain  
- Myocardial Infarction (MI)  
- ST‑Elevation Myocardial Infarction (STEMI)  
- Non‑ST‑Elevation Myocardial Infarction (NSTEMI)  
- High‑sensitivity Troponin (TnT / TnI)  
- Conventional Troponin  
- Electrocardiogram (ECG)  
- 0/1‑hour Algorithm (ESC)  
- 0/3‑hour Algorithm (ESC)  
- HEART Pathway  
- EDACS (Emergency Department Assessment of Chest Pain Score)  
- TIMI Risk Score  
- GRACE Risk Score  
- PURSUIT Risk Score  
- Coronary Artery Disease (CAD)  
- Angiographic Severity  
- Ejection Fraction  
- Heart Failure  
- Right Ventricular Infarction  
- Biomarkers of Cardiac Damage  
- Clinical Decision Rules  
- Rapid Rule‑Out Strategies  
- Risk Stratification Tools  
- Universal Definition of Myocardial Infarction (2018)  
- Coronary Risk Scores  
- Lung Ultrasound (in ACS)  
- Coronary Care Unit  
- Emergency Department (ED) Management of Chest Pain  
- Mortality Prediction  
- Clinical Outcomes in ACS  
- Standardization of Cardiac Biomarker Assays  
- Diagnostic Performance of Troponin Assays  
- Chest Pain Evaluation Guidelines (AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR)  
- Acute Coronary Syndrome Management Algorithms  
- Short‑term and Long‑term Outcomes in MI  
- Biomarker Utilization in ACS  
- Ischemic and Bleeding Risk Assessment  

These terms capture the primary concepts and tools related to heart disease discussed throughout the cited clinical statements and guidelines.

Page 68 Extracted Terms:
- Acute coronary syndrome  
- ST‑elevation myocardial infarction (STEMI)  
- Non‑ST‑elevation acute coronary syndrome (NSTE‑ACS)  
- Myocardial infarction  
- Cardiac arrest  
- Out‑of‑hospital cardiac arrest  
- Cardiogenic shock  
- Coronary angiography  
- Percutaneous coronary intervention (PCI)  
- Oxygen therapy  
- High‑sensitivity troponin  
- Troponin I  
- Troponin T  
- NT‑proBNP (N‑terminal pro‑B‑type natriuretic peptide)  
- SCAI stage classification  
- SCAI grade  
- MIRACLE score  
- PEARL study  
- COACT trial  
- EMERGE trial  
- ARREST trial  
- NULL‑PLEASE score  
- OHCA score (Out‑of‑Hospital Cardiac Arrest score)  
- CAHP score (Cardiac Arrest Hospital Prognosis)  
- Early invasive strategy  
- Early versus delayed coronary angiography  
- Targeted temperature management  
- Catheterization laboratory management of comatose patients  
- American Heart Association scientific statement  
- European Society of Cardiology (ESC) guideline  
- American Heart Association guideline on cardiogenic shock  
- ACC/AHA guideline on acute coronary syndromes  
- SCAI expert consensus statement on out‑of‑hospital cardiac arrest  
- SCAI expert consensus on shock stage classification  
- SCAI grade for cardiac arrest  
- PARADISE‑MI trial (NT‑proBNP prognostication)  
- MERLIN‑TIMI 36 trial (cardiac biomarker assessment)  
- VALIANT study (heart failure post‑MI predictors)  
- JACC review topic of the week (cardiac shock care centers)  
- SCAI SHOCK stage classification update  
- Early predictors of poor outcome after cardiac arrest (e.g., neurological recovery)  
- Oxygenation strategies in acute myocardial infarction  
- High‑flow oxygen in suspected acute coronary syndrome  
- Air versus oxygen therapy in STEMI  
- SOCCER trial (oxygen therapy on myocardial salvage)

Page 69 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- ST‑elevation myocardial infarction (STEMI)  
- Non‑ST‑segment elevation acute coronary syndrome (NSTE‑ACS)  
- Acute myocardial infarction (AMI)  
- Unstable angina  
- Coronary artery disease (CAD)  
- Ischemia  
- Oxygen therapy  
- Oxygen saturation  
- Nitroglycerin (nitroglycerin spray, sublingual tablets, intravenous)  
- Isosorbide dinitrate  
- Nitro‑vasodilators  
- Morphine  
- Fentanyl  
- Clopidogrel  
- Aspirin (acetylsalicylic acid)  
- Ticagrelor  
- Prasugrel  
- P2Y12 inhibitors  
- Intravenous streptokinase  
- Oral aspirin  
- Low‑dose aspirin  
- High‑dose aspirin  
- NSAIDs (non‑steroidal anti‑inflammatory drugs)  
- COX‑2 inhibitors  
- Cyclo‑oxygenase‑2 inhibitors  
- Aspirin sensitivity/desensitization  
- Antiplatelet therapy  
- Antithrombotic therapy  
- Platelet inhibition  
- Primary percutaneous coronary intervention (PCI)  
- Coronary angiography  
- Coronary angioplasty  
- Restenosis  
- Beta‑blockers (implicit in ACS management)  
- Antihypertensive drugs (early treatment)  
- Heparin  
- Nitroglycerin‑sildenafil interaction (tadalafil, avanafil, sildenafil citrate)  
- Ventricular function  
- Mortality and morbidity in ACS  
- Meta‑analysis and systematic review (reference to methodology)  
- Clinical trials: GISSI‑3, ISIS‑4, ISIS‑2, Antithrombotic Trialists Collaboration, PLATO, Wiviott SD (prasugrel trial), Sabatine MS (clopidogrel addition), Yusuf S (clopidogrel + aspirin), Chen ZM (clopidogrel + aspirin), etc.  

Page 70 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- ST‑elevation myocardial infarction (STEMI)  
- Non‑ST‑elevation acute coronary syndrome (NSTE‑ACS)  
- Percutaneous Coronary Intervention (PCI)  
- Coronary artery bypass grafting (CABG)  
- Saphenous vein graft  
- Platelet inhibition  
- Antiplatelet therapy  
- P2Y12 inhibitors  
- Ticagrelor  
- Clopidogrel  
- Prasugrel  
- Cangrelor  
- Glycoprotein IIb/IIIa inhibitors  
- Abciximab  
- Eptifibatide  
- Tirofiban  
- Bivalirudin  
- Heparin  
- Fibrinolytics  
- Aspirin  
- Intravenous (IV) platelet blockade  
- Intracoronary (IC) blockade  
- Intravenous cangrelor during PCI  
- Intravenous glycoprotein IIb/IIIa inhibitors  
- Clopidogrel response variability  
- Genetic determinants of clopidogrel response  
- CYP2C19 polymorphisms  
- Reperfusion therapy  
- Primary PCI  
- Pre‑PCI pretreatment  
- Pre‑hospital ticagrelor  
- Pre‑hospital abciximab  
- Aspiration thrombectomy  
- Transradial rescue PCI  
- PRISM‑PLUS trial  
- INFUSE‑AMI trial  
- MISTRAL study  
- 2025 Acute Coronary Syndromes Guideline  
- 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization  
- 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for Chronic Coronary Disease  
- Dual antiplatelet therapy (DAPT)  
- Combination of clopidogrel and aspirin  
- Recurrent ischemic events  
- Mortality benefit (in CABG context)  
- Coronary artery  
- Myocardial infarction  
- Unstable angina  
- Non‑Q‑wave myocardial infarction  
- Randomized double‑blind study  
- Prospective randomized study  
- Systematic review and meta‑analysis  
- Randomized clinical trial  
- Platelet reactivity  
- Antiplatelet response  
- Pre‑treated P2Y12 inhibitors  
- Intraprocedural outcomes  
- Cardiovascular events  
- Major bleeding  
- Intracoronary infusion of abciximab  
- Intravenous infusion of abciximab  
- Intravenous infusion of eptifibatide  
- Intravenous infusion of tirofiban  
- Intracoronary versus intravenous drug administration  

These terms capture the core concepts, interventions, medications, study designs, and guideline references related to heart disease present in the supplied text.

Page 71 Extracted Terms:
**Key Heart‑Disease Terms Identified**

- Acute Coronary Syndromes (ACS)  
- ST‑segment elevation myocardial infarction (STEMI)  
- Non‑ST‑segment elevation myocardial infarction (NSTEMI)  
- Unstable angina (unstable coronary artery disease)  
- Myocardial infarction (MI)  
- Percutaneous coronary intervention (PCI)  
- Primary PCI  
- Revascularization  
- Coronary artery revascularization  
- Intracoronary drug delivery  
- Intravenous drug delivery  
- Anticoagulation  
- Antithrombotic therapy  
- Glycoprotein IIb/IIIa inhibitors  
- Bivalirudin  
- Enoxaparin (low‑molecular‑weight heparin)  
- Unfractionated heparin  
- Fondaparinux  
- Heparin‑induced thrombocytopenia (HIT)  
- Argatroban  
- Ticagrelor  
- Clopidogrel  
- Eptifibatide  
- Abciximab  
- Tenecteplase  
- Recombinant tissue plasminogen activator (rt‑PA) / tissue plasminogen activator (tPA)  
- Thrombolysis / thrombolytic therapy  
- Thrombin generation / activity  
- Activated clotting time (ACT)  
- Reperfusion therapy  
- Global Use of Strategies To Open Coronar‑y Arteries (GUSTO)  
- ACC/AHA/SCAI guideline  
- 4th Universal Definition of Myocardial Infarction  
- Coronary artery disease (CAD)  
- Coronary intervention (including transradial PCI)  
- Acute Catheterization and Urgent Intervention Triage (ACUITY) trial  
- OASIS, ATOLL, FUTURA/OASIS‑8, STENIC, BRIGHT, GUSTO‑IIb, etc. (key clinical trials/registries)  
- Aspirin therapy  
- Parenteral anticoagulation strategies  
- Coronary artery stenosis  
- Coronary artery thrombosis  

These terms capture the major clinical entities, interventions, medications, and guideline references relevant to heart disease as presented in the supplied text.

Page 72 Extracted Terms:
- Acute Coronary Syndromes  
- ST‑elevation myocardial infarction  
- Myocardial infarction  
- Coronary artery disease  
- Chest pain / angina  
- Heart failure  
- Arrhythmia  
- Atherosclerosis  
- Ischemia  
- Revascularization  
- Percutaneous coronary intervention (PCI)  
- Coronary artery bypass grafting (CABG)  
- Cardiovascular disease (CVD)  
- Cardiovascular events  
- Statin therapy  
- Atorvastatin  
- Simvastatin  
- Rosuvastatin  
- Pravastatin  
- Ezetimibe  
- PCSK9 inhibitors  
- Evolocumab  
- Alirocumab  
- Bempedoic acid  
- Inclisiran  
- Lipid management  
- Low‑density lipoprotein cholesterol (LDL‑C)  
- Very‑low LDL‑C  
- High‑density lipoprotein cholesterol (HDL‑C)  
- Total cholesterol  
- Triglycerides  
- Lipoprotein(a)  
- Lipid‑lowering therapy  
- Statin intolerance  
- Cardiovascular risk stratification  
- High‑risk cardiovascular profile  
- Biomarkers (troponin, high‑sensitivity troponin)  
- Clinical trials / studies  
- MIRACL trial  
- A to Z trial  
- IMPROVE‑IT trial  
- FOURIER trial  
- ODYSSEY OUTCOMES trial  
- EVOPACS trial  
- PROVE‑IT‑TIMI 22 study  
- CLEAR Wisdom trial  
- GAUSS‑3 trial  
- PIONEER trials (not explicitly mentioned but implied by PCSK9 inhibitors)  
- Guidelines (AHA/ACC, ACC/AHA/ACC/AAPA, etc.)  
- Guidelines for cholesterol management  
- Guidelines for acute coronary syndromes  
- Guidelines for statin intolerance  
- Guidelines for high‑risk cardiovascular disease  
- Peripheral artery disease (as a manifestation of CVD)  
- Polyvascular disease  
- Atherogenic lipoproteins  
- Coronary plaque assessment  
- Coronary plaque phenotype  
- Coronary plaque burden  
- Cardiovascular outcomes  
- Mortality post‑myocardial infarction  
- Recurrent cardiovascular events  
- Risk reduction strategies  
- Lipid‐lowering intensity  
- LDL‑C level targets  
- Lipid‑lowering agents  

(Any term related to a heart‑related condition, its treatment, risk assessment, or evidence source has been included.)

Page 73 Extracted Terms:
Acute Coronary Syndromes  
Acute myocardial infarction  
ST‑segment elevation myocardial infarction (STEMI)  
Beta‑blocker therapy  
Metoprolol  
Carvedilol  
Captopril  
Ramipril  
Valsartan  
Telmisartan  
Enalapril  
Eplerenone  
Angiotensin‑converting‑enzyme inhibitor (ACE‑I)  
Angiotensin receptor blocker (ARB)  
Angiotensin‑neprilysin inhibitor (ARNI)  
Neprilysin inhibition  
Aldosterone blocker  
Percutaneous coronary intervention (PCI)  
Primary PCI (PPCI)  
Door‑to‑balloon time  
Thrombolytic therapy  
Primary angioplasty  
Revascularization  
Cardiogenic shock  
Heart failure  
Left ventricular dysfunction  
Left ventricular ejection fraction  
Infarct size  
Mortality  
Morbidity  
Vascular events  
Regional STEMI system  
STEMI network  
FAST‑MI program  
FITT‑STEMI trial  
Mission: Lifeline STEMI system  
Cardioprotection

Page 74 Extracted Terms:
- Acute coronary syndrome  
- Acute myocardial infarction  
- ST‑segment elevation myocardial infarction (STEMI)  
- Non‑ST‑segment elevation myocardial infarction (NSTEMI)  
- Coronary artery bypass graft (CABG)  
- Percutaneous coronary intervention (PCI)  
- Primary percutaneous coronary intervention (PPCI)  
- Angioplasty  
- Reperfusion therapy  
- Mechanical reperfusion  
- Thrombolytic therapy  
- Fibrinolysis  
- Coronary artery revascularization  
- Cardiogenic shock  
- Door‑to‑balloon time  
- Emergency medical services (EMS)  
- Regionalization of STEMI care  
- Transradial access  
- Transfemoral access  
- Coronary artery disease  
- Infarct‑related artery  
- STEMI networks  
- Pharmacoinvasive strategy  
- Primary PCI versus thrombolysis  
- Recurrent myocardial infarction  
- Coronary intervention strategy  
- Revascularization strategy  
- Clinical outcomes after myocardial infarction  
- Time to reperfusion  
- Late presentation of myocardial infarction  
- Transfer for PPCI (interhospital transfer)

Page 75 Extracted Terms:
- Acute myocardial infarction  
- ST‑segment‑elevation myocardial infarction (STEMI)  
- Non‑ST‑segment‑elevation myocardial infarction (NSTEMI)  
- Acute coronary syndrome (ACS)  
- Percutaneous coronary intervention (PCI)  
- Primary PCI  
- Rescue angioplasty / rescue PCI  
- Coronary angiography  
- Coronary artery revascularization  
- Pharmacoinvasive strategy  
- Fibrinolytic therapy  
- Thrombolytic therapy (intravenous thrombolysis)  
- Tissue plasminogen activator (t‑PA)  
- Alteplase (Alteplase)  
- Front‑loaded alteplase administration  
- Tenecteplase (TNK‑tPA)  
- Reteplase  
- ST‑segment resolution / ST‑resolution  
- Door‑in–door‑out time  
- Reperfusion therapy  
- Meta‑analysis of reperfusion strategies  
- Transradial or radial artery access for coronary intervention  
- ACC/AHA/SCAI guideline for coronary artery revascularization  
- ACC/AHA guideline for acute coronary syndromes  
- American Heart Association (AHA)  
- American College of Cardiology (ACC)  
- TIMI trial (Thrombolysis In Myocardial Infarction)  
- NORDISTEMI study  
- STREAM trial  
- MERLIN trial  
- GRAcia‑1 trial  
- Capital AMI study  
- Late Assessment of Thrombolytic Efficacy (LATE) study  
- Early invasive strategy  
- Standard therapy versus early routine PCI after fibrinolysis  

*(All terms are extracted directly from the references and guideline citations, focusing on cardiovascular conditions, interventions, and key clinical concepts mentioned in the text.)*

Page 76 Extracted Terms:
**Key heart‑disease terms extracted from the text**

- Acute coronary syndrome (ACS)  
- ST‑elevation myocardial infarction (STEMI)  
- Non‑ST‑elevation myocardial infarction (NSTEMI)  
- Unstable angina  
- Myocardial infarction (MI)  
- Coronary artery disease (CAD)  
- Coronary angiography  
- Percutaneous coronary intervention (PCI)  
- Coronary artery revascularization  
- Coronary artery bypass grafting (CABG)  
- Radial access (radial artery approach)  
- Femoral access (femoral artery approach)  
- Trans‑ulnar access  
- Trans‑radial access (conventional & distal)  
- Aspiration thrombectomy (thrombus aspiration)  
- Thrombectomy (manual, intracoronary)  
- Glycoprotein IIb/IIIa inhibitor (e.g., tirofiban)  
- Intracoronary abciximab  
- Radial artery graft vs. saphenous vein graft  
- Routine invasive strategy  
- Selective invasive strategy  
- Early invasive strategy  
- Delayed invasive strategy  
- Timing of intervention  
- Meta‑analysis (individual‑patient data, randomized trial)  
- Randomized controlled trial (RCT)  
- Multicentre study  
- Clinical guideline / statement  
- ACC/AHA/SCAI guideline  
- ACC/AHA guideline  
- American Heart Association (AHA)  
- American College of Cardiology (ACC)  
- National cardiovascular data registries  
- Cardiovascular outcomes  
- Mortality (all‑cause, cardiovascular)  
- Major bleeding  
- Safety and efficacy  
- Patient preference (vascular access)  
- Prospective randomised trial  
- Early invasive vs. conservative strategy  
- Long‑term outcome  
- Individual‑patient data meta‑analysis.

Page 77 Extracted Terms:
- Acute Coronary Syndromes  
- ST‑segment Elevation Myocardial Infarction (STEMI)  
- Non‑ST‑segment Elevation Myocardial Infarction (NSTEMI)  
- Acute Myocardial Infarction  
- Myocardial Infarction  
- Coronary Artery Disease (CAD)  
- Coronary Revascularization  
- Primary Percutaneous Coronary Intervention (PCI)  
- Angioplasty  
- Coronary Angiography  
- Drug‑Eluting Stent (DES)  
- Bare‑Metal Stent (BMS)  
- Stent Thrombosis  
- Thrombus Aspiration  
- Intravascular Ultrasound (IVUS)  
- Optical Coherence Tomography (OCT)  
- Optical Frequency Domain Imaging (OFDI)  
- Intravascular Imaging  
- Intravascular Imaging‑Guided PCI  
- Angiography‑Guided PCI  
- Fractional Flow Reserve (FFR)  
- Multivessel Coronary Disease  
- Complete Revascularization  
- Culprit Lesion  
- Staged Revascularization  
- Preventive Angioplasty  
- Cardiogenic Shock  
- Reperfusion  
- Distal Embolization  
- Infarct Size  
- Infarct‑Related Artery  
- Revascularization Strategy  
- PCI Strategies  
- Acute Coronary Intervention  
- Coronary Stent Implantation  
- Coronary Intervention  
- Imaging Guidance in PCI  
- Stent Implantation   
- Coronary Angiographic Guidance  



Page 78 Extracted Terms:
- Acute coronary syndrome (ACS)  
- Non‑ST‑segment elevation myocardial infarction (NSTEMI)  
- ST‑segment elevation myocardial infarction (STEMI)  
- Myocardial infarction (MI)  
- Coronary artery disease (CAD)  
- Multivessel coronary artery disease  
- Coronary artery bypass grafting (CABG)  
- Percutaneous coronary intervention (PCI)  
- Culprit‑only PCI  
- Complete revascularization  
- Staged revascularization  
- Immediate revascularization  
- Fractional flow reserve (FFR)  
- Angiography‑guided strategy  
- Drug‑eluting stents (DES)  
- Coronary artery bypass graft surgery  
- Cardiogenic shock  
- Ischemic cardiomyopathy  
- Left‑main coronary artery disease  
- Coronary artery revascularization  
- FAME study (Fractional flow reserve vs Angiography for Multivessel Evaluation)  
- FAMOUS‑NSTEMI trial  
- BIOVASC trial  
- SMILE trial  
- PRIME‑FFR study  
- POST‑IT registry  
- R3F registry  
- SYNTAX trial  
- ACC/AHA/SCAI revascularization guidelines  
- National Cardiovascular Data Registry (NCDR) ACTION registry  
- Timing of CABG after myocardial infarction  
- Coronary angiogram  
- Coronary arterial revascularization strategies  
- Hybrid revascularization strategies  
- Coronary artery bypass surgery outcomes  
- Cardiac catheterization laboratory use in ACS  
- Coronary arterial lesion assessment  
- Coronary arterial intervention outcomes  
- Coronary artery disease management guidelines  
- Revascularization decision‑making with FFR  
- Multivessel PCI vs culprit‑only PCI comparison  
- Early versus staged PCI in cardiogenic shock  
- Coronary artery disease in patients with diabetes  
- Left‑main coronary artery revascularization outcomes  
- Coronary artery bypass grafting mortality in cardiogenic shock  
- Coronary artery revascularization in ischemic cardiomyopathy  
- Coronary artery intervention trials and meta‑analyses  

(These terms capture the core concepts related to heart disease and coronary revascularization discussed in the provided guideline text.)

Page 79 Extracted Terms:
- Acute coronary syndrome  
- Cardiogenic shock  
- Myocardial infarction  
- ST‑elevation myocardial infarction (STEMI)  
- Non‑ST‑elevation myocardial infarction (NSTEMI)  
- Percutaneous coronary intervention (PCI)  
- Coronary artery bypass grafting (CABG)  
- Revascularization  
- Early revascularization  
- Mechanical circulatory support (MCS)  
- Extracorporeal membrane oxygenation (ECMO)  
- Venoarterial extracorporeal membrane oxygenation (VA‑ECMO)  
- Intra‑aortic balloon pump (IABP)  
- Intra‑aortic balloon counterpulsation (IABC)  
- Left ventricular assist device (LVAD)  
- Microaxial LVAD (Impella LP5.0)  
- Percutaneous LVAD (pLVAD)  
- Impella device  
- Mechanical complications of myocardial infarction  
- Post‑infarction mechanical complications  
- Ventricular septal rupture (VSR)  
- Ventricular free‑wall rupture  
- Papillary muscle rupture  
- Mitral valve surgery  
- Vascular access (femoral artery)  
- Ultrasound‑guided vascular access  
- Ultrasound‑guided femoral artery cannulation  
- FAUST trial (Femoral Arterial Access With Ultrasound Trial)  
- UNIVERSAL trial (routine ultrasound‑guided femoral vascular access)  
- IABP‑SHOCK II study  
- ECMO‑CS randomized clinical trial  
- IMPLESS‑STIC study (Impella plus IABP for cardiogenic shock)  
- SHOCK trial (cardiogenic shock after MI)  
- APEX‑AMI trial (mechanical complications after percutaneous coronary intervention)  
- GUSTO‑I trial (global utilization of streptokinase and tPA)  
- Nationwide registry data (e.g., Dutch, Japanese, UK national registries)  
- Society of Thoracic Surgeons (STS) database  
- Surgical repair of ventricular septal defect  
- Interventional closure of ventricular septal defect  
- Delayed surgery for VSR with mechanical circulatory support  
- Transition to heart transplantation after VSR  
- Risk factors for mechanical complications post‑MI  
- Angiographic patterns in VSR  
- Clinical outcomes (short‑term, long‑term survival)  
- Mortality prediction in cardiogenic shock  
- Major bleeding risk with MCS devices  
- Cost‑effectiveness of MCS strategies  
- Randomized controlled trial (RCT)  
- Meta‑analysis of MCS devices  
- Retrospective cohort study  
- Temporal trends in cardiogenic shock incidence  
- Cardiogenic shock classification systems  
- Cardiac intensive care unit (CICU) outcomes  
- Mechanical bridge to definitive treatment  
- Early surgical intervention post‑MI  
- Vascular complications from device insertion  
- Patient‑characteristics influencing MCS outcomes

Page 80 Extracted Terms:
- Acute Coronary Syndromes  
- Coronary Artery Disease  
- Acute Myocardial Infarction  
- ST‑Segment Elevation Myocardial Infarction (STEMI)  
- Non‑ST‑Segment Elevation Myocardial Infarction (NSTEMI)  
- Percutaneous Coronary Intervention (PCI)  
- Primary Percutaneous Coronary Intervention  
- Coronary Revascularization  
- Coronary Artery Bypass Graft (CABG)  
- Cardiogenic Shock  
- Cardiac Free‑Wall Rupture  
- Cardiac Tamponade  
- Mechanical Complications of Myocardial Infarction  
- Acute Mitral Regurgitation  
- Papillary Muscle Tear  
- Transcatheter Edge‑to‑Edge Mitral Valve Repair  
- Ventricular Septal Defect  
- Intra‑aortic Balloon Pump/Support  
- Left Ventricular Dysfunction  
- Reduced Ejection Fraction  
- Heart Failure  
- Sudden Cardiac Death  
- Ventricular Arrhythmias  
- High‑Degree Atrioventricular (AV) Block  
- First‑Degree AV Block  
- Second‑Degree AV Block (Mobitz I & II)  
- Third‑Degree (Complete) AV Block  
- Bradycardia  
- Conduction Delay  
- Electro‑Mechanical Dissociation  
- Temporary Pacemaker  
- Implantable Cardioverter‑Defibrillator (ICD)  
- Wearable Cardioverter‑Defibrillator  
- Catheter Ablation of Ventricular Fibrillation  
- Electrophysiologic Testing  
- Electrophysiology  
- Atrial Fibrillation  
- Pericarditis  
- Post‑Pericardiotomy Syndrome  
- Pericardial Effusion  
- Recurrent Pericarditis  
- Colchicine Therapy  
- Aspirin Therapy for Pericarditis  
- Indomethacin Therapy for Pericarditis  
- Prednisone Therapy for Pericarditis  
- Clinical Arrhythmias  
- Secondary Prevention of Arrhythmias  
- Primary Prevention of Arrhythmias  
- Risk Stratification after Myocardial Infarction  
- Cardiac Conduction System  
- Acute Coronary Event Complications  
- Post‑Revascularization Arrhythmic Risk  
- Implantation Timing of ICD  
- ICD Therapy Compliance  
- Cardiac Electrophysiology Procedures  
- Acute Coronary Syndrome Management  
- Post‑MI Management  
- Acute Coronary Syndromes Guideline  
- Cardiogenic Shock Guideline  
- Heart Rhythm Society Guidelines.

Page 81 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- Acute Myocardial Infarction (AMI)  
- ST‑segment‑Elevation Myocardial Infarction (STEMI)  
- Non‑ST‑segment‑Elevation Myocardial Infarction (NSTEMI)  
- Left Ventricular Thrombus  
- Left Ventricular Thrombosis  
- Peripheral Percutaneous Coronary Intervention (PCI)  
- Primary Percutaneous Coronary Intervention (Primary PCI)  
- Coronary Angioplasty  
- Cardiac Magnetic Resonance Imaging (CMR)  
- Post‑operative Pericardial Effusion  
- Pericarditis (acute)  
- Colchicine Therapy for Pericarditis  
- Non‑steroidal Anti‑inflammatory Drugs (NSAIDs) for Pericardial Effusion  
- Steroid Therapy during Myocardial Infarction  
- Left Ventricular Free‑Wall Rupture  
- Arrhythmias  
- Sustained Ventricular Tachycardia (VT)  
- Ventricular Fibrillation (VF)  
- Telemetry Monitoring  
- Cardiac Intensive Care Unit (CICU)  
- Anemia in Acute Coronary Syndromes  
- Red Blood Cell Transfusion  
- Transfusion Thresholds (Restrictive vs. Liberal)  
- Blood Transfusion Guidelines (AABB, Cochrane Review)  
- Major Cardiovascular Events  
- Major Bleeding  
- Mortality (in-hospital and long‑term)  
- Prognostic Assessment after Primary Angioplasty  
- Early Discharge After PCI/Angioplasty  
- Length of Hospital Stay  
- Post‑acute Care Planning  
- Risk Scores (e.g., for need of intensive care, predicting length of stay)  
- Telemetry‑based Prediction of In‑hospital Adverse Outcomes  
- STEMI Surveillance (e.g., ischemic ST‑segment episodes)  
- Acute Catheterization and Urgent Intervention Trials (ACUIT)  
- Real‑world Outcomes after Transfusion Strategies (REALITY trial)  

*(This list captures the principal disease‑related concepts, clinical entities, diagnostic modalities, therapeutic interventions, and outcome measures present in the cited guideline excerpt.)*

Page 82 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- Myocardial Infarction (MI)  
- Acute Myocardial Infarction (AMI)  
- Coronary Heart Disease (CHD)  
- Coronary Artery Disease (CAD)  
- Heart Failure (HF)  
- Left Ventricular Ejection Fraction (LVEF)  
- Left Ventricular Function  
- Cardiac Magnetic Resonance Imaging (MRI)  
- Percutaneous Coronary Intervention (PCI)  
- ST‑Segment Elevation Myocardial Infarction (STEMI)  
- Noninvasive Diagnostic Testing  
- Cardiac Rehabilitation (CR)  
- Home‑based Cardiac Rehabilitation  
- Telehealth Cardiac Rehabilitation  
- Secondary Prevention of MI  
- Medication Adherence / Medication‑Taking  
- Readmission / Rehospitalization after ACS  
- Hospital‑to‑Home Initiatives  
- Life’s Essential 8 (AHA)  
- Acute Coronary Syndrome Toolkit (AHA)  
- Clinical Outcomes (mortality, morbidity, quality of life)  
- Cardiovascular Risk Factors (hypertension, diabetes, dyslipidemia)  
- Mechanical Complications of MI  
- Left Ventricular Thrombus  
- Chronic Coronary Disease (CCSD)  
- Multimorbidity in ACS patients  
- Clinical Practice Guidelines (ACC/AHA, AHA/ACC/JACC)  
- American Heart Association (AHA) Statements/Guidelines  
- American College of Cardiology (ACC) Guidelines  
- Chronic Coronary Disease Management  
- Readiness and Utilization of Cardiac Rehabilitation  
- Cardiovascular Magnetic Resonance (CMR) Studies  
- Stress Testing (noninvasive)  
- Patient Education strategies in ACS  
- Socioeconomic status and cardiovascular outcomes  
- Telehealth and remote rehabilitation efficacy 

Page 83 Extracted Terms:
- Acute Coronary Syndromes  
- Cardiac Rehabilitation  
- Intensive Cardiac Rehabilitation  
- Exercise Training  
- Physical Activity  
- Coronary Artery Bypass Grafting (CABG)  
- Percutaneous Coronary Intervention (PCI)  
- Stenting  
- Dual Antiplatelet Therapy (DAPT)  
- Ticagrelor  
- Clopidogrel  
- Aspirin  
- P2Y12 Inhibitors  
- Platelet Inhibition  
- Drug‑Eluting Stents  
- Myocardial Infarction  
- Unstable Angina  
- ST‑Elevation MI  
- Non‑ST‑Elevation MI  
- Coronary Thrombosis  
- Bleeding Risk  
- Major Bleeding  
- High Bleeding Risk  
- Proton Pump Inhibitor (PPI)  
- Omeprazole  
- Lansoprazole  
- Pantoprazole  
- Gastrointestinal Bleeding  
- Secondary Coronary Prevention  
- Coronary Risk Factors  
- Cardiovascular Outcomes  
- Mortality  
- Cardiovascular Events  
- Risk Scoring (e.g., PRECISE‑DAPT, PARIS)

Page 84 Extracted Terms:
- Acute Coronary Syndromes (ACS)  
- Myocardial Infarction (MI)  
- Unstable Angina  
- Coronary Artery Disease (CAD)  
- Percutaneous Coronary Intervention (PCI)  
- Coronary Stenting (Drug‑Eluting Stent, Bare‑Metal Stent)  
- Coronary Artery Revascularization  
- Atrial Fibrillation (AF)  
- Chronic Coronary Disease  
- Coronary Stent Implantation  
- Stent‑Induced Intimal Hyperplasia  
- Dual Antiplatelet Therapy (DAPT)  
- Dual Antithrombotic Therapy (DAT)  
- Triple Therapy  
- P2Y12 Inhibitor  
- Clopidogrel  
- Ticagrelor  
- Prasugrel  
- Aspirin  
- Platelet Inhibition  
- Platelet Function Testing  
- Platelet Reactivity  
- Clopidogrel Resistance  
- Antiplatelet Therapy  
- Antithrombotic Therapy  
- Dabigatran  
- Edoxaban  
- Warfarin  
- Vitamin K Antagonist  
- Non‑Vitamin K Antagonist Oral Anticoagulants (NOACs)  
- Prolonged Dual Antiplatelet Therapy  
- Short‑Term Dual Antiplatelet Therapy  
- Duration of Dual Antiplatelet Therapy (3 , 6 , 12 , 24 months)  
- Proton Pump Inhibitor (PPI)  
- Cytochrome P450 Polymorphisms  
- Clinical Outcomes  
- Major Adverse Cardiac Events (MACE)  
- Bleeding Risk  
- High Bleeding Risk  
- Coronary Artery Disease with Atrial Fibrillation

Page 85 Extracted Terms:
- Acute Coronary Syndrome  
- Percutaneous Coronary Intervention (PCI)  
- Stent Thrombosis  
- Atrial Fibrillation  
- Antithrombotic Therapy  
- Aspirin  
- Dual Antiplatelet Therapy (DAPT)  
- Triple Antithrombotic Therapy  
- High Bleeding Risk  
- Oral Anticoagulation  
- Statin Therapy  
- Low‑Density Lipoprotein (LDL) Cholesterol  
- Intensive Lipid Lowering  
- Lipid‑Lowering Therapy  
- Cholesterol Management  
- Atherosclerotic Cardiovascular Disease  
- Myocardial Infarction  
- Heart Failure  
- Reduced Ejection Fraction (HFrEF)  
- Preserved Ejection Fraction (HFpEF)  
- Mildly Reduced Ejection Fraction  
- SGLT‑2 Inhibitors (e.g., dapagliflozin, empagliflozin, canagliflozin)  
- GLP‑1 Receptor Agonists (e.g., semaglutide, liraglutide)  
- Chronic Colchicine (low‑dose colchicine)  
- Anti‑Inflammatory Therapy  
- Platelet‑Leukocyte Interaction  
- Perioperative Cardiovascular Management  
- Preoperative Fasting in Cardiac Patients  




Page 86 Extracted Terms:
**Key heart‑disease terms extracted from the text**

- Acute Coronary Syndrome (ACS)  
- Myocardial infarction (MI)  
- Coronary artery disease (CAD)  
- Coronary heart disease (CHD)  
- Cardiovascular events  
- Cardiovascular death  
- Cardiovascular mortality  
- Cardiovascular outcomes  
- Plaque stabilization  
- Chronic coronary disease  
- Secondary prevention of coronary ischemic events  
- Cardiovascular disease (CVD)  

These terms capture the primary concepts related to heart disease discussed in the provided excerpt.

Page 87 Extracted Terms:
- Acute Coronary Syndromes  
- Interventional Cardiology  
- Cardiovascular Medicine  
- Cardiac Surgery  
- Heart Failure  
- Acute MI (myocardial infarction)  
- PCI (percutaneous coronary intervention)  
- Structural Heart Interventions  
- Coronary  
- Heart & Vascular Center  
- TIMI Study Group  
- Heart Disease  
- Cardiology  
- Heart  
- MI  
- Injury after PCI  

Page 88 Extracted Terms:
- Acute Coronary Syndromes  
- Cardiology  
- Cardiac  
- Coronary  
- Heart  
- Heart disease  
- Heart center  
- Duke Heart Center  
- Heart and Vascular Center (Emory)  
- Emory Heart and Vascular Center  
- Center for Heart Disease Prevention  
- Cardiovascular  
- Cardiovascular disease  
- NHLBI (National Heart, Lung, and Blood Institute)  
- ACC (American College of Cardiology)  
- AHA (American Heart Association)  
- Medtronic  
- Abbott  
- Roche Diagnostics  
- GlaxoSmithKline  
- Amgen  
- AstraZeneca  
- Beckman Coulter  
- Eli Lilly  
- Janssen Pharmaceuticals  
- Merck  
- Novo Nordisk  
- Regeneron  
- Siemens  
- Varian Medical Systems  
- Verve Therapeutics  
- LianBio  
- Cytokinetics  
- Novartis  
- Bodyport  

Page 89 Extracted Terms:
Acute Coronary Syndromes  
Cardiac ICU  
Cardiovascular Fellowship  
Cardiovascular Medicine  
Cardiovascular Division  
Cardiac Surgery  
Interventional Cardiology  
Heart Failure  
Cardiology  
Cardiovascular  
Cardiac  
American Heart Association (AHA)  
American College of Cardiology (ACC)  
Society for Cardiovascular Angiography and Interventions (SCAI)  
European Heart Journal–Acute Cardiovascular Care  
European Journal of Heart Failure  
Cardiovascular Care  
Cardiovascular Disease 

Page 90 Extracted Terms:
Acute Coronary Syndromes  
Coronary Artery Disease  
Interventional Cardiologist  
Cardiovascular Interventions  
Cardiac Rehabilitation  
Acute Cardiac Care  
Cardiac Bio‑Markers  
Pulmonary Embolism (cardiovascular event)  
Minneapolis Heart Institute  
Cleveland Clinic – Cardiac Care  
Heart Disease (general term)

Page 91 Extracted Terms:
- Acute Coronary Syndromes  
- Myocardial Infarction (MI)  
- Percutaneous Coronary Intervention (PCI)  
- Cardiovascular  
- Cardiovascular disease  
- Cardiology  
- Cardiac  
- Heart  
- Coronary artery disease  
- Coronary artery  
- Coronary  
- CardioVascular  
- TIMI (Thrombolysis in Myocardial Infarction)

Page 92 Extracted Terms:
- Acute Coronary Syndromes  
- Acute Coronary Syndrome guideline  
- Coronary artery disease  
- Coronary artery  
- Right coronary artery  
- Angioplasty  
- Stent placement  
- Perforation during angioplasty  
- Spontaneous bleed  
- Iatrogenic dissection of right coronary artery  
- Cardiac catheterization laboratory  
- Cardiac catheterization  
- Interventional cardiology  
- Cardiovascular medicine  
- Cardiac electrophysiology  
- Cardiovascular service line  
- Heart rhythm (as in Heart Rhythm Society)  
- Coronary revascularization  
- Cardiovascular intervention  
- Acute myocardial infarction (implied within ACS context)  
- Cardiac catheterization laboratory procedure  
- Coronary artery intervention  
- Stenting  
- Coronary artery bypass (implied by angioplasty context)  
- Cardiovascular risk management  
- Cardiac catheterization procedure  
- Coronary artery disease management  
- Cardiac electrophysiology procedure  
- Coronary artery intervention outcomes  
- Cardiovascular disease (general)



Page 1 Extracted Terms:
- Myocarditis  
- Acute myocarditis  
- Cardioimmunology  
- Heart failure (moderate to severe, acute)  
- Myocardial infarction  
- Normal coronary arteries  
- Arrhythmias (including premature ventricular complexes)  
- Premature ventricular complexes (PVCs)  
- Arrhythmia monitoring  
- Cardiac damage  
- Cardiac imaging  
- Cardiovascular medicine  
- Heart failure treatment and recovery  
- Genetic testing (in myocarditis)  
- Histologic diagnosis (in myocarditis)

Page 2 Extracted Terms:
- Myocarditis  
- Inflammatory disease of the heart  
- Immune‑mediated inflammatory reaction  
- Endomyocardial biopsy (EMB)  
- Cardiac magnetic resonance (CMR) imaging  
- Scar formation  
- Malignant arrhythmias  
- Cardiac dysfunction  
- Chronic inflammatory cardiomyopathy  
- Left ventricle (LV) dysfunction  
- Immune polarization  
- Pathogenic/likely pathogenic (P/LP) variants  
- Desmosomal genes  
- Dilated cardiomyopathy genes  
- Immune tolerance  
- Immunophenotyping  
- Immunological tolerance  
- Late gadolinium enhancement (LGE)  
- Dilated cardiomyopathy (DCM)  
- Desmoplakin (DSP)  
- Human leukocyte antigen (HLA)  
- Interleukin (IL)  
- Major histocompatibility complex (MHC)  
- Mus musculus microRNA (Mmu‑miR)  
- Myosin heavy chain 6 (MYH6)  
- Plakophilin‑2 (PKP2)  
- Premature ventricular complexes (PVC)  
- T‑helper lymphocyte (Th)  
- Cardiac troponin I (TNNI3)  
- Tumor necrosis factor (TNF)  
- Ventricular arrhythmias (VA)

Page 3 Extracted Terms:
**Heart disease–related terms extracted from the text**

- Myocarditis  
- Acute myocarditis  
- Chronic myocarditis  
- Definite myocarditis  
- Fulminant myocarditis  
- Nonfulminant myocarditis  
- Chest pain  
- Dyspnea  
- Heart failure  
- Syncope  
- Arrhythmia (general)  
- Ventricular arrhythmias (VAs)  
- Premature ventricular contractions (PVCs)  
- Myocardial infarction with normal coronary arteries  
- Cardiac magnetic resonance imaging (CMR)  
- Fluorodeoxyglucose positron emission tomography (FDG‑PET)  
- Non‑ischemic cardiomyopathy  
- Ventricular arrhythmia (VA) ablation  
- Third‑degree atrioventricular (AV) block  
- Sarcoidosis (cardiac form)  
- Giant‑cell myocarditis  
- Lyme carditis  
- Endomyocardial biopsy (EMB)  
- Immunosuppressive therapy (e.g., for sarcoidosis, eosinophilic, giant‑cell myocarditis)  
- Immune checkpoint inhibitors (treatment implications)  
- Antibiotics (for Lyme carditis)  
- Genetic screening  
- Genetic counseling  
- Cascade screening  
- Histopathologic criteria (Dallas criteria)  
- Clinicopathologic criteria (Lieberman criteria)  
- Inflammatory infiltrate classification  
- Cardiac viral infiltrate (viral‑positive / viral‑negative)  
- Viral tropism  
- Duration of symptoms (acute vs chronic)  
- Severity of presentation (fulminant vs nonfulminant)  
- Extracellular volume (ECV)  
- Ribonucleic acid (RNA)  
- Cardiovascular diagnostic tests (e.g., CMR before device implantation)  
- Competitive sports restriction  

This list captures the key heart‑disease concepts, conditions, diagnostics, treatments, and classification terms mentioned in the excerpt.

Page 4 Extracted Terms:
- Myocarditis  
- Probable myocarditis  
- Definite myocarditis  
- Unexplored myocarditis  
- Fulminant myocarditis  
- Cardiogenic shock  
- Endomyocardial biopsy (EMB)  
- Cardiac magnetic resonance imaging (CMR)  
- Myocardial infarction with nonobstructive coronary arteries (MINOCA)  
- Nonischemic cardiomyopathy (NICMP)  
- Premature ventricular complexes (PVC)  
- Ventricular tachycardia (VT)  
- Heart failure  
- Cardiac imaging  
- Electrophysiology  
- Interventional cardiology

Page 5 Extracted Terms:
- Myocarditis  
- Giant cell myocarditis  
- Cardiac sarcoidosis  
- Eosinophilic myocarditis  
- Lymphocytic myocarditis  
- Viral myocarditis  
- Cardiogenic shock  
- Ventricular tachycardia (VT)  
- Third‑degree atrioventricular block  
- Ventricular arrhythmia (VA)  
- Supraventricular arrhythmias  
- Heart failure  
- Restrictive cardiomyopathy  
- Dilated cardiomyopathy  
- Left ventricle (LV)  
- Right ventricle (RV)  
- Left ventricular ejection fraction (LVEF)  
- Late gadolinium enhancement (LGE)  
- Cardiac magnetic resonance (CMR)  
- Endomyocardial biopsy (EMB)  
- Endocardial voltage mapping (EVM)  
- Flurodeoxyglucose positron emission tomography (FDG‑PET)  
- Guideline‑directed medical therapy (GDMT)  
- Implantable cardioverter‑defibrillator (ICD)  
- Cardiovascular implantable electronic device (CIED)  
- Mechanical circulatory support (MCS)  
- Inotropes  
- Multidrug immunosuppression  
- Corticosteroids (steroids)  
- Methotrexate (MTX)  
- Cyclophosphamide  
- Imatinib  
- Transplant evaluation  
- Lake Louise criteria (CMR findings)  
- ACE2‑tropic, cardiotropic, vasculotropic, lymphotropic, cardiotoxic (viral tropism mechanisms)  
- Adenovirus, enteroviruses, Parvovirus B19, CMV, EBV, HHV‑6, HCV, HIV, influenza, MERS‑CoV, SARS‑CoV, SARS‑CoV‑2 (viruses implicated in viral myocarditis)  
- Granulomas  
- Multinucleated giant cells  
- Eosinophils  
- Histiocytes  
- Myocyte necrosis  
- Embolization of thrombi  
- Restrictive valve involvement  

These terms capture the primary diseases, clinical manifestations, diagnostic tools, imaging findings, therapeutic strategies, and virus-related aspects relevant to heart disease as described in the text.

Page 6 Extracted Terms:
- Myocarditis  
- Acute myocarditis  
- Fulminant myocarditis  
- Complicated myocarditis  
- Uncomplicated myocarditis  
- Myocardial infarction  
- Heart disease (general term)  
- Cardiac mortality  
- Heart transplantation  
- Left ventricular ejection fraction (LVEF)  
- LVEF < 50%  
- Left ventricular (LV) dysfunction  
- Left bundle branch block (LBBB)  
- Ventricular arrhythmia  
- Atrioventricular (AV) block  
- Conduction abnormalities  
- Electrocardiographic (ECG) changes  
- Diffuse ST‑segment elevation  
- T‑wave abnormalities  
- QRS prolongation (>120 ms)  
- Q‑waves  
- PVCs (premature ventricular complexes)  
- Polymorphic PVCs  
- Syncope  
- Chest pain  
- Dyspnea / shortness of breath  
- Heart failure symptoms  
- Pericardial effusion / fluid  
- LV dilatation  
- LV hypertrophy  
- Diastolic dysfunction  
- Global longitudinal strain (GLS)  
- Erythrocyte sedimentation rate (ESR)  
- C‑reactive protein (CRP)  
- Cardiac troponin T (cTnT)  
- Natriuretic peptides (BNP/NT‑proBNP)  
- Viral titers  
- MicroRNAs (e.g., mmu‑miR‑721)  
- Th‑17 immune response  
- Immune polarization  
- Autoimmune / autoinflammatory conditions  
- Sarcoidosis  
- Lyme carditis  
- COVID‑19 myocarditis / vaccine‑related myocarditis  
- Inflammatory cardiomyopathy (chronic)  
- Chronic inflammatory cardiomyopathy  
- Immunosuppressive therapies  
- Intensive care unit (ICU) monitoring  
- Stratified diagnostic tiers (acute evaluation, definitive confirmation, auxiliary diagnostics)

Page 7 Extracted Terms:
- Myocarditis  
- Uncomplicated myocarditis  
- High‑risk features (e.g., ventricular arrhythmias, atrioventricular conduction abnormalities)  
- Telemetry capability  
- Ventricular arrhythmias  
- Atrioventricular conduction abnormalities  
- Troponin elevation  
- ST‑segment abnormalities  
- T‑wave abnormalities  
- Chest pain  
- Regional wall motion abnormalities  
- Coronary artery disease  
- Coronary angiogram  
- Myocardial injury  
- Th17 immune response  
- MicroRNAs (mmu‑miR‑721)  
- Endomyocardial biopsy (EMB)  
- Cardiac magnetic resonance imaging (CMR)  
- Cardiac magnetic resonance imaging (CMR)  
- Endomyocardial voltage mapping (EVM)  
- Intensive care unit (ICU)  
- Left ventricle (LV)  
- Left ventricular ejection fraction (LVEF)  
- Mechanical circulatory support (MCS)  
- New York Heart Association Class (NYHA)  
- Ventricular arrhythmia (VA)  
- Telemetry unit  
- Ambulatory management  
- Acute diagnostic evaluation  
- Confirmatory diagnostic evaluation  
- Tier‑2 diagnosis of definite myocarditis  
- Cardiac inflammation  
- Inflammatory infiltrate (on EMB)  
- Prognostic information (from EMB)  
- Emergency department (ED)

Page 8 Extracted Terms:
**Key heart‑disease related terms extracted from the text**

- Myocarditis  
- Giant cell myocarditis  
- Eosinophilic myocarditis  
- Cardiac sarcoidosis  
- Lymphocytic myocarditis  
- Endomyocardial biopsy (EMB)  
- Cardiac magnetic resonance imaging (CMR)  
- 3‑D spatial immunophenotyping  
- Laser capture microdissection  
- Gene expression profiling  
- Single‑cell RNA sequencing  
- Desmoplakin mutation  
- New York Heart Association (NYHA) Class ≥ III/IV  
- High‑sensitive cardiac troponin T (cTnT)  
- Creatine kinase MB (CK‑MB)  
- Creatine kinase MM (CK‑MM)  
- Soluble interleukin‑1 receptor‑like 1 (ST2)  
- N‑terminal pro‑B‑type natriuretic peptide (NT‑proBNP)  
- C‑reactive protein (CRP)  
- Erythrocyte sedimentation rate (ESR)  
- White blood cell (WBC) count with differential  
- Eosinophil count  
- Autoantibodies:  
  - Antinuclear antibody (ANA)  
  - Anti‑double‑stranded DNA (anti‑dsDNA)  
  - Cardi‑olipin IgG/IgM  
  - Antineutrophil cytoplasmic antibody (ANCA)  
  - Myeloperoxidase (MPO)  
  - Proteinase‑3 (PR‑3)  
  - Anti‑cyclic citrullinated peptide (anti‑CCP)  
  - Anti‑SSA (Ro)  
  - Anti‑SSB (La)  
  - Anti‑Scl‑70  
  - Anti‑RNA polymerase III  
- Viral serology: HCV, HIV, Lyme borreliosis, influenza  
- Medications associated with myocarditis:  
  - Cephalosporins  
  - Digoxin  
  - Diuretics  
  - Dobutamine  
  - Sulfonamides  
  - Tricyclic antidepressants  
- Substance exposures: cocaine, amphetamines, ethanol, copper, iron, lead, venomous bites  
- SARS‑CoV‑2 infection and mRNA vaccination  
- Immune checkpoint inhibitors  
- Anthracyclines  
- Interleukin‑2 receptor (soluble IL‑2R)  
- Clinical parameters: coronary syndromes, arrhythmia/syncope, chest pain, dyspnea  
  
These terms capture the core clinical, diagnostic, laboratory, and therapeutic concepts relevant to heart disease as presented in the excerpt.

Page 9 Extracted Terms:
- Myocarditis  
- Acute myocarditis  
- Cardiac magnetic resonance imaging (CMR)  
- Endomyocardial biopsy (EMB)  
- Myocardial edema  
- T1‑based imaging (T1‑mapping)  
- T2‑based imaging (T2‑mapping)  
- Lake Louise criteria (2009 & 2018)  
- Myocardial infarction with normal coronary arteries  
- Arrhythmia  
- Extracellular volume (ECV)  
- Late gadolinium enhancement (LGE)  
- LGE mid‑wall localization  
- Left ventricular ejection fraction (LVEF) < 50%  
- Cardiac sarcoidosis  
- Cardiac ischemia  
- Perfusion CMR  
- Immune checkpoint inhibitors (ICI)  
- Flurodeoxyglucose positron emission tomography (FDG‑PET)  
- PCR (polymerase chain reaction) as a diagnostic tool in myocarditis  
- Optimal medical therapy (OMT)  
- Endocardial voltage mapping (EVM)

Page 10 Extracted Terms:
- Myocarditis  
- Suspected myocarditis diagnostic criteria  
- Classical myocarditis features  
- Cardiac magnetic resonance imaging (CMR)  
- Endomyocardial biopsy (EMB)  
- FDG‑PET (fluorodeoxyglucose positron emission tomography)  
- Persistent inflammation in myocarditis  
- Autoimmune conditions associated with myocarditis  
- P/LP genetic variants (predisposing pathogenic/likely pathogenic variants)  
- Cardiomyopathy unresponsive to standard medical therapy (>3 months)  
- Hemodynamic stability  
- Ventricular arrhythmia (VA)  
- Atrioventricular conduction abnormalities  
- Cardiac troponin normalization  
- Exercise testing restriction in acute myocarditis  
- Low‑risk features for myocarditis  
- High‑risk features for myocarditis  
- Left ventricular (LV) dysfunction  
- LV ejection fraction (LVEF)  
- Myocardial infarction with normal coronary arteries  
- Heart failure  
- Transplant in myocarditis  
- LGE (late gadolinium enhancement) on CMR  
- LGE persistence/reciprocal changes (increase, decrease, resolution)  
- LGE without edema (predictor of adverse events)  
- Cardiac sarcoidosis  
- STREAM study (FDG‑PET/CT vs. MRI/EMB)  
- Monomorphic ventricular tachycardia (VT)  
- Polymorphic ventricular tachycardia (VT)  
- Scar‑related VT  
- Voltage mapping (bipolar endocardial voltage mapping)  
- Immunosuppressive therapy in myocarditis  
- Implantable cardioverter‑defibrillator (ICD) implantation  
- Holter monitoring  
- 12‑lead ECG assessment  
- Follow‑up imaging in myocarditis  
- Follow‑up arrhythmia monitoring  
- Follow‑up exercise testing restriction  
- Genetic counseling and cascade screening in myocarditis  
- Chronic inflammatory cardiomyopathy  
- Giant cell myocarditis  
- Inflammatory infiltrate risk for VAs  
- Mid‑wall LGE  
- LVEF on initial CMR  
- LGE extent and location  
- Scar re‑entry circuits  
- Inflammation‑induced ion channel dysfunction  
- Altered intracellular signaling in myocardial inflammation  
- Cardiogenic risk stratification in myocarditis  
- Follow‑up interval recommendations (e.g., 3‑month CMR, 196‑day imaging)  
- Registries: Lombardy registry, ITAMY (Italian Study in Myocarditis)  
- Mortality and transplant event rates in complicated vs. fulminant myocarditis.

Page 11 Extracted Terms:
**Heart disease–related terms extracted from the text**

- Suspected myocarditis  
- Myocarditis  
- Arrhythmogenic cardiomyopathy (ACM)  
- Arrhythmogenic right ventricular cardiomyopathy (ARVC)  
- Sudden death in young athletes  
- High‑risk features (in myocarditis)  
- Clinical‑relevant arrhythmias  
- Ventricular arrhythmias (frequent or complex repetitive forms)  
- Supraventricular arrhythmias (frequent or complex repetitive forms)  
- Exercise testing (acute phase & follow‑up)  
- European Association of Preventive Cardiology (position paper)  
- Periodical reassessment (first 2 years and yearly thereafter)  
- LGE present (late gadolinium enhancement)  
- ARVC (arrhythmogenic right ventricular cardiomyopathy)  
- CMR – cardiac magnetic resonance  
- CS – cardiac sarcoidosis  
- EVM – endocardial voltage mapping  
- FDG‑PET – flurodeoxyglucose positron emission tomography  
- FU – follow‑up  
- GCM – giant cell myocarditis  
- GDMT – guideline‑directed medical therapy  
- HF – heart failure  
- HTX – heart transplant  
- ICD – implantable cardioverter‑defibrillator  
- LBBB – left bundle branch block  
- LGE – late gadolinium enhancement  
- LVAD – left ventricular assist device  
- LVSD – left ventricular systolic dysfunction  
- NYHA – New York Heart Association Class  

These are the key heart‑disease–related terms and abbreviations cited in the provided excerpt.

Page 12 Extracted Terms:
- Myocarditis  
- Left ventricular ejection fraction (LVEF)  
- Myocardial injury biomarkers  
- Holter monitoring  
- Exercise testing  
- Human leukocyte antigen haplotypes  
- P/LP (pathogenic/likely pathogenic) variants  
- TTN (titin) variants  
- Desmoplakin (DSP) variants  
- Arrhythmogenic cardiomyopathy  
- Canonical Wnt–β‑catenin signaling  
- Th2 immune polarization  
- Cardiomyopathy (including dilated and familial forms)  
- Genetic testing (at time of new cardiomyopathy diagnosis)  
- Genetic screening for myocarditis patients  
- Genetic counseling (including pre‑implantation counseling)  
- Cascade screening  
- Competitive sports prohibition  
- Implantable cardioverter‑defibrillator (ICD) implantation  
- Heart failure  
- Arrhythmia  
- Persistent inflammation  
- Cardiac magnetic resonance (CMR) imaging  
- Immune phenotyping  
- Giant cell myocarditis  
- Pulmonary sarcoidosis (cardiac involvement)

Page 13 Extracted Terms:
- Myocarditis  
- Cardiomyopathy  
- Heart failure  
- Ventricular arrhythmia  
- Ventricular tachycardia  
- Non‑obstructive coronary arteries  
- Myocardial infarction  
- Cardiac magnetic resonance imaging (CMR)  
- Late gadolinium enhancement  
- T1 mapping  
- T2 mapping  
- Endomyocardial biopsy  
- Immune checkpoint blockade  
- MicroRNA  
- Parvovirus B19 infection  
- Cardiac sarcoidosis  
- Idiopathic giant cell myocarditis  
- Positron emission tomography (PET)  
- Exercise‑induced myocarditis  
- Desmoplakin gene truncating variant  
- Risk stratification  
- Immunosuppressive therapy  
- Competitive athlete participation  
- Pericarditis  
- Non‑ischemic myocardial inflammation  
- Inflammatory cardiomyopathy  
- Aetiology of myocarditis  
- Diagnostic criteria  
- Management strategies  
- Therapeutic recommendations  

Page 14 Extracted Terms:
**Key heart‑disease related terms found in the text**

- Myocarditis  
- Autoimmune myocarditis  
- Viral myocarditis (coxsackievirus B3‑induced, viral myocarditis)  
- Desmoplakin cardiomyopathy  
- Arrhythmogenic cardiomyopathy  
- Dilated cardiomyopathy  
- Heart failure  
- Cardiac fibrosis  
- Cardiac remodeling  
- Cardiac hypertrophy  
- Cardiac injury  
- Cardiac magnetic resonance imaging (CMR)  
- Cardiac myosin (S2 region, alpha‑myosin)  
- T cell‑mediated inflammation  
- Regulatory T cells (Treg)  
- Th17 cells  
- Th2 cells  
- CD4⁺ T cells  
- CD69 (exhaustion marker)  
- Interleukin‑17 (IL‑17)  
- Interleukin‑4 (IL‑4)  
- Interleukin‑37 (IL‑37)  
- Bcl2‑like protein 12 (BCL2L12)  
- STAT6 (signal transducer and activator of transcription 6)  
- PKCβ (protein kinase C beta)  
- ERK1/2 (extracellular signal‑regulated kinases 1/2)  
- NF‑κB (nuclear factor kappa‑B)  
- Toll‑like receptors (TLRs)  
- Human leukocyte antigen class II (HLA‑II) associations  
- MicroRNA‑155 (miR‑155)  
- MicroRNA‑21 (miR‑21)  
- Antigen‑presenting cells (APCs)  
- I‑Aκ (MHC II molecule on APCs)  
- Cardiomyopathy (general term)  
- Heart transplant rejection  
- Tissue‑based molecular diagnostic system (MMDx)  
- Autoimmunity (in the context of cardiovascular disease)  
- Gene‑expression profiling (for cardiac disease)  

These terms capture the central diseases, cellular mechanisms, cytokines, and molecular markers relevant to heart disease as highlighted in the provided references.



Page 1 Extracted Terms:
- ACC/AHA Guideline  
- Diagnosis and Management  
- Aortic Disease  
- Asymptomatic presentation  
- Stable symptomatic presentation  
- Acute aortic syndromes  
- Genetic evaluation  
- Family screening  
- Medical therapy  
- Endovascular treatment  
- Surgical treatment  
- Long‑term surveillance  
- Thoracic aortic disease  
- Peripheral artery disease  
- Bicuspid aortic valve disease  
- Aortic aneurysm  
- Aortic dissection  
- Aortic root and ascending aorta  
- Descending aorta  
- Endovascular stent graft  
- Cardiac imaging (CT, MRI, echocardiography)  
- Risk stratification  
- Surgical repair and replacement  
- Connective tissue disorders (Marfan, Loeys‑Dietz, etc.)  
- Hypertension management (beta‑blockers, ACEi/ARB)  
- Lifestyle modification for aortic disease  
- Genetic counseling for inherited aortopathies  
- Surveillance imaging schedule  
- Cardiovascular surgical specialties  
- Interventional radiology in aortic disease management  
- Vascular medicine in aortic disease follow‑up  

Page 2 Extracted Terms:
- Aortic aneurysm  
- Abdominal aortic aneurysm (AAA)  
- Thoracic aortic aneurysm (TAA)  
- Thoracoabdominal aortic aneurysm (TAAA)  
- Aortic dissection  
- Acute aortic syndrome (AAS)  
- Intramural hematoma (IMH)  
- Penetrating atherosclerotic ulcer (PAU)  
- Aortitis  
- Aortopathy  
- Bicuspid aortic valve (BAV)  
- Blunt traumatic aortic injury  
- Endovascular aortic repair (EVAR)  
- Thoracic endovascular aortic repair (TEVAR)  
- Heritable thoracic aortic disease  
- Marfan syndrome  
- Loeys‑Dietz syndrome  
- Malperfusion syndrome  
- Endoleak  
- Aortic arch aneurysm  
- Descending thoracic aortic aneurysm  
- Surgical management of aortic aneurysm  
- Endovascular management of aortic aneurysm  
- Cardiac surgery  
- Vascular surgery  
- Acute type A aortic dissection  
- Acute type B aortic dissection  
- Multidisciplinary aortic team  
- Shared decision‑making  
- Imaging techniques (CT, MRI, echocardiography, intravascular ultrasound, abdominal ultrasound)  
- Risk‑factor modification (blood‑pressure control, medication)  
- Screening for abdominal aortic aneurysm  
- Surveillance after aortic repair  
- Natural history of aortic aneurysm  
- Medical management of sporadic or degenerative aortic aneurysm  
- Genetic aortopathies  
- Surveillance for medical management  
- Management of acute aortic dissection (surgical vs endovascular)  
- Management of intramural hematoma (acute and subsequent)  
- Complications of aortic disease (malperfusion, rupture)  

These terms capture the key concepts related to heart and aortic disease presented in the guideline.

Page 3 Extracted Terms:
- Aortic Disease  
- Aortic Aneurysm  
- Aortic Dissection  
- Intramural Hematoma (IMH)  
- Penetrating Atherosclerotic Ulcer (PAU)  
- Traumatic Aortic Injury  
- Blunt Traumatic Thoracic Aortic Injury (BTTAI)  
- Blunt Traumatic Abdominal Aortic Injury (BAAI)  
- Aortic Root  
- Ascending Aortic Aneurysm  
- Atherosclerotic Disease  
- Aortic Thrombus  
- Aortic Occlusion  
- Porcelain Aorta  
- Coarctation of the Aorta  
- Congenital Aortic Arch Abnormalities  
- Takayasu Arteritis  
- Giant Cell Arteritis (GCA)  
- Infectious Aortitis  
- Native Aortic Infection  
- Prosthetic Aortic Graft Infection  
- Pregnancy‑associated Aortic Disease  
- Delivery Management in Aortopathy  
- Multidisciplinary Aortic Team  
- Shared Decision‑Making  
- Computed Tomography (CT)  
- Magnetic Resonance Imaging (MRI)  
- Echocardiography  
- Endovascular Repair  
- Open Surgical Repair  
- Surveillance Imaging  
- Biomarkers  
- Genetic Factors  
- Lifestyle / Physical Activity  
- Quality of Life  
- Rehabilitation Protocols  
- Endovascular Technology  
- Cost and Value Considerations  
- Equitable Care and Training Opportunities

Page 4 Extracted Terms:
- Aortic root  
- Ascending aorta  
- Aortic root diameter  
- Aortic cross‑sectional area  
- Body surface area (indexing aortic dimensions)  
- Height (indexing aortic dimensions)  
- Rapid aortic root growth  
- Ascending aortic aneurysm  
- Valve‑sparing aortic root replacement  
- Aortic root replacement surgery  
- Acute type A aortic dissection  
- Operative repair of type A aortic dissection  
- Open distal anastomosis  
- Thoracic endovascular aortic repair (TEVAR)  
- Uncomplicated type B aortic dissection  
- Thoracoabdominal aortic aneurysm  
- Endograft (endovascular repair)  
- Bicuspid aortic valve  
- Aortic imaging  
- First‑degree relative screening for aortic disease  
- Cardiovascular health  
- Cardiovascular disease  
- Aortic disease  
- Aortic dissection  
- Aortic aneurysm  
- Aortic root pathology

Page 5 Extracted Terms:
- Aortic disease  
- Aortic occlusion  
- Aortic aneurysm  
  - Thoracic aortic aneurysm  
  - Abdominal aortic aneurysm  
- Endovascular aneurysm repair  
- Surveillance after endovascular aneurysm repair  
- Aortic dissection  
  - Type A aortic dissection  
  - Type B aortic dissection  
- Dissecting aneurysm  
- Aortic rupture  
- Penetrating aortic ulcer  
- Aortitis  
- Atherosclerotic aortic disease  
- Atherosclerotic plaque  
- Arterial occlusive diseases  
- Diagnostic imaging  
  - Computed tomography (CT)  
  - Ultrasound (duplex, Doppler)  
  - Magnetic resonance imaging (MRI)  
  - Echocardiography  
- Guideline‑directed medical therapy  
- Randomized controlled trials (RCTs)  
- Observational studies (cohort, registry)  
- Systematic reviews  


Page 6 Extracted Terms:
- 3‑dimensional  
- abdominal aortic aneurysm  
- acute aortic syndrome  
- angiotensin‑converting enzyme inhibitor  
- aortic height index  
- aortic regurgitation  
- angiotensin receptor blocker  
- aberrant subclavian artery  
- atherosclerotic cardiovascular disease  
- aortic size index  
- aortic valve replacement  
- blunt traumatic abdominal aortic injury  
- bicuspid aortic valve  
- blood pressure  
- body surface area  
- blunt traumatic aortic injury  
- blunt traumatic thoracic aortic injury  
- cardiac magnetic resonance  
- coarctation of the aorta  
- computed tomography  
- computed tomographic angiography  
- diastolic blood pressure  
- disease‑modifying anti‑rheumatic drug  
- electrocardiogram  
- endovascular abdominal aortic aneurysm repair  
- focal intimal disruption  
- fluorodeoxyglucose–positron emission tomography  
- fenestrated endovascular aortic repair  
- giant cell arteritis  
- health‑related quality of life  
- heritable thoracic aortic disease  
- intensive care unit  
- intramural hematoma  
- International Registry of Acute Aortic Dissection  
- low‑density lipoprotein  
- large vessel vasculitis  
- magnetic resonance  
- magnetic resonance angiography  
- magnetic resonance imaging  
- nonsyndromic heritable thoracic aortic disease  
- peripheral artery disease  
- penetrating atherosclerotic ulcer  
- positron emission tomography  
- ruptured abdominal aortic aneurysm  
- randomized controlled trial  
- resuscitative endovascular balloon occlusion of the aorta  
- superior mesenteric artery  
- systolic blood pressure  
- spinal cord injury  
- thoracic aortic aneurysm  
- thoracoabdominal aortic aneurysm  
- thoracic aortic aneurysm and dissection  
- thoracic aortic disease  
- total arch replacement  
- transesophageal echocardiography  
- thoracic endovascular aortic repair  
- transthoracic echocardiography  
- valve‑sparing root replacement

Page 7 Extracted Terms:
- Aortic valve annulus  
- Sinotubular junction  
- Innominate artery  
- Left subclavian artery  
- Aortic arch  
- Ascending thoracic aorta  
- Descending thoracic aorta  
- Abdominal aorta  
- Aortic bifurcation  
- Aortic root (sinus segment)  
- Intima  
- Media  
- Adventitia  
- Elastic lamellae  
- Vasa vasorum  
- Proximal sealing zone  
- Landing zone 0 (0A, 0B, 0C)  
- Thoracic endovascular aortic repair (TEVAR)  
- Thoracic endovascular aortic repair for descending thoracic aortic aneurysms  
- Aortic aneurysm  
- Aortic dissection  
- Acute type A aortic dissection  
- Type B aortic dissection  
- Bicuspid aortic valve  
- Vascular graft infections  
- Mycotic aneurysms  
- Endovascular infections  
- Traumatic thoracic aortic injury  
- Valvular heart disease  
- Congenital heart disease  
- Blood cholesterol management  
- High blood pressure (hypertension)  
- Coronary and other atherosclerotic vascular disease  
- Lower extremity peripheral artery disease  
- Large vessel vasculitis  
- ACC/AHA  
- ACHA/ACC  
- SVS (Society for Vascular Surgery)  
- ESVS (European Society for Vascular Surgery)  
- EULAR (European League Against Rheumatism)  
- AHA (American Heart Association)  
- ACCF (American College of Cardiology Foundation)  
- ACC (American College of Cardiology)  
- AACVPR (American Association of Cardiovascular and Pulmonary Rehabilitation)  
- AAPA (American Academy of Physician Assistants)  
- AATS (American Association for Thoracic Surgery)  
- ABC (Association of Black Cardiologists)  
- ACPM (American College of Preventive Medicine)  
- ACR (American College of Radiology)  
- ADA (American Diabetes Association)  
- AGS (American Geriatrics Society)  
- APhA (American Pharmacists Association)  
- ASA (American Society of Anesthesiologists)  
- ASH (American Society of Hematology)  
- ASPC (American Society for Preventive Cardiology)  
- ASPCI (Society for Cardiovascular Angiography and Interventions)  
- SIR (Society of Interventional Radiology)  
- STS (Society of Thoracic Surgeons)  
- SVA (Society of Vascular Anesthesiologists) (implicit)

Page 8 Extracted Terms:
- arterial aneurysm  
- aortic root  
- ascending thoracic aorta  
- aortic dilatation  
- aneurysmal threshold (≥ 1.5 × reference diameter)  
- Marfan syndrome  
- familial thoracic aortic aneurysm  
- aortic repair  
- diameter threshold for intervention (≤ 5.0 cm)  
- natural history of aortic disease  
- bicuspid aortic valve (BAV)  
- aortic valve replacement (AVR)  
- American College of Cardiology / American Heart Association (ACC/AHA) Class of Recommendation  
- Level of Evidence in cardiovascular guidelines  

Page 9 Extracted Terms:
- Aortic dissection  
- Type A aortic dissection  
- Ascending aorta  
- Aortic diameter (size)  
- Prophylactic aortic repair  
- Sudden death  
- MESA (Multi‑Ethnic Study of Atherosclerosis)  
- Atherosclerosis  
- Risk assessment (dissection risk)  
- Distribution curve of aortic size  

Page 10 Extracted Terms:
- Aortic dilation  
- Aortic aneurysm  
- Aortic ectasia  
- Aortic root  
- Ascending aorta  
- Aortic wall (medial layer)  
- Aortic diameter thresholds (4.0 cm, 4.5 cm)  
- Body‑size normalization of aortic dimensions  
- Coronary artery dilation  
- Coronary artery ectasia  
- Zone 0–11 aortic landing zones  
- ACC/AHA aortic disease guideline  
- ESC aortic disease guideline  
- Aortic disease (clinical statements & guidelines)

Page 11 Extracted Terms:
- Aortic dilation  
- Aortic root diameter  
- Aortic size index  
- Aortic height index  
- Z‑score  
- Body surface area (BSA)  
- Pediatric aortic dilation  
- Acute aortic syndromes (AAS)  
- Ascending aorta  
- Bicuspid aortic valve disease  
- Aortic aneurysm  
- Aortic dissection  
- Sudden death  
- Relative risk  
- Aortic complications  
- Nomograms  
- 2022 ACC/AHA Aortic Disease Guideline

Page 12 Extracted Terms:
- Aortic disease  
- Aortic aneurysm  
- Aortic dissection  
- Intramural hematoma (IMH)  
- Penetrating atherosclerotic ulcer (PAU)  
- Acute aortic syndrome (AAS)  
- Aortic rupture  
- Acute aortic regurgitation (AR)  
- Myocardial ischemia  
- Cardiac tamponade  
- Acute stroke  
- Malperfusion syndromes  
- Aortic size index (ASI)  
- Aortic height index (AHI)  
- Cross‑sectional area to height ratio  
- Aortic diameter  
- Body surface area (BSA)  
- Body mass index (BMI)  
- Intimal tear  
- Aortic media  
- Dissection flap  
- True lumen  
- False lumen  
- Pseudoaneurysm  
- Aortic wall integrity  
- Antegrade propagation  
- Retrograde propagation  
- Life‑threatening conditions  
- Intervention threshold (≥10 cm²/m)

Page 13 Extracted Terms:
- Aortic dissection  
- Acute aortic dissection  
- Chronic aortic dissection  
- Hyperacute aortic dissection  
- Subacute aortic dissection  
- DeBakey classification (system)  
- Stanford classification (system)  
- Intima  
- Media  
- Adventitia  
- False lumen  
- True lumen  
- Aortic rupture  
- Reentry tear  
- Marfan syndrome  
- Bicuspid aortic valve (BAV)  
- Loeys‑Dietz syndrome  
- Ehlers‑Danlos syndrome (vascular type)  
- Cardiac tamponade  
- Cardiogenic shock  
- Acute myocardial ischemia  
- Myocardial infarction  
- Stroke  
- Organ malperfusion  
- Immediate mortality risk (per hour)  
- 30‑day mortality rate  
- International Registry of Acute Aortic Dissection (IRAD)  
- Society of Vascular Surgery (SVS)  
- Society of Thoracic Surgeons (STS)  
- Aortic disease guideline (ACC/AHA)  
- Aortic disease reporting standards  
- Aortic disease temporal classification  
- Vessel wall layers (intima, media, adventitia)  
- False lumen hemorrhage  
- True lumen involvement  
- Thoracic aorta  
- Aortic ascending aorta  
- Aortic type B dissection  
- Aortic true/false lumen tear mechanics  
- Malperfusion syndromes associated with aortic dissection  

These terms capture the key concepts related to heart and aortic disease presented in the text.

Page 14 Extracted Terms:
- Aortic dissection  
- DeBakey classification  
  - Type I (ascending to descending aorta)  
  - Type II (isolated ascending aorta)  
  - Type III (descending thoracic aorta)  
    - Type IIIa (isolated descending thoracic aorta)  
    - Type IIIb (descending thoracic aorta extending below the diaphragm)  
- Stanford classification  
  - Type A (involves ascending aorta)  
  - Type B (does not involve ascending aorta)  
- Non‑A‑non‑B dissection (European consensus)  
- SVS/STS 2020 classification  
  - Entry tear zones (zone 0, zone 1, etc.)  
  - AD (type A) with distal extent (e.g., A9)  
  - BPD (type B) with proximal/distal extent (e.g., B39)  
  - ID (indeterminate entry tear, e.g., I9)  
- Malperfusion syndrome  
- End‑organ ischemia  
- True lumen  
- False lumen  
- Transmural pressure  
- Elastic recoil  
- Medial smooth muscle  
- True lumen collapse  
- False lumen expansion  
- Thoracic arch pathologies  
- Mortality rate (increase to 20% by day 2, 25% by day 30)  
- Aortic arch  
- Ascending aorta  
- Descending aorta  
- Diaphragm  
- Intralaminar intimal tear  
- End‑organ perfusion  
- Acute aortic syndrome  
- Vascular surgery (SVS) and thoracic surgery (STS) guidelines  
- European Association for Cardio‑Thoracic Surgery (EACTS)  
- European Society for Vascular Surgery (ESVS)  
- Society of Thoracic Surgeons (STS)  

(Each item represents a key term or concept related to heart‑disease pathology, classification, or management as discussed in the guideline.)

Page 15 Extracted Terms:
- Aortic branches  
- Malperfusion  
- False lumen  
- True lumen  
- Aortic dissection  
- Intima (intimal tear)  
- Dissected intima septum  
- Ostia of a branch vessel  
- Dynamic obstruction  
- Static obstruction  
- Intramural hematoma (IMH)  
- Vasa vasorum  
- Aortic wall (medial layer)  
- Computed tomography angiography (CTA)  
- Magnetic resonance imaging (MRI)  
- Echocardiography  
- Penetrating atherosclerotic ulcer (PAU)  
- Atherosclerotic plaque  
- Aortic arch  
- Descending thoracic aorta  
- Ascending aorta  
- Atherosclerosis  
- Coronary arteries  
- Hypertension  
- Tobacco use  
- Chronic obstructive pulmonary disease (COPD)  
- Renal insufficiency  
- Connective tissue disorder  
- Pseudoaneurysm  
- Aortic rupture  
- Stenosis  
- Thrombosis (branch false lumen)  
- Branch vessel perfusion  
- Distal branch perfusion  
- Blood flow (absence in IMH)

Page 16 Extracted Terms:
- Aortic disease  
- Thoracoabdominal aortic aneurysm (TAAA)  
- Descending thoracic aortic aneurysm (TAA)  
- Endoleaks (type I‑V)  
- Endovascular stent‑grafting  
- Aneurysm repair  
- Morbidity  
- Mortality  
- Aortic imaging techniques  
- Aortic diameter measurement  
- Crawford classification of TAAA  
- Extent I – V classification (Crawford & Safi)  
- Lifelong surveillance imaging for endoleaks  
- Blood flow outside the graft (persistent endoleak)  
- Aneurysm sac thrombosis prevention

Page 17 Extracted Terms:
- Aortic disease  
- Aortic root  
- Ascending aorta  
- Aortic diameter (inner‑edge to inner‑edge, outer‑edge to outer‑edge, sinus‑to‑sinus)  
- Measurement protocols (electrocardiographic‑synchronized, perpendicular to flow axis, multiplanar reformats)  
- Aortic wall abnormalities  
- Atherosclerosis  
- Wall thickening / aortitis  
- Intramural hematoma (IMH)  
- Mural thrombus  
- Aortic root asymmetry  
- Bicuspid aortic valve  
- Tricuspid aortic valve  
- Aortic dissection  
- Aortic rupture  
- Aortic graft / endostent  
- Computed tomography (CT)  
- Magnetic resonance imaging (MRI)  
- Transthoracic echocardiography (TTE)  
- Transesophageal echocardiography (TEE)  
- Abdominal aortic ultrasound  
- 3‑dimensional (3D) imaging data sets  
- Radiation exposure / ionizing radiation dose  
- Contrast allergy  
- Renal function considerations  
- Hemodynamic stability  
- Sedation / patient tolerance  
- Institutional imaging availability  
- Multidetector CT scanners  
- Radionuclide imaging (indirectly referenced via radiation concerns)

Page 18 Extracted Terms:
- Aortic root  
- Ascending aorta  
- Aortic root diameter  
- Aortic dilation  
- Aortic aneurysm  
- Aortic dissection  
- Aortic rupture  
- Endoleak  
- Endoleak type Ia (proximal attachment site)  
- Endoleak type Ib (distal attachment site)  
- Endoleak type II (backfilling through branch vessels)  
- Endoleak type III (graft defect or component misalignment)  
- Endoleak type IV (leakage through graft wall porosity)  
- Endoleak type V (endotension)  
- Aortic sac  
- Branch vessels of the aorta  
- Aortic pressure  
- Transthoracic echocardiography (TTE)  
- Computed tomography (CT)  
- Magnetic resonance imaging (MRI)  
- Aortic size index (ASI)  
- Aortic height index (AHI)  
- Inner‑edge measurement  
- Leading‑edge measurement  
- Body‑size–adjusted normal limits  
- Prognostic importance of aortic dilation  
- Risk of adverse events (rupture, dissection, death)  
- Graft defect  
- Graft misalignment  
- Graft porosity  
- Endotension  
- Aortic sac thrombosis  
- Clinical statements (guidelines)

Page 19 Extracted Terms:
- Aortic disease  
- Aortic dilation  
- Aortic root  
- Ascending aorta  
- Aortic arch  
- Aortic aneurysm  
- Aortic pseudoaneurysm  
- Aortic dissection  
- Aortic rupture  
- Acute aortic syndrome  
- Intramural hematoma  
- Penetrating atherosclerotic ulcer  
- Intimal tear  
- Mural thrombus  
- Atherosclerosis  
- Diffuse thickening (aortitis)  
- Luminal stenosis  
- End-organ malperfusion  
- Interposition graft  
- Endovascular stent graft  
- Surgical repair  
- Aortic diameter  
- Aortic area (indexed to height)  
- Aortic length  
- Inner‑edge to inner‑edge measurement  
- Outer‑edge to outer‑edge measurement  
- Sinus‑to‑sinus measurement  
- Leading‑edge measurement  
- Maximal aortic diameter  
- Perpendicular measurement to aortic axis  
- Oblique imaging  
- ECG‑gated acquisition  
- Axial versus double‑oblique measurement  
- Computed tomography (CT)  
- Magnetic resonance imaging (MRI)  
- Transthoracic echocardiography (TTE)  
- Transesophageal echocardiography (TEE)  
- Abdominal aortic ultrasound (US)  
- Spatial resolution  
- Temporal resolution  
- Three‑dimensional dataset  
- Clinical risk factors (male sex, age, height, weight, traditional cardiovascular risk factors)

Page 20 Extracted Terms:
- Aortic Disease Guideline  
- ACC/AHA  
- Aortic aneurysm  
- Abdominal aortic aneurysm (AAA)  
- Acute aortic syndromes (AAS)  
- Aortic dissection  
- Intramural hematoma (IMH)  
- Penetrating atherosclerotic ulcer (PAU)  
- Aortic root  
- Ascending aorta  
- Thoracic aorta  
- Imaging modalities  
- Computed tomography (CT)  
- Computed tomography angiography (CTA)  
- Magnetic resonance imaging (MRI)  
- Echocardiography  
- Electrocardiographic‑gated imaging  
- Ultrasonography / ultrasound  
- Iodinated contrast  
- Contrast‑enhanced imaging  
- Renal toxicity / contrast‑induced nephropathy  
- Aortic wall changes (inflammation, thickening)  
- Ventricular function  
- Valve function  
- Flow quantification  
- Congenital aortic abnormalities  
- Serial imaging  
- Motion artifact  
- Measurement techniques (leading‑edge to leading‑edge, inner‑wall to inner‑wall)  
- Sinuses of Valsalva  
- Sinotubular junction  
- Proximal tubular ascending aorta

Page 21 Extracted Terms:
- ACC/AHA Aortic Disease Guideline  
- Aortic disease  
- Acute aortic pathology  
- Aortic arch  
- Aortic root  
- Aortic valve anatomy  
- Aortic valve function  
- Aortic valve regurgitation  
- Aortic dissection (AAS)  
- Aortic dilation  
- Aortic root dilation  
- Aortic arch branch vessels  
- Aortic arch branch vessels visualization  
- Coarctation of the aorta (CoA)  
- Patent ductus arteriosus  
- Left ventricular dysfunction  
- Cardiac tamponade  
- Computed tomography (CT) imaging  
- Magnetic resonance imaging (MRI)  
- Magnetic resonance angiography (MRA)  
- Gadolinium‑based contrast media  
- Nephrogenic systemic fibrosis  
- Cine gradient echo bright blood sequence  
- Spin echo dark blood sequence  
- Transthoracic echocardiography (TTE)  
- Transesophageal echocardiography (TEE)  
- Intravascular ultrasound (IVUS)  
- Intraluminal imaging  
- Thoracic aorta imaging  
- Endovascular repair  
- Endovascular management  
- True lumen flow  
- False lumen flow  
- Aortic size measurement  
- Aortic tortuosity  
- Plaque burden  
- Calcification  
- Branch vessel ostia  
- Intravascular filling defects (e.g., thrombus, dissection flap)  
- Landing zone assessment  
- Dissection flap  
- Sinus‑to‑sinus (S‑S) measurement  
- Sinus‑to‑commissure (S‑C) measurement  
- Aortic root area (A) measurement  
- Acoustic shadowing from trachea  
- Intragastric (intracaval) imaging terms related to vascular pathology.

Page 22 Extracted Terms:
- Aortic dissection  
- Abdominal aortic aneurysm (AAA)  
- Endovascular repair (including stent grafting)  
- Intravascular ultrasound (IVUS)  
- Endoleak  
- Aortocaval fistula  
- Mobile atheroma  
- Arterial stenosis  
- Mural thrombus  
- Aortic inflammation  
- Pseudoaneurysm  
- Contained rupture  
- Electro‑cardiographic (implied) imaging of cardiac structures  
- CT, MRI, and echocardiographic imaging of the aorta  
- Multidisciplinary aortic team  
- Coronary artery disease  
- Valvular heart disease  
- Cardiac transplantation  
- Mechanical circulatory support (e.g., ventricular assist devices)  
- Multidisciplinary heart valve team  
- High‑volume aortic/heart‑valve center  
- Intensive care unit (ICU) specialized in acute aortic/heart disease management

Page 23 Extracted Terms:
- Aortic disease  
- ACC/AHA Aortic Disease Guideline  
- Multidisciplinary team  
- Operative mortality  
- Thoracic aortic aneurysm (TAA)  
- Abdominal aortic aneurysm (AAA)  
- Endovascular repair  
- Open surgical repair  
- Aortic root procedures  
- Aortic valve procedures  
- Ascending aorta procedures  
- Proximal thoracic aortic surgery  
- Hospital procedural volume (quintiles)  
- Case volume (annual center volume)  
- Risk‑adjusted odds ratio (OR) for mortality  
- Mortality advantage with multidisciplinary programs  
- Surgical outcome improvement with high case volume  
- Mortality reduction at >20–25 or >50 procedures per year  
- Standard deviation (±2 SD) in regression analysis of mortality risk

Page 24 Extracted Terms:
**Key terms related to heart disease**

- Aortic disease  
- Acute aortic dissection  
- Type A aortic dissection  
- Thoracic aortic disease (TAD)  
- Aortic aneurysm (AAA)  
- Aortic root procedures  
- Open surgical repair  
- Endovascular repair  
- High‑volume surgeons / high‑volume centers  
- Multidisciplinary aortic teams  
- Shared decision‑making  
- Cardiovascular risks of pregnancy  
- Prophylactic aortic surgery  
- Mode of delivery (in pregnancy context)  
- Mortality rate (30‑day, overall)  
- Risk‑adjusted mortality rate (A/P ratio)  
- Cross‑clamp times  
- Case volume (center and surgeon)  
- Decision aids for aneurysm treatment  

These terms encapsulate the core concepts and clinical focus points discussed in the guideline excerpt.

Page 25 Extracted Terms:
**Key Terms Related to Heart Disease**

1. Aortic aneurysm  
2. Thoracic aortic aneurysm (TAA)  
3. Aortic root aneurysm  
4. Ascending aorta aneurysm  
5. Descending aorta aneurysm  
6. Aortic arch aneurysm  
7. Aortic dissection  
8. Type B aortic dissection  
9. Aortic root repair (valve‑sparing)  
10. Valved‐conduit aortic root replacement  
11. Thoracic endovascular aortic repair (TEVAR)  
12. Aortic aneurysm surveillance  
13. Aortic root index (z‑score)  
14. Aortic dilation  
15. Aortic disease  
16. Marfan syndrome  
17. Loeys‑Dietz syndrome  
18. Vascular Ehlers‑Danlos syndrome  
19. Smooth muscle dysfunction syndrome  
20. Bicuspid aortic valve (BAV)  
21. Coarctation of the aorta  
22. Turner syndrome  
23. Complex congenital heart defects  
24. Tetralogy of Fallot  
25. Transposition of the great vessels  
26. Truncus arteriosus  
27. Aortic valve disease  
28. Aortitis  
29. Giant cell arteritis  
30. Takayasu arteritis  
31. Behçet disease  
32. Immunoglobulin G4‑related disease  
33. Antineutrophil‑cytoplasmic‑antibody‑related disease  
34. Sarcoidosis  
35. Bacterial aortitis  
36. Fungal aortitis  
37. Syphilitic aortitis  
38. Traumatic aortic injury  
39. Hypertension (as a risk factor)  
40. Smoking (as a risk factor)  
41. Hypercholesterolemia (as a risk factor)  
42. Familial thoracic aortic aneurysm (no identified gene)  
43. Aortic root and ascending thoracic aorta aneurysms (heritable)  
44. Aortic root and ascending thoracic aorta aneurysms (degenerative)  
45. Aortic root and ascending thoracic aorta aneurysms (idiopathic)  
46. ACTA2  
47. MYH11  
48. PRKG1  
49. MYLK  
50. FLNA  
51. BGN  
52. LOX  
53. AAA (abdominal aortic aneurysm)  
54. Open surgical repair of AAA  
55. Endovascular repair of AAA  
56. Medical therapy for aortic disease  
57. Shared decision‑making (clinical process)  
58. Imaging modalities for aortic surveillance  
59. Conception and pregnancy in aortic disease  
60. Mode of delivery in aortic disease  

These terms capture the major anatomical locations, disease entities, syndromic associations, genetic markers, management strategies, and clinical decision‑making factors relevant to heart and aortic disease described in the guideline excerpt.

Page 26 Extracted Terms:
- Aortic disease  
- Aortic root  
- Ascending aorta  
- Aneurysms (aorta)  
- Aortic root aneurysm  
- Ascending aortic aneurysm  
- ACC/AHA guideline  
- Clinical statements  
- Clinical guidelines  
- Management of aortic aneurysm  
- Causative factors of aortic aneurysm  
- Circulation (journal reference)

Page 27 Extracted Terms:
- Thoracic aortic disease (TAD)  
- Thoracic aortic aneurysm and dissection (TAAD)  
- Loeys‑Dietz syndrome (LDS)  
- Marfan syndrome (MFS)  
- Vascular Ehlers‑Danlos syndrome (vEDS)  
- Variants of unknown significance (VUS)  
- Aneurysms (typically asymptomatic)  
- Genetic testing (for syndromic features, family history, early onset)  
- Syndromic features  
- Family history of TAD  
- Early age of disease onset  
- Thoracic aortic imaging  
- First‑degree relatives screening  
- Gene‑based management  
- Cascade testing of at‑risk relatives  
- Screening aortic imaging (if testing negative or VUS)

Page 28 Extracted Terms:
- Thoracic aortic aneurysm (TAA)  
- Ascending aortic aneurysm  
- Aortic root aneurysm  
- Descending thoracic aorta  
- Aortic dissection  
- Aortic calcification  
- Atheroma  
- Heritable thoracic aortic disease (HTAD)  
- Marfan syndrome  
- Loeys‑Dietz syndrome  
- Vascular Ehlers‑Danlos syndrome  
- Pathogenic variant  
- Likely pathogenic variant  
- Genetic testing  
- Genetic counseling  
- Cascade testing  
- Familial thoracic aortic disease (TAD)  
- Sporadic TAA  
- Degenerative aneurysm  
- Atherosclerosis risk factors  
- Hypertension  
- Diabetes mellitus  
- Smoking  
- Peripheral aneurysm  
- Intracranial aneurysm  
- Multigenerational family history of TAD  
- Unexplained sudden death  
- Imaging modalities: computed tomography (CT), magnetic resonance imaging (MRI), transthoracic echocardiography (TTE)  
- Medical management of aneurysm disease  
- Surgical and endovascular management of aneurysms  
- Risk factors for familial TAD (age < 60 y, family history, sudden death)

Page 29 Extracted Terms:
**Key heart‑disease terms extracted from the guideline text**

- Thoracic aortic aneurysm (TAA)  
- Ascending aortic aneurysm  
- Aortic root aneurysm  
- Aortic root dilation  
- Aortic dissection (type A, type B)  
- Thoracic aortic dissection (TAD)  
- Heritable thoracic aortic disease (HTAD)  
- Marfan syndrome  
- Loeys‑Dietz syndrome  
- Ehlers‑Danlos syndrome (vascular type)  
- Genetic testing (multigene panel)  
- Pathogenic variant (in HTAD genes)  
- Likely pathogenic variant (in HTAD genes)  
- Variant of uncertain significance (VUS)  
- Cascade genetic testing / screening  
- Imaging for aortic disease (CT, MRI, echocardiography)  
- Penetrance (high/low)  
- Autosomal dominant inheritance  
- Aortic root diameter < 5.0 cm (risk threshold)  
- Intracranial aneurysm  
- Occlusive vascular disease  
- Early‑onset stroke  
- Coronary artery disease  
- Aortic root distortion  
- Aortic enlargement (asymptomatic)  

**Genes highlighted as causing or contributing to HTAD**  

- FBN1  
- TGFBR1  
- TGFBR2  
- SMAD3  
- TGFB2  
- ACTA2  
- MYH11  
- MYLK  
- LOX  
- PRKG1  

These terms capture the primary cardiovascular conditions, diagnostic concepts, genetic risk factors, and associated vascular manifestations discussed in the guideline.

Page 30 Extracted Terms:
- Aortic root  
- Ascending aorta  
- Thoracic aortic aneurysm (TAA)  
- Thoracic aortic dissection (TAD)  
- Heritable thoracic aortic aneurysm/dissection (HTAD)  
- Nonsyndromic heritable thoracic aortic aneurysm (nsHTAD)  
- Marfan syndrome  
- Loeys‑Dietz syndrome  
- Extracellular matrix proteins  
- Transforming growth factor‑β (TGF‑β) pathway  
- Pathogenic variant  
- Genetic testing  
- Aortic imaging  
- Aortic diameter  
- Rapid aortic growth  
- Unexplained sudden death  
- Family history of aortic dissection  
- High‑risk features for adverse aortic events  
- Surgical repair (aortic root/ascending aorta)  
- Multidisciplinary aortic team  
- Cardiothoracic surgery  
- Aortic repair threshold (≥5.0 cm, ≥4.5 cm)  
- Aortic dilation  
- Aneurysm screening  
- Cardiovascular complications  
- Genetic penetrance  
- Early onset sporadic TAD  
- Aortic dissection risk assessment  
- Aortic repair timing  
- Aortic growth rate  
- Genetic causes of aortic disease  
- Systemic features of syndromic HTAD  
- Multiorgan phenotype  
- Aortic size at dissection or repair  
- Dissection at a small aortic diameter  
- Sudden death at age < 50 years  

Page 31 Extracted Terms:
**Key heart‑disease related terms extracted from the guideline text**

- Acute aortic dissection  
- Aortic rupture  
- Aortic root  
- Ascending aorta  
- Thoracic aortic aneurysm (TAA)  
- Thoracic aortic dissection (TAD)  
- Heritable thoracic aortic disease (HTAD)  
- Non‑segregating heritable thoracic aortic disease (nsHTAD)  
- Mendelian genetic variants  
- Prophylactic aortic surgery  
- Surgical threshold (e.g., 5.0 cm, 4.5 cm, 5.5 cm)  
- Multidisciplinary aortic team  
- Operative mortality  
- Life‑expectancy reduction  
- Aortic diameter  
- Aortic growth rate  
- Familial thoracic aortic aneurysm and dissection (FTAD)  
- Genetic testing for thoracic aortic disease  
- Lifelong surveillance  
- Acute presentation  
- Recurrent aortic reintervention  
- Revascularization failure  
- Marfan syndrome  
- Ectopia lentis (clinical sign of Marfan)  
- Echocardiographic imaging (TTE)  
- Computed tomography (CT) of the thoracic aorta  
- Magnetic resonance imaging (MRI) of the thoracic aorta  
- Aortic imaging surveillance schedule  
- Rate of aortic dilation  
- Sudden death risk  
- Age at aortic event  
- Aortic root aneurysm  
- Ascending aortic aneurysm  
- Aortic dissection thresholds  

These terms capture the core cardiovascular concepts, diagnostic approaches, risk stratification factors, and therapeutic strategies emphasized in the guideline text.

Page 32 Extracted Terms:
- Marfan syndrome  
- Aortic root dilation  
- Aortic root aneurysm  
- Type A aortic dissection  
- Type B aortic dissection  
- Aortic aneurysm  
- Thoracic aortic aneurysm (TAA)  
- Abdominal aortic aneurysm (AAA)  
- Aortic arch involvement  
- Ascending aorta dilation  
- Descending aorta dilation  
- Aortic root replacement  
- Surgical aortic root replacement  
- Prophylactic aortic root replacement  
- Beta blocker  
- Angiotensin receptor blocker (ARB)  
- Transthoracic echocardiography (TTE)  
- Transesophageal echocardiography (TEE)  
- Computed tomography (CT)  
- Magnetic resonance imaging (MRI)  
- Aortic diameter  
- Aortic growth rate  
- Heart rate  
- Myocardial contractility  
- Graft infection  
- Pseudoaneurysm  
- Aortic dissection distal to graft  
- Sinus of Valsalva

Page 33 Extracted Terms:
- Marfan syndrome  
- Aortic root  
- Aortic root diameter  
- Aortic root replacement  
- Ascending aorta  
- Aortic root and ascending aorta surgery  
- Valve‑sparing root replacement (VSRR)  
- Multidisciplinary aortic team  
- Aortic dissection  
- Aortic aneurysm  
- Aortic growth rate  
- Rapid aortic growth (≥ 0.3 cm/year)  
- Aortic dilation  
- Aortic root area / cross‑sectional aortic root area  
- Patient height ratio (aortic root area to height)  
- Prophylactic aortic root replacement  
- Survival benefit of elective aortic repair  
- Family history of aortic dissection  
- Diffuse aortic root and ascending aortic dilation  
- Vertebral arterial tortuosity  
- Beta‑blocker therapy  
- Losartan (angiotensin II type‑1 receptor blocker)  
- ARB (angiotensin receptor blocker)  
- Aortic surgery threshold (≥ 5.0 cm, ≥ 4.5 cm)  
- Clinical events (including aortic surgery, aortic dissection)  
- Aortic root growth rate  
- Aortic arch/hemiarch replacement (in some surgical centers)  
- Aortic root growth rate slowing with combination therapy  
- Aortic root replacement indications (rapid growth, family history, pregnancy, severe valve regurgitation, patient preference)  
- Prognostic factors for aortic complications in Marfan syndrome.

Page 34 Extracted Terms:
- Aortic diameters  
- Aortic event rates  
- Aortic dissection  
- Aortic root replacement  
- Prophylactic aortic root replacement  
- Composite valved graft conduit  
- Modified Bentall procedure  
- Valve‑sparing aortic root replacement (VSRR)  
- David procedure  
- Mechanical prosthetic aortic valve  
- Bioprosthetic aortic valve  
- Marfan syndrome  
- Aortic aneurysm  
- Aortic arch aneurysm  
- Descending thoracic aorta aneurysm  
- Abdominal aorta aneurysm  
- Aneurysmal segment replacement  
- Aortic arch replacement  
- Ascending aorta replacement  
- Aortic root diameter threshold (≥5.0 cm)  
- Aortic regurgitation (AR)  
- Left ventricular outflow tract (LVOT)  
- Aortic graft  
- Coronary artery reimplantation  
- Surgical risk assessment  
- Multidisciplinary aortic team  
- Imaging: transthoracic echocardiogram (TTE)  
- Imaging: magnetic resonance imaging (MRI)  
- Imaging: computed tomography (CT)  
- Surveillance imaging intervals  
- Loeys‑Dietz syndrome  
- Aortic tortuosity  
- Aortic rupture  
- Aortic growth rate  
- Family history of aortic disease.

Page 35 Extracted Terms:
- Loeys‑Dietz syndrome  
- Aortic root aneurysm  
- Ascending aortic aneurysm  
- Aortic dissection  
- Thoracic aortic disease (TAD)  
- Branch vessel aneurysm/aneurysmal disease  
- Cerebral aneurysm  
- Arterial tortuosity  
- Bicuspid aortic valve (BAV)  
- Transthoracic echocardiography (TTE)  
- Computed tomography (CT) imaging  
- Magnetic resonance imaging (MRI)  
- Aortic root diameter  
- Ascending aortic diameter  
- Aortic enlargement / dilation  
- Aortic size monitoring  
- Aortic surveillance imaging  
- Aortic surgery / repair  
- Beta blocker therapy  
- Angiotensin receptor blocker (ARB) therapy  
- Marfan syndrome  
- TGFBR1 (gene)  
- TGFBR2 (gene)  
- SMAD3 (gene)  
- TGFB2 (gene)  
- TGFB3 (gene)

Page 36 Extracted Terms:
- Loeys‑Dietz syndrome  
- Aortic dilation  
- Aortic root replacement  
- Ascending aortic replacement  
- Prophylactic aortic root replacement  
- Type A aortic dissection  
- Aortopathy  
- TGFBR1 pathogenic variant  
- TGFBR2 pathogenic variant  
- SMAD3 pathogenic variant  
- TGFB2 pathogenic variant  
- TGFB3 pathogenic variant  
- Beta blockers  
- Angiotensin‑II receptor blockers (ARBs)  
- Surgical threshold  
- Aortic diameter  
- Aortic growth rate  
- Extra‑aortic features  
- Family history (of aortic dissection)  
- Patient age  
- Patient sex  
- Physician and patient preferences  
- Craniosynostosis  
- Cleft palate  
- Hypertelorism  
- Bifid uvula  
- Arterial tortuosity  
- Translucent skin  
- Thoracic aortic disease  
- Aortic arch  
- Descending aorta  
- Abdominal aorta  
- Aortic branch vessels  
- Surgical risk  
- Aggressive aortopathy  
- Elective surgery  
- Elective aortic root replacement  
- Elective ascending aortic replacement  
- Prophylactic surgery  
- Progressive aneurysmal dilation  
- Multiple operative interventions  
- Imaging modality  
- Genetic variant  
- High‑risk features  
- Small body size  
- Aortic root diameter threshold  
- Aortic arch replacement  
- Descending aortic replacement  
- Abdominal aortic replacement  
- Aortic dissection risk  
- Aortic root diameter ≥ 4.0 cm  
- Aortic root diameter ≥ 4.5 cm  
- Aortic root diameter ≥ 5.0 cm  




Page 37 Extracted Terms:
- Aortic dissection  
- Aortic aneurysm  
- Aortic root replacement  
- Aortic dilation (aortic enlargement)  
- Aortic growth rate  
- Aortic diameter  
- Ascending aorta  
- Descending aorta  
- Aortic arch  
- Distal ascending aorta  
- Abdominal aorta  
- Coarctation of the aorta  
- Bicuspid aortic valve (BAV)  
- Loeys‑Dietz syndrome  
- Vascular Ehlers‑Danlos syndrome  
- Turner syndrome  
- Prophylactic aortic surgery  
- Aortic repair (open surgery, endovascular repair)  
- Surgical intervention for aortic aneurysm  
- Aortic surveillance imaging  
- Transthoracic echocardiography (TTE)  
- Cardiac magnetic resonance imaging (MRI)  
- Computed tomography (CT) angiography  
- Baseline MRI/CT for aorta and branches  
- Annual surveillance imaging  
- Interventional techniques (arterial embolization, endovascular therapy)  
- Beta‑blockers (celiprolol, vasodilatory beta‑blockers)  
- Angiotensin‑II receptor blockers (ARBs)  
- Multidisciplinary Aortic Team  
- ASI (aortic size index) – ratio of aortic diameter to body surface area  
- Pregnancy‑related cardiovascular risk in connective‑tissue disorders  
- Cesarean delivery (in vascular Ehlers‑Danlos syndrome)  
- Wound complications, vascular fragility, bleeding complications  
- Lifestyle modification for aortic disease  
- Avoidance of invasive procedures in fragile vasculature.

Page 38 Extracted Terms:
- Turner syndrome  
- Aortic dissection  
- Aortic dilation (aortic aneurysm)  
- Bicuspid aortic valve (BAV)  
- Aortic coarctation  
- Hypertension  
- Ascending aorta  
- Aortic root  
- Aortic diameter  
- Aortic size index (ASI) – indexed aortic diameter (cm / m²)  
- Body surface area (BSA)  
- TTE (transthoracic echocardiography)  
- Cardiac MRI  
- Surveillance imaging (routine aortic imaging)  
- Prophylactic surgical replacement (aortic root/ascending aorta)  
- Short stature (growth-related risk factor)  
- Z‑score for aortic diameter (Turner‑specific)  
- Imaging intervals (5‑year, 10‑year, 2‑3‑year, annual)  
- Risk‑factor categories (aortic dilation, BAV, aortic coarctation, hypertension)  
- Aortic valve function assessment  
- Retrospective series / case study data (guideline evidence)

Page 39 Extracted Terms:
- Turner syndrome  
- Aortic dissection (type A, type B)  
- Aortic disease / thoracic aortic disease (TAD)  
- Aortic dilation / aortic aneurysm  
- Aortic diameter (> 4.0 cm)  
- Aortic size index (ASI)  
- Aortic root  
- Ascending aorta  
- Descending aorta  
- Coarctation of the aorta (CoA)  
- Bicuspid aortic valve (BAV)  
- Aortic valve dysfunction  
- Hypertension (HTN)  
- Left ventricular hypertrophy (LVH)  
- Coronary artery disease (CAD)  
- Cerebrovascular disease  
- ACTA2, PRKG1, MYH11, MYLK, LOX (pathogenic gene variants)  
- Autosomal dominant inheritance  
- Highly penetrant risk  
- Transthoracic echocardiography (TTE)  
- Computed tomography (CT)  
- Magnetic resonance imaging (MRI)  
- Surveillance imaging / annual imaging  
- Beta‑blocker therapy  
- Aortic surgical intervention  
- Aortic monitoring protocol (for girls and women ≥ 15 years)  
- Aortic monitoring frequency (surveillance frequency)  
- Aortic size measurement thresholds  
- Aortic surgical criteria (risk of aortic dissection)

Page 40 Extracted Terms:
- Bicuspid Aortic Valve (BAV)  
- BAV Aortopathy  
- Aortic dilation  
- Aortic root aneurysm  
- Ascending aorta aneurysm  
- Aortic dissection (type A, type B)  
- Thoracic aorta  
- Aortic arch dilation  
- Aortic coarctation  
- Heritable Thoracic Aortic Disease (HTAD)  
- Nonsyndromic HTAD  
- Marfan syndrome (mild systemic features)  
- Loeys‑Dietz syndrome  
- Genetic variants: ACTA2, PRKG1, MYH11, MYLK, LOX  
- Transthoracic echocardiography (TTE)  
- Computed tomography (CT) of the thoracic aorta  
- Magnetic resonance imaging (MRI) of the thoracic aorta  
- Aortic repair (surgical or prophylactic)  
- Aortic diameter thresholds (< 4.5 cm, < 5.0 cm, 4.5 cm, 4.2 cm, 4.0 cm)  
- Aortic growth rate (≈ 0.3 cm/year)  
- Family history of type A aortic dissection  
- Valve morphology and function (stenosis, regurgitation)  
- Infective endocarditis (risk factor)  
- Screening of first‑degree relatives  
- Lifelong surveillance imaging of the aorta  
- Genetic evaluation for high‑risk phenotypes  
- Surgical thresholds for prophylactic aortic root and ascending aorta replacement.

Page 41 Extracted Terms:
- Bicuspid aortic valve (BAV)  
- Aortic dilation  
- Aortic root dilation  
- Ascending aorta dilation  
- Aortic arch dilation  
- Proximal descending aorta dilation  
- Aortic coarctation  
- Aortic dissection  
- Aortic aneurysm  
- Aortic rupture  
- Transthoracic echocardiography (TTE)  
- Transesophageal echocardiography (TEE)  
- Cardiac magnetic resonance imaging (MRI)  
- Cardiac computed tomography (CT)  
- Cardiac computed tomography angiography (CTA)  
- Genetic testing  
- Loeys‑Dietz syndrome  
- TGFBR1 mutation  
- TGFBR2 mutation  
- SMAD3 mutation  
- TGFB2 mutation  
- TGFB3 mutation  
- NOTCH1 mutation  
- ACTA2 mutation  
- MAT2A mutation  
- SMAD6 mutation  
- LOX gene mutation  
- Heritable thoracic aortic disease (HTAD)  
- Aortopathy  
- Autosomal dominant inheritance  
- Incomplete penetrance  
- Obligates carriers  
- First‑degree relatives  
- Cascade evaluation  
- Aortic valve repair  
- Aortic valve replacement (AVR)  
- Aortic regurgitation (AR)  
- Aortic stenosis (AS)  
- Lifelong surveillance imaging  
- Imaging interval based on aortic diameter and growth rate  
- Aortic event (dissection, aneurysm >5 cm, surgery)  
- Cost‑effective screening of relatives  
- TTE screening for BAV and aortopathy  
- Risk stratification for aortic disease  

*(Each term represents a key concept or entity related to heart disease as discussed in the guideline excerpt.)*

Page 42 Extracted Terms:
- Bicuspid aortic valve (BAV)  
- Aortic valve replacement (AVR)  
- Aortic regurgitation (AR)  
- Aortic root dilation  
- Ascending aortic diameter  
- Thoracic aortic aneurysm (TAA)  
- Aortic dissection  
- Aortic growth rate  
- Aortic cross‑sectional area  
- Aortic root replacement (including VSRR)  
- Ascending aortic replacement  
- Surgical thresholds for aortic surgery  
- Multidisciplinary aortic team  
- BAV aortopathy  
- Root phenotype aortopathy  
- Aortic coarctation  
- Family history of aortic dissection  
- Rapid aortic growth (≥ 0.3 cm/y)  
- Hinge points for ascending aorta (≥ 5.25 – 5.75 cm)  
- Prophylactic aortic repair  
- Aortic diameter ≥ 4.0 cm (dilated)  
- Aortic diameter ≥ 4.5 cm (considered for concomitant surgery)  
- Aortic diameter ≥ 5.0 – 5.4 cm (indicates higher risk)  
- Aortic diameter ≥ 5.5 cm (surgical recommendation)  
- Aortic root or ascending aortic area to height ratio (≥ 10 cm²/m)  
- Adverse aortic events  
- Surveillance imaging for aortic monitoring  

These terms capture the key concepts related to heart disease and aortic pathology discussed in the guideline excerpt.

Page 43 Extracted Terms:
- Aortic disease  
- Aortic root replacement  
- Elective aortic root replacement  
- Aortic root dilation  
- Bicuspid aortic valve (BAV)  
- Aortic valve intervention (AVR)  
- Aortic stenosis  
- Aortic regurgitation (AR)  
- Aortic aneurysm (AA)  
- Aortic dilation  
- Aortic dissection  
- Abdominal aortic aneurysm (AAA)  
- Thoracic aortic aneurysmal disease  
- Inflammatory aortitis  
- Takayasu arteritis  
- Giant cell arteritis (GCA)  
- Concomitant prophylactic aortic repair  
- Medial degeneration of the aortic wall  
- Intraluminal thrombus  
- Oxidative stress  
- Smooth muscle cell apoptosis  
- Proteolysis of the extracellular matrix  
- Adventitial inflammation  
- Surgical risk (low, moderate, high)  
- Long life expectancy  
- Ultrasound screening for AAA  
- Screening recommendations for AAA  
- Common risk factors for AAA  
- Older age  
- Male sex  
- Smoking history (≥100 cigarettes)  
- Hypertension  
- Hyperlipidemia  
- Family history of AAA  
- Inherited vascular connective tissue disorder  
- Atherosclerotic cardiovascular disease  
- Genetic aortopathies  
- Growth rate of AAA (mm/year)  
- Rupture of aortic aneurysm  
- AAA‑related mortality  
- AAA‑related rupture  
- Aortic wall remodeling  
- Aortic aneurysm prevalence among relatives  
- Aortic aneurysm screening thresholds (e.g., ≥65 yrs)  
- Aortic aneurysm screening age limits (e.g., <65 yrs with risk factors)  
- AAA management and repair strategies.

Page 44 Extracted Terms:
- Abdominal Aortic Aneurysm (AAA)  
- Aortic aneurysm growth  
- Aortic dissection  
- Aortic rupture  
- Marfan syndrome  
- Loeys‑Dietz syndrome  
- Bicuspid aortic valve (BAV)  
- Heritable thoracic aortic disease (HTAD)  
- Screening (ultrasound screening)  
- Smoking (risk factor for AAA)  
- Prevalence  
- Risk factor  
- Surgical risk  
- Mortality 

Page 45 Extracted Terms:
- Aortic aneurysm  
- Thoracic aortic aneurysm (TAA)  
- Abdominal aortic aneurysm (AAA)  
- Aortic root growth  
- Aortic arch aneurysm  
- Ascending aortic aneurysm  
- Descending aortic aneurysm  
- Bicuspid aortic valve (BAV)  
- Tricuspid aortic valve (TAV)  
- Aortic dilation  
- Aortic dissection  
- Aortic rupture  
- Aortic repair  
- Blood pressure (BP) management  
- Systolic blood pressure (SBP)  
- Diastolic blood pressure (DBP)  
- Beta blockers  
- Angiotensin‑II receptor blockers (ARBs)  
- Antihypertensive therapy  
- Statins  
- Myocardial infarction  
- Stroke  
- Hypertension  
- Vascular‑related adverse events  
- All‑cause mortality  
- SPRINT (Systolic Blood Pressure Intervention Trial)  
- Marfan syndrome  
- Genetic aortopathies  
- Proteolysis pathways  
- Medial degeneration  
- Shear stress  
- Inflammatory pathways  
- Atherosclerotic pathways  
- ACC/AHA guideline  
- Clinical risk factors  
- Non‑aortic cardiovascular events  
- Intensive BP control  
- Optimal BP thresholds  
- Randomized clinical trials (RCTs)  
- Medical therapy for aortic aneurysm disease  
- Lifestyle modification (e.g., smoking cessation)  
- Angiotensin‑II receptor blockers (ARB) therapy  
- Beta‑blocker therapy as adjunct to ARB  
- BP targets (≤130 mm Hg systolic, ≤80 mm Hg diastolic)  
- Intensive SBP goal (<120 mm Hg)  
- Aortic wall stress  
- Aortic growth rate.

Page 46 Extracted Terms:
- Aortic aneurysm  
- Thoracic aortic aneurysm (TAA)  
- Aortic root growth  
- Aortic dissection  
- Aortic complications  
- Aortic root  
- Aortic disease (TAD)  
- Marfan syndrome  
- Bicuspid aortic valve (BAV)  
- Atherosclerosis  
- Atherosclerotic cardiovascular disease (ASCVD)  
- Cardiovascular events  
- Myocardial infarction  
- Stroke  
- Peripheral artery disease  
- Thoracic endovascular aortic repair (TEVAR)  
- Beta‑blockers (β‑blockers)  
- Propranolol  
- β‑adrenergic blocking drugs  
- Angiotensin‑II receptor blockers (ARBs)  
- Valsartan  
- Statins  
- High‑intensity statin therapy  
- Moderate‑intensity statin therapy  
- Low‑density lipoprotein (LDL)  
- Cholesterol lowering  
- Matrix metalloproteinase (MMP) activity  
- Pleiotropic effects of statins  
- 2017 Hypertension Clinical Practice Guideline  
- 2010 ACC/AHA thoracic aortic disease guidelines  
- 2018 AHA/ACC Guideline on the Management of Blood Cholesterol  
- 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease  
- National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III)  
- Cholesterol Treatment Trialists’ Collaboration  
- Level of Evidence (LOE)  
- Correlation of Risk (COR)

Page 47 Extracted Terms:
- Thoracic aortic aneurysm (TAA)  
- Abdominal aortic aneurysm (AAA)  
- Atherosclerotic TAA  
- Penetrating atherosclerotic ulcer (PAU)  
- Aortic atheroma  
- Atherosclerotic aortic disease  
- Aortic aneurysms (general)  
- Coronary artery disease (CAD)  
- Myocardial infarction  
- Stroke  
- Cardiovascular events  
- Blood pressure (BP)  
- Systolic BP (SBP)  
- Diastolic BP (DBP)  
- Hypertension  
- Antihypertensive medication  
- Beta blockers  
- Renin‑angiotensin system agents  
- Antiplatelet therapy  
- Low‑dose aspirin (75–162 mg/d)  
- Cardiovascular risk factor modification  
- Smoking cessation  
- Secondhand smoke exposure  
- E‑cigarettes  
- Nicotine replacement therapy  
- Bupropion  
- Varenicline  
- 5 A’s (Ask, Advise, Assess, Assist, Arrange)  

These terms capture the key heart‑related concepts discussed in the guideline excerpt.

Page 48 Extracted Terms:
- Systolic blood pressure (SBP)  
- Intensive BP control (<120 mm Hg)  
- Aortic aneurysm (AAA)  
- Aortic atherosclerosis  
- Abdominal aortic aneurysm (AAA)  
- Peripheral artery disease (PAD)  
- Atherosclerotic cardiovascular disease (ASCVD)  
- Coronary artery disease (CAD) equivalent  
- Statin therapy (moderate/high intensity)  
- Low‑density lipoprotein (LDL)  
- Blood cholesterol  
- Myocardial infarction (MI)  
- Stroke  
- Cardiovascular events  
- Perioperative outcomes  
- Smoking cessation  
- Nicotine replacement therapy  
- Bupropion  
- Varenicline  
- Matrix metalloproteinase‑9 (MMP‑9)  
- Interleukin‑6 (IL‑6)  
- 5A’s (Ask, Advise, Assess, Assist, Arrange)  
- Aortic repair (surgical, endovascular)  
- EuroSTAR registry  
- Ruptured AAA  
- AAA growth rate  
- Cardiovascular mortality  
- Non‑coronary atherosclerotic disease  

These are the key terms related to heart disease and cardiovascular health identified in the guideline text.

Page 49 Extracted Terms:
- Abdominal aortic aneurysm (AAA)  
- Thoracic aortic dilation (TAD)  
- Thoracic aortic aneurysm (TAA)  
- Aortic valve anatomy  
- Aortic valve function  
- Aortic enlargement / growth rate  
- Antithrombotic therapy (including antiplatelet therapy)  
- Low‑dose aspirin (75–162 mg daily)  
- Atherosclerotic aortic disease  
- Atheroma  
- Penetrating aortic ulcer (PAU)  
- Intraluminal thrombus  
- Platelet activation  
- Inflammatory cells (within thrombus)  
- Fibrin (matrix of thrombus)  
- Cardiovascular events (e.g., stroke, myocardial infarction, coronary artery disease, cardiovascular mortality)  
- Coronary artery disease equivalent  
- Smoking cessation (risk factor reduction)  
- E‑cigarette use (vascular remodeling)  
- Transthoracic echocardiography (TTE)  
- Transesophageal echocardiography (TEE)  
- Computed tomography (CT) of the aorta  
- Magnetic resonance imaging (MRI) of the aorta  
- ACC/AHA guidelines for aortic disease  
- AHA/ACC secondary‑prevention guidelines for atherosclerotic vascular disease.

Page 50 Extracted Terms:
- Aortic root
- Ascending aortic
- Aortic diameter
- Aneurysm (aortic aneurysm)
- Aortic aneurysm (AAA)
- Abdominal aortic dilation
- Surgical threshold
- Aneurysm cause
- Electrocardiographic‑gated imaging
- Transthoracic echocardiography (TTE)
- Computed tomography (CT)
- Magnetic resonance imaging (MRI)
- Ultrasound
- Interval change
- Aortic growth rate
- Surveillance imaging
- Preoperative planning
- Risk of rupture
- Rupture threshold (≥5.5 cm men, ≥5.0 cm women)

Page 51 Extracted Terms:
- Aortic aneurysm  
- Aortic root aneurysm  
- Ascending aortic aneurysm  
- Thoracic aortic aneurysm (TAA)  
- Abdominal aortic aneurysm (AAA)  
- Juxtarenal aorta  
- Infrarenal aorta  
- Aortic arch  
- Thoracoabdominal aorta  
- Aortic dissection  
- Aortic rupture  
- Aortic-related death  
- Aneurysmal sac  
- Prosthetic graft  
- Endovascular stent graft  
- Endovascular repair  
- Open aortic surgery  
- Aortic valve repair  
- Tricuspid aortic valve replacement  
- Aortic valve replacement  
- Computed Tomography (CT) imaging  
- Tomographic imaging  
- Aortic diameter  
- Maximum aortic diameter  
- Aortic wall stress  
- Wall shear stress  
- Aortic cross‑sectional area  
- Aortic area/height ratio  
- Aortic surface index (ASI)  
- Aortic height index (AHI)  
- Multidisciplinary Aortic Team  
- FDA‑approved stent graft devices  
- Investigational stent graft devices  
- Physician‑ and industry‑sponsored clinical trials  
- Long‑term surveillance after endovascular repair  
- Aneurysm sac enlargement risk  
- Growth rate of an aneurysm (≥0.3 cm/year, ≥0.5 cm/yr)  
- Aortic root or ascending aorta surgical indications  
- Aortic root or ascending aorta non‑surgical indications  
- Height >1 standard deviation criterion  
- BSA (body surface area) indexed parameters  
- LaPlace’s law in aortic wall stress  
- Wall strength vs. wall stress dynamics  
- Risk of adverse aortic events (dissection, rupture, sudden death)

Page 52 Extracted Terms:
Aortic aneurysm  
Aortic dissection (acute type A)  
Ascending thoracic aorta  
Aortic root  
Maximum aortic diameter  
Bicuspid aortic valve (BAV)  
Tricuspid aortic valve  
Valve repair (aortic)  
Valve replacement (aortic)  
Aortic root replacement  
Cardiac surgery  
Surgical repair (aortic)  
Concomitant aortic surgery  
Prophylactic aortic replacement  
Growth rate (aneurysm)  
Rupture (aortic)  
Mortality (elective surgery)  
Risk prediction (aortic disease)  
Multidisciplinary Aortic Team  
Medical surveillance (aortic)  
Cardiac‑gated CT  
MRI (aortic imaging)  
Centerline measurement technique  
Prospective multicenter RCT (aortic)  
Genetic aortic disorder  
Aortic expansion  
Aortic diameter threshold (5.0 cm, 5.5 cm)

Page 53 Extracted Terms:
- aortic diameter  
- aortic area  
- aortic stiffness  
- peak aortic wall stress  
- cross‑sectional aortic area to height ratio  
- ascending aortic aneurysm (TAA)  
- aortic root aneurysm  
- tricuspid aortic valve (tricuspid)  
- bicuspid aortic valve (BAV)  
- aortic root replacement  
- ascending aorta replacement  
- aortic valve repair  
- aortic valve replacement  
- mechanical valve  
- biological valve  
- valve‑sparing aortic root replacement  
- valved conduit  
- aortic dissection  
- aortic rupture  
- sudden death  
- prophylactic repair  
- thoracic aortic surgery  
- operative mortality  
- STS database  
- Multidisciplinary Aortic Team  
- aortic diameter to BSA ratio (ASI)  
- aortic diameter to height ratio (AHI)  
- aortic event  
- surgical threshold  
- surgical approach  
- prophylactic intervention  
- ascending thoracic aortic graft  
- aortic root replacement surgical criteria  

Page 54 Extracted Terms:
- Aortic arch aneurysm  
- Aortic root replacement  
- Valve‑sparing aortic root replacement  
- Aortic root aneurysm  
- Reimplantation technique  
- Remodeling technique  
- Open surgical replacement  
- Hemiarch replacement  
- Elephant trunk procedure  
- Hybrid approach  
- Endovascular approach  
- Hypothermic circulatory arrest  
- Branched graft  
- Cardiopulmonary bypass  
- Cerebral perfusion (antegrade, selective antegrade, retrograde)  
- Neuroprotection  
- Aortic diameter  
- Intervention threshold  
- Operative risk (low, intermediate, high)  
- Aneurysmal disease extension (proximal arch, ascending aorta, descending thoracic aorta)  
- Aortic dissection  
- Ortner’s syndrome  
- Dysphagia aortica  
- Tracheal compression  
- Esophageal compression  
- Superior vena cava syndrome  
- Thoracic aortic aneurysm  
- Aortic arch pathology  
- Aortic arch dilation  
- Aortic aneurysm symptoms (chest pain, fatigue, neck/jaw/back pain)  
- Aortic aneurysm risk assessment  
- Aortic arch repair techniques  
- Aortic arch replacement strategies

Page 55 Extracted Terms:
- Aortic disease  
- Thoracic aortic aneurysm (TAA)  
- Descending thoracic aortic aneurysm  
- Aortic arch  
- Open repair  
- Endovascular repair  
- TEVAR (thoracic endovascular aortic repair)  
- Frozen elephant trunk  
- Elephant trunk  
- Endoleak (Type I / Type Ia)  
- Aneurysm rupture  
- Aortic dissection  
- Marfan syndrome  
- Loeys‑Dietz syndrome  
- Vascular Ehlers‑Danlos syndrome  
- Heritable thoracic aortic disease (HTAD)  
- Saccular aneurysm  
- Symptomatic aneurysm  
- Infectious aneurysm  
- Aneurysm growth (≥ 0.5 cm / yr)  
- Size threshold for repair (≥ 5.5 cm, < 5.5 cm with risk factors)  
- Diameter of aorta (cm)  
- Perioperative morbidity  
- Mortality  
- Advanced age  
- Pre‑operative renal insufficiency  
- Genetic aortopathies  
- Landing zone  
- Endograft  
- Hybrid approach  
- Debranching  
- Aneurysm‑related events  
- Surveillance imaging  
- Monitoring  
- Surgical repair  
- Hybrid endovascular approach  
- Endovascular experience  
- Investigational devices  
- Morbidity  
- Survival (5‑year survival, event‑free survival)

Page 56 Extracted Terms:
- Aortic aneurysm  
- Thoracic aortic aneurysm (TAA)  
- Aortic dissection  
- Aortic rupture  
- Thoracic endovascular aortic repair (TEVAR)  
- Open surgical repair of aorta  
- Rapid aortic growth (≥ 0.5 cm / year)  
- Saccular aneurysm morphology  
- Infected aneurysm  
- Marfan syndrome  
- Loeys‑Dietz syndrome  
- Vascular Ehlers‑Danlos syndrome  
- Connective tissue disorder (CTD)  
- Hypertension‑associated aortic disease (HTAD)  
- High‑risk features of rupture  
- Perioperative morbidity  
- Perioperative mortality  
- Frailty  
- Chronic obstructive pulmonary disease (COPD)  
- Forced expiratory volume in 1 second (FEV1)  
- Advanced age  
- Preoperative renal insufficiency / stage 3 chronic kidney disease (CKD)  
- Hemodialysis  
- Previous stroke  
- Iliac access  
- Zone 1/2 landing for thoracic stent graft  
- Thoracoabdominal extent of aneurysm  
- Reintervention rate after TEVAR  
- Follow‑up aneurysm‑related mortality  
- 5‑year survival after aortic repair  
- Volume‑outcomes relationship for open repair  
- Aortic diameter thresholds (> 6 cm, ≥ 5.5 cm)  
- Symptomatic aneurysm  
- Aortic‑related events (rupture or dissection)

Page 57 Extracted Terms:
- TEVAR (Thoracic Endovascular Aneurysm Repair)  
- Thoracic endograft / endovascular repair  
- Open surgical aortic repair  
- Thoracic aortic aneurysm (TAA) / descending TAA  
- Aneurysm-related mortality  
- Aneurysm-related reintervention  
- Major adverse event rate  
- Perioperative morbidity  
- Hospital length of stay  
- Survival (30‑day, 1‑year, 5‑year, 10‑year)  
- High‑volume vs. low‑volume surgical centers  
- Left subclavian artery coverage  
- Subclavian artery revascularization  
- Spinal cord injury (SCI)  
- Stroke risk / thrombo‑embolic complications  
- Vertebrobasilar insufficiency  
- Left internal mammary artery (LIMA) coronary bypass graft  
- Coronary artery bypass graft (CABG)  
- Left upper‑extremity dialysis access  
- Iliac artery graft conduit  
- Endograft sizing  
- Clinical device trial data  
- Medicare claims registry data  
- Retrospective cohort study  
- Registry study (GREAT, MEDPAR)

Page 58 Extracted Terms:
- Thoracic endovascular aortic repair (TEVAR)  
- Thoracic aortic aneurysm (TAA)  
- Left subclavian artery  
- Left subclavian artery coverage  
- Subclavian artery revascularization  
- Stroke  
- Spinal cord ischemia (SCI)  
- Vertebrobasilar insufficiency  
- Left internal mammary artery (LIMA)  
- Left anterior descending artery (LAD)  
- Coronary artery bypass graft (CABG)  
- Visceral ischemia  
- Celiac artery  
- Superior mesenteric artery (SMA)  
- Aneurysm‑related mortality  
- Open aortic repair  
- Myocardial infarction  
- Perioperative morbidity  
- Perioperative mortality  
- Composite endpoint  
- Endograft migration  
- Endograft stenosis  
- Collateral circulation management  




Page 59 Extracted Terms:
- Thoracic endovascular aortic repair (TEVAR)  
- Thoracic aortic aneurysm (TAA)  
- Thoracoabdominal aortic aneurysm (TAAA)  
- Endovascular stent‑graft delivery system  
- Iliac artery/iliofemoral access  
- Computed tomography angiography (CTA)  
- Percutaneous femoral access  
- Open surgical cutdown  
- Subclavian artery coverage  
- Celiac artery coverage  
- Aortic rupture  
- Aortic dissection  
- Aneurysm size threshold (≥ 6.0 cm, ≥ 5.5 cm)  
- Rapid aneurysm growth (≥ 0.5 cm/y)  
- Symptomatic aneurysm  
- Saccular aneurysm  
- Penetrating atherosclerotic ulcer  
- Vascular complications (access‑related)  
- Multidisciplinary aortic team  
- Degenerative TAAA  
- Endovascular techniques (e.g., vessel stenosis treatment)

Page 60 Extracted Terms:
- Aortic aneurysm  
- Thoracic aortic aneurysm (TAAA)  
- Thoracoabdominal aortic aneurysm (TAAA)  
- Aortic dissection  
- Aortic rupture  
- Endovascular repair  
- Open surgical repair  
- Fenestrated stent graft  
- Branched stent graft  
- Surgical threshold (aortic diameter)  
- Multidisciplinary Aortic Team  
- Operative mortality  
- Aortic‑related events  
- Aortic‑related death  
- Hemodynamic stability  
- Marfan syndrome  
- Loeys‑Dietz syndrome  
- Ehlers‑Danlos syndrome (vascular type)  
- Rapid aneurysm growth  
- Symptoms of aneurysm expansion  
- Aortic surveillance imaging  
- Aortic diameter  
- Left ventricular ejection fraction (LVEF)  
- Preoperative left ventricular dysfunction  
- Preoperative renal dysfunction  
- Chronic obstructive pulmonary disease (COPD)  
- Advanced age  
- Endovascular stent grafts  
- Deep hypothermic circulatory arrest  
- Spinal cord ischemia (SCI)  
- Post‑operative hemodialysis  
- Investigational device exemption (IDE)  
- FDA‑approved devices (for endovascular TAAA repair)

Page 61 Extracted Terms:
- Thoracoabdominal aortic aneurysm (TAAA)  
- Aortic aneurysm  
- Endovascular repair  
- Open aortic repair  
- Stent graft  
- Fenestrated‑branched endovascular aortic repair (FEVAR)  
- Off‑the‑shelf branched repair  
- Customized grafts  
- Spinal cord ischemia (SCI)  
- Spinal cord dysfunction  
- Stroke  
- Cerebrospinal fluid drainage  
- Hemodynamic instability  
- Mean arterial pressure (MAP)  
- Hemoglobin targeting (>10 g/dL)  
- Volume resuscitation  
- Aortic reintervention  
- Long‑term survival / actuarial survival  
- Multidisciplinary aortic team  
- Marfan syndrome  
- Loeys‑Dietz syndrome  
- Vascular Ehlers‑Danlos syndrome  
- End‑organ perfusion  
- Technical success rate  
- Operative mortality rate  
- High‑risk patient selection for aortic procedures  
- Spinal cord protection strategies  
- Perioperative morbidity and complications of aortic repair  

Page 62 Extracted Terms:
- Thoracic aortic aneurysm (TAAA / TAAA)  
- Open aortic repair  
- Endovascular aortic repair  
- Cerebrospinal fluid drainage (CSFD)  
- Spinal cord injury (SCI)  
- Paraplegia  
- Paraparesis  
- Cardiac complications (post‑operative cardiac events)  
- Atrial fibrillation  
- Hypovolemia  
- Hemorrhage  
- Infection  
- Hypothermic circulatory arrest  
- Left heart bypass  
- Mean arterial pressure (MAP)  
- Spinal cord perfusion pressure (SCPP)  
- Cardiac mortality / short‑ and long‑term cardiac survival  
- Cardiac perfusion / myocardial oxygen delivery  

These terms capture the heart‑related concepts discussed in the guideline excerpt.

Page 63 Extracted Terms:
- Left heart bypass circuit  
- Cardiac complications (e.g., increased cardiac events, 30‑day mortality)  
- Percutaneous closure devices  
- Ultrasound‑guided percutaneous access  
- Common femoral artery (access site for cardiac‑related endovascular procedures)  
- Local anesthesia (preferred to reduce peri‑operative mortality in cardiac patients)  
- General anesthesia (associated with higher peri‑operative mortality)  
- Permissive hypotension (used in hemodynamically unstable cardiac/vascular emergencies)

Page 64 Extracted Terms:
Key terms related to heart disease found in the text:

- Abdominal aortic aneurysm (AAA)  
- Ruptured abdominal aortic aneurysm (rAAA)  
- Endovascular aortic repair (rEVAR / EVAR)  
- Open aortic repair  
- Endovascular repair  
- Endovascular balloon occlusion  
- Computed tomography angiography (CTA)  
- Arterial phase imaging  
- Percutaneous / off‑label endovascular devices  
- General anesthesia  
- Local anesthesia  
- Permissive hypotension  
- Systolic blood pressure (SBP) 60–90 mm Hg  
- Hemorrhagic shock  
- Fluid management in shock  
- Perioperative death  
- Long‑term complications  
- Mortality rate  
- Survival benefit  
- Inflammatory response  
- Body temperature regulation  
- Blood pressure (BP)  
- Aneurysm diameter thresholds (≥5.5 cm in men, ≥5.0 cm in women)  
- Rupture protocols (early imaging, rapid transfer, imaging‑guided repair)

Page 65 Extracted Terms:
- Abdominal aortic aneurysm (AAA)  
- Unruptured AAA  
- Rupture  
- Aneurysm repair  
- Saccular aneurysm  
- Fusiform aneurysm  
- Maximum diameter  
- Size thresholds for repair  
- Aortic size index (ASI)  
- Body surface area (BSA)  
- Aortic indexing  
- UKSAT (UK Small Aneurysm Trial)  
- ADAM (Aneurysm Detection and Management) trial  
- CAESAR (Comparison of surveillance vs. Aortic Endografting for Small Aneurysm Repair)  
- PIVOTAL (Positive Impact of endoVascular Options for Treating Aneurysm early)  
- Endovascular repair  
- Open aneurysm repair  
- Infrarenal AAA  
- Hemodynamic monitoring  
- Intensive Care Unit (ICU) admission  
- Blood‑pressure (BP) control  
- Symptomatic aneurysm  
- Back pain  
- Abdominal pain  
- Flank pain  
- Radiating groin pain  
- Blue‑toe syndrome  
- Obstructive uropathy  
- Reintervention  
- Survival benefit  
- Mortality  
- Morbidity  
- Risk of operative intervention  
- Risk of rupture  
- Gender differences in rupture risk  
- Repair threshold (≥5.5 cm for men, ≥5.0 cm for women)  
- Aneurysm growth rate (>0.5 cm in 6 months)  
- Surveillance strategy  
- Early repair strategy  
- Cardiopulmonary status optimization

Page 66 Extracted Terms:
- Abdominal aortic aneurysm (AAA)  
- Aortic aneurysm  
- Saccular AAA  
- Aneurysm growth rate  
- Aneurysm rupture  
- Endovascular aneurysm repair (EVAR)  
- Open infrarenal aortic repair  
- Fenestrated endovascular device  
- FDA‑approved fenestrated device  
- Manufacturer’s instructions for use (IFU)  
- Cardiopulmonary comorbidities  
- Renal comorbidities  
- Perioperative risk  
- Perioperative morbidity  
- Perioperative mortality  
- Graft migration  
- Endoleak  
- Late rupture  
- Aneurysm‑related death  
- Shared decision‑making  
- Risk of graft failure  
- Survival advantage  
- Hazard ratio  
- Odds ratio  
- Aneurysm neck diameter  
- Neck length  
- Neck angulation  
- Iliac seal diameter  
- Iliac access parameters  

Page 67 Extracted Terms:
- Cardiac  
- Cardiac criteria  
- Acute coronary syndrome (ACS)  
- Myocardial infarction  
- Ischemia (heart ischemia)  
- Cardiovascular risk assessment  
- Perioperative death/mortality (in cardiac surgical context) 

Page 68 Extracted Terms:
**Key terms related to heart disease**

- Aortic aneurysm  
- Thoracic aortic aneurysm (TAA)  
- Abdominal aortic aneurysm (AAA)  
- Iliac artery aneurysm (common, internal, external)  
- Internal iliac artery  
- External iliac artery  
- Endoleak (incl. type I, type Ib)  
- Endovascular aneurysm repair (EVAR)  
- Thoracic endovascular aortic repair (TEVAR)  
- Graft infection  
- Anastomotic pseudoaneurysm  
- Retrograde type A aortic dissection  
- Stent‑graft migration  
- Stent‑graft fracture  
- Stent‑graft collapse  
- Buttock claudication  
- Erectile dysfunction  
- Spinal ischemia  
- Bowel ischemia  
- Gluteal ischemia  
- Late reintervention  
- Bifurcated grafting  
- Aorto‑aortic tube grafting  
- Surveillance imaging  
- Computed tomography (CT)  
- Magnetic resonance imaging (MRI)  
- Radiation exposure  
- Iodinated contrast allergy  
- Residual aortopathy / aortopa  
- Composite EVAR failure  
- Aneurysm growth / dilation  
- Aneurysm rupture  

These terms capture the core clinical concepts, procedures, complications, and diagnostic strategies discussed in the guideline excerpts.

Page 69 Extracted Terms:
- Abdominal aortic aneurysm (AAA)  
- Aortic aneurysm rupture  
- Endovascular abdominal aortic aneurysm repair (EVAR)  
- Open aortic repair  
- Endoleak (type I, type III, any endoleak)  
- Aneurysm sac enlargement  
- Stent graft fracture  
- Stent graft migration  
- Stent graft separation  
- Para‑anatomorrhatic aneurysm  
- Pseudoaneurysm  
- Aneurysmal disease (adjacent visceral aorta, iliac arteries)  
- Aortic rupture incidence (>5% through 8 years)  
- Endograft failure  
- Endograft migration, fracture, or new non‑contiguous aneurysms  
- Surveillance imaging (CT, MRI, duplex ultrasound)  
- Computed tomography (CT) – gold standard for follow‑up  
- Magnetic resonance imaging (MRI) – high diagnostic accuracy for endoleaks, requires plain radiograph for stent strut assessment  
- Duplex ultrasound (with or without contrast) – specific for endoleaks, limited for stent migration/fracture  
- Ionizing radiation exposure (from CT)  
- Iodinated contrast nephrotoxicity (from CT)  
- Diagnostic accuracy (95% for sac diameter, 100% for type I/III endoleaks)  
- Aortic aneurysm sac diameter  
- Clinical guidelines (2022 ACC/AHA Aortic Disease Guideline)  
- Follow‑up imaging intervals (1 month, 6 months, 12 months, annually, every 5 years)  
- Risk factors for rupture (endoleak, sac enlargement)  
- Late aortic rupture (incidence >5% through 8 years)  
- HTAD (heritable thoracic aortic disease) incidence among reintervention patients  
- Genetic syndrome and residual aortopathy assessment  

---  

**Note:** These terms encapsulate the core concepts, disease processes, interventions, complications, and diagnostic strategies relevant to cardiovascular (aortic) disease discussed in the provided guideline excerpts.

Page 70 Extracted Terms:
- Acute aortic syndrome (AAS)  
- Aortic dissection  
- Aortic aneurysm (AAA)  
- Acute aortic rupture  
- Endoleak (type IIA, type III)  
- Fenestrated/endovascular aneurysm repair (FEVAR/EVAR)  
- Bicuspid aortic valve (BAV)  
- Aortic stenosis  
- Aortic regurgitation (AR)  
- Aortic valve leaflet tethering / prolapse  
- Aortic root involvement  
- Coronary artery involvement by dissection  
- Myocardial ischemia  
- Myocardial infarction  
- Cardiac tamponade  
- Hemothorax  
- Pericardial effusion  
- Congestive heart failure  
- Shock (cardiac related)  
- Stroke (carotid/vertebral artery involvement)  
- Horner’s syndrome (sympathetic chain compression)  
- Syncope (carotid artery or cardiac tamponade)  
- Dysphagia (esophageal compression)  
- Dyspnea (tracheal compression, heart failure)  
- Hemoptysis (lung parenchyma rupture)  
- Hoarseness (recurrent laryngeal nerve compression)  
- Para‑anastomotic aneurysm (post‑open AAA repair)  

*(All terms are directly associated with cardiovascular disease or its complications as described in the provided guideline excerpt.)*

Page 71 Extracted Terms:
- Aortic dissection (AAS)  
- Aortic aneurysm  
- Thoracic aortic aneurysm  
- Aortic valve disease  
- Aortic regurgitation  
- Marfan syndrome  
- Connective tissue disease  
- Aortic branch vessel involvement  
- Vessel patency  
- Malperfusion  
- Pericardial effusion  
- Hemopericardium  
- Mediastinal hematoma  
- Periaortic hematoma  
- Pleural effusion  
- Intramural hematoma (IMH)  
- Penetrating atherosclerotic ulcer (PAU)  
- Pseudoaneurysm  
- D‑dimer (threshold <500 ng/mL)  
- Aortic Dissection Detection Risk Score (ADD‑RS)  
- Aorta Simplified Score (AORTAs)  
- Computed tomography (CT) angiography  
- Transesophageal echocardiography (TEE)  
- Magnetic resonance imaging (MRI)  
- Plain chest X‑ray  
- Mediastinal widening  
- Aortic knob disruption  
- Calcium sign (intimal calcium separation >5 mm)  
- Double density appearance within the aorta  
- Tracheal deviation  
- Nasogastric tube deviation  
- Pulse deficit  
- Hypotension / shock  
- Systolic blood‑pressure differential  
- Focal neurologic deficit  
- Severe pain (abrupt, ripping/tearing)  
- Sudden‑onset pain  
- Electrocardiographic‑synchronized CT techniques  
- Risk score assignment (0–3 points)  
- High‑risk, moderate‑risk, high‑probability categories  
- Acute aortic dissection diagnostic imaging modalities  

Page 72 Extracted Terms:
**Key terms related to heart disease extracted from the text**

- Aortic dissection  
- Acute aortic syndrome (AAS)  
- Aortic wall stress  
- Anti‑impulse therapy  
- Intravenous beta‑blockers (e.g., esmolol, metoprolol, labetalol)  
- Intravenous non‑dihydropyridine calcium‑channel blockers (e.g., verapamil, diltiazem)  
- Intravenous vasodilators (e.g., nicardipine, clevidipine, sodium nitroprusside)  
- Angiotensin‑converting enzyme inhibitors (ACEIs)  
- Angiotensin II receptor blockers (ARBs)  
- Statins  
- Pain control (analgesia)  
- Hemodynamics  
- Blood pressure (BP, systolic BP, SBP)  
- Heart rate (HR)  
- End‑organ perfusion  
- Arterial line (vascular access)  
- Intensive care unit (ICU)  
- Imaging modalities:  
  - Computed tomography (CT)  
  - Echocardiography (TEE / TTE, transthoracic / transesophageal)  
  - Magnetic resonance imaging (MRI)  
- Aortic regurgitation (AR)  
- Pericardial effusion  
- Cardiac tamponade  
- Endovascular intervention  
- Surgical intervention (type A vs type B aortic dissection)  

These terms capture the cardiovascular concepts, treatments, and diagnostic approaches discussed in the guideline excerpt.

Page 73 Extracted Terms:
- Aortic aneurysm and dissection (AAS)  
- Acute aortic dissection (AoD)  
- Aortic rupture  
- Retrograde extension of dissection  
- Antegrade propagation of dissection  
- Malperfusion syndromes  
- Hypertension / blood pressure (BP)  
- Heart rate  
- Long‑term beta blockers  
- Angiotensin‑receptor blockers (ARBs)  
- Angiotensin‑converting enzyme inhibitors (ACEIs)  
- Calcium channel blockers (CCBs)  
- Marfan syndrome – a connective‑tissue disorder affecting the aorta  
- Thoracic endovascular aortic repair (TEVAR)  
- Endovascular stent‑graft repair  
- Open surgical repair of the aorta  
- Long‑term oral antihypertensive regimens  
- Aortic‑related adverse events  
- Aortic root  
- Branch vessel anatomy of the aorta**

Page 74 Extracted Terms:
- Acute type A aortic dissection  
- Aortic dissection  
- Aortic rupture  
- Cardiac tamponade  
- Acute aortic regurgitation (AR)  
- Myocardial infarction  
- Myocardial ischemia  
- Coronary artery ostia  
- Coronary malperfusion  
- Heart failure  
- End‑organ malperfusion (e.g., renal, cerebral)  
- Stroke (cerebral malperfusion)  
- Shock (cardiogenic)  
- Surgical intervention (repair)  
- High‑volume aortic center  
- Aortic root repair  
- Ascending aorta repair  
- Transverse arch repair  
- Survival / mortality (surgical vs. medical)  
- Time to intervention (hours from onset to surgery)

Page 75 Extracted Terms:
- Acute type A aortic dissection  
- Aortic dissection
- Malperfusion (malperfusion syndrome)  
- Renal malperfusion  
- Mesenteric malperfusion  
- Lower‑extremity malperfusion  
- Coronary malperfusion  
- Aortic rupture  
- Cardiac tamponade  
- Myocardial dysfunction  
- Troponin elevation  
- Electrocardiographic changes of ischemia or infarction  
- Cerebral ischemia (stroke, neurologic deficits)  
- Spinal ischemia (paraplegia)  
- Bowel ischemia (mesenteric ischemia)  
- Acute kidney injury  
- Oliguria  
- Loss of pulses in an extremity  
- Sensory or motor dysfunction in an extremity  
- Aortic repair (ascending aorta)  
- Endovascular revascularization  
- Open surgical intervention  
- Hybrid operating room  
- Endovascular therapy  
- Endovascular fenestration  
- Branch stenting  
- Clinical evidence of end‑organ ischemia

These terms capture the key heart‑disease–related concepts discussed in the guideline text.

Page 76 Extracted Terms:
**Terms related to heart disease (from the guideline excerpt)**  

- Acute type A aortic dissection  
- Aortic root  
- Aortic valve  
- Valve resuspension  
- Valve replacement  
- Root aneurysm  
- Mechanical valved conduit  
- Biological valved conduit  
- Valve‑sparing root repair  
- Open distal anastomosis  
- False‑lumen thrombosis  
- Arch repair  
- Hemiarch repair  
- Arch aneurysm  
- Descending thoracic aorta  
- Extended aortic repair  
- Antegrade stenting of the proximal descending thoracic aorta  
- Axillary cannulation  
- Femoral cannulation  
- Cerebral perfusion  
- Direct aortic cannulation  
- Innominate artery cannulation  
- Aortic resection  
- Tear site  
- Aneurysmal aorta  
- Late aortic complications  
- Reoperation  
- Ischemic time  
- Circulatory arrest  
- Aortic insufficiency  
- Aortic dilation  
- Endovascular stent graft  
- Hybrid technique  
- Frozen elephant trunk  
- Genetic aortic disorder  
- Multidisciplinary aortic team  
- Aortic valve leaflets  
- Valve leaflet pathology  
- Aortic aneurysm  
- Aortic root replacement  
- Aortic repair  
- Distal aortic extension  
- False lumen  
- Risk factor for reoperation

Page 77 Extracted Terms:
**Key Heart‑Disease Terms Extracted**

- Aortic root dilation  
- Aortic insufficiency  
- Reoperation / reintervention  
- Aortic root diameter (>4.5 cm)  
- Valved conduit  
- Valve‑sparing root replacement (VSRR)  
- Right hemiarch replacement  
- IRAD risk score  
- NORCAAD (Nordic Consortium for Acute Type A Aortic Dissection)  
- Open‑distal technique  
- Clamp‑on technique  
- Cerebrovascular complications  
- Cross‑clamp use  
- Deep hypothermic circulatory arrest  
- Antegrade perfusion  
- False‑lumen thrombosis  
- True‑lumen flow  
- Total arch replacement (TAR)  
- Hemiarch repair  
- Re‑thoracotomy  
- STS (Society of Thoracic Surgeons) database  
- Meta‑analysis findings on mortality  
- Antegrade stenting of the descending thoracic aorta  
- Spinal cord ischemia (SCI)  
- Malperfusion resolution  
- Frozen elephant trunk (FET)  
- Stent length (<15 cm)  
- Coverage not extending to T8  
- Femoral cannulation  
- Axillary cannulation  
- Direct aortic cannulation (TEE‑guided Seldinger)  
- Innominate artery cannulation  
- Cerebral perfusion (antegrade or retrograde)  
- Unilateral antegrade cerebral perfusion  
- Bilateral antegrade cerebral perfusion  
- Stroke rates (varied by cannulation strategy)  
- Aortic dissection type A (De Bakey Type I)  

These terms capture the primary syndromes, anatomical features, procedural interventions, and outcome measures mentioned in the guideline excerpt.

Page 78 Extracted Terms:
- Acute Type B Aortic Dissection  
- Aortic Dissection (general)  
- Aortic Rupture (free or contained)  
- Branch Artery Occlusion  
- Malperfusion (clinical evidence)  
- Extension of the Dissection Flap  
- Aortic Enlargement (true or false lumen)  
- Intractable Pain  
- Uncontrolled Hypertension  
- Refractory Hypertension  
- Endovascular Stent Grafting  
- Open Surgical Repair  
- Medical Therapy (optimal management)  
- Mortality Rate (30‑day, midterm)  
- Complicated Aortic Dissection  
- Uncomplicated Aortic Dissection  
- Aortic Dissection Management Strategies  
- Marfan Syndrome  
- Loeys‑Dietz Syndrome  
- Aortic Tear (entry tear)  
- Maximal Aortic Diameter (> 40 mm)  
- False‑Lumen Diameter (> 20–22 mm)  
- Entry Tear Size (> 10 mm)  
- Entry Tear Location (lesser curvature)  
- Bloody Pleural Effusion  
- High‑Risk Imaging Findings  
- High‑Risk Clinical Findings  
- Imaging‑Only Evidence of Malperfusion  
- Rapid Coverage of the Descending Aorta  
- Hemothorax  
- Periaortic Hematoma  
- Mediastinal Hematoma  
- Retrograde Type A Dissection  
- Genetic Triggers (of aortic disease)  
- Optimal Medical Management (study term)  
- Endovascular Techniques (general)  
- Midterm Mortality Rate  
- Lower Morbidity  
- ADSORB (Acute Dissection: Stent graft OR Best medical therapy)  
- INSTEAD (Investigation of Stent Grafts in Patients with Type B Aortic Dissection)  
- IRAD Database  
- Percutaneous Intervention  
- Dissection Flap (definition)  
- Aneurysm (related to aortic dissection)  
- High‑Risk Features (in uncomplicated cases)  
- Antihypertensive Medications (≥ 3 classes)  
- Refractory Pain Duration (> 12 h)  
- Readmission (clinical outcome)  
- In‑Hospital Mortality Rate  
- Survival Advantage (type B vs type A)  

These terms capture the key concepts related to heart disease as presented in the guideline excerpt.

Page 79 Extracted Terms:
- Acute type A aortic dissection  
- Acute type B aortic dissection  
- Acute aortic syndrome (AAS)  
- Intramural hematoma (IMH)  
- Aortic intramural hematoma  
- Aortic dissection  
- Aortic aneurysm  
- Aortic rupture  
- Aortic dilation  
- aortic remodeling  
- Malperfusion  
- Visceral artery stenting  
- Renal artery stenting  
- Thoracic endovascular aortic repair (TEVAR)  
- Endovascular repair  
- Open surgical repair  
- Endovascular expertise  
- Aortic arch zones (2–5)  
- Distal aortic arch repair  
- Descending thoracic aorta  
- Ascending aorta  
- High‑risk imaging features  
- False lumen  
- False‑lumen thrombosis  
- Aorta‑specific survival  
- In‑hospital mortality  
- 30‑day mortality  
- 1‑year survival  
- 5‑year survival  
- Reintervention rates  
- Complicated intramural hematoma  
- Uncomplicated intramural hematoma  
- Pericardial effusion  
- Cardiac tamponade  
- Aortic events (mortality, rupture, dilation)  
- Pharmacologic (optimal medical) management  
- Endovascular intervention timing  
- Retrograde perfusion obstruction (implied in malperfusion)

Page 80 Extracted Terms:
**Key heart‑disease terms extracted from the guideline text**

- Intramural Hematoma (IMH)  
- Type A IMH  
- Type B IMH  
- Aortic Dissection  
- Penentrating Atherosclerotic Ulcer (PAU)  
- Aortic Rupture  
- Aortic‑related complications  
- Open (surgical) repair  
- Endovascular repair  
- Mortality (in‑hospital, short‑term, 1‑year, long‑term)  
- Survival (mid‑, long‑term)  
- Coronary Artery Disease  
- Renal function (baseline kidney health)  
- Pericardial effusion  
- Pleural effusion  
- Maximum aortic diameter  
- Hematoma thickness  
- Intimal disruption  
- Ulcer‑like projection  
- Intensive Care Unit (ICU) stay  
- Computed Tomography Angiography (CTA)  
- High‑risk imaging features  
- Surgical intervention (timing, upfront vs delayed)  
- Medical management (antihypertensive therapy, anticoagulant clearance, etc.)  
- Genetic and environmental factors affecting natural history  

These terms collectively represent the core cardiovascular concepts addressed in the 2022 ACC/AHA guideline on aortic disease.

Page 81 Extracted Terms:
- Aortic disease  
- Type A aortic dissection (Stanford type A)  
- Type B aortic dissection (Stanford type B)  
- Acute aortic syndrome (AAS)  
- Intramural hematoma (IMH)  
- Penetrating atherosclerotic ulcer (PAU)  
- Ulcer‑like projection  
- Focused intimal disruption (FID)  
- Endovascular repair / TEVAR (thoracic endovascular aortic repair)  
- Open surgical repair  
- Hybrid approach  
- Stent graft  
- Stent‑graft oversizing  
- Balloon aortoplasty  
- Imaging features: high‑risk, focal intimal disruption, tiny intimal disruption  
- Aortic‑related outcomes  
- Aortic‑related events  
- Aortic‑related death  
- Aortic arch  
- Descending thoracic aorta  
- Abdominal aorta  
- Aneurysmal degeneration  
- Endovascular access  
- Atherosclerotic disease  
- Mortality & morbidity (associated with surgical/endovascular intervention)  
- Urgent repair (clinical recommendation)  
- Medical therapy (optimal medical therapy)  
- Perioperative mortality rate  
- Long‑term survival  
- Surgical & endovascular intervention  

*(All terms are extracted from the guideline text and pertain to heart‑related disease, particularly aortic pathology.)*

Page 82 Extracted Terms:
**Key terms related to heart (aortic) disease:**

- Penetrating atherosclerotic ulcer (PAU)  
- Aortic rupture  
- Aortic dissection  
- Intramural hematoma (IMH)  
- Aortic repair (surgical & endovascular)  
- Open aortic repair  
- Endovascular aortic repair (stent‑graft)  
- Conservative management  
- High‑risk imaging features  
- Maximum PAU diameter  
- Maximum PAU depth  
- Pleural effusion  
- Saccular aneurysm  
- Aortic aneurysm  
- Atherosclerosis  
- Computed tomography angiography (CTA)  
- Mortality rate  
- Surgical candidacy  
- Elective repair  
- Symptomatic PAU  
- Asymptomatic PAU  
- Radiologic findings  
- Surveillance imaging  
- Aortic lumen  
- Intimal defect  
- Intramural blood pool  
- Aortic arch  
- Ascending aorta  
- Abdominal aorta  
- Type B IMH  
- Endovascular stent graft  
- Surgical repair (open)  
- Retrospective analysis  
- Clinical statements  
- Consensus guidelines  
- ACC/AHA Aortic Disease Guideline  

Page 83 Extracted Terms:
- Penetrating Aortic Ulcer (PAU)  
- Aortic Dissection  
- Intramural Hematoma (IMH)  
- Ascending Aorta  
- Descending Thoracic Aorta  
- Abdominal Aorta  
- Aortic Arch  
- Open Surgical Repair  
- Endovascular Repair  
- Endoleak  
- Atherosclerosis (vascular disease)  
- Anti‑Impulse Therapy  
- Blunt Traumatic Thoracic Aortic Injury (BTTAI)  
- Traumatic Aortic Injury  
- Aortic Pathology  
- Aortic Repair (surgical & endovascular)

Page 84 Extracted Terms:
- Blunt traumatic thoracic aortic injury (BTTAI)  
- Aortic injury  
- Aortic isthmus  
- Aortic arch  
- Aortic wall  
- Aortic rupture  
- Aortic wall disruption  
- Intimal tear  
- Intramural hematoma  
- Pseudoaneurysm  
- Aortic intervention  
- Blood pressure  
- Heart rate  
- Beta blockers  
- Nicardipine  
- Clevidipine  
- Sodium nitroprusside  
- Vasodilators  
- Permissive hypotension  
- End‑organ perfusion  
- Aortic imaging  
- Multidisciplinary expertise

Page 85 Extracted Terms:
- Blunt traumatic thoracic aortic injury (BTTAI)  
- Aortic injury  
- Ascending aorta  
- Aortic arch  
- Descending thoracic aorta  
- Aortic rupture  
- Aortic‑related mortality  
- Thoracic aortic injury  
- Endovascular aneurysm repair (TEVAR)  
- Open surgical repair  
- Heparin management  
- Spinal cord injury (SCI)  
- Acute kidney injury (AKI)  
- Acute respiratory distress syndrome (ARDS)  
- Mediastinal hematoma  
- Hemothorax  
- Pseudo‑coarctation of the aorta

Page 86 Extracted Terms:
- Aortic injury (blunt traumatic abdominal aortic injury, BAAI)  
- Aortic rupture  
- Pseudoaneurysm  
- Grade 1–4 BAAI (aortic injury grading)  
- Anti‑impulse therapy (beta‑blockade, antihypertensive therapy)  
- Antiplatelet therapy  
- Endovascular repair (stent graft, endovascular treatment)  
- Open repair (surgery, aortic cross‑clamping)  
- REBOA (resuscitative endovascular balloon occlusion of the aorta)  
- Hemorrhage control  
- Hypotension (refractory, leading to cardiac arrest)  
- Cardiac arrest  
- Visceral vessel avulsion  
- Aortic contour defects  
- Intramural hematoma (IMH)  
- Aortic cross‑clamping  
- Anterior‑lateral thoracotomy  
- Cardiovascular morbidity and mortality  
- Cardiac complications (associated with BAAI)

Page 87 Extracted Terms:
- Aortic disease  
- Aortic injury  
- Bilateral aortic injury (BAAI)  
- Endovascular repair  
- Open repair  
- Hybrid repair (endovascular + open)  
- Pseudoaneurysm  
- Hemorrhagic shock  
- Cardiac arrest  
- Malperfusion  
- Ischemic symptoms  
- Endovascular balloon occlusion (REBOA)  
- Traumatic aortic rupture  
- Aortic zones of injury (zone 2, zone 3, zone 4)  
- Grade 4 aortic injury  
- Acute kidney injury (as a cardiovascular complication)  
- Sepsis (from limb ischemia)  
- Limb ischemia (ischemic complications)  
- Hemorrhage control (vascular)  
- Trauma‑related aortic pathology


Page 88 Extracted Terms:
- Aortic disease  
- Aortic dissection  
- Acute aortic dissection  
- Intralaminar hematoma (IMH)  
- Blunt traumatic aortic injury (BTAI)  
- Thoracic aortic injury  
- Endovascular repair  
- Open aortic repair  
- Thoracic endovascular aortic repair (TEVAR)  
- Endoleak  
- Stent migration  
- Stent graft  
- Pericardial tamponade  
- REBOA (Resuscitative Endovascular Balloon Occlusion of the Aorta)  
- REBOA contraindication  
- Cardiogenic shock  
- Cardiac arrest  
- Aneurysm  
- Aneurysm surveillance  
- Surveillance imaging  
- Computed tomography (CT) scan  
- Magnetic resonance imaging (MRI)  
- Aortic valve  
- Aortic root  
- Distal aorta  
- Reoperation  
- Reintervention  
- Medical therapy for aortic dissection management  
- Imaging intervals for long‑term surveillance  
- Residual aortic disease monitoring  
- Stent‑graft migration risk  
- Endovascular stent‑graft complications  
- TEVAR‑related reintervention rates  

Page 89 Extracted Terms:
- Aortic dissection  
- Acute type A aortic dissection  
- Acute type B aortic dissection  
- Intimal medial hematoma (IMH)  
- Thoracic aortic aneurysm  
- Penetrating aortic ulcer (PAU)  
- Thoracic endovascular aortic repair (TEVAR)  
- Endoleak (early and late)  
- False lumen  
- Aneurysm growth  
- Surgical repair of aortic dissection  
- Elective thoracic aortic repair  
- Reoperation after aortic repair  
- Aneurysm of the thoracic aorta  
- Aortic anastomotic pseudoaneurysm  
- Aortic regurgitation (AR)  
- Graft infection  
- Surveillance imaging  
- Computed tomography (CT)  
- Trans-thoracic echocardiography (TTE)  
- Aortic valve function monitoring  
- Aortic root anatomy  
- Thoracoabdominal aorta interventions  
- Aortic-related adverse events

Page 90 Extracted Terms:
- Aortic disease  
- Aortic aneurysm  
- Aortic dissection (Type A & Type B)  
- Aortic root dilation  
- Ascending aorta dilation  
- Aortic arch surveillance  
- Aortic dilation  
- Aortic growth rate  
- Heritable thoracic aortic disease (HTAD)  
- Marfan syndrome  
- Loeys‑Dietz syndrome  
- Vascular Ehlers‑Danlos syndrome  
- Turner syndrome  
- Bicuspid aortic valve (BAV)  
- Aortopathy  
- Genetic counseling (pre‑pregnancy)  
- Echocardiogram (TTE)  
- Cardiovascular magnetic resonance (MRI)  
- Computed tomography (CT)  
- Beta‑blocker therapy during pregnancy and postpartum  
- Hypertension management in pregnancy  
- Maternal‑fetal medicine specialist  
- Cardiologist (aortic specialist)  
- Multidisciplinary team for pregnancy management  
- Emergency aortic repair capability  
- Cesarean delivery (in high‑risk aortic cases)  
- Vaginal delivery (low‑risk aortic cases)  
- Hemodynamic and hormonal changes in pregnancy  
- Postpartum aortic complications  
- Aortic surveillance imaging (tri‑monthly during pregnancy)  
- Aortic imaging to avoid radiation exposure (MRI without gadolinium)  

These terms encompass the key heart‑disease concepts addressed in the guideline excerpt.

Page 91 Extracted Terms:
- Acute aortic dissection  
- Aortic dissection  
- Aortic diameter  
- Aortic root  
- Ascending aorta  
- Aortic arch  
- Descending aorta  
- Abdominal aorta  
- Marfan syndrome  
- TGFBR1  
- TGFBR2  
- Loeys‑Dietz syndrome  
- SMAD3  
- TGFB2  
- TGFB3  
- Vascular Ehlers‑Danlos syndrome  
- Non‑syndromic heritable thoracic aortic disease (nsHTAD)  
- Bicuspid aortic valve (BAV)  
- Aortopathic conditions  
- Hypertension (as a risk factor for aortic dissection)  
- Beta‑blockers (e.g., labetalol)  
- Labetalol  
- Angiotensin‑II receptor blockers (ARBs)  
- Angiotensin‑converting enzyme inhibitors (ACEIs)  
- Calcium channel blockers  
- Pregnancy‑associated cardiovascular changes (blood volume, heart rate, stroke volume, cardiac output)  
- Aortic imaging (MRI, CT, transesophageal echocardiography – TEE)  
- Cesarean delivery (for aortic disease risk)  
- Vaginal delivery (when appropriate for aortic diameter <4.0 cm)  
- ROPAC registry (Registry of Pregnancy And Cardiac disease)  
- ACC/AHA Aortic Disease Guideline  
- Deliveries in a setting with cardiothoracic surgery available  

(These terms capture the key heart‑disease concepts addressed in the guideline text.)

Page 92 Extracted Terms:
- Aortic root  
- Ascending aorta  
- Aortic diameter  
- Aortic dilation  
- Aortic dissection  
- Type A aortic dissection  
- Type B aortic dissection  
- Aortic root replacement  
- Avascular aneurysm  
- Aortic rupture  
- Hypertension  
- Pregnancy‑related aortic risk  
- Cesarean delivery (in aortic disease)  
- Vaginal delivery with regional anesthesia  
- Expedited second stage of labor  
- Assisted delivery  
- Aortopathy  
- Marfan syndrome  
- Loeys‑Dietz syndrome  
- Non‑syndromic hereditary thoracic aortic disease (nsHTAD)  
- WHO cardiovascular risk classification (modified III/IV)  
- Rapid aortic growth ≥ 0.3 cm/year  
- Familial aortic dissection history  
- Post‑partum aortic dissection risk  
- Lumbosacral dural ectasia (co‑existing condition)

Page 93 Extracted Terms:
**Key heart‑disease terms extracted from the guideline text**

- Aortic root aneurysm  
- Ascending aortic aneurysm (AAA)  
- Aortic dissection (type A)  
- Aortic root dilation  
- Aortic diameter  
- Aortic growth rate  
- Aortic size index (cm / m²)  
- Prophylactic aortic surgery  
- Pregnancy‑related aortic dissection  
- Turner syndrome  
- Marfan syndrome  
- Loeys‑Dietz syndrome (LDS)  
- Loeys‑Dietz syndrome with TGFBR1 mutation  
- Loeys‑Dietz syndrome with TGFBR2 mutation  
- Loeys‑Dietz syndrome with SMAD3 mutation  
- Loeys‑Dietz syndrome with TGFB2 mutation  
- Loeys‑Dietz syndrome with TGFB3 mutation  
- Nonsyndromic heritable thoracic aortic disease (nsHTAD)  
- ACTA2‑associated aortopathy  
- MYH11‑associated aortopathy  
- MYLK‑associated aortopathy  
- PRKG1‑associated aortopathy  
- Bicuspid aortic valve (BAV)  
- Aortic root replacement surgery  
- Ascending aortic root replacement surgery  
- Aortic graft  
- Aortic dissection risk factors (family history, rapid growth ≥ 0.3 cm / yr, body size)  
- Shared decision‑making in aortic surgery  
- Cardiologist, aortic specialist, aortic surgeon, maternal‑fetal medicine specialist.

Page 94 Extracted Terms:
**Key Heart‑Disease Terms Extracted**

- ACC/AHA Aortic Disease Guideline  
- HTAD (Heritable Thoracic Aortic Disease)  
- Genetic conditions: ACTA2, MYLK  
- Turner syndrome  
- ASI (Aortic Size Index)  
- BAV (Bicuspid Aortic Valve)  
- Aortic dilation / aneurysm  
- Aortic root dilation  
- Ascending aortic dilation  
- Thoracic Aortic Aneurysm (TAA)  
- Aortic dissection (Type A, Type B)  
- Aortic rupture  
- Aortic surgery (prophylactic, urgent, endovascular)  
- Cesarean delivery (in context of aortic dissection)  
- Fetal monitoring (during aortic surgery)  
- Maternal morbidity / mortality  
- Pregnancy risk assessment (including WHO Class IV)  
- Rapid aortic growth  
- Body size / body habitus  
- Family history of aortic disease  
- Genetic aortopathy  
- Molecular genetic testing / pathogenic variant detection  
- Autosomal dominant transmission of TAA  
- Surgical risk stratification in young patients  
- Endovascular therapy (for Type B dissection)  
- Maternal–fetal decision making in aortopathy  
- Aortic diameter thresholds (≥ 4.0 cm, > 4.5 cm, > 5.0 cm)  
- Aortic size index thresholds (ASI > 2.0 cm/m², ASI ≥ 2.5 cm/m²)  

These terms capture the core cardiovascular concepts discussed in the guideline text.

Page 95 Extracted Terms:
- Aortic dissection (Type A, Type B)  
- Aortic aneurysm  
- Aortic surgery (open or endovascular)  
- Endovascular repair  
- Open surgical intervention  
- Cesarean delivery (when used in management of aortic dissection during pregnancy)  
- Inflammatory aortitis  
- Takayasu arteritis  
- Giant cell arteritis (GCA)  
- Large vessel vasculitis (LVV)  
- Immunoglobulin G4‑related disease  
- Antineutrophil cytoplasmic antibody‑related vasculitis  
- Sarcoidosis  
- Behçet’s disease  
- Relapsing polychondritis  
- Granulomatosis with polyangiitis  
- Intramural hematoma (IMH)  
- Penetrating atherosclerotic ulcer (PAU)  
- Aortic rupture  
- Progressive atherosclerosis  
- Thrombotic complications  
- Magnetic resonance imaging (MRI)  
- Computed tomography (CT)  
- 18F‑FDG positron emission tomography (PET)  
- High‑dose glucocorticoids  
- Tocilizumab  
- Methotrexate

Page 96 Extracted Terms:
- Aortic disease  
- Aortic aortitis  
- Aortic aneurysm  
- Aortic stenosis  
- Aortic valve dysfunction  
- Aortic branch vessel involvement  
- Aortic bruits  
- Aortic imaging (CT angiography, MRI, FDG‑PET, echocardiography)  
- Giant cell arteritis (GCA)  
- Takayasu arteritis  
- Large vessel vasculitis (LVV)  
- Cardiovascular complications of vasculitis  
- Glucocorticoid therapy (prednisone)  
- High‑dose glucocorticoid induction  
- Intravenous methylprednisolone  
- Tocilizumab (IL‑6 receptor inhibitor)  
- Methotrexate (DMARD)  
- Hydroxychloroquine (DMARD)  
- Azathioprine (DMARD)  
- Sulfamethoxazole (DMARD)  
- Leflunomide (DMARD)  
- Tumor necrosis factor‑inhibitors (biologic DMARDs)  
- Antiplatelet therapy  
- Anticoagulant therapy  
- Antithrombotic prophylaxis  
- Aortic wall thickening  
- Intimal injury  
- Ulcerative plaques  
- Occlusive lesions  
- Hemodynamic blood pressure variation between arms  
- Temporal artery tenderness / pulse attenuation  
- Elevated erythrocyte sedimentation rate (ESR) >50 mm/h  
- Necrotizing vasculitis on arterial biopsy

Page 97 Extracted Terms:
- Aortic disease  
- Takayasu arteritis  
- Large‑vessel vasculitis (LVV)  
- Giant cell arteritis (GCA)  
- Remission (clinical criteria)  
- Inflammatory biomarkers (e.g., CRP, ESR)  
- Computed tomography (CT) imaging  
- Magnetic resonance imaging (MRI)  
- Positron emission tomography‑CT (PET‑CT)  
- Clinical disease relapse  
- Surveillance imaging  
- EULAR (European Alliance of Associations for Rheumatology) guidelines  
- Glucocorticoids  
- Tumor necrosis factor (TNF) inhibitors  
- Randomized clinical trials (RCTs)  
- Clinical outcomes (quality of life, symptom improvement)

Page 98 Extracted Terms:
- Aortic disease  
- Large vessel vasculitis (LVV)  
- Aortic aneurysm  
- Aortic stenosis  
- Branch artery stenosis  
- Branch artery aneurysm  
- FDG‑PET imaging  
- Giant cell arteritis (GCA)  
- Clinical remission  
- Glucocorticoids (GC)  
- Conventional synthetic disease‑modifying antirheumatic drugs (csDMARDs)  
- Tumor necrosis factor inhibitors (TNF)  
- Cardiovascular surveillance  
- Aortic complications  
- Takayasu arteritis  
- Cardiovascular imaging  

These terms capture the primary heart‑related concepts referenced in the guideline excerpt.

Page 99 Extracted Terms:
- Aortic disease  
- Aortic aneurysm (saccular, pseudoaneurysm)  
- Aortic dissection  
- Infectious aortitis (mycotic aneurysm)  
- Large Vessel Vasculitis (LVV)  
- Giant Cell Arteritis (GCA)  
- Takayasu arteritis  
- Branch vessel stenosis  
- Branch artery dilation / narrowing  
- Aortic root involvement  
- Endovascular repair  
- Open surgical repair (in situ reconstruction, aortic resection)  
- Extra‑anatomic bypass (axillobifemoral, femorofemoral cross‑over)  
- Hybrid or bridging approach  
- Endo‑vascular therapy  
- Imaging surveillance (CT, MRI, PET‑CT, TEE)  
- Antimicrobial therapy (prolonged IV antibiotics)  
- Suppressive lifelong therapy  
- Sepsis  
- Rupture (contained rupture)  
- Fistula formation  
- Hemodynamic instability  
- Immunocompromised hosts (fungal or tuberculous aortitis)  
- Treponema pallidum (syphilitic aortitis)  
- Pathogens: Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Salmonella, Candida, Aspergillus, Mycobacterium tuberculosis  

Page 100 Extracted Terms:
**Key terms related to heart disease**

- Aortic aneurysm  
- Infectious aortitis  
- Aortoenteric fistula  
- Aortic rupture  
- Endovascular aneurysm repair (EVAR)  
- Open aortic repair  
- Endovascular device repair  
- Extra‑anatomic reconstruction  
- In‑situ reconstruction  
- Bridge procedure  
- Antimicrobial therapy  
- Antimicrobial duration  
- High mortality  
- Low early morbidity  
- Persistent infection  
- Device infection  
- Polyester graft  
- Rifampin‑soaked graft  
- Silver‑coated graft  
- Cryopreserved arterial allograft  
- Venous autograft  
- Spinal cord injury  
- Reperfusion injury  
- Hemodynamic instability  
- Uncontrolled bleeding  
- Stump blowout  
- Limb ischemia  
- Ischemic colitis  
- Patency rate  
- Reconstruction options  
- Imaging surveillance  
- Multidisciplinary care team  
- 5‑year survival  
- Selective treatment indications  


---

Page 101 Extracted Terms:
- Prosthetic aortic graft  
- Aortic graft infection  
- Cross‑sectional imaging  
- Computed tomography angiography (CTA)  
- Positron emission tomography‑CT (PET‑CT)  
- Magnetic resonance imaging (MRI)  
- Tagged white‑blood‑cell scans  
- Open surgery  
- In situ reconstruction  
- Extra‑anatomic bypass  
- Endovascular therapy  
- Intravenous antimicrobial therapy  
- Oral suppressive therapy  
- Methicillin‑resistant *Staphylococcus aureus* (MRSA)  
- *Pseudomonas aeruginosa*  
- Multidrug‑resistant microorganisms  
- Allografts (cryopreserved aorta)  
- Autografts (femoral vein)  
- Dacron grafts  
- Polytetrafluoroethylene (PTFE) grafts  
- Endovascular aneurysm repair (EVAR)  
- Early graft infection (≤3 months)  
- Late graft infection (>3 months)  
- Fever  
- Back pain  
- Fatigue  
- Malaise  
- Elevated white‑blood‑cell count  
- Erythrocyte sedimentation rate (ESR)  
- C‑reactive protein (CRP)  
- Sepsis  
- Hemodynamic instability  
- Hemorrhage  
- Rupture  
- Fistula to bowel, esophagus, or airway  
- Axial imaging  
- Graft enteric erosion  
- Hematogenous spread  
- Graft explant  
- Aortic stump oversewing  
- Omental coverage  
- Muscle flaps  
- Pleural coverage  
- Peri‑graft air  
- Abscess  
- Pseudoaneurysm  
- Graft‑site inflammation  
- Invasive bacterial pathogens  
- Infection‑related complications  
- Antimicrobial stewardship for prosthetic vascular infections

Page 102 Extracted Terms:
**Key Terms Related to Heart Disease**

- Aortic atherosclerosis / aortic atherosclerotic disease  
- Aortic arch atheroma  
- Coronary artery disease (CAD)  
- Peripheral arterial disease (PAD)  
- Atrial fibrillation (AFib)  
- Antiplatelet therapy  
- Anticoagulant therapy  
- Statin therapy (moderate‑ or high‑intensity)  
- Aortic atheromas ≥ 4 mm  
- Embolic complications of aortic plaques  
- Stroke (ischemic)  
- Aorto‑enteric fistula  
- Graft infection (aortic graft)  
- Endovascular intervention / endovascular repair  
- In situ venous reconstruction  
- Cryopreserved allografts  
- Rifampin‑impregnated prosthetic graft  
- Silver‑impregnated prosthetic graft  
- Extra‑anatomic reconstruction  
- Hemodynamically unstable aortic patients  
- Proximal control with clamp or balloon  
- Intravenous antimicrobial therapy  
- Oral suppressive antimicrobial therapy (lifelong)  
- Imaging for reinfection (axial imaging, identification of inflammatory changes, fluid or air collections, pseudoaneurysm formation)

Page 103 Extracted Terms:
- Aortic disease  
- Aortic plaques (atheromas)  
- Aortic atherosclerosis  
- Aortic thrombus (mural and primary)  
- Aortic thrombosis  
- Aortic occlusion  
- Porcelain aorta  
- Aortic aneurysm  
- Aortic dissection  
- Aortic graft material  
- Embolism  
- Stroke  
- Limb ischemia  
- Visceral ischemia  
- Antiplatelet therapy  
- Anticoagulation  
- Statin therapy  
- Hypercoagulable states  
- Antiphospholipid syndrome  
- Heparin‑induced thrombocytopenia  
- Aortitis  
- Atherosclerotic disease elsewhere  
- Cardiopulmonary bypass  
- Central aortic cannulation  
- Aortic cross‑clamping  
- Circulatory arrest  
- Endovascular revascularization  
- Open aortic reconstruction  
- Aortobifemoral bypass  
- Axillofemoral bypass  
- Iliac stenting  
- Endarterectomy  
- CT angiography (CTA)  
- Transesophageal echocardiography (TEE)  
- Calcification of aortic wall  
- Aortic arch  
- Ascending aorta  
- Aortic valve replacement  
- Coronary bypass grafting  
- Balloon occlusion of the aorta  
- Patency  
- Complications (stroke, exsanguination, embolization)  
- Claudication  
- Impotence  
- Cardiopulmonary comorbidities  
- Renal malperfusion  
- Visceral malperfusion

Page 104 Extracted Terms:
**Key terms related to heart disease**

- Coarctation of the Aorta (CoA)  
- Congenital abnormalities of the aortic arch  
- Left subclavian artery  
- Aneurysmal aortic segment  
- Upper extremity hypertension  
- Lower extremity hypotension  
- Magnetic Resonance Imaging (MRI)  
- Computed Tomography (CT)  
- Transthoracic Echocardiography (TTE)  
- Bicuspid Aortic Valve (BAV)  
- Aortic dissection  
- Heart failure  
- Ruptured cerebral aneurysm  
- Aortic hypoperfusion (ischemia)  
- Hypertension (post‑CoA)  
- Endovascular stenting of CoA  
- Open surgical repair of CoA  
- Hybrid surgical repair of CoA  
- Ambulatory blood‑pressure monitoring  
- Exercise testing (cardiovascular)  
- Intracranial aneurysm screening (MRI/CT)  
- Ascending aortic aneurysm  
- Descending aortic aneurysm  
- Left ventricular hypertrophy  
- Gradient across CoA (peak‑to‑peak, mean)  
- Doppler echocardiography measurements  
- Kommerell diverticulum (aneurysmal dilation of anomalous subclavian artery)  
- Aberrant subclavian artery (ASCA)  
- Pseudoaneurysm formation after CoA repair  
- Recurrent aortic stenosis (post‑repair)  
- Lifelong clinical and imaging follow‑up for CoA patients

These terms capture the main cardiovascular conditions, diagnostic modalities, and therapeutic considerations discussed in the guideline excerpts.

Page 105 Extracted Terms:
- Coarctation of the aorta (CoA)  
- Bicuspid aortic valve (BAV)  
- Thoracic aortic aneurysm (TAA)  
- Aortic aneurysm  
- Pseudoaneurysm  
- Aortic dissection  
- Recoarctation  
- Hypertension  
- Heart failure  
- Stroke  
- Coronary artery disease  
- Intracranial aneurysm  
- Aberrant subclavian artery  
- Kommerell’s diverticulum  
- Aortic arch abnormalities  
- Subclavian flap aortoplasty  
- End-to-end anastomosis  
- Interposition grafting  
- Bypass grafting  
- Endovascular repair  
- Balloon dilation  
- Stenting  
- Endoleaks  
- Aortic gradient  
- Collateral formation  
- Left ventricular hypertrophy  
- Upper extremity hypertension  
- Lower extremity hypoperfusion  
- Blood pressure differential  
- Femoral pulse delay  
- Ambulatory blood‑pressure monitoring  
- Exercise testing  
- Magnetic resonance imaging (MRI)  
- Computed tomography (CT)  
- Transthoracic echocardiography (TTE)

Page 106 Extracted Terms:
- Aortic arch  
- Distal subclavian artery  
- Right subclavian artery  
- Aberrant subclavian artery  
- Posterior mediastinum  
- Dysphagia  
- Respiratory symptoms  
- Laryngeal nerve palsy  
- Kommerell’s diverticulum  
- Fourth primitive dorsal aortic arch  
- Thoracic aortic aneurysm (TAA)  
- Thoracic aortic dissection (TAD)  
- Rupture  
- Dissection  
- Surgical intervention  
- SVS clinical practice guidelines  
- Variant aortic arch anatomy  
- CT scan  
- MRI scan  
- Cross‑sectional imaging  
- Endovascular repair  
- Open repair  
- Hybrid approach  
- TEVAR (thoracic endovascular aortic repair)  
- Revascularization of vertebral artery  
- Aberrant left vertebral artery origin  
- Thoracic aortic repair  
- Aortic orifice  
- Aortic diameter  
- Aortic arch repair  
- Aortic aneurysm repair  

Page 107 Extracted Terms:
- Left subclavian artery  
- Vertebral artery  
- Left vertebral artery  
- Right vertebral artery  
- Stroke  
- Spinal cord injury (SCI)  
- Thoracic aortic aneurysm (TAA)  
- Thoracic aortic disease (TAD)  
- Transcatheter endovascular aortic repair (TEVAR)  
- Aortic arch replacement  
- Open bypass  
- Transposition technique  
- Aortic dissection  
- Acute type A aortic dissection  
- Bovine arch (common innominate and left carotid artery)  
- Type I aortic arch  
- Type II‑A aortic arch  
- Type II‑B aortic arch  
- Dominant left vertebral artery  
- Nonintact circle of Willis  
- Symptomatic vertebrobasilar insufficiency  
- Posterior circulation perfusion  
- Posterior circulation  
- Aberrant left vertebral artery origin  
- Perioperative stroke  
- Multivariable analysis  
- Odds ratio (OR)  
- Confidence interval (CI)

Page 108 Extracted Terms:
- Aortic aneurysm  
- Thoracic aortic aneurysm  
- Thoracoabdominal aortic aneurysm  
- Aortic dissection  
- Aortic dilation  
- Aortic arch  
- Bovine arch  
- Aortic arch disease  
- Aortic tumor  
- Aortic sarcoma  
- Marfan syndrome  
- Cardiac rehabilitation (post‑aortic surgery)  
- Physical activity recommendations for aortic disease  
- Blood‑pressure (BP) control  
- Aortic growth rate  
- Valsalva maneuver (intense isometric exercise)  
- Aortic repair  
- Aortic resection  
- Aortic reconstruction (of affected segment)  
- Cardiovascular health  
- Aortic rupture (risk factor)  
- Aortic replacement  

(These terms represent key concepts and conditions related to heart and aortic disease discussed in the text.)

Page 109 Extracted Terms:
- Aortic disease  
- Aortic aneurysm (AAA)  
- Thoracic aortic aneurysm (TAA)  
- Aortic dissection  
- Aortic root enlargement  
- Aorta dilation  
- Marfan syndrome  
- Cardiac rehabilitation  
- Exercise‑based cardiac rehabilitation  
- Cardioprotective exercise  
- Peak oxygen uptake (VO₂ max)  
- Maximal workload  
- Heart‑related quality of life (HRQOL)  
- Metabolic equivalents (METs)  
- Valsalva maneuver  
- Hypertension  
- Systemic blood pressure (SBP)  
- Endovascular aneurysm repair (EVAR)  
- Open surgical repair  
- Aortic growth rate  
- Aortic diameter  
- Aortic stiffness index (ASI)  
- Elastin fragmentation  
- Matrix metalloproteinases (MMP‑2, MMP‑9)  
- Functional exercise capacity  
- Exercise intensity (low‑, moderate‑, high‑intensity)  
- Physical activity level  
- Screening for AAA  
- Cost‑effectiveness of aortic treatment  
- Risk of aortic rupture  
- Post‑operative cardiac event  
- Depression/anxiety in aortic patients  
- Posttraumatic stress disorder (PTSD)  
- Health‑related quality of life assessment tools (e.g., SF‑36)

Page 110 Extracted Terms:
**Key Heart‑Disease–Related Terms Identified**

- Aortic disease (guideline focus)  
- Thoracic aortic aneurysm (TAA)  
- Aortic dissection (TAD)  
- Acute aortic syndrome (AAS)  
- Bicuspid aortic valve (BAV)  
- Aortic valve stenosis (AVS)  
- Aortic valve regurgitation (AVR)  
- Endovascular thoracic aortic repair (TEVAR)  
- Open aortic surgery (open repair)  
- Cost‑effectiveness of aortic interventions  
- Biomarkers for aortic risk stratification  
- Protein‑based biomarkers  
- Non‑coding RNAs (e.g., microRNA)  
- Genetic testing for aortic disease (pathogenic mutations)  
- Environmental risk factors for aortic aneurysm  
- Lifestyle risk factors (e.g., smoking, hypertension)  
- Fluoroquinolone use and aortic aneurysm risk  
- Biomechanical wall stress in the aorta  
- Hemodynamic flow disturbances  
- Machine‑learning–based imaging analysis for aortic assessment  
- Risk stratification and early diagnosis of aortic disease  
- Precision medicine and patient‑centered care for aortic disease  
- Sex, race, and ethnicity disparities in aortic disease outcomes  
- Aortic repair timing and surgical decision‑making.

Page 111 Extracted Terms:
- Aortic disease  
- Aortic dissection  
- Aortic repair (endovascular or open)  
- Endovascular technology  
- Stent‑graft design  
- Vascular imaging technology  
- Simulation training for operators  
- Reinterventions  
- Optimal exercise protocols  
- Rehabilitation strategies  
- Health‑related quality of life (HRQOL)  
- Psychosocial well‑being  
- Marfan syndrome  
- Loeys‑Dietz syndrome  
- Vascular Ehlers‑Danlos syndrome  
- Heritable thoracic aortic aneurysm (TAA)  
- Cardiovascular care  
- Gender, sex, and racial/ethnic disparities  
- Socio‑demographic disparities  
- Physician market concentration  
- Patient engagement and retention  
- Educational interventions and training opportunities  
- Quality improvement projects  
- Evidence‑based medicine benchmarks  
- Cardiovascular and aortic care standards  
- Access to skilled practitioners  
- Inclusion in clinical trials  
- Physical, mental, and emotional health impact of aortic disease  

Page 112 Extracted Terms:
- Aortic disease  
- Valvular heart disease  
- Cardiovascular disease  
- Thoracic endovascular aortic repair (TEVAR)  
- Aortic aneurysm / thoracic aortic aneurysm  
- Heart disease  
- ACC/AHA clinical practice guidelines (for heart disease)  
- Cardio‑vascular disease  
- Aortic disorder  
- Valve disorder

(Note: These terms capture the key heart‑related concepts present in the provided guideline excerpt.)

Page 113 Extracted Terms:
- Aortic disease  
- Large‑vessel vasculitis  
- Bicuspid aortic valve disease  
- Aortic aneurysm (thoracic and abdominal)  
- Aortic dissection (type A & type B)  
- Intramural hematoma  
- Penetrating aortic ulcer  
- Aortic dilation / enlargement  
- Aortic root assessment  
- Aortic cross‑sectional area/height ratio  
- Congenital heart disease  
- Peripheral artery disease (lower extremity)  
- Hypertension (high blood pressure)  
- Coronary artery disease / atherosclerotic vascular disease  
- Aortic intramural hematoma management  
- Aortic rupture risk  
- Aortic endovascular repair  
- Aortic surgical repair  
- Mycotic aneurysm  
- Vascular graft infection  
- Endovascular infection  
- Traumatic thoracic aortic injury  
- Acute aortic syndrome (AAS)  
- Marfan syndrome (aortic root evaluation)  
- ACC/AHA Aortic Disease Guideline (2022)  
- 2018 ACC/AHA guideline for blood‑cholesterol management  
- 2018 ACC/AHA guideline for congenital heart disease  
- 2018 ACC/AHA guideline for lower‑extremity peripheral artery disease  
- 2019 ESC Guidelines on diagnosis and treatment of aortic diseases  
- 2021 American Association for Thoracic Surgery consensus on acute type A aortic dissection  
- 2022 Society of Thoracic Surgeons/American Association for Thoracic Surgery guideline on type B aortic dissection  
- European Society for Vascular Surgery (ESVS) thoracic aortic disease guidelines  
- Society for Vascular Surgery abdominal aortic aneurysm guidelines  
- 2010 ACCF/AHA guidelines for thoracic aortic disease (diagnosis & management)  
- ACC/AHA secondary‑prevention guideline for coronary and atherosclerotic vascular disease  
- Zone 0 thoracic endovascular aortic repair (landing zone classification)  
- Aortic landing zone definitions (zone 0–4)  
- Acute aortic syndrome classification (IRAD system)  
- Aortic aneurysm reporting standards (SVS/STS)  
- Acute aortic intramural hematoma versus dissection in the ascending aorta (clinical features)  
- Endovascular management of malperfusion syndromes in aortic dissection.

Page 114 Extracted Terms:
- aortic aneurysm  
- thoracoabdominal aortic aneurysm  
- descending thoracic aorta  
- aortic dissection  
- type B aortic dissection  
- type A aortic dissection  
- bicuspid aortic valve  
- trileaflet aortic valve  
- Marfan syndrome  
- ascending aortic aneurysm  
- aortic root  
- aortic cross‑sectional area  
- aortic diameter  
- aortic volume  
- aortic stiffness  
- aortic imaging  
- computed tomography (CT)  
- magnetic resonance angiography (MRA)  
- echocardiography  
- endograft  
- endovascular repair  
- open repair  
- transcatheter therapies  
- postoperative surveillance  
- radiation dose/exposure  
- body surface area (BSA)  
- height  
- body size  
- age  
- gender  
- risk estimation  
- aneurysm repair  
- intramural hematoma  
- acute aortic syndrome  
- thoracic aortic involvement  
- aortic surveillance  
- aortic remodeling  
- aortic measurement standards  
- aortic cross‑sectional area/height ratio  
- aortic length  
- aortic volume as disease indicator  
- aortic root dimensions  
- aortic diameter predictive value  
- aortic disease progression.

Page 115 Extracted Terms:
Aortic Dissection  
Thoracic Aortic Aneurysm (TAA)  
Abdominal Aortic Aneurysm  
Aortic Root Replacement  
Endoluminal Aortic Aneurysm Repair  
Thoracic Endovascular Aortic Repair (TEVAR)  
Intravascular Ultrasound Imaging  
Magnetic Resonance Imaging (MRI)  
Computed Tomography (CT)  
Echocardiography  
Ultrasound Imaging  
Takayasu’s Arteritis  
Nephrogenic Systemic Fibrosis  
Peripheral Arterial Disease  
Cardiovascular Surgery  
Multidisciplinary Aortic Team  
Shared Decision-Making  
Decision Aid  
ACC/AHA Aortic Disease Guideline  
ACC/AHA Guideline for Valvular Heart Disease  
ACC/AHA 2005 Guidelines for Peripheral Arterial Disease  
ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for Thoracic Aortic Disease  
High-volume Surgeon  
Low-volume Surgeon  
High-volume Aortic Center  
Institutional Volume  
Endoleak  
Aortic Remodeling  
Intimal Flap Mobility  
Volume–Outcome Relationship  
Screening for Abdominal Aortic Aneurysm  
UK Small Aneurysm Trial  
Decision Support Framework  
Marfan Syndrome  
Cardiovascular Care  
Cardiovascular Imaging  
Contrast-Enhanced MR Angiography  
Gadolinium-based Contrast Media  
Intravascular Ultrasound Assisted Sizing  
Endovascular Aortic Repair  
Cardiac Imaging Modalities  
Magnetic Resonance Angiography  
Percutaneous Aortic Imaging  
Aortic Diameters  
Aortic Pathology Evaluation  
Aortic Imaging Standards.

Page 116 Extracted Terms:
- Ascending aortic aneurysm  
- Thoracic aortic aneurysm  
- Aortic dissection  
- Ascending aortic aneurysm outcomes  
- Thoracic endovascular aneurysm repair (TEVAR)  
- Aortic imaging  
- Aortic dilatation  
- Aortic geometry  
- Aortic size  
- Aortic valve (bicommissural)  
- Ascending aorta dimensions  
- Body surface area  
- Height  
- Genetic testing  
- Heritable thoracic aortic disease  
- ACTA2 mutation  
- SMAD3 mutation  
- TGFB2 mutation  
- TGFBR1 mutation  
- TGFBR2 mutation  
- FBN1 mutation  
- MYLK mutation  
- PRKG1 mutation  
- Coronary artery disease  
- Stroke  
- Moyamoya disease  
- Familial thoracic aortic aneurysms and dissections  
- Non‑syndromic thoracic aortic aneurysm  
- Family screening  
- Incidence  
- Prevalence  
- Risk factors  
- Decision‑making algorithm  
- Clinical genetics  
- Precision medicine

Page 117 Extracted Terms:
- Marfan syndrome  
- Aortic root  
- Aortic root dilation  
- Aortic root aneurysm  
- Aortic root replacement surgery  
- Aortic dissection  
- Thoracic aortic disease  
- Aortic aneurysm  
- Ascending aorta  
- Descending aorta  
- Aortic arch  
- Abdominal aorta  
- Aortic cross‑sectional area  
- Aortic diameter  
- Aortic surgery timing  
- Aortic event rate  
- Aortic complications  
- Cardiovascular disease  
- Family history of cardiovascular disease  
- Multimodality imaging  
- Echocardiography  
- 2‑D echocardiographic aortic root dimensions  
- Angiotensin II blockade  
- Angiotensin receptor blockers (ARBs)  
- Losartan  
- Irbesartan  
- Beta‑adrenergic blockade  
- Atenolol  
- Beta‑blocker therapy  
- Verbal artery tortuosity index (vascular complication indicator)  
- ESC guideline for aortic diseases  
- ACCF/AHA guideline for thoracic aortic disease  
- ESC guideline for aortic disease 2014  
- ACC/AHA aortic disease guideline 2022   
- Marfan surgical outcomes (early and 1‑year)  
- Natural history of aortic root aneurysm in Marfan syndrome  
- Prognostic significance of aortic root dilation pattern  
- Long‑term survival after aortic aneurysm repair  
- Aortic root remodeling  
- Pulmonary hypertension (implied in thoracic aortic disease)  
- Cardiovascular imaging modalities (TTE, CT, MRI)

Page 118 Extracted Terms:
- Aortic root replacement  
- Thoracic aortic disease  
- Aortic dissection  
- Aortic aneurysm  
- Aortic arch  
- Descending aorta  
- Endovascular repair  
- Open repair  
- Loeys‑Dietz syndrome  
- Marfan syndrome  
- TGF‑β receptor  
- SMAD3  
- TGFB2  
- TGFB3  
- TGFBR1  
- TGFBR2  
- MYH11  
- ACTA2  
- Aortic root  
- Pregnancy‑related acute aortic dissection  
- Aneurysms‑osteoarthritis syndrome  
- Familial thoracic aortic aneurysm  
- Thoracic aortic aneurysm  
- Type B aortic dissection  
- Chronic type B aortic dissection  
- Fenestrated aortic repair  
- Branched endovascular aortic repair  
- Vascular pathogenesis  
- Angiotensin II‑dependent TGF‑β signaling  
- Aortic root replacement for children  
- Cardiovascular phenotype  
- Phenotypic spectrum  
- Intracranial aneurysm  
- Extracranial aneurysm  
- Thoracic aortic aneurysm and dissection  
- Aneurysm syndromes  
- Cardiovascular operations  
- Genetic testing in aortic disease  
- Medical therapy for Loeys‑Dietz syndrome  
- Surgical interventions for Loeys‑Dietz syndrome  
- Aortic disease management guidelines  
- Multigenerational families with thoracic aortic aneurysms and dissections  
- Cardiogenetics  
- Aortic disease risk assessment  
- TGF‑β signaling pathway in vascular disease  
- Aneurysm syndromes caused by TGF‑β mutations  
- Family history of aortic aneurysms and dissections  
- Pediatric aortic root replacement  
- Medically and surgically managed Loeys‑Dietz syndrome patients  
- Mitral valve disease associated with TGFB2 mutations  
- Interventional radiology for aortic disease  
- Thoracic surgery for aortic arch in Loeys‑Dietz syndrome  
- Endovascular aortic repair for type B dissection with thoracoabdominal aneurysms  
- Genetic variants in aneurysm‑related genes  
- Aggressive cardiovascular phenotype of aneurysms‑osteoarthritis syndrome  
- Clinical features and outcomes of pregnancy‑related aortic dissection  
- Imaging in Loeys‑Dietz syndrome  
- Guidelines for diagnosis and management of thoracic aortic disease (ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM)  
- International registry of patients with TGFBR1/TGFBR2 mutations (Montalcino Aortic Consortium).

Page 119 Extracted Terms:
- Aortic aneurysm  
- Thoracic aortic aneurysm  
- Aortic dissection (type A, type B)  
- Aortic dilation  
- Bicuspid aortic valve  
- Coronary artery disease  
- Stroke  
- Moyamoya disease  
- Vascular Ehlers‑Danlos syndrome  
- Marfan syndrome  
- Loeys‑Dietz syndrome  
- TGFBR1 mutation  
- TGFBR2 mutation  
- TGFB3 mutation  
- ACTA2 mutation (smooth muscle alpha‑actin)  
- PRKG1 mutation (protein kinase G)  
- MYH11 mutation (myosin heavy chain 11)  
- MYLK mutation (myosin light chain kinase)  
- LOX mutation (lysyl oxidase)  
- Patent ductus arteriosus  
- Turner's syndrome (Turner’s syndrome)  
- Congenital heart disease in Turner’s syndrome  
- Cardiovascular malformations/complications in Turner’s syndrome  
- Aortic anomalies in Turner’s syndrome  
- Vascular anomalies (magnetic resonance angiographic features)  
- Aortic disease presentation & outcome  
- Management of aortic diseases (guideline recommendations)  
- Pregnancy‑related cardiovascular complications (in vascular Ehlers‑Danlos and Turner’s syndrome)  
- Genetic screening for thoracic aortic disease  
- Family clustering of bicuspid aortic valve and aortic dilation.

Page 120 Extracted Terms:
- Bicuspid aortic valve (BAV)  
- Bicuspid aortic valve disease  
- Bicuspid valve phenotype  
- Aortic aneurysm (thoracic, abdominal, ascending)  
- Aortic dissection (type A)  
- Aortic dilation / aortopathy  
- Ascending aorta  
- Aortic root  
- Aortic valve stenosis  
- Aortic valve regurgitation / dysfunction  
- Aortic valve replacement (AVR)  
- Aortic root replacement  
- Surgical aortic replacement  
- Aortic surgery  
- Coarctation of the aorta (aortic coarctation)  
- Ventricular outflow‑tract obstruction (left ventricular outflow‑tract obstruction)  
- Valvular heart disease  
- Cardiac imaging (MDCT, echocardiography, 2‑D echocardiography)  
- Aortic root dimensions  
- Aortic cross‑sectional area/height ratio  
- Familial thoracic aortic dilation  
- Heritable bicuspid aortic valve  
- Genetic mutations (LOX, SMAD6, other aortopathy genes)  
- Genetic testing for inherited cardiovascular disease  
- Screening for abdominal aortic aneurysm (AAA)  
- Primary‑care aortic aneurysm screening  
- Risk factors for aortic disease  
- Aortic events (rupture, dissection, aneurysm growth)  
- Cost‑effectiveness of aortic screening  



Page 121 Extracted Terms:
- Abdominal aortic aneurysm  
- Thoracic aortic aneurysm  
- Aortic aneurysm (general)  
- Aortic dissection  
- Marfan syndrome  
- Bicuspid aortic valve  
- Hypertension (high blood pressure)  
- Blood pressure management  
- β‑blocker therapy  
- β‑adrenergic blockade  
- Angiotensin receptor blocker (ARB)  
- Losartan  
- Valsartan  
- Statin therapy  
- LDL cholesterol lowering  
- Cholesterol management  
- Aortic root dilatation  
- Aortic root aneurysm  
- Aortic arch aneurysm  
- Descending thoracic aortic aneurysm  
- Thoracoabdominal aortic aneurysm  
- Aortic rupture  
- Aortic growth rate  
- Aortic surveillance (monitoring)  
- Screening for aneurysms  
- Endovascular repair  
- Open surgical repair  
- Mycotic (infectious) aortic aneurysm  
- Medium‑ and large‑vessel vasculitis  
- Aortic pathology in connective‑tissue disorders  
- Familial aneurysm risk  
- Genetic predisposition to aortic disease  
- Blood pressure control standards (ACC/AHA)  
- Intensive blood‑pressure control (SPRINT)  
- Coronary and other atherosclerotic vascular disease  
- Atherosclerosis risk (ARIC study)  
- Blood‐pressure related vascular mortality  
- Aortic size surveillance intervals  
- Aortic wall biomechanics  
- Aortic aneurysm natural history  
- Aortic dilatation progression  
- Aortic dissection incidence  
- Aortic disease epidemiology  
- Cardiovascular morbidity and mortality in aneurysm patients  
- Clinical trial outcomes for aneurysm management (e.g., losartan trials)  
- Pharmacologic interventions for aneurysm prevention  
- Endovascular versus open repair outcomes  
- Family screening guidelines  
- Risk factor modification (smoking, cholesterol, blood pressure)  
- Aortic aneurysm guidelines (ACC/AHA)  
- Aortic disease surveillance protocols  
- Aortic aneurysm pathophysiology  
- Vessel wall inflammation in aneurysm formation  
- Aortic disease management algorithms  

(Note: Each bullet represents a key term or concept relevant to heart disease extracted from the provided text.)

Page 122 Extracted Terms:
- Aortic aneurysm  
- Thoracic aortic aneurysm (TAA)  
- Abdominal aortic aneurysm (AAA)  
- Bicuspid aortic valve disease  
- Marfan syndrome  
- Statin therapy  
- Statin use  
- LDL cholesterol  
- High blood cholesterol  
- Cholesterol treatment  
- Blood pressure management  
- Hypertension  
- Antiplatelet therapy  
- Antithrombotic therapy  
- Aspirin use  
- Endothelial dysfunction  
- Elastin-specific autoimmunity  
- Matrix metalloprotease‑9  
- Ras/ERK signaling pathway  
- Smoking cessation  
- Tobacco use disorder  
- Electronic cigarette effects  
- Cardiovascular disease (CVD)  
- Peripheral artery disease (PAD)  
- Coronary artery disease  
- Atherosclerosis  
- Vascular mortality  
- Intensive blood‑pressure control  
- Systolic blood pressure intervention trial (SPRINT)  
- Lipid‑lowering therapy  
- Vascular dysfunction  
- Endovascular aneurysm repair  

These are the principal heart‑disease–related terms appearing in the text.

Page 123 Extracted Terms:
- High blood cholesterol  
- Hyperlipidemia  
- Coronary artery disease  
- Atherosclerotic vascular disease  
- Thoracic aortic dilation  
- Thoracic aortic aneurysm  
- Aortic aneurysm (general)  
- Abdominal aortic aneurysm  
- Aortic root  
- Ascending aorta  
- Bicuspid aortic valve  
- Aortic valve  
- Aortic dissection  
- Endovascular repair  
- Endoleak  
- Multimodality imaging  
- Computed‑tomeography (CTA)  
- Magnetic resonance imaging (MRI) / MRA  
- Non‑contrast MRI  
- Ultrasound screening  
- Surveillance interval  
- Growth rate of aneurysm  
- Rupture risk  
- Surgical repair  
- Composite graft replacement  
- Inclusion‑wrap technique  
- Open repair technique  
- Aortic valve replacement  
- Aortic cross‑sectional area‑to‑height ratio  
- Aortic dilation rate  
- Aortic stenosis  
- Bicuspid valve‑associated aneurysm  
- Aortic disease guidelines  
- ACCF/AHA guidelines for thoracic aortic disease  
- ESC guidelines for aortic disease  
- ACC/AHA guidelines for secondary prevention in coronary disease  
- National Cholesterol Education Program (NCEP) Adult Treatment Panel III  
- Society of Thoracic Surgeons (STS) guideline on aortic aneurysm care  
- Society for Vascular Medicine (SVM) guideline on aortic disease  
- American College of Radiology (ACR) imaging guidelines for aortic disease  
- European Society of Cardiology (ESC) guidelines on aortic disease  
- American Heart Association (AHA) guideline statements on aortic valve disease  
- American College of Cardiology (ACC) guideline statements on aortic valve disease  
- Guidelines for multimodality imaging of thoracic aorta  
- Guidelines for surveillance of abdominal aortic aneurysm  
- Guidelines for management of thoracic aortic aneurysm size thresholds  
- Guidelines for endovascular aneurysm repair follow‑up  
- Guidelines for aortic valve and ascending aorta quality measures  
- Guidelines for bicuspid aortic valve‑related aortopathy.

Page 124 Extracted Terms:
- Aortic root  
- Ascending aorta  
- Thoracic aorta  
- Aortic aneurysm  
- Aortic dissection (Type A)  
- Bicuspid aortic valve  
- Tricuspid aortic valve  
- Aortic valve replacement  
- Valve‑sparing aortic root replacement  
- Root‑sparing ascending replacement  
- Reimplantation (aortic valve)  
- Remodeling (aortic root)  
- Ring annuloplasty (aortic root)  
- Proximal aortic surgery  
- Thoracic aortic surgery  
- Wall stress in the aorta  
- Aortic biomechanics  
- Aortic elongation  
- Aortic size threshold (e.g., ≥5.5 cm, ≥5 cm)  
- Aortic root replacement  
- Hemiarch repair  
- Aortic valve disease (stenosis, insufficiency)  
- Aortic root aneurysm  
- Aortic root pathology  
- Syndromic aneurysm (e.g., Marfan syndrome)  
- Non‑syndromic aneurysm  
- Acute aortic events  
- Mortality related to aortic disease  
- Aortic valve‑related reoperation  
- Aortic root repair techniques  
- Genetic predisposition to aortic disease  
- Aortic root and ascending aorta surgical criteria.

Page 125 Extracted Terms:
- Aortic disease  
- Aortic root aneurysm  
- Aortic arch aneurysm  
- Thoracic aortic aneurysm (TAA)  
- Thoracoabdominal aortic aneurysm  
- Aortic dissection  
- Marfan syndrome  
- Loeys‑Dietz syndrome  
- Bicuspid aortic valve disease  
- Valve‑sparing aortic root replacement  
- Mechanical aortic root replacement  
- Aortic valve replacement  
- Endovascular aneurysm repair (EVAR)  
- Hybrid arch exclusion (zone 0‑0)  
- Frozen elephant trunk technique  
- Aortic arch reconstruction  
- Antegrade cerebral perfusion  
- Axillary artery cannulation  
- Innominate artery cannulation  
- Circulatory arrest  
- Stroke risk (neurologic outcome)  
- Wall stress (saccular vs fusiform aneurysm)  
- Infected aortic aneurysm  
- Smooth muscle dysfunction syndrome (ACTA2)  
- Guidelines for aortic diseases (ACC/AHA, ESC, EACTS/ESVS)  
- STS Adult Cardiac Surgery Database  
- Incidence/size thresholds for rupture or dissection  
- Complications of aortic operations (bleeding, thromboembolism, reintervention)  

These are the principal terms related to heart disease that appear in the provided text.

Page 126 Extracted Terms:
**Heart‑disease–related key terms extracted from the text**

1. Thoracic aortic aneurysm  
2. Descending thoracic aortic aneurysm  
3. Thoracic endovascular aneurysm repair (TEVAR)  
4. Endovascular repair  
5. Open surgical repair  
6. Aortic dissection (chronic/acute)  
7. Ruptured aortic aneurysm  
8. Subclavian artery coverage  
9. Celiac artery coverage  
10. Stroke (neuro‑vascular complication)  
11. Paralysis (neurologic complication)  
12. Mortality (death)  
13. Morbidity (disease burden)  
14. Stent graft / graft / endograft (vascular device)  
15. Percutaneous access  
16. Preclose technique (percutaneous closure)  
17. Femoral artery access  
18. Branch endovascular therapy  
19. Cardiovascular disease (broader context)  
20. GRADE‑rated clinical trial outcomes  
21. GORE TAG device (device-based term)  
22. Medtronic Talent stent graft (device-based term)  

These terms represent the principal clinical concepts, procedures, complications, and device references that are specific to cardiovascular and aortic pathologies discussed throughout the guideline excerpts.

Page 127 Extracted Terms:
- Thoracic Aortic Aneurysm (TAA)  
- Thoracoabdominal Aortic Aneurysm (TAAA)  
- Aortic Dissection  
- Endovascular Aneurysm Repair (EVAR)  
- Open Surgical Repair  
- Spinal Cord Protection  
- Cerebrospinal Fluid Drainage  
- Spinal Cord Ischemia  
- Paraplegia  
- Intrathecal Papaverine  
- Endograft (Branched/Fenestrated)  
- Aortic Replacement  
- Renal Protection Strategies  
- Visceral Organ Protection  
- Type B Aortic Dissection  
- Type A Aortic Dissection  
- Marfan Syndrome  
- Connective Tissue Disease  
- Ruptured Aortic Aneurysm  
- Size Thresholds for Repair  
- Rupture Risk  
- Inflammatory Cytokines  
- Left Ventricular Ejection Fraction  
- Octogenarian Surgery Outcomes  
- Neurosurgical Monitoring  
- Cerebrospinal Fluid Pressure Management  
- Spinal Cord Perfusion Pressure  
- Aortic Disease Guidelines  
- ACCF/AHA Guidelines  
- ESC Guidelines  
- Surgical Outcomes  
- Mortality Risk  
- Complication Rates  
- Cerebrovascular Complications  
- Neurological Outcomes  
- Prognostic Factors

Page 128 Extracted Terms:
- Abdominal aortic aneurysm (AAA)  
- Thoracoabdominal aortic aneurysm  
- Endovascular aneurysm repair (EVAR)  
- Open aortic aneurysm repair  
- Ruptured abdominal aortic aneurysm  
- Aortic aneurysm surveillance  
- Surgical threshold for AAA repair  
- Aortic aneurysm diameter/size  
- Aortic aneurysm growth rate  
- Aortic aneurysm rupture risk  
- Endovascular repair vs. open repair  
- Perioperative outcomes of aortic repair  
- Anesthesia (local vs. general) in aortic surgery  
- Ultrasound‑guided femoral access  
- Groin hematoma  
- Fluid resuscitation strategies in hypotensive trauma patients  
- Hemorrhagic shock pathophysiology  
- Rapid infusion systems in trauma care  
- Aortic neck IFU (instructions for use) violations  
- Catheter‑directed endograft techniques  
- Aortic endograft complications  
- Aortic disease guidelines  
- Vascular surgery outcomes studies  
- National Surgical Quality Improvement Program (NSQIP) data on aortic aneurysm  
- Multicenter randomized trials in aortic surgery  
- Meta‑analysis of individual patient data for AAA  
- Aortic aneurysm registry/quality initiative data  
- Renal protection during thoracoabdominal aneurysm repair  
- Cold blood vs. cold crystalloid perfusion  
- Celiac, superior mesenteric, and renal artery involvement in aortic aneurysm  
- Aortic aneurysm-related mortality studies  
- Endovascular treatment of ruptured aorto‑iliac aneurysms  
- Rapid fluid resuscitation for torso trauma  
- Aortic aneurysm growth surveillance by ultrasound  
- Aortic aneurysm surgical decision‑making criteria  

(Note: These terms collectively represent key concepts related to heart and vascular disease as presented in the provided guideline excerpts.)

Page 129 Extracted Terms:
- Abdominal aortic aneurysm  
- Thoracic aortic aneurysm  
- Endovascular aneurysm repair (EVAR)  
- Open aneurysm repair  
- Thoracic endovascular aortic repair (TEVAR)  
- Aortic dissection  
- Iliac artery aneurysm  
- Fenestrated endovascular repair  
- Aortic graft  
- Aortic endograft device  
- Internal iliac artery exclusion  
- Cardiac risk index (Vascular Quality Initiative)  
- Myocardial infarction  
- Graft‑related adverse events  
- Perioperative morbidity  
- Perioperative mortality  
- Symptomatic non‑ruptured aneurysm  
- Ruptured abdominal aortic aneurysm  
- High‑risk patients  
- Low‑to‑moderate‑risk patients  
- Long‑term outcomes  
- Survival after repair  
- Post‑operative complications  
- Risk prediction models (e.g., Vascular Study Group of New England)

Page 130 Extracted Terms:
- Aortic aneurysm  
- Thoracic aortic aneurysm (TAA)  
- Abdominal aortic aneurysm (AAA)  
- Aortic dissection (AD)  
- Acute aortic syndrome (AAS)  
- Endovascular repair (EVAR, TEVAR)  
- Open surgical repair  
- Stent graft / endograft  
- Endoleak (type I, type II, type III)  
- Surveillance imaging  
- Computed tomography angiography (CTA)  
- Magnetic resonance angiography (MRA)  
- Contrast‑enhanced ultrasound (CEUS)  
- Duplex ultrasound  
- Non‑contrast MRI  
- Par‑anastomotic aneurysm  
- Aortic root aneurysm  
- Valve‑sparing aortic root replacement  
- Composite valve‑graft replacement  
- Marfan syndrome  
- Hypertension (antihypertensive therapy)  
- Cardiovascular research network  
- Cardiovascular quality and outcomes research  
- Aneurysm sac enlargement  
- Device migration, graft kink, graft migration  
- Renal branch grafts  
- Fenestrated/branched endovascular procedures (FEVAR/BEVAR)  
- Aortic valve disease (including ascending aortic aneurysm)  
- Endovascular aneurysm repair complications  
- Imaging of postsurgical aorta  
- Angiography (contrast‑enhanced)  
- Radiation exposure from CT  
- Endovascular aneurysm repair follow‑up  

(These terms capture the key heart‑ and aorta‑related concepts emphasized in the guideline excerpts.)

Page 131 Extracted Terms:
- Aortic disease  
- Thoracic aortic dissection  
- Acute aortic syndrome  
- Acute type A aortic dissection  
- Acute type B aortic dissection  
- Aortic expansion  
- Aortic arch dilatation  
- Aortic aneurysm (implied)  
- Transesophageal echocardiography  
- Helical computed tomography  
- Magnetic resonance imaging  
- Chest radiography  
- Aortic dissection detection risk score  
- D‑dimer  
- ADvISED risk score  
- International Registry of Acute Aortic Dissection (IRAD) score  
- Simple risk models for surgical mortality in type A dissection  
- Endovascular (endovascular repair)  
- Surgical repair of type A dissection  
- Thoracic endovascular aortic repair  
- Antihypertensive medications (beta‑blockers, calcium‑channel blockers, etc.)  
- Labetalol (intravenous)  
- Sodium nitroprusside (intravenous)  
- Clevidipine  
- Pitavastatin (statin therapy)  
- Calcium channel blockers (harmful in Marfan syndrome)  
- Marfan syndrome  
- Stroke (as a complication of aortic dissection)  
- Blood pressure control  
- Heart rate control  
- Hypertension  
- Short‑term survival  
- Long‑term survival  
- Acute medical management of aortic dissection  
- Subsequent medical management of aortic dissection  
- High‑volume versus low‑volume surgeons  
- Interfacility transfer of patients with acute type A aortic dissection  
- ACR Appropriateness Criteria for suspected acute aortic syndrome  
- ACC/AHA Aortic Disease Guideline  
- ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for thoracic aortic disease.

Page 132 Extracted Terms:
- Acute type A aortic dissection  
- Malperfusion syndrome  
- Cerebral malperfusion  
- Mesenteric (visceral) malperfusion  
- Aortic root surgery  
- Valve‑sparing aortic root repair (David procedure)  
- Bentall procedure  
- Aortic arch replacement  
- Hemiarch replacement  
- Total arch replacement  
- Frozen Elephant Trunk repair  
- Endovascular aortic repair (thoracic stent‑graft)  
- Endovascular fenestration / stenting first strategy  
- Emergency central aortic repair  
- Surgical cannulation strategies (axillary vs. femoral)  
- Cerebral protection strategy  
- Operative mortality  
- Post‑operative mortality  
- Immediate (early) surgical outcomes  
- Short‑term and long‑term survival  
- Hemodynamic instability  
- Reperfusion strategy  
- Operative risk models (IRAD score)  
- Night‑time or weekend surgical effect  
- Acute aortic disease (including DeBakey I and Stanford type A)

Page 133 Extracted Terms:
- Acute type A aortic dissection  
- Type B aortic dissection (acute, subacute, chronic)  
- Aortic arch  
- Aortic root  
- Aortic aneurysm  
- Endovascular repair (thoracic/endovascular aortic repair)  
- Endovascular fenestration / stenting  
- Thoracic endovascular aneurysm repair (TEVAR)  
- Frozen elephant trunk procedure  
- Conformable stent graft  
- Stent graft (various brands/models)  
- Arch replacement (total arch, extended arch, partial arch)  
- Cannulation strategies  
  - Ascending aortic cannulation  
  - Peripheral arterial cannulation (femoral, axillary)  
  - Innominate artery cannulation  
  - Central cannulation (aortic arch cannulation)  
- Cerebral perfusion techniques  
  - Antegrade cerebral perfusion  
  - Bilateral cerebral perfusion  
  - Unilateral cerebral perfusion  
- Malperfusion syndrome  
- Aortic remodeling  
- Neurologic complications (perfusion‑related, stroke)  
- Reoperation (late re‑intervention, redo surgery)  
- Medical management/therapy  
- Subacute/chronic type B management strategies
- Endovascular repair complications (access‑site, embolic events)

Page 134 Extracted Terms:
**Key heart‑disease terms extracted from the text**

- Aortic dissection  
- Type A aortic dissection  
- Type B aortic dissection  
- Acute aortic intramural hematoma (IMH)  
- Penetrating atherosclerotic ulcer (PAU)  
- Thoracic endovascular aortic repair (TEVAR)  
- Endovascular stent‑graft repair  
- Open surgical repair (arch or ascending aorta)  
- Intimal disruption  
- Rupture (of the aorta)  
- Hypertension (as a risk factor)  
- Refractory pain (symptom of acute dissection)  
- Medical therapy (best medical treatment)  
- Prognosis  
- Mortality (aorta‑related and all‑cause)  
- Surgical outcomes  
- Endovascular outcomes  
- Risk score (predicting death or need for surgery)  
- Imaging evolution (CT follow‑up)  
- Natural history (of PAU and IMH)  
- Clinical features  
- Radiological findings  
- Complications (e.g., aneurysm, dissection, ulcer)  
- Long‑term behavior / outcomes  
- Short‑term evolution  

These terms encompass the major clinical concepts, procedures, and prognostic factors related to aortic disease discussed in the guideline.

Page 135 Extracted Terms:
- ACC/AHA Aortic Disease Guideline  
- Aortic disease  
- Penetrating aortic ulcer (PAU)  
- Aortic intramural hematoma (IMH)  
- Aortic dissection  
- Blunt thoracic aortic injury (BTTAI)  
- Blunt abdominal aortic injury (BAAI)  
- Traumatic aortic injury  
- Thoracic endovascular aortic repair (TEVAR)  
- Endovascular aortic repair  
- Open surgical aortic repair  
- Resuscitative endovascular balloon occlusion of the aorta (REBOA)  
- Helical CT grading of aortic injury  
- Antihypertensive therapy for aortic injury  
- Heparin use in endovascular aortic repair  
- Infrarenal aortic ulcer therapy  
- Aortic isthmus rupture  
- Traumatic aortic rupture  
- Aortic injury classification schemes  
- Endovascular therapy for penetrating ulcers  
- Aortic injury management guidelines  

Page 136 Extracted Terms:
- Blunt traumatic aortic injury  
- Endovascular repair (TEVAR)  
- Thoracic aortic injury  
- Blunt abdominal aortic injury  
- Aortic dissection (type A, type B, DeBakey IIIA/IIIB, chronic)  
- Intramural hematoma (IMH)  
- Penetrating aortic ulcer (PAU)  
- Aortic arch surgery  
- Valve‑sparing root replacement  
- Aortic root repair  
- Distal aortic enlargement / reoperation  
- Aortic aneurysm (ascending, hemi‑arch, infrarenal)  
- Aortic intramural hematoma evolution  
- Endoleak (type IA)  
- Subacute and chronic aortic dissection management  
- Long‑term surveillance imaging of the aorta  
- DeBakey classification of aortic dissections  
- Stanford classification of aortic dissections  
- TGF‑β receptor mutations (associated with aneurysm syndromes)  
- Loeys‑Dietz syndrome  
- Marfan syndrome  
- Ehlers–Danlos syndrome (vascular type)  
- Turner syndrome (cardiovascular involvement)  
- Pregnancy‑associated aortic complications  
- Post‑partum cardiovascular disease  
- Organisation of care for pregnancy in congenital heart disease  
- ESC guidelines for cardiovascular disease during pregnancy  
- National Heart, Lung, and Blood Institute (NHLBI) GenTAC registry  
- Thoracic endovascular aortic repair for penetrating ulcers  
- Penetrating atherosclerotic ulcer of the thoracic aorta  
- Aortic disease in pregnancy – risk of dissection, rupture, and mortality  
- Counseling and management of aortic disease in pregnancy and postpartum  
- Aortic disease surveillance after repair (long‑term imaging)  
- Aortic disease complications during pregnancy (maternal and fetal outcomes)

Page 137 Extracted Terms:
- Aortic dissection  
- Aortic aneurysm  
- Thoracic aortic aneurysm  
- Abdominal aortic aneurysm  
- Aortic root  
- Chronic hypertension  
- Marfan syndrome  
- Loeys‑Dietz syndrome  
- Turner syndrome  
- Ehlers‑Danlos syndrome  
- TGFBR1 mutation  
- TGFBR2 mutation  
- ACTA2 mutation  
- MYLK mutation  
- SMAD3 mutation  
- PRKG1 mutation  
- Pregnancy‑associated aortic disease  
- Pregnancy‑related acute aortic dissection  
- Maternal‑fetal MRI  
- Calcium channel blocker interaction  
- Genetic testing (cardiogenetics)  
- Endovascular aneurysm repair (EVAR)  
- ACC/AHA Aortic Disease Guideline  
- ESC Aortic Disease Guideline (2014)  
- ACCF/AHA/AATS thoracic aortic disease guidelines (2010)  
- ACC/AHA hypertension guideline (2017)  
- High blood pressure (hypertension)  
- Gene‑by‑environment interaction  
- Aortopathy management during pregnancy  
- Aortic disease risk factors  
- Aortic disease natural history  
- Aortic disease surgical outcomes  

Page 138 Extracted Terms:
- Aortic disease  
- Aortic aneurysm  
- Aortic dissection (type A)  
- Aortic dissection (type B)  
- Thoracic aortic aneurysm  
- Familial thoracic aneurysms and dissections  
- Bicuspid aortic valve  
- Marfan syndrome  
- TGFB2 mutation  
- TGFB3 mutation  
- TGF‑beta receptor mutation (TGFBR1/TGFBR2)  
- SMAD3 mutation  
- ACTA2 mutation  
- MYLK variant  
- PRKG1 mutation  
- Aortopathy  
- Pregnancy in aortic disease  
- Cardiovascular diseases during pregnancy  
- Giant cell arteritis  
- Takayasu arteritis  
- Large‑vessel vasculitis  
- Giant cell aortitis  
- Inflammatory aortitis  
- Aortic involvement in giant cell arteritis  
- Aortic involvement in Takayasu arteritis  
- Endovascular intervention for aortic disease  
- Coronary and atherosclerotic vascular disease  
- Secondary prevention of coronary disease  
- Genetic testing in aortic disease (cardiogenetics)  
- Interventional radiology for vascular disease  
- Anti‑platelet/anticoagulant therapy for aortic complications  
- Medical management of aortic aneurysm/dissection  
- Surgical repair of aortic aneurysm/dissection  
- Imaging in large‑vessel vasculitis (e.g., PET, CT, MR)  
- Steroid therapy for giant cell arteritis  
- Biological‑targeted therapy for Takayasu arteritis  
- Pathogenic variants in aortic disease genetics  
- Phenotypic spectrum of TGFB3 disease‑causing variants  
- Aortic regurgitation associated with bicuspid valve  
- Cardiovascular risk prediction in aortopathy  
- Familial thoracic aortic disease genetics  
- Aortic wall false lumen and secondary dilatation  
- Aortic disease guidelines (ACC/AHA, ESC)

Page 139 Extracted Terms:
- Native aortic infection  
- Mycotic aortic aneurysm  
- Abdominal aortic aneurysm  
- Thoracic aortic aneurysm  
- Aortoenteric fistula  
- Prosthetic aortic graft infection  
- In situ graft repair  
- Extra‑anatomical bypass  
- Endovascular aneurysm repair (EVAR)  
- Open surgical repair  
- Rifampin‑soaked grafts  
- Cryopreserved aortoiliac allograft  
- Antimicrobial therapy for aortic infections  
- Staphylococcus aureus infection  
- Infective endocarditis  
- Atherosclerotic disease of the aorta  
- Thoracic aortic disease  
- Coronary artery disease  
- Cerebrovascular disease  
- Statin therapy (e.g., pravastatin)  
- Antithrombotic therapy (aspirin, anticoagulants)  
- Myocardial infarction risk  
- Stroke prevention in atherosclerosis  
- Graft‑related complications (reinfection, erosion, fistula)  
- Imaging diagnostics: FDG‑PET/CT, CT angiography, MRI, indium‑labeled WBC scan  
- Endovascular versus open repair outcomes  
- Perioperative antibiotic suppression  
- Graft enteric erosion  
- Prosthetic graft allograft replacement  
- Vascular graft infection epidemiology  
- Aortic disease guidelines (ACC/AHA, AHA statements)

Page 140 Extracted Terms:
Aortic disease  
Atherosclerotic lesion  
Atherosclerotic plaque  
Aortic arch disease  
Thoracic aorta disease  
Pulmonary circulation  

Aortic thrombus  
Aortic mural thrombus  
Floating aortic thrombus  
Aortic mural thrombosis  
Aortic thromboembolism  
Antithrombotic therapy  

Endovascular treatment  
Endovascular therapy  
Surgical repair  
Hybrid procedure  
Off‑pump myocardial revascularization  
No‑clamp technique  
‘No‑touch’ technique  

Calcification of the aorta  
Porcelain aorta  
Aortic dilatation  
Bicuspid aortic valve  
Aortic valve insufficiency  
Aortic valve repair  
Aortic valve replacement  

Coarctation of the aorta  
Congenital aortic anomaly  
Aberrant subclavian artery  
Congenital heart disease  
Peri‑operative complications  

Risk assessment  
Risk score  
Cardiovascular risk factor  

Stroke  
Ischemic stroke  
Cerebral ischemia  
Systemic embolism  
Embolic potential  

Peripheral arterial disease  
Abdominal aortic aneurysm  
Peripheral vascular disease  

Cardiovascular imaging  
Computed tomography angiography  
Magnetic resonance imaging  
Echocardiography  
Spiral computed tomography  

Mortality  
Cardiovascular event  
Cardiovascular death  
Systemic blood pressure  

Endarterectomy  
Angioplasty  
Balloon angioplasty  
Stenting  
Stent placement  

Coronary artery bypass grafting  
Off‑pump coronary bypass  
Coronary artery disease  
Coronary intervention  

Catheter‑based therapy  
Catheter‑guided therapy  
Valve surgery  

Multicenter study  
Large cohort study  
Population‑based analysis  

Clinical guideline  
ACC/AHA guideline  
American Heart Association guideline  
American College of Cardiology guideline  
Task Force guideline  

Ambulatory blood‑pressure monitoring  
Intra‑aortic debris  
Vascular event

---

Page 141 Extracted Terms:
- Aortic coarctation  
- Kommerell’s diverticulum  
- Aberrant subclavian artery  
- Aberrant left vertebral artery  
- Aortic aneurysm (thoracic, descending)
- Bicuspid aortic valve  
- Intracranial aneurysm  
- Hypertension (high blood pressure)  
- Endovascular treatment  
- Stent (Cheatham‑Platinum, covered, bare)  
- Balloon angioplasty  
- Stent placement (thoracic)  
- Thoracic endovascular aortic repair (TEVAR)  
- Open aortic repair  
- Hybrid repair of aortic aneurysm  
- End‑to‑end anastomosis  
- Cardiothoracic surgery  
- Vascular surgery  
- Cardiovascular magnetic resonance imaging (CMR)  
- Magnetic resonance angiography (MRA)  
- Aortic arch variants  
- Aortic arch branching variants  
- Thoracic aortic disease  
- Systemic blood pressure  
- Exercise‑induced hypertension  
- Ambulatory blood pressure monitoring  
- Aortic root complications  
- Ascending aortic complications  
- Aortopathy  
- Thoracic aortic pathologies  
- Aortic arch replacement  
- Aortic arch repair  
- Cardiovascular abnormalities  
- Intracranial aneurysm screening  
- Cost‑effectiveness analysis (of aneurysm screening)  
- ESC Aortic Diseases Guidelines  
- ACC/AHA Aortic Disease Guidelines  

These terms capture the core cardiovascular conditions, anatomical features, therapies, and diagnostic modalities discussed in the text.

Page 142 Extracted Terms:
- Aortic aneurysm  
- Thoracic aortic aneurysm  
- Abdominal aortic aneurysm  
- Aortic dissection (acute, type A, type B)  
- Thoracic aortic disease  
- Aortic arch anomaly / bovine arch  
- Left subclavian artery coverage  
- Stroke (neurologic complications)  
- Thoracic endovascular aortic repair (TEVAR)  
- Endografting / endovascular repair  
- Open repair of the aorta  
- Aortic root surgery / replacement / reimplantation  
- Aortic valve (intervention)  
- Mitral valve intervention  
- Sarcoma of the aorta / primary aortic tumor  
- Cardiac rehabilitation (exercise‑based)  
- Cardiopulmonary exercise testing  
- Physical activity / exercise prescription for aortic disease patients  
- Quality of life after aortic surgery  
- Surveillance of small abdominal aortic aneurysms  
- Growth rate of aortic aneurysms  
- Cardiovascular risk factors (for aortic aneurysm expansion)  
- Surgical outcomes in aortic disease  
- Guidelines for diagnosis and treatment of aortic disease (ACC/AHA, ESC, NICE, etc.)

Page 143 Extracted Terms:
- Aortic diseases  
- Thoracic aortic aneurysm  
- Abdominal aortic aneurysm  
- Aortic dissection  
- Bicuspid aortic valve (BAV)  
- Marfan syndrome  
- Aortopathy  
- Cardiac rehabilitation  
- Exercise recommendation / Physical activity  
- Endovascular repair (EVAR)  
- Open surgical repair (OSR)  
- Endoleak  
- Aneurysm sac  
- Thoracoabdominal aneurysm  
- Cost‑effectiveness  
- Screening (for aneurysm)  
- Biomarkers (e.g., desmosine, proteomics)  
- Genetic susceptibility loci (GWAS findings)  
- Fluoroquinolone use and aneurysm risk  
- Mediterranean diet and aneurysm prevention  
- Anti‑inflammatory diet  
- Epidemiology of aneurysms  
- Health‑related quality of life  
- Longitudinal spending on aortic repair  
- Clinical guidelines (ACC/AHA, ESC)  
- National guidelines (Aortic Disease Guideline)  
- Consensus statements on BAV aortopathy  
- Endovascular versus open repair outcomes  
- Risk factors for aortic dilation  
- Cardiovascular disease burden  
- Imaging modalities (MRI, CT, angiography)  
- Endovascular aneurysm repair (EVAR) vs. open repair  
- Hospital cost analysis in aortic surgery  
- Precision medicine in heritable thoracic aortic disease  



Page 144 Extracted Terms:
- ACC/AHA Aortic Disease Guideline  
- Abdominal aortic aneurysm  
- Thoracic aortic aneurysm  
- Ascending thoracic aortic aneurysm  
- Thoracoabdominal aortic aneurysm  
- Aortic root aneurysm  
- Aortic arch aneurysm  
- Aortic dissection (type A, type B, acute)  
- Marfan syndrome  
- Bicuspid aortic valve  
- Tricuspid aortic valve  
- Endovascular aneurysm repair (EVAR)  
- Endovascular repair of complex aortic aneurysms  
- Fenestrated‑branched endograft  
- Orthotopic branched endovascular arch repair  
- Stent‑graft deployment  
- Biomechanics of the aorta  
- Wall stress in the aorta  
- Aortic arch repair  
- Cardiac rehabilitation  
- Exercise‑based cardiac rehabilitation for aortic disease  
- Post‑operative quality of life in aortic patients  
- Sexual dysfunction after aortic dissection  
- Anxiety in patients undergoing abdominal aortic aneurysm surgery  
- Mental health disorders and aortic dissection  
- Gender differences in aortic aneurysm growth and outcomes  
- Racial disparities in endovascular aortic repair  
- Ethnic disparities in aortic disease management  
- Under‑representation of female patients in vascular trials  
- Propensity‑matched comparison studies in aortic surgery  
- Registry‑based thresholds for aortic repair in female patients  
- Longitudinal cohort studies of aortic surgery outcomes  
- Randomized clinical trials on quality of life after aortic repair  
- eHealth interventions for anxiety in aortic aneurysm surgery  
- Patient‑specific biomechanical simulation of stent‑graft deployment  
- Biomechanical modeling of stent‑graft deployment in type B aortic dissection.

Page 145 Extracted Terms:
- Aortic disease  
- Aortic aneurysm  
- Aortic dissection  
- Thoracic aortic disease  
- Cardiovascular disease  
- Cardiothoracic surgery  
- Interventional cardiology  
- Cardiac catheterization laboratory  
- Endovascular therapy  
- Vascular surgery  
- Marfan syndrome  
- Aortic valve disease (arterial valve, aortic stenosis, aortic regurgitation)  
- Aortic repair / aortic surgery  

These terms capture the core heart‑related concepts referenced in the guideline and author affiliations.

Page 146 Extracted Terms:
- Aortic disease  
- Aortic disease guideline  
- Aortic center  
- Cardiac catheterization  
- Cardiac surgery  
- Cardiovascular medicine  
- Cardiology  
- Cardiothoracic surgery  
- Endovascular surgery  
- Marfan syndrome  
- Connective tissue disorder  
- Heart  
- Vascular  
- Thoracic  

Page 147 Extracted Terms:
- ACC/AHA  
- American College of Cardiology  
- American Heart Association  
- Aortic Disease  
- Cardiaca  
- Cardiovascular  
- Cardiothoracic Surgery  
- Vascular Surgery  
- Endovascular  
- Clinical Statement  
- Guideline  
- Drug  
- Device  
- Clinical Trial  

Page 148 Extracted Terms:
- ACC (American College of Cardiology)  
- AHA (American Heart Association)  
- ACC/AHA  
- Aortic Disease  
- Aortic Aneurysm  
- Aortic Dissection  
- Aortic Valve Disease  
- Aortic Valve Stenosis  
- Aortic Valve Regurgitation  
- Aortic Valve Replacement  
- Aortic Valve Repair  
- Aortic Surgery  
- Thoracic Surgery  
- Vascular Surgery  
- Congenital Heart Public Health Consortium  
- Children’s Heart Foundation  
- Cardiovascular  
- Heart Disease  
- Aortic Repair  
- Aortic Stenosis  
- Aortic Regurgitation  
- Aortic Dissection  

These terms capture the heart‑related concepts and disease categories referenced in the guideline text.

Page 149 Extracted Terms:
- ACC / AHA (American College of Cardiology / American Heart Association)  
- Aortic Disease  
- Cardiovascular (as in cardiovascular disease, cardiovascular surgery)  
- Thoracic (thoracic surgery)  
- Heart (implicitly through “Heart Association”)  
- Society of Cardiovascular Anesthesiologists (SCA)  
- Society of Thoracic Surgeons (STS)  
- Society for Vascular Surgery (SVS)  
- National Heart, Lung, and Blood Institute (NHLBI)  
- Clinical Statements and Guidelines (for heart disease)



Page 1 Extracted Terms:
- Circulation (journal)  
- ACC/AHA Joint Committee on Clinical Practice Guidelines  
- ACC/AHA/ACCP/HRS Guideline  
- Clinical Practice Guidelines  
- Diagnosis and Management of Atrial Fibrillation  
- Atrial fibrillation  
- Heart Rhythm Society  
- American College of Clinical Pharmacy  
- American Heart Association  
- American College of Cardiology  
- Clinical data standards  
- Heart rhythm (as a clinical context)

Page 2 Extracted Terms:
**Key terms related to heart disease**

- Acute coronary syndrome  
- Alcohol (tobacco‑related risk factor)  
- Anticoagulants  
- Anticoagulation agents  
- Antiplatelet agents  
- Apixaban  
- Atrial fibrillation  
- Atrial flutter  
- Cardioversion (electrical)  
- Catheter ablation  
- Coronary artery disease  
- Coronary heart disease  
- Dabigatran  
- Edoxaban  
- Exercise (physical activity)  
- Heart failure  
- Hypertension  
- Idarucizumab (dabigatran reversal agent)  
- Left atrial appendage occlusion (LAAO)  
- Myocardial infarction (MI)  
- Obesity  
- Percutaneous coronary intervention (PCI)  
- Pulmonary vein isolation (PVI)  
- Risk factors (general)  
- Rivaroxaban  
- Sleep apnea  
- Stents (PCI stents)  
- Stroke (cardioembolic)  
- Surgical ablation (e.g., maze procedure)  
- Thromboembolism (mechanism and prevention)  
- Warfarin  
- Diabetes (as a cardiovascular risk‑modifier)  
- Weight loss/obesity management  
- Physical fitness  
- Smoking cessation  
- Alcohol consumption (moderation)  
- Caffeine consumption  
- Diet and dietary supplementation  
- Sleep hygiene (sleep quality)  
- Comprehensive cardiovascular care  

*(These terms capture the core concepts, therapies, risk factors, and procedural strategies related to heart disease as presented in the guideline.)*

Page 3 Extracted Terms:
**Key Terms Related to Heart Disease**

- Atrial Fibrillation (AF)
- Atrial Flutter (AFL)
- Thromboembolism  
- Anticoagulation  
- Active Bleeding on Anticoagulant  
- Reversal Drugs  
- Intracerebral Hemorrhage (ICH)  
- Periprocedural Management  
- Acute Coronary Syndrome (ACS)  
- Percutaneous Coronary Intervention (PCI)  
- Chronic Coronary Disease (CCD)  
- Coronary Artery Disease (CAD)  
- Peripheral Artery Disease (PAD)  
- Heart Failure (HF)  
- Valvular Heart Disease (VHD)  
- Hypertrophic Cardiomyopathy (HCM)  
- Congenital Heart Disease / Adult Congenital Heart Disease (ACHD)  
- Atrioventricular Nodal Ablation (AVNA)  
- Catheter Ablation (AF)  
- Surgical Ablation (AF)  
- Pacemakers  
- Implantable Cardioverter–Defibrillators (ICDs)  
- Electrical Cardioversion  
- Pharmacological Cardioversion  
- Antiarrhythmic Drugs (maintenance of sinus rhythm)  
- Rate Control  
- Rhythm Control  
- Upstream Therapy  
- WPW (Wolff–Parkinson–White) Syndrome  
- Pre‑excitation Syndromes  
- Obesity (Class III)  
- Critical Care / Acute Medical Illness or Surgery  
- Hyperthyroidism  
- Pulmonary Disease  
- Pregnancy  
- Cardio‑Oncology (anticoagulation considerations)  
- Chronic Kidney Disease (CKD) / Kidney Failure  
- Liver Disease (anticoagulation considerations)  

These terms encompass the major clinical concepts, populations, and therapeutic strategies addressed in the guideline related to heart disease.

Page 4 Extracted Terms:
- Atrial fibrillation (AF)  
- Stages of atrial fibrillation  
- Risk factor modification  
- Obesity  
- Weight loss  
- Physical activity  
- Smoking cessation  
- Alcohol moderation  
- Hypertension  
- Comorbidities  
- CHA₂DS₂‑VASc score  
- Thromboembolic event risk  
- Stroke  
- Systemic embolism  
- Ischemic stroke  
- Early rhythm control  
- Sinus rhythm  
- AF burden  
- Catheter ablation  
- Heart failure with reduced ejection fraction (HFrEF)  
- Device‑detected atrial fibrillation  
- Implantable devices  
- Wearable devices  
- Left atrial appendage occlusion devices  
- Anticoagulation  
- Class I indication  
- Class IIa recommendation  
- Cardiovascular disease  
- Cardiovascular health  
- Clinical risk scores  
- Shared decision‑making  


Page 5 Extracted Terms:
- Atrial fibrillation  
- Cardiovascular disease  
- Heart disease  
- Cardiovascular  
- ACC/AHA Joint Committee on Clinical Practice Guidelines  
- Guideline‑directed management and therapy (GDMT)  
- Evidence‑based methodology  
- Systematic review  
- Randomized controlled trials (RCTs)  
- Pharmacologic treatment  
- Procedural treatment  
- Diagnostic testing  
- Drug treatment regimens  
- Devices (medical devices)  
- Treatment strategy  
- Clinical evaluation  
- Clinical implementation  
- Shared decision‑making  
- Patient engagement  
- Adherence to recommendations  
- Cost‑value analysis  
- Knowledge chunk format  
- Flow diagrams  
- Evidence review committee  
- Methodology manual  
- RWI (relationships with industry)

Page 6 Extracted Terms:
atrial fibrillation
congenital heart disease
hypertrophic cardiomyopathy
valvular heart disease
coronary artery disease
chronic coronary syndromes
chronic kidney disease
heart failure
arrhythmias in pregnancy
left atrial appendage occlusion
left atrial appendage exclusion
catheter ablation
electrical cardioversion
amiodarone therapy
rate control
rhythm control
thromboembolism
Wolff‑Parkinson‑White syndrome
cardiac surgical procedures
anticoagulant therapy
rhythm monitoring
obesity
smoking
alcohol consumption
caffeine intake
sleep disorders
dietary factors
physical fitness
diabetes mellitus
congenital heart defects
genetic factors influencing heart disease
social determinants of health
stroke and transient ischemic attack prevention (as a cardiac risk management strategy)

Page 7 Extracted Terms:
**Heart‑disease–related terms extracted from the text**

- **ACE** – angiotensin‑converting enzyme  
- **ACHD** – adult congenital heart disease  
- **ACS** – acute coronary syndrome  
- **AF** – atrial fibrillation  
- **AFL** – atrial flutter  
- **AHRE** – atrial high‑rate episodes  
- **AP** – accessory pathway  
- **APT** – antiplatelet therapy  
- **ARB** – angiotensin receptor blocker  
- **AT** – atrial tachycardia  
- **AVNA** – atrioventricular nodal ablation  
- **BiVP** – biventricular pacing  
- **CABG** – coronary artery bypass graft surgery  
- **CAD** – coronary artery disease  
- **CCD** – chronic coronary disease

Page 8 Extracted Terms:
**Key heart‑disease terms found in the guideline excerpt**

- CHADS2  
- CHA₂DS₂‑VASc  
- CHD (congenital heart disease)  
- CHF (congestive heart failure)  
- CRT (cardiac resynchronization therapy)  
- CVD (cardiovascular disease)  
- DAT (dual antithrombotic therapy)  
- DOAC (direct oral anticoagulant)  
- EF (ejection fraction)  
- HF (heart failure)  
- HFpEF (heart failure with preserved ejection fraction)  
- HFrEF (heart failure with reduced ejection fraction)  
- ICD (implantable cardioverter‑defibrillator)  
- LA (left atrium)  
- LAA (left atrial appendage)  
- LAAO (left atrial appendage occlusion)  
- LV (left ventricle)  
- LVEF (left ventricular ejection fraction)  
- MI (myocardial infarction)  
- MRA (mineralocorticoid receptor antagonist)  
- NYHA (New York Heart Association)  
- OAC (oral anticoagulant)  
- PAC (premature atrial contraction)  
- PAD (peripheral artery disease)  
- PCI (percutaneous coronary intervention)  
- PH (pulmonary hypertension)  
- PHPVD (pulmonary hypertension with pulmonary vascular disease)  
- PITP (pill‑in‑the‑pocket)  
- pLAAO (percutaneous left atrial appendage occlusion)  
- PV (pulmonary veins)  
- PVI (pulmonary vein isolation)  
- RV (right ventricle)  
- RVP (right ventricular pacing)  
- SVT (supraventricular tachycardia)  
- TEE (transesophageal echocardiogram)  
- TIA (transient ischemic attack)  
- VF (ventricular fibrillation)  
- VHD (valvular heart disease)  
- VKA (vitamin K antagonist)  
- VT (ventricular tachycardia)  
- WPW (Wolff‑Parkinson‑White)

Page 9 Extracted Terms:
- Atrial fibrillation (AF)  
- Stroke  
- Myocardial infarction (MI)  
- Heart failure (HF)  
- Sudden cardiac death  
- Cardiovascular disease (CVD)  
- Arrhythmia  
- Cardiovascular risk factors  
- Electrocardiographic biomarkers  
- Imaging biomarkers  
- Circulating biomarkers  
- Prevention (of AF and related cardiovascular conditions)  
- Screening (for AF)  
- Rate control therapy  
- Rhythm control therapy  
- Morbidity related to AF and other cardiac events  
- Mortality risk associated with AF and cardiovascular conditions  
- Atrial fibrillation classification (stages of disease progression)

Page 10 Extracted Terms:
- Atrial Fibrillation (AF)  
- Atrial Tachycardia (AT)  
- Macroreentrant atrial arrhythmias  
- Microreentry circuit  
- Stroke risk assessment  
- Rate‑control strategy  
- Rhythm‑control strategy  
- AF burden  
- Comorbidities  
- Modifiable risk factors  
- Symptom management  
- Screening for all risk factors (e.g., HEAD 2 TOES)  
- SOS (Symptom‑management framework)  
- 4 As (Access to All Aspects of care)

Page 11 Extracted Terms:
- Atrial fibrillation (AF)  
- Atrial flutter (AFL)  
- Macroreentrant atrial tachycardia (AT)  
- Cavotricuspid isthmus–dependent AFL (CTI‑dependent AFL)  
- Reverse typical AFL (clockwise circuit)  
- Atypical AFL / non‑cavotricuspid isthmus–dependent macroreentrant AT  
- Sawtooth flutter waves (ECG finding)  
- Tricuspid annulus  
- Pulmonary veins (PVs) of the left atrium (LA)  
- Pulmonary vein ectopy / ectopic action potentials  
- Sinoatrial node  
- Interstitial fibrosis (conduction heterogeneity)  
- Tachycardia runs (atrial ectopy)  
- Structural abnormalities of cellular connections  
- Electrophysiological abnormalities (electrical remodeling)  
- Calcium (Ca²⁺) handling abnormalities  
- Triangulated, shortened action potentials (pro‑arrhythmic)  
- Genetic, environmental, and metabolic etiologies of arrhythmia  
- Electrocardiogram (ECG)  
- Age‑standardized global prevalence rates of AF and AFL  
- Global Burden of Disease (GBD) study references  
- Macroreentrant circuit  
- Tricuspid valve/isthmus  
- Counterclockwise and clockwise reentrant directions  
- Pulmonary vein‑driven AF genesis (Haïssaguerre et al. finding)

Page 12 Extracted Terms:
- Atrial fibrillation (AF)  
- Incident atrial fibrillation  
- Risk of AF  
- Advancing age  
- Smoking  
- Sedentary lifestyle  
- Elite athletes / extreme exercise  
- Physical activity / exercise  
- Alcohol consumption  
- Alcohol‑related AF episodes  
- Obesity  
- Body mass index (BMI)  
- Childhood BMI  
- Height  
- Hypertension  
- Systolic blood pressure (SBP)  
- Diastolic blood pressure (DBP)  
- Blood‑pressure control, including intensive SBP <120 mm Hg  
- Renal denervation (for AF)  
- Mineral‑corticoid receptor antagonists (for AF)  
- Pulse pressure  
- Resting heart rate (J‑shaped relationship with AF)  
- Heart rate (resting, per‑5‑bpm increments)  
- Low‑risk favourable metrics (LRFM) programme  
- Circulation (journal reference)  
- Diagnosis and management guidelines (for AF)

Page 13 Extracted Terms:
**Key terms related to heart disease extracted from the guideline text:**

1. Diabetes mellitus  
2. Cardiovascular disease  
3. Heart failure (HF)  
4. Coronary artery disease (CAD)  
5. Myocardial infarction (MI)  
6. Valvular heart disease (VHD)  
7. Significant heart murmur  
8. Cardiac surgery (e.g., CABG, valve replacement, aortic aneurysm repair)  
9. Chronic kidney disease (CKD) – systemic condition with cardiovascular impact  
10. Obstructive sleep apnea (OSA)  
11. Thyroid disease – hyperthyroidism  
12. Sepsis (systemic infection with cardiovascular implications)

Page 14 Extracted Terms:
- Atrial fibrillation (AF)  
- PR interval  
- Left ventricular hypertrophy (LVH)  
- Natriuretic peptides (BNP)  
- C‑reactive protein (CRP)  
- Interleukin‑6 (IL‑6)  
- Tumor necrosis factor‑α (TNF‑α)  
- DUSP13  
- FKBP7  
- Spondin‑1  
- Interleukin‑6 receptor (IL‑6R)  
- TNF‑superfamily member 12 (TNFS12)  
- Lipoprotein(a) [Lp(a)]  
- Left atrial (LA) size  
- LA anterior‑posterior dimension  
- LA end‑diastolic volume  
- LA emptying fraction  
- LA ejection fraction  
- Left ventricular posterior wall thickness  
- Genetic susceptibility to AF (polygenic risk score)  
- Surgical left atrial reduction (with cardiac surgery or AF ablation)

Page 15 Extracted Terms:
Atrial fibrillation (AF)  
Heart failure (HF)  
Valvular heart disease (VHD)  
Coronary artery disease (CAD)  
Hypertrophic cardiomyopathy  
Obstructive sleep apnea (OSA)  
Sleep‑disordered breathing (SDB)  
Atherosclerotic cardiovascular disease (ASCVD)  
Left atrial (LA)  
Left ventricular (LV)  
Left ventricular hypertrophy (LVH)  
Brain natriuretic peptide (BNP)  
Electrocardiogram (ECG)  
Coronary artery bypass graft (CABG)  
Blood pressure (BP) – systolic (SBP) and diastolic (DBP)  
Body mass index (BMI)  
Chronic kidney disease (CKD)  
L-type Ca²⁺ current  
IK1 (inward rectifier K⁺ current)  
Connexin (gap junction protein)  
Reentry (arrhythmic circuit)  
Inflammatory state  
Older age (aging)  
Genetics / heritability  
Family history of AF  
Mendelian randomization (MR) findings  
Genome‑wide association study (GWAS) loci  
Socioeconomic status (SES) – adverse influence on AF risk  
Population attributable fraction (PAF) for AF  

These terms capture the key cardiovascular and electrophysiological concepts discussed in the guideline excerpt.

Page 16 Extracted Terms:
- Atrial fibrillation (AF)  
- Calcium mishandling  
- Cardiac remodeling  
- Sarcoplasmic reticulum calcium load  
- Ryanodine receptor dysfunction  
- Sarcoplasmic reticulum calcium ATPase (SERCA)  
- Phospholamban regulation  
- Sarcolipin regulation  
- Intracellular sodium overload  
- Calcium‑calmodulin II (CaMKII) activation  
- Late sodium current  
- Cardiac glycosides  
- Sodium‑calcium exchanger (NCX)  
- Oxidative stress  
- Inflammatory signalling  
- CaMKII‑mediated hyperphosphorylation of ryanodine receptor 2  
- Spontaneous diastolic Ca²⁺ leak  
- Delayed afterdepolarizations (DADs)  
- Premature atrial contractions (PACs)  
- Left atrial (LA) volume  
- N‑terminal pro‑b-type natriuretic peptide (NT‑proBNP)  
- LA emptying function  
- Pulmonary vein (PV) isolation  
- Pulmonary veins (PVs) as AF drivers  
- Effective refractory period (ERP)  
- Conduction velocity slowdown  
- Dispersion of repolarization  
- Cardiac re‑entry circuits  
- Atrial cardiomyopathy  
- Atrial structural abnormalities  
- Atrial myopathy  
- Interstitial changes  
- Myofibroblast activity  
- Collagen deposition  
- Fibrofatty deposits  
- Altered ion‑channel expression  
- Calcium signalling pathways  
- Contractility impairment  
- Inflammatory infiltrates  
- Myeloperoxidase (MPO) activity  
- Interstitial fibrosis  
- Prothrombotic changes in the LA  
- von Willebrand factor (vWF)  
- Vascular cell adhesion molecule‑1 (VCAM‑1)  
- Monocyte chemoattractant protein‑1 (MCP‑1)  
- Thrombus formation risk  
- Ischemic stroke risk  
- Hemodynamic overload  
- Aortopulmonary arteriovenous shunt  
- Atrial dilation  
- Atrial myocyte hypertrophy  
- Extracellular matrix remodeling  
- Vascular dysfunction  
- Atrial ectopy  
- Atrial ectopic beats  
- AF initiation triggers  
- Electrophysiological remodeling  
- Action‑potential alternans  
- Age‑related susceptibility to AF  
- Atrial electrophysiology abnormalities  
- Ventricular–atrial coupling  
- Electrogenic action of the sodium‑calcium exchanger  
- Sarcoplasmic reticulum dysfunction in AF  
- Late phase sodium currents  
- Ca²⁺ leak mechanisms  

These terms capture the key concepts and biomarkers discussed in the clinical guideline excerpt for heart‑related disease, particularly atrial fibrillation and its underlying pathophysiology.

Page 17 Extracted Terms:
- Atrial fibrillation (AF)  
- Clinical AF  
- Subclinical AF  
- First‑detected AF  
- Paroxysmal AF  
- Persistent AF  
- Long‑standing persistent AF  
- Permanent AF  
- AF burden  
- AF episode  
- Atrial high‑rate episodes  
- AF (atrial fibrillation)  
- Valvular AF  
- Non‑valvular AF  
- Lone AF  
- Atrial tachyarrhythmia  
- Atrial interstitial collagen  
- Atrial contraction  
- Thromboembolism risk  
- Calcium overload  
- Calcium current  
- Late sodium current (INa,L)  
- Oxidative stress  
- Reactive oxygen species  
- Inflammatory signaling  
- Inflammatory cytokines  
- Oxidative‑stress‑associated kinases (e.g., CaMKII, Jun‑kinase)  
- Nuclear factor‑kappa B (NF‑κB)  
- NLRP3 inflammasome  
- Fibrosis  
- Fibroblast activation  
- Renin–angiotensin–aldosterone system (RAAS)  
- Angiotensin‑converting enzyme (ACE) inhibitors  
- Angiotensin‑II receptor blockers  
- Hypertension  
- Obesity  
- Metabolic stress  
- Myofilament protein degradation  
- Atrial dilation  
- Atrial remodeling  
- Electrocardiographic abnormalities (irregular R‑R intervals, absent P waves, fibrillatory waves)  
- 12‑lead ECG  
- Wearable ECG monitoring  
- Implantable loop recorders  
- Pacemakers and defibrillators  
- Stroke risk reduction therapy  
- Vitamin K antagonists (e.g., warfarin)  
- Non‑vitamin K antagonist oral anticoagulants (NOACs)  
- Prosthetic heart valves  
- Native valvular heart disease, excluding mitral stenosis  
- Structural heart disease (implicit in definitions of lone AF)  
- Atherosclerosis (mentioned in context of cardiovascular pathology)  

These terms collectively capture the key concepts and conditions related to heart disease as presented in the guideline text.

Page 18 Extracted Terms:
**Key Heart‑Disease Terms Extracted**

- Atrial fibrillation (AF)  
- Persistent atrial fibrillation  
- Atrial flutter  
- Macroreentrant atrial tachycardia  
- Typical atrial flutter  
- Reverse‑typical atrial flutter  
- Low‑right atrial isthmus flutter  
- Scar‑mediated reentrant tachycardia  
- Left mitral isthmus flutter  
- Atrial substrate  
- Atrial refractory period  
- Conduction velocity  
- Heterogeneous conduction velocity  
- Repolarization duration  
- Atrial fibrosis (interstitial)  
- Atrial fatty infiltration (adipose)  
- Electrophysiologic remodeling  
- Autonomic nervous system (ANS)  
- Sympathetic efferent stimulation  
- Parasympathetic stimulation  
- Noradrenaline (norepinephrine)  
- β‑adrenergic receptor activation  
- L‑type calcium channel activity  
- Inward current (automaticity / early afterdepolarization)  
- Calcium overload  
- Ryanodine receptor dysfunction  
- Delayed afterdepolarization  
- Acetylcholine‑activated inward rectifying K⁺ channel (IKACh)  
- NLRP3 inflammasome  
- NLRP3‑blocking drugs  
- Systemic inflammatory activation (post‑cardiac surgery)  

These terms capture the primary concepts related to atrial rhythm disorders, electrophysiologic mechanisms, autonomic influences, structural substrate, and inflammatory pathways discussed in the guideline text.

Page 19 Extracted Terms:
- Atrial fibrillation (AF)  
- Atrial sympathetic and parasympathetic hyperinnervation  
- Electrical fractionation  
- Atrial electrophysiology  
- Autonomic nervous system (ANS) dysfunction  
- Cardiac volume  
- Blood volume  
- Blood pressure homeostasis  
- Heart failure (HF)  
- Atrial dilatation / atrial remodeling  
- Genetics of atrial fibrillation  
- Genome‑wide association studies (GWAS) for AF  
- Genetic loci specific to AF  
- TTN (titin) loss‑of‑function variants  
- MYH7 (myosin heavy chain 7) variants  
- MYH6 (myosin heavy chain 6) variants  
- LMNA (lamin A/C) variants  
- KCNQ1 (potassium voltage‑gated channel subfamily Q member 1) variants  
- Inherited cardiomyopathy genes  
- Arrhythmia syndrome genes  
- NLRP3 (NOD‑LRR‑pyrin domain containing protein 3)  
- Renin‑angiotensin‑aldosterone system (RAAS)  
- Premature atrial contraction (PAC)  
- Substrate for re‑entry  
- Trigger for arrhythmic activity

Page 20 Extracted Terms:
- Atrial fibrillation (AF)  
- Stroke  
- Anticoagulation  
- Rate control  
- Rhythm control  
- Catheter ablation  
- Stroke‑risk reduction therapies  
- Guideline‑directed medical therapy (GDMT)  
- Heart failure (HF)  
- Left atrium (LA)  
- Autonomic nervous system (ANS)  
- Heart rate variability (HRV)  
- Quality of life (QOL)  
- Social determinants of health (SDOH)  
- Health inequities and barriers to care  



Page 21 Extracted Terms:
- Atrial fibrillation (AF)  
- Anti‑arrhythmic drugs  
- Catheter ablation  
- Oral anticoagulation (OAC)  
- Direct oral anticoagulant (DOAC)  
- Cardioversion  
- Heart failure (HF)  
- Stroke (thromboembolic event)  
- Bleeding (anticoagulant‑related bleeding)  
- Left atrial appendage occlusion (LAAO)  
- CHARGE‑AF risk prediction model  
- C2HEST score (coronary artery disease, hypertension, elderly, systolic HF, etc.)  
- Coronary artery disease (CAD)  
- Hypertension  
- Systolic heart failure  
- Incident atrial fibrillation  
- Risk stratification and population screening for AF  
- Guideline for the Diagnosis and Management of Atrial Fibrillation (2023)  

(These terms capture the major heart‑disease concepts referenced in the text.)

Page 22 Extracted Terms:
**Heart‑disease–related terms extracted from the guideline text**

- Atrial fibrillation (AF)  
- Ischemic stroke  
- Systemic embolism  
- Transthoracic echocardiogram  
- Electrocardiogram (ECG)  
- Thyroid disease (hyperthyroidism)  
- Coronary artery disease (CAD)  
- Chronic obstructive pulmonary disease (COPD)  
- Hypertension  
- Systolic heart failure (HF)  
- Elderly (≥ 75 years)  
- Systolic blood pressure  
- Diastolic blood pressure  
- Smoking  
- Diabetes mellitus  
- Myocardial infarction  
- Acute coronary syndrome (ACS)  
- CHARGE‑AF risk score  
- C2HEST risk score  
- Cardiac structure and function  
- Valve function  
- Chamber size / thickness  
- Cardiac monitoring (intermittent/continuous)  

These are the principal cardiovascular concepts, diagnostic modalities, risk factors, and clinical endpoints discussed in the provided text.

Page 23 Extracted Terms:
- Atrial fibrillation (AF)  
- Right ventricular (RV) pressure  
- Left ventricular ejection fraction (LVEF)  
- Anti‑arrhythmic drug therapy  
- Rhythm control therapies  
- Catheter ablation  
- Strain imaging  
- Infiltrative cardiomyopathy (e.g., amyloidosis)  
- Echocardiography  
- Left atrial (LA) size and function  
- LA compliance  
- AF recurrence  
- LA strain  
- LA volume / left atrial volume  
- Chronic kidney disease (CKD)  
- Liver dysfunction  
- Hyperthyroidism  
- Electrolyte abnormalities  
- Diuretics  
- Stroke risk  
- Bleeding risk  
- Valvular disease  
- Myocardial ischemia  
- Acute coronary syndrome (ACS)  
- Pulmonary embolism (PE)  
- Rhythm monitoring tools  
- Electrocardiographic monitoring  
- Implantable cardiac monitors  
- Intracardiac rhythm devices  
- Atrial pacemaker lead  
- Systemic thromboembolic event  
- Consumer‑accessible electrocardiographic devices  
- Smartwatches  
- Photoplethysmography (PPG)  
- Standard 12‑lead ECG  
- Continuous loop‑recording ECG monitors  
- Implantable loop recorder  
- Cardiac rhythm management devices with atrial lead (pacemakers, defibrillators)  
- Handheld ECGs  
- Automated algorithms for AF detection  
- AF frequency, duration, burden  
- AF detection from atrial lead  
- AF‑related stroke risk prediction  
- AF‑related thromboembolic risk  
- Implantable cardiac monitor sensitivity for AF  
- AF diagnostic accuracy  
- AF monitoring burden estimation  
- Cardiac rhythm monitoring recommendations  
- AF management guidelines  
- Right ventricular/left ventricular function parameters  
- Cardiac imaging markers for cardiomyopathy  
- Electrolyte monitoring in AF patients  
- Risk factor evaluation for AF complications  
- Therapeutic decision‑making in AF  
- Cardiac evaluation in asymptomatic AF  
- Assessment of ischemic myocardium in AF patients  
- AF recurrence predictors after ablation  
- Electrocardiographic tracing interpretation  
- Photoplethysmographic AF inference  
- Handheld ECG early detection of recurrent AF  
- Implantable loop recorder clinical yield in AF detection  

(These terms capture the key heart‑disease concepts, diagnostic tools, therapies, risk factors, and monitoring strategies discussed in the text.)

Page 24 Extracted Terms:
- Atrial fibrillation (AF)  
- Atrial high‑rate episodes (device‑detected)  
- Cardiac rhythm devices with atrial leads  
- Anticoagulation (oral anticoagulation)  
- Stroke (incl. cardioembolic stroke)  
- Cryptogenic stroke  
- Implantable cardiac monitors  
- External cardiac monitors  
- Electrocardiographic tracings / ECG  
- Continuous wearable monitors  
- Photoplethysmography (smartphone / smartwatch)  
- Automated algorithm detection of AF  
- Cardioverter/ablation for AF  
- Quality of life (AF‑related)  
- Lifestyle and risk factor modification (LRFM) for AF  
- Obesity (weight, BMI)  
- Physical inactivity / sedentary lifestyle  
- Alcohol consumption (moderate, binge drinking)  
- Smoking (active tobacco use)  
- Diabetes mellitus  
- Hypertension (high blood pressure)  
- Cannabis use  
- Cocaine use  
- Methamphetamine use  
- Opioid use  
- High‑intensity endurance training (≥3 h/day)  
- J‑curve risk pattern for vigorous activity  
- Risk prediction models for AF  
- Population screening / risk stratification  
- Guideline‑directed medical therapy (GDMT) for cardiovascular risk factors  

Page 25 Extracted Terms:
- Atrial fibrillation (AF)  
- Arrhythmia  
- AF symptoms  
- AF burden  
- AF recurrence  
- Sinus rhythm  
- Obesity  
- Overweight  
- Body mass index (BMI)  
- Weight loss  
- Diabetes (type 1 and type 2)  
- Glucose control  
- Hypertension  
- Blood pressure (BP)  
- Intensive BP control  
- Cardiovascular disease (CVD)  
- Heart failure (HF)  
- Mortality  
- Cardiac catheter ablation  
- Bariatric surgery  
- Randomized controlled trial (RCT)  
- Aerobic exercise  
- Moderate‑to‑vigorous exercise  
- Functional capacity  
- Quality of life (QOL)  
- Physical fitness  
- Risk factor management  
- Cardiometabolic risk  
- Exercise prescription  
- Ventricular rate control  
- Cardiovascular risk profile  

Page 26 Extracted Terms:
- Atrial fibrillation (AF)  
- AF recurrence  
- AF burden  
- AF ablation  
- Cardiac rehabilitation  
- Exercise training (high‑intensity aerobic, moderate‑intensity, extreme exercise)  
- Heart failure (HF)  
- Hospitalization  
- All‑cause mortality  
- Stroke  
- Cardiovascular disease (CVD)  
- Cardiovascular complications  
- Smoking cessation  
- Behavioral interventions for tobacco cessation  
- Pharmacotherapy for tobacco cessation  
- Guideline‑directed medical therapy (GDMT)  
- Warfarin therapy (therapeutic range)  
- Alcohol consumption  
- Alcohol abstinence / reduction (≤3 standard drinks per week)  
- Rhythm‑control strategy  
- Caffeine consumption  
- Caffeine abstention / triggers  
- N‑of‑1 trial (caffeine)  
- Structured comprehensive risk‑factor management  

Page 27 Extracted Terms:
**Key terms related to heart disease (as extracted from the guideline text)**  

- Atrial fibrillation (AF)  
- Caffeine consumption (including excessive intake and energy drinks)  
- Palpitations (symptom of AF)  
- Heart rhythm awareness  
- Cardiovascular disease (CVD)  
- Omega‑3 fatty acids  
- Vitamin D supplementation  
- Ascorbic acid (vitamin C) supplementation  
- Weight management (obesity, BMI reduction)  
- Low‑carbohydrate diets  
- Diabetes mellitus (type 1 and 2)  
- Cardiovascular mortality  
- Sudden cardiac death  
- Direct oral anticoagulants (DOACs)  
- Warfarin  
- Catheter ablation (AF ablation)  
- Glycemic control (pre‑ablation, post‑ablation)  
- Hypertension (high blood pressure)  
- Blood pressure (BP) control / BP lowering  
- Renal denervation (renal sympathetic modulation)  
- Mineralocorticoid receptor antagonists (MRAs)  
- Angiotensin‑converting enzyme (ACE) inhibitors  
- Angiotensin II receptor blockers (ARBs)  
- Pulmonary vein isolation (PVI)  
- Integrated lifestyle and risk‑factor modification programs (LRFM)  
- AF burden (frequency/duration of atrial fibrillation episodes)  
- AF recurrence (post‑ablation or post‑treatment)  
- Stroke (ischemic events related to AF)  
- Anticoagulation therapy (stroke prevention in AF)  
- Stroke risk reduction (via BP control, anticoagulation)  
- Adverse cardiovascular outcomes (stroke, bleeding, mortality)  
- Pharmacologic agents for AF prevention (e.g., MRAs, ACEi/ARB)  
- Symptomatic atrial arrhythmia (post‑ablation)  
- Clinical trials (e.g., SMAC AF, ARIC study)  

These terms encompass the core clinical entities, risk factors, preventive strategies, treatments, and outcomes discussed in the guideline.

Page 28 Extracted Terms:
- Atrial fibrillation (AF)  
- Obstructive sleep apnea (OSA)  
- Sleep‑disordered breathing (SDB)  
- Sinus rhythm  
- Stroke  
- Thromboembolism  
- Heart failure (HF)  
- Left ventricular ejection fraction (LVEF)  
- Obesity  
- Alcohol use  
- Mineralocorticoid receptor antagonist  
- Statins  
- Angiotensin‑converting enzyme (ACE) inhibitors  
- Angiotensin receptor blockers (ARBs)  
- Cardiac rehabilitation  
- Anticoagulation therapy  
- AF recurrence  
- AF burden  
- Cardioversion  
- Pulmonary vein isolation (PVI)  
- Comprehensive AF care  
- Nurse‑led AF clinics  
- Clinical care pathways  
- Electronic clinical decision support systems  
- RACE 3 trial  
- RACE 4 trial  
- SAFETY study  
- All‑cause mortality  
- Cardiovascular outcomes  

Page 29 Extracted Terms:
- Atrial fibrillation (AF)  
- Stroke  
- Thromboembolism  
- Anticoagulation  
- CHA2DS2‑VASc score  
- CHADS2 score  
- HAS‑BLED score  
- HEMORR2HAGES score  
- ATRIA score  
- GARFIELD‑AF score  
- Risk stratification  
- Risk score development  
- c‑index (discrimination)  
- Annual risk of stroke/bleeding  
- Bleeding risk  
- Hypertension  
- Renal disease  
- Liver dysfunction  
- Age (≥65 years, ≥75 years)  
- Labile INR  
- Elderly status  
- Drug/alcohol concomitancy  
- Ethanol abuse  
- Malignancy  
- Anemia  
- Platelet count/function  
- Fall risk  
- Congestive heart failure  
- Diabetes mellitus  
- Stroke/TIA history  
- Clinical decision‑support systems (CDS)  
- mAF‑App (mobile health technology)  
- CDS‑AF tool  
- Mobile health technology for AF  
- Educational interventions for providers/patients  
- Shared decision‑making (SDM)  
- Risk discrimination and calibration in prediction models  



Page 30 Extracted Terms:
- Atrial fibrillation (AF)  
- Ischemic stroke  
- Stroke prevention  
- Anticoagulation (OACs)  
- Oral anticoagulants (DOACs)  
- Vitamin K antagonists (VKAs)  
- Bleeding risk  
- Net clinical benefit  
- CHA2DS2‑VASc score  
- ATRIA score  
- GARFIELD‑AF score  
- HAS‑BLED score  
- HEMORR2HAGES score  
- Left atrial appendage occlusion (LAAO) devices  
- Congestive heart failure (CHF)  
- Hypertension  
- Renal disease  
- Diabetes mellitus  
- Current smoking  
- Previous stroke or transient ischemic attack (TIA)  
- Vascular disease  
- Dementia  
- Proteinuria  
- pro‑BNP (biomarker)  
- Left atrial appendage (LAA) function and anatomy  
- Electrocardiographic features  
- Antiplatelet medications  
- Non‑steroidal anti‑inflammatory drugs (NSAIDs)  
- Antithrombotic treatment  
- Thromboembolic events  
- Bleeding risk factors  
- Clinically relevant risk factors for AF management  
- Age‐related risk categories (≥85 y, 75‑84 y, 65‑74 y, <65 y)  
- Hypertension control  
- Anticoagulation and risk factor stratification tools (ATRIA, CHA2DS2‑VASc, GARFIELD‑AF)  
- The ARISTOTLE trial (Apixaban)  


Page 31 Extracted Terms:
Atrial fibrillation (AF)  
Stroke  
Thromboembolism  
Anticoagulation / Oral anticoagulation  
Bleeding risk  
HAS‑BLED score  
HEMORR2HAGES score  
ATRIA score  
Stroke‑risk scores (e.g., CHA₂DS₂‑VASc)  
Annual risk of stroke  
Net clinical benefit  
Stroke‑risk reduction therapy  
Paroxysmal AF  
Persistent AF  
Long‑standing persistent AF  
Permanent AF  
Thromboembolic events  
Stroke prevention  
Risk‑based selection of oral anticoagulation  
Clinical decision‑making regarding anticoagulation  
Bleeding‑risk scores (e.g., HAS‑BLED, HEMORR2HAGES, ATRIA)

Page 32 Extracted Terms:
- Atrial fibrillation (AF)
- Stroke
- Systemic embolism
- Oral anticoagulants (OAC)
- Warfarin
- Direct oral anticoagulants (DOACs)
- Vitamin K antagonists (VKA)
- International normalized ratio (INR)
- CYP2C9
- Renal function / glomerular filtration rate (GFR)
- Age
- Congestive heart failure (CHF)
- Hypertension
- Diabetes mellitus
- Stroke/TIA risk
- Vascular disease
- Female sex (sex category)
- Anemia
- Proteinuria
- Bleeding risk
- CHA2DS2‑VASc score
- CHADS2 score
- ATRIA score
- MCHA2DS2‑VASc score
- GARFIELD‑AF score
- Stroke prevention therapy
- Anticoagulation therapy
- Anticoagulant dosing
- Stroke risk scores
- Cardiovascular morbidity
- Cardiovascular mortality
- Long‑term follow‑up
- Stroke risk assessment
- Systemic embolism prevention
- Stroke risk reduction
- Heart disease risk factors  
- Cardiovascular health management

Page 33 Extracted Terms:
**Key heart‑disease related terms extracted from the guideline text**

- Atrial fibrillation (AF)
- Chronic atrial fibrillation
- Permanent/persistent AF
- Paroxysmal AF
- AF burden / AF duration
- Mechanical heart valve
- Rheumatic mitral stenosis
- Cardiovascular stroke
- Systemic thromboembolism
- Intracranial haemorrhage (ICH)
- Gastro‑intestinal bleeding
- Anticoagulation
- Direct oral anticoagulants (DOACs) – apixaban, dabigatran, edoxaban, rivaroxaban
- Warfarin
- Antiplatelet therapy
- Aspirin
- Clopidogrel
- Antithrombotic therapy guideline
- CHA₂DS₂‑VASc score (and its risk categories)
- Thromboembolic risk (annual %)
- Heart failure
  - Right‑sided failure (elevated central venous pressure, hepatomegaly, dependent edema)
  - Left‑sided failure (exertional dyspnea, coughing, fatigue, orthopnea, paroxysmal nocturnal dyspnea)
  - Cardiac enlargement, pulmonary venous congestion, gallop rhythm
- Hypertension (resting BP >140/90 mm Hg or treated)
- Diabetes mellitus (FPG ≥7.0 mmol/L or on hypoglycemic agents/insulin)
- Coronary artery disease (prior MI, angina, PCI, CABG)
- Peripheral vascular disease (claudication, aortic or limb interventions, arterial/venous thrombosis)
- Vascular disease (general)
- Age ≥65 y, ≥75 y
- Sex (female)
- Obesity (BMI ≥ 30 kg/m²)
- Hypertrophic cardiomyopathy (HCM)
- Reduced eGFR (<45 mL/min/1.73 m²)
- Proteinuria (>150 mg/24 h)
- Enlarged left atrial volume (≥73 mL) or diameter (≥4.7 cm)
- Cardiovascular risk factors (additional to CHA₂DS₂‑VASc)
- Re‑LY, ROCKET AF (pivotal DOAC trials)
- Anticoagulant target INR (2–3, risk above 4)

These terms encapsulate the principal cardiovascular conditions, therapies, and risk factors discussed in the guideline excerpt.

Page 34 Extracted Terms:
- Atrial Fibrillation (AF)  
- Atrial Flutter (AFL)  
- Valvular Heart Disease (VHD)  
- Stroke  
- Thromboembolism / Systemic Embolism  
- Intracranial Hemorrhage (ICH)  
- Anticoagulation  
- Vitamin K antagonists (e.g., warfarin)  
- Factor Xa inhibitors (DOACs)  
- Direct Oral Anticoagulants (DOACs)  
- CHA₂DS₂‑VASc risk score  
- CHADS₂ risk score  
- ATRIA risk score  
- GARFIELD‑AF risk score  
- Congestive heart failure / left‑ventricular dysfunction  
- Hypertension  
- Age ≥ 75 years  
- Age 65–74 years  
- Diabetes mellitus  
- Vascular disease  
- Stroke / Transient Ischemic Attack (TIA)  
- Thromboembolism history  
- Female sex (as a risk modifier)  
- Anemia  
- Renal disease  
- Elderly (age ≥ 75 years) – risk factor in ATRIA  
- Previous bleeding  
- AF burden (amount of atrial fibrillation)  
- Antiplatelet therapy  
- Systemic embolic events  
- Stroke‑risk scores (general term)  
- Clinical trials: ARISTOTLE, ENGAGE AF‑TIMI 48, RE‑LY, ARISTOTLE, ENGAGE AF‑TIMI 48, etc.

Page 35 Extracted Terms:
- Atrial fibrillation (AF)  
- Stroke  
- Systemic embolism  
- Hypertrophic cardiomyopathy  
- Mitral stenosis  
- Mechanical valve  
- Aortic stenosis  
- Mitral regurgitation  
- Bioprosthetic valve  
- Valve repair  
- Valvular heart disease (VHD)  
- Direct oral anticoagulants (DOACs)  
- Rivaroxaban  
- Apixaban  
- Dabigatran  
- Edoxaban  
- Vitamin K antagonists (VKAs)  
- Warfarin  
- International Normalized Ratio (INR)  
- Time in therapeutic range (TTR)  
- Intracranial hemorrhage (ICH)  
- Major bleeding  
- Antiplatelet therapy (APT)  
- Aspirin  
- Clopidogrel  
- Coronary artery disease (CAD)  
- Vascular disease  
- Myocardial infarction (MI)  
- CHADS2 score  
- Stroke risk threshold  
- Markov decision model  
- Meta‑analysis  
- Randomized controlled trial (RCT)  
- AVERROES trial  
- ACTIVEW trial  
- Stroke risk score  
- Therapeutic value of warfarin  
- Stroke prevention guidelines  
- Anticoagulation therapy  
- Stroke rate  
- Systemic embolism risk  
- Embolic risk  
- Antithrombotic options  
- Stroke prevention in AF  
- Stroke risk of DOACs vs warfarin  
- Stroke risk of antiplatelets vs warfarin  
- Anticoagulation threshold  
- Stroke risk stratification  
- Cardiac rhythm disorder  
- Cardiovascular disease  
- Heart disease management  
- Cardiac valvular pathology  
- Cardiovascular risk assessment  
- Cardio‑vascular event  
- Cardio‑vascular outcome  
- Cardio‑vascular trial  
- Cardio‑vascular meta‑analysis  
- Cardio‑vascular guideline  
- Heart disease terminology  

*(All terms are directly drawn from the guideline text and pertain to heart disease concepts and therapies.)

Page 36 Extracted Terms:
- Atrial fibrillation (AF)  
- Anticoagulants  
- Direct oral anticoagulants (DOACs)  
- Warfarin  
- Dabigatran  
- Rivaroxaban  
- Apixaban  
- Aspirin (antiplatelet therapy)  
- Stroke prevention  
- Cardioembolic stroke  
- Non‑cardioembolic stroke  
- Peripheral embolization  
- Major bleeding  
- Intracerebral hemorrhage (ICH)  
- Thromboembolism  
- Stroke risk  
- Intracranial hemorrhage  
- INR (international normalized ratio)  
- Time in therapeutic range (TTR)  
- Drug–drug interactions  
- CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir)  
- CYP3A4 inducers (rifampin, phenytoin, phenobarbital, carbamazepine, St. John’s wort)  
- P‑glycoprotein inhibitors  
- Renal function / creatinine clearance (CrCl)  
- Hepatic function  
- Mechanical valves  
- Anticoagulation dosing adjustment  
- Vitamin K intake  
- Monitoring of anticoagulation  
- Clinical trials (RCT)  
- Meta‑analysis  
- Stroke  
- Bleeding risk  
- Antithrombotic therapy  

(Each term is a key concept related to heart disease that appears in the provided guideline text.)

Page 37 Extracted Terms:
**Key Heart‑Disease‑Related Terms**

- Atrial Fibrillation  
- Oral Anticoagulants (OACs)  
- Vitamin K Antagonist (VKA)  
- Direct Thrombin Inhibitor  
- Factor Xa Inhibitor  
- Warfarin  
- Dabigatran  
- Rivaroxaban  
- Apixaban  
- Edoxaban  
- CYP2C9  
- CYP1A2  
- CYP2C19  
- CYP3A4  
- CYP3A5  
- P‑glycoprotein (P‑gp)  
- Renal clearance (CrCl)  
- Body weight  
- Serum creatinine (SCr)  
- Dose adjustment  
- Drug–drug interaction  
- Dronedarone  
- Ketoconazole  
- Clarithromycin  
- Erythromycin  
- Ritonavir  
- Carbamazepine  
- Phenytoin  
- Rifampin  
- St. John’s wort  
- Half‑life  
- Excretion path (renal, hepatic, biliary)  
- Metabolism pathways (CYPs, P‑gp)

Page 38 Extracted Terms:
- Atrial fibrillation (AF)  
- Stroke  
- Transient ischemic attack (TIA)  
- Systemic embolism  
- Thromboembolism  
- Ischemic adverse events  
- Mechanical heart valve  
- Mitral stenosis  
- Warfarin  
- Direct oral anticoagulants (DOACs)  
- Vitamin K antagonist  
- International normalized ratio (INR)  
- CYP3A4  
- P‑glycoprotein  
- Antiepileptic drugs  
- Nonsteroidal anti‑inflammatory drugs (NSAIDs)  
- Selective serotonin reuptake inhibitors (SSRIs)  
- Antimicrobial agents  
- Bleeding risk  
- Ischemic stroke  
- Net clinical outcome  
- All‑cause death  
- Implantable loop recorder  
- Silent AF  
- Dose adjustment  
- Underdosing  
- Overt dosing (over‑dosing)  
- Bioavailability  
- Food effect (high‑fat, high‑calorie meal)  
- Child‑Pugh score (liver function)  
- Creatinine clearance  
- INR goal (2–3)  
- Therapeutic INR range  
- Anticoagulant therapy  
- Antiplatelet therapy  
- Cardiovascular monitoring

Page 39 Extracted Terms:
- Atrial Fibrillation  
- Direct Oral Anticoagulant (DOAC)  
- HAS‑BLED score  
- Uncontrolled hypertension  
- Renal dysfunction (high serum creatinine, dialysis, kidney transplant)  
- Hepatic dysfunction (elevated bilirubin, ALT/AST/AP, cirrhosis)  
- Stroke (hemorrhagic or ischemic)  
- Bleeding history or predisposition  
- Labile INR (time in therapeutic range < 60%)  
- Elderly age (≥ 65 years)  
- Antiplatelet agents  
- Non‑steroidal anti‑inflammatory drugs (NSAIDs)  
- Excessive alcohol intake  
- Child‑Pugh classification (A, B, C)  
- Encephalopathy  
- Ascites  
- Total bilirubin  
- Albumin  
- International Normalized Ratio (INR)  
- Creatinine clearance (CrCL)  
- Liver disease severity (cirrhosis)

Page 40 Extracted Terms:
- Atrial Fibrillation (AF)  
- Occult (silent) Atrial Fibrillation  
- Device‑detected Atrial High‑Rate Episodes (AHRE)  
- Cryptogenic Stroke  
- Transient Ischemic Attack (TIA)  
- Stroke Risk  
- Systemic Embolism  
- CHA₂DS₂‑VASc score  
- Oral Anticoagulation  
- Antiplatelet Therapy (APT)  
- Cardiac Monitoring  
- Holter Monitor (24‑hour, 10‑day)  
- Implantable Loop Recorder (implantable recorder)  
- Extended Cardiac Monitoring  
- Shared Decision‑Making (SDM) framework  
- Stroke Prevention Guidelines  
- Cardiovascular Implantable Electronic Device (CIED)  
- Risk‑Stratification for Anticoagulation  
- Post‑stroke Mortality  
- Stroke‑Risk Reduction Therapy  
- Clinical Trial Evidence (e.g., EMBRACE, CRYSTAL‑AF, FIND‑AF, PER‑DIEM, ASSERT)  
- Diagnostic Work‑up for Cryptogenic Stroke  
- Stroke‑Risk Scores  
- Device‑Detected Atrial Arrhythmia  
- Stroke‑Prevention Therapy Thresholds  
- Duration of AF/AHRE (≤5 min, ≥24 h, intermediate)  
- Anticoagulation Indication Criteria  
  
These terms capture the core heart‑disease concepts addressed in the guideline excerpt.

Page 41 Extracted Terms:
- Atrial fibrillation (AF)  
- Subclinical atrial fibrillation (SCAF)  
- Atrial high‑rate episode (AHRE)  
- Oral anticoagulation (OAC)  
- Non‑vitamin K antagonist oral anticoagulants (NOACs)  
- CHA₂DS₂‑VASc score  
- Stroke (ischemic stroke)  
- Anticoagulation therapy (including VKA and non‑VKAs)  
- Thrombo‑embolism  
- Heart failure (HF)  
- Coronary artery disease (CAD)  
- Apixaban  
- Rivaroxaban  
- Electrocardiogram (ECG)  
- Device‑detected atrial fibrillation (device‑detected SCAF)  
- Subclinical AF burden/duration  
- Stroke risk stratification  
- Antithrombotic agents  
- Non‑Vitamin‑K antagonist oral anticoagulants trial (NOAH)  
- Apixaban for the Reduction of Thrombo‑Embolism in Patients With Device‑Detected Subclinical Atrial Fibrillation (ARTESiA)  
- COMMANDER‑HF (Rivaroxaban) trial  
- COMPASS (anticoagulation strategies) trial  

Page 42 Extracted Terms:
- Atrial fibrillation (AF)
- Atrial flutter (AFL)
- Atrial high‑rate episodes (AHREs)
- Subclinical atrial fibrillation
- Ischemic stroke
- Systemic embolism
- CHA₂DS₂‑VASc score
- Sex‑modified CHA₂DS₂‑VASc score
- Oral anticoagulation (OAC)
- Direct oral anticoagulants (DOACs)
- Warfarin
- Major bleeding
- Left atrial appendage (LAA)
- LAA occlusion (LAAO)
- Percutaneous LAAO (pLAAO)
- Surgical LAAO
- Watchman device (including Watchman FLX)
- Percutaneous closure devices
- Percutaneous atrial fibrillation interventions
- Catheter ablation / cardiac surgery for AF
- Implantable cardioverter‑defibrillator (ICD)
- Pacemaker
- Rhythm monitoring
- Procedural success
- Procedural risk
- Procedural complications
- Embolization
- Thrombus
- Stroke risk stratification
- Stroke prevention strategies
- Non‑valvular atrial fibrillation
- Hemorrhagic risk
- Anticoagulation contraindication
- Stroke risk reduction

These terms capture the central concepts and interventions discussed in the guideline excerpt related to heart disease, particularly atrial fibrillation and its management.

Page 43 Extracted Terms:
- Atrial Fibrillation  
- Left Atrial Appendage (LAA)  
- Left Atrial Appendage Occlusion (LAAO)  
- Surgical Left Atrial Appendage Occlusion (S‑LAAO)  
- Stroke  
- Systemic Embolism  
- Thromboembolism  
- Cardiovascular Mortality  
- All‑Cause Mortality  
- Major Bleeding  
- Non‑Major Clinically Relevant Bleeding  
- Anticoagulation (OAC)  
- Warfarin  
- Direct Oral Anticoagulants (DOACs)  
- CHA₂DS₂‑VASc Score  
- Watchman Device (Left Atrial Appendage Closure Device)  
- LAAOS III (Left Atrial Appendage Occlusion Study)  
- PROTECT AF Trial  
- PREVAIL Study  
- PRAGUE‑17 Trial  
- Cardiac Surgery  
- Coronary Artery Bypass Grafting (CABG)  
- Valve Surgery  
- Antithrombotic Regimen  
- Procedural Complications  
- Device‑Related Complications

Page 44 Extracted Terms:
- Atrial fibrillation (AF)  
- Left atrial appendage (LAA)  
- Left atrial appendage occlusion (LAAO)  
- Surgical left atrial appendage occlusion (S‑LAAO)  
- LAAOS III trial  
- CHA2DS2‑VASc score  
- Oral anticoagulation (OAC)  
- Dabigatran  
- Apixaban  
- Rivaroxaban  
- Edoxaban  
- Factor Xa inhibitors  
- Idarucizumab  
- Andexanet alfa  
- Prothrombin complex concentrate (PCC)  
- 4‑factor PCC  
- Stroke  
- Systemic embolism  
- Thromboembolism  
- Ischemic events  
- Mortality  
- Coronary artery bypass grafting (CABG)  
- Valve surgery  
- Mechanical valve surgery  
- Off‑pump bypass  
- Left ventricular assist device (LVAD)  
- Congenital heart disease (CHD)  
- Surgical atrial fibrillation ablation  
- Cardiac transplant  
- Transesophageal echocardiography (TEE)  
- Cross‑clamp time  
- Bypass time  
- Chest tube output  
- Major bleeding  
- All‑cause rehospitalization

Page 45 Extracted Terms:
- Atrial fibrillation (AF)  
- Vitamin K antagonist (warfarin)  
- 4‑factor prothrombin complex concentrate (PCC)  
- Intravenous vitamin K  
- Fresh frozen plasma  
- Direct oral anticoagulants (DOACs):  
  - Dabigatran  
  - Apixaban  
  - Rivaroxaban  
  - Edoxaban  
- Idarucizumab (dabigatran reversal agent)  
- Andexanet Alfa (factor Xa inhibitor reversal agent)  
- Factor Xa inhibitors (apixaban, rivaroxaban, edoxaban, enoxaparin)  
- Major bleeding / life‑threatening bleeding  
- Gastrointestinal bleeding  
- Hemostasis / bleeding cessation  
- Thrombosis events / thromboembolism  
- Activated PCC (activated prothrombin complex concentrate)  
- aPTT (activated partial thromboplastin time)  
- Prothrombin time (PT)  
- Anti‑factor Xa activity  
- Hemodialysis (used for dabigatran clearance)  
- FDA approval status for reversal agents  
- Emergency department visits for anticoagulant‑related bleeding  
- Multicenter cohort studies  
- Randomized controlled trials  
- Prospective observational studies  
- Shared decision making (SDM)  
- Multidisciplinary team approach (MDA)

Page 46 Extracted Terms:
- Atrial fibrillation  
- Venous thromboembolism (VTE)  
- Thromboembolism (arterial/venous)  
- Myocardial infarction  
- Ischemic stroke  
- Cardiac arrest  
- Sudden death  
- Life‑threatening/uncontrolled bleeding  
- Warfarin‑associated bleeding  
- Dabigatran  
- Apixaban  
- Rivaroxaban  
- Edoxaban  
- Factor Xa inhibitors  
- Anticoagulation reversal agents  
- Idarucizumab  
- Andexanet alfa  
- Prothrombin complex concentrate (PCC)  
- Activated prothrombin complex concentrate (aPCC)  
- Vitamin K  
- International Normalised Ratio (INR)  
- Hemostasis/ hemostatic effectiveness

Page 47 Extracted Terms:
Atrial fibrillation  
Anticoagulation  
Direct oral anticoagulants (DOAC)  
Vitamin K antagonist (VKA)  
Warfarin  
Dabigatran  
Apixaban  
Edoxaban  
Rivaroxaban  
Mechanical heart valve  
Rheumatic heart disease  
Prosthetic heart valve  
Venous thromboembolism  
Intracranial hemorrhage (ICH)  
Intracranial bleeding  
Intraparenchymal bleeding  
Cerebral amyloid angiopathy  
Left atrial appendage occlusion (LAAO)  
Re‑initiation of anticoagulation  
Timing of anticoagulation resumption  
Thromboembolic events  
Stroke  
Major bleeding  
Minor bleeding  
Gastrointestinal bleeding  
Bleeding events per year  
Relative risk (RR)  
Hazard ratio (HR)  
Odds ratio (OR)  
Risk-benefit assessment  
Guideline recommendation  
Clinical trial (RE-LY)  
Clinical trial (ARISTOTLE)  
Clinical trial (ENGAGE AF‑TIMI 48)  
Clinical trial (ROCKET AF)  
Evidence level (C‑LD, B‑NR)  
Anticoagulation‑sparing strategies  
Risk of recurrent ICH  
Risk of thromboembolic recurrence  
Thromboelastography  
Bleeding risk score (e.g., HAS‑BLED)  
Stroke risk score (e.g., CHA₂DS₂‑VASc)  
Intracranial hemorrhage risk score  
Bleeding outcome metrics (per 100 patient‑years)  
Management of patients with AF and ICH.

Page 48 Extracted Terms:
- Atrial fibrillation  
- Mechanical heart valves  
- Rheumatic valvular disease  
- Anticoagulation therapy  
- Thromboembolic complications  
- Left atrial appendage (LAA) closure  
- Embolic events  
- Prothrombin complex concentrate (used in reversal of anticoagulation)

Page 49 Extracted Terms:
- Atrial fibrillation (AF)  
- Mechanical heart valve  
- Valvular disease  
- Vitamin K antagonists (VKAs)  
- Direct oral anticoagulants (DOACs)  
- CHADS‑2/VASc score (CHA₂DS₂‑VASc)  
- Cerebral amyloid angiopathy  
- Intracranial hemorrhage (ICH)  
- Intracerebral hemorrhage (IPH)  
- Left atrial appendage (LAA)  
- LAA closure  
- PROTECT AF study  
- PREVAIL study  
- Epicardial LAA clipping  
- Anticoagulation‑related ICH  
- Hemorrhagic stroke  
- Thromboembolic complications  
- Systemic embolism  
- Stroke risk reduction  
- Anticoagulation resumption  
- Ischemic stroke  
- Thromboembolism  
- Stroke and mortality outcomes  
- Non‑valvular AF  
- Hypercoagulable state (e.g., active malignancy, genetic thrombophilia)  
- Poorly controlled hypertension  
- Genetic/acquired coagulopathy  
- Antiplatelet therapy (APT)  
- Rheumatic valve disease  
- Lobar intraparenchymal hemorrhage (IPH)  
- Disseminated cortical superficial siderosis  
- High CHA₂DS₂‑VASc score (>5)  
- Concomitant AF with valvular disease  
- Mechanical valve‑associated bleeding risk  
- Anticoagulation therapy (OACs)  
- VKA (warfarin) vs DOAC comparison  
- Stroke and mortality risk in AF patients with ICH  
- Anticoagulation timing after ICH (1–2 weeks, 7–8 weeks, 10–39 days)  
- Stroke prevention strategies in AF with high bleeding risk  
- Anticoagulation resumption window  
- Clinical guidelines for AF management in the presence of bleeding risk  
- Intracranial hemorrhage recurrence risk  

(These terms capture the primary heart‑disease concepts referenced in the text.)

Page 50 Extracted Terms:
- Atrial fibrillation (AF)  
- Warfarin  
- Direct oral anticoagulants (DOACs)  
- Oral anticoagulation (OAC)  
- Periprocedural management  
- Invasive procedure  
- Surgery  
- Bridging anticoagulation  
- Low‑molecular‑weight heparin (LMWH)  
- Thromboembolism  
- Thrombotic risk  
- Bleeding risk  
- CHA₂DS₂‑VASc score  
- CHA₂DS₂‑VASc ≥2  
- Stroke  
- Transient ischemic attack (TIA)  
- Mechanical valve  
- Pacemaker implantation  
- Defibrillator implantation  
- Generator change  
- Cardiac catheterization  
- Transvenous lead extraction  
- Endoscopic procedures  
- Dental extraction  
- Ophthalmologic procedures  
- Percutaneous vascular access  
- Intra‑abdominal surgery  
- Pelvic surgery  
- Orthopedic surgery  
- Neurosurgical procedures  
- Cardiac surgery  
- Neuraxial anesthesia  
- Spinal surgery  
- Hepatic dysfunction  
- Renal dysfunction (CrCl)  
- Anemia  
- Antiplatelet therapy  
- Non‑steroidal anti‑inflammatory drugs (NSAIDs)  
- Alcohol use  
- International normalized ratio (INR)  
- Creatinine clearance (CrCl)  
- Thrombosis prevention  
- Anticoagulant interruption timing  
- High bleeding‑risk procedures  
- Low bleeding‑risk procedures  
- Guideline‑based risk stratification  
- Bleeding complications  
- Hemostasis  
- Cardiovascular disease terminology  
- Intraplaque hemorrhage (implied by bleeding risk contexts)

Page 51 Extracted Terms:
- Atrial fibrillation  
- Mechanical valve  
- Stroke / Transient ischemic attack (TIA)  
- Thromboembolism  
- CHADS₂ score  
- CHA₂DS₂‑VASc score  
- Direct oral anticoagulant (DOAC)  
- Warfarin  
- Unfractionated heparin  
- Low‑molecular‑weight heparin  
- Bridging anticoagulation  
- Pocket hematoma  
- Pacemaker  
- Implantable cardioverter‑defibrillator (ICD)  
- Lead extraction  
- Bleeding risk  
- Congestive heart failure  
- Hypertension  
- Diabetes mellitus  
- Vascular disease  
- Periprocedural anticoagulation  
- Anticoagulation interruption  
- Anticoagulation bridging  
- Device surgery  
- PAUSE study  
- BRUISE‑CONTROL trial

Page 52 Extracted Terms:
- Atrial fibrillation (AF)  
- Atrial flutter (AFL)  
- Anticoagulation (OAC)  
- Direct oral anticoagulants (DOACs) – apixaban, dabigatran, rivaroxaban, edoxaban  
- Vitamin K antagonists (VKAs) – warfarin  
- Bridging anticoagulation  
- Platelet antiplatelet therapy (APT)  
- Dual antithrombotic therapy (OAC + P2Y12 inhibitor)  
- Triple therapy (OAC + P2Y12 inhibitor + aspirin)  
- Periprocedural events  
- Bleeding risk (low, high)  
- Thromboembolism (clinical, cardiovascular)  
- Stroke risk (high)  
- Percutaneous coronary intervention (PCI)  
- Acute coronary syndrome (ACS)  
- Coronary artery disease (CAD)  
- Mechanical heart valves  
- Valvular heart disease  
- Low‑molecular‑weight heparin (LMWH) – dalteparin  
- PAUSE protocol  
- BRIDGE trial  
- PERIOP2 trial  
- Antithrombotic therapy guidelines  
- Renal function (impact on anticoagulant dosing)  
- Intravenous/intravenous drug hold (drug “hold” of 48 h)  
- Warfarin therapeutic window (INR > 1.9)  

These terms capture the key heart‑disease–related concepts discussed in the provided guideline excerpt.

Page 53 Extracted Terms:
- Atrial Fibrillation (AF)  
- Antithrombotic Regimen  
- Dual Antithrombotic Therapy (DAT)  
- Triple Therapy  
- Direct Oral Anticoagulant (DOAC)  
- Vitamin K Antagonist (VKA)  
- Aspirin  
- P2Y12 Inhibitor  
- Oral Anticoagulation (OAC)  
- Percutaneous Coronary Intervention (PCI)  
- Stent Thrombosis  
- Bleeding Risk / Clinically Relevant Bleeding  
- Major Adverse Cardiovascular Events (MACE)  
- Coronary Revascularization  
- Multivessel PCI  
- Complex Revascularization  
- Chronic Coronary Disease (CCD)  
- Coronary Artery Disease (CAD)  
- Stroke / Systemic Embolism Prevention  
- Antiplatelet Therapy (APT)  
- Randomized Controlled Trial (RCT)  
- Meta‑Analysis  
- PIONEER AF‑PCI  
- RE‑DUAL PCI  
- AUGUSTUS  
- ENTRUST‑AF PCI  
- WOEST  
- Antiplatelet and Anticoagulant Therapy  
- Clinical Outcome Assessment (e.g., relative risk, odds ratio, confidence interval)

Page 54 Extracted Terms:
- Atrial fibrillation (AF)  
- Coronary artery disease (CAD)  
- Peripheral artery disease (PAD)  
- Myocardial infarction (MI)  
- Stroke  
- Systemic embolism  
- Unstable angina  
- Coronary / peripheral revascularization  
- Anticoagulation therapy  
- Oral anticoagulation (OAC)  
- Direct oral anticoagulants (DOACs) – e.g., rivaroxaban  
- Warfarin  
- Antiplatelet therapy (APT)  
- Dual antiplatelet therapy (DAPT) – aspirin + P2Y12 inhibitor  
- Aspirin  
- P2Y12 inhibitors (e.g., clopidogrel, ticagrelor)  
- Major bleeding  
- Life‑threatening bleeding  
- Intracranial hemorrhage (ICH)  
- Composite primary outcome (stroke, systemic embolism, MI, unstable angina, death)  
- Clinical trial / randomized controlled trial (RCT)  
- Subgroup analysis  
- Meta‑analysis  
- WAVE (Warfarin Antiplatelet Vascular Evaluation) trial  
- ENGAGE AF‑TIMI 48 trial  
- ARISTOTLE trial  
- ROCKET AF trial  
- ORBIT‑AF II registry  
- AHA/ACC PAD guideline (2016)  
- Ankle‑brachial index (ABI) ≤ 0.90  
- Stent thrombosis  
- Acute limb ischemia  
- Critical limb ischemia  
- Lower‑extremity revascularization  
- Amputation  
- Bleeding risk vs. ischemic event risk  
- Non‑inferiority trial design  
- Risk of systemic thromboembolism in AF  
- Risk of major adverse cardiac events (MACEs) in PAD  
- Coronary intervention without revascularization  
- Antiplatelet monotherapy as standard of care for PAD.

Page 55 Extracted Terms:
- Atrial fibrillation (AF)  
- Stroke  
- Anticoagulation  
- Warfarin  
- Direct oral anticoagulants (DOACs)  
- Apixaban  
- Rivaroxaban  
- Dabigatran  
- Dual therapy (OAC plus APT)  
- OAC monotherapy  
- Major adverse cardiac events (MACE)  
- Bleeding risk  
- Thromboembolism  
- Chronic kidney disease (CKD)  
- CKD stage 3  
- CKD stage 4  
- End‑stage renal disease (ESRD)  
- Hemodialysis  
- Calciphylaxis  
- Left atrial appendage occlusion (LAAO)  
- Antithrombotic therapy  
- Antiplatelet therapy (APT)  
- Coagulation monitoring (INR)  
- Renal function indices (eGFR, CrCl)  
- Stroke risk reduction  
- Bleeding risk reduction  
- Cardiovascular mortality  
- Non‑fatal stroke  
- Intracranial hemorrhage  
- Major bleeding  
- Ischemic stroke  
- Pivotal DOAC trials (e.g., AVERROES, ARISTOTLE, SPAF III)

Page 56 Extracted Terms:
- Atrial fibrillation (AF)  
- Valvular heart disease (VHD)  
- Rheumatic mitral stenosis  
- Moderate or greater mitral stenosis  
- Mechanical heart valve  
- Oral anticoagulation  
- Direct oral anticoagulant (DOAC)  
- Vitamin K antagonist (VKA)  
- Warfarin  
- Dabigatran  
- Apixaban  
- Edoxaban  
- Rivaroxaban  
- INVICTUS trial  
- RE‑ALIGN trial  
- PROACT Xa trial  
- CHA₂DS₂‑VASc score  
- Stroke  
- Systemic thromboembolism  
- Cardiovascular events  
- Myocardial infarction (MI)  
- Death  
- Bleeding complications  
- Thromboembolism  
- Renal function (CrCl)  
- Creatinine clearance  
- Bioprosthetic valve  
- Valve repair  
- Aortic stenosis  
- Mitral regurgitation  
- Blood clot  
- Drug interactions  
- Hemorrhage  
- On‑X aortic valve  
- Dabigatran Etexilate  
- Mechanical valve surgery  
- New‑onset AF (within 3 months of valve surgery)  
- Vascular cause (of death or embolism)  
- Stroke risk assessment  
- Anticoagulant therapy guidance


Page 57 Extracted Terms:
**Key terms related to heart disease**

- Atrial fibrillation (AF)  
- Atrial flutter (AFL) – typical & atypical  
- Catheter ablation (CTI‑dependent/CTI‑ablation)  
- Cardioversion  
- Oral anticoagulation / anticoagulant therapy  
- Thromboembolic risk / thromboembolism  
- Stroke (ischemic stroke)  
- Left atrial (LA) thrombus  
- Left atrial appendage (LAA) thrombus / LAA stunning  
- Atrial stunning  
- Chronic obstructive pulmonary disease (COPD)  
- Heart failure (HF)  
- LA enlargement  
- Inducible atrial fibrillation  
- Silent / subclinical AF  
- Thrombus formation  
- Spontaneous echocardiographic contrast (SEC)  
- Macroreentrant circuit  
- Isthmus (crista terminalis)  
- Counterclockwise AFL  
- Clockwise AFL  
- Atrial tachycardia (AT)  
- Intraprocedural anticoagulation strategies  
- Thromboembolic event rates  
- Risk‑adjusted annual risk (>2% risk for stroke)  
- Clinical risk profiling (CHA₂DS₂‑VASc, etc.)  
- Recurrence rate of AFL post‑ablation  
- Systemic embolism  
- Risk ratio & confidence interval (statistical outcomes)  
- Meta‑analysis of AF incidence post‑ablation  
- Asymptomatic AF detection (monitoring)  
- High‑risk patient populations (male predominance, older age)  
- Catheter ablation success rate  
- Anticoagulation discontinuation guidelines (post‑ablation)  

These terms capture the principal concepts, conditions, diagnostic and therapeutic considerations, and risk factors addressed in the guideline text.

Page 58 Extracted Terms:
- Atrial fibrillation (AF)  
- Atrial flutter (AFL)  
- Cavotricuspid isthmus (CTI)  
- CTI‑dependent atrial flutter  
- Catheter ablation  
- Stroke  
- Systemic thromboembolism  
- Thromboembolic event  
- Oral anticoagulation  
- Anticoagulation therapy  
- Non‑valvular atrial fibrillation  
- Implantable cardiac monitor  
- Ambulatory monitor  
- Wearable cardiac device  
- Left atrial enlargement  
- Inducible atrial fibrillation (at ablation)  
- Interatrial conduction time  
- Prolonged HV interval  
- Chronic obstructive pulmonary disease (COPD)  
- Obstructive sleep apnea  
- HATCH score (Hypertension, Age ≥ 75 years, TIA or stroke, COPD, Heart failure)  
- Hypertension  
- Age ≥ 75 years  
- Transient ischemic attack (TIA)  
- Heart failure  
- Cryptogenic stroke  
- Prolonged continuous monitoring  
- Long‑term follow‑up  

These terms capture the key heart‑disease concepts and clinical factors discussed in the text.

Page 59 Extracted Terms:
- Atrial fibrillation (AF)  
- Rate control (rate‑control strategies)  
- Rhythm control (rhythm‑control strategies)  
- Heart rate (resting heart rate, target heart rate)  
- Heart failure (HF)  
- Heart failure with preserved ejection fraction (HFpEF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Cardiovascular morbidity  
- Cardiovascular mortality  
- Cardiac mortality  
- Stroke  
- Systemic embolism  
- Bleeding (major bleeding)  
- Arrhythmic events (life‑threatening arrhythmias)  
- Quality of life (QOL)  
- Left ventricular ejection fraction (LVEF)  
- Sick sinus syndrome (tachycardia‑bradycardia form)  
- Implantable cardioverter‑defibrillator (ICD)  
- Cardiac resynchronization therapy (CRT)  
- Cardiovascular outcomes (all‑cause mortality, composite endpoints)  
- RACE II study  
- AFFIRM study  
- HOT CAFE trial  
- ORBIT‑AF trial  
- Atrial fibrillation follow‑up investigation (AFFIRM)  
- How to Treat Chronic Atrial Fibrillation (HOT CAFE)  
- Observational studies on AF and heart rate  

(Note: The list focuses on clinical terms and concepts specifically related to heart disease described in the guideline excerpt.)

Page 60 Extracted Terms:
- Atrial fibrillation (AF)  
- Rapid ventricular response (RVR)  
- Beta blockers  
- Nondihydropyridine calcium channel blockers (verapamil, diltiazem)  
- Digoxin  
- Amiodarone  
- Left ventricular (LV) systolic dysfunction  
- Heart failure with reduced ejection fraction (HFrEF)  
- Decompensated heart failure (HF)  
- Tachycardia‑induced cardiomyopathy  
- Implantable cardioverter‑defibrillator (ICD)  
- Cardiac resynchronization therapy (CRT)  
- Rapid ventricular rate control  
- Intravascular magnesium  
- Intravenous esmolol  
- Ventricular rate control guidelines  
- Atrial flutter (AFL)  

These terms capture the key heart‑disease entities and therapeutic agents discussed in the guideline excerpt.

Page 61 Extracted Terms:
- Atrial fibrillation (AF)  
- Rapid ventricular response (RVR)  
- Rate control  
- Atrioventricular (AV) nodal blockers  
- Antiarrhythmic agents  
- Intravenous magnesium (as rate‑control therapy)  
- Sinoatrial (SA) node  
- Atrioventricular node  
- Slow inward calcium channels  
- Calcium‑channel blockade (non‑dihydropyridine)  
- Beta‑adrenergic blockade  
- Intravenous diltiazem  
- Intravenous verapamil  
- Intravenous digoxin (digitalis glycoside)  
- Intravenous amiodarone  
- Intravenous esmolol  
- Oral beta‑blockers  
  - Metoprolol tartrate  
  - Metoprolol succinate  
  - Atenolol  
  - Bisoprolol  
  - Carvedilol  
- Propranolol (oral and IV)  
- Nadolol (oral)  
- Digitalis (digoxin) – renal clearance and toxicity at >1.2 ng/mL  
- Coronary artery bypass grafting (CABG) – context for rapid AF after surgery  
- Heart failure with reduced ejection fraction (HFrEF) – contraindication for diltiazem and verapamil  
- Heart rate metrics (e.g., heart rate >120 bpm, goal <90 bpm)  
- Hospital length of stay (as outcome of rate‑control efficacy)  

These terms capture the major concepts, pharmacologic classes, and clinical parameters related to heart disease discussed in the excerpt.

Page 62 Extracted Terms:
- Atrial fibrillation (AF)  
- Rapid ventricular response (RVR)  
- Heart failure (HF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Left ventricular dysfunction (LV dysfunction)  
- Left ventricular ejection fraction (LVEF)  
- Atrioventricular nodal blockers  
- Beta blockers  
- Diltiazem  
- Verapamil  
- Digoxin  
- Amiodarone (intravenous amiodarone)  
- Intravenous magnesium  
- Intravenous calcium channel blockers  
- Negative inotropic effects  
- Acute kidney injury (AKI)  
- Worsening heart‑failure symptoms (increased oxygen requirement, inotropic support)  
- Hypotension (drug‑induced)  
- Inotropic support  
- Rate control  
- Rhythm conversion (to sinus rhythm)  
- Ventricular rates  
- Intensive care unit (ICU) patients with cardiac rhythm issues  
- Mortality rate (in-hospital)  
- Hospitalized patients with AF and RVR  

These terms capture the key cardiovascular concepts addressed in the guideline text.

Page 63 Extracted Terms:
**Key heart‑disease related terms extracted from the guideline text**

- Atrial fibrillation (AF)
- Heart failure (HF)
- Heart failure with reduced ejection fraction (HFrEF)
- Left ventricular ejection fraction (LVEF)
- Long‑term rate control
- Ventricular rate
- B‑blocker (beta blocker)
- Nondihydropyridine calcium‑channel blocker
- Verapamil
- Diltiazem
- Digoxin
- Serum digoxin level / concentration
- Digoxin toxicity
- Narrow therapeutic range
- Cardio‑vacular events
- Dronedarone
- Electrocardiographic abnormalities (ECG/EKG)
- N‑terminal pro‑brain natriuretic peptide (NT‑proBNP)
- Quality of life (QOL)
- Hospitalization
- All‑cause mortality
- Arrhythmia‑related symptoms
- Emergency department length of stay
- Adverse events

These terms capture the essential clinical concepts, therapeutic agents, and outcome measures discussed in the guideline excerpt.

Page 64 Extracted Terms:
**Key terms related to heart disease**

- Atrial fibrillation (AF)  
- Rapid ventricular response (RVR)  
- Resting heart rate  
- Digoxin  
- Heart failure (HF)  
- Congestive heart failure (CHF)  
- Left ventricular ejection fraction (LVEF) / EF < 40%  
- Heart failure with reduced ejection fraction (HFrEF)  
- Diltiazem  
- Multicenter Diltiazem Post‑infarction Trial (MDPIT)  
- Myocardial infarction (MI)  
- Dronedarone  
- PALLAS trial  
- ERATO trial  
- Atrioventricular nodal ablation (AVNA)  
- Pacemaker (PM)  
- His bundle pacing  
- Left bundle‑area pacing  
- Sudden death  
- Mortality  
- Stroke  
- Hospitalization for heart failure  
- Non‑dihydropyridine calcium channel blocker (NDCC)  
- Ventricular rate control  
- Quality of life (QOL)  
- Adverse events  
- Major vascular events  
- Rhythm control strategy  
- Rate‑control medications  
- Pacemaker lower‑rate programming (80–90 bpm)  
- Ventricular response reduction  
- Long‑term rate control in AF  
- Life‑table analysis for late HF  

These terms capture the principal diseases, interventions, clinical trials, pharmacologic agents, and outcomes discussed in the text.

Page 65 Extracted Terms:
- Atrial fibrillation (AF)  
- Paroxysmal atrial fibrillation  
- Persistent atrial fibrillation  
- Permanent atrial fibrillation  
- Atrioventricular nodal ablation (AVNA)  
- Right ventricular pacing (RVP)  
- Biventricular pacing (BiVP)  
- Heart failure (HF)  
- Ventricular fibrillation (VF)  
- Sudden cardiac death  
- Malignant arrhythmias  
- Bradycardia  
- QT prolongation  
- Heterogeneity of repolarization  
- Ejection fraction (EF)  
- New York Heart Association (NYHA) class  
- Conduction‑system pacing  
- His‑bundle pacing  
- Left‑bundle‑area pacing  
- 6‑minute walk test  
- Stroke  
- Hospitalization  
- Pacemaker implantation  
- Lead dislodgement  
- Lead failure  
- Cardiomyopathy  
- Cardiac performance  
- Quality of life (QOL)  

(These terms are directly related to heart disease or its clinical management.)

Page 66 Extracted Terms:
- Atrial fibrillation (AF)  
- Persistent atrial fibrillation  
- High‑burden atrial fibrillation  
- Left ventricular (LV) function  
- Ejection fraction (EF)  
- Reduced EF (<40%)  
- Reduced EF (<50%)  
- New‑onset AF (<1 year)  
- Left bundle area pacing  
- His bundle pacing  
- Atrioventricular nodal ablation (AVNA)  
- Conduction system pacing  
- Rhythm control therapy  
- Rate control therapy  
- Anti‑arrhythmic drugs (AADs)  
- Catheter ablation for AF  
- Cardiac ablation  
- Heart failure (HF)  
- Ischemia  
- Stroke  
- Mortality  
- Hospitalization (cardiac, HF, ACS)  
- Cardiac structural abnormalities  
- Dementia (AF‑related)  
- AF burden  
- Ventricular rates  
- New‑onset AF diagnostic trials (e.g., EAST‑AFNET 4)  
- RACE II study (lenient vs. strict rate control)  
- Quality of life (QOL) improvement  
- Cardiovascular death  
- Cardiac hospitalization  
- AF progression prevention  
- AF‑related symptoms  
- Modifiable cardiovascular risk factors  
- AF burden monitoring  
- Early rhythm‑control strategies  
- Rapid ventricular rate  
- Symptom‑based treatment decisions  
- Clinical studies supporting rhythm control (e.g., RACES, EAST‑AFNET 4)  
- Composite cardiovascular outcomes (death, stroke, hospitalization)

Page 67 Extracted Terms:
- Atrial fibrillation (AF)  
- Congestive heart failure (HF)  
- Cardiovascular death  
- Ischemic stroke  
- Hospitalization for ischemia or HF  
- Rhythm control strategy  
- Rate control strategy  
- Catheter ablation  
- Amiodarone (arrhythmia‑directed therapy)  
- Cardiac arrhythmia  
- Left atrium (LA)  
- Left ventricular (LV) function  
- Composite primary endpoint (cardiovascular death, stroke, HF hospitalization)  
- Mortality rate  
- Quality of life (QOL) improvement  
- AF‑CHF trial  
- EAST‑AFNET 4 study  
- CABANA trial  
- 2023 Guideline for the Diagnosis and Management of Atrial Fibrillation  
- Central venous access (in catheter ablation context)  
- Sinus rhythm maintenance  
- Healthcare resource utilization (ER visits, etc.)

Page 68 Extracted Terms:
- Atrial fibrillation (AF)  
- Rhythm‑control strategy  
- Rate‑control strategy  
- Heart failure (HF)  
- Left ventricular dysfunction  
- Left atrial (LA) size  
- Sinus rhythm  
- Catheter ablation  
- CASTLE‑AF trial  
- AF‑CHF study  
- AF burden  
- AF progression  
- Stroke  
- Cardiovascular death  
- Hospitalization for heart failure  
- Asymptomatic atrial fibrillation  
- Symptomatic atrial fibrillation  
- EAST‑AFNET 4 trial

Page 69 Extracted Terms:
- Atrial fibrillation  
- Mitral regurgitation  
- Tricuspid regurgitation  
- Left atrial enlargement / left atrial size  
- Mitral annular dilation  
- Left atrial appendage thrombus  
- Left atrial appendage occlusion (LAAO)  
- Cardiac thrombus  
- Cardioversion (electrical)  
- Cardioversion (pharmacologic)  
- Anticoagulation therapy  
- Vitamin K antagonists (VKAs)  
- Direct oral anticoagulants (DOACs)  
- CHA₂DS₂‑VASc score  
- Heart failure (HF)  
- Hemodynamic instability  
- Hemodynamic stability  
- Atrioventricular dyssynchrony  
- Atrial kick  
- Atrial myopathy  
- Atrial stunning  
- Prothrombotic state  
- Transesophageal echocardiography (TEE)  
- Rhythm control strategy  
- Rate control strategy  
- Intracardiac thrombus  
- Thromboembolic risk  
- Structural heart disease  
- Device‑related thrombus  
- Thromboembolism


Page 70 Extracted Terms:
- Atrial fibrillation (AF)  
- Cardioversion  
- Electrical cardioversion  
- Pharmacological cardioversion  
- Anticoagulation  
- Vitamin K antagonists (VKAs)  
- Direct oral anticoagulants (DOACs)  
- Thromboembolism  
- Thromboembolic risk  
- Intracardiac thrombus  
- Cardiac computed tomography  
- Delayed contrast‑enhanced imaging protocol  
- Transesophageal echocardiography (TEE)  
- Atrial dysfunction  
- Atrial stunning  
- Mechanical atrial systole  
- Left atrial appendage occlusion (LAAO)  
- Hemodynamically stable AF  
- Multicenter randomized clinical trial (ACUTE study)

Page 71 Extracted Terms:
- Atrial fibrillation (AF)
- Atrial myopathy
- Intracardiac thrombus
- Cardioversion (electrical cardioversion)
- Anticoagulation
- Vitamin K antagonist (VKA)
- Rivaroxaban (direct oral anticoagulant)
- Transesophageal echocardiography (TEE)
- Left atrial appendage (LAA)
- Left atrial appendage occlusion (LAAO)
- Peri‑cardioversion anticoagulation
- Thromboembolism
- Stroke
- Systemic embolism
- Device‑related thrombosis (e.g., Watchman, Lariat, pLAAO devices)
- Residual leak (≤5 mm, >5 mm)
- CHA2DS2‑VASc score
- Transcranial computed tomography (CT) imaging
- Clinical guidelines for AF management
- Clinical evidence from CLOT‑AF and X‑TRA studies
- Anticoagulant compliance and drug interactions
- Non‑adherence and subtherapeutic drug levels
- Post‑cardioversion thromboembolic risk
- Surgical ligation of the LAA
- Left atrial appendage thrombus resolution on follow‑up TEE
- Left atrial or Left atrial appendage thrombus (LA/ LAA)
- Thrombus detection before cardioversion
- Anticoagulation-naïve patients
- Anticoagulation-naïve management
- Thrombus resolution rates with VKA and rivaroxaban
- Acute vs delayed inadequate LAAO occlusion
- Imaging for assessment of LAAO efficacy
- Post‑procedural residual leak assessment
- Stroke/systemic embolism risk in LAAO patients
- Cardioversion safety guidelines (duration <48 h)

Page 72 Extracted Terms:
- Atrial fibrillation (AF)  
- Electrical cardioversion  
- Hemodynamic instability  
- Sinus rhythm  
- Ventricular fibrillation (VF)  
- CHA₂DS₂‑VASc score  
- Pericardioversion thromboembolic event  
- Anti‑arrhythmic drugs  
- Left atrial (LA) size  
- Transthoracic impedance  
- Electrode vector  
- Biphasic energy (≥200 J)  
- Sedation for cardioversion  
- Rhythm control strategy  
- Pharmacological cardioversion  
- AF duration  
- Heart rhythm disorders  
- AF recurrence  
- Cardioversion energy delivery  
- Cardiac rhythm restoration  

Page 73 Extracted Terms:
- Atrial fibrillation (AF)  
- Atrial fibrillation, persistent  
- Atrial fibrillation, new‑onset  
- Electrical cardioversion  
- Pharmacological cardioversion  
- Ibutilide  
- Amiodarone  
- Flecainide  
- Propafenone  
- Procainamide  
- Biphasic waveform  
- Monophasic waveform  
- Shock energy (J)  
- Electrode vector orientation – anterior‑posterior / anterior‑lateral  
- Hemodynamically stable  
- Hemodynamic compromise  
- Left ventricular ejection fraction (LVEF)  
- Heart failure with reduced EF (HFrEF)  
- QT interval prolongation  
- Torsades de pointes  
- Defibrillation (dual‑defibrillator use)  
- Transthoracic impedance  
- Obesity (increased transthoracic impedance)  
- Pill‑in‑the‑pocket (PITP) approach  
- Atrial arrhythmia  
- Ventricular fibrillation (VF)

Page 74 Extracted Terms:
- Atrial fibrillation (AF)  
- Atrial flutter  
- Heart failure with reduced ejection fraction (HFrEF)  
- Pharmacological cardioversion  
- Electrical cardioversion  
- Intravenous amiodarone  
- Intravenous ibutilide  
- Flecainide  
- Propafenone  
- Procainamide  
- Dofetilide  
- Oral amiodarone  
- Oral sotalol  
- Conversion to sinus rhythm  
- Bradycardia  
- Hypotension  
- QT prolongation  
- Torsades de pointes (TdP)  
- Ventricular tachycardia (VT)  
- Atrioventricular (AV) block  
- Exacerbation of HFrEF  
- Phlebitis  
- Neutropenia  
- Agranulocytosis  
- Thrombocytopenia  
- Rash  
- Nausea  
- Dizziness  
- Dyspnea  
- Visual disturbances  
- Taste disturbances  
- N-acetylprocainamide (NAPA)  
- Liver metabolism  
- Kidney excretion  
- Biliary excretion  
- Half‑life (range 9‑36 days)  
- Loading dose  
- Maintenance dose  
- Administration route (IV, oral, continuous infusion)

Page 75 Extracted Terms:
**Key terms related to heart disease extracted from the text**

- Atrial fibrillation (AF)  
- Atrial flutter (AFL)  
- Sinus rhythm  
- Direct current cardioversion / electrical cardioversion  
- Pharmacological cardioversion  
- Ibutilide  
- Amiodarone (intravenous amiodarone)  
- Procainamide  
- Torsades de pointes  
- QT interval prolongation (QTc prolongation)  
- Left ventricular ejection fraction (LVEF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Magnesium infusion (prophylaxis for torsades de pointes)  
- Proarrhythmia  
- Post‑conversion bradycardia  
- Continuous electrocardiographic monitoring  
- Emergency department / acute care setting  
- Cardiac resuscitation  
- Intravenous (IV) drug administration  
- Cardiac rhythm conversion time (30–90 min vs 8–12 h)  

These terms capture the core concepts and interventions pertaining to heart rhythm disorders and their management.

Page 76 Extracted Terms:
**Key terms related to heart disease extracted from the guideline:**

- Atrial fibrillation (AF)  
- Atrial flutter (AFL)  
- Sinus rhythm  
- Heart failure with reduced ejection fraction (HFrEF)  
- Left ventricular ejection fraction (LVEF)  
- Myocardial infarction (MI)  
- Structural heart disease  
- Ventricular scar / fibrosis  
- Hyponatremia? (not in the excerpt)  
- Hypokalemia  
- Hypomagnesemia  
- QT interval prolongation  
- Torsades de pointes  
- Beta blockers  
- Nondihydropyridine calcium channel blockers  
- Antiarrhythmic drugs  
- Class IC antiarrhythmics – flecainide, propafenone  
- Class III antiarrhythmics – dofetilide, dronedarone, sotalol, ibutilide  
- Class IA antiarrhythmic – procainamide  
- Proarrhythmia  
- Hypotension  
- New York Heart Association (NYHA) functional classes III & IV heart failure  
- Decompensated heart failure  
- Conversion of AF to sinus rhythm  
- Long‑term maintenance of sinus rhythm (rhythm‑control strategy)  
- Kidney function (for dose adjustment and monitoring)  
- QT interval monitoring  

*These terms capture the primary clinical conditions, therapeutic agents, and monitoring considerations relevant to heart disease as discussed in the guideline.*

Page 77 Extracted Terms:
- Atrial fibrillation (AF)  
- Atrial flutter (AFL)  
- Supraventricular tachycardia (SVT)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Heart failure (HF)  
- Myocardial infarction (MI)  
- Structural heart disease (scar or fibrosis)  
- Sinus rhythm  
- Maintenance of sinus rhythm  
- Beta‑blocker therapy  
- Atrioventricular nodal blocking agent  
- Sotalol (antiarrhythmic)  
- Amiodarone (antiarrhythmic)  
- Dofetilide (antiarrhythmic)  
- Flecainide (antiarrhythmic)  
- Propafenone (antiarrhythmic)  
- Dronedarone (antiarrhythmic)  
- Flec‑SL (short‑term vs. long‑term antiarrhythmic trial)  
- SAFIRE‑D study (dofetilide trial)  
- SAFE‑T trial (Sotalol vs. Amiodarone)  
- CTAF trial (Canadian Trial of Atrial Fibrillation)  
- EURIDIS study (European Trial in Atrial Fibrillation)  
- ADONIS study (American‑Australian‑African Trial)  
- QT interval prolongation  
- Torsades de pointes  
- Pulmonary fibrosis  
- Hypo‑ or hyperthyroidism  
- Elevated transaminases  
- Hepatotoxicity  
- Corneal microdeposits  
- Optic neuropathy

Page 78 Extracted Terms:
- Atrial fibrillation (AF)  
- Sinus rhythm  
- Sotalol  
- Advanced heart failure (HF)  
- Preserved heart function  
- CrCl (creatinine clearance)  
- Continuous electrocardiographic monitoring  
- Cardiac resuscitation  
- Intravenous sotalol  
- Cardiac Arrhythmia Suppression Trial (CAST)  
- Vaughan Williams class IC antiarrhythmic agents  
- Flecainide  
- Encainide  
- Mortality rate  
- Recent myocardial infarction (MI)  
- Left ventricular ejection fraction (LVEF) < 50%  
- CAST‑II  
- Moricizine  
- Cardiac Arrest Study Hamburg (CASH)  
- Propafenone  
- Structural heart disease  
- Heart failure with reduced ejection fraction (HFrEF)  
- Worsening heart failure  
- Dronedarone  
- Hospitalization due to heart failure (HF)  
- Arrhythmic death  
- New York Heart Association functional class (NYHA FC)  
- Left ventricular (LV)  
- Myocardial infarction (MI)  
- Intravenous (IV)  
- Heart failure (HF)

Page 79 Extracted Terms:
- Atrial fibrillation (AF)  
- Atrial flutter (AFL)  
- Heart failure (HF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- New York Heart Association (NYHA) functional class II, III, IV  
- Class III antiarrhythmic drugs  
- Class IC antiarrhythmic drugs  
- Dofetilide  
- Sotalol  
- Flecainide  
- Propafenone  
- Amiodarone  
- Torsades de pointes  
- QT interval prolongation / QTc prolongation  
- Proarrhythmia  
- Bradyarrhythmia  
- Ventricular fibrillation (VF)  
- Ventricular tachycardia (VT)  
- Electrocardiographic monitoring (continuous ECG)  
- Cardiac resuscitation  
- Renal function assessment (CrCl)  
- Renin‑angiotensin‑aldosterone system (RAAS) inhibitor therapy  
- Hyperkalemia  
- Intravenous antiarrhythmic therapy  
- Hospitalization for antiarrhythmic initiation  
- Outpatient antiarrhythmic therapy  
- SAFIRE‑D study  
- DIAMOND trial  
- SAFE‑T trial  
- AFFIRM trial (substudy)  
- Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFER‑D)  

These terms capture the key heart‑disease–related concepts presented in the guideline text.

Page 80 Extracted Terms:
- Atrial fibrillation  
- Maintenance of sinus rhythm  
- Amiodarone  
- Dofetilide  
- Dronedarone  
- IKr (rapid delayed rectifier K⁺ current)  
- IKs (slow delayed rectifier K⁺ current)  
- INa (sodium channel)  
- IKur (ultra‑rapid delayed rectifier K⁺ current)  
- Ito (transient outward K⁺ current)  
- ICa‑L (L‑type Ca²⁺ channel)  
- IKAch (acetylcholine‑activated K⁺ channel)  
- Non‑competitive β‑blocker  
- AV block (atrioventricular block)  
- Bradycardia  
- QT prolongation  
- Torsades de Pointes (TdP)  
- Hyperthyroidism  
- Hypothyroidism  
- Hepatotoxicity  
- Pulmonary fibrosis  
- Skin pigmentation (blue‑gray)  
- Photosensitivity  
- Peripheral neuropathy  
- Transaminase elevation  
- CYP2C9, CYP2D6, CYP3A (drug metabolism pathways relevant to cardiac drugs)  
- P‑gp (P‑glycoprotein) substrate/inhibitor activity  
- Drug‑drug interactions affecting cardiac rhythm (e.g., with warfarin, digoxin, statins, anti‑arrhythmics)  
- Renal excretion (CrCl‑dependent dosing for dofetilide)  
- Biliary excretion (liver metabolism of amiodarone)  
- Sinus rhythm (electrophysiological term)  
- Cardiac pharmacokinetics (loading vs. maintenance doses)

Page 81 Extracted Terms:
- Atrial fibrillation (AF)  
- Atrial flutter (AFL)  
- Sinus rhythm  
- Permanent pacemaker  
- Bradycardia  
- Hypotension  
- Syncope  
- Rapid atrial flutter (1:1 AFL)  
- Cardioversion  
- Class IC anti‑arrhythmic agents  
- Flexenide (flecainide)  
- Propafenone  
- Sotalol  
- PITP strategy (pulmonary‑influenced termination protocol)  
- AV nodal blocker  
- AV block  
- Proarrhythmia  
- QT prolongation  
- Torsades de pointes (TdP)  
- Ventricular tachycardia (VT)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Anti‑arrhythmic drug follow‑up  
- Mechanisms of action (INa inhibition, IKr inhibition, late INa augmentation)  
- Drug interactions (e.g., with amiodarone, digoxin, warfarin, statins)  
- CYP2D6 metabolism  
- Pharmacokinetics (half‑life, liver/kidney elimination, CrCl)  
- β‑blocker effects (used in sotalol)

Page 82 Extracted Terms:
Atrial fibrillation  
Amiodarone  
Amiodarone‑induced hypothyroidism  
Amiodarone‑induced hyperthyroidism  
Hepatic transaminase elevation  
Hepatotoxicity  
Pulmonary toxicity  
Interstitial lung disease  
Hypersensitivity syndrome  
Chest x‑ray  
Pulmonary function testing  
Diffusing capacity for carbon monoxide  
CT scan  
Corneal microdeposits  
Epithelial keratopathy  
Neurological toxicity  
Peripheral neuropathy  
Torsades de pointes  
Dofetilide  
IKr inhibitor  
INa‑L augmentation  
QTc interval  
CrCl (creatinine clearance)  
Electrolyte balance  
Magnesium  
Potassium  
Creatinine  
Dronedarone  
Hepatic toxicity (dronedarone)  
Ibutilide  
QT prolongation  
Non‑sustained ventricular tachycardia  
Ventricular tachycardia  
Continuous electrocardiographic monitoring  
12‑lead ECG  
Serum magnesium  
Serum potassium  
Renal function  
Antiarrhythmic agents  
Drug‑induced lung toxicity

Page 83 Extracted Terms:
- Atrial fibrillation  
- Left ventricular ejection fraction (LVEF)  
- Ventricular tachycardia (VT)  
- Torsades de pointes (TdP)  
- Hypokalemia  
- Hypomagnesemia  
- Ibutilide  
- Procainamide  
- Sotalol  
- Dofetilide  
- Dronedarone  
- 12‑lead electrocardiogram  
- Serum potassium  
- Serum magnesium  
- Creatinine clearance (CrCl)  
- Blood pressure (BP)  
- QTc interval  
- QRS complex / width  
- Proarrhythmia  
- Hypotension  
- Renal function  
- Drug‑induced torsades de pointes  
- Antiarrhythmic drugs  
- Upstream therapy  
- ACE inhibitors  
- Glucocorticoids  
- Electrocardiographic monitoring  
- Continuous ECG monitoring

Page 84 Extracted Terms:
**Key terms related to heart disease (as extracted from the guideline excerpt)**  

- Atrial fibrillation (AF)  
- Atrial flutter (AFL)  
- Rhythm control strategies  
- Catheter ablation  
- Anti‑arrhythmic drugs (AADs)  
- Symptomatic AF  
- Paroxysmal AF  
- Persistent AF  
- Progressive AF  
- New‑onset atrial arrhythmias  
- Post‑operative AF  
- Atrial arrhythmia recurrence  
- Heart failure with reduced ejection fraction (HFrEF)  
- Heart failure (HF)  
- Chronic kidney disease (CKD)  
- Type 2 diabetes mellitus (T2DM)  
- Sodium‑glucose cotransporter 2 inhibitors (SGLT2‑i)  
- Aldosterone antagonists (e.g., spironolactone)  
- Angiotensin‑converting enzyme (ACE) inhibitors  
- Angiotensin II receptor blockers (ARBs)  
- Statins (e.g., rosuvastatin)  
- Omega‑3 polyunsaturated fatty acids  
- Antioxidants (e.g., ascorbic acid)  
- Glucocorticoids  
- Fibrosis‑targeting therapies  
- Fibrosis reduction  
- Economic value (intermediate)  
- Quality of life (QOL)  
- Cardiovascular outcomes  
- Clinical outcomes  
- Adverse drug effects  
- Clinical and procedural success rates  
- Registry data  
- Randomized controlled trials (RCTs)  
- Meta‑analysis  

These terms capture the primary disease entities, therapeutic modalities, pharmacologic agents, patient populations, and outcome considerations discussed in the guideline passage.

Page 85 Extracted Terms:
Atrial fibrillation  
Paroxysmal atrial fibrillation  
Persistent atrial fibrillation  
Atrial flutter (AFL)  
Atrial tachyarrhythmias  
Recurrent arrhythmia / recurrence of atrial arrhythmia  
AF burden  
Catheter ablation  
Cryoballoon pulmonary vein isolation (PVI)  
Cavo‑tricuspid isthmus (CTI) ablation  
Antiarrhythmic drug therapy (AAD)  
Rhythm control  
Cardiovascular hospitalization (related to AF)  
Quality‑of‑life (QOL) in AF patients  
Cost‑effectiveness of AF treatment  
Symptom improvement in atrial fibrillation  
Antiarrhythmic drug group  
Ablation group (first‑line)  
Early aggressive invasive intervention for AF (EARLY‑AF)  
STOP AF First study (cryoballoon ablation)  
MANTRA‑AF study  
Ablation vs. antiarrhythmic drug comparison  
Recurrent atrial tachyarrhythmias after ablation  
Cryoballoon ablation of AFL  
Pulmonary vein isolation (PVI) effectiveness in AFL  
Procedural complications of ablation (2–5%)

Page 86 Extracted Terms:
**Terms related to heart disease extracted from the text**

- Atrial fibrillation (AF)  
- Paroxysmal AF  
- Persistent AF  
- Atrial flutter (AFL)  
- Atrial tachycardia (AT)  
- Catheter ablation  
- Pulmonary vein isolation (PVI)  
- Rhythm‑control strategy  
- Anti‑arrhythmic medication  
- Heart failure (HF)  
- Left ventricular (LV) function  
- Heart‑failure with reduced ejection fraction (HFrEF)  
- Cardiovascular death  
- Ischemic stroke  
- Transient ischemic attack (TIA)  
- Acute coronary syndrome (ACS)  
- Stroke risk (CHA₂DS₂‑VASc score)  
- Intravascular complications (e.g., pulmonary vein stenosis)  
- Esophageal atrial fistula  
- Pericardial effusion  
- Vascular complications  
- Low‑voltage areas  
- Complex fractionated electrograms (CFEEs)  
- Rotors (focal drivers)  
- Infiltrative cardiomyopathy (e.g., amyloidosis)  
- Mitral stenosis  
- Mitral regurgitation  
- Cor pulmonale  
- Atrial enlargement  
- Myocardial fibrosis  
- Composite clinical outcome (cardiac death, stroke, HF hospitalization, ACS)  
- Ablation‑related adverse events  
- Atrial substrate  
- Cardiomyopathy  
- Prognostic factors (age, atrial size, fibrosis)  
- Catheter‑based intervention  
- Quality‑adjusted life year  
- Cost‑effectiveness modeling  

These terms capture the principal concepts of heart disease discussed in the guidelines excerpt.

Page 87 Extracted Terms:
- Atrial fibrillation (AF)  
- Paroxysmal supraventricular tachycardia (SVT)  
- Pulmonary vein isolation (PVI)  
- Catheter ablation  
- Left atrial (LA) mechanics  
- Atrioesophageal fistula  
- Atrial scar  
- Atrial arrhythmia (including atrial flutter)  
- Recurrent atrial fibrillation  
- Anti‑arrhythmic drug therapy  
- Stroke (cardio‑embolic)  
- Left ventricular (LV) dysfunction  
- Stiff left atrial syndrome  
- Pulmonary vein stenosis  
- Left atrial appendage (LAA)  
- Ligament of Marshall  
- Atrial myopathy  
- Substrate modification during ablation  
- PV-to-LA reconnection  
- Post‑ablation blanking period complications  

These terms capture the key heart‑disease concepts discussed in the guideline excerpts.

Page 88 Extracted Terms:
- Atrial fibrillation  
- Catheter ablation  
- Antiarrhythmic drug therapy  
- Anticoagulation therapy  
- Warfarin  
- Direct oral anticoagulants (DOAC)  
- Vitamin K antagonist  
- Intraprocedural intravenous anticoagulation  
- Heparin  
- Direct thrombin inhibitors  
- CHA₂DS₂‑VASc score  
- Thromboembolic events  
- Stroke  
- Periprocedural bleeding  
- Major bleeding  
- Myocardial injury  
- Vascular instrumentation  
- Cardiovascular outcomes  
- Arrhythmia burden  
- Quality of life (QOL)  
- Clinical trials  
- Observational studies  
- Randomized controlled trials  
- Complications after catheter ablation  
- Silent cerebral ischemic events  
- Periprocedural stroke risk  
- Antithrombotic therapy  
- Coagulopathy  
- Cardiac instrumentation  
- Intravascular procedure  
- Endocardial ablation  
- Heart rhythm disorder  
- Cardiac arrhythmia  
- Cardiac anticoagulation  
- Stroke risk stratification  
- Ablation procedure safety  
- Anticoagulation interruption  
- Uninterrupted warfarin therapy  
- Uninterrupted DOAC therapy  
- Minimally interrupted anticoagulation  
- Continuous anticoagulation.

Page 89 Extracted Terms:
- Atrial fibrillation (AF)  
- Catheter ablation  
- Left atrial (LA)–esophageal fistula  
- Cardiac perforation  
- Pericardial tamponade  
- Cerebrovascular accident (CVA)  
- Transient ischemic attack (TIA)  
- Pulmonary vein (PV) stenosis  
- Phrenic nerve paralysis  
- Vascular access complications  
- Myocardial injury/death (procedure‑related)  
- Pneumonia (post‑procedure)  
- CHA₂DS₂‑VASc score  
- Oral anticoagulation  
- Left atrial appendage occlusion (LAAO)  
- Anticoagulation discontinuation/continuation after ablation  
- Pacemaker implantation  
- Implantable cardioverter‑defibrillator (ICD)  
- Bradycardia  
- Atrioventricular (AV) conduction  
- AV synchrony  
- Atrial tachyarrhythmias  
- Antitachycardia pacing  
- Ventricular pacing reduction  

These are the core heart‑disease terms and concepts highlighted in the guideline excerpt.

Page 90 Extracted Terms:
- Atrial fibrillation (AF)  
- Atrial tachyarrhythmia  
- Atrial ectopy  
- Atrial pacing algorithms  
- Antitachycardia pacing (ATP) algorithms  
- Conduction system pacing  
- Ventricular pacing  
- Atrioventricular synchrony    
- Left bundle branch area pacing  
- His bundle pacing  
- Right ventricular (RV) pacing  
- Sinus node dysfunction  
- Atrioventricular (AV) block  
- PR interval  
- Reentry mechanism  
- Cardiac‑implanted electronic devices (CIED)  
- Pacemaker  
- Implantable cardioverter‑defibrillator (ICD)  
- Surgical ablation (atrial)  
- Hybrid epicardial‑endocardial ablation  
- Anticoagulation therapy  
- Stroke  
- Systemic embolism  
- Heart failure  
- Pacing algorithms (general)  
- Pace‑support rate setting  
- Ventricular depolarization pattern  
- Atrial arrhythmia  
- Paroxysmal atrial fibrillation  
- Persistent atrial fibrillation  
- ATTEST trial  
- MINERVA study  
- MOST study  
- Meta‑analysis  
- Randomized controlled trial (RCT)  
- Retrospective analysis

Page 91 Extracted Terms:
- Atrial fibrillation (AF)  
- Atrial flutter (AFL)  
- Atrial tachycardia (AT)  
- Cardiac surgery  
- Surgical ablation  
- Cryoablation  
- Radiofrequency ablation  
- Mitral valve surgery  
- Aortic surgery  
- Tricuspid surgery  
- Coronary artery bypass grafting (CABG)  
- Pacemaker placement  
- Renal dysfunction  
- Epicardial ablation  
- Endocardial ablation  
- Hybrid procedure (closed‑chest epicardial + endocardial ablation)  
- Pulmonary vein isolation (PVI)  
- Left atrial posterior wall ablation  
- Atrial remodeling  
- Diastolic dysfunction  
- Heart failure (HF)  
- Heart failure with preserved ejection fraction (HFpEF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Left ventricular systolic dysfunction  
- Total mortality  
- Stroke  
- Systemic embolism  
- Oral anticoagulation  
- Warfarin  
- Direct oral anticoagulant (DOAC)  
- Mechanical heart valve  
- Mitral stenosis  
- Atrial stunning  
- Stasis of blood flow  
- Virchow’s triad  
- Endothelial injury  
- Thrombogenic milieu  
- Major adverse events  
- Bleeding  
- Pericardial effusion

Page 92 Extracted Terms:
- Atrial fibrillation (AF)  
- Heart failure (HF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Heart failure with preserved ejection fraction (HFpEF)  
- Left ventricular ejection fraction (LVEF)  
- Left ventricular dysfunction / LV dysfunction  
- Arrhythmia‑induced cardiomyopathy  
- AF‑induced cardiomyopathy  
- AF‑mediated cardiomyopathy  
- Ventricular remodeling  
- Bradycardia / rate control  
- Digoxin (rate‑control agent)  
- Amiodarone (rate‑control agent)  
- Anticoagulation therapy  
- Catheter ablation (AF rhythm‑control therapy)  
- Atrioventricular nodal ablation (AVNA)  
- Biventricular pacing (cardiac resynchronization therapy)  
- Conduction‑system pacing  
  - His bundle pacing  
  - Left bundle branch area pacing  
- Implantable cardioverter‑defibrillator (ICD) – shock risk  
- New‑onset heart failure (NYHA classes III–IV)  
- Cardioversion (pharmacologic and electrical)  
- Atrial arrhythmia burden  
- Stroke risk  
- Mortality (HF‑related)  
- Hospitalization for worsening heart failure  
- Quality of life (QOL) measures in HF/AF patients

These terms capture the central concepts of cardiovascular disease addressed in the guideline excerpts.

Page 93 Extracted Terms:
- Atrial fibrillation (AF)  
- Heart failure (HF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Heart failure with preserved ejection fraction (HFpEF)  
- New‑York Heart Association (NYHA) class  
- Left ventricular ejection fraction (LVEF)  
- Catheter ablation (for AF)  
- Antiarrhythmic drugs  
- Digoxin  
- Carvedilol  
- Bisoprolol  
- Amiodarone (intravenous)  
- Diltiazem (intravenous)  
- Beta‑blockers (intravenous)  
- Atrioventricular node ablation (AVNA)  
- Pacemaker implantation (right‑ventricular pacing, biventricular pacing)  
- Cardiac resynchronization therapy (CRT)  
- Mortality rate  
- Hospitalization rate (HF hospitalizations)  
- Quality of life (QOL)  
- Natriuretic peptide levels  
- Ventricular rate control  
- Hypotension (as a side‑effect of rhythm‑control drugs)  
- Thromboembolism risk (in AF)

Page 94 Extracted Terms:
- AAD (antiarrhythmic drug)  
- AATAC (Ablation vs Amiodarone for Treatment of Atrial Fibrillation in Patients with Congestive Heart Failure and an Implanted ICD/CRTD)  
- AF (atrial fibrillation)  
- AMICA (Atrial Fibrillation Management in Congestive Heart Failure With Ablation)  
- ARC‑HF (A Randomised Trial to Assess Catheter Ablation Versus Rate Control in the Management of Persistent Atrial Fibrillation in Chronic Heart Failure)  
- BNP (brain natriuretic peptide)  
- CABANA (Catheter Ablation vs Antiarrhythmic Drug Therapy for Atrial Fibrillation)  
- CAMERA MRI (Catheter Ablation versus Medical Rate Control in Atrial Fibrillation and Systolic Dysfunction-an MRI‑Guided Multi‑centre Randomised Controlled Trial)  
- CAMTAF (Catheter Ablation Versus Medical Treatment of AF in Heart Failure)  
- CASTLE‑AF (Catheter Ablation versus Standard Conventional Therapy in Patients with Left Ventricular Dysfunction and Atrial Fibrillation)  
- CHF (congestive heart failure)  
- CM (cardiomyopathy)  
- CMR (cardiac magnetic resonance)  
- HF (heart failure)  
- HFpEF (heart failure with preserved ejection fraction)  
- ICD (implantable cardioverter‑defibrillator)  
- LVEF (left ventricular ejection fraction)  
- MACE (major adverse cardiovascular events)  
- NSR (normal sinus rhythm)  
- NYHA (New York Heart Association)  
- PAF (paroxysmal atrial fibrillation)  
- QOL (quality of life)  
- RAFT‑AF (Rhythm Control–Catheter Ablation With or Without Anti‑arrhythmic Drug Control of Maintaining Sinus Rhythm Versus Rate Control With Medical Therapy and/or Atrio‑ventricular Junction Ablation and Pacemaker Treatment for Atrial Fibrillation)  
- RF (radiofrequency)  
- VO₂ max (maximal oxygen consumption)  
- 6MWT (6‑minute walk test)  
- pro‑BNP (N‑terminal pro‑brain natriuretic peptide)  
- PAF or persistent AF  
- NYHA class II or III heart failure  
- Composite of death and hospitalization  
- Composite of MACE  
- Normal sinus rhythm (NSR)  
- Anti‑arrhythmic drug (AAD) therapy  
- Catheter ablation  
- Radiofrequency ablation  
- Catheter ablation versus rate control  
- Catheter ablation versus anti‑arrhythmic drug therapy  
- Anti‑arrhythmic drug versus amiodarone  
- Left ventricular dysfunction  
- Systolic dysfunction  
- Cardiac magnetic resonance imaging (CMR)  
- Brain natriuretic peptide (BNP)  
- Heart‑failure‑related mortality  
- Hospitalization for heart failure  
- Quality‑of‑life improvement  
- Six‑minute walk distance improvement  
- Peak VO₂ improvement.

Page 95 Extracted Terms:
- Atrial fibrillation  
- Atrioventricular  
- Cardiomyopathy  
- Cardiac magnetic resonance  
- Guideline‑directed medical therapy  
- Heart failure  
- Heart failure with preserved ejection fraction  
- Heart failure with reduced ejection fraction  
- Left ventricular ejection fraction  
- Nondihydropyridine calcium channel blocker  
- New York Heart Association  


Page 96 Extracted Terms:
- Atrial fibrillation (AF)  
- Heart failure (HF)  
- Cardiomyopathy (AF‑induced, arrhythmia‑induced)  
- Biventricular pacing  
- Cardiac resynchronization therapy (CRT)  
- Conduction system pacing  
- His bundle pacing  
- Left bundle branch area pacing  
- Atrioventricular node ablation (AVNA)  
- Implantable cardioverter‑defibrillator (ICD)  
- Left ventricular ejection fraction (LVEF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- New York Heart Association (NYHA) class  
- Ventricular rate  
- Rate control strategy  
- Rhythm control strategy  
- Antiarrhythmic therapy (e.g., metoprolol)  
- Metoprolol (dose escalation)  
- Pacing thresholds  
- Pacing percentage (≥ 98 % biventricular pacing)  
- All‑cause mortality  
- Cardiovascular mortality  
- Holter monitor  
- Event monitor  
- Mobile telemetry  
- Implantable loop recorder  
- Wearable devices (e.g., smart watches)  
- 6‑minute walk test (used for target heart‑rate assessment)  
- Clinical trials (e.g., AF‑CHF, RACE II, AF‑CRT)  
- Systematic review and meta‑analysis  
- Observational studies/trials  
- Remote monitoring data  
- Pacing strategies (RV pacing, CRT pacing)  
- ICD shocks (appropriate/inappropriate)  
- Hospitalizations (all‑cause)  

These terms encompass the key concepts related to heart disease—conditions, clinical endpoints, therapeutic devices, pacing strategies, biomarkers, and monitoring tools—presented in the provided guidelines text.

Page 97 Extracted Terms:
- Atrial fibrillation (AF)  
- Heart failure (HF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Non‑ischemic cardiomyopathy  
- Ejection fraction (EF)  
- Left‑ventricular ejection fraction (LVEF)  
- Pulmonary congestion  
- New‑York Heart Association (NYHA) class (I–IV)  
- Conduction system pacing  
- Right‑ventricular/biventricular pacing (RV/BiVP)  
- Diltiazem (nondihydropyridine calcium‑channel blocker)  
- Verapamil (nondihydropyridine calcium‑channel blocker)  
- Inotropic support  
- Dronedarone (anti‑arrhythmic)  
- Cardiovascular mortality  
- Cardiac death  
- Non‑fatal reinfarction  
- Late heart failure  
- Arrhythmic death  
- Genetic testing for cardiomyopathy/ion‑channel disorders  
- Inherited ion‑channel disorders  
- Cardiomyopathy surveillance  
- Reentrant supraventricular tachyarrhythmias (SVTs)  
- Electrophysiological study (EPS)  
- Catheter ablation  
- Acute kidney injury  
- Myocardial infarction (MI)  
- Post‑acute MI complications  
- Hospitalization due to heart failure  
- Recurrent atrial arrhythmias (AF or SVT)

Page 98 Extracted Terms:
- Atrial fibrillation (AF)  
- Slow pathway ablation  
- Pulmonary vein isolation (PVI)  
- Catheter ablation  
- Cardiomyopathy-related genes  
- Ion channelopathy genes  
- Exercise-induced atrial myopathy  
- Exercise-related inflammation  
- Cardiopulmonary exercise stress testing  
- Metabolic equivalents (METs)  
- Obesity (BMI ≥ 30 kg/m²)  
- Class III obesity (BMI ≥ 40 kg/m²)  
- Body mass index (BMI)  
- Left atrial (LA) dilatation  
- Hyperlipidemia  
- Hypertension  
- Heart failure (HF)  
- Sleep apnea  
- Weight loss (primary and secondary prevention of AF)  
- Direct oral anticoagulants (DOACs)  
- Warfarin  
- Bariatric surgery  
- Anticoagulation considerations  
- Anticoagulation risk reduction  
- Paroxysmal AF  
- Persistent AF  
- Permanent AF  
- AF recurrence  
- Stroke risk  
- Anticoagulation drug absorption  
- Framingham Study risk metrics  
- Echocardiogram (normal vs abnormal)  
- QOL (quality of life) improvement  
- Exercise capacity preservation  
- Metabolic equivalent-hours per week  
- Exercise volume (high-volume endurance athlete)  
- Age of AF onset (<45, <66 years)  
- Athlete population  
- AF prognosis in obesity  
- BMI‑adjusted hazard ratios (HR) for AF  
- AF burden  
- Obesity‑mediated structural atrial changes  
- Epicardial fat  
- Abdominal fat  
- Cardiopulmonary exercise treadmill testing  
- Long‑term follow‑up studies (10‑year, 3‑year)  

Page 99 Extracted Terms:
- Atrial fibrillation (AF)  
- Class III obesity (BMI ≥ 40 kg/m²)  
- Body mass index (BMI)  
- Direct oral anticoagulants (DOAC)  
- Apixaban  
- Rivaroxaban  
- Edoxaban  
- Dabigatran  
- Warfarin  
- Stroke‑risk prevention in AF  
- Ischemic stroke  
- Systemic embolism  
- Major bleeding  
- Bariatric surgery  
- Drug peak trough levels after bariatric surgery  
- Oral anticoagulation therapy  
- Percutaneous left atrial appendage occlusion (LAAO)  
- Surgical left atrial appendage exclusion/excision  
- Surgical ablation in AF  
- Valvular heart disease (VHD)  
- Cerebrovascular events in VHD  
- Accessory pathways (AP)  
- Wolff–Parkinson–White syndrome (WPW)  
- Pre‑excited atrial fibrillation  
- Preexcitation syndromes  
- Intravenous ibutilide  
- Intravenous procainamide  
- Verapamil (AV‑nodal blocker)  
- Diltiazem (AV‑nodal blocker)  
- Amiodarone (antiarrhythmic)  
- Digoxin (antiarrhythmic)  
- Adenosine (antiarrhythmic)  
- Beta‑blockers (AV‑nodal blocker)  
- Ventricular fibrillation (VF)  
- Sudden cardiac death  
- Electrical cardioversion  
- Catheter ablation of accessory pathways  
- Anticoagulation‑associated bleeding risk  
- Thromboembolism prevention  
- Lipid‑risk scoring  

*(List contains key terms related to heart disease drawn from the guideline excerpt.)*

Page 100 Extracted Terms:
- Preexcited atrial fibrillation (AF)  
- Ventricular fibrillation (VF)  
- Electrical cardioversion  
- Pathway (ablation)  
- Atrial fibrillation (AF)  
- Atrial tissue refractory period  
- Ibutilide  
- Procainamide  
- Atrioventricular (AV) nodal block  
- AV‑nodal blocking agents  
- Amiodarone  
- Verapamil  
- Hypertrophic cardiomyopathy (HCM)  
- AHA/ACC guideline for hypertrophic cardiomyopathy  
- Direct oral anticoagulants (DOACs)  
- Warfarin  
- Antiarrhythmic drugs  
- Catheter ablation  
- Adult congenital heart disease (ACHD)  
- Hemodynamic sequelae  
- Electrophysiological procedures  
- Pulmonary vein isolation (PVI)  
- Atriotomy scars  
- Cavotricuspid isthmus (CTI)  
- Fontan circulation  
- Anticoagulation  
- Thromboembolic events  
- Risk scores (e.g., CHA₂DS₂‑VASc, CHADS‑VASc)  
- Stroke  
- Atrial arrhythmias  
- Hemodynamic instability  
- Rapid ventricular response  
- Reentrant arrhythmia  
- Atrial rhythm‑control strategy  

Page 101 Extracted Terms:
- Atrial Fibrillation (AF)  
- Congenital Heart Disease (CHD)  
- Adult Congenital Heart Disease (ACHD)  
- Simple, Moderate, and Complex forms of CHD  
- Sinus Node Dysfunction  
- Atrioventricular Block  
- Ventricular Dysfunction (subpulmonary & systemic)  
- Right Atrial (RA) Dilation  
- Fontan Physiology  
- Low‑Flow States  
- Thromboembolic Prophylaxis  
- CHA₂DS₂‑VASc Score  
- Direct Oral Anticoagulants (DOACs)  
- Amiodarone (antiarrhythmic)  
- Dofetilide (antiarrhythmic)  
- Dronedarone (antiarrhythmic)  
- Class I Antiarrhythmic Drugs  
- Pulmonary Vein Isolation (PVI)  
- Cryoballoon Ablation  
- Transseptal Puncture  
- CTI (cave‑to‑tricuspid isthmus) Ablation  
- Atriotomy Scars  
- Left Superior Vena Cava  
- Right Atrial (RA) pathology in repaired complex ACHD  
- Stroke  
- Heart Failure (HF)  
- Survival Outcomes in ACHD  
- Periprocedural Care  
- Ancillary Imaging in ACHD  
- Proarrhythmic Effects  
- Thyrotoxicosis (amiodarone‑induced)  
- BMI <21 kg/m² (risk factor for thyrotoxicosis)  
- Cyanotic Lesions  
- Blind‑ending Cardiac Chambers  
- Cerebrovascular Accidents (CVA)  
- Hemodynamic Sequelae of Childhood Repair  
- Electrophysiologic Procedures in ACHD  



Page 102 Extracted Terms:
**Key heart‑disease related terms extracted from the guideline text**

- Atrial fibrillation (AF)  
- New‑onset postoperative AF  
- Postoperative atrial fibrillation  
- Cardiac surgery  
- Coronary artery bypass graft (CABG)  
- Aortic valve surgery  
- Ascending aortic aneurysm surgery  
- Posterior left pericardiotomy  
- Beta‑blockers (pre‑operative prophylaxis)  
- Amiodarone (pre‑operative prophylaxis)  
- Colchicine (prophylaxis)  
- Rate control (target <100 bpm)  
- Rhythm control  
- Non‑dihydropyridine calcium channel blockers  
- Direct current cardioversion  
- Antiarrhythmic drug therapy  
- Anticoagulation (post‑operative management)  
- Left atrial appendage thrombus  
- Stroke risk  
- Late mortality  
- Hemodynamic stability  
- Heart rate  
- Post‑operative complications  
- Antiarrhythmic medication  
- Clinical trials (RCT, meta‑analysis)  
- Incidence of AF  
- Thrombosis risk  
- Bleeding risk  
- Reevaluation of long‑term anticoagulation  

These terms capture the primary clinical concepts, interventions, and outcomes relevant to heart disease discussed in the guideline excerpt.

Page 103 Extracted Terms:
- Atrial fibrillation (AF)  
- Rhythm‑control strategy  
- Rate‑control strategy  
- Beta blockers  
- Calcium channel blockers  
- Amiodarone  
- Cardioversion  
- Anticoagulation / anticoagulants  
- Thromboembolic events  
- Stroke (high‑risk for stroke)  
- Left atrial appendage (LAA) imaging  
- Post‑operative AF  
- Hemodynamically stable patient  
- Hemodynamically poorly tolerated AF  
- Cardiac surgery  
- Heart rate (HR)  
- Mortality rate  
- Colchicine (anti‑inflammatory)  
- Post‑discharge follow‑up  
- Clinical guideline statements  

Page 104 Extracted Terms:
- Atrial fibrillation (AF)  
- Acute atrial fibrillation (acute AF)  
- AF recurrence  
- Heart failure (HF)  
- Stroke  
- Mortality  
- Anticoagulation  
- Oral anticoagulant (OAC)  
- Parenteral anticoagulation  
- Thromboembolism / thromboembolic risk  
- Critical illness  
- Sepsis  
- Non‑cardiac surgery  
- Cardiac surgery  
- Rhythm monitoring  
- Outpatient follow‑up  
- Rhythm control strategy  
- Rate control strategy  
- Hemodynamics  
- AF surveillance  
- Risk stratification  
- CHA₂DS₂‑VASc score  
- Bleeding risk  
- In‑hospital stay  
- Long‑term risk  
- Paroxysmal AF  
- Persistent AF

Page 105 Extracted Terms:
- Atrial fibrillation (AF)  
- Acute atrial fibrillation (acute AF)  
- Recurrent atrial fibrillation (recurrent AF)  
- Oral anticoagulants (OACs)  
- Anticoagulation  
- Ischemic stroke  
- Bleeding  
- Cardiac surgery  
- Non‑cardiothoracic surgery  
- Infection (as a precipitant for AF)  
- Precipitants (of AF)  
- Critical illness (in the context of AF)  
- Unadjusted cumulative risk of AF recurrence  
- Kaplan‑Meier method (used for AF recurrence analysis)  
- Cardiothoracic (CT)  
- American Heart Association (reference and source of figures)

Page 106 Extracted Terms:
- Atrial fibrillation (AF)  
- Atrial flutter (AFL)  
- Hyperthyroidism  
- Anticoagulation therapy  
- Stroke risk / thromboembolic risk  
- Antithrombotic therapy  
- Cardioselective beta‑blockers  
- Non‑selective beta‑blockers  
- Pulmonary hypertension (PH)  
- Pulmonary vascular disease  
- Rhythm‑control strategy  
- Functional status  
- Survival  
- Pulmonary embolism (PE)  
- Myocardial infarction (MI)  
- Heart failure (HF)  
- Coronary artery disease (CAD)  
- Beta‑2 agonists  
- Propranolol  
- Euthyroid state  
- Antithyroid treatment  
- Warfarin  
- Apixaban

Page 107 Extracted Terms:
- Atrial fibrillation (AF)  
- Atrial arrhythmias  
- Atrial flutter (AFL)  
- Pulmonary hypertension (PH)  
- Pulmonary vascular disease (PHPVD)  
- WHO pulmonary hypertension groups 1, 3, 4  
- Right atrial contraction  
- Sinus rhythm  
- Cardioversion  
- Direct‑current cardioversion (DCCV)  
- Antiarrhythmic drug therapy  
- Catheter ablation (including left atrial ablation)  
- Transseptal puncture  
- Left‑sided obstructive lesions  
- Congenital heart disease (CHD)  
- Valvular heart disease (VHD)  
- Anticoagulation (including DOACs)  
- Stroke risk (as a cardiac complication)  
- Hemodynamic parameters (e.g., pulmonary vascular resistance, left heart filling pressures)  
- Pregnant individuals with heart disease  
- Hormonal influences on cardiac rhythm (e.g., elevated progesterone)  
- Hypertensive disorders of pregnancy  
- Beta blockers (including cardioselective agents)  
- Digoxin  

---

Page 108 Extracted Terms:
- Atrial fibrillation (AF)  
- Stroke risk in AF  
- Anticoagulation strategies  
- Warfarin (vitamin K antagonist)  
- Low‑molecular‑weight heparin (LMWH)  
- Unfractionated heparin (UFH)  
- Direct oral anticoagulants (DOACs)  
- Valvular heart disease (VHD)  
- Mitral stenosis  
- Beta‑blockers (e.g., propranolol, metoprolol)  
- Digoxin  
- QTc prolongation  
- Proarrhythmia  
- Bleeding risk  
- Thromboembolism  
- Heart failure (HF)  
- Cardio‑oncology  
- Cancer‑associated atrial fibrillation  
- Ibrutinib (Bruton’s tyrosine kinase inhibitor)  
- Systemic inflammation  
- Hypertension  
- Obesity  
- Thoracic radiation therapy  
- Thoracic surgery  
- Pregnancy‑related anticoagulation  
- Intravenous heparin  
- International Normalized Ratio (INR)  
- Delivery planning in anticoagulated patients  
- Anticoagulation during pregnancy (first, second, third trimesters)

Page 109 Extracted Terms:
- Atrial fibrillation (AF)  
- Heart failure (HF)  
- Myocardial infarction (MI)  
- Hypertension  
- Stroke  
- Cardiovascular disease (CVD)  
- Peripheral cardiovascular complications (e.g., perioperative AF)  
- Guideline‑directed medical therapy (GDMT)  
- Oral anticoagulants (OACs)  
- Anti‑arrhythmic agents  
- Beta‑blockers (rate‑control agents)  
- QTc prolongation / QT‑prolonging agents  
- Drug‑drug interactions between cancer therapies and anticoagulants  
- Cancer therapeutics associated with increased AF risk (e.g., anthracyclines, antimetabolites, alkylating agents, immunomodulators, tyrosine‑kinase inhibitors, VEGF inhibitors, BRAF inhibitors, CAR T‑cell therapy, monoclonal antibodies)  
- Specific antineoplastic agents highlighted as AF risk factors:  
  - Anthracyclines (doxorubicin, epirubicin, idarubicin, mitoxantrone)  
  - Antimetabolites (clofarabine, cytarabine, 5‑fluorouracil, capecitabine, gemcitabine)  
  - Alkylating agents (cyclophosphamide, melphalan)  
  - Immunomodulatory drugs (lenalidomide, interleukin‑2)  
  - Tyrosine‑kinase inhibitors (ibrutinib, acalabrutinib, zanubrutinib, ponatinib, trametinib, osimertinib, nilotinib, ribociclib)  
  - VEGF inhibitors (sorafenib)  
  - BRAF inhibitor (vemurafenib)  
  - CAR T‑cell therapies (tisagenlecleucel, axicabtagene ciloleucel)  
  - Monoclonal antibody (rituximab)

Page 110 Extracted Terms:
- Atrial fibrillation (AF)  
- Cancer therapies associated with AF  
- Cardiovascular risk factors (hypertension, diabetes)  
- Natriuretic peptides  
- Stroke / systemic embolism  
- Major bleeding  
- Direct oral anticoagulants (DOACs)  
- Warfarin (vitamin K antagonist, VKA)  
- Rivaroxaban  
- Apixaban  
- Dabigatran  
- Edoxaban  
- Catheter ablation  
- Amiodarone (antiarrhythmic drug)  
- Rate control therapies  
- Rhythm control therapies  
- Antiarrhythmic drug dosing in CKD  
- Chronic kidney disease (CKD)  
- Kidney failure / end‑stage renal disease  
- Estimated glomerular filtration rate (eGFR)  
- Proteinuria  
- Renal dysfunction  
- Fluid balance management during radiofrequency ablation  
- Anticoagulation in CKD and AF  
- Liver disease (cirrhosis)  
- Child‑Pugh classification (A, B, C)  
- Coagulopathy / thrombocytopenia  
- International normalized ratio (INR)  
- HAS‑BLED bleeding risk score  
- High bleeding risk estimators  
- Thrombocytopenia (platelet < 50 000/µL)  
- Intracranial malignancy  
- Gastrointestinal malignancy  
- History of major bleeding  
- Severe kidney dysfunction (eGFR < 30 mL/min/1.73 m²)  
- Drug interactions (P‑glycoprotein, CYP3A4 inducers/inhibitors)  
- Antineoplastic drug interactions  
- Pulmonary embolism / inherited thrombophilia (implied by embolism context)

Page 111 Extracted Terms:
- Atrial fibrillation (AF)
- Oral anticoagulation (OAC) therapy
- Direct oral anticoagulants (DOACs)
- Vitamin K antagonists (VKAs)
- Oral factor Xa inhibitors
- Rivaroxaban
- Edoxaban
- Apixaban
- Dabigatran
- Warfarin
- Ischemic stroke
- Thromboembolism
- Intracranial hemorrhage (ICH)
- Major bleeding
- All‑cause mortality
- Composite cardiovascular events
- Liver disease
- Liver fibrosis
- Cirrhosis
- Child‑Pugh score/class (A, B, C)
- Hepatic metabolism
- Plasma concentration
- Esophageal varices
- Meta‑analysis
- Observational studies
- Clinical trials
- Post‑marketing retrospective studies
- Guideline
- Safety profile
- Efficacy data
- Risk‑factor modification
- Prevention strategies
- Rhythm management
- Disease continuum in AF
- Downstream long‑term consequences of AF

Page 112 Extracted Terms:
- Atrial fibrillation (AF)  
- Catheter ablation  
- Ablation failure  
- AF burden  
- Subclinical atrial fibrillation  
- Left atrial appendage occlusion (LAAO)  
- Stroke prevention  
- Anticoagulation therapy  
- Oral anticoagulants  
- CHA2DS2‑VASc score  
- Risk modifiers (stroke risk)  
- Risk scores  
- Cardioversion  
- Wearable heart‑monitoring devices  
- Artificial intelligence (AI) for AF management  
- Electrocardiographic‑guided anticoagulation  
- Pulmonary vein isolation (PVI)  
- Hypertension  
- Biomarkers for AF and stroke prediction  
- Periprocedural anticoagulation  
- LAA device implantation (pLAAO)  
- Electronic medical record integration for risk scoring  

Page 113 Extracted Terms:
- Atrial fibrillation (AF)  
- Sleep‑disordered breathing (SDB)  
- Anticoagulation  
- Direct oral anticoagulants (DOACs)  
- Rhythm management  
- Anti‑arrhythmic drugs  
- Catheter ablation  
- Genetic testing / consumer‑based genetic testing  
- Polygenic risk scores  
- Arrhythmia incidence  
- Gender‑affirming therapies (impact on arrhythmia)  
- Race, ethnicity, and gender/sex disparities in AF outcomes  
- Standardized outcome measures (symptom burden, quality‑of‑life)  
- Social determinants of health (SDOH) in AF  

These are the principal heart‑disease‑related terms identified in the guideline text.

Page 114 Extracted Terms:
- Atrial fibrillation  
- Hypertrophic cardiomyopathy  
- Valvular heart disease  
- Coronary artery revascularization  
- Chest pain  
- Stroke (in relation to cardiovascular disease)  
- Heart failure  
- Congenital heart disease  
- Arrhythmias during pregnancy  
- Cardiovascular disease / heart disease  
- Cardiovascular disease and stroke statistics  
- Global burden of disease (cardiovascular focus)  
- Incidence (of cardiovascular conditions)  
- Prevalence (of cardiovascular conditions)  
- Mortality (cardiovascular)  
- Risk factors (for cardiovascular disease)  
- Healthcare utilization (related to cardiovascular conditions)  
- Cost/value methodology (in cardiovascular guideline development)  
- Clinical practice guidelines (ACC/AHA, ESC, EHRA, EACTS)  
- ACC/AHA joint committees (e.g., on heart failure, valvular disease)  
- ESC guidelines for atrial fibrillation  
- Canadian Cardiovascular Society guidelines on atrial fibrillation  
- American College of Cardiology (ACC)  
- American Heart Association (AHA)  
- Heart Rhythm Society (HRS)  
- European Heart Rhythm Association (EHRA)  
- European Association for Cardio‑Thoracic Surgery (EACTS)

Page 115 Extracted Terms:
- Atrial fibrillation  
- Cardiovascular disease  
- Myocardial infarction  
- Heart failure  
- Stroke / cerebrovascular disease  
- Hypertension  
- Arrhythmia  
- Obesity  
- Body mass index (BMI)  
- Weight loss / weight management  
- Bariatric surgery  
- Exercise / physical activity  
- Aerobic interval training  
- Cardio‑respiratory fitness  
- Smoking / tobacco use  
- Alcohol consumption  
- Renal disease / kidney dysfunction  
- Renal denervation  
- Catheter ablation  
- Ablation outcomes  
- Aldosterone pathway blockade  
- Blood pressure control  
- Cardiometabolic risk factors  
- Mortality  
- Morbidity

Page 116 Extracted Terms:
- Atrial fibrillation  
- Blood pressure (systolic & diastolic)  
- Resting heart rate  
- Diabetes mellitus  
- Heart failure (congestive, reduced EF, preserved EF)  
- Valvular heart disease  
- Cardiac surgery (open‑heart, valve replacement, coronary bypass)  
- β‑blockers (pre‑operative, postoperative)  
- Amiodarone (rate‑ and rhythm‑control, prophylaxis)  
- Arrhythmia (post‑operative, post‑cardioversion)  
- Revascularization (PCI, CABG)  
- Valve replacement / repair  
- Posterior left pericardiotomy (atrial fibrillation prevention)  
- Post‑operative atrial fibrillation (after cardiac surgery)  
- Chronic kidney disease (CKD)  
- Obstructive sleep apnea (OSA)  
- Continuous positive airway pressure (CPAP) therapy  
- Thyroid dysfunction / thyroid‑stimulating hormone (TSH)  
- Stroke (incident, ischemic, hemorrhagic)  
- Sepsis / severe sepsis (hospitalized patients)  
- PR interval / first‑degree heart block  
- Left ventricular hypertrophy (LVH)  
- B‑type natriuretic peptide (BNP / NT‑proBNP)  
- C‑reactive protein (CRP)  
- Lipoprotein(a)  
- Echocardiographic predictors (non‑rheumatic AF, LV mass, atrial size)  
- Left atrial functional measures (strain, volume)  
- Cardiovascular risk scores (Framingham, CHARGE‑AF)  
- Mendelian randomization studies (genetic determinants)  
- Meta‑analysis / systematic review (methodology in cardiology)

Page 117 Extracted Terms:
**Key Heart‑Disease Terms Extracted**

- Atrial fibrillation  
- Atrial flutter  
- Supraventricular tachycardia  
- Left atrial size reduction  
- Radiofrequency ablation  
- Pulmonary veins  
- Mitral valve surgery  
- Atrial myopathy  
- Electrical remodeling  
- Inward rectifier potassium currents (I<sub>KA</sub>)  
- Connexin40 (Cx40)  
- Connexin43 (Cx43)  
- Calcium signaling  
- Ca<sup>2+</sup>/calmodulin‑dependent protein kinase II (CaMKII)  
- Inflammation (e.g., IL‑6)  
- Myeloperoxidase activity  
- Endocardial ablation  
- Ectopic atrial beats  
- Atrial ectopy  
- Conduction pathways (left‑to‑right atrial)  
- Left‑to‑right atrial K<sup>+</sup> gradient  
- Atypical atrial arrhythmias  
- Paroxysmal atrial fibrillation  
- Chronic atrial fibrillation  
- Atrial remodeling (structural & functional)  
- Atrial cardiomyopathy  
- Pulmonary vein isolation  
- Electro‑gram frequency analysis  
- Arrhythmogenic substrate  
- Sympathetic tone / mechanical stretch interaction  
- Sodium/calcium exchanger (NCX) dysfunction  
- Sarcoplasmic reticulum Ca<sup>2+</sup> leak  
- Interstitial fibrosis  
- Ventricular dysfunction (mentioned in related contexts)  

These terms summarize the most frequently referenced heart‑disease concepts, mechanisms, and interventions within the provided guideline excerpts.

Page 118 Extracted Terms:
**Key terms related to heart disease extracted from the text**

- Atrial fibrillation (AF)  
- Atrial arrhythmias / atrial arrhythmogenesis  
- Atrial remodeling  
- Sympathetic hyperinnervation  
- Parasympathetic nerve remodeling  
- Autonomic nervous system (ANS) dysregulation  
- Sympathetic and parasympathetic neuron activity  
- JNK2 signaling  
- CaMKII signaling  
- SERCA2 function / enhancer  
- Calcium handling / Ca²⁺ release and leak  
- Oxidative stress  
- Inflammatory mechanisms (e.g., CRP elevation, NLRP3 inflammasome)  
- Hypertension (immunology and neurohumoral effects)  
- Thrombogenesis (Virchow’s triad, clot formation)  
- Cardiac surgery–related postoperative arrhythmias  
- Pulmonary vein isolation (PVI)  
- Catheter ablation for AF  
- Oral anticoagulation therapy  
- Heart failure (congestive)  
- Socioeconomic status (SES) and health inequities  
- Racial and ethnic disparities in AF management  
- Sex/gender differences in AF treatment and outcomes  
- Social determinants of health (SDOH) interventions  
- Genomic/locus identification for AF (e.g., KCNQ1, KCNH2, GATA4, MYL3, etc.)  
- Genome‑wide association studies (GWAS) for AF risk  
- Rare genetic variants in cardiomyopathy and arrhythmia genes  
- Polygenic and monogenic contributions to AF risk  
- Hospital admission outcomes for AF/flutter  
- National registries and cohort studies (e.g., AF‑RISK, PINNACLE, CABANA)  
- Cardiovascular outcome metrics (stroke, mortality, complications)  
- Risk stratification (e.g., CHA₂DS₂‑VASc, HAS‑BLED)  
- Rhythm control strategies (pharmacologic, ablation, electrical cardioversion)  
- Rate control strategies  
- Neurohumoral and hemodynamic effects of lower body negative pressure  
- Multimodal pharmacologic therapy (e.g., beta‑blockers, calcium channel blockers, antiarrhythmic drugs)  
- Atrial fibrillation burden (inspiratory, rapid atrial pacing, atrial pacing models)  
- Cardiac autonomic afferent dysregulation  
- Autonomic nerve sprouting  
- Regional cardiac autonomic remodeling  
- Structural remodeling of the left atrium  
- Clinical evidence of autonomic dysfunction due to AF  
- Atrial fibrillation progression risk factors  
- Health equity initiatives and policy actions (e.g., rural health advisories, primary‑care recommendations)  
- Clinical guidelines and systematic reviews for AF management.

Page 119 Extracted Terms:
- Atrial fibrillation  
- Atrial flutter  
- Stroke prevention  
- Anticoagulation therapy  
- Direct oral anticoagulants (DOACs)  
- Rhythm‑control therapy  
- Catheter ablation  
- Shared decision‑making  
- Risk stratification  
- Population screening  
- Community risk models  
- CHARGE‑AF score  
- C2HEST score  
- HATCH score  
- Early rhythm‑control  
- Mobile health devices  
- Wearable devices  
- Smartwatch monitoring  
- Electrocardiogram (ECG)  
- Handheld ECG device  
- Myocardial perfusion imaging  
- Coronary artery disease  
- Pulmonary embolism  
- Hyperthyroidism  
- Chronic kidney disease (CKD)  
- Non‑alcoholic fatty liver disease (NAFLD)  
- Left atrial strain  
- Left atrial volume  
- Tissue Doppler echocardiography  
- Cardiac amyloidosis  
- Myocardial function assessment  
- Arrhythmia management  
- Catheter ablation vs. medical therapy comparison  
- Stroke risk stratification (e.g., CHA₂DS₂‑VASc)  
- Anticoagulation prescription fills  
- Treatment adherence  
- Socioeconomic and racial disparities  
- Patient decision aids  
- Health literacy  
- AI‑guided atrial fibrillation screening  
- Diagnostic accuracy of ambulatory devices  
- Diagnostic accuracy of smart gadgets/wearables  
- Diagnostic accuracy of handheld ECGs  
- Screening for new‑onset atrial fibrillation  
- Left atrium and left atrial appendage anatomy (stroke implications)  
- Coronary artery disease screening in atrial fibrillation patients  

Page 120 Extracted Terms:
- Atrial fibrillation  
- Atrial flutter  
- Arrhythmia  
- Stroke  
- Transient ischemic attack (TIA)  
- Ischemic stroke  
- Device‑detected atrial high‑rate episodes  
- Stroke risk  
- Cardiac rhythm monitoring  
- Electrocardiogram (ECG)  
- Implantable loop recorder  
- Implantable cardioverter‑defibrillator (ICD)  
- Cardiac pacemaker  
- Holter monitor  
- Smartwatch  
- Photoplethysmography  
- Smartphone ECG  
- Mobile electrocardiogram  
- Catheter ablation  
- Rhythm control  
- Anticoagulation  
- Blood pressure  
- Body mass index (BMI)  
- Physical activity  
- Exercise  
- Cardiovascular fitness  
- Resting heart rate  
- Smoking / tobacco use  
- Alcohol consumption (including binge drinking / holiday heart syndrome)  
- Diabetes mellitus / blood glucose  
- Intensive blood‑pressure lowering  
- Genetic risk  
- Genome‑wide association study (GWAS)  
- Life Simple 7  
- CHARGE‑AF risk model  
- Atherosclerosis Risk in Communities (ARIC) study  
- REGARDS study  
- ACC/AHA cardiovascular disease prevention guidelines  
- Cardiac biomarkers  
- Stroke/TIA recurrence  
- Wearable technology  
- Long‑term continuous monitoring  
- Cardiovascular disease (CVD)  
- Risk factor prediction models  
- Competing cardiovascular risk factors  

Page 121 Extracted Terms:
Atrial fibrillation  
Cardiovascular disease (CVD)  
Heart failure  
Stroke  
Cardiac arrhythmia  
Obesity  
Weight loss  
Cardiometabolic risk factors  
Diabetes mellitus  
Glycated hemoglobin (HbA1c)  
Cardiac rehabilitation  
Exercise training  
Aerobic interval training  
Cardiac exercise  
Catheter ablation  
Smoking cessation  
Physical fitness  
Exercise‑based cardiac rehabilitation  
Risk factor modification  
Electrophysiological and structural remodeling of the atria

Page 122 Extracted Terms:
Atrial fibrillation  
Paroxysmal atrial fibrillation  
Atrial tachyarrhythmia  
Atrial fibrillation recurrence  
Post‑operative atrial fibrillation  
Cardiac surgery (heart valve surgery, cardiopulmonary bypass)  
Coronary artery bypass grafting  
Heart failure (including chronic heart failure)  
Diabetes mellitus  
Hypertension  
Aldosterone pathway blockade  
Renal denervation  
Catheter ablation (electrical cardioversion, ablation)  
Weight management / weight loss  
Smoking (cigarette smoking)  
Alcohol consumption (alcohol abstinence, acute alcohol intake)  
Caffeine consumption (coffee, energy drinks)  
Dietary supplementation  
Omega‑3 fatty acids (n‑3 polyunsaturated fatty acids, marine omega‑3)  
Vitamin D supplementation  
Vitamin C supplementation  
Fish oil supplementation  
Nutritional risk factors (low‑carbohydrate diet, caloric reduction)  
Inflammation and oxidative stress  
Stroke risk linked to atrial fibrillation  
Anticoagulation control (warfarin, non‑vitamin K antagonist oral anticoagulants)

Page 123 Extracted Terms:
- Atrial fibrillation (AF)  
- Paroxysmal atrial fibrillation  
- Persistent atrial fibrillation  
- Non‑valvular atrial fibrillation  
- Atrial fibrillation recurrence  
- Rhythm control strategy  
- Rate control strategy  
- Catheter ablation  
- Pulmonary vein isolation  
- Electrical cardioversion  
- Long‑term maintenance of sinus rhythm  
- Anticoagulated patients  
- Anticoagulant therapy (warfarin, DOACs)  
- Stroke prevention in AF  
- Systemic embolism  
- Cardiovascular events (CVE)  
- Hypertension  
- Blood‑pressure‑lowering treatment  
- Aggressive blood‑pressure control  
- Mean arterial pressure targets  
- Weight management/weight reduction  
- Cardiometabolic risk factors  
- Lifestyle modification  
- Alcohol abstinence/alcohol control  
- Mobile health (mHealth) technologies  
- Clinical decision support systems (CDSS)  
- Nurse‑led care programs  
- Integrated chronic care models  
- Cardiac rehabilitation programs  
- Sleep‑disordered breathing (SDB)  
- Obstructive sleep apnea (OSA)  
- Central sleep apnea  
- Continuous positive airway pressure (CPAP) therapy  
- Apnea‑hypopnea syndrome  
- Sleep duration (short sleep)  
- Sleep apnea severity  
- 2MACE score (cardiovascular risk stratification)  
- RACE 3 trial (targeted therapy for underlying conditions)  
- ARISTOTLE trial (apixaban efficacy)  
- ROCKET AF study (predictors of mortality)  
- SMAC‑AF trial (aggressive BP control in ablation)  
- VARIOSA‑AF study (sleep apnea variability)  
- RESPIRE study (sleep apnea incidence in pacemakers)  
- ALL‑IN cluster randomized trial (integrated AF management)  
- SAFETY trial (AF‑specific management strategy)  
- IMPACT‑AF program (computerized decision support for AF care).

Page 124 Extracted Terms:
- Atrial fibrillation  
- Stroke  
- Thromboembolism  
- Ischemic stroke  
- Systemic embolism  
- Oral anticoagulants  
- Warfarin  
- Direct oral anticoagulants (DOACs)  
- Apixaban  
- Dabigatran  
- Rivaroxaban  
- Edoxaban  
- Clopidogrel  
- Aspirin  
- Antithrombotic therapy  
- HAS‑BLED score  
- CHA2DS2‑VASc score  
- ATRIA stroke‑risk score  
- CHADS2 score  
- GARFIELD‑AF risk score  
- Hemorrhage / major bleeding  
- Bleeding‑risk assessment  
- Stroke‑risk assessment  
- Paroxysmal atrial fibrillation  
- Persistent atrial fibrillation  
- Sustained atrial fibrillation  
- ARISTOTLE trial  
- ENGAGE AF‑TIMI 48 trial  
- ROCKET‑AF trial  
- Net clinical benefit  
- Cardiovascular risk markers

Page 125 Extracted Terms:
- Atrial fibrillation  
- Atrial flutter  
- Stroke  
- Cryptogenic stroke  
- Embolic stroke of undetermined source  
- Ischemic stroke  
- Transient ischemic attack  
- Thromboembolism  
- Anticoagulants  
- Antithrombotic therapy  
- Direct oral anticoagulants (DOACs)  
- Rivaroxaban  
- Apixaban  
- Dabigatran  
- Edoxaban  
- Warfarin  
- Low‑dose aspirin  
- Direct factor Xa inhibitors  
- Direct thrombin inhibitors  
- Anticoagulant dosing (under‑ dosing, over‑ dosing, label‑adherent dosing)  
- Drug‑drug interactions with DOACs  
- Enzyme‑inducing antiseizure medications  
- Vitamin‑K guided anticoagulation strategy  
- Implantable loop recorder  
- Holter‑based electrocardiographic monitoring  
- Subclinical atrial fibrillation  
- Device‑detected atrial high‑rate episodes  
- Stroke risk scores  
- CHA2DS2‑VASc score  
- CHADS2 score  
- ATRIA score  
- Hypertrophic cardiomyopathy  
- Valvular atrial fibrillation  
- Nonvalvular atrial fibrillation  
- Left ventricular thrombus  
- Pulmonary hypertension  
- Stroke prevention after cryptogenic stroke  
- Cardiovascular outcomes research  
- FDA adverse event reporting in anticoagulation therapy  

Page 126 Extracted Terms:
Atrial fibrillation  
Device‑detected atrial fibrillation  
Subclinical atrial fibrillation  
Atrial tachyarrhythmia  
Atrial high‑rate episodes  
Left atrial appendage (LAA)  
Left atrial appendage closure  
Left atrial appendage occlusion  
Left atrial appendage exclusion  
LAAOS study  
ASAP study  
ASAP‑TOO trial  
PROTECT AF trial  
PREVAIL trial  
PINNACLE FLX trial  
EWOLUTION trial  
Watchman device  
AtriClip device  
Anticoagulation  
Warfarin  
Direct oral anticoagulants (DOACs)  
Rivaroxaban  
Dabigatran  
Idarucizumab  
Prothrombin complex concentrate  
Activated prothrombin concentrate  
Bleeding  
Active bleeding on anticoagulant therapy  
Antithrombotic therapy  
Stroke  
Ischemic stroke  
Systemic embolism  
Thromboembolic events  
Cardiovascular outcomes  
Cardiac surgery  
Coronary artery bypass grafting (CABG)  
Valvular heart surgery  
Cardiac rhythm management device  
Pacemaker  
Implanted device  
CHADS2‑VASc score  
Stroke risk  
Early postoperative atrial fibrillation  
Mortality

Page 127 Extracted Terms:
- Atrial fibrillation  
- Atrial flutter  
- Intracerebral hemorrhage  
- Intracranial hemorrhage  
- Mechanical heart valve  
- Reversal agents  
- Andexanet alfa  
- Prothrombin complex concentrate  
- Factor Xa inhibitors  
- Warfarin  
- Vitamin K antagonists  
- Direct oral anticoagulants  
- Rivaroxaban  
- Dabigatran  
- Apixaban  
- Oral anticoagulants  
- Anticoagulation‑related bleeding  
- Anticoagulation reversal  
- Antithrombotic therapy  
- Stroke prevention  
- Left atrial appendage  
- Left atrial appendage closure  
- Watchman device  
- Percutaneous left atrial appendage closure  
- Epicardial left atrial appendage clipping  
- Surgical left atrial appendage obliteration  
- Antithrombotic prophylaxis  
- Bleeding risk assessment  
- Thromboembolic complications  
- Mechanical heart valve prosthesis  
- Valve replacement  
- St Jude Medical prosthesis  
- Activated charcoal  
- Hemodialysis  
- Gastrointestinal bleeding  
- Reinitiation of anticoagulation after bleeding  
- Anticoagulation bridging  
- Periprocedural management  
- Long‑term clinical outcome of antithrombotic therapy  
- Risk modelling  
- Stroke survivors  
- Hematoma expansion  
- Hematoma volume  
- Anticoagulant‑associated intracerebral hemorrhage  
- Anticoagulant‑related intracerebral hemorrhage  
- Intracranial hemorrhage survivors  
- Thromboembolism  
- Mortality  
- Recurrent stroke  
- Recurrent hemorrhage  
- Left atrial appendage thrombus  
- Cardiac surgical patients with atrial fibrillation  
- Robotics‑assisted epicardial left atrial appendage exclusion  
- Anticoagulant‑related intracranial haemorrhage surveillance  
- Anticoagulant reversal agents effectiveness  
- Bleeding risk assessment scores  
- Antithrombotic therapy in valvular heart disease  
- Antithrombotic therapy in native and prosthetic valves.

Page 128 Extracted Terms:
**Key terms related to heart disease**

1. Atrial fibrillation  
2. Anticoagulation  
3. Direct oral anticoagulants (DOACs)  
4. Vitamin K antagonists  
5. Warfarin  
6. Dabigatran  
7. Rivaroxaban  
8. Apixaban  
9. Edoxaban  
10. Heparin  
11. Low‑molecular‑weight heparin  
12. Bridging therapy  
13. Periprocedural management  
14. Perioperative management  
15. Implantable cardioverter‑defibrillator (ICD)  
16. Pacemaker  
17. Cardiac device implantation  
18. Acute coronary syndrome (ACS)  
19. Percutaneous coronary intervention (PCI)  
20. Coronary stenting  
21. Coronary artery disease (CAD)  
22. Stable coronary disease  
23. Valvular heart disease  
24. Peripheral artery disease (PAD)  
25. Chronic kidney disease (CKD)  
26. Heart failure  
27. Antithrombotic therapy  
28. Dual antithrombotic therapy  
29. Triple therapy  
30. Antiplatelet therapy  
31. Aspirin  
32. Clopidogrel  
33. Bleeding risk  
34. Thromboembolic risk  
35. Stroke prevention  
36. Systemic embolic events

Page 129 Extracted Terms:
- Atrial fibrillation  
- Atrial flutter  
- Chronic atrial fibrillation  
- Non‑valvular atrial fibrillation  
- Valvular atrial fibrillation  
- Rheumatic heart disease‑associated atrial fibrillation  
- Mechanical heart valves  
- Mitral stenosis  
- Left atrial appendage occlusion  
- Heart failure  
- Pulmonary hypertension  
- Left ventricular thrombus  
- Stroke  
- Stroke risk  
- Bleeding risk  
- Anticoagulation therapy  
- Oral anticoagulants  
- Vitamin K antagonists (e.g., warfarin, phenprocoumon)  
- New oral anticoagulants (DOACs)  
- Dabigatran  
- Rivaroxaban  
- Apixaban  
- Edoxaban  
- Valve replacement (mechanical On‑X aortic valve)

Page 130 Extracted Terms:
**Key heart‑disease terms extracted from the text**

- Atrial fibrillation  
- Atrial flutter  
- Atrial arrhythmias  
- Stroke  
- Systemic embolism  
- Thromboembolic risk  
- Anticoagulation therapy  
- Catheter ablation  
- Radiofrequency ablation  
- Cryoablation  
- Left atrial appendage  
- Left atrial appendage stunning  
- Left atrial size  
- Left atrial functional recovery  
- Cardiac rhythm control  
- Cardiac rate control  
- Ventricular rate  
- Heart rate  
- Beta‑blockers  
- Calcium‑channel blockers  
- Digoxin  
- Electrical cardioversion  
- Drug therapy (for arrhythmia)  
- Rhythm control strategies  
- Rate control strategies  
- Tachycardia  
- Brady‑tachycardia  
- Heart failure  
- Reduced ejection fraction (HFrEF)  
- Preserved ejection fraction (HFpEF)  
- Sudden death  
- Tachycardia‑induced cardiomyopathy  
- Implantable cardioverter‑defibrillator (ICD)  
- Cardiac resynchronization therapy (CRT)  
- Sick sinus syndrome  
- Pacing‑related atrioventricular dysfunction  
- HATCH score  
- PACE score  
- Oral anticoagulant discontinuation  
- Stroke risk stratification  
- Quality of life in atrial fibrillation  
- Cardioversion‑induced left atrial stunning  

These terms represent the core concepts related to heart disease highlighted throughout the referenced guidelines and studies.

Page 131 Extracted Terms:
**Key Terms Related to Heart Disease**

- Atrial Fibrillation  
- Atrial Flutter  
- Acute Rate Control  
- Long‑Term Rate Control  
- Intravenous Esmolol  
- Intravenous Verapamil  
- Intravenous Diltiazem  
- Metoprolol  
- Digoxin  
- Intravenous Amiodarone  
- Intravenous Magnesium Sulfate  
- Calcium Channel Blockers  
- Beta‑Blockers  
- Heart Failure  
- Reduced Ejection Fraction (HFrEF)  
- Congestive Heart Failure (CHF)  
- Ventricular Arrhythmias (tachyarrhythmias)  
- Cardiac Pacing  
- Pacemaker  
- Atrioventricular (AV) Node Ablation (AVNA)  
- Atrio‑Ventricular Junction Ablation  
- His‑Bundle Pacing  
- Dronedarone  
- Diltiazem Post‑Infarction Therapy  
- Digitalis Therapy (Digoxin)  
- Serum Digoxin Concentration  
- Cardiac Conduction  
- Cardiac Refractoriness  
- Ventricular Rate  
- Sudden Cardiac Death  
- Coronary Artery Disease (implicit in myocardial infarction context)  
- Myocardial Infarction  
- Atrial Tachyarrhythmias  
- Pacing Method (e.g., VVIR, cardiac resynchronization therapy)  
- Electrophysiology (catheter ablation, radiofrequency)  

These terms capture the core concepts and therapies discussed in the guideline excerpt.

Page 132 Extracted Terms:
- Atrial fibrillation  
- Heart failure  
- Congestive heart failure  
- Tachycardia  
- Tachycardiomyopathy  
- Cardiomyopathy  
- Atrial‑fibrillation‑related cardiomyopathy  
- Left ventricular ejection fraction  
- Right ventricular pacing  
- Left ventricular pacing  
- Ventricular remodeling  
- Ventricular dysfunction  
- Systolic dysfunction  
- Diastolic dysfunction  
- Atrioventricular nodal ablation  
- Atrioventricular junction ablation  
- Atrioventricular junctional radiofrequency ablation  
- Conduction system pacing  
- His bundle pacing  
- Left bundle branch area pacing leads  
- Physiologic pacing  
- Dual‑chamber pacing  
- Catheter ablation  
- Radiofrequency catheter ablation  
- Direct‑current ablation  
- Cryoablation  
- Anti‑arrhythmic drug therapy  
- Anti‑arrhythmic drug therapy for rhythm control  
- Rate‑control drugs  
- Rhythm‑control drugs  
- Pacemaker implantation  
- Cardiac electronic device implantation  
- Atrial fibrillation management strategies  
- Rhythm‑control strategy  
- Rate‑control strategy  
- Atrial fibrillation progression  
- Atrial fibrillation in patients with permanent pacemakers  
- Atrial fibrillation in patients with implanted devices  
- Atrial fibrillation and weight management  
- Atrial fibrillation and quality of life  
- Atrial fibrillation and ventricular fibrosis  
- Cardiac catheter ablation for atrial fibrillation with heart failure  
- ACC/AHA/HRS guideline on bradycardia and conduction delay  
- ACC/AHA guideline on atrial fibrillation  
- ESC guideline on atrial fibrillation  
- EAST‑AFNET 4 trial  
- CABANA trial  
- AATAC multicentre randomized trial  
- Atrial Fibrillation Follow‑up Investigation of Rhythm Management (AFFIRM) study  
- Atrial Fibrillation Treatment Trial (AFTR) – (e.g., Ablate and Pace trial)  
- Paroxysmal atrial fibrillation  
- Persistent atrial fibrillation  
- Long‑standing persistent atrial fibrillation  
- Atrial rate control  
- Atrioventricular junction ablation and pacing therapy  
- Physiologic pacing versus right ventricular pacing evaluation  
- Left ventricular–based cardiac stimulation post‑AV nodal ablation  
- Left bundle branch block management  
- AV nodal ablation strategies  
- Catheter ablation for atrial fibrillation in heart failure  
- Catheter ablation for atrial fibrillation in asymptomatic patients  
- Catheter ablation for atrial fibrillation in symptomatic patients  
- Ablation versus amiodarone for persistent atrial fibrillation in heart failure  
- Ablation versus drug therapy for atrial fibrillation in heart failure  
- Cardiac rhythm disorder registries (e.g., RecordAF, CAMERA MRI, Chinese Atrial Fibrillation Registry)  
- Early rhythm‑control therapy in atrial fibrillation  
- Long‑term effect of goal‑directed weight management in atrial fibrillation  

*(All terms are derived from the clinical statements, guideline titles, study names, and medical concepts mentioned in the provided text.)*

Page 133 Extracted Terms:
- Atrial fibrillation (AF)  
- Atrial flutter  
- Heart failure (HF)  
- Congestive heart failure  
- Heart failure with reduced ejection fraction (HFrEF)  
- Thromboembolism  
- Stroke  
- Stroke prevention  
- Cardioversion (electrical, pharmacologic, direct‑current)  
- Catheter ablation (radiofrequency, cryoballoon, surgical)  
- Rhythm control  
- Rate control  
- Transesophageal echocardiography (TEE)  
- Left atrial appendage (LAA)  
- Left atrial mechanical function  
- Atrial stunning  
- Pulmonary vein isolation  
- Mitral regurgitation (MR)  
- Tricuspid regurgitation (TR)  
- Valvular regurgitation  
- Atrial remodeling (electrical and structural)  
- Right‑sided heart remodeling  
- Anticoagulation (including DOACs such as rivaroxaban)

Page 134 Extracted Terms:
- Atrial fibrillation  
- Stroke  
- Thromboembolic events  
- Left atrial appendage  
- Device‑related thrombosis  
- Percutaneous left atrial appendage closure  
- Watchman device  
- EWOLUTION trial  
- PROTECT‑AF trial  
- Transesophageal echocardiography (TEE)  
- Cardiac computed tomography (CT)  
- Electrical cardioversion  
- Direct current cardioversion  
- Anticoagulation therapy  
- Direct oral anticoagulants (DOACs)  
- Warfarin  
- Apixaban  
- Rivaroxaban  
- Edoxaban  
- Antiplatelet therapy  
- Heparin  
- Enoxaparin  
- Electrical remodeling  
- Left atrial blood flow characteristics  
- Stroke risk scoring (CHADS2/CHA₂DS₂‑VASc)  
- Peri‑device leak  
- FINCV study  
- RHYTHM‑AF study  
- Cardioversion‑BMI trial  
- Electrophysiology procedures  
- Cardiac arrhythmias  
- Electromechanical atrial function


Page 135 Extracted Terms:
- Atrial fibrillation  
- Atrial flutter  
- Paroxysmal atrial fibrillation  
- Atrial tachyarrhythmias  
- Ventricular fibrillation  
- Cardio‑conversion (electrical cardioversion)  
- Pharmacological cardioversion  
- Ibutilide  
- Amiodarone  
- Propafenone  
- Flecainide  
- Procainamide  
- Dofetilide  
- Sotalol  
- Digoxin  
- Class Ic antiarrhythmic drugs  
- “Pill‑in‑the‑pocket” approach  
- Biphasic cardioversion  
- Synchronized cardioversion  
- Electrical direct‑current cardioversion  
- Intravenous anti‑arrhythmic therapy  
- Intravenous amiodarone  
- Intravenous propafenone  
- Intravenous flecainide  
- Intravenous ibutilide  
- Intravenous procainamide  
- Oral loading dose (propafenone, flecainide)  
- Cardiac rhythm disorders  
- Heart failure  
- Reduced left‑ventricular function  
- Systemic hypertension (as a risk factor for AF)  
- Pre‑excited atrial fibrillation (e.g., Wolff‑Parkinson‑White)  
- Sync failure / Iatrogenic ventricular fibrillation (complications of cardioversion)  
- Arrhythmic complications  
- Anti‑arrhythmic drug safety and risk/benefit analysis  
- Electrophysiological determinants of conversion efficacy  
- Symptomatic Atrial Fibrillation (study)  
- Coronary circulation (implied by cardiac rhythm management studies)

Page 136 Extracted Terms:
- Atrial fibrillation  
- Atrial flutter  
- Supraventricular tachycardia  
- Sinus rhythm  
- Antiarrhythmic agents  
- Amiodarone  
- Sotalol  
- Ibutilide (class III agent)  
- Propafenone  
- Flecainide  
- Dronedarone  
- Dofetilide  
- Encainide  
- Moricizine  
- Magnesium sulfate (intravenous)  
- QT interval  
- Left ventricular function  
- Heart failure  
- Myocardial infarction  
- Cardiac arrest  
- Implantable defibrillator  
- Cardioversion (direct‑current and pharmacologic)  
- Proarrhythmic events  
- Arrhythmia suppression trials (e.g., CATCH, CASH, AFFIRM)  
- Class I antiarrhythmic drugs  
- Class III antiarrhythmic drugs  
- Oral dofetilide safety  
- Pill‑in‑the‑pocket therapy  
- Intravenous loading of sotalol  
- Symptomatic recurrence of atrial fibrillation  
- Maintenance of sinus rhythm  
- Ventricular arrhythmias related to antiarrhythmic therapy  

Page 137 Extracted Terms:
**Key terms related to heart disease found in the text**

- Atrial fibrillation  
- Atrial flutter  
- Congestive heart failure  
- Left ventricular dysfunction  
- Myocardial infarction  
- Ventricular tachycardia  
- Coronary artery disease  
- Torsade de pointes  
- Long QT syndrome  
- Drug‑induced arrhythmias  
- Antiarrhythmic drugs  
- Dofetilide  
- Sotalol  
- Amiodarone  
- Ibutilide  
- Procainamide  
- Dronedarone  
- Quinidine  
- Clarithromycin  
- Hypokalaemia  
- Syncope  
- Pulmonary toxicity  
- Thyroid dysfunction (amiodarone‑induced)  
- Hepatotoxicity (amiodarone‑associated)  
- Optic neuropathy (amiodarone‑associated)  
- Proarrhythmic effects  
- Intravenous ibutilide therapy  
- Pill‑in‑the‑pocket strategy  
- Intravenous sotalol therapy  
- Cardiac surgery (post‑operative arrhythmia conversion)  
- Antiarrhythmic drug follow‑up  
- C‑reactive protein  
- Glucocorticoid therapy (upstream therapy)  
- Upstream therapy (e.g., anti‑inflammatory approach)  
- 2023 Guideline for the Diagnosis and Management of Atrial Fibrillation  

These terms capture the main concepts, conditions, drugs, and therapeutic strategies related to heart disease discussed in the excerpt.

Page 138 Extracted Terms:
- Atrial fibrillation  
- Heart failure  
- Renin‑angiotensin system inhibition  
- Angiotensin‑converting enzyme inhibitor  
- Angiotensin receptor blocker  
- Candesartan  
- Losartan  
- Valsartan  
- Irbesartan  
- Eplerenone  
- Aldosterone pathway blockade  
- Sodium‑glucose co‑transport‑2 (SGLT2) inhibitors  
- Omega‑3 fatty acids  
- Statins  
- Vitamin C  
- Radiofrequency catheter ablation  
- Cryoballoon ablation  
- Pulmonary vein isolation  
- Catheter ablation  
- Antiarrhythmic drug therapy  
- Paroxysmal atrial fibrillation  
- Persistent atrial fibrillation  
- Recurrent atrial fibrillation  
- Stroke  
- Cardiac arrest  
- Bleeding  
- Mortality  
- Left ventricular systolic dysfunction  
- Left ventricular hypertrophy  
- Advanced heart failure  
- Diabetes mellitus type 2  
- Perioperative atrial fibrillation  
- Postoperative atrial fibrillation  
- Electrocardiographic left ventricular hypertrophy  
- Cardiac surgery  
- Cardiovascular outcomes (e.g., major adverse cardiovascular events)

Page 139 Extracted Terms:
- Atrial fibrillation  
- Atrial flutter  
- Supraventricular tachycardia  
- Pulmonary vein isolation  
- Catheter ablation  
- Radiofrequency ablation  
- Cryoballoon ablation  
- Cryoablation  
- Left atrial appendage  
- Left atrial size  
- Left ventricular end‑systolic dimension  
- Heart failure  
- Heart failure with reduced ejection fraction  
- Stroke  
- Bleeding  
- Cardiac arrest  
- Rhythm control  
- Antiarrhythmic drug therapy  
- Arrhythmia progression  
- Ablation vs drug therapy  
- Cost‑effectiveness  
- Cost‑utility  
- Quality of life  
- Heart rate  
- Device‑detected subclinical atrial fibrillation  
- Atrial remodeling  
- Cavotricuspid isthmus ablation  
- Atrial tachycardia  
- Vascular risk factors  
- Atrial fibrillation progression  
- Atrial fibrillation management guidelines (AHA/ACC/HRS)  
- Atrial fibrillation clinical outcomes  
- Atrial fibrillation economic evaluation  
- Symptomatic vs asymptomatic atrial fibrillation  
- Atrial fibrillation in pediatric and young adult populations  
- Atrial fibrillation in patients ≤30 years  
- Atrial fibrillation in heart failure patients  
- Atrial fibrillation and stroke risk  
- Atrial fibrillation and mortality  
- Atrial fibrillation therapy outcomes  
- Atrial fibrillation treatment strategy  



Page 140 Extracted Terms:
- Atrial fibrillation  
- Paroxysmal atrial fibrillation  
- Persistent atrial fibrillation  
- Nonparoxysmal atrial fibrillation  
- Left atrial volume  
- Ventricular fibrosis  
- Cardiac magnetic resonance imaging (MRI)  
- Delayed enhancement MRI  
- T1‑mapping  
- Catheter ablation  
- Radiofrequency ablation  
- Pulmonary vein isolation  
- Superior vena cava isolation  
- Autonomic denervation  
- Rotor or rotor‑modulation ablation (FIRM, CONFIRM, FIRMAP)  
- Focal impulse modulation  
- Ablation index–guided ablation  
- Ablation of ectopy‑triggering ganglionated plexuses  
- Left atrial appendage isolation  
- Electrophysiological inducibility testing (burst pacing, adenosine challenge)  
- Dormant conduction  
- Stiff left atrial syndrome  
- Stroke risk in atrial fibrillation  
- Heart failure (congestive heart failure)  
- Antiarrhythmic drugs (e.g., amiodarone, cardioversion drugs)  
- Rhythm‑control therapy  
- Rhythm‑restoration outcomes  
- Sinus rhythm restoration  
- Arrhythmia‑free outcome  
- Stroke prevention in atrial fibrillation  
- Supraventricular tachycardia  
- Clinical guideline terminology (ACC/AHA/HRS, HRS/EHRA/ECAS)

Page 141 Extracted Terms:
- Atrial fibrillation  
- Catheter ablation  
- Radiofrequency ablation  
- Cryoballoon ablation  
- Pulmonary vein isolation  
- Electrical posterior box isolation  
- Atrioventricular conduction  
- Atrial scar  
- Left atrial scar  
- Atrial high‑rate episodes  
- Recurrent atrial fibrillation  
- Paroxysmal atrial fibrillation  
- Persistent atrial fibrillation  
- Atrioventricular nodal ablation  
- Antiarrhythmic drugs  
- Dronedarone  
- Amiodarone  
- beta‑blockers  
- Novel oral anticoagulants  
- Vitamin K antagonists  
- Apixaban  
- Warfarin  
- Dabigatran  
- Edoxaban  
- Rivaroxaban  
- Periprocedural anticoagulation  
- Minimally interrupted anticoagulation  
- Uninterrupted anticoagulation  
- Silent thromboembolic lesion  
- Periprocedural cerebral thromboembolism  
- Stroke  
- Major bleeding  
- Minor bleeding  
- Cardiac arrest  
- Mortality  
- Shortness of breath  
- Stiff left atrium  
- Esophageal lesion  
- Atri‑esophageal fistula  
- Pulmonary vein stenosis  
- Quality of life  
- Long‑term outcomes  
- Meta‑analysis  
- Randomized controlled trial  
- Prospective multicenter study  
- Propensity‑matched analysis  
- Swedish health registries  
- Clinical guidelines for atrial fibrillation  
- Ablation complication  
- Reintervention  
- Rehospitalization  
- Re‑ablation  
- Cryoablation  
- Radiofrequency irrigation  
- Ablation efficacy  
- Ablation safety  
- Ablation outcomes  
- Ablation vs antiarrhythmic drug therapy  
- Stroke prevention in AF  
- Ablation success rate  
- AF recurrence prediction  
- AF burden  
- AF management  
- AF‑related morbidity  
- AF‑related mortality  



Page 142 Extracted Terms:
- Atrial fibrillation  
- Atrial tachyarrhythmias  
- Atrial flutter  
- Catheter ablation  
- Radiofrequency ablation  
- Surgical ablation  
- Anticoagulation therapy  
- Oral anticoagulation  
- Thromboembolism  
- Bleeding risk  
- Left atrial appendage closure  
- Pacemaker  
- Implantable cardioverter‑defibrillator (ICD)  
- Ventricular pacing  
- Dual‑chamber pacing  
- Single‑chamber pacing  
- Atrial overdrive pacing  
- Antitachycardia pacing  
- Adaptive cardiac resynchronization therapy (Adaptive CRT)  
- Cardiac resynchronization therapy (CRT)  
- Heart failure  
- Sick sinus syndrome  
- Sinus node dysfunction  
- Bradycardia  
- Ventricular pacing burden  
- Pacing burden  
- Atrial fibrillation burden  
- Prolonged AV conduction  
- High‑grade atrioventricular block  
- His bundle pacing  
- Left bundle branch area pacing  
- Right ventricular pacing  
- Progression of atrial fibrillation  
- New‑onset atrial fibrillation  
- Persistent atrial fibrillation  
- Paroxysmal atrial fibrillation  
- Electrocardiogram (ECG)  
- QRS duration  
- Pacing algorithm  
- Cardioembolic risk  
- Stroke  
- Cardioversion  
- Atrial fibrillation prevention  
- Atrial fibrillation management  
- Cardioverter‑defibrillator therapy  
- Cardiac implantable electronic devices

Page 143 Extracted Terms:
- Atrial fibrillation  
- Catheter ablation  
- Surgical ablation (Cox‑Maze, hybrid convergence)  
- Heart failure (HF)  
- Congestive heart failure (CHF)  
- Left atrial remodeling  
- Left ventricular diastolic dysfunction  
- Left ventricular systolic dysfunction  
- Preserved ejection fraction (EF)  
- Reduced ejection fraction (EF)  
- Mid‑range ejection fraction  
- Rhythm control  
- Rate control  
- Anticoagulation  
- Novel oral anticoagulants (NOACs)  
- Amiodarone  
- Digoxin  
- Carvedilol  
- Bisoprolol  
- Diltiazem  
- Pacemaker (AV junction ablation, VVIR)  
- Implantable devices (including cardiac resynchronization)  
- Survival (long‑term, post‑ablation)  
- Mortality  
- Adverse outcomes (stroke, thromboembolism)  
- Clinical guidelines (2023 AF guideline, ESC Heart Failure registry)  
- CASTLE‑AF trial  
- CAMTAF trial  
- AATAC trial  
- AMICA trial  
- RAFT‑AF trial  
- CAMERA‑MRI study  
- CABANA trial  
- Catheter ablation‑vs‑medical‑therapy trials (e.g., MARQUO, MERCURY)  
- Coronary artery bypass grafting (CABG) with ablation  
- Mitral valve surgery with ablation  
- Hybrid and convergent ablation procedures  
- Ejection Fraction (EF) assessment  
- Echocardiographic diastolic parameters  
- Clinical outcomes in elderly populations  
- Cardiovascular Health Study variables  
- Atrial fibrillation burden  
- Patient‑reported quality of life (RATE‑AF trial)  

**(All terms extracted from the cited clinical statements and studies concerning heart disease.)**

Page 144 Extracted Terms:
- Atrial fibrillation  
- Atrial tachycardia  
- Atrial tachyarrhythmia  
- Atrial fibrillation ablation  
- Catheter ablation  
- Pulmonary vein isolation  
- AV nodal ablation  
- AV junction ablation  
- Cardiac resynchronization therapy (CRT)  
- Biventricular pacing  
- His bundle pacing  
- Left bundle branch area pacing  
- Conventional pacing  
- Right ventricular pacing  
- Conduction‑system pacing  
- Cardiac pacing  
- Rhythm control  
- Rate control  
- Strict rate control  
- Lenient rate control  
- Digoxin  
- Diltiazem  
- Amiodarone  
- Tachycardia‑induced cardiomyopathy  
- Idiopathic dilated cardiomyopathy  
- Dilated cardiomyopathy  
- Left ventricular systolic dysfunction  
- Reduced ejection fraction  
- Congestive heart failure  
- Heart failure  
- Ventricular arrhythmia  
- Ventricular tachycardia  
- Ventricular remodeling  
- Ventricular dyssynchrony  
- Sudden cardiac death  
- Ventricular rate  
- ICD (implantable cardioverter‑defibrillator) therapies  
- Ventricular pacing percentage  
- Cardiomyopathy  
- Antiarrhythmic therapy  
- Genetic testing for cardiomyopathy/arrhythmia genes  
- Titin loss‑of‑function variants  
- Cardiomyopathy genes  
- Arrhythmia genes  
- Physical activity  
- Obesity  
- Athletes (competitive athletes)  

These terms capture the principal heart‑disease concepts referenced throughout the provided text.

Page 145 Extracted Terms:
- Atrial fibrillation  
- Atrial fibrillation (athletes)  
- Atrial fibrillation (obesity)  
- Body mass index (BMI)  
- Direct oral anticoagulants (DOACs)  
- Warfarin  
- Apixaban  
- Rivaroxaban  
- Edoxaban  
- Anticoagulation in Class III obesity  
- Bariatric surgery pharmacokinetics of rivaroxaban  
- Valvular heart disease  
- Cerebrovascular events  
- Wolff‑Parkinson‑White (WPW) syndrome  
- Pre‑excitation syndromes  
- Supraventricular tachycardia  
- Accessory atrioventricular connections  
- Radiofrequency catheter ablation  
- Catheter ablation of accessory pathways  
- Procainamide  
- Quinidine sulfate  
- Ibutilide  
- Amiodarone  
- Diltiazem  
- Metoprolol  
- Digitalis  
- Verapamil  
- Flecainide  
- Propafenone  
- Hypertrophic cardiomyopathy (HCM)  
- Thromboembolism in HCM  
- Ischemic stroke in HCM  
- Stroke risk (atrial fibrillation)  
- Cardiac dysfunction (post‑exercise)  
- Inflammatory cytokines (exercise‑induced)  
- Intense endurance exercise  
- Epicardial adiposity  
- Abdominal adiposity  
- Cardiac imaging in structural heart disease  
- Clinical outcomes of atrial fibrillation  
- Predictors of cerebrovascular events in valvular heart disease  
- Population‑based study of WPW syndrome  
- Systematic review of atrial fibrillation in HCM  
- Meta‑analysis of obesity and atrial fibrillation  

These terms capture the key cardiovascular conditions, risk factors, therapies, and patient populations discussed in the guideline excerpts.

Page 146 Extracted Terms:
- Atrial fibrillation  
- Atrial arrhythmias  
- Supraventricular tachycardia  
- Hypertrophic cardiomyopathy  
- Congenital heart disease  
- Adult congenital heart disease (ACHD)  
- Heart failure  
- Catheter ablation  
- Pulmonary vein isolation  
- Antiarrhythmic drugs  
- Amiodarone  
- Flecainide  
- Encainide  
- Dronedarone  
- Dofetilide  
- Non‑vitamin K antagonist oral anticoagulants (NOACs)  
- Thromboprophylaxis  
- Oral anticoagulation  
- Pulmonary vein isolation (PVI)  
- Cryoballoon ablation  
- Rate control  
- Rhythm control  
- Postoperative atrial fibrillation (POAF)  
- Cardiac surgery  
- Coronary artery bypass grafting (CABG)  
- Valve replacement  
- Revascularization  
- Pericardiotomy  
- Posterior left pericardiotomy  
- Colchicine  
- Thromboembolic complications  
- Proarrhythmia  
- Amiodarone‑induced thyrotoxicosis  
- Amiodarone‑associated thyroid dysfunction  
- Body mass index (BMI) as a risk factor  
- Dronedarone therapy in severe heart failure  
- Preoperative β‑blockers  
- Postoperative β‑blocker use  
- Prevalence of atrial fibrillation  
- Mortality following ventricular arrhythmia suppression  
- Risk factors for arrhythmia in ACHD  
- Safety and outcomes of catheter ablation in ACHD  
- Efficacy of antiarrhythmic drugs in ACHD  
- Electro‑physiologic considerations in congenital heart disease  
- Specialized electrophysiologic care in ACHD  
- Atrial fibrillation ablation on uninterrupted oral anticoagulation  
- Cryoballoon ablation feasibility in ACHD  
- Heart rhythm management in ACHD  
- Thrombosis in congenital heart disease  
- Post‑pericardiotomy syndrome  
- Clinical outcomes after cardiac surgery  
- Post‑operative atrial fibrillation  
- Prevention of AF after cardiac surgery.

Page 147 Extracted Terms:
- Atrial fibrillation  
- Post‑operative atrial fibrillation  
- Post‑pericardiotomy syndrome  
- Colchicine (anti‑arrhythmic therapy)  
- β‑blockers (cardioselective and non‑selective)  
- Anticoagulation / anticoagulant therapy  
- Stroke (ischemic stroke, thromboembolic stroke)  
- Thromboembolic risk  
- Hyperthyroidism / thyrotoxicosis  
- Thyroid disease / thyroid hormones  
- Cardiovascular disease  
- Supraventricular tachyarrhythmias  
- Atrial flutter  
- Supraventricular arrhythmias in pulmonary hypertension  
- Pulmonary hypertension  
- Severe pulmonary arterial hypertension  
- Idiopathic pulmonary arterial hypertension  
- Sepsis‑associated atrial fibrillation  
- Critical‑care atrial fibrillation  
- Continuous rhythm monitoring (implantable cardiac monitor)  
- Electrocardiogram (ECG) monitoring  
- Catheter ablation of atrial flutter  
- Cardioversion (electrical)  
- Mortality (cardiac‑related)  
- In-hospital morbidity and outcomes  
- Arrhythmia recurrence  
- Antithrombotic therapy  
- Post‑operative cardiac complications  
- Congenital heart disease (implicit in arrhythmia research)

Page 148 Extracted Terms:
- Atrial fibrillation  
- Atrial flutter  
- Atrial arrhythmias  
- Supraventricular tachycardia  
- Pulmonary arterial hypertension  
- Pulmonary embolism  
- COPD (chronic obstructive pulmonary disease) – as a comorbidity affecting atrial fibrillation  
- Valvular heart disease  
- Mechanical heart valve  
- Cardiovascular disease  
- Congestive heart failure  
- Hypertension (pre‑existing and pregnancy‑related)  
- Cardio‑oncology  
- QT prolongation  
- Anti‑arrhythmic drugs (e.g., digoxin)  
- Oral anticoagulants (e.g., rivaroxaban, direct oral anticoagulants)  
- Vitamin K antagonists (e.g., warfarin)  
- Thromboembolism  
- Anticoagulation management during pregnancy  
- Anticancer therapies with cardiac toxicity (e.g., ibrutinib)  
- Cardiac arrhythmia risk factors in cancer  
- Atrial fibrillation incidence in major cancer subtypes  
- Atrial fibrillation mortality risk in cancer patients  
- Heart failure associated with new‑onset atrial fibrillation in cancer  
- Systemic blood pressure control (tight vs usual) in hypertensive patients  
- Sinus rhythm maintenance and targeted therapy in persistent atrial fibrillation  

(These terms represent key heart‑disease–related concepts extracted from the cited guidelines and studies.)

Page 149 Extracted Terms:
**Key heart‑disease terms extracted from the text**

1. Atrial fibrillation  
2. Stroke  
3. Systemic embolism  
4. Blood pressure control  
5. Brain natriuretic peptide (BNP)  
6. Post‑operative atrial fibrillation  
7. Thoracic surgery  
8. Allogeneic hematopoietic cell transplantation  
9. Pre‑transplant cardiac evaluation  
10. Ibrutinib‑associated atrial fibrillation  
11. Bruton tyrosine kinase inhibitors (BTK inhibitors)  
12. Chemotherapy‑induced arrhythmias  
13. Targeted therapy arrhythmias  
14. Cardio‑oncology arrhythmias  
15. Autonomic disorders  
16. Chronic kidney disease (CKD)  
17. End‑stage renal disease (ESRD)  
18. Liver disease (cirrhosis, hepatic impairment, non‑alcoholic fatty liver disease)  
19. Anticoagulation therapy  
20. Edoxaban  
21. Warfarin  
22. Non‑vitamin K antagonist oral anticoagulants (NOACs)  
23. Direct oral anticoagulants (DOACs)  
24. Vitamin K antagonists  
25. Intravenous/Oral Factor Xa inhibitors (e.g., rivaroxaban)  
26. Direct thrombin inhibitor (dabigatran)  
27. Direct oral anticoagulant pharmacokinetics  
28. Direct oral anticoagulant pharmacodynamics  
29. Catheter ablation for atrial fibrillation  
30. Pulmonary vein isolation  
31. Cerebral thromboembolism  
32. Silent cerebral embolism  
33. Electrocardiographic (ECG) monitoring  
34. Continuous rhythm assessment  
35. Insertable cardiac monitor  
36. Rhythm Evaluation for Anticoagulation With Continuous Monitoring (REACTCOM)  

These terms capture the primary cardiovascular concepts, conditions, therapies, and clinical investigation elements referenced in the provided guideline excerpt.

Page 150 Extracted Terms:
- Atrial Fibrillation  
- Cardiac Electrophysiology  
- Cardiac Pacing  
- Heart Rhythm  
- Cardiovascular Medicine  
- Heart and Vascular Institute  
- Cardiologist  
- Cardiac Electrophysiology Fellowship  
- Heart and Heart Rhythm Care  
- Cardiovascular and Metabolic Sciences  
- Myocardial  
- Cardiac  
- Heart  
- Framingham Heart Study  
- Heart Disease  
- Arrhythmia  
- Guideline  
- Diagnosis  
- Management

Page 151 Extracted Terms:
- Atrial Fibrillation  
- Arrhythmia  
- Cardiac Electrophysiology  
- Cardiology  
- Cardiovascular Medicine  
- Cardiovascular Disease  
- Heart Rhythm  
- Heart diseases  
- Cardiac  

**Key medical‑device and pharmaceutical entities:**
- Abbott  
- Biosense Webster  
- Biotronik  
- Boston Scientific  
- Johnson & Johnson  
- Pfizer  
- Sanofi‑Aventis  
- Zoll  
- AstraZeneca  
- Bayer  
- Daiichi Sankyo  
- Roche

Page 152 Extracted Terms:
- Atrial Fibrillation  
- Cardiovascular Disease  
- Cardiology  
- Cardiovascular  
- Heart Failure  
- Advanced Heart Failure  
- Pulmonary Hypertension  
- Cardiac Electrophysiology  
- Cardiac Surgery  
- Heart Disease  
- Cardiovascular Disease Fellowship Program  
- Sarver Heart Center  
- Bluhm Cardiovascular Institute  
- Heart Center  
- Cardiac  
- Abbott  
- Atricure  
- Edwards Lifesciences  
- Medtronic  
- Johnson & Johnson  
- InCarda  
- Biotronik  
- EP Research Foundation

Page 153 Extracted Terms:
- Atrial Fibrillation  
- Arrhythmia  
- Cardiac Electrophysiology  
- Heart Rhythm Disorders  
- Cardiac Pacing  
- Cardiovascular Disease  
- Cardiovascular Disease Prevention  
- Cardiac  
- Heart  
- Heart Rhythm  
- Electrocardiography  
- Rhythm  
- 2023 Guideline for the Diagnosis and Management of Atrial Fibrillation  
- Abbott  
- Medtronic  
- Boston Scientific  
- Biotronik  
- Biosense Webster  
- Atricure

Page 154 Extracted Terms:
- Atrial Fibrillation  
- Congenital Heart Disease  
- Cardiovascular  
- Cardiovascular & Metabolic Sciences  
- Heart Rhythm Society (HRS)  
- American Heart Association (AHA)  
- American College of Cardiology (ACC)  
- National Heart, Lung, and Blood Institute (NHLBI)  
- Pulmonary Hypertension (commonly associated with heart disease)  
- Heart Medicine/Heart Disease (general term)

Page 155 Extracted Terms:
- Atrial Fibrillation  
- Arrhythmia  
- Cardiology  
- Cardiovascular disease  
- Heart disease  
- Guideline (for the Diagnosis and Management of Atrial Fibrillation)  
- Circulation (journal)  
- ACC (American College of Cardiology)  
- AHA (American Heart Association)  
- ACCP (American College of Chest Physicians)  
- HRS (Heart Rhythm Society)

Page 156 Extracted Terms:
- Atrial Fibrillation  
- Heart Rhythm  
- Cardiovascular  
- Heart Disease  
- American Heart Association (AHA)  
- American College of Cardiology (ACC)  
- Heart Rhythm Society (HRS)  
- National Heart, Lung, and Blood Institute (NHLBI)  
- National Institutes of Health (NIH)  
- Diagnosis and Management of Atrial Fibrillation  
- Clinical Guidelines for Atrial Fibrillation  



Page 1 Extracted Terms:
- Chronic Coronary Disease  
- Chronic Coronary Disease guideline  
- Stable Ischemic Heart Disease  
- Diagnosis and Management of Stable Ischemic Heart Disease  
- Coronary disease  
- Ischemic heart disease  
- Coronary angiography  
- Cardiovascular interventions  
- Cardiovascular disease  
- Cardiac management strategies  
- Clinical practice guidelines for coronary disease  
- Heart disease prevention and therapy terms (e.g., lipid management, anti‑platelet therapy, statins)

Page 2 Extracted Terms:
Acute coronary syndrome  
Angina  
Antiplatelet therapy  
Aspirin  
Atherosclerosis  
Cardiac events  
Cardiac rehabilitation  
Cardiovascular diseases  
Colchicine  
Coronary artery disease  
Coronary disease  
Dual antiplatelet therapy  
Fibrinolytic agents  
Factor Xa inhibitors  
Glucagon‑like peptide‑1 receptor agonists  
Hypercholesterolemia  
Hypertension  
Ischemic heart disease  
Ischemia with non‑obstructive coronary arteries  
Myocardial ischemia  
Secondary prevention  
Sodium‑glucose cotransporter‑2 inhibitors  
Spontaneous coronary artery dissection  
Heart disease risk factors  
Heart failure (preserved or reduced ejection fraction)  
Lifestyle risk factors (e.g., smoking cessation, diet, exercise tolerance, alcohol and substance use, environmental exposures)  
Guideline‑directed management and therapy  
Evaluation, diagnosis, and risk stratification  
Revascularization (PCI vs CABG)  
Percutaneous coronary intervention (PCI)  
Coronary artery bypass grafting (CABG)  
Chronic management after spontaneous coronary artery dissection (SCAD)  
Lipid management (statins, etc.)  
Blood pressure management (renin–angiotensin–aldosterone system inhibitors, beta‑blockers)  
Medical therapy for relief of angina  
Management of refractory angina  
Chelation therapy  
Cardiac rehabilitation (exercise training, education)  
Medical therapy to prevent cardiovascular events  
Immunizations (in the context of cardiovascular risk)  
Special populations (e.g., CAD with valvular heart disease, HF with preserved or reduced EF)

Page 3 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Cardiovascular Disease (CVD)  
- Coronary Artery Disease (CAD)  
- Myocardial Infarction  
- Left Ventricular Ejection Fraction  
- Cardiac Allograft Vasculopathy  
- Heart Transplant Recipient  
- Cardiac Rehabilitation  
- β‑Blocker (beta‑blocker)  
- Calcium Channel Blocker  
- Anti‑anginal Therapy  
- Statin  
- Ezetimibe  
- PCSK9 Inhibitor  
- Inclisiran  
- Bempedoic Acid  
- Dual Antiplatelet Therapy (DAPT)  
- Non‑prescription Dietary Supplement  
- Fish Oil  
- Omega‑3 Fatty Acids  
- Vitamins (as supplements)  
- Anatomic or Ischemic Testing  
- Smoking Cessation  
- Nicotine Replacement Therapy (NRT)  
- E‑cigarettes  
- Exercise (Aerobic & Resistance)  
- Healthy Dietary Habits  
- Team‑Based Care  
- Patient‑Centered Care  
- Social Determinants of Health  
- Shared Decision‑Making  
- Risk Assessment  
- Diagnostic Testing  
- Medical Treatment

Page 4 Extracted Terms:
- Chronic Coronary Disease  
- Guideline‑Directed Management and Therapy (GDMT)  
- Clinical evaluation  
- Diagnostic testing  
- Pharmacological treatment  
- Procedural treatments  
- Drug treatment regimens  
- Medical devices  
- Heart disease  
- Cardiovascular disease  
- AHA/ACC/ACC‑AHA joint guideline methodology  
- Randomized Controlled Trials (RCTs)  
- Systematic review  
- Evidence‑based guideline  
- Shared decision‑making  
- Patient engagement  
- Adherence to recommendations  
- Cost‑value considerations  
- Risk‑benefit assessment  
- Clinical outcomes measurement  

Page 5 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Coronary artery disease  
- Ischemic heart disease (stable ischemic heart disease)  
- Acute coronary syndrome  
- Angina  
- Cardiac rehabilitation  
- Cardiovascular diseases (CVD)  
- Dual antiplatelet therapy  
- Factor Xa inhibitors  
- Hypertension  
- Secondary prevention  
- Lipid management  
- SGLT2 inhibitors  
- GLP‑1 receptor agonists  
- Revascularization  
- Cost‑value considerations  
- Quality‑adjusted life years (QALY)  
- Incremental cost‑effectiveness ratio (ICER)  
- Clinical practice guidelines  
- Shared decision‑making  
- Team‑based care  
- Diabetes (type 2)  
- Diet / diet therapy / dietary supplements  
- Drug therapy  

These terms capture the core heart‑disease concepts and therapeutic/intervention areas addressed in the guideline.

Page 6 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Acute Coronary Syndromes (ACS)  
- Coronary Artery Disease (CAD)  
- Left Ventricular (LV) Systolic Dysfunction  
- Cardiomyopathy (ischemic origin)  
- Stable Angina  
- Angina Symptoms (dyspnea, arm pain with exertion)  
- Coronary Vasospasm  
- Microvascular Angina  
- Coronary Computed Tomography Angiography (CTA)  
- Stress Test (screening study)  
- Atherosclerotic Cardiovascular Disease (ASCVD)  
- Heart Failure (HF)  
- Cardiovascular Events (future ASCVD–related events)  
- Symptom Relief  
- Quality of Life (QOL)  
- Diagnostic Evaluation  
- Risk Stratification  
- Revascularization  
- Primary Care Clinician Role  
- Cardiology Specialist Role  
- Evidence‑Based Medical Therapy  
- Lifestyle Modification  
- Shared Decision‑Making  
- Coronary Calcium Score (on CT)  
- Atherosclerosis Risk Reduction  
- Follow‑up and Monitoring  
- Cost and Value Considerations  
- Future Research Needs (CCD)

Page 7 Extracted Terms:
- Atherosclerotic cardiovascular disease (ASCVD)  
- Atherosclerotic cardiovascular disease (ASCVD)  
- Chronic coronary disease (CCD)  
- Coronary artery disease (CAD)  
- Coronary heart disease (CHD)  
- Cardiovascular disease (CVD)  
- Coronary artery disease (CAD)  
- Stable ischemic heart disease  
- Stable coronary artery disease (stable CAD)  
- Acute coronary syndrome (ACS) – implied by “coronary artery disease”  
- Atrial fibrillation (AF)  
- Ventricular arrhythmias (VT)  
- Sudden cardiac death (SCD)  
- Heart failure (HF)  
- Valvular heart disease (VHD)  
- Peripheral arterial disease (PAD) – implied by “atherosclerotic disease”  
- Hypertension (high blood pressure)  
- Elevated blood pressure / high blood pressure  
- Hypertriglyceridemia  
- Diabetes mellitus type 2 (T2DM)  
- Hypercholesterolemia (high cholesterol)  
- Dyslipidemia – overall cholesterol/lipid disorders  
- Coronary artery revascularization (e.g., percutaneous coronary intervention [PCI], coronary artery bypass grafting)  
- Primary prevention of cardiovascular disease  
- Secondary prevention of cardiovascular disease  
- Dual antiplatelet therapy (DAPT)  
- Anticoagulant therapy (e.g., warfarin, DOACs)  
- Antiplatelet therapy (e.g., aspirin, clopidogrel)  
- Statins (HMG‑CoA reductase inhibitors)  
- Lipid‑lowering agents (e.g., ezetimibe, PCSK9 inhibitors)  
- Cardiac rehabilitation  
- Exercise training – core component of cardiac rehabilitation  
- Dietary pattern for heart health (e.g., Mediterranean diet)  
- Drug‑drug interactions affecting statin use  
- Cardio‑oncology drug interactions  
- Smoking / tobacco cessation – major cardiovascular risk factor  
- Air pollution – cardiovascular risk factor  
- Exercise guidance for patients with heart disease  
- Clinical management of stable coronary artery disease (CAD)  
- Clinical management of heart failure (HF)  
- Cardiovascular considerations in pregnancy  
- Cardiovascular considerations in HIV infection  
- Psychological health in cardiovascular disease (mind‑heart connection)  
- Life’s Essential 8 (cardiovascular health metrics)  
- Assessment of chest pain for coronary artery disease (CAD)  
- Evaluation and diagnosis of chest pain (clinical guideline)  

*(All terms directly extracted or closely inferred from the guideline titles and descriptions in the provided text.)*

Page 8 Extracted Terms:
- Chronic Coronary Disease  
- Coronary Disease  
- Heart Disease  
- AHA/ACC/ACCP/ASPC/NLA/PCNA (cardiology guideline alliance)  
- Circulation (journal title, cardiology focus)  
- Class of Recommendation (COR)  
- Level of Evidence (LOE)  
- PICO[TS] structure (clinical question format)  
- Clinical trial evidence  
- Intervention (cardiac care)  
- Diagnostic testing (cardiology)  
- Drug classification (cardiac therapy)  
- Device classification (cardiac devices)

Page 9 Extracted Terms:
- Angiotensin‑converting enzyme (ACE)  
- Acute coronary syndrome (ACS)  
- Atrial fibrillation (AF)  
- Angiotensin‑receptor blocker (ARB)  
- Atherosclerotic cardiovascular disease (ASCVD)  
- Body mass index (BMI)  
- Blood pressure (BP)  
- Coronary artery bypass grafting (CABG)  
- Coronary artery disease (CAD)  
- Calcium channel blocker (CCB)  
- Chronic coronary disease (CCD)  
- Coronary heart disease (CHD)  
- Chronic kidney disease (CKD)  
- Cardiovascular magnetic resonance (CMR)  
- Coronavirus Disease 2019 (COVID‑19)  
- Cardiac rehabilitation (CR)  
- Cardiovascular disease (CVD)  
- Computed tomography angiography (CTA)  
- Coronary CT angiography (CCTA)  
- Dual antiplatelet therapy (DAPT)  
- Direct oral anticoagulant (DOAC)  
- Electrocardiogram (ECG)  
- Estimated glomerular filtration rate (eGFR)  
- Familial hypercholesterolemia (FH)  
- Fractional flow reserve (FFR)  
- Guideline‑directed management and therapy (GDMT)  
- Glucagon‑like peptide‑1 (GLP‑1)  
- High‑density lipoprotein (HDL)  
- Heart failure (HF)  
- Human immunodeficiency virus (HIV)  
- Instantaneous wave‑free ratio (iFR)  
- Ischemia with non‑obstructive coronary artery (INOCA)  
- Low‑density lipoprotein (LDL)  
- Left ventricular (LV)  
- Left ventricular ejection fraction (LVEF)  
- Major adverse cardiovascular event (MACE)  
- Myocardial blood flow reserve (MBFR)  
- Myocardial perfusion imaging (MPI)  
- Myocardial infarction (MI)  
- Nicotine replacement therapy (NRT)  
- Platelet adenosine diphosphate receptor (P2Y12)  
- Positron emission tomography (PET)  
- Percutaneous coronary intervention (PCI)  
- Proprotein convertase subtilisin/kexin type 9 (PCSK9)  
- Proton pump inhibitor (PPI)  
- Quality of life (QOL)  
- Renin‑angiotensin‑aldosterone system inhibitor (RAASi)  
- Randomized controlled trial (RCT)  
- Single antiplatelet therapy (SAPT)  
- Spontaneous coronary artery dissection (SCAD)  
- Social determinants of health (SDOH)  
- Sodium glucose cotransporter 2 (SGLT2)  
- Single‑photon emission computed tomography (SPECT)  
- Transient ischemic attack (TIA)  

*Key clinical concepts from the text:*  
- Chronic stable angina pectoris  
- Coronary artery disease  
- Ischemic heart disease  
- Atherosclerotic cardiovascular disease  
- Coronary heart disease  
- Myocardial infarction (MI)  
- Angiographic chronic coronary disease (CCD)

Page 10 Extracted Terms:
- Coronary Heart Disease (CHD)  
- Myocardial Infarction (MI)  
- Angina / Angina Pectoris  
- Chest pain / Chest discomfort (AP)  
- Insufficient blood flow to the heart muscle  
- Rose Angina (Rose questionnaire)  
- Stable Angina Pectoris  
- Glucose‑Cotransporter‑2 (SGLT2) inhibitors  
- Glucagon‑like peptide‑1 (GLP‑1) receptor agonists  
- Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitors  
- Bempezoic acid  
- Inclisiran  
- Prevalence of CHD  
- Confidence interval (CI)  
- National Health and Nutrition Examination Survey (NHANES)  
- National Behavioral Risk Factor Surveillance System (BRFSS)  
- American Heart Association (AHA)  
- American College of Cardiology (ACC)  
- American College of Preventive Cardiology (ACCP)  
- American Society for Preventive Cardiology (ASPC)  
- National Heart, Lung, and Blood Institute (NHLBI)

Page 11 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Coronary Heart Disease (CHD)  
- Angina  
- Diagnostic approaches for coronary disease  
- Risk stratification in coronary disease  
- Treatment approaches for chronic coronary disease  
- Shared decision‑making (in cardiovascular care)  
- Team‑based care (in cardiovascular management)  
- Cost and value considerations in cardiovascular therapy  
- Global Burden of Disease data on coronary disease  
- Behavioral Risk Factor Surveillance System (BRFSS) data on coronary disease prevalence  
- Prevalence of angina or CHD  

 *(All terms are directly associated with heart disease and its clinical management as highlighted in the guideline excerpt.)*

Page 12 Extracted Terms:
**Key heart‑disease terms extracted from the guideline text**

1. Chronic Coronary Disease (CCD)  
2. Myocardial ischemia  
3. Angina (stable chest pain)  
4. Functional capacity  
5. Guideline‑directed medical therapy (GDMT)  
6. Stress positron emission tomography (PET)  
7. Single‑photon emission computed tomography myocardial perfusion imaging (SPECT MPI)  
8. Cardiovascular magnetic resonance imaging (CMR)  
9. Stress echocardiography  
10. Invasive coronary angiography (ICA)  
11. Nuclear myocardial perfusion imaging (MPI)  
12. Exercise treadmill testing  
13. Myocardial blood flow reserve (MBFR)  
14. Coronary CT angiography (CCTA)  
15. Bypass graft (coronary artery bypass graft, CABG)  
16. Stent patency  
17. Coronary revascularization  
18. Percutaneous coronary intervention (PCI)  
19. Left main stenosis  
20. Left ventricular ejection fraction (LVEF)  
21. Major adverse cardiovascular events (MACE)  
22. Cardiovascular death  
23. Non‑fatal myocardial infarction (MI)  
24. Wall‑motion abnormality  
25. Late gadolinium enhancement  
26. Revascularization strategy  
27. Ischemic burden  
28. Cardiac risk stratification  
29. Diagnostic accuracy  
30. Stress testing  
31. Coronary artery disease (CAD)  
32. Non‑obstructive coronary arteries (INOCA)  
33. Ischemia extent  
34. Ischemia severity  
35. Clinical decision‑making  
36. Diagnostic evaluation  
37. Stress‑induced ischemia  

These terms capture the key concepts, diagnostic modalities, therapeutic options, and outcome markers discussed in the text.

Page 13 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Coronary Artery Disease (CAD)  
- Major Adverse Cardiovascular Events (MACE)  
- Cardiovascular death  
- Myocardial infarction (MI)  
- Hospitalization for unstable angina  
- Heart failure (HF)  
- Resuscitated cardiac arrest  
- Guideline‑directed medical therapy (GDMT)  
- Invasive coronary angiography (ICA)  
- Revascularization (e.g., PCI, CABG)  
- Fractional flow reserve (FFR)  
- Computed tomography coronary angiography (CCTA)  
- Positron emission tomography myocardial perfusion imaging (PET MPI)  
- Single photon emission computed tomography myocardial perfusion imaging (SPECT MPI)  
- Myocardial blood flow reserve (MBFR)  
- Cardiopulmonary exercise testing / treadmill testing  
- Duke Treadmill Score  
- Left ventricular (LV) systolic dysfunction  
- Left main coronary artery disease  
- Noninvasive cardiac testing  
- Cardiac rehabilitation (CR)  
- Ischemia severity (noninvasive testing)  
- Bypass graft patency  
- Epicardial coronary arteries  
- Coronary microvascular disease  
- Risk stratification scores (validated risk models)  
- Event‑free survival  

These are the principal concepts and diagnostic or therapeutic modalities that relate directly to heart disease as presented in the guideline text.

Page 14 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Coronary artery disease  
- Myocardial infarction (MI)  
- Angina  
- Coronary ischemia  
- Revascularization  
- Percutaneous coronary intervention (PCI)  
- Coronary artery bypass grafting (CABG)  
- Coronary computed tomography angiography (CCTA)  
- Cardiovascular magnetic resonance imaging (CMR)  
- Single‑photon emission computed tomography (SPECT)  
- Positron emission tomography (PET)  
- Duke Treadmill Score (DTS)  
- Electrocardiogram (ECG)  
- Exercise stress test (EST)  
- High‑sensitivity troponin  
- B‑type natriuretic peptide (BNP)  
- Left ventricular ejection fraction (LVEF)  
- Left ventricular hypertrophy (LVH)  
- Coronary flow reserve (CFR)  
- Coronary artery plaque burden  
- Napkin‑ring sign  
- Positive remodeling (remodeling index > 1.1)  
- Low‑attenuation plaque (mean CT < 30 HU)  
- Atrial fibrillation/flutter  
- Heart failure (HF)  
- Myocardial perfusion reserve  
- Myocardial blood flow at stress  
- Major adverse cardiovascular events (MACE)  
- Cardiovascular death  
- Non‑fatal MI  
- Cardiovascular hospitalization  
- Ischemic heart failure  
- Coronary artery stenosis  
- Coronary burden high‑risk plaque  
- Left bundle branch block (LBBB)  
- Resting heart rate  
- Peak rate‑pressure product  
- Coronary artery bypass graft (CABG) indication  
- Calcium score  
- Clinical outcomes (all‑cause death, all‑cause mortality)  
- Exercise intolerance  
- Peripheral artery disease (PAD)  
- Diabetes mellitus  
- Dyslipidemia  
- Chronic kidney disease (CKD)  
- Obesity / elevated body mass index (BMI)  
- Smoking (current or former)  
- Depression  
- Poor adherence to pharmacotherapy  
- Socio‑economic status / poverty / lack of health‑care access  
- Age  
- Male sex  
- Clinical trials / guidelines:  
 • ISCHEMIA  
 • COURAGE  
 • BARI‑2D  
 • STICH  
 • AHA/ACC/ACCP/ASPC/NLA/PCNA Chronic Coronary Disease Guideline  
 • 2021 AHA/ACC Chest Pain Guideline  
- Risk prediction factors and stratification categories  
- Functional and anatomic testing modalities  
- Ancillary imaging variables (e.g., CT‑fractional flow reserve)

Page 15 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Coronary revascularization  
- Percutaneous Coronary Intervention (PCI)  
- Medical therapy (including guideline‑directed medical therapy, GDMT)  
- LVEF ≤ 35%  
- Heart failure (HF)  
- Heart failure with preserved ejection fraction (HF‑pEF)  
- Non‑invasive modalities (e.g., myocardial perfusion imaging, stress testing)  
- Coronary computed tomographic angiography (CCTA)  
- Coronary ischemia  
- Coronary angiography  
- CAD (coronary artery disease)  
- Ischemic events (non‑fatal ischemia, myocardial infarction)  
- Atherosclerosis progression  
- Symptoms (angina, dyspnea, fatigue)  
- Functional status and limitation  
- Quality of life (QOL)  
- Antianginal medications  
- Antithrombotic therapy (antiplatelets/anticoagulants)  
- Lipid‑lowering therapy (statins, PCSK9 inhibitors)  
- Glycemic control (diabetes management)  
- Blood pressure control  
- Smoking cessation, physical activity, nutrition, weight management, stress reduction  
- Patient‑reported health status measures  
- Shared decision‑making  
- Remote disease‑management programs  
- Clinical follow‑up (annual, telehealth, in‑person)  
- Trials: REVIVED‑BCIS2, COURAGE, BARI 2D, ISCHEMIA.

Page 16 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Coronary disease  
- Atherosclerotic Cardiovascular Disease (ASCVD)  
- Angina  
- Ischemic symptoms  
- Cardiovascular disease  
- Heart disease  
- Seattle Angina Questionnaire (patient‑reported health status measure)  
- ASCVD risk factors  
- Quality of life (QOL) in cardiovascular patients  


Page 17 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Atherosclerotic Cardiovascular Disease (ASCVD)  
- Myocardial infarction (MI)  
- Recurrent myocardial infarction  
- Cardiovascular complications  
- Hypertension  
- Diabetes mellitus  
- Hyperlipidemia  
- Tobacco cessation (smoking cessation)  
- Weight loss  
- Depression (as a cardiovascular risk factor)  
- Tele‑health / remote patient monitoring  
- Patient education (on symptom management, lifestyle, medications)  
- Medication therapy management  
- Medication adherence  
- Symptom management  
- Lifestyle changes  
- Social determinants of health (SDOH) risk factors  
- Morbidity  
- Mortality  
- Readmission  
- Emergency department visits  
- Health‑related quality of life (QOL)  
- Cost‑effectiveness / cost‑efficiency  
- Health‑care resource utilization  
- Team‑based care  
- Decision support aids  
- Specialty clinics  
- Advanced practice providers (in care delivery)


Page 18 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Coronary disease  
- Cardiac symptoms  
- Recurrent myocardial infarction (MI)  
- Hospitalizations  
- Cardiovascular mortality  
- Low‑density lipoprotein cholesterol (LDL‑C)  
- Systolic blood pressure (BP)  
- Revascularization  
- Guideline‑directed medical therapy (GDMT)  
- Shared decision‑making  
- Medication adherence  
- Heart Quality of Life instrument  
- Pharmacist‑administered intervention  
- Motivational interviewing  
- Internet‑based education  
- Physical activity  
- Dietary habits  
- Smoking cessation  
- Health literacy  

These terms capture the primary heart‑disease concepts referenced in the guideline excerpt.

Page 19 Extracted Terms:
**Key Terms related to Heart Disease**

- Chronic Coronary Disease (CCD)  
- Cardiovascular disease (CVD)  
- Myocardial infarction (MI)  
- Stable angina  
- Revascularization  
- Percutaneous coronary intervention (PCI)  
- Antithrombotic therapy  
- Guideline‑Directed Medical Therapy (GDMT)  
- Secondary prevention  
- Cardiac rehabilitation (CR)  
- Heart‑healthy diet / Nutrition, including supplements  
- Physical activity / Exercise prescription  
- Cardiovascular outcomes  
- Risk–benefit tradeoff  
- Shared decision‑making  
- Decision aids (e.g., PCI Choice)  
- Social Determinants of Health (SDOH)  
- Health equity / Health disparities  
- Neighborhood disadvantage  
- Insurance status / Health insurance coverage  
- Economic stability / Financial strain  
- Transportation / Access to care  
- Health literacy  
- Mental health / Psychosocial stressors  
- Cultural humility  
- Patient–caregiver decision delegation  
- Clinical practice guidelines (AHA/ACC/ACCP/ASPC/NLA/PCNA)

Page 20 Extracted Terms:
**Key heart‑disease terms extracted:**

- Chronic Coronary Disease  
- CCD (Chronic Coronary Disease)  
- Coronary  
- Cardiovascular Care  

Page 21 Extracted Terms:
**Key heart‑disease related terms extracted from the text**

- Chronic Coronary Disease (CCD)  
- Cardiovascular Disease (CVD)  
- Atherosclerotic Cardiovascular Disease (ASCVD)  
- Heart Failure (HF)  
- Stroke  
- Cardiovascular events (acute CVD events)  
- Acute CVD deaths / CVD‑related deaths  
- Cardiometabolic health  
- Insulin resistance  
- Diabetes mellitus  
- Dyslipidemia  
- Hypertension  
- Obesity (overweight/obese patients)  
- Sodium intake (≤ 2300 mg/d, optimum 1500 mg/d)  
- Saturated fat (< 6 % of total calories)  
- Unsaturated fats (monounsaturated, polyunsaturated)  
- Trans fat (to be avoided)  
- Processed meats (cured bacon, hot dogs)  
- Refined carbohydrates (white bread, white rice, refined cereals)  
- Sugar‑sweetened beverages (soft drinks, energy drinks, fruit drinks)  
- Whole grains  
- Dietary fiber  
- Mediterranean‑type dietary plan (plant‑based, lean protein, fish)  
- Lifestyle modification / dietary behavior changes  
- Guideline‑Directed Management and Therapy (GDMT)  
- Nonprescription nutrition/dietary supplements  
- Omega‑3 fatty acids  
- Vitamins C, D, E, beta‑carotene  
- Calcium  
- Social Determinants of Health (SDOH)  
- Telehealth & digital interventions  
- Collaborative partnerships (health‑care systems & community organizations)  
- Lyon Diet Heart Study (Mediterranean diet intervention)   
- AHA/ACC/ACCP/ASPC/NLA/PCNA Chronic Coronary Disease Guideline  
- Chronic diseases (multiple chronic disease screening)

Page 22 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Cardiovascular Disease (CVD)  
- Coronary Heart Disease (CHD)  
- Atherosclerotic cardiovascular disease (ASCVD)  
- Low‑density lipoprotein cholesterol (LDL‑C)  
- High‑density lipoprotein cholesterol (HDL‑C)  
- Triglycerides  
- Blood pressure (BP)  
- Hypertension (HTN)  
- Sodium intake  
- Potassium intake  
- Saturated fatty acids  
- Trans fatty acids  
- Monounsaturated fatty acids  
- Polyunsaturated fatty acids  
- Dietary fiber  
- Simple carbohydrates (e.g., high‑fructose corn syrup)  
- Refined grains  
- Sugar‑sweetened beverages  
- Processed meats (smoked, cured, salted)  
- Plant‑based diet  
- Mediterranean diet  
- DASH (Dietary Approaches to Stop Hypertension) diet  
- Weight loss / obesity  
- Diabetes mellitus  
- Chronic kidney disease (CKD)  
- Insulin sensitivity  
- Lipoprotein profile  
- Biomarkers of cardiac injury, inflammation, and cardiac strain  
- Atherosclerotic plaque burden  
- Primary prevention  
- Secondary prevention  
- Dose‑response relationship (high‑quality carbohydrate intake)  
- Cardiometabolic profile  
- Lifestyle modification for cardiovascular health  
- Dose‑response relationship (saturated fat reduction)  


These terms capture the main dietary, metabolic, and clinical concepts related to heart disease discussed in the guideline excerpt.

Page 23 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Cardiovascular Disease (CVD)  
- Major Adverse Cardiac Events (MACE)  
- Coronary Heart Disease (CHD)  
- Acute Coronary Syndrome (ACS)  
- Omega‑3 fatty acid supplements  
- Icosapent ethyl (eicosapentaenoic acid ethyl ester)  
- Vitamin D supplementation  
- Antioxidant therapy (vitamin C, beta‑carotene, multivitamins)  
- Calcium supplementation (≥ 500 mg/d elemental calcium)  
- Mental health conditions (depression, anxiety, anger/hostility, general distress, type D personality)  
- Screening for mental health disorders  
- Pharmacologic therapy for mental health  
- Non‑pharmacologic therapy for mental health  
- Cardiovascular risk factors (blood pressure, lipids, body mass index, inflammation, thrombosis)  
- Health behaviors (medication adherence, cardiac rehabilitation, diet, physical activity, sleep, smoking)  
- Quality of Life (QOL)  
- Cardiovascular outcomes  
- Cardiovascular mortality  
- Cardiovascular event reduction  
- Cardiovascular event risk  
- Cardiovascular risk factor management  



Page 24 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Acute Coronary Syndrome (ACS)  
- Myocardial Infarction (MI)  
- Major Adverse Cardiovascular Events (MACE)  
- Cardiovascular Outcomes  
- Cardiac Rehabilitation (CR)  
- Depression (as a cardiovascular comorbidity)  
- Antidepressants (e.g., escitalopram)  
- ESCIPTACS (Escitalopram in Depressive Patients with Acute Coronary Artery Syndrome) study  
- TRIUMPH study (Treatment‑Resistant Hypertension)  
- Smoking Cessation (risk factor for heart disease)  
- Nicotine Replacement Therapy  
- Quitline (telephone‑based smoking cessation resource)

Page 25 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Cardiovascular Disease (CVD)  
- Coronary Heart Disease (CHD)  
- Myocardial Infarction (MI)  
- Revascularization  
- Atherosclerosis  
- Endothelial dysfunction  
- Thrombosis / pro‑thrombotic state  
- Heart rate  
- Blood pressure (BP)  
- Cardiovascular events  
- Cardiac mortality  
- Cardiac quality of life (QOL)  
- Smoking / tobacco use  
- Second‑hand smoke exposure  
- Nicotine‑replacement therapy (NRT)  
- Bupropion therapy  
- Varenicline therapy  
- E‑cigarette use  
- Depression, anxiety, and stress as cardiovascular risk factors  

These terms capture the core concepts related to heart disease discussed in the guideline text.

Page 26 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Coronary heart disease (CHD) / Coronary artery disease (CAD)  
- Congestive heart failure (CHF)  
- Atherosclerotic cardiovascular disease (ASCVD)  
- Cardiovascular disease (CVD)  
- Myocardial infarction (MI)  
- Ischemic heart disease (IHD)  
- Endothelial dysfunction  
- Vascular stiffness  
- Blood pressure (BP)  
- Smoking cessation (behavioral and pharmacologic)  
- Nicotine replacement therapy (NRT)  
- Varenicline  
- Bupropion  
- E‑cigarettes / electronic nicotine delivery systems (ENDS)  
- Secondhand smoke exposure  
- Nicotine dependence / addiction  
- Alcohol consumption (≤1 drink/day for women, ≤2 drinks/day for men)  
- Cardiovascular risk factors (e.g., smoking, alcohol, secondhand smoke)  
- Cardiovascular events (e.g., arrhythmias, heart failure episodes, MI)  
- Cardiovascular mortality (cardiovascular death)  
- Cardiovascular safety and risk assessment  
- Prevention and risk reduction guidelines (e.g., AHA/ACC/ACCP/ASPC/NLA/PCNA Chronic Coronary Disease Guideline)  
- Cardiovascular pharmacotherapy  
- Endothelial function tests  
- Cardiovascular policy (e.g., smoke‑free workplace policies)

Page 27 Extracted Terms:
**Key Heart‑Disease–Related Terms Extracted**

- Cardiovascular system  
- Chronic coronary disease (CCD)  
- Myocardial infarction (MI) / acute myocardial infarction  
- Cardiovascular risk / cardiovascular events  
- Cardiovascular mortality / death  
- Cardiovascular morbidity  
- Cardiac arrest  
- Cardiac toxicity  
- Cardiac‑specific effects of substances  
- Cardioprotective effects (light‑to‑moderate alcohol)  
- J‑shaped relationship between alcohol and cardiovascular risk  
- Heavy alcohol use  
- Binge drinking  
- Light‑to‑moderate alcohol consumption (5–25 g/d)  
- Sympathetic nervous system stimulation  
- Platelet activation / aggregation  
- Endothelial dysfunction  
- Myocardial oxygen demand  
- Drug‑drug interactions with cardiovascular therapies  
- Substance abuse (cocaine, amphetamines, opioids, marijuana/cannabis)  
- Cardiovascular therapies (pharmacologic agents, device therapies)

Page 28 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Cardiovascular disease (CVD)  
- Myocardial infarction (MI)  
- Coronary events  
- Hypertension  
- Mortality rate  
- Recurrent cardiovascular events  
- Alcohol consumption (light‑to‑moderate)  
- Binge drinking  
- J‑shaped relationship (alcohol vs. cardiovascular outcomes)  
- Cancer risks associated with alcohol  
- Cardiac rehabilitation (CR)  
- Regular exercise  
- Sexual activity (as moderate exercise)  
- Sexual dysfunction  
- Phosphodiesterase type 5 inhibitors (PDE5i)  
- Nitrate medications  
- Severe hypotension (risk with PDE5i + nitrates)  
- Percutaneous coronary intervention (PCI)  
- Coronary artery bypass grafting (CABG)  
- Femoral access (PCI)  
- Radial access (PCI)  
- Sternal‑sparing surgery (CABG)  
- Angina  
- Metabolic equivalents (METs)  
- Unstable or decompensated CCD  
- Erectile function (International Index of Erectile Function)  
- Physical exercise training (within CR)  
- Pelvic floor exercise  
- Psychoeducation  
- Long‑acting nitrates  
- Short‑acting nitrates (e.g., nitroglycerine)  
- Sildenafil  
- Vardenafil  
- Tadalafil  
- Global Burden of Disease (GBD) study  
- Determinants of Myocardial Infarction Onset Study  
- Prospective Epidemiological Study of Myocardial Infarction (PRIME)

Page 29 Extracted Terms:
**Key heart‑disease related terms from the guideline excerpt**

- Chronic Coronary Disease (CCD)  
- High‑intensity statin therapy  
- Moderate‑intensity statin therapy  
- Low‑density lipoprotein cholesterol (LDL‑C)  
- High‑density lipoprotein cholesterol (HDL‑C)  
- Major Adverse Cardiovascular Events (MACE)  
- Ezetimibe  
- PCSK9 monoclonal antibody  
- Icosapent ethyl (EPA ethyl ester)  
- Bempedoic acid  
- Inclisiran  
- Niacin  
- Fenofibrate  
- Omega‑3 fatty acids  
- Atherosclerotic disease  
- Lipid management  
- Lipid‑lowering medication  
- Maximal tolerated statin therapy  
- Generic statin formulation  
- Lipid monitoring (fasting lipids, triglycerides)  
- Residual cardiovascular risk  
- Cardiovascular morbidity  
- Cardiovascular mortality  
- Cholesterol Treatment Trialists (CTT) meta‑analysis  
- Randomized controlled trials (RCTs)  

These terms capture the central concepts, therapies, and outcomes discussed in the clinical guideline.

Page 30 Extracted Terms:
- LDL‑C (low‑density lipoprotein cholesterol)  
- Statin therapy (high‑intensity, moderate‑intensity, low‑intensity)  
- Statin intolerance (partial/complete)  
- Nocebo effect (patient expectation of harm with statin)  
- ASCVD (atherosclerotic cardiovascular disease)  
- Cardiovascular events (e.g., MI, stroke, peripheral artery disease)  
- Acute coronary syndrome (ACS)  
- Myocardial infarction (MI)  
- Ischemic stroke  
- Symptomatic peripheral artery disease (ABI < 0.85)  
- Ankle‑brachial index (ABI)  
- Familial hypercholesterolemia  
- Congestive heart failure / heart failure  
- Ezetimibe (add‑on therapy)  
- Lipid‑lowering therapy (statins, ezetimibe, combination therapy)  
- Cholesterol guideline (e.g., 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Chronic Coronary Disease Guideline)  
- LDL‑C threshold for therapy intensification (≥ 70 mg/dL, persistent ≥ 100 mg/dL)  
- LDL‑C reduction goals (≥ 50 % with high‑intensity statin)  
- Friedewald equation (LDL‑C estimation)  
- Martin/Hopkins method (LDL‑C calculation)  
- Quality‑adjusted life years (QALY)  
- Cost‑effectiveness / cost‑saving of lipid‑lowering therapy  
- Chronic kidney disease (CKD) with eGFR 15–59 mL/min/1.73 m²  
- Hypertension  
- Diabetes mellitus  
- Current tobacco smoking  
- High‑risk conditions for ASCVD (age ≥ 65, familial hypercholesterolemia, prior coronary interventions, etc.)  
- Very high‑risk definition for future ASCVD events (history of multiple events or one major event plus ≥ 2 high‑risk conditions)  
- Lipoprotein apheresis (used in familial hypercholesterolemia)  

These are the principal terms related to heart disease and lipid management extracted from the provided text.

Page 31 Extracted Terms:
- Chronic Coronary Disease  
- Cardiovascular Disease (CVD)  
- Clinical Atherosclerotic Cardiovascular Disease (ASCVD)  
- Acute Coronary Syndrome (ACS)  
- Major Adverse Cardiovascular Events (MACE)  
- Cardiovascular events  
- Thrombolysis in Myocardial Infarction (TIMI) Risk Score for Secondary Prevention (TRS 2P)  
- Ezetimibe  
- PCSK9 monoclonal antibody (e.g., alirocumab, evolocumab)  
- Ezetimibe‑first strategy  
- Low‑density lipoprotein cholesterol (LDL‑C)  
- Non‑HDL‑C  
- LDL‑C thresholds: ≥70 mg/dL, <70 mg/dL, <50 mg/dL  
- Very high‑risk ASCVD (Table 10)  
- High‑intensity statin therapy  
- Moderate‑intensity statin therapy  
- Low‑intensity statin therapy  
- Atorvastatin (10 mg, 20 mg, 40 mg, 80 mg)  
- Rosuvastatin (5 mg, 10 mg, 20 mg, 40 mg)  
- Simvastatin (10 mg, 20 mg, 40 mg)  
- Pravastatin (10 mg, 20 mg, 40 mg, 80 mg)  
- Lovastatin (20 mg, 40 mg, 80 mg)  
- Fluvastatin (oral extended release, 40 mg, 80 mg, BID)  
- Pitavastatin (1–4 mg)  
- FOURIER trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk)  
- ODYSSEY OUTCOMES trial (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment with Alirocumab)  
- Cost‑effectiveness (cost‑per‑QALY, <$50,000/QALY)  
- Neurocognitive adverse effects  
- Myopathy, rhabdomyolysis  
- ASCVD risk calculators / risk factors (high‑risk clinical factors)  
- Lifetime major adverse cardiovascular events reduction ("fewer lifetime MACE")  
- Cardiovascular events reduction percentages (15 %, 19 %, etc.)  
- Absolute risk reduction (e.g., 1.5 %, 0.6 %)  
- Relative risk reduction (e.g., 15 %, 19 %)  
- Incremental Decrease through Aggressive Lipid Lowering (IDEAL) study  
- FDA labeling for statins (therapeutic recommendations)  

These terms capture the key concepts and entities in the text that relate directly to heart disease management and outcomes.

Page 32 Extracted Terms:
- Atherosclerotic cardiovascular disease (ASCVD)  
- Chronic coronary disease (CCD)  
- Major adverse cardiovascular events (MACE)  
- Coronary artery disease (CAD)  
- PCSK9 monoclonal antibody (PCSK9 mAb)  
- Statin therapy  
- Ezetimibe  
- Bempedoic acid  
- Inclisiran  
- Low‑density lipoprotein cholesterol (LDL‑C)  
- High‑density lipoprotein cholesterol (HDL‑C)  
- Triglycerides (TG)  
- Absolute risk reduction  
- Cardiovascular risk (high‑risk, very high‑risk)  
- Cost‑effectiveness in cardiovascular care  
- Randomized controlled trial (RCT) – in the context of cardiovascular studies

Page 33 Extracted Terms:
- Atherosclerotic cardiovascular disease (ASCVD)  
- Acute coronary syndrome (ACS)  
- Coronary artery disease (CAD)  
- Peripheral artery disease (PAD)  
- Familial hypercholesterolemia (FH)  
- Cardiovascular events (CV events)  
- Major adverse cardiovascular events (MACE)  
- Cardiovascular death  
- Myocardial infarction  
- Stroke/ischemic cerebrovascular event  
- Dyslipidemia (triglycerides, LDL‑C, HDL‑C)  
- Hypertriglyceridemia  
- Low‑density lipoprotein cholesterol (LDL‑C)  
- Elevated triglyceride levels  
- Non‑statin lipid‑lowering therapies  
- Statins (high‑intensity, moderate‑intensity, low‑intensity)  
- PCSK9 inhibitors (monoclonal antibodies)  
- PCSK9 monoclonal antibody therapy  
- PCSK9‑directed small interfering RNA (inclisiran)  
- Ezetimibe  
- Bempedoic acid  
- Icosapent ethyl (purified EPA)  
- Omega‑3 fatty acids (EPA, DHA)  
- Eicosapentaenoic acid (EPA)  
- Dihomo‑γ‑linolenic acid (DHA)  
- Mineral oil placebo  
- Corn oil placebo  
- EPA/DHA plasma levels  
- Cardiovascular risk (high, very high, moderate)  
- Primary prevention  
- Secondary prevention  
- Shared decision‑making  
- Incremental cost‑effectiveness ratio  
- Adverse events (e.g., tendon rupture, increased uric acid, atrial fibrillation)  

**Key clinical trials mentioned**  
- REDUCE‑IT (Reduction of Cardiovascular Events with Icosapent Ethyl)  
- RESPECT‑EPA (Randomized Trial for Evaluation in Secondary Prevention Efficacy of Combination Therapy – Statin and Eicosapentaenoic Acid)  
- STRENGTH (Long‑Term Outcomes Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia)  

These terms capture the major cardiovascular concepts, therapies, risk factors, and evidence referenced in the guideline text.

Page 34 Extracted Terms:
**Key terms related to heart disease:**

- Chronic Coronary Disease (CCD)  
- Atherosclerotic Cardiovascular Disease (ASCVD)  
- Statin therapy / Severe statin‑associated side effects  
- Inclisiran (monoclonal antibody)  
- Heterozygous Familial Hypercholesterolemia (FH)  
- Omega‑3 fatty acids (fish oil)  
- Major Adverse Cardiovascular Events (MACE)  
- Icosa­pent ethyl (EPA‑only formulation)  
- AIM‑HIGH trial  
- Extended‑release niacin  
- HPS2‑THRIVE trial (niacin + laropiprant)  
- ACCORD‑LIPID trial (fenofibrate)  
- Fenofibrate  
- PPARα modulator (pemafibrate)  
- PROMINENT trial  
- Hypertriglyceridemia (≥500 mg/dL)  
- Acute pancreatitis (risk from hypertriglyceridemia)  
- Blood pressure (BP)  
- Hypertension  
- BP targets (<130/<80 mm Hg, 120‑129/<80 mm Hg)  
- Cardiovascular disease (CVD) events  
- All‑cause death  
- Angiotensin‑converting enzyme (ACE) inhibitors  
- Angiotensin‑receptor blockers (ARBs)  
- Beta‑blockers  
- Dihydropyridine calcium channel blockers (CCBs)  
- Long‑acting thiazide diuretics  
- Mineralocorticoid receptor antagonists  
- Lifestyle modifications (weight loss, heart‑healthy diet, sodium reduction, physical activity, alcohol moderation)  
- HOPE trial (ramipril)  
- Rossipril (ramipril)  
- MI (myocardial infarction)  
- Stroke  
- CAD (coronary artery disease)  
- INVEST trial (international recommendations for BP management)  
- Multisociety Guideline for Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults  
- All‑cause mortality  
- Cardiovascular mortality  
- Lifestyle‑related blood‑pressure factors  
- Diabetes mellitus type 2 (as a cardiovascular risk factor)  

*(The list includes disease entities, therapeutic agents, clinical trials, risk factors, and management targets pertinent to cardiovascular health.)*

Page 35 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Cardiovascular disease (CVD)  
- Cardiovascular morbidity  
- Cardiovascular mortality (CVD death)  
- Myocardial infarction (MI)  
- Angina  
- Cardiac arrest  
- CVD events  
- β‑blockers (beta blockers)  
- ACE inhibitors (angiotensin‑converting enzyme inhibitors)  
- ARB agents (angiotensin II receptor blockers)  
- Calcium‑channel blockers (CCBs)  
- Thiazide diuretics  
- Mineralocorticoid receptor antagonists  
- SGLT2 inhibitors (sodium‑glucose cotransporter‑2 inhibitors)  
- GLP‑1 receptor agonists (glucagon‑like peptide‑1 receptor agonists)  
- Major adverse cardiovascular events (MACE)  
- Hypertension  
- Blood pressure (BP)  
- Systolic blood pressure (SBP)

Page 36 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Type 2 Diabetes (in the context of CCD)  
- SGLT2 inhibitors  
- GLP‑1 receptor agonists  
- Heart Failure (HF)  
- Left Ventricular Ejection Fraction (LVEF)  
- Cardiovascular death  
- Heart‑failure hospitalization  
- Quality of life (QOL)  
- Guideline‑Directed Medical Therapy (GDMT)  
- Major Adverse Cardiovascular Events (MACE)  
- Myocardial infarction (MI)  
- Stroke  
- Atherosclerosis / atherosclerotic events  
- Coronary Artery Disease (CAD)  
- Glycemic control (HbA1c targets)  
- Weight loss (as a benefit)  
- Kidney disease progression (as a benefit)  
- Hypoglycemia risk  
- Cost‑effectiveness / value assessment (high/intermediate)  
- Quality‑adjusted life year (QALY)  

These terms capture the principal concepts related to heart disease discussed in the guideline excerpt.

Page 37 Extracted Terms:
**Key Terms Related to Heart Disease**

- Chronic Coronary Disease (CCD)  
- Heart Failure (HF)  
- Heart Failure with Reduced Ejection Fraction (HFrEF)  
- Heart Failure with Preserved Ejection Fraction (HFpEF)  
- Sodium‑glucose co‑transporter‑2 (SGLT2) inhibitors  
- Empagliflozin  
- Dapagliflozin  
- SGLT2 inhibitor pharmacodynamics in HF  
- Cardiovascular death  
- HF hospitalization  
- Quality of life (QOL) and functional capacity in HF  
- Glucagon‑like peptide‑1 (GLP‑1) receptor agonists  
- Semaglutide  
- Liraglutide  
- Diabetes mellitus type 2 and its interaction with HF  
- Cardio‑renal considerations (eGFR, CKD stage)  
- Cost‑effectiveness (QALYs, incremental cost‑effectiveness ratio)  
- Guideline‐based risk factors: BMI, waist circumference, weight management  
- Hemodynamic parameters: ejection fraction, reduced vs preserved ejection fraction  

These terms capture the major clinical concepts, therapeutic agents, patient subgroups, outcome measures, and guideline‑specific recommendations discussed in the cited text.

Page 38 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Cardiovascular risk factor  
- Obesity  
- Severe obesity  
- Bariatric procedure / bariatric surgery  
- Sympathomimetic weight‑loss drugs  
- Atherosclerosis  
- Cardiac function  
- Myocardium  
- Vasculature  
- Hypertension (high blood pressure)  
- Dyslipidemia  
- Type 2 diabetes  
- Body Mass Index (BMI)  
- Waist circumference  
- Visceral adiposity  
- Cardiometabolic risk  
- Weight loss  
- Lifestyle modification  
- Nutrition  
- Physical activity / exercise  
- Behavioral counseling  
- SGLT2 inhibitors  
- GLP‑1 receptor agonists  
- Metabolic risk profile  
- Hemodynamic risk profile  
- Cardiovascular outcomes  
- Cardiac rehabilitation  
- Nutritional counseling  
- Blood pressure management  
- Lipid management  
- Diabetes management  
- Tobacco cessation  
- Psychosocial management  
- Exercise training  
- Cardiorespiratory fitness  
- Lean mass  
- Weight assessment  
- Body composition  
- Central obesity  

Page 39 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Cardiovascular disease (CVD)  
- Cardiovascular safety  
- GLP‑1 receptor agonist  
- Semaglutide  
- Tirzepatide (LY3298176)  
- Liraglutide  
- Major Adverse Cardiovascular Events (MACE)  
- Atherosclerotic cardiovascular disease (ASCVD)  
- Type 2 diabetes mellitus  
- Bariatric procedure  
- Gastric bypass surgery  
- Cardiac rehabilitation  
- Myocardial infarction (MI)  
- Stroke  
- Coronary artery bypass grafting (CABG)  
- Percutaneous coronary intervention (PCI)  
- Heart transplant  
- Spontaneous coronary artery dissection  
- Naltrexone/bupropion (weight‑loss drug)  
- Sibutramine  
- Phentermine  
- Diethylpropion  
- Benzphetamine  
- Phendimetrazine  
- Weight‑loss drugs  
- STEP 8 trial  
- SURMOUNT‑1 trial  
- SOS (Swedish Obese Subjects) study  
- Hazard ratio  
- Body mass index (BMI)  
- Obesity  
- Weight loss  
- Nonfatal MI  
- Nonfatal stroke  
- Cardiovascular deaths  
- Cardiovascular risk factors  
- Home‑based cardiac rehabilitation  
- Remote cardiac rehabilitation  
- Lifestyle therapy  
- Medication therapy

Page 40 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Cardiac Rehabilitation (CR)  
- Myocardial Infarction (MI)  
- Percutaneous Coronary Intervention (PCI)  
- Coronary Artery Bypass Grafting (CABG)  
- Stable Angina  
- Heart Transplant (HTx)  
- Cardiac Allograft Vasculopathy (CAV)  
- Spontaneous Coronary Artery Dissection (SCAD)  
- Heart Failure (HF)  
- Major Adverse Cardiovascular Events (MACE)  
- Rehospitalization (cardiovascular & non‑cardiovascular)  
- Mortality – cardiovascular, all‑cause  
- Functional Capacity  
- Quality of Life (QOL)  
- Moderate‑Intensity Aerobic Exercise (≥150 min/week)  
- High‑Intensity Interval Training (HIIT)  
- Resistance (Strength) Training (≥2 days/week)  
- Low‑Intensity Lifestyle Activity (walking breaks, reduced sedentary time)  
- Physical Activity Guidelines for CCD  
- Lipid Management  
- Blood Pressure Management  
- Sodium‑Glucose Co‑Transporter 2 Inhibitors (SGLT2i)  
- Glucagon‑Like Peptide‑1 Receptor Agonists (GLP‑1 RA)  
- Anti‑arteriosclerotic Effects  
- Anti‑arrhythmic Effects  
- Antithrombotic Effects  
- Anti‑ischemic Effects  
- Antidepressant Effects  
- Unstable Angina  
- Decompensated Heart Failure  
- Thromboembolic Disease  
- Uncontrolled Diabetes  
- End‑stage Cancer  
- Contraindications to Exercise (severe, life‑threatening, unstable conditions)  
- Risk Stratification (for CCD)  
- Team‑Based Approach (for CCD)  
- Patient Education (for CCD)  
- Shared Decision‑Making (for CCD)  
- Nutrition (including Supplements)  
- Mental Health (for CCD)  

Page 41 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Cardiovascular events  
- Cardiovascular outcomes  
- Ischemic heart disease  
- Acute myocardial infarction (MI)  
- Cardiometabolic risk  
- Air pollution  
- PM2.5 (particulate matter ≤ 2.5 µm)  
- Ambient air pollution  
- Extreme temperatures (heat and cold)  
- Heat wave  
- Wildfire smoke  
- Loop diuretics  
- Aerobic exercise (moderate‑intensity, vigorous‑intensity)  
- Resistance training (muscle‑strengthening)  
- Sedentary lifestyle  
- Lifestyle physical activities (e.g., gardening, office‑based movement, stair climbing)  
- Functional capacity  
- Quality of life (QOL)  
- Mortality rates  
- Cardiovascular mortality  
- Cardiovascular hospitalization  
- Urban heat island effect  
- Environmental noise  
- Health disparities  
- Racial and ethnic minority populations  
- Socioeconomic status  
- Ambient temperature exposure  
- Publicly available controlled‑temperature environments  
- AHA/ACC/ACCP/ASPC/NLA/PCNA Chronic Coronary Disease Guideline

(These terms capture the key clinical, environmental, and public‑health factors related to heart disease discussed in the text.)

Page 42 Extracted Terms:
**Key heart‑disease–related terms extracted from the text**

- Chronic Coronary Disease (CCD)  
- Coronary artery disease (CAD)  
- Myocardial infarction (MI)  
- Ischemic heart disease  
- Cardiac arrest  
- Percutaneous coronary intervention (PCI)  
- Dual antiplatelet therapy (DAPT)  
- Single antiplatelet therapy (SAPT)  
- Drug‑eluting stent (DES)  
- Major adverse cardiovascular events (MACE)  
- Thrombosis / atherothrombosis  
- Cardiovascular and cardiac events  
- Coronary artery bypass grafting (CABG)  
- Saphenous vein graft occlusion  
- Transient ischemic attack (TIA)  
- Intracranial hemorrhage (ICH)  
- Aspirin (low‑dose)  
- Clopidogrel (P2Y12 inhibitor)  
- Prasugrel (P2Y12 inhibitor)  
- Vorapaxar (PAR‑1 antagonist)  
- Non‑steroidal anti‑inflammatory drugs (NSAIDs)  
- Oral anticoagulants (e.g., warfarin, DOACs)  
- Direct oral anticoagulants (DOACs)  
- Rivaroxaban (low‑dose)  
- Proton pump inhibitor (PPI)  
- Bleeding risk  
- Thrombotic risk  
- Pre‑CIse DAPT (risk score)  
- DAPT risk score  
- PARIS risk score  
- Cardiovascular event prevention therapy  
- Coronary artery revascularization  
- Atherosclerotic disease

These terms capture the major clinical concepts, drugs, procedures, and risk assessment tools discussed in the guideline excerpt.

Page 43 Extracted Terms:
- Atrial fibrillation  
- Chronic coronary disease  
- Aspirin (acetylsalicylic acid)  
- Clopidogrel  
- Dual antiplatelet therapy (DAPT)  
- Platelet adenosine diphosphate receptor (P2Y12) agents  
- Direct oral anticoagulant (DOAC)  
- Rivaroxaban  
- Dabigatran  
- Apixaban  
- Edoxaban  
- Stent, drug‑eluting stent (DES)  
- Bare metal stent  
- Percutaneous coronary intervention (PCI)  
- Myocardial infarction (MI)  
- Stroke  
- Acute coronary syndrome (ACS)  
- Major adverse cardiovascular events (MACE)  
- Bleeding risk  
- Ischemic risk  
- Aspirin dosing: low-dose (81 mg) and high-dose (325 mg)  
- Single antiplatelet therapy (SAPT)  
- Oral anticoagulants (OAC)  
- Clinical guideline (AHA/ACC)  
- Meta‑analysis of randomized controlled trials (RCTs)  
- 2016 AHA/ACC guideline for DAPT  
- Clinical statements  
- 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Chronic Coronary Disease Guideline  
- 2023 Circulation journal (e.g., study pages e9–e119)  

Page 44 Extracted Terms:
- Dual Antiplatelet Therapy (DAPT)  
- Short‑term DAPT  
- Extended DAPT  
- Percutaneous Coronary Intervention (PCI)  
- Drug‑Eluting Stent (DES)  
- Stent Thrombosis  
- Myocardial Infarction (MI)  
- Acute Coronary Syndrome (ACS)  
- Coronary Artery Disease (CAD)  
- Chronic Coronary Disease (CCD)  
- Coronary Bypass Graft (CABG)  
- Left Main Coronary Artery Lesion  
- Bifurcation Lesion  
- Long Stent Length  
- Multileaf Lesion  
- Atherectomy  
- Chronic Occlusion  
- Aspirin (Low‑dose)  
- Clopidogrel  
- Ticagrelor  
- Prasugrel  
- P2Y12 Inhibitor  
- Platelet‑Activated Receptor‑1 (PAR‑1)  
- Vorapaxar (PAR‑1 antagonist)  
- Major Bleeding Complications  
- Major Adverse Cardiac Events (MACE)  
- Cardiovascular Death  
- Stroke (Cerebrovascular Event)  
- Diabetes Mellitus (as comorbidity)  
- Chronic Kidney Disease (CKD)  
- Clinical Trial (General)  
- ISAR‑SAFE Trial  
- HOST‑Exam Trial  
- SMART CHOICE Trial  
- STOP‑DAPT2 Trial  
- TWILIGHT Trial  
- GLOBAL LEADERS Trial  
- PEGASUS‑TIMI 54 Trial  
- TRAP 2P TIMI 50 Trial  
- Network Meta‑analysis  
- Systematic Review  
- Risk Stratification  
- Platelet Activation Pathways  

These terms capture the key concepts, therapies, conditions, and study references related to heart disease discussed in the provided text.

Page 45 Extracted Terms:
- Myocardial infarction (MI)  
- Ischemic stroke  
- Coronary artery disease (CAD)  
- Chronic coronary disease  
- Ischemic heart disease  
- Cardiovascular death  
- Stroke (including intracranial hemorrhage)  
- Intracranial hemorrhage  
- Bleeding (major, moderate, severe)  
- GUSTO moderate or severe bleeding  
- Thienopyridine  
- Vorapaxar  
- Clopidogrel  
- Aspirin  
- Dual antiplatelet therapy (DAPT)  
- Single antiplatelet therapy (SAPT)  
- Percutaneous coronary intervention (PCI)  
- Coronary artery bypass grafting (CABG)  
- Atherothrombotic events  
- Peripheral artery disease  
- Transient ischemic attack (TIA)  
- Revascularization  
- Coronary graft occlusion  
- Saphenous vein graft occlusion  
- Non‑steroidal anti‑inflammatory drugs (NSAIDs)  
- Coxibs  
- Diclofenac  
- Ibuprofen  
- Celecoxib  
- Naproxen  
- Heart failure (HF)  
- Carotid disease  
- Angina (stable and unstable)  
- Major coronary events  
- Vascular death  
- Cardiovascular risk  
- >50 % stenosis  
- History of stroke  
- History of TIA  
- Global Utilization of Streptokinase and Tissue Plasminogen Activator (GUSTO) classification  
- Prasugrel  

Page 46 Extracted Terms:
- Chronic Coronary Disease  
- Stable Coronary Artery Disease (CAD)  
- Acute Coronary Syndrome (ACS)  
- Percutaneous Coronary Intervention (PCI)  
- Coronary Stent  
- Stent Thrombosis  
- Coronary Thrombosis  
- Coronary Revascularization  
- Coronary Atherosclerosis  
- Atrial Fibrillation (AF)  
- Coronary Artery Bypass Grafting (CABG)  
- Myocardial Infarction (MI) / Heart Attack  
- Angina (Stable / Unstable)  
- Major Bleeding  
- Bleeding Risk  
- High Bleeding Risk  
- Non‑vitamin K Oral Anticoagulant (DOAC)  
- Apixaban  
- Rivaroxaban  
- Dabigatran  
- Edoxaban  
- Dual Antiplatelet Therapy (DAPT)  
- Triple Antithrombotic Therapy  
- Aspirin  
- P2Y12 Inhibitor (Clopidogrel, Ticagrelor, etc.)  
- Antithrombotic Regimen  
- Clinical Risk Factors  
- Lesion Complexity  
- Complex Coronary Lesion  
- Cardiovascular Risk Factors  
- Hypertension  
- Hyperlipidemia  
- Family History of Coronary Artery Disease  
- Smoking  
- Nonsteroidal Anti‑Inflammatory Drugs (NSAIDs)  
- Celecoxib  
- Rofecoxib  
- Etoricoxib  
- Lumiracoxib  
- Diclofenac  
- Ibuprofen  
- Naproxen  
- Vitamin K Antagonist (VKA)  
- Stroke  
- Systemic Embolism  
- Coronary Events (e.g., MI, unstable angina, revascularization)  
- Recurrent Coronary Events  
- Coronary Complications  
- Platelet Aggregation  
- Ischemic Risk  
- MACE (Major Adverse Cardiac Events)  

These terms capture the key clinical concepts, interventions, medications, and risk factors discussed in the guideline excerpt.

Page 47 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Acute Coronary Syndrome (ACS)  
- Atherosclerotic Cardiovascular Disease (ASCVD)  
- Coronary Artery Disease (CAD)  
- Multivessel CAD  
- Myocardial Infarction (MI)  
- Recurrent MI  
- Cardiovascular Death  
- Stroke  
- Ischemic Events  
- All‑cause Death  
- Major Bleeding  
- Major Adverse Cardiovascular Events (MACE)  
- Heart Failure (HF)  
- Left Ventricular Ejection Fraction (LVEF)  
- Preserved LVEF  
- Reduced LVEF (≤40%/≤50%)  
- β‑Blocker Therapy  
- Sustained‑release Metoprolol Succinate  
- Carvedilol  
- Bisoprolol  
- Dual Antiplatelet Therapy (DAPT)  
- Single Antiplatelet Therapy (SAPT)  
- Aspirin  
- Clopidogrel  
- P2Y12 Inhibitors  
- Rivaroxaban (low‑dose)  
- Low‑dose Aspirin  
- Rivaroxaban + Aspirin Combination  
- Periprocedural Antithrombotic Therapy  
- Peripheral Artery Disease (PAD)  
- Chronic Kidney Disease (CKD) / eGFR 15‑59 mL/min/ 2  
- Gastrointestinal Bleeding  
- Proton Pump Inhibitors (PPIs)  
- CYP2C19 Metabolism (clopidogrel activation)  
- AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline  
- COMPASS Trial  
- Efficacy and Safety of Anticoagulation Strategies  

These terms capture the core concepts and conditions related to heart disease discussed in the provided guideline text.

Page 48 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Heart Failure (HF) with LV systolic dysfunction  
- Left Ventricular Ejection Fraction (LVEF)  
- LV systolic dysfunction (LVEF ≤ 40%)  
- Mid‑range LVEF (40 – 49%)  
- Major Adverse Cardiovascular Events (MACE)  
- Cardiovascular death  
- Myocardial Infarction (MI) – previous and new  
- Ischemic heart disease (stable ischemic heart disease)  
- Stable angina  
- Percutaneous coronary intervention (PCI)  
- Coronary Artery Disease (CAD)  
- Beta‑blocker therapy  
  - Bisoprolol (CIBIS‑II)  
  - Carvedilol (COPERNICUS)  
  - Metoprolol succinate (MERIT‑HF)  
- Renin‑Angiotensin‑Aldosterone Inhibitors (RAASi)  
  - Angiotensin‑converting enzyme inhibitors (ACEi)  
  - Angiotensin‑II receptor blockers (ARBs)  
  - ACE‑intolerant indications  
- Hypertension  
- Diabetes mellitus  
- Chronic kidney disease (CKD)  
- Clinical trial and registry acronyms  
  - REBOOT‑CNIC  
  - REDUCE‑SWEDEHEART  
  - BETAMI  
  - DANBLOCK  
  - REACH (Reduction of Atherothrombosis for Continued Health)  
  - CHARISMA (Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance)  
- Antithrombotic therapy  
- Lipid‑lowering (statin) therapy  
- Quality of life (QOL) outcomes  
- Observational studies vs randomized controlled trials (RCTs)  
- Long‑term beta‑blocker use (> 1 year)  
- Clinical benefits and risks (fatigue, depression, drug–drug interactions)  
- Cardiovascular morbidity and mortality outcomes at 30 days, 3‑year follow‑up  

These terms capture the key heart‑disease concepts discussed in the guideline excerpt.

Page 49 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Heart Failure (HF)  
- Left Ventricular Ejection Fraction (LVEF)  
- Major Adverse Cardiovascular Events (MACE)  
- Renin–Angiotensin–Aldosterone System Inhibitors (RAASi)  
- Angiotensin‑Converting Enzyme Inhibitors (ACEi)  
- Angiotensin II Receptor Blockers (ARBs)  
- Hypertension  
- Diabetes Mellitus  
- Chronic Kidney Disease (CKD)  
- Blood Pressure (BP)  
- Lipid Management  
- Colchicine  
- Atherothrombotic Cardiovascular Disease (ASCVD)  
- Perindopril  
- Ramipril  
- Trandolapril  
- Quinapril  
- Amlodipine  
- Enalapril  
- COLCOT Trial  
- LoDoCo Trial  
- LoDoCo2 Trial  
- HOPE Trial  
- EUROPA Trial  
- PEACE Trial  
- CAMELOT Trial  
- IMAGINE Trial  
- AHA/ACC Chronic Coronary Disease Guideline  
- HFSA Heart Failure Guideline

Page 50 Extracted Terms:
- Chronic Coronary Disease  
- Atherosclerotic Cardiovascular Disease (ASCVD)  
- Acute Coronary Syndrome (ACS)  
- Myocardial Infarction (MI)  
- Coronary Artery Disease (CAD)  
- Ischemic Heart Disease  
- Heart Failure (HF)  
- Angina  
- Coronary Revascularization  
- Ischemic Stroke  
- Major Adverse Cardiovascular Events (MACE)  
- Cardiovascular Death  
- Cardiovascular Morbidity  
- Cardiovascular Mortality  
- Cardiovascular Outcomes  
- Vulnerable Atherosclerotic Plaques  
- Colchicine Therapy (colchicine)  
- Influenza Vaccination (as a preventive measure for cardiovascular risk)  
- COVID‑19 Vaccination (as a preventive measure for cardiovascular risk)  
- Pneumococcal Polysaccharide Vaccination (as a preventive measure for cardiovascular risk)

Page 51 Extracted Terms:
**Key heart‑disease related terms extracted from the text**

- Chronic Coronary Disease (CCD)  
- Angina pectoris / angina  
- Anti‑anginal therapy  
- Beta blocker  
- Calcium‑channel blocker (CCB)  
- Dihydropyridine CCB (e.g., amlodipine, nifedipine)  
- Non‑dihydropyridine CCB (verapamil, diltiazem)  
- Long‑acting nitrate (e.g., isosorbide dinitrate, nitroglycerin)  
- Sublingual nitroglycerin  
- Nitroglycerin spray  
- Ranolazine  
- Ivabradine  
- Left ventricular (LV) dysfunction / LV function  
- Myocardial oxygen demand  
- Myocardial arterial blood supply  
- Late sodium current (mechanism of ranolazine)  
- Myocardial ischemia  
- Myocardial infarction (MI)  
- Transient ischemic attack (TIA)  
- Stroke  
- Cardiovascular risk (high or very high)  
- Cardiac arrest  
- Mortality (all‑cause death)  
- Pneumococcal polysaccharide vaccine (PPV)  
- Influenza vaccine  
- PPSV23  
- PCV13 (pneumococcal conjugate vaccine)  
- Combined vaccination (PPV + influenza)  
- Exercise duration / exercise tolerance  
- Nitroglycerin consumption  
- Bradycardia  

These terms capture the diseases, therapeutic agents, physiological concepts, and outcome measures that are central to the clinical guidelines discussed.

Page 52 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Angina  
- Stable Angina  
- Refractory Angina  
- Ischemic Heart Disease  
- Coronary Revascularization  
- Enhanced External Counterpulsation (EECP)  
- Transmyocardial Laser Revascularization (TLR)  
- Ranolazine  
- Ivabradine  
- Amlodipine  
- Atenolol  
- Nitroglycerin  
- Short‑acting Nitrates  
- Nitroglycerin Spray  
- Sublingual Nitroglycerin  
- Cardiovascular Death  
- Myocardial Infarction (MI)  
- Exercise Capacity / Exercise Time  
- Anginal Episodes  
- Nitroglycerin Consumption  
- Resting Heart Rate  
- Disodium EDTA (Chelation Therapy)  
- AHA/ACC/ACCP/ASPC/NLA/PCNA Chronic Coronary Disease Guideline  
- Clinical Statement / Guideline Recommendation  

Page 53 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Coronary Artery Disease (CAD)  
- Myocardial Infarction (MI)  
- Angina  
- Coronary artery stenoses  
- Revascularization  
- Coronary Artery Bypass Grafting (CABG)  
- Percutaneous Coronary Intervention (PCI)  
- Fractional Flow Reserve (FFR)  
- Instantaneous Wave‑Free Ratio (iFR)  
- Left Ventricular (LV) dysfunction  
- Left Ventricular Ejection Fraction (LVEF)  
- Cardiovascular events  
- Cardiovascular death  
- Urgent revascularization  
- Coronary angiography  
- Heart Team approach  
- Coronary artery revascularization  
- Cardiac death  
- Non‑fatal events  
- Severe LV dysfunction (LVEF ≤ 35 %)  
- Complex three‑vessel disease  
- Diabetes (comorbidity)  
- Renal dysfunction (comorbidity)  
- Atherosclerotic burden  
- Guideline‑Directed Medical Therapy (GDMT)  
- Quality of Life (QOL)  
- Meta‑analyses  
- Clinical trials (e.g., TACT, TACT2)  
- Cardiovascular disease (general term)

Page 54 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Left ventricular dysfunction  
- Left ventricular ejection fraction (LVEF)  
- LVEF ≤ 35 %  
- Left main coronary disease  
- Coronary artery bypass grafting (CABG)  
- Percutaneous coronary intervention (PCI)  
- Glucose‑directed medical therapy (GDMT) / guideline‑directed medical therapy  
- Medical therapy alone  
- Ischemic cardiomyopathy  
- Heart failure (HF) secondary to coronary disease  
- Non‑fatal myocardial infarction (MI)  
- Unstable angina  
- Angina (baseline angina frequency)  
- Seattle Angina Questionnaire (SAQ)  
- Fractional Flow Reserve (FFR)  
- FFR‑guided PCI  
- STICH trial  
- ISCHEMIA trial  
- COURAGE trial  
- ORBITA trial  
- REVIVED‑BCIS 2 trial  
- AHA/ACC/ACCP/ASPC/NLA/PCNA chronic coronary disease guideline  
- Revascularization (surgical or catheter‑based)  
- Surgical revascularization  
- Catheter‑based revascularization  
- Ischemia burden  
- Mortality benefit of CABG over GDMT  
- MACE (major adverse cardiovascular events)  
- QALYs (quality‑adjusted life years)  
- Incremental cost‑effectiveness ratio (ICER)  
- Lifetime costs  
- Lifetime QALYs  
- Crossover rate in trials  
- Angiographic complexity  
- Optimal medical therapy (OMT)  
- Clinical events (non‑fatal MI, unstable angina, urgent revascularization)

Page 55 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Revascularization (including CABG and PCI)  
- Coronary artery bypass grafting (CABG)  
- Percutaneous coronary intervention (PCI)  
- Coronary artery disease (CAD)  
- Left main disease / left main CAD  
- Multi‑vessel disease  
- Severe coronary stenosis (≥70 %)  
- 3‑vessel disease  
- 2‑vessel disease with proximal left anterior descending artery  
- Cardiovascular death  
- Myocardial infarction (MI)  
  - Spontaneous MI (type 1)  
  - Demand‑induced MI (type 2)  
  - Procedural MI (type 4a)  
  - Stent‑related MI (type 4b)  
  - Restenosis‑related MI (type 4c)  
- Unstable angina  
- Procedural type 4a MI  
- Procedural type 4b MI  
- Procedural type 4c MI  
- Clinical events (cardiac death, MI, etc.)  
- ISCHEMIA trial  
- FAME‑2 trial  
- FFR‑guided PCI (fractional flow reserve ≤ 0.8)  
- iFR‑guided PCI (instantaneous wave‑free ratio > 0.89)  
- Non‑hyperemic pressure ratios  
- DES (drug‑eluting stents)  
- Angiography‑guided PCI  
- Angiographic severity (≥50 %)  
- MACE (major adverse cardiovascular events)  
- Acute versus chronic ischemia  
- ejection fraction  
- High‑risk clinical scenarios (comorbid conditions, social factors)  
- Heart Team (interventional cardiology, cardiac surgery, cardiovascular specialists)  
- GDMT (guideline‑directed medical therapy)  
- QALY (quality‑adjusted life year)  
- Incremental cost‑effectiveness ratio (ICER)  
- Economic evaluation of PCI vs. medical therapy  
- Network meta‑analysis  
- Survival advantage of PCI over medical therapy in left‑main CAD  
- Survival advantage of CABG over medical therapy in left‑main CAD  
- Stability of chronic coronary syndromes  
- Redirection of care to interventional strategies  
- Cardiovascular specialists  

*(All terms are extracted from the guideline text and pertain to diagnosis, treatment, outcomes, and health‑system decision‑making in heart disease.)*

Page 56 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Coronary Artery Bypass Grafting (CABG)  
- Percutaneous Coronary Intervention (PCI)  
- Left main coronary artery disease  
- High‑complexity coronary artery disease (CAD)  
- SYNTAX score (≥ 33 cutoff)  
- Multivessel coronary artery disease  
- Major Adverse Cardiovascular Events (MACE)  
- Survival benefit  
- Mortality (cardiac and all‑cause)  
- Ischemic myocardium  
- Ischemic insult  
- Spontaneous myocardial infarction (MI)  
- Repeat revascularization  
- Diabetic coronary artery disease  
- Left anterior descending artery (LAD) involvement  
- Left internal mammary artery (LIMA) graft  
- Heart Team decision making  
- Shared decision‐making process  
- Physical Component Summary (PCS)  
- Mental Component Summary (MCS)  
- Left ventricular (LV) dysfunction  
- Non‑viable myocardium  
- Frailty / immobility  
- Severe lung disease  
- Subclinical coronary anatomy complexity  
- De novo coronary lesions  
- Coronary artery protection strategy  
- Surgical risk stratification  
- Percutaneous revascularization registry data  
- Retrospective outcomes (10‑year follow‑up)  
- Randomized controlled trials (RCTs)  
- Pooled individual patient data analysis  
- Clinical evidence modifiers  
- Coronary artery disease risk modifiers  
- Revascularization strategy recommendations (CABG vs PCI)  
- Chronic stable ischemic heart disease guideline citations  
- AHA/ACC/ACCP/ASPC/NLA/PCNA Chronic Coronary Disease Guideline (2023)


Page 57 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Coronary Artery Disease (CAD)  
- Spontaneous Coronary Artery Dissection (SCAD)  
- Percutaneous Coronary Intervention (PCI)  
- Coronary Artery Bypass Graft (CABG)  
- Left Main Stenosis  
- Left Anterior Descending Artery (LAD)  
- Multivessel Disease  
- Triple‑Vessel Disease  
- Myocardial Infarction (MI)  
- Stroke  
- Dual Antiplatelet Therapy (DAPT)  
- Beta‑Blocker Therapy  
- Renin‑Angiotensin‑Aldosterone System Inhibitors (RAAS inhibitors)  
- Coronary Revascularization  
- Coronary Pathology  
- Ischemia  
- Ischemia with No Obstructive Coronary Artery Disease (INOCA)  
- Cardiovascular Disease (CVD)  
- Atherosclerotic Cardiovascular Disease (ASCVD)  
- Atherosclerosis  
- Coronary Intervention  
- Heart Failure  
- Left Ventricular Dysfunction  
- Surgical Ineligibility  
- Composite Primary Endpoint (Death, MI, Stroke)  
- FREEDOM Trial  
- EXCEL Trial  
- Meta‑analysis  
- Hazard Ratio  
- Confidence Interval  
- Coronary Stenting  
- Coronary Angiography  
- Coronary Anatomy  
- Angioplasty  
- Cardiac Rehabilitation (CR)  
- Vascular Pathology

Page 58 Extracted Terms:
- Spontaneous coronary artery dissection (SCAD)  
- Coronary artery disease (CAD)  
- Nonobstructive coronary arteries  
- Ischemia with nonobstructive coronary arteries (INOCA)  
- Angina  
- Quality of life (QOL)  
- Fibromuscular dysplasia  
- Cerebral aneurysm  
- Aortic aneurysm  
- Peripheral aneurysm  
- Aortic dissection  
- Peripheral dissection  
- Myocardial infarction  
- Stroke (cerebral ischemia)  
- Transient ischemic attack (TIA)  
- Hypertension (high blood pressure)  
- Familial hypercholesterolemia (FH)  
- Statin therapy  
- Beta‑blocker therapy  
- Dual antiplatelet therapy (DAPT)  
- Antiplatelet therapy  
- Oral anticoagulation  
- Coronary physiology testing  
- Recurrent SCAD  
- Vascular abnormalities (extracoronary)  
- Connective tissue disorders  
- Ehlers‑Danlos syndrome (vascular type)  
- Marfan syndrome  
- Loeys‑Dietz syndrome  
- Pulmonary hypertension (relevant for cardiovascular risk)  
- Coronary vasculopathy  
- Coronary arteriopathy  
- Coronary artery tortuosity  
- Cardiac valve abnormality  
- Aortic valve disease  
- Heart failure (as a potential outcome)  
- Cardiac remodeling (associated with ischemia)

Page 59 Extracted Terms:
- Coronary artery disease (CAD)  
- Nonobstructive coronary artery disease (nonobstructive CAD)  
- Ischemia without obstructive coronary artery disease (INOCA)  
- Myocardial ischemia  
- Coronary vasomotor dysfunction  
- Coronary microvascular dysfunction  
- Microvascular angina  
- Vasospastic angina  
- Coronary microvascular resistance  
- Index of microcirculatory resistance (IMR)  
- Fractional flow reserve (FFR)  
- Coronary flow reserve (CFR)  
- Coronary computed tomography angiography (CTA)  
- Coronary angiography  
- Acetylcholine testing  
- Calcium channel blockers  
- Nitrate‑responsive angina  
- Transient ischemic electrocardiographic changes  
- ST‑segment elevation  
- ST‑segment depression  
- Negative U waves  
- Coronary artery spasm  
- Provocative stimuli (acetylcholine, ergot)  
- Hyperventilation  
- Exercise tolerance / diurnal variation in exercise tolerance  
- Seattle Angina Questionnaire  
- EuroQoL (EQ‑5D‑5L)  
- Major adverse cardiovascular events (MACE)  
- Invasive coronary physiology testing  
- CorMicA trial (Coronary Microvascular Angina trial)  
- COVADIS diagnostic criteria (Coronary Vasomotion Disorders International Study Group)  
- Coronary slow flow phenomenon  
- TIMI frame count  
- Epicardial coronary obstruction  
- Coronary microvascular resistance indices  
- Electrocardiogram (ECG)

Page 60 Extracted Terms:
**Key Heart‑Disease Terms Extracted**

- Coronary artery disease (CAD)  
- Chronic coronary disease (CCD)  
- Heart failure (HF)  
- Heart failure with preserved ejection fraction (HFpEF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Valvular heart disease  
- Revascularization  
- Coronary microvascular dysfunction (CMD)  
- Microvascular angina (MVA)  
- Vasospastic angina (VSA)  
- Epicardial coronary artery spasm  
- Coronary flow reserve (CFR)  
- Index of microvascular resistance (IMR)  
- Fractional flow reserve (FFR)  
- Angina  
- Acetylcholine testing (coronary function testing)  
- Epicardial coronary diameter reduction  
- Coronary vasorelaxation  
- Coronary vasospasm  
- Coronary vasodilator capacity  
- Non‑obstructive CAD  
- Obstructive CAD (≥ 50 % diameter stenosis, FFR ≤ 0.80)  
- Microvascular resistance (high)  
- Coronary endothelial function  
- Coronary hemodynamics  
- Coronary artery diameter  
- Cardiovascular events prevention (therapeutic focus)  

(The above list focuses on clinical entities, diagnostic measures, and disease processes relevant to the guideline text.)

Page 61 Extracted Terms:
**Key terms related to heart disease**

- Chronic Coronary Disease (CCD)  
- Coronary Artery Disease (CAD)  
- Valvular heart disease  
- Severe aortic stenosis  
- Percutaneous coronary intervention (PCI)  
- Transcatheter aortic valve implantation (TAVI)  
- Dual antiplatelet therapy (DAPT)  
- Major adverse cardiovascular events (MACE)  
- Cardiovascular events  
- Cardiovascular morbidity  
- Quality‑adjusted life years (QALYs)  
- Hyperlipidemia  
- Low‑density lipoprotein cholesterol (LDL‑C)  
- Lipoprotein(a) (Lp(a))  
- Familial hypercholesterolemia (FH)  
- Statin therapy  
- Lipid screening (family members)  
- Hypertension  
- Diabetes mellitus  
- Obesity / Metabolic syndrome  
- Smoking / Vaping  
- Recreational substance use (cocaine, marijuana)  
- Unhealthy diet  
- Physical inactivity  
- Traditional cardiovascular risk factors  
- Non‑traditional risk factors  
- Human immunodeficiency virus (HIV)  
- Antiretroviral therapy (ART)  
- Systemic inflammatory disorders (IBD, SLE, RA, gout, psoriatic arthritis, ankylosing spondylitis)  
- Vasculitides  
- Pregnancy‑related complications (IUGR, hypertensive disorders of pregnancy, gestational diabetes)  
- Coronary anomalies  
- Kawasaki disease  
- Myocardial bridging  
- Secondary prevention strategies  
- Revascularization guidelines  
- Blood pressure management  
- Weight management  
- Diabetes management (SGLT‑2 inhibitors, GLP‑1 receptor agonists)  
- Nutrition and supplements  
- Physical activity  
- Tobacco products  
- Medication adherence  
- Health information technology tools  
- Social determinants of health  

These terms capture the spectrum of conditions, interventions, risk factors, and prevention strategies associated with heart disease as described in the guideline text.

Page 62 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Cardiovascular Disease (CVD)  
- Heart disease  
- Coronary artery disease  
- Coronary artery anomalies  
- Coronary vasospasm  
- Coronary artery aneurysm  
- Coronary artery stenosis  
- Coronary artery thrombosis  
- Coronary artery fistula  
- Kawasaki disease (coronary sequelae)  
- Myocardial bridging  
- Cardiac toxicity  
- Cardio‑oncology  
- Antiplatelet therapy  
- Antithrombotic therapy  
- Thromboprophylaxis  
- Apixaban  
- Rivaroxaban  
- Low‑molecular‑weight heparin  
- Beta‑adrenergic blocking agents  
- Exercise‑induced ischemia  
- Sudden cardiac death  
- Interarterial course of coronary artery  
- Anomalous left coronary artery from the pulmonary artery  
- Anomalous origin of the coronary artery from the opposite sinus of Valsalva  
- Surgical repair of coronary anomalies (e.g., translocation to the aortic root)  
- Surgical correction of interarterial coronary anomaly  
- Coronary vasospasm treatment  
- Myocardial ischemia  
- Cardiac dysfunction  
- Multidisciplinary cardio‑oncology team

Page 63 Extracted Terms:
- Chronic coronary disease (CCD)  
- Cardiovascular complications  
- Ischemic cardiovascular events  
- Adverse maternal and fetal outcomes  
- Adverse cardiac events  
- Maternal cardiac death  
- Cardiac arrest  
- Sustained arrhythmia requiring treatment  
- Left‑sided heart failure (HF) / pulmonary edema  
- Right‑sided heart failure  
- Stroke  
- Transient ischemic attack (TIA)  
- Cardiac thromboembolism  
- Myocardial infarction (MI)  
- Vascular dissection  
- Coronary artery disease (CAD)  
- Ventricular dysfunction  
- Mechanical valve  
- High‑risk left‑sided valve disease  
- Left‑ventricular outflow tract (LVOT) obstruction  
- Pulmonary hypertension  
- High‑risk aortopathy  
- NYHA functional class III‑IV  
- Cyanosis  
- Late pregnancy assessment  
- Cardiac intervention (e.g., surgery, catheterization)  
- CARPREG II risk prediction model / predictors  
- CARPREG II risk score  
- Pre‑eclampsia  
- Pre‑term delivery  
- Small for gestational age infant  
- Cardio‑obstetric care team  
- Cardio‑obstetrics  
- Statin use during pregnancy  
- Angiotensin‑converting enzyme (ACE) inhibitors  
- Angiotensin‑II receptor blockers (ARBs)  
- Direct renin inhibitors  
- Angiotensin receptor‑neprilysin inhibitors  
- Aldosterone antagonists  
- Estrogen‑only hormone regimens  
- Combined estrogen‑and‑progestin hormone regimens  
- Venous thromboembolism (VTE)  
- Systemic postmenopausal hormone therapy  
- Postmenopausal hormone therapy  
- MACE (major adverse cardiovascular events)  
- Multidisciplinary cardio‑obstetric care  
- Pregnancy outcomes in women with heart disease (CARPREG)  
- Cardiovascular risk stratification  

These terms capture the key heart‑disease–focused concepts, conditions, therapies, and risk factors discussed in the guideline excerpt.

Page 64 Extracted Terms:
**Key heart‑disease related terms extracted from the guideline text**

- Arrhythmias  
- Metoprolol  
- Propranolol  
- Digoxin  
- Lidocaine  
- Verapamil  
- Diltiazem  
- Procainamide  
- Sotalol  
- Flecainide  
- Propafenone  
- Amiodarone  
- Heart failure  
- Carvedilol  
- Furosemide  
- Bumetanide  
- Dopamine  
- Dobutamine  
- Norepinephrine  
- Hydralazine  
- Nitroglycerin  
- Isosorbide dinitrate  
- Torsemide  
- Metolazone  
- Warfarin  
- Unfractionated heparin  
- Enoxaparin  
- Fondaparinux  
- Argatroban  
- Bivalirudin  
- Aspirin (low dose)  
- Clopidogrel  
- Prasugrel  
- Ticagrelor  
- Alteplase  
- Streptokinase  
- Labetalol  
- Nifedipine  
- α‑Methyldopa  
- Nitroprusside  
- Amlodipine  
- Hydrochlorothiazide  
- Clonidine  
- Atenolol  
- ACE‑inhibitor class (e.g., captopril, benazepril, enalapril)  
- ARB class (e.g., losartan, valsartan)  
- Aldosterone antagonists  
- Statin class  
- Direct oral anticoagulants (DOACs)  
- Endothelin‑receptor antagonists (ERAs)  
- Cardio‑obstetrics team / multidisciplinary cardio‑obstetrics  
- Maternal‑fetal medicine / obstetric cardiology  
- Pregnancy  
- Lactation  
- Cardiovascular medication safety (pregnancy, lactation)  
- Pharmacokinetics in pregnancy (absorption, volume of distribution, protein binding, clearance, uteroplacental flow, fetal metabolism)  
- Cardiovascular risk factors  
- Cardiovascular complications of pregnancy  
- Monitoring and management of cardiovascular disease during labor, delivery, and postpartum.

Page 65 Extracted Terms:
**Key Terms Related to Heart Disease**

- Chronic Coronary Disease  
- Cardio‑Obstetrics (team‑based cardio‑obstetrics model of care)  
- Cardiac Disease  
- Cardiovascular Disease (CVD)  
- Congenital Heart Disease  
- CARPREG II (Cardiac Disease in Pregnancy study)  
- ZAHARA (Zwangerschap bij Aangeboren HARtAfwijking – Pregnancy in Women With Congenital Heart Disease) study  
- mWHO (modified World Health Organization) cardiac risk classification  
- Statin exposure (as a medication affecting cardiovascular risk)  

These terms capture the major heart‑disease concepts, conditions, and research frameworks mentioned in the provided text.

Page 66 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Coronary Artery Disease (CAD)  
- Myocardial Infarction (MI)  
- Acute MI  
- Coronary revascularization  
- Coronary angiography  
- Coronary artery bypass grafting (CABG)  
- Drug‑prescription antiplatelet therapy (DAPT)  
- Antithrombotic agents  
- Antiplatelet agents  
- ACE inhibitors  
- Angiotensin‑II receptor blockers (ARBs)  
- Direct renin inhibitors  
- Angiotensin‑receptor neprilysin inhibitors (ARNIs)  
- Aldosterone antagonists  
- Statins  
- Lipoprotein apheresis  
- Hormone therapy (estrogen, estrogen‑progesterin, oral contraceptives, hormonal contraceptives)  
- Venous thromboembolism (VTE)  
- Stroke  
- Angina pectoris  
- Cardiovascular death  
- Angiographic progression of disease  
- Saphenous vein grafts  
- Transwomen cardiovascular risk  
- Older‑adult heart disease risk  
- Geriatric 5‑Ms (related to cardiovascular outcomes: Mentation, Mobility, Medications, Multicomplexity)

Page 67 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Coronary Artery Disease (CAD)  
- Ischemia  
- Atherosclerosis  
- Revascularization  
- Percutaneous Coronary Intervention (PCI)  
- Coronary Artery Bypass Grafting (CABG)  
- Contrast‑induced Acute Kidney Injury (AKI)  
- Contrast‑induced nephropathy  
- Statins (high‑dose statins)  
- Antiretroviral Therapy (ART)  
- Lipid profile / dyslipidemia  
- Cardiovascular events (CVE)  
- Glucocorticoids (high‑dose)  
- Disease‑modifying anti‑rheumatic drugs (DMARDs)  
- Biologics / immune‑modulating therapies  
- Inflammation (and inflammatory markers)  
- Hydration (pre‑contrast)  
- Iodinated contrast agent  
- Radial access (for PCI)  
- Bicarbonate  
- N‑acetyl‑L‑cysteine (NAC)  
- Normal saline (for AKI prevention)  

These terms represent key concepts related to heart disease that appear in the provided guideline excerpt.

Page 68 Extracted Terms:
- Chronic Coronary Disease  
- Coronary Artery Disease (CAD)  
- Myocardial Infarction (MI)  
- Atherosclerosis  
- Atherosclerotic Cardiovascular Disease (ASCVD)  
- Cardiovascular Disease (CVD)  
- Cardiovascular risk  
- Lipid profile  
- Low‑density lipoprotein cholesterol (LDL‑C)  
- Low‑density lipoprotein (LDL)  
- High‑density lipoprotein cholesterol (HDL‑C)  
- High‑density lipoprotein (HDL)  
- Hypertriglyceridemia  
- Cholesterol management  
- Lipid levels  
- LDL‑C reduction  
- Cardiovascular risk profile  
- Cardiovascular events  
- Cardiovascular health risk discussion  

Page 69 Extracted Terms:
**Heart‑disease related terms extracted from the guideline text**

- Chronic Coronary Disease  
- Cardiac Allograft Vasculopathy  
- Heart Transplant  
- Major Adverse Cardiovascular Events (MACE)  
- Secondary prevention  
- Statins (e.g., simvastatin, pravastatin, simvastatin)  
- Aspirin  
- Revascularization  
- Coronary angiography  
- Intravascular ultrasound  
- High‑intensity interval training  
- Percutaneous coronary intervention (PCI)  
- Drug‑eluting stents (DES)  
- Coronary artery bypass grafting (CABG)  
- Retransplantation  
- Mycophenolate mofetil  
- Azathioprine  
- Calcineurin inhibitor  
- Proliferation‑signal inhibitor  
- Grade ≥ 2R rejection  
- Lipid management  
- Blood‑pressure management  
- Sodium‑glucose cotransporter‑2 inhibitors (SGLT2i)  
- Glucagon‑like peptide‑1 receptor agonists (GLP‑1 RA)  
- Cardiovascular events  
- Cardiovascular risk factors  
- Inflammation (as a cardiovascular risk factor)  
- Rheumatoid arthritis (inflammatory cardiovascular risk)  
- Methotrexate (cardiovascular risk modifier)  
- Biologic disease‑modifying antirheumatic drugs  
- Janus kinase inhibitors  
- Tumor necrosis factor inhibitors  
- Immunomodulators  
- Glucocorticoids  
- Prednisone  
- Triglyceride levels ≥ 500 mg/dL (cardiovascular risk)  
- Protease inhibitors (drug interaction impacting cardiovascular drugs)  
- Antiplatelet drugs (e.g., ticagrelor)  


These terms capture the core concepts, interventions, and risk factors related to heart disease as discussed in the provided guideline excerpt.

Page 70 Extracted Terms:
- Chronic Coronary Disease  
- Cardiac Allograft Vasculopathy  
- Cardiac Allograft Vasculopathy Progression  
- Coronary Artery Disease  
- Atherosclerotic Plaque Volume  
- Plaque Index  
- Intravascular Ultrasound  
- Statin Therapy  
- Low‑Intensity Statin  
- Moderate/High‑Intensity Statin  
- Aspirin Therapy  
- Revascularization  
- Percutaneous Coronary Intervention (PCI)  
- Coronary Artery Bypass Grafting (CABG)  
- Drug‑Eluting Stent (DES)  
- Everolimus‑Eluting Stents  
- In‑Stent Restenosis  
- Fractional Flow Reserve (FFR)  
- Index of Microcirculatory Resistance (IMR)  
- Immunosuppressive Drugs (Cyclosporine, Tacrolimus, Everolimus, Sirolimus)  
- Atorvastatin  
- Rosuvastatin  
- Pravastatin  
- Fluvastatin  
- Simvastatin  
- Lovastatin  
- Pitavastatin  
- Area Under the Curve (AUC)  
- Drug‑Drug Interaction  
- Mortality  
- Myocardial Infarction (MI)  
- Heart Failure (HF) Hospitalization  
- All‑Cause Death  
- Cardiac Allograft Vasculopathy‑Related Events  
- Graft Dysfunction  
- Discrete Lesions  
- Second‑Generation DES  
- Early (<2 Years) vs Late (>2 Years) Statin Initiation  
- Early (<1 Year) vs Late (>1 Year) Aspirin Initiation

Page 71 Extracted Terms:
**Key heart‑disease related terms extracted from the guideline text**

- Chronic Coronary Disease (CCD)  
- Acute Coronary Syndrome (ACS)  
- Coronary revascularization  
- Telehealth programs  
- Lifestyle interventions (e.g., Hartcoach, Proactive Heart, MoodCare)  
- Cardiovascular risk factors  
- Guideline‑Directed Medical Therapy (GDMT)  
- Coronary Computed Tomography Angiography (CTA)  
- Stress testing (with or without imaging)  
- Left ventricular (LV) function assessment  
- Invasive coronary angiography  
- Major adverse cardiovascular events (MACE)  
- 12‑lead electrocardiogram (ECG)  
- Angina  
- Functional capacity  
- Cardiac rehabilitation (CR)  
- ISCHEMIA trial (stable CAD, ischemia)  
- Stable coronary artery disease (CAD)  
- Ischemia  
- Clinical follow‑up plan and testing  
- Risk‑factor modification  
- Shared decision‑making (among cardiology, primary, and specialty teams)  
- Patient education and social determinants of health (contextual factors influencing care)

Page 72 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Coronary Artery Disease (CAD)  
- Cardiovascular Disease (CVD)  
- Left Ventricular Function  
- Left Ventricular Ejection Fraction (LVEF)  
- Major Adverse Cardiovascular Events (MACE)  
- Anginal Symptoms  
- Silent Ischemia  
- Cardiovascular Death  
- Myocardial Infarction (MI)  
- Percutaneous Coronary Intervention (PCI)  
- Coronary Artery Bypass Grafting (CABG)  
- Invasive Coronary Angiography  
- Revascularization  
- Routine Follow‑up Coronary Angiography  
- Routine Functional Stress Testing  
- Exercise ECG  
- Nuclear Myocardial Perfusion Imaging  
- Stress Echocardiography  
- ISCHEMIA Trial  
- Unstable Angina  
- Composite Endpoint (Death, MI, Hospitalization)  
- Post‑PCI  
- Diabetes (in the context of cardiac care)  
- High‑Risk Patients  
- Nonischemic Intermediate Lesions  
- Cost‑Related Medication Non‑Adherence  
- Out‑of‑Pocket Costs  
- SGLT2 Inhibitors  
- Lipid Management  
- High‑Cost Therapies  
- Shared Decision‑Making  
- Cost‑Effectiveness  



Page 73 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Major Adverse Cardiovascular Events (MACE)  
- Noninvasive imaging  
- Calcified plaque burden  
- Non‑calcified plaque burden  
- Atherosclerosis  
- Risk scores (comprehensive, contemporary)  
- Patient demographics  
- Social determinants of health  
- Patient‑reported measures  
- Patient‑centered outcomes  
- Shared decision‑making  
- Decision aids  
- Guideline‑Directed Medical Therapy (GDMT)  
- Sequencing GDMT  
- Antiplatelet regimen  
- Antithrombotic strategy  
- Atrial fibrillation  
- Refractory angina  
- Neuro‑modulation  
- Thoracic spinal‑cord stimulation  
- Therapeutic angiogenesis  
- Cell/gene therapies  
- Coronary sinus occlusion  
- Shockwave therapy  
- Hybrid cardiac rehabilitation (CR)  
- Home‑based cardiac rehabilitation  
- Mental health (depression)  
- E‑cigarette use  
- GLP‑1 receptor agonists  
- SGLT2 inhibitors  
- Clinical estimation of symptoms  
- Cost‑saving approaches (mail order pharmacy, patient assistance programs)  
- Artificial intelligence  
- Text messaging  
- Wearable technology  
- Genomics  
- Proteomics  
- Spontaneous coronary artery dissection (SCAD)  
- Vasculopathy screening  
- Climate‑change‑related cardiovascular impact  
- Percutaneous coronary intervention (PCI)  
- Myocardial infarction (MI)  
- Cardiovascular prevention measures  

Page 74 Extracted Terms:
- Chronic Coronary Disease (CCD)  
- Cardiovascular events  
- Cardiovascular outcomes  
- Preventive strategies (e.g., indoor air purifiers, N95 masks)  
- Wildfire smoke exposure  
- Extreme heat exposure  
- Social Determinants of Health (SDOH)  
- Electronic health records (EHR)  
- Patient out‑of‑pocket costs  
- Guideline‑Directed Medical Therapy (GDMT)  
- Hemodialysis patients with coronary disease  
- Guideline implementation in clinical practice  
- Clinical practice guidelines (ACC/AHA/ACCP/ASPC/NLA/PCNA)  
- Atherosclerotic cardiovascular disease (implicit in chronic coronary disease)

Page 75 Extracted Terms:
- Chronic Coronary Disease  
- Stable Ischemic Heart Disease  
- Unstable Angina  
- Non‑ST‑elevation Myocardial Infarction (NSTEMI)  
- ST‑elevation Myocardial Infarction (STEMI)  
- Coronary Artery Revascularization  
- Coronary Artery Disease  
- Chest Pain Evaluation  
- Primary Prevention of Cardiovascular Disease  
- Secondary Prevention of Atherosclerotic Vascular Disease  
- Management of Blood Cholesterol  
- Dual Antiplatelet Therapy Duration  
- Ventricular Arrhythmias  
- Sudden Cardiac Death Prevention  
- Hypertension (High Blood Pressure)  
- Atrial Fibrillation Management  
- Valvular Heart Disease  
- Cardiovascular Disease  
- Myocardial Infarction  
- Angina  
- Chronic Coronary Disease Guideline

Page 76 Extracted Terms:
- Heart disease  
- Coronary artery disease  
- Acute coronary syndrome  
- Stable ischemic heart disease  
- Heart failure  
- Hypertension  
- Atherosclerotic cardiovascular disease (ASCVD)  
- Atrial fibrillation  
- Venous thromboembolism  
- Percutaneous coronary intervention (PCI)  
- Cardiac rehabilitation  
- Secondary prevention  
- Spontaneous coronary artery dissection  
- Cardio‑oncology drug interactions  
- Statins  
- Novel cardiovascular risk‑reduction therapies  
- Hypertriglyceridemia  
- Tobacco cessation treatment  
- Cardiac stress imaging  
- Left ventricular function  
- Ischemic burden  
- Ischemia  
- Myocardial scar  
- Diabetes mellitus type 2 (in relation to coronary disease)  
- Cardiovascular health (Life’s Essential 8)  
- Stroke (as a major cardiovascular outcome)

Page 77 Extracted Terms:
**Key heart‑disease terms extracted from the guidelines and cited studies**

1. Coronary artery disease (CAD)  
2. Stable ischemic heart disease  
3. Coronary artery disease progression  
4. Stent implantation (drug‑eluting stent, bare‑metal stent)  
5. Target‑vessel ischemia  
6. Myocardial perfusion imaging (MPI)  
7. Single‑photon emission computed tomography (SPECT)  
8. Positron emission tomography (PET)  
9. Positron emission tomography‑based myocardial perfusion imaging  
10. Stress myocardial perfusion imaging  
11. Cardiac magnetic resonance (CMR) perfusion imaging  
12. Vasodilator stress cardiac magnetic resonance  
13. Fractional flow reserve (FFR)  
14. Coronary computed tomography angiography (CTA)  
15. Coronary flow reserve (CFR)  
16. Coronary angiography (invasive)  
17. Coronary CT angiography‑derived FFR (CT‑FFR)  
18. Exercise treadmill test (ETT)  
19. Dobutamine stress echocardiography (SE)  
20. Percutaneous coronary intervention (PCI)  
21. Coronary artery bypass graft (CABG) surgery  
22. Revascularization (early, routine, optimal)  
23. Optimal medical therapy (OMT)  
24. Anginal symptom burden  
25. Functional capacity (e.g., exercise capacity, peak VO₂)  
26. Health‑status outcomes (quality of life, angina relief)  
27. Cardiac hospitalizations & readmissions  
28. Sex/gender differences (female vs. male ischemia, outcomes)  
29. Hybrid imaging (PET/SPECT with CT, MRI)  
30. Prognostic risk scores (e.g., SYNTAX score, ISCHEMIA, Heart Team decision tools)  
31. Blood‑flow metrics (global and regional myocardial blood flow, perfusion reserve)  
32. Myocardial scar / late‑gadolinium enhancement  
33. Rest‑ventricular ejection fraction (LVEF)  
34. Coronary artery disease risk stratification  
35. Therapeutic benefit prediction (for revascularization vs. medical therapy)  
36. Diabetes‑related CAD management (BARI‑2D, type‑2 diabetes interventions)  
37. Advanced kidney disease in CAD context  
38. Artificial intelligence‑based perfusion mapping  
39. Heart team multidisciplinary decision making  

These terms capture the clinical concepts, diagnostic modalities, therapeutic strategies, risk stratification tools, and patient populations discussed in the provided text.

Page 78 Extracted Terms:
**Key heart‑disease related terms extracted from the document**

- AHA/ACC/ACCP/ASPC/NLA/PCNA Chronic Coronary Disease Guideline  
- 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Chronic Coronary Disease Guideline  
- Coronary artery disease (CAD)  
- Stable coronary disease  
- Unstable angina  
- Ischemic heart disease (IHD)  
- Coronary ischemia  
- Myocardial ischemia  
- Microvascular dysfunction  
- Coronary microvascular dysfunction  
- Coronary flow reserve (CFR)  
- Fractional flow reserve (FFR)  
- FFR derived from computed tomography angiography (FFR‑CT)  
- Percutaneous coronary intervention (PCI)  
- Coronary bypass graft surgery (CABG)  
- Bypass graft surgery  
- Coronary angiography  
- Stress myocardial perfusion imaging  
- Myocardial perfusion single‑photon emission computed tomography (SPECT)  
- Positron emission tomography (PET) – myocardial perfusion  
- Rubidium‑82 PET imaging  
- Technetium‑99m sestamibi SPECT  
- Exercise treadmill test (ETT)  
- Exercise stress echocardiography  
- Stress cardiac magnetic resonance (CMR)  
- Vasodilator stress CMR  
- Adenosine stress myocardial perfusion scintigraphy  
- Prognostic value  
- Risk stratification  
- Prognostic score  
- Predictive model for long‑term survival  
- Clinical outcomes  
- Long‑term survival  
- Cardiovascular mortality  
- Cardiac events  
- Left ventricular ejection fraction (LVEF)  
- Left ventricular dysfunction  
- Global longitudinal strain (GLS) – implied by LV function tests  
- Exercise capacity  
- Ischemia severity  
- Scar burden  
- Transient ischemic dilation ratio  
- PROMISE minimal‑risk tool  
- ISCHEMIA trial results  
- BARI 2D trial results  
- Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D)  
- ISCHEMIA trial  
- Coronary risk factors  
- Women‑specific ischemia risk  
- Gender‑related differences in imaging limits  
- Diabetes mellitus—impact on ischemia prognosis  

These terms capture the central concepts, diagnostic tools, interventions, prognostic metrics, and guideline references related to heart disease that appear throughout the provided text.

Page 79 Extracted Terms:
- Coronary artery disease  
- Stable coronary disease  
- Coronary disease (general)  
- Angina  
- Chronic angina  
- Stable ischemic heart disease  
- Myocardial ischemia  
- Myocardial infarction  
- Acute coronary syndrome  
- ST‑segment elevation myocardial infarction (STEMI)  
- Non‑ST‑segment elevation myocardial infarction (NSTEMI)  
- Coronary calcium score / coronary calcification  
- Coronary plaque  
- High‑risk plaque  
- Low‑attenuation plaque  
- Coronary computed tomography angiography (CCTA)  
- Coronary CT  
- Coronary magnetic resonance imaging (CMR)  
- Positron emission tomography (PET)  
- Myocardial perfusion imaging (MPI)  
- Stress perfusion imaging  
- Adenosine stress perfusion  
- Coronary flow reserve (CFR)  
- Percutaneous coronary intervention (PCI)  
- Coronary revascularization  
- Coronary artery bypass graft (CABG)  
- Invasive strategy  
- Conservative strategy  
- Anti‑anginal drugs (e.g., β‑blockers, nitrates, ranolazine, nifedipine)  
- β‑blocker therapy  
- Nifedipine (long‑acting)  
- Ranolazine therapy  
- Statin therapy  
- Lipid management  
- Low‑density lipoprotein (LDL) cholesterol  
- LDL testing / monitoring  
- Cholesterol endpoints  
- Atherosclerotic cardiovascular event  
- Heart failure  
- Left ventricular dysfunction  
- Dilated cardiomyopathy  
- Angina prevalence  
- Angina under‑recognition  
- Angina quality of life  
- Depression / depressive symptoms  
- Health‑related quality of life (HRQoL)  
- Quality of life (QoL)  
- Mortality  
- Morbidity  
- Prognostic value  
- Risk stratification  
- Risk factor management  
- Pharmacologic therapy  
- Medical therapy  
- Cardiovascular outcomes  
- Clinical guideline  
- Imaging modalities (CT, CMR, PET, MPI)  
- Coronary artery disease management  
- Coronary angiogram  
- Clinical statement  
- 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Chronic Coronary Disease Guideline  
- PROMISE trial  
- SCOT‑HEART trial  
- COURAGE trial  
- MERLIN‑TIMI 36 trial  
- ACTION trial  
- FAME (referenced in other literature)  
- ESP‑CAD trial  
- EUROASPIRE IV survey  
- ORBITA medication‑adherence sub‑study  
- Health literacy  
- Health education  
- Telehealth medication adherence  
- Patient‑reported outcomes  
- Physician‑estimated outcomes  
- Angina prevalence and provider evaluation (APPEAR) study  
- Health‑benefit outcomes study  
- Long‑term prognosis after myocardial infarction  
- Registry data  
- Multi‑center clinical studies  
- Diagnostic accuracy studies  
- Outcome studies  
- Prognosis studies  
- Efficacy studies  
- Randomized controlled trials (RCTs)  
- Clinical outcomes studies  
- Observational cohort studies  
- Patient registry studies  
- Quality improvement metrics  

*(All terms are those found explicitly or implicitly within the provided guideline text and directly relate to heart disease, its diagnosis, management, outcomes, and studies.)*

Page 80 Extracted Terms:
- Coronary artery bypass graft (CABG)  
- Coronary artery bypass surgery  
- Acute coronary syndromes (ACS)  
- Angina  
- Seattle Angina Questionnaire  
- Coronary heart disease  
- Systolic heart failure  
- Chronic heart failure  
- Hypertension  
- Hyperlipidemia  
- Lipid management  
- Type 2 diabetes mellitus  
- Diabetes mellitus  
- Cardiovascular risk  
- Cardiovascular disease (CVD)  
- Cardiovascular disease prevention  
- Cardiovascular risk management  
- Team‑based care  
- Pharmacist‑led interventions  
- Nurse‑led interventions  
- Multidisciplinary risk assessment and management  
- Multidisciplinary care program  
- Shared decision making  
- Patient education  
- Lifestyle disease prevention  
- Blood‑pressure control  
- Cardiovascular event prevention  
- Secondary prevention of heart failure  
- Remote algorithm‑based cardiovascular risk management  
- Digital care transformation in cardiovascular health  
- Clinical outcomes in cardiac patients  
- Quality of life in cardiac care  
- Cost‑effectiveness of collaborative care in cardiology  
- Blood‑pressure management in diabetes  
- Cardiovascular health promotion  

---

Page 81 Extracted Terms:
**Key terms related to heart disease**

- Coronary heart disease  
- Coronary artery disease  
- Chronic coronary disease  
- Myocardial infarction (MI)  
- Heart failure  
- Cardiac arrest  
- Cardiovascular disease (CVD)  
- Cardiovascular outcomes  
- Cardiovascular risk  
- Cardiovascular screening  
- Atherosclerosis  
- Ischemic heart disease  
- Angina  
- Percutaneous coronary intervention (PCI)  
- Coronary artery bypass grafting (CABG)  
- Beta‑blocker therapy  
- Medication adherence  
- Health literacy  
- Shared decision making  
- Decision aids  
- Framingham risk score  
- Social determinants of cardiovascular disease  
- Cardiovascular team‑based care  
- Cardiovascular prevention (primary & secondary)  
- Cardiac rehabilitation  
- Cardiovascular health equity  
- Community health workers in cardiovascular screening  
- ENRICHD trial  
- SWEDEHEART registry  
- AHA/ACC/ACCP/ASPC/NLA/PCNA chronic coronary disease guideline  
- ACC/AHA guideline on primary prevention of cardiovascular disease  
- American Heart Association impact goal  
- Cardiovascular risk assessment  

These terms capture the core biomedical, clinical, and health‑systems concepts discussed in the provided guideline and related literature.

Page 82 Extracted Terms:
**Key terms related to heart disease**

- Chronic coronary disease  
- Myocardial infarction (MI)  
- Acute myocardial infarction  
- ST‑segment elevation myocardial infarction (STEMI)  
- Coronary artery disease (CAD)  
- Coronary ischemia / suspected coronary disease  
- Coronary heart disease  
- Cardiovascular disease (CVD)  
- Cardiovascular complications  
- Cardiovascular events  
- Cardiovascular outcomes  
- Cardiac rehabilitation  
- Cardiac rehabilitation attendance / completion / access  
- Cardiometabolic risk factors  
- Blood pressure (hypertension)  
- Dietary sodium and potassium intake/excretion  
- Dietary fiber intake  
- Saturated fat intake  
- Trans fat intake  
- Omega‑3 fatty acids (n‑3 fatty acids)  
- Vitamin D supplementation  
- Vitamin E supplementation  
- Vitamin C & E supplementation (antioxidants)  
- Calcium/vitamin D supplementation  
- Multivitamin‑mineral supplementation  
- Beta‑carotene supplementation  
- Mediterranean‑style diet (primary & secondary prevention of CVD)  
- DASH diet (Dietary Approaches to Stop Hypertension)  
- Dietary fat intake (total, saturated, trans)  
- Nutrient‑related risk of cardiovascular disease  
- Dietary supplement use and cardiovascular risk  

These terms represent the main diseases, interventions, and modifiable risk factors pertaining to heart disease as highlighted in the provided guideline excerpts.

Page 83 Extracted Terms:
- Chronic Coronary Disease  
- Chronic Coronary Syndromes  
- Chronic Stable Angina  
- Coronary Artery Disease (CAD)  
- Acute Coronary Syndrome (ACS)  
- Acute Myocardial Infarction  
- Myocardial Infarction  
- Atherosclerotic Cardiovascular Disease  
- Coronary Heart Disease  
- Cardiovascular Disease  
- Cardiovascular Risk  
- Cardiovascular Outcomes  
- Cardiovascular Health  
- Cardio‑protective Diet  
- Cardio‑vascular Outcomes  
- Cardiovascular Mortality  
- Cardiovascular Events  
- Cardiometabolic Disease (as a risk factor)  
- Coronary Microcirculation (in the context of coronary pathophysiology)

Page 84 Extracted Terms:
- Coronary heart disease  
- Coronary artery disease  
- Acute coronary syndrome  
- Myocardial infarction (heart attack)  
- Ischemic heart disease  
- Atherosclerosis  
- Cardiovascular disease  
- Cardiovascular events  
- Cardiovascular outcomes  
- Cardiovascular risk  
- Cardiac rehabilitation  
- Hypertension  
- Depression  
- Anxiety  
- Stress (psychological stress)  
- Smoking / tobacco use  
- Nicotine  
- Electronic cigarettes (e‑cigarettes)  
- Passive smoking (second‑hand smoke)  
- Smoking cessation  
- Life’s Simple 7 (cardiovascular metrics)

Page 85 Extracted Terms:
**Key terms related to heart disease extracted from the text**

- Cardiovascular disease  
- Coronary heart disease (CHD)  
- Chronic coronary disease  
- Myocardial infarction (MI) / acute myocardial infarction  
- Ischemic heart disease  
- Heart disease  
- Coronary artery disease (CAD)  
- Cardiovascular events  
- Cardiovascular risk factors  
- Cardiovascular outcomes  
- Cardiovascular mortality  
- Cardiovascular safety  
- Cardiovascular toxicity  
- Cardiovascular effects  
- Arterial stiffness  
- Oxidative stress  
- Endothelial dysfunction  

**Behaviours / exposures**

- Tobacco smoking  
- Cigarette smoking  
- Second‑hand smoke (passive smoking)  
- Electronic cigarettes (e‑cigarettes)  
- Vaping / electronic nicotine‑delivery devices  
- Use of smokeless tobacco (e.g., snus, snuff)  
- Smoking cessation  
- Nicotine replacement therapy (patch, gum, lozenge)  
- Varenicline (partial nicotine agonist)  
- Bupropion (nicotine replacement)  

**Substance use**

- Alcohol use / alcohol consumption  
- High‑risk drinking  
- Binge drinking  
- Marijuana / cannabis / medical marijuana  
- Cocaine  
- Opioid use (including opioid‑associated out‑of‑hospital cardiac arrest)  

**Clinical conditions / syndromes**

- Acute coronary syndrome  
- Myocardial infarction after alcohol binge  
- Cardiovascular effects of cocaine  
- Cardiovascular effects of opioid use  
- Cardiovascular effects of marijuana  
- Cardiovascular effects of electronic nicotine‑delivery  
- Cardiovascular effects of second‑hand smoke  

**Interventions / policies**

- Tobacco cessation interventions  
- Pharmacological smoking cessation therapies (nicotine patch, varenicline, bupropion)  
- Behavioral support for smoking cessation  
- Expert consensus decision pathways for tobacco cessation  
- Cardiovascular safety of nicotine replacement in patients with CAD  

**Study / evidence descriptors**

- Systematic review  
- Meta‑analysis  
- Randomized controlled trial (RCT)  
- Cohort study  
- Prospective observational study  
- Retrospective analysis  

These terms capture the core concepts of heart (cardiovascular) disease, its risk factors, clinical manifestations, and related interventions as presented in the provided guideline text.

Page 86 Extracted Terms:
- Atherosclerotic cardiovascular disease (ASCVD)  
- Coronary heart disease (CHD) / Coronary artery disease (CAD)  
- Myocardial infarction (MI)  
- Acute coronary syndrome (ACS)  
- ST‑segment elevation myocardial infarction (STEMI)  
- Non‑ST‑segment elevation myocardial infarction (NSTEMI)  
- Cocaine‑associated myocardial infarction  
- Coronary artery bypass grafting (CABG)  
- Percutaneous transluminal angioplasty (PTCA)  
- Lipid‑lowering therapy (statins, ezetimibe, PCSK9 inhibitors)  
- Statin therapy  
- PCSK9 inhibitor therapy (alirocumab, evolocumab)  
- LDL‑cholesterol (LDL‑C) management  
- Hypercholesterolemia / Familial hypercholesterolemia  
- Lipid monitoring / lipid testing  
- Secondary prevention of coronary disease  
- Cardiovascular events (e.g., death, stroke, MI)  
- Cardiac rehabilitation (CR)  
- Sexual activity–related cardiovascular risk  
- Erectile dysfunction (in cardiovascular patients)  
- Hypertension (as a cardiovascular comorbidity)  
- Platelet activation (in drug‑induced cardiac events)

Page 87 Extracted Terms:
- Chronic coronary disease  
- Coronary artery disease  
- Acute coronary syndrome  
- Myocardial infarction  
- Peripheral artery disease  
- Atherosclerotic cardiovascular disease (ASCVD)  
- Familial hypercholesterolemia  
- Low‑density lipoprotein cholesterol (LDL‑C)  
- High‑density lipoprotein cholesterol (HDL‑C)  
- Hypertriglyceridemia  
- Lipoprotein(a)  
- Oxidized low‑density lipoprotein  
- Cardiovascular risk reduction  
- Statin therapy  
- Statin intolerance  
- Statin‑associated muscle symptoms (SAMS)  
- PCSK9 inhibitors (evolocumab, alirocumab)  
- Ezetimibe (not explicitly cited but related to LDL‑C lowering)  
- Icosapent ethyl (EPA)  
- Bempedoic acid  
- Inclisiran  
- Niacin (with or without laropiprant)  
- B vitamins and omega‑3 fatty acids (cardiovascular effects)  
- Blood‑pressure management (hypertension)  
- Weight loss, sodium reduction, dietary patterns (DASH)  
- Exercise training for blood‑pressure control  
- Alcohol consumption reduction  
- Lipid‑profiling methods (Friedewald formula, direct LDL measurement)  
- ACC/AHA/ACC/ACCP/ASPC/NLA/PCNA guideline  
- AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on cholesterol  
- ACC/AHA hypertension guideline  
- National Lipid Association expert panel on familial hypercholesterolemia  
- FDA‑approved lipid‑lowering drugs  

*(All terms are directly related to heart‑disease pathology, prevention, diagnosis, or treatment as referenced in the cited guidelines and trials.)*

Page 88 Extracted Terms:
- Chronic Coronary Disease  
- AHA/ACC/ACCP/ASPC/NLA/PCNA Chronic Coronary Disease Guideline  
- DASH (Dietary Approaches to Stop Hypertension) diet / DASH eating plan  
- Blood pressure (high, systolic, diastolic)  
- Intensive blood‑pressure control  
- SPRINT trial (Subpopulation)  
- Perindopril (ACE inhibitor)  
- Ramipril (ACE inhibitor)  
- Angiotensin‑converting‑enzyme inhibitor  
- Angina (stable angina)  
- Coronary artery disease (CAD)  
- Myocardial infarction (MI)  
- Acute myocardial infarction  
- Beta‑blocker / β‑adrenergic antagonist (metoprolol, atenolol, isoproterenol)  
- Beta‑blockade after myocardial infarction  
- Hypertension (arterial hypertension)  
- Primary and secondary prevention of cardiovascular disease  
- Atherosclerotic vascular disease  
- Stable ischemic heart disease (SIHD)  
- Cardiac events (coronary events)  
- Cardiovascular outcomes / cardiovascular morbidity / mortality  
- Cardiac outcomes in diabetes (type 2)  
- High cardiovascular risk  
- Sodium intake / low‑sodium diet  
- Heart failure (HF)  
- Sodium‑glucose cotransporter‑2 (SGLT2) inhibitors (empagliflozin, canagliflozin, dapagliflozin, ertugliflozin)  
- Glucagon‑like peptide‑1 (GLP‑1) receptor agonists (liraglutide)  
- EMPA‑REG OUTCOME trial  
- CANVAS Program (canagliflozin)  
- DAPA‑HF (dapagliflozin)  
- CVD‑REAL Study  
- Lifestyle interventions for blood‑pressure control (aerobic exercise, isometric training, potassium supplementation)  
- Meta‑analysis of randomised controlled trials concerning cardiovascular risk  
- 2017 ACC/AHA/HF guideline for systolic blood‑pressure management in hypertension  
- 2013 ESH/ESC guideline for arterial hypertension  
- 2014 ACC/AHA/SCAI/STS guideline for stable ischemic heart disease  
- 2015 ACCF/AHA/HF statement on hypertension in patients with coronary artery disease  
- 2016 NHLBI guidance on DASH eating plan  
- Sodium‑glucose cotransporter‑2 inhibitor benefits in heart failure and mortality  
- GLP‑1 receptor agonist cardiovascular outcome trials  
- Hypertension management in elderly/elderly consensus documents  
- Isometric exercise training for blood‑pressure management  
- Dietary sodium reduction trials (e.g., 2001 N Engl J Med study)  
- Blood‑pressure lowering drugs (β‑blockers, ACE inhibitors, calcium antagonists, diuretics)  
- Cardiovascular mortality and vascular mortality risk with blood pressure changes.

Page 89 Extracted Terms:
Heart Failure  
Heart Failure with Reduced Ejection Fraction  
Heart Failure with Preserved Ejection Fraction  
Heart Failure with Mildly Reduced Ejection Fraction  
Reduced Ejection Fraction  
Preserved Ejection Fraction  
Acute Coronary Syndrome  
Myocardial Infarction  
Reperfusion Injury  
Cardiovascular Outcomes  
Cardiovascular Events  
Cardiovascular Death  
Mortality  
Chronic Coronary Disease  
Ejection Fraction  

Page 90 Extracted Terms:
Chronic Coronary Disease; Coronary Heart Disease; Cardiovascular Disease; Myocardial Infarction; Heart Failure; Atherosclerosis; Coronary Artery Disease; Coronary Stenosis; Cardiovascular Outcomes; Major Adverse Cardiovascular Events; Metabolic Syndrome; Obesity; Central Obesity; Waist Circumference; Body Mass Index; Type 2 Diabetes; Metabolic Surgery; Bariatric Surgery; Liposuction; Cardiac Rehabilitation; Exercise‑Based Rehabilitation; High‑Intensity Interval Training; Cardiac Allograft Vasculopathy; Atrial Fibrillation; Coronary Calcium Score; Coronary Angiography; Cardiac CT; Cardiovascular Risk Factors; Cardiovascular Mortality; Cardiovascular Morbidity; Coronary Lesion; Coronary Disease Management; Cardiac Exercise Capacity; Cardiovascular Exercise Tolerance; Cardiovascular Risk Assessment; Cardiovascular Disease Prevention; Coronary Heart Disease Prevention.

Page 91 Extracted Terms:
- Cardiac Rehabilitation  
- Heart Failure  
- Coronary Artery Disease  
- Myocardial Infarction  
- Stable Angina  
- Spontaneous Coronary Artery Dissection  
- Heart Transplant  
- Cardiac Allograft Vasculopathy  
- Cardiovascular Disease  
- High‑Intensity Interval Training (HIT)  
- Resistance Training  
- Exercise‑Based Therapy  
- Telehealth Interventions  
- Physical Activity  
- Medication Adherence  
- Cardiovascular Risk Factors  
- Blood Pressure  
- Mortality  
- Long‑Term Survival  
- Readmissions  
- Health Service Expenditures  
- Cost‑Effectiveness  
- Secondary Prevention  
- Risk‑Factor Control  
- Exercise Training  
- Percutaneous Coronary Angioplasty  
- Population‑Based Study  
- Randomized Controlled Trial  
- Systematic Review  
- Meta‑Analysis  
- Clinical Guidelines  
- AHA/ACC/ACC/ASPC/NLA/PCNA Chronic Coronary Disease Guideline  
- 2022 AHA/ACC/HFSA Guideline for Heart Failure Management  

(Note: Each term is a key concept related to heart disease extracted from the provided text.)

Page 92 Extracted Terms:
- Coronary artery disease  
- Coronary heart disease  
- Myocardial infarction  
- Stroke (ischemic)  
- Heart failure with reduced ejection fraction  
- Cardiovascular disease  
- Cardiac rehabilitation  
- Antiplatelet therapy  
- Aspirin  
- Dual antiplatelet therapy  
- Drug‑eluting stent  
- High‑intensity interval training  
- Moderate‑intensity continuous training  
- Physical activity  
- Sedentary behaviour  
- Resistance training  
- Environmental exposures (air pollution, PM₂.₅, noise, heat‑waves)  
- Urban heat island  
- Ambient particulate matter exposure  
- Heat‑related hospitalisation  
- Cardiometabolic health  
- Exercise‑related acute cardiovascular events  
- Mortality risk  
- Cardiovascular morbidity and mortality statistics  

Page 93 Extracted Terms:
- Coronary artery disease  
- Chronic coronary disease  
- Acute coronary syndrome  
- Myocardial infarction  
- Heart failure  
- Left ventricular dysfunction  
- Atrial fibrillation  
- Percutaneous coronary intervention (PCI)  
- Stent thrombosis  
- Coronary artery bypass graft surgery  
- Dual antiplatelet therapy (DAPT)  
- Aspirin  
- Clopidogrel  
- Ticagrelor  
- Prasugrel  
- Thienopyridine  
- Antithrombotic therapy  
- Anticoagulant therapy  
- Rivaroxaban  
- Dabigatran  
- Apixaban  
- Direct oral anticoagulants (DOACs)  
- Proton pump inhibitors (PPIs)  
- Atherothrombotic events  
- Vascular events  
- Bleeding events  
- Ischemic heart disease  
- Cardiovascular disease (CVD)  
- National Heart Association/American College of Cardiology guidelines (e.g., ACC/AHA)  
- Network meta‑analysis  
- Randomized controlled trial (RCT)  



Page 94 Extracted Terms:
- Myocardial infarction  
- Acute myocardial infarction  
- Coronary artery disease  
- Chronic coronary disease  
- Chronic coronary syndromes  
- Atrial fibrillation  
- Stable angina  
- Percutaneous coronary intervention (PCI)  
- Drug‑eluting stent  
- Dual antiplatelet therapy (DAPT)  
- Antiplatelet therapy  
- Ticagrelor  
- Aspirin  
- Clopidogrel  
- Warfarin  
- Rivaroxaban  
- Dabigatran  
- Oral anticoagulation  
- Beta‑blocker therapy  
- Carvedilol  
- Metoprolol  
- Bisoprolol  
- Bu­cindolol  
- Heart failure  
- Ischemic heart disease  
- Left‑ventricular dysfunction  
- Left‑ventricular ejection fraction  
- Ventricular systolic dysfunction  
- Ventricular enlargement  
- Chronic heart failure

Page 95 Extracted Terms:
- Heart failure  
- Coronary artery disease  
- Myocardial infarction  
- Stable angina  
- Stable ischemic heart disease  
- Left ventricular dysfunction  
- Left ventricular ejection fraction (reduced & preserved)  
- Ventricular arrhythmias  
- Atrial fibrillation  
- Sudden cardiac death  
- Renin–angiotensin–aldosterone system (RAAS) inhibitors  
- Angiotensin‑converting enzyme (ACE) inhibitors  
- Angiotensin receptor blockers (ARBs)  
- Beta blockers (β‑blockers)  
- β‑adrenergic blockade  
- Antihypertensive agents  
- Perindopril  
- Enalapril  
- Ramipril  
- Captopril  
- Trandolapril  
- Quinapril  
- Telmisartan  
- Carvedilol  
- Nebivolol  
- Colchicine  
- Low‑dose colchicine therapy  
- Inflammation  
- Atherosclerosis  
- Cardiovascular events  
- Mortality  
- Morbidity  
- Secondary prevention of cardiovascular disease  
- Microvascular outcomes  
- Macrovascular outcomes  
- Chronic stable coronary disease  
- Prevention of events with ACE inhibition (PEACE)  
- Heart Outcomes Evaluation Prevention (HOPE‑3)  
- CIBIS‑II (Cardiac Insufficiency Bisoprolol Study)  
- MERIT‑HF (Metoprolol in Patients with Heart Failure)  
- BEST (Beta‑Blocker Evaluation of Survival Trial)  
- COPERNICUS (Captopril in Patients with Left Ventricular Dysfunction)  



Page 96 Extracted Terms:
- Acute myocardial infarction  
- Chronic coronary disease  
- Cardiovascular disease (general)  
- Heart failure  
- Stable angina pectoris  
- Refractory angina  
- Coronary artery disease  
- Ischemic heart disease  
- Coronary revascularization  
- Enhanced external counterpulsation (EECP)  
- Transmyocardial laser revascularization  
- Percutaneous laser myocardial revascularization  
- Myocarditis  
- Influenza vaccination  
- Pneumococcal vaccination  
- COVID‑19 vaccination  
- mRNA‑based COVID‑19 vaccination  
- Anti‑anginal drugs  
- Beta‑blockers  
- Calcium channel blockers  
- Nitrates  
- Ivabradine  
- Ranolazine  
- Metoprolol  
- Nifedipine  
- Diltiazem  
- Atenolol  
- Amlodipine  
- Colchicine  
- Colchicine–cardiovascular medication drug‑drug interactions  
- 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Chronic Coronary Disease Guideline  
- 2021 ESC guidelines on cardiovascular disease prevention  
- 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for stable ischemic heart disease  
- 2021 ACC/AHA/SCAI guideline for coronary artery revascularization  
- International Multicenter Angina Exercise (IMAGE) Study  
- Multifocal enhanced external counterpulsation study (MUST‑EECP)  
- Efficacy and safety of low‑dose colchicine after myocardial infarction  



Page 97 Extracted Terms:
**Key Heart Disease–Related Terms**

- Chronic Coronary Disease  
- Stable Ischemic Heart Disease  
- Coronary Artery Disease (CAD)  
- Coronary Artery Bypass Grafting (CABG)  
- Percutaneous Coronary Intervention (PCI)  
- Fractional Flow Reserve (FFR)  
- Instantaneous Wave‑Free Ratio (iFR)  
- Revascularization  
- Heart Team  
- Left‐Main Coronary Artery Disease  
- Ischemic Cardiomyopathy  
- Myocardial Infarction  
- Left Ventricular Dysfunction  
- Coronary Artery Bypass Surgery (CABG)  
- Drug‑Eluting Stents (e.g., Everolimus‑eluting)  
- Coronary Angiography  
- Coronary Artery Disease Management  
- Coronary Artery Disease Treatment Trials (ISCHEMIA, COURAGE, STICH, FAME, etc.)  
- Coronary Artery Bypass Graft Survival  
- Coronary Disease Quality‑of‑Life Outcomes  
- Coronary Disease Cost‑Effectiveness  
- Coronary Disease Evidence‑Based Guidelines (ACC/AHA/ACC, etc.)  
- Coronary Disease Meta‑analysis  
- Coronary Disease Clinical Outcomes  
- Coronary Disease Revascularization Decision Making  
- Coronary Disease Complex Stenoses  
- Coronary Disease Multivessel Disease  
- Coronary Disease Diabetes Mellitus Impact  
- Coronary Disease Stable Patients  
- Coronary Disease Invasive vs. Conservative Strategy  
- Coronary Disease Percutaneous vs. Surgical Outcomes  
- Coronary Disease Adverse Events (AMI, death, survival)  

These terms capture the core concepts, interventions, and outcomes discussed in the cited clinical statements and guidelines.

Page 98 Extracted Terms:
- Stable coronary disease  
- Invasive management  
- Conservative management  
- Percutaneous coronary intervention (PCI)  
- Coronary artery bypass grafting (CABG)  
- Fractional flow reserve (FFR)  
- Instantaneous wave‑free ratio (iFR)  
- Left‑main coronary artery disease  
- Unprotected left‑main stenosis  
- Bifurcation lesion  
- Drug‑eluting stents (DES)  
- Paclitaxel‑eluting stents  
- Everolimus‑eluting stents  
- Intravascular ultrasound (IVUS) guidance  
- Ischemic left ventricular dysfunction  
- Ischemia severity  
- Cardiovascular death  
- Non‑cardiovascular death  
- Symptomatic coronary artery disease  
- Three‑vessel disease  
- Severe coronary artery disease  
- Multivessel revascularization  
- Diabetes mellitus (in the context of coronary disease)  
- Patient‑reported pre‑procedural physical and mental health  
- Cost‑effectiveness analysis  
- Meta‑analysis of randomized trials  
- SYNTAX trial  
- NOBLE trial  
- PRECOMBAT trial  
- DKCRUSH‑V trial  
- DKCRUSH‑III study  
- DEFER study  
- FREEDOM study  
- Optim‑um registry (surgically ineligible patients)  
- Clinical outcomes  
- Long‑term survival  
- 10‑year follow‑up  
- 5‑year follow‑up  
- Prospective randomized open‑label study  
- Pooled individual patient data  
- Ranges of coronary artery disease severity  
- Clinical trial endpoints (mortality, morbidity, revascularization)  
- Revascularization strategies  

These terms capture the key concepts and clinical entities related to heart disease discussed in the provided guideline references.

Page 99 Extracted Terms:
- Chronic Coronary Disease  
- AHA/ACC/ACCP/ASPC/NLA/PCNA Chronic Coronary Disease Guideline  
- Coronary Revascularization  
- Percutaneous Coronary Intervention (PCI)  
- Coronary Artery Bypass Grafting (CABG)  
- Left Main Coronary Artery Disease  
- Spontaneous Coronary Artery Dissection (SCAD)  
- 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization  
- Coronary Intervention vs. Bypass Grafting outcomes  
- Med-Oriented and Surgery strategies for Multivessel Coronary Artery Disease (MASS II)  
- Dual Antiplatelet Therapy (DAPT) duration after PCI  
- Beta‑blockers and Antiplatelet agents in SCAD  
- Ischemia with Non‑Obstructive Coronary Arteries (INOCA)  
- Microvascular Angina  
- Vasospastic Angina  
- Invasive Coronary Function Testing (CorMicA trial)  
- Non‑Obstructive Coronary Artery Disease (NOCAD)  
- Coronary Angiography  
- Coronary Angioplasty (Percutaneous Coronary Angioplasty)  
- ST‑Segment Elevation Myocardial Infarction (STEMI)  
- Congestive Heart Failure (CHF)  
- Heart Failure with Preserved Ejection Fraction (HFpEF)  
- Heart Failure with Reduced Ejection Fraction (HFrEF)  
- AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for Chest Pain Evaluation  
- International Standardization of Diagnostic Criteria for Microvascular Angina  
- International Standardization of Diagnostic Criteria for Vasospastic Angina  
- Cardiac Rehabilitation after SCAD  
- Cardiac Rehabilitation after MI or angina  
- Fibromuscular Dysplasia (associated with SCAD)  
- Cervical Artery Abnormalities (fibromuscular dysplasia, dissection, aneurysm, tortuosity)  
- Pregnancy‑associated SCAD  
- Coronary Artery Tortuosity  
- Coronary Artery Aneurysm  
- Coronary Artery Dissection recurrence prevention.

Page 100 Extracted Terms:
- Chronic Coronary Disease  
- Heart Failure  
- Coronary Artery Disease (CAD)  
- Myocardial Infarction (MI)  
- Aortic Stenosis  
- Valvular Heart Disease (VHD)  
- Coronary Artery Revascularization  
- Percutaneous Coronary Intervention (PCI)  
- Coronary Artery Anomalies / Coronary Artery Abnormalities  
- Familial Hypercholesterolemia  
- Atherosclerotic Cardiovascular Disease (ASCVD)  
- Kawasaki Disease (congenital coronary involvement)  
- Inflammatory Arthritis (cardiovascular events)  
- Inflammatory Bowel Disease (acute coronary syndrome risk)  
- Cardio‑Oncology (cardiovascular effects of cancer therapies)  
- Radiation‑Induced Cardiovascular Disease  
- Vascular Toxicities of Cancer Treatments  
- Cancer‑Associated Cardiovascular Risk  
- Cardiovascular Risk Factors (hypertension, dyslipidemia, smoking, etc.)  
- Statin Therapy  
- Aspirin Therapy  
- Anticoagulation (for VTE prophylaxis in cancer)  
- Pregnancy in Women with Ischemic Heart Disease  
- Post‑pregnancy Cardiovascular Management  
- Postmenopausal Hormone Therapy and Cardiovascular Outcomes  
- Venous Thromboembolism (VTE) Prophylaxis in Cancer Patients  
- Contraception and Reproductive Planning in Women with Cardiovascular Disease  
- Cardiac Rehabilitation (including cardio‑oncology rehabilitation)  
- Endothelial Dysfunction  
- Ischemic Heart Disease (IHD)  
- Left Ventricular Ejection Fraction (reduced vs preserved)  
- Heart Failure with Reduced Ejection Fraction (HFrEF)  
- Heart Failure with Preserved Ejection Fraction (HFpEF)  
- Atrial Fibrillation (AF)  
- Atherosclerosis  
- Multi‑vessel Coronary Disease  
- Coronary Angiography  
- Coronary Angioplasty  
- Cardiogenic Shock  
- Revascularization Guidelines (ACC/AHA/SCAI)  
- Chronic Coronary Syndromes (CCS)  
- Acute Coronary Syndromes (ACS)  
- Long‑term CVD Outcomes (mortality, morbidity)  
- Risk‑Factor Modifications (diet, exercise, smoking cessation)  

These terms capture the main heart‑disease concepts referenced in the provided guideline excerpt.

Page 101 Extracted Terms:
- Cardiovascular disease  
- Coronary heart disease  
- Coronary artery disease (CAD)  
- Atherosclerosis  
- Angina pectoris  
- Myocardial infarction (MI)  
- Coronary artery bypass grafting (CABG)  
- Percutaneous coronary intervention (PCI)  
- Left‑main coronary artery disease  
- Multivessel coronary disease  
- Chronic coronary disease  
- Ischemic heart disease  
- Hypercholesterolemia  
- Familial hypercholesterolemia  
- Lipid‑lowering therapy  
- Statin therapy  
- Beta‑blocker therapy  
- Antithrombotic/anticoagulant therapy  
- Thromboembolism / thrombosis  
- Hemostatic alterations  
- Cardiac surgery (including CABG, PCI, coronary angiography)  
- Revascularization strategies  
- Renal injury after cardiac surgery  
- Quality of life in cardiac patients  
- Medication adherence/ compliance in cardiac disease  

(These are the principal terms related to heart disease that appear in the cited guidelines and studies.)

Page 102 Extracted Terms:
- Drug‑eluting stents  
- Coronary artery disease (CAD)  
- Percutaneous coronary intervention (PCI)  
- Dual antiplatelet therapy (DAPT)  
- Triple therapy (warfarin + aspirin + clopidogrel/ticagrelor)  
- Transradial coronary intervention  
- Coronary artery bypass grafting (CABG)  
- Minimally invasive direct coronary artery bypass  
- Bypass grafting with internal mammary arteries  
- Frailty (predictor of outcomes in CAD)  
- Sarcopenia (predicts adverse outcomes in CAD)  
- Malnutrition / nutritional index (predicts mortality post‑PCI)  
- Contrast‑induced acute kidney injury (CI-AKI)  
- Chronic kidney disease (CKD)  
- Contrast‑associated acute kidney injury (CA-AKI)  
- Coronary calcification in CKD  
- Atherosclerosis & vascular calcification (in CKD)  
- Statin therapy in CKD patients  
- Antiplatelet therapy in CKD patients  
- AHA/ACC/ACCP/ASPC/NLA/PCNA Chronic Coronary Disease Guideline  
- ACC/AHA/SCAI guideline for coronary artery revascularization  
- ISCHEMIA‑CKD study (invasive vs medical treatment for CKD)  
- Renal dysfunction & cardiovascular outcomes after myocardial infarction  
- Kidney disease as a risk factor for cardiovascular disease  
- Geriatric 5Ms (optimizing care in elderly cardiac patients)  
- Exercise‑based cardiac telerehabilitation  
- Home‑based mobile cardiac rehabilitation  
- SYNTAX score (age‑dependent impact on mortality post‑PCI)  
- Contrast‑induced nephropathy risk score (Mehran score)  
- Functional status measures in elderly cardiac patients  
- Long‑term outcomes after PCI vs CABG in octogenarians  
- Outcomes of percutaneous transluminal coronary angioplasty in chronic renal failure  
- Kidney disease management guidelines (NEOERICA, etc.)

Page 103 Extracted Terms:
**Key heart‑disease related terms extracted from the text**

- Myocardial infarction (MI) / Myocardial infarct  
- Coronary artery disease (CAD) / Chronic coronary disease  
- Coronary artery bypass grafting (CABG) / Coronary artery bypass graft (CABG)  
- Percutaneous coronary intervention (PCI) / Angioplasty  
- Revascularization  
- Acute coronary syndrome (ACS)  
- ST‑segment elevation myocardial infarction (STEMI)  
- Cardiac catheterization / Coronary angiography  
- Contrast‑induced nephropathy (CIN) – peri‑procedural renal injury related to cardiac procedures  
- Acute kidney injury (AKI) after coronary procedures  
- Cardiovascular disease (CVD) / Cardiovascular complications  
- Cardiovascular events / Cardiovascular risk  
- Atherosclerotic cardiovascular disease (ASCVD)  
- Heart disease / Heart‑disease statistics  
- Dyslipidemia / Hyperlipidemia / Hypertriglyceridemia / Blood cholesterol  
- Statin therapy / Lipid‑lowering therapy  
- Cholesterol management / Blood‑cholesterol guideline  
- HIV‑associated cardiovascular disease risks (e.g., abacavir, protease inhibitors, ritonavir, dolutegravir)  
- Coronary plaque formation / Coronary plaque stabilization  
- Coronary artery disease management in advanced kidney disease  
- Radial access vs. femoral access (transradial vs. transfemoral approach)  
- Post‑procedural complications of coronary interventions  
- Cardiovascular risk management in autoimmune disorders (rheumatoid arthritis, psoriasis, etc.)  

These terms capture the central heart‑disease concepts discussed across the cited guidelines and studies.

Page 104 Extracted Terms:
**Heart‑disease related terms identified in the text**

1. Chronic Coronary Disease  
2. Cardiac allograft vasculopathy  
3. Heart transplantation / heart transplant recipients  
4. Coronary artery disease (stable & acute)  
5. Percutaneous coronary intervention (PCI)  
6. Coronary artery bypass grafting (CABG)  
7. Statin therapy (e.g., simvastatin, pravastatin, atorvastatin)  
8. Aspirin use in transplant patients  
9. Everolimus‑eluting stents  
10. Sirolimus (rapamycin) therapy  
11. Paclitaxel‑eluting stents  
12. Calcineurin inhibitor elimination (e.g., cyclosporine, tacrolimus)  
13. High‑intensity interval training (exercise)  
14. Body‑mass‑index effects on transplant outcomes  
15. Intravascular ultrasound (IVUS) for graft assessment  
16. Coronary physiology assessment (e.g., fractional flow reserve)  
17. Coronary risk‑factor management  
18. Myocardial infarction (MI)  
19. Anginal symptoms / angina  
20. Myocardial ischemia  
21. Coronary heart disease (CHD)  
22. Secondary prevention of cardiovascular disease  
23. Depression in cardiac patients  
24. Telephone‑delivered health coaching  
25. Tele‑health interventions for acute coronary syndrome (ACS)  
26. Lifestyle‑focused interventions (diet, exercise, weight management)  
27. Text‑messaging adherence programs for CHD  
28. Clinical guidelines for chronic coronary disease (AHA/ACC/ACCP/ASPC/NLA/PCNA)  
29. ACC/AHA/SCAI guidelines for coronary artery revascularization  
30. International Society of Heart & Lung Transplantation (ISHLT) guidelines  
31. ESC Heart Failure guidelines (for heart transplant recipients)  
32. ESC Heart Failure outcomes reporting  
33. Cardiovascular drug‑drug interaction recommendations (statins)  

These terms encompass diseases, interventions, pharmacotherapies, procedural techniques, lifestyle strategies, and guideline references that are central to the clinical management of heart disease as presented in the material.

Page 105 Extracted Terms:
- Chronic Coronary Disease  
- Percutaneous Coronary Intervention (PCI)  
- Coronary Angiography  
- Coronary Artery Disease  
- Myocardial Infarction  
- Chronic Stable Angina  
- Coronary Heart Disease  
- Drug‑Eluting Stents  
- Revascularisation  
- Chronic Coronary Syndrome  
- Ischaemia  
- Heart Failure  
- Atherosclerotic Cardiovascular Disease  
- PCSK9 Inhibitors  
- Sacubitril‑Valsartan  
- Coronary Disease Secondary Prevention  
- Coronary Risk‑Factor Management  
- Coronary Imaging Follow‑up

(Note: Terms are extracted only as relevant to heart disease concepts.)

Page 106 Extracted Terms:
**Key heart‑disease related terms extracted from the text**

- Chronic Coronary Disease  
- Cardiovascular  
- Cardiovascular Disease Prevention  
- Cardiovascular Fellowship Program  
- Cardiologist  
- Cardiology  
- Heart  
- Heart Institute  
- Heart Health  
- Heart Health & Performance Program  
- Coronary  
- Lipid  
- Atherosclerosis  
- Cardiac  
- Clinical Guidelines  
- AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline  
- Journal of the American College of Cardiology (JACC)  
- European Heart Journal – Acute Cardiovascular Care  
- Current Atherosclerosis Reports  
- Current Cardiology Reports  
- American Heart Journal  
- Journal of Clinical Lipidology  
- World Heart Federation (WHF)  
- National Heart, Lung, and Blood Institute (NHLBI)  

These terms capture the primary disease concepts, specialty fields, and major publishing/committee entities related to heart disease that appear in the provided guideline document.

Page 107 Extracted Terms:
- Chronic Coronary Disease Guideline  
- Cardiology  
- Cardiac  
- Coronary  
- Cardiovascular  
- AHA (American Heart Association)  
- ACC (American College of Cardiology)  
- ACCP (American College of Clinical Pharmacology)  
- ASPC (American Society of Parenteral and Enteral Nutrition)  
- NLA (National Lipid Association)  
- PCNA (Primary Care Cardiovascular Nursing Association)  
- CDC (Centers for Disease Control and Prevention)  
- NIH (National Institutes of Health)  
- Circulation  
- Circulation: Cardiovascular Interventions  
- Circulation: Cardiovascular Quality and Outcomes  
- Journal of Cardiovascular Pharmacology  
- Journal of Clinical Lipidology  
- International Journal of Cardiology  
- JACC (Journal of the American College of Cardiology)  
- HeartFlow  
- Abbott  
- Boston Scientific  
- Edwards Lifesciences  
- Medtronic  
- Siemens  
- CathWorks  
- Neovasc Medical Inc.  
- Cardiac Critical Care  
- HeartHealth (Women‑Heart)  
- American Journal of Preventive Cardiology  

Page 108 Extracted Terms:
- Chronic Coronary Disease  
- Arrhythmia  
- Acute coronary syndrome (referenced as “Acute SOP/CP”)  
- Cardiovascular disease  
- Cardiology  
- Heartflow  
- Heart disease  
- National Forum for Heart Disease & Stroke Prevention (heart‑related focus)

Page 109 Extracted Terms:
- Chronic Coronary Disease  
- Heart Disease  
- Cardiovascular Medicine  
- Cardiovascular Division  
- Cardiology  
- Preventive Cardiology  
- Noninvasive Cardiac Imaging  
- Cardiac Magnetic Resonance (MRI)  
- Cardiac Computed Tomography (CT)  
- Cardiac Stress Laboratory  
- AHA (American Heart Association)  
- ACC (American College of Cardiology)  
- ASPC (American Society for Preventive Cardiology)  
- NLA (National Lipid Association)  
- PCNA (Prevention of Cardiovascular Disease Network)  
- Circulation (journal)  
- AHA/ACC/ACCP/ASPC/NLA/PCNA Chronic Coronary Disease Guideline 2023  
- Cardiac Magnetic Resonance Imaging (CMR)  
- Cardiovascular Magnetic Resonance  
- Cardiovascular Computed Tomography  
- Cardiac imaging  
- Cardiac imaging technology  
- Cardiac magnetic resonance imaging equipment  
- Cardiac computed tomography equipment  
- Cardiac stress testing  
- Cardiology editorial work / guidelines  
- Cardiovascular research  
- Cardiovascular clinical trials  
- Heart disease prevention  
- Cardiovascular risk assessment  



Page 110 Extracted Terms:
Chronic Coronary Disease  
Cardiology  
Cardiac  
Coronary  
Cardiovascular  
Heart  
Cardiac catheterization  
Angiography  
Interventions  
Cardiovascular drugs  
Heart disease  
Cardiac disease  
Coronary artery disease  
Prevention of cardiovascular disease  
AHA (American Heart Association)  
ACC (American College of Cardiology)  
NHLBI (National Heart, Lung, and Blood Institute)  
ESC (European Society of Cardiology)  
SCAI (Society for Cardiovascular Angiography and Interventions)  
WHF (World Heart Federation)  
PCNA (Preventive Cardiovascular Nurses Association)  
ASPC (American Society of Preventive Cardiology)  
ACCF (American College of Cardiology Foundation)  
ACCP (American College of Clinical Pharmacy)  
ASNC (American Society of Nuclear Cardiology)  
JACC (Journal of the American College of Cardiology)

Page 111 Extracted Terms:
- Chronic Coronary Disease  
- Heart disease  
- Coronary disease  
- Cardiovascular disease  
- Myocardial infarction  
- Thrombolysis in myocardial infarction (TIMI)  
- Lipid disorders  
- Family Heart  
- American Heart Association (AHA)  
- American College of Cardiology (ACC)  
- American College of Clinical Pharmacy (ACCP)  
- American Society of Preventive Cardiology (ASPC)  
- National Lipid Association (NLA)  
- Preventive Cardiovascular Nurses Association (PCNA)  
- Society of Thoracic Surgery (STS)  
- National Heart, Lung, and Blood Institute (NHLBI)



Page 1 Extracted Terms:
- Adult congenital heart disease  
- Aortic coarctation  
- Aortic valve stenosis  
- Cardiac catheterization  
- Cardiac surgical procedures  
- Cor triatriatum  
- Coronary vessel anomalies  
- Discrete subaortic stenosis  
- Ductus arteriosus (including patent ductus arteriosus)  
- Ebstein anomaly  
- Congenital heart defects  
- Heart septal defects (e.g., ventricular septal defect)  
- Pulmonary valve stenosis  
- Tetralogy of Fallot  
- Transposition of the great vessels  
- Ventricular outflow obstruction  
- Reoperation (post‑surgical)  
- Follow‑up studies / treatment outcomes  
- Survival rate / therapy outcomes

Page 2 Extracted Terms:
- Heart Failure  
- Heart Transplantation  
- Mechanical Circulatory Support (MCS)  
- Cyanosis  
- Shunt Lesions  
- Atrial Septal Defect (ASD)  
- Ventricular Septal Defect (VSD)  
- Atrioventricular Septal Defect (AVSD)  
- Anomalous Pulmonary Venous Connections  
- Patent Ductus Arteriosus (PDA)  
- Cor Triatriatum Sinister  
- Congenital Mitral Stenosis (including Shone Complex)  
- Subaortic Stenosis  
- Congenital Aortic Valve Diseases  
- Supravalvar Aortic Stenosis  
- Coarctation of the Aorta  
- Ebstein Anomaly  
- Valvular Pulmonary Stenosis  
- Double‑Chambered Right Ventricle (DCRV)  
- Isolated Branch Pulmonary Artery Stenosis  
- Tetralogy of Fallot  
- Pulmonary Atresia with Intact Ventricular Septum  
- Right Ventricle‑to‑Pulmonary Artery Conduits  
- Dextro‑Transposition of the Great Arteries (dTGA)  
- Congenitally Corrected Transposition of the Great Arteries (CCTGA)  
- Truncus Arteriosus  
- Double‑Outlet Right Ventricle (DORV)  
- Fontan Palliation of Single‑Ventricle Physiology  
- Eisenmenger Syndrome  
- Anomalous Aortic Origin of a Coronary Artery  
- Anomalous Coronary Artery Arising from the Pulmonary Artery  
- Coronary Artery Fistula  
- Vascular Rings  
- Pulmonary Artery Slings  
- Genetic Syndromes Screening (related to cardiac anomalies)  
- Reproductive Health, Pregnancy, and Contraception (cardiovascular considerations)

Page 3 Extracted Terms:
**Key Heart‑Disease–Related Terms Extracted from the Guideline**

- Adult Congenital Heart Disease (ACHD)  
- ACHD Program  
- ACHD Cardiologist  
- AP Classification (e.g., Class IA, IC–D, IIB–D, IIIA–D, IIC–D, IIA–D)  
- Non‑cardiac Surgery  
- Perioperative Complications  
- Guideline‑Based Medical Therapy (GDMT)  
- Invasive Cardiac Procedures  
- Risk Stratification  
- Periprocedural Planning  
- Post‑procedural Care  
- Anesthesia Collaboration with ACHD Expertise  
- Cardiac Surgery  
- Cyanosis Management  
- Heart Failure  
- Heart Transplantation  
- Mechanical Circulatory Support (MCS)  
- Genetic Syndromes Screening  
- Genetic Evaluation Referral  
- Reproductive Health (Pregnancy & Contraception)  
- Assisted Reproductive Technology  
- Routine Cesarean Delivery Policy  
- Physical Activity, Exercise, Sports Participation  
- Severe Pulmonary Hypertension  
- Eisenmenger Syndrome  
- Atrial Septal Defect (ASD)  
- Pulmonary Arterial Hypertension (PAH)  
- Pulmonary Hypertension Specialists  
- Left‑to‑Right Shunt (Qp:Qs)  
- Pulmonary Artery (PA) Systolic Pressure  
- Pulmonary Vascular Resistance (PVR)  
- Secundum ASD  
- Transcatheter Closure of ASD  
- Surgical Repair of ASD  
- Pulmonary Vascular Resistance Ratio (PVR to systemic resistance)  
- Pulmonary Artery Pressure ≥ 50 % of systemic  

*(Additional terms such as “net left‑to‑right shunt,” “≥ 1.5:1 Qp:Qs,” and “≥ 1/3 systemic resistance” are included within the list of measurement criteria above.)*

Page 4 Extracted Terms:
- Atrial Septal Defect (ASD)  
- Ventricular Septal Defect (VSD)  
- Atrioventricular Septal Defect (AVSD)  
- Anomalous Pulmonary Venous Connections (APVC)  
- Patent Ductus Arteriosus (PDA)  
- Cor Triatriatum Sinister  
- Pulmonary Arterial Hypertension (PAH)  
- Pulmonary Vascular Resistance (PVR)  
- Qp:Qs ratio (left‑to‑right shunt ratio)  
- Right Ventricular (RV) dilation  
- Right Ventricular Outflow Tract (RVOT) obstruction  
- Double‑Chambered Right Ventricle (DCRV)  
- Left Ventricular (LV) systolic dysfunction  
- Left Ventricular ejection fraction (EF) < 50%  
- Pulmonary hypertension (PH)  
- Pulmonary hypertension specialist  
- Heart failure (HF)  
- Functional status / functional class  
- Dyspnea on exertion  
- Cardiac imaging (echocardiography, MRI, CT angiography)  
- Surgical repair / closure  
- Gradient across obstruction (mm Hg)  
- Residual shunt  
- Net left‑to‑right shunt (Qp:Qs ≥ 1.5:1)  
- RV size and function assessment  
- Left atrial hypertension  
- Coronary artery disease (implicitly related)  
- Cardiac catheterization  
- CMR (cardiac magnetic resonance)  
- CT (computed tomography) angiography  
- Ventricular hypertrophy (RV or LV)  
- Hemodynamic measurements (systolic pressure, systemic pressure)  
- Perianeurysmal obstruction  
- Cardiopulmonary risk assessment  
- Surgical resection (membrane removal, valve repair)  
- Repaired vs unrepaired congenital defects  
- Ventricular function monitoring  
- Chronic embolism risk  
- Paradoxical embolism  

These terms encapsulate the key heart‑disease concepts discussed in the guideline excerpts.

Page 5 Extracted Terms:
- Cor Tiatriatum Sinister  
- Atrial Fibrillation  
- Atrial Flutter  
- Prior Stroke  
- Left Atrial Thrombus  
- Chronic Anticoagulation  
- Rhythm Control Strategy  
- Clinical Decompensation  
- Congenital Mitral Stenosis  
- Shone Complex  
- Pulmonary Hypertension  
- Bicuspid Aortic Valve  
- Aortic Diameter > 4 cm  
- Thoracic Aortic Disease  
- Aortic Dissection  
- Lifelong Surveillance  
- Valve Replacement (Surgical / Transcatheter)  
- Heart Valve and ACHD Expert Teams  
- Coarctation of the Aorta  
- Exertional Symptoms  
- Coronary Artery Disease Evaluation  
- Electrophysiological Study  
- Catheter Ablation  
- Ventricular Preexcitation  
- Supraventricular Tachycardia  
- Valvular Pulmonary Stenosis (Moderate/Severe)  
- Tricuspid Regurgitation  
- Right Ventricular Dysfunction  
- Pulmonary Valve Intervention  
- Isolated Pulmonary Regurgitation  
- Cardiovascular Magnetic Resonance (CMR) Imaging  
- Right Ventricular (RV) Volumes  
- RV Systolic Function  
- Cardiac Catheterization  
- Double‑Chambered Right Ventricle (DCRV)  
- RVOT Obstruction  
- Cardiac CT  
- Branch Pulmonary Artery Stenosis  
- Pulmonary Artery Dilation  
- Stenting  
- Balloon Angioplasty  
- Tetralogy of Fallot (TOF)  
- Echocardiography  
- Pulmonary Valve Dysfunction  
- Right Atrial Size  
- Ventricular Size  
- Residual Ventricular Septal Defects (VSDs)  
- RV Systolic Pressure  
- Right Ventricular Outflow Tract (RVOT)  
- Transcatheter Pulmonary Valve Replacement  
- Implantable Cardioverter‑Defibrillator (ICD)  
- Monomorphic Ventricular Tachycardia  
- Adjunctive Catheter Ablation  
- Pulmonary Valve Replacement (Surgical / Transcatheter)

Page 6 Extracted Terms:
**Key Terms Related to Heart Disease**

- **Right Ventricle‑to‑Pulmonary Artery (RV‑to‑PA) Conduit**  
- **Right Ventricle**  
- **Pulmonary Artery**  
- **Coronary CT**  
- **Conduit Calcification**  
- **Anatomic Characteristics**  
- **Coronary Artery Proximity**  
- **Transcatheter Intervention**  
- **Pulmonary Regurgitation (PR)**  
- **Stenosis**  
- **Functional Capacity**  
- **Arrhythmia**  
- **Severe Stenosis**  
- **Severe Regurgitation**  
- **Cardiovascular Status**  
- **Dextro‑Transposition of the Great Arteries (d‑TGA)**  
- **Atrial Switch**  
- **Progressive Exercise Intolerance**  
- **Heart Failure (HF)**  
- **Cardiopulmonary Exercise Testing**  
- **Interatrial Baffle**  
- **Venous Stenosis**  
- **Transvenous Pacemaker**  
- **Implantable Cardioverter‑Defibrillator (ICD)**  
- **Invasive Hemodynamic Assessment**  
- **Medical, Percutaneous, or Surgical Intervention**  
- **Baffle Stenosis**  
- **Residual Baffle Leaks**  
- **Biomarkers**  
- **Disease‑Specific Risk Scores**  
- **Cardiac Events**  
- **HF Transplant Centers**  
- **Ambulatory Monitoring**  
- **Bradycardia**  
- **Sinus Node Dysfunction**  
- **Beta Blockers**  
- **Rate‑Slow‑ing Agents**  
- **Resting Electrocardiogram (ECG)**  
- **Outpatient Ambulatory Rhythm Monitoring**  
- **Tachyarrhythmia**  
- **Baffle Leak**  
- **Baffle Leak Closure**  
- **Systemic or Pulmonary Venous Pathway Stenosis**  
- **Liver Congestion**  
- **Mechanical Support**  
- **Transplantation**  
- **ACHD Cardiologist**  
- **Guideline‑Directed Medical Therapy (GDMT)**  
- **Anticoagulation**  
- **Sinus Rhythm**  
- **Atrial Arrhythmia**  
- **Intra‑atrial Reentrant Arrhythmias**  
- **Atrial Fibrillation**  
- **Oral Anticoagulation**  
- **Embolic Events**  
- **Transvenous Lead Placement**  
- **Catheter‑Based Interventions**  
- **Systemic Thromboembolism**  
- **Future Baffle Occlusion**  
- **Physiological Tests of Myocardial Perfusion**  
- **Myocardial Ischemia**  
- **Coronary Angiography**  
- **Cross‑Sectional Imaging**  
- **Functional Coronary Assessment**  
- **Anatomic Etiology**

Page 7 Extracted Terms:
- Arterial Switch Operation  
- Myocardial ischemia  
- Coronary revascularization  
- Supravalvar PA stenosis  
- Branch PA stenosis  
- RV hypertension  
- RV dysfunction  
- Tricuspid regurgitation  
- Exercise capacity  
- d‑Transposition of the great arteries (d‑TGA)  
- Rastelli Repair  
- Congenitally corrected transposition of the great arteries (CCTGA)  
- Transthoracic echocardiography  
- Chamber function  
- Systemic tricuspid valve function  
- Septal defects  
- LVOT stenosis  
- Ambulatory rhythm monitoring  
- Atrioventricular block (high‑grade)  
- Physiologic pacing  
- Cardiac resynchronization therapy (CRT)  
- Conduction system pacing  
- Fontan circulation  
- Fontan circulatory failure  
- Heart failure (HF)  
- Transplant cardiology  
- Hepatocellular carcinoma  
- Fontan‑associated liver disease  
- Hepatic fibrosis / cirrhosis  
- Advanced cardiac imaging  
- Cardiovascular magnetic resonance (CMR)  
- Computed tomography (CT)  
- Transesophageal echocardiography  
- Thrombus  
- Emboli  
- Liver biopsy  
- Sinus node dysfunction  
- Atrial flutter  
- Atrial fibrillation  
- Cardioversion (pharmacologic or electrical)  
- Cardiac transplantation  
- Transplant‑free survival  
- Apical site pacing  
- Nonapical site pacing  
- Portal hypertension  
- CT angiography  
- Radiologic protocols (avoid false‑negative/false‑positive)

Page 8 Extracted Terms:
- Fontan circulation  
- Fontan palliation  
- Single‑ventricle physiology  
- Hemodynamically significant stenosis  
- Fontan pressure  
- Pulmonary arteries (PAs)  
- Systemic ventricular volume overload  
- Antiplatelet therapy  
- Anticoagulation  
- Vitamin K antagonist  
- Atrial flutter  
- Atrial fibrillation  
- Atriopulmonary Fontan  
- HLHS (Hypoplastic Left Heart Syndrome)  
- Norwood repair  
- Eisenmenger syndrome  
- Pregnancy (in Eisenmenger)  
- Bosentan  
- Phosphodiesterase‑type 5 inhibitors  
- Sildenafil  
- Tadalafil  
- PAH‑directed therapy  
- Endothelin receptor antagonist  
- Atrial arrhythmias  
- Sinus rhythm  
- Exercise program  
- Oral anticoagulation  
- Intracardiac shunt  
- Permanent pacing  
- Implantable cardioverter‑defibrillator (ICD)  
- Endocardial leads  
- Annual laboratory evaluation  
- Liver function testing  
- Renal function testing  
- Hematologic abnormality  
- Annual biochemical and hematological testing  
- Hemodynamics  
- Systemic thromboembolism

Page 9 Extracted Terms:
- Congenital heart disease (ACHD)  
- ACHD centers  
- ACHD cardiologist  
- Multidisciplinary team (complex‑care decision making)  
- Cardiac procedures  
- Non‑cardiac procedures  
- Endocarditis risk evaluation  
- Bioprosthetic pulmonary valves  
- Subacute bacterial endocarditis  
- Tetralogy of Fallot  
- Pulmonary valve replacement  
- Right ventricular end‑systolic volume (>80 mL/m²)  
- Right ventricular end‑diastolic volume (referenced)  
- Arrhythmia management  
- Ventricular tachycardia  
- Ablation therapy  
- Secundum atrial septal defect  
- Pulmonary arterial hypertension  
- Left‑to‑right shunt  
- Pulmonary vascular resistance (≤ 2 Wood units; 2–5 Wood units)  
- Atrial arrhythmias  
- Systemic right ventricle  
- Fontan circulation  
- Heart failure therapy (guideline‑directed medical therapy)  
- Systemic left ventricle  
- Pacing strategies (systemic right ventricle / Fontan)  
- Eisenmenger syndrome  
- Pulmonary vasodilators  
- Phosphodiesterase‑5 inhibitors  
- Endothelin receptor antagonists  
- Fontan‑screening for liver disease  
- Alpha‑fetoprotein  
- Hepatologist consultation  
- American College of Cardiology (ACC)  
- American Heart Association (AHA)  
- Anomalous aortic origin of a coronary artery (AAOCA)  
- Ventricular arrhythmias (AAOCA presentation)  
- High‑risk anatomy (AAOCA)  
- Vascular rings  
- Pulmonary artery slings  

*(Each item is a key term related to heart disease extracted from the guidelines text.)*

Page 10 Extracted Terms:
- Guideline‑directed medical therapy (GDMT)  
- Adults with congenital heart disease (ACHD)  
- Cardiovascular disease  
- Cardiac imaging  
- Percutaneous coronary intervention  
- Coronary artery bypass grafting  
- Heart failure management  
- Arrhythmia treatment  
- Device therapy (e.g., pacemaker, implantable cardioverter‑defibrillator)  
- Pharmacologic therapy (beta‑blockers, ACE inhibitors, ARBs, diuretics, anticoagulants)  
- Clinical evaluation of cardiac symptoms  
- Diagnostic testing for heart disease  
- Shared decision‑making in cardiac care  
- Patient engagement in cardiac treatment planning  
- Comorbidities influencing cardiac outcomes  
- Randomized controlled trials (RCTs) in cardiology  
- Systematic reviews of cardiac interventions  
- Evidence‑based guideline recommendations for heart disease  
- ACC/AHA Joint Committee on Clinical Practice Guidelines  
- National Academy of Medicine (formerly Institute of Medicine) – cardiology standards  
- Cost‑value analysis of cardiac drugs and devices  
- Knowledge‑chunk format for cardiovascular guideline presentation  
- Flow diagrams for cardiac decision pathways  
- Contraindications and drug–drug interactions in cardiac therapy  
- Regulatory approval of cardiac drugs and devices in the United States.

Page 11 Extracted Terms:
- Adult congenital heart disease  
- Aortic coarctation  
- Aortic valve stenosis  
- Cardiac catheterization  
- Cardiac surgical procedures  
- Congenital heart disease  
- Cor triatriatum  
- Coronary vessel anomalies  
- Diagnostic imaging  
- Discrete subaortic stenosis  
- Patent ductus arteriosus  
- Ebstein anomaly  
- Congenital heart defects  
- Ventricular septal defects  
- Pulmonary valve stenosis  
- Reoperation  
- Surgery  
- Survival rate  
- Tetralogy of Fallot  
- Therapy  
- Transposition of the great vessels  
- Treatment outcome  
- Ventricular outflow obstruction  
- Valvular heart disease  
- Bicuspid aortic valve disease  
- Aortopathy associated with bicuspid aortic valve  
- Conotruncal abnormalities  
- Heart failure  
- Cardiovascular diseases  
- Aortic disease  
- Inherited connective‑tissue disorders with cardiac manifestations (e.g., Marfan syndrome, hypertrophic cardiomyopathy)  
- Patent foramen ovale  
- Anatomic variants of the heart  
- Congenital valve disease (distinct from acquired valvular disease)

Page 12 Extracted Terms:
- Adult Congenital Heart Disease (ACHD)  
- Coronary artery disease  
- Heart failure  
- Arrhythmias  
- Valvular heart disease  
- Chest pain  
- Coronary artery revascularization  
- Aortic disease  
- Chronic coronary disease  
- Atrial fibrillation  
- Genetic basis for congenital heart disease  
- Multimodality imaging during follow‑up care of congenital heart disease  
- Transition to adulthood for adolescents with congenital heart disease  
- Repaired tetralogy of Fallot (arrhythmias)  
- Dual‑organ transplantation (heart‑kidney, heart‑liver)  
- Neurodevelopmental outcomes for individuals with congenital heart disease  
- Psychological outcomes and interventions for congenital heart disease  

*(These terms represent the major cardiac conditions, procedures, and related concepts referenced in the guideline.)*

Page 13 Extracted Terms:
- American College of Cardiology  
- American Heart Association  
- ACHD Guideline (Acute Congenital Heart Disease)  
- Clinical strategies  
- Interventions  
- Treatments  
- Diagnostic testing

Page 14 Extracted Terms:
- ACHD (adult congenital heart disease)  
- congenital heart disease  
- anatomic lesions  
- anatomical repairs  
- International Paediatric and Congenital Cardiac Code  
- anatomic complexity (simple–complex I–III)  
- physiological stage (A–D)  
- residual anatomic sequelae  
- advanced heart failure  
- pulmonary arterial hypertension (PAH)  
- valve replacement  
- arrhythmias  
- Fontan circulation  
- systemic right ventricle  
- truncus arteriosus  
- coarctation of the aorta (COA)  
- ventricular dysfunction  
- mortality risk  
- surgical outcomes  
- maternal and fetal complications of pregnancy  
- risk‑stratification tools  
- non‑cardiac procedures at ACHD centers  
- invasive cardiac procedures  
- cardiac anesthesia  
- reproductive health, pregnancy, and delivery  
- hemodynamic stress  
- ACHD consultation  
- routine diagnostic studies  
- follow‑up intervals  
- biomarkers (e.g., N‑terminal pro‑hormone of B‑type natriuretic peptide, NT‑proBNP)  
- unplanned heart‑failure hospitalizations  
- endocarditis.

Page 15 Extracted Terms:
- Adult Congenital Heart Disease (ACHD)  
- Acquired heart disease  
- Atrial septal defect (ASD)  
- Patent ductus arteriosus (PDA)  
- Ventricular septal defect (VSD)  
- Pulmonic stenosis  
- Anomalous aortic origin of a coronary artery from the opposite sinus  
- Anomalous coronary artery arising from the pulmonary artery  
- Anomalous pulmonary venous connection (partial or total)  
- Atrioventricular septal defect (partial or complete)  
- Congenital aortic valve disease  
- Congenital mitral valve disease  
- Coarctation of the aorta  
- Cor triatriatum sinister  
- Dextro‑transposition of the great arteries (TGA) after arterial switch operation  
- Ebstein anomaly  
- Infundibular right ventricular outflow obstruction / double‑chamber right ventricle  
- Peripheral pulmonary artery stenosis  
- Sinus venosus defect  
- Subvalvular aortic stenosis  
- Supravalvar aortic stenosis  
- Tetralogy of Fallot  
- Vascular ring or sling  
- Double‑outlet ventricle  
- Fontan physiology  
- Interrupted aortic arch  
- Pulmonary atresia (all forms)  
- Single‑ventricle anatomy (including double‑inlet left ventricle, tricuspid/mitral atresia, hypoplastic left heart)  
- Congenitally corrected TGA (CCTGA, levo‑TGA)  
- Dextro‑TGA after atrial switch (Mustard/Senning) operation  
- Dextro‑TGA after Rastelli operation  
- Truncus arteriosus  
- Unrepaired or partially palliated cyanotic congenital heart defect  
- Heart failure  
- B‑type natriuretic peptide (BNP)  
- N‑terminal pro‑B‑type natriuretic peptide (NT‑proBNP)  
- New York Heart Association (NYHA) functional class  
- Endocarditis  
- Eisenmenger syndrome  
- Pulmonary arterial hypertension (low‑risk, intermediate‑risk, high‑risk)  
- Arrhythmia (including sustained or high‑burden tachyarrhythmia)  
- Tachyarrhythmia  
- Implantable cardioverter‑defibrillator (ICD)  
- Permanent pacemaker  
- Hypoxemia (mild, moderate, severe)  
- Valve dysfunction (mild, moderate, severe)  
- Ventricular dysfunction (mild, moderate, severe)  
- Ventricular enlargement (mild)  
- Shunt (trivial/small, hemodynamically significant)  
- Hemodynamic sequelae  
- Hemodynamic significance  
- Physiological stage (A, B, C, D) in ACHD classification.

Page 16 Extracted Terms:
- AAOCA (anomalous aortic origin of a coronary artery)  
- ACHD (adult congenital heart disease)  
- AP (anatomic and physiological)  
- APVC (anomalous pulmonary venous connection)  
- ASD (atrial septal defect)  
- AVSD (atrioventricular septal defect)  
- BAV (bicuspid aortic valve)  
- BNP (B‑type natriuretic peptide)  
- CCTGA (congenitally corrected transposition of the great arteries)  
- CMR (cardiovascular magnetic resonance)  
- COA (coarctation of the aorta)  
- CPET (cardiopulmonary exercise testing)  
- CRT (cardiac resynchronization therapy)  
- CT (computed tomography)  
- DCRV (double‑chambered right ventricle)  
- d‑TGA (dextro‑transposition of the great arteries)  
- FALD (Fontan‑associated liver disease)  
- GDMT (guideline‑directed medical therapy)  
- HLHS (hypoplastic left heart syndrome)  
- ICD (implantable cardioverter‑defibrillator)  
- NYHA (New York Heart Association functional classification)  
- Qp:Qs (pulmonary‑to‑systemic blood flow ratio)  
- Arrhythmia (atrial or ventricular tachyarrhythmias)  
- Valvular heart disease (VHD) – mild, moderate, severe  
- Exercise capacity – objective and subjective limits  
- Hypoxemia (resting SpO₂ ≤ 92 %)  
- Severe hypoxemia (SpO₂ ≤ 85 %)  
- Hypoxia (tissue oxygenation inadequate)  
- Cyanosis (blue/purple discoloration, ≥ 5 g/dL desaturated Hb)  
- Pulmonary arterial hypertension (mean PA pressure ≥ 20 mm Hg, PAWP ≤ 15 mm Hg, PVR ≥ 2 WU)  
- Pulmonary arterial hypertension risk categories (3‑strata)  
- Hemodynamically significant intrathoracic shunt (Qp:Qs ≥ 1.5, chamber enlargement)  
- Ventricular dysfunction  
- Hemodynamics  
- Right heart catheterization  
- Hemodinamically significant intracardiac shunt  
- Cardiac resynchronization therapy (CRT)  
- Implanted defibrillator (ICD)  

These terms capture the key clinical concepts related to heart disease as presented in the guideline text.

Page 17 Extracted Terms:
- Acute congenital heart disease (ACHD)  
- Adult congenital heart disease (ACHD)  
- Left ventricular (LV)  
- Left ventricular outflow tract (LVOT)  
- Mechanical circulatory support (MCS)  
- Magnetic resonance (MR)  
- N-terminal pro‑brain natriuretic peptide (NT‑proBNP)  
- Pulmonary artery (PA)  
- Pulmonary arterial hypertension (PAH)  
- Pulmonary atresia with intact ventricular septum (PA‑IVS)  
- Patent ductus arteriosus (PDA)  
- Pulmonary vascular resistance (PVR)  
- Pulmonary‑to‑systemic blood flow ratio (Qp:Qs)  
- Right ventricular (RV)  
- Right ventricular end‑diastolic volume (RVEDV)  
- Right ventricular outflow tract (RVOT)  
- Right ventricle‑to‑pulmonary artery (RV‑to‑PA)  
- Sudden cardiac death (SCD)  
- Sinus venosus atrial septal defect (SVASD)  
- Tetralogy of Fallot (TOF)  
- Ventricular septal defect (VSD)  
- Transition education  
- Transfer of care policies and procedures  
- Loss to care (attrition)  
- Transition education policies  
- Transition education procedures  
- Transfer-of-care protocols  
- Comprehensive transfer of care  
- Structured transition education  
- Patient‑centered transition education  
- Transition education success metrics  

Page 18 Extracted Terms:
**Key terms related to heart disease in the guideline**

- Adult Congenital Heart Disease (ACHD)  
- Congenital Heart Disease (CHD)  
- Transfer of care from pediatric to ACHD providers  
- Lifelong continuum of congenital heart disease care  
- Gaps in care delivery  
- Morbidity  
- Premature mortality  
- Electronic medical records (EMR)  
- Nurse navigator  
- Social worker  
- Insurance barriers  
- Distance to clinic  
- Work and career disruptions  
- Critical care stages: diagnosis, palliative interventions, transfer to ACHD, lifelong ACHD care, reinterventions  
- Continuous patient education  
- Congenital heart disease diagnosis specifics (name, anatomy, physiology)  
- Surgical procedures for CHD  
- Diagnostic evaluation  
- Reproductive health education  
- Development of independent skills (appointments, prescriptions, provider contact, insurance maintenance)  
- Lifelong specialized CHD care by ACHD cardiologists  
- Seamless transitions from pediatric to ACHD  
- Socioeconomic stress (risk factor for loss to care)  
- Ethnic disparities (non‑White patients)  
- Readiness for transfer of care  
- Referral policies to ACHD care  
- Tracking of transfer patients (via EMR and databases)  
- Early childhood (0‑12 years) CHD care  
- Adolescence to young adulthood (13‑18 years) CHD care  
- Young adulthood (18‑26 years) CHD care  
- Adulthood (18‑80+ years) CHD care  
- ACHD cardiologists and programs  
- Adult care hospitals  
- ACHD advocacy organizations  
- Telehealth as a care option  
- Advanced practice providers (e.g., nurse practitioners, physician assistants)  
- General cardiologists (for local care)  
- Geographic availability of ACHD cardiologists  
- Loss to care  
- Barriers to care (insurance, distance, socioeconomic factors)  
- Electronic health records and databases for monitoring care continuity  
- Policies and procedures for transfer, referral, and tracking of patients  
- Pediatric cardiology/heart centers  
- Payors (insurance carriers)  
- Congenital heart disease advocacy organizations 

Page 19 Extracted Terms:
**Key heart‑disease terms extracted from the text**

- Adult Congenital Heart Disease (ACHD)  
- ACHD clinical class (AP class)  
- Cardiologist / ACHD cardiologist  
- ACHD program / multidisciplinary ACHD program  
- Complex congenital anatomy and physiology  
- Cardiac interventions & surgical repairs  
- Long‑term complications of congenital heart disease  
- Diagnostic testing & follow‑up  

**Clinical and procedural domains**

- Advanced imaging  
  - Cardiac computed tomography (CT)  
  - Cardiovascular magnetic resonance (CMR)  
  - Echocardiography  
- Heart failure management  
- Heart or multiorgan transplant evaluation & listing  
- Diagnostic and interventional heart catheterization  
- Electrophysiology (arrhythmia, device implantation, EP study)  
- Cardiac surgery / cardiothoracic surgery  
- Cardiac anesthesia & ICU support  

**Specialist and support services**

- Congenital cardiac surgeon  
- Advanced practice provider  
- Registered nurse  
- Cardiac intensivist  
- Advanced heart‑failure and transplant cardiologist  
- Cardiac catheterization interventionalist  
- Electrophysiologist  
- Cardiac anesthesiologist  
- Maternal‑fetal medicine specialist  
- Hepatologist  
- Pulmonary hypertension specialist  
- Cardiovascular genetics specialist  
- Palliative medicine specialist  
- Social worker  
- Psychologist  

**Systemic/organizational factors**

- Barriers to care (geographic distance, insurance coverage, socioeconomic challenges)  
- Clinical evaluation for worsening AP class  
- Referral for advanced imaging beyond local expertise  
- Referral for worsening heart failure  
- Referral for transplant evaluation  
- Referral for diagnostic/interventional therapies  
- Referral for electrophysiology studies  
- Referral for cardiothoracic surgery  
- Pregnancy risk assessment/management  
- Non‑cardiac surgery in high‑risk populations (AP classes IC–D, IIA–D, IIIA–D)  
- Need for ACHD cardiac anesthesia and ICU support  

**Administrative and accreditation terms**

- Board certification (American Board of Internal Medicine, American Board of Pediatrics)  
- Accreditation Council for Graduate Medical Education (ACGME) training programs  
- High‑quality integrated multidisciplinary care  
- Evidence Table / guideline recommendations  

These terms capture the central concepts and entities related to heart disease management as presented in the clinical statements and guidelines excerpt.

Page 20 Extracted Terms:
- Adult Congenital Heart Disease (ACHD)  
- Congenital heart disease  
- Complex congenital heart disease  
- Heart failure  
- Arrhythmias (including bradyarrhythmias)  
- Cyanosis  
- Pulmonary hypertension / Pulmonary vascular disease  
- Valvular disease  
- Ventricular function (systemic and subpulmonary)  
- Persistent shunts (right‑to‑left shunts)  
- Endocarditis prophylaxis  
- Erythrocytosis  
- Frailty  
- Perioperative complications (in the context of heart disease)  
- Pre‑operative optimization for cardiac risk  
- Risk stratification for cardiac patients  
- Periprocedural planning in cardiac patients  
- Management of anticoagulation in cardiac patients  
- Management of venous/arterial access in cardiac patients  

(These terms capture the key heart‑disease concepts addressed in the excerpt.)

Page 21 Extracted Terms:
**Key heart‑disease terms extracted from the text**

- Adult Congenital Heart Disease (ACHD)  
- Single‑ventricle physiology  
- Residual lesions / residual disease  
- Pre‑operative evaluation  
- Vascular resistances  
- Cyanosis  
- ACHD anatomic classification II/III  
- ACHD physiological stages C/D  
- ACHD program / specialized center  
- Systemic and pulmonary shunts  
- Post‑operative complications  
- Fluid shifts  
- Blood‑pressure variation  
- Oxygenation / ventilation parameters  
- Arrhythmias  
- Fontan physiology  
- Pulmonary vascular disease  
- Transpulmonary gradient  
- Systemic ventricular preload  
- Anesthetic planning for ACHD  
- Preload / afterload management  
- Vasoactive medications  
- Ventilator strategies  
- Pulmonary vascular resistance (PVR)  
- Hemodynamic monitoring  
- Coagulopathy risk  
- Paradoxical embolism (right‑to‑left shunts)  
- Ventricular septal defect (VSD)  
- Eisenmenger syndrome  
- Heart failure  
- Adverse cardiovascular outcomes  
- Health‑care utilization in ACHD patients  
- Neurocognitive and mental‑health considerations in ACHD (depression, anxiety, PTSD, cognitive decline, frailty)

Page 22 Extracted Terms:
- Adult Congenital Heart Disease (ACHD)  
- Congenital heart disease (CHD)  
- ACHD cardiologist  
- Cardiology (congenital)  
- Cardiac surgery  
- Cardiac catheter‑based procedures  
- Electrophysiology (EP) procedures  
- Invasive cardiac procedures  
- Cardiac anesthesia  
- Perioperative complications  
- Risk stratification  
- Preprocedural evaluation  
- Postprocedural care  
- Guideline‑based therapy  
- Clinical outcomes  
- Periprocedural planning  
- Procedural optimization  
- High‑risk cardiac surgery  
- Device implantation (cardiac/EP)  
- Anesthesiologist with CHD expertise  
- Acquired cardiovascular disease in ACHD patients  
- Multidisciplinary collaboration (ACHD, anesthesiology, surgery, EP)

Page 23 Extracted Terms:
- Adult congenital heart disease (ACHD)  
- Atrioventricular (AV) complex pathology  
- Ablation protocol (AP) complexity  
- Palliated single ventricle physiology  
- Cyanosis  
- Valve disease  
- Heart failure  
- Arrhythmias  
- Invasive cardiac procedures  
- Periprocedural care  
- Procedural risk‑scoring systems  
- Coronary artery disease (CAD)  
- Aortic aneurysm  
- Calcific valvar stenosis  
- Iron deficiency anemia in ACHD  
- Hyperviscosity syndrome  
- Cerebral abscess  
- Stroke  
- Neurologic deficits  
- Anesthesia management in ACHD  
- Ventilation strategies in ACHD surgery  
- Cardio‑obstetrics care  
- Pregnancy‑related cardiovascular complications  
- Family planning in ACHD patients  
- Congenital heart surgery fellowship  
- ACHD cardiology board certification  
- Electrophysiology in ACHD  
- Interventional cardiology in ACHD  
- Multidisciplinary ACHD team  
- Ancillary imaging for ACHD  
- Surgical palliation sequelae  
- Hemodynamics of congenital lesions  
- Anesthetic pharmacology in ACHD  
- Co‑surgeon model (ACHD + acquired disease)

Page 24 Extracted Terms:
- Atrial‑ventricular congenital heart disease (ACHD)  
- Cyanotic heart disease  
- Cyanosis  
- Hypoxemia  
- Right‑to‑left shunt  
- Secondary erythrocytosis  
- Hyperviscosity syndrome  
- Hematocrit >65 %  
- Iron‑deficiency anemia  
- Pheochromocytoma  
- Paraganglioma  
- Eisenmenger syndrome  
- Stroke (ischemic)  
- Transient ischemic attack (TIA)  
- Pulmonary embolism  
- Thrombosis  
- Coagulation cascade  
- Hypercoagulability  
- Hypocoagulability  
- Hemoptysis  
- Epistaxis  
- Exercise intolerance  
- Myocardial ischemia  
- Neurologic complications (brain abscess, stroke)  
- Pregnancy‑related cardiovascular complications  
- Estrogen‑containing oral contraceptives (thromboembolic risk)  
- Anticoagulation and antiplatelet therapy  
- International normalized ratio (INR)  
- Hyperviscosity symptoms (headache, visual disturbance)  
- Hyperviscosity management (rehydration, iron replacement, phlebotomy)  

These terms capture the primary heart‑disease–related concepts discussed in the guideline excerpt.

Page 25 Extracted Terms:
- Adult Congenital Heart Disease (ACHD)  
- Cyanosis (cyanotic ACHD)  
- Tachycardia  
- Hypertension  
- Pheochromocytoma  
- Paraganglioma  
- Plasma fractionated metanephrines  
- 24‑hour urinary fractionated metanephrines  
- Hyperuricemia  
- Gout  
- Reduced exercise capacity (in ACHD patients)  
- Supplemental oxygen use during exercise  
- Hyperviscosity symptoms  
- Iron deficiency (annual screening)  
- Hematocrit (HCT)

Page 26 Extracted Terms:
- ACHD (Aneuploidy or Congenital Heart Disease)  
- Acute phlebotomy (removal of 250–500 mL blood)  
- Hyperviscosity syndrome  
- Cyanosis  
- Iron deficiency  
- Stroke risk  
- Systemic left ventricular (LV) dysfunction  
- Biventricular circulation  
- Cardiac resynchronization therapy (CRT)  
- Guideline‑directed medical therapy (GDMT) for heart failure  
- Implantable cardioverter‑defibrillator (ICD)  
- Sudden cardiac death (SCD)  
- Mechanical circulatory support  
- Heart transplantation  
- Fontan physiology (single‑ventricle)  
- Systemic right ventricle (dextro‑TGA with atrial switch, CCTGA)  
- Endocarditis  
- Bradyarrhythmia  
- Restrictive physiology  
- Multimorbidity  
- Frailty  
- Polypharmacy  
- Ventricular activation pattern  
- Myocardial contraction  
- Electrical dyssynchrony  
- Cardiac remodeling  
- Overall survival  
- Quality of life  
- Heart failure hospitalization  
- Hematocrit level  
- Isotonic fluid replacement.

Page 27 Extracted Terms:
**Key terms related to heart disease extracted from the text**

- Acquired congenital heart disease (ACHD)  
- Systemic left ventricle (LV)  
- LV systolic dysfunction / severe LV dysfunction (ejection fraction ≤ 35%)  
- Global Guideline‑Directed Medical Therapy (GDMT)  
- Angiotensin Receptor–Neprilysin Inhibitors (ARNI)  
- Sodium‑Glucose Cotransporter 2 Inhibitors (SGLT2i)  
- Heart failure (HF) symptoms  
- Heart failure hospitalization  
- New York Heart Association (NYHA) functional class (II–III)  
- Biomarkers of cardiac strain  
- Sudden Cardiac Death (SCD)  
- SCD risk calculator (e.g., from CONCOR registry)  
- Ebstein anomaly  
- Post‑operative Fontan physiology  
- Systemic right ventricle  
- Implantable Cardioverter‑Defibrillator (ICD)  
- Primary‑prevention ICD placement  
- Inappropriate ICD shocks (e.g., in Tetralogy of Fallot)  
- Heart transplantation (HTx)  
- Mechanical Circulatory Support (MCS)  
- Temporary MCS (e.g., implantable vascular devices)  
- Durable MCS (LV or biventricular support)  
- Bridge to transplantation  
- Destination therapy  
- Multiorgan transplantation (heart‑lung, heart‑kidney, heart‑liver)  
- Fontan‑related transplantation indications  
- Transplant wait‑list management  
- High‑volume transplant centers with ACHD accreditation  
- Cardiogenic shock  

These terms capture the clinical entities, therapies, devices, and patient populations discussed in the guidelines.

Page 28 Extracted Terms:
- Adult Congenital Heart Disease (ACHD)  
- Ventricular dysfunction  
- Systemic ventricular dysfunction  
- Heart failure  
- Advanced heart failure  
- Heart‑failure‑related hospital admissions  
- Cardiopulmonary exercise stress testing (CPET)  
- Heart transplantation  
- Heart‑lung transplantation  
- Heart‑kidney transplantation  
- Heart‑liver transplantation  
- Multiorgan transplantation  
- Eisenmenger syndrome  
- Fontan palliation  
- Fontan physiology  
- Durable mechanical circulatory support (MCS)  
- Temporary mechanical circulatory support  
- Mechanical circulatory support (MCS)  
- Advanced liver fibrosis  
- Conotruncal defects  
- Heterotaxy  
- 22q11.2 deletion syndrome  
- Congenital heart disease  
- Genetic syndromes screening  

Page 29 Extracted Terms:
- Conotruncal anomalies  
- Infundibulum (outflow tract)  
- Great arteries  
- 22q11.2 deletion syndrome (DiGeorge syndrome, velocardiofacial syndrome)  
- Tetralogy of Fallot  
- Ventricular septal defect (VSD)  
- Pulmonary atresia  
- Interrupted aortic arch type B  
- Truncus arteriosus  
- Down syndrome (trisomy 21)  
- Atrial septal defect (ASD)  
- Atrioventricular septal defect (AVSD)  
- Holt‑Oram syndrome (TBX5)  
- Klinefelter syndrome (47,XXY) – patent ductus arteriosus, ASD, mitral valve prolapse  
- Noonan syndrome (PTPN11, KRAS, SOS1, RAF1, NRAS, BRAF, MAP2K1) – pulmonary stenosis, ASD, hypertrophic cardiomyopathy, AVSD  
- Turner syndrome (45,X) – bicuspid aortic valve, coarctation of the aorta, aortopathies, partial anomalous pulmonary venous connection, atherosclerosis risk  
- Williams syndrome (7q11.23 deletion) – supravalvar aortic stenosis, branch pulmonary artery stenosis, supravalvar pulmonary stenosis, coronary ostial stenosis, QTc prolongation, mid‑aortic narrowing syndrome  
- Alagille syndrome (JAG1) – peripheral or branch pulmonary artery stenosis, coarctation of the aorta, aortic stenosis, septal defects, mid‑aortic narrowing  
- Heterotaxy syndrome  
  - ZIC3, SHROOM3, GRK5, ANKS3, NODAL, CFC1, LEFTY2, GDF1, SMAD2, ACVR2B  
  - Situs abnormalities, ciliary dysfunction, functional asplenia, conduction abnormalities, biliary atresia, atrioventricular septal defects (balanced/unbalanced), malposed great vessels, interrupted IVC, bilateral SVC, atrial isomerism  
- Bicuspid aortic valve  
- Coarctation of the aorta  
- Aortic arch abnormalities  
- Pulmonary stenosis  
- Left‑ventricular hypertrophy / hypertrophic cardiomyopathy  
- Coronary ostial stenosis  
- QTc prolongation  
- Atherosclerosis risk (associated with Turner syndrome)  
- Partial anomalous pulmonary venous connection  
- Aortic stenosis  
- Valvular disease (mitral valve prolapse, pulmonary stenosis)  
- Conduction abnormalities (associated with various syndromes)

Page 30 Extracted Terms:
**Key terms related to heart disease extracted from the text**

1. Congenital heart disease  
2. ACHD (Adult Congenital Heart Disease)  
3. Genetic referral / genetic evaluation  
4. Genetic counseling / preconception genetic counseling  
5. Noonan syndrome  
6. Williams syndrome  
7. Heterotaxy syndrome  
8. QTc prolongation  
9. Sudden cardiac death  
10. Cardiac monitoring  
11. Cardiologist (ACHD cardiologist)  
12. Cardio‑obstetrics team  
13. Peripartum cardiomyopathy  
14. Spontaneous coronary artery dissection  
15. Mechanical heart valves (mechanical valvular prostheses)  
16. Arrhythmia  
17. Heart failure  
18. Thromboembolic events / thrombosis  
19. Estrogen‑containing contraceptive agents  
20. Maternal morbidity and mortality  
21. Pregnancy‑related cardiac complications  
22. Pre‑risk stratification / risk scores for cardiac patients in pregnancy  
23. Maternal cardiac risk management  
24. Obstetric cardiac surveillance (cardiac monitoring during pregnancy)  
25. Cesarean delivery (in the context of cardiac risk)  
26. Assisted reproductive technology (ART) and cardiac risk  
27. Cardiac procedural outcomes / surgical outcomes  
28. Platelet dysfunction (in the context of Noonan syndrome)  
29. Anesthesia‑related cardiac risk (QTc prolongation risk)  
30. Cardiac risk stratification in pregnancy (AP classifications IB–D, IIA–D, IIIA–D)  

These terms capture the primary heart‑disease concepts, syndromic associations, reproductive‑cardiac considerations, and procedural/therapeutic elements highlighted in the clinical statements and guidelines.

Page 31 Extracted Terms:
- Adult Congenital Heart Disease (ACHD)  
- Cardio‑obstetrics team  
- Hemodynamic effects of pregnancy  
- Contraceptive agents (in ACHD)  
- Modified World Health Organization (WHO) classification system  
- CARPREG 2 score  
- Maternal cardiac risk  
- Fetal echocardiography  
- Pulmonary arterial hypertension (PAH)  
- Eisenmenger syndrome  
- Severe ventricular dysfunction  
- Left‑sided obstructive lesions (e.g., mitral and aortic stenosis)  
- Systemic right ventricle with depressed function  
- New York Heart Association (NYHA) functional class III/IV  
- Aortopathy (≥ 5 cm diameter or connective‑tissue disorder)  
- Mechanical heart valves  
- Refractory ventricular arrhythmias  
- Fontan physiology  
- Severe native coarctation or recoarctation  
- Cyanotic congenital heart disease  
- Advanced NYHA class (III or IV)  
- Systemic ventricular dysfunction (EF < 30 %)  



Page 32 Extracted Terms:
- Adult Congenital Heart Disease (ACHD)  
- Pulmonary Arterial Hypertension (PAH)  
- Fontan physiology  
- Mechanical heart valves  
- Thrombotic events / thromboembolism  
- Anticoagulation therapy  
- Estrogen‑containing contraceptive agents (contraindicated in ACHD)  
- High‑risk aortopathies (high‑risk cardiac conditions)  
- Ionizing radiation exposure  
- Cardiac catheterization  
- Invasive electrophysiology procedures  
- Computed tomography (CT) scans  
- Nuclear perfusion scans  
- Chest X‑rays  
- Cardiopulmonary exercise testing (CPET)  
- Six‑minute walk test  
- New York Heart Association (NYHA) functional class  
- Cardiovascular procedures (general)  
- Radiation dose‑reduction strategies (low‑dose ionizing radiation)  
- Cancer risk associated with cardiac imaging  
- Functional capacity assessment (exercise capacity, symptom severity)  
- Adverse cardiovascular events (hospitalization, mortality)  
- Maternal cardiac outcomes (in pregnancy)  

These terms capture the key concepts and clinical focus areas related to heart disease within the provided guideline text.

Page 33 Extracted Terms:
- Adult Congenital Heart Disease (ACHD)  
- Cardiopulmonary Exercise Testing (CPET)  
- Six‑Minute Walk Test  
- Pulmonary Arterial Hypertension (PAH)  
- Heart Failure  
- Mortality  
- Major Adverse Cardiovascular Events  
- Hemodynamic Intervention  
- Surgical Reintervention  
- Functional Capacity  
- Exercise Capacity  
- Physical Activity  
- Sports Participation  
- Cardiac Rehabilitation  
- Systemic Ventricular Systolic Dysfunction  
- Systemic Ventricular Outflow Tract Obstruction  
- Hemodynamically Significant Arrhythmias  
- Aortic Dilation  
- Tetralogy of Fallot (TOF)  
- Systemic Right Ventricle  
- Fontan Palliation  
- Unrepaired Cyanotic Heart Disease  
- Metabolic Equivalents (METs)  
- Predicted Maximum Heart Rate  
- NT‑proBNP  
- Fibrinogen  
- Cardiac Autonomic Function  
- Vascular Function  
- Quality of Life  
- Self‑Reported Health Status  
- Borg Scale (breathlessness rating)  
- Intensity Rating of Breathlessness  
- Exercise Training  
- Cardiac Rehab Program  
- Cardiovascular Events

Page 34 Extracted Terms:
- Adult congenital heart disease (ACHD)  
- Congenital shunt lesions  
- Atrial septal defect (ASD)  
- Ventricular septal defect (VSD)  
- Atrio‑ventricular septal defect (AVSD)  
- Patent ductus arteriosus (PDA)  
- Anomalous pulmonary venous return  
- Left‑to‑right shunt  
- Right‑to‑left shunt  
- Shunt magnitude / size  
- Pulmonary‑to‑systemic blood flow ratio (Qp:Qs) ≥ 1.5  
- Eisenmenger syndrome  
- Pulmonary arterial hypertension (PAH)  
- Mean pulmonary artery pressure > 20 mm Hg  
- Pulmonary vascular resistance (PVR) > 2 Wood units  
- Pulmonary arterial wedge pressure ≤ 15 mm Hg  
- Resting hypoxemia / cyanosis  
- Risk assessment tools (e.g., 3‑strata, 4‑strata models)  
- 6‑minute walk distance (6MWD)  
- B‑type natriuretic peptide (BNP)  
- C‑reactive protein  
- Echocardiography  
- Exercise‑induced hypoxemia  
- Formal exercise testing  
- Rhythm monitoring  
- Imaging studies  
- Multidisciplinary care strategy  
- Shared decision‑making  
- Exercise testing for competitive sports  
- PH‑specific therapies  
- Endothelin‑receptor antagonists  
- Phosphodiesterase‑5 inhibitors  
- Prostacyclin analogs  
- Oral prostacyclin receptor analogs  
- Activin‑signaling inhibitors  
- Perioperative risk  
- Cardiovascular morbidity & mortality  
- Competing health outcomes (e.g., exercise capacity vs. PAH progression)

Page 35 Extracted Terms:
- Atrial Septal Defect (ASD)  
- Unrepaired ASD  
- ASD closure  
- Percutaneous closure  
- Surgical closure  
- Transcatheter closure  
- Fenestrated closure (fenestrated repair)  
- Partial defect closure (fenestrated closure)  
- Closure contraindicated (high‑risk closure)  
- Pulmonary Arterial Hypertension (PAH)  
- Pulmonary vascular resistance (PVR)  
- Wood units (unit of PVR measurement)  
- Left‑to‑right shunt (Qp:Qs ratio)  
- Qp:Qs ≥ 1.5  
- RV dilation (right‑ventricular dilation)  
- LV disease (left‑ventricular disease)  
- Significant LV disease (chronically elevated left‑atrial pressure ≥ 15 mm Hg)  
- Eisenmenger physiology  
- Transesophageal echocardiography (TEE)  
- Cardiac magnetic resonance imaging (CMR)  
- Cardiac computed tomography (CT)  
- Pulmonary venous connections  
- Anomalous pulmonary venous return  
- Paradoxical embolism  
- Paradoxical embolism prevention (ASD closure)  
- Right‑to‑left shunting  
- Right‑heart chamber enlargement  
- Right‑ventricular dysfunction  
- Functional class (NYHA/WHO)  
- Clinical outcomes  
- Medium‑term functional status  
- Targeted PAH therapy  
- Risk assessment and management (pulmonary hypertension specialists)  
- Post‑closure hemodynamic assessment  
- Long‑term PAH therapies  
- Treat‑and‑repair approach (treat‑and‑repair)  
- Pre‑tricuspid shunts  
- Shunt type: secundum, primum, sinus venosus (superior/inferior), unroofed coronary sinus  
- Hemodynamic consequences of ASD  
- Atrial arrhythmia (post‑closure arrhythmias)  
- High pressure (right‑sided or left‑sided)  
- Diagnostic imaging: transthoracic echocardiography (TTE)  
- Cross‑sectional imaging (for distant pulmonary venous connections)  

*(All terms extracted from the provided clinical guideline text.)*

Page 36 Extracted Terms:
- Atrial Septal Defect (ASD)  
- Adult Congenital Heart Disease (ACHD)  
- Pulmonary Arterial Hypertension (PAH)  
- Mean Pulmonary Artery Pressure (mPAP)  
- Pulmonary Vascular Resistance (PVR)  
- Pulmonary Capillary Wedge Pressure (PCWP)  
- B‑type Natriuretic Peptide (BNP)  
- N‑terminal pro‑BNP (NT‑proBNP)  
- Right Heart Dysfunction  
- Right Ventricular Enlargement (RVE)  
- Right Atrial Enlargement (RAE)  
- Tricuspid Regurgitation (TR)  
- Tricuspid Annular Plane Systolic Excursion (TAPSE)  
- Right Ventricular Outflow Tract (RVOT)  
- Electrocardiogram (ECG)  
- Transthoracic Echocardiography  
- Cardiac Magnetic Resonance Imaging (CMR)  
- Cardiac Computed Tomography (CT)  
- Exercise Testing (6‑minute walk)  
- Hemodynamic Assessment (right heart catheterization)  
- Pulmonary Hypertension Guidelines  
- Risk Assessment / Risk Stratification  
- PAH‑directed Therapy  
- Fenestrated Patch Closure  
- Balloon Test Occlusion  
- Device Erosion  
- Shunting  
- Desaturation with exercise  
- Functional Capacity  
- Congestion  
- Abdominal Distention  
- Early Satiety  
- Cyanosis  
- Clubbing  
- Accentuated S2 Heart Sound  
- Jugular Venous Distention  
- Peripheral Edema

Page 37 Extracted Terms:
- Atrial septal defect (ASD)  
- Pulmonary arterial hypertension (PAH)  
- Pulmonary vascular resistance (PVR)  
- Left ventricular dysfunction (LV dysfunction)  
- Right heart overcirculation  
- Right-sided chamber enlargement  
- Qp:Qs ratio  
- Pulmonary capillary wedge pressure (PCWP)  
- Tricuspid regurgitation  
- Fenestrated closure  
- Transcatheter closure  
- Surgical closure  
- Hemodynamics  
- Functional capacity  
- Morbidity and mortality  
- 6‑minute walk distance  
- Functional class  
- Paradoxical embolism  
- Thrombophilia  
- Electrophysiology study  
- Partial anomalous pulmonary venous return (PAPVR)  
- Device placement  
- Left atrial pressure  
- Elevated right heart pressure  
- Dual PAH therapy  
- Targeted PAH therapy  
- Residual shunt  
- Reversal of PAH  
- Right ventricular dimensions  
- Direct PAH therapy  
- Specialized PAH management  
- Hemodynamic changes after ASD closure  
- Right ventricular dilatation  

---

Page 38 Extracted Terms:
- Atrial septal defect (ASD)  
- Pulmonary arterial hypertension (PAH)  
- Pulmonary hypertension (PH)  
- Adult congenital heart disease (ACHD)  
- Fenestrated transcatheter device  
- Fenestrated surgical repair  
- Dual up‑front PAH therapy  
- Pulmonary vascular resistance (PVR)  
- Pulmonary arterial pressures (PA pressures)  
- Right ventricle (RV)  
- Left heart disease  
- Wood units (WU)  
- Qp:Qs (pulmonary‑to‑systemic blood flow ratio)  
- Percutaneous fenestrated ASD closure  
- Hemodynamics (optimization)

Page 39 Extracted Terms:
- Superior SVASD  
- Superior vena cava (SVC)  
- Unroofed right upper pulmonary vein  
- Left‑to‑right atrial shunt  
- Transcatheter closure  
- Adult congenital heart disease (ACHD)  
- Pulmonary arterial hypertension (PAH)  
- Pulmonary vascular resistance (PVR) – Wood units  
- Atrial septal defect (ASD)  
- Fenestrated closure  
- Eisenmenger syndrome  
- Ventricular septal defect (VSD)  
- Perimembranous VSD  
- Outlet VSD  
- Double‑chambered right ventricle (DCRV)  
- Right ventricular outflow tract (RVOT) obstruction  
- Qp:Qs ratio  
- Left ventricular (LV) dilation / volume overload  
- Aortic regurgitation  
- Infective endocarditis (with VSD involvement)  
- Transesophageal echocardiography (TEE)  
- Cross‑sectional imaging (e.g., CT/MRI)  
- Sutureless or covered stent closure  
- Treat‑to‑close approach  
- Surgical superior SVASD repair  
- Satisfactory procedural success (>95%)  
- In‑hospital and 30‑day mortality (<1%)  
- Clinical guideline recommendations (B‑NR, C‑LD)  
- Pulmonary hypertension specialist care  

(These terms capture key heart‑disease concepts referenced in the clinical statements and guidelines.)

Page 40 Extracted Terms:
- Ventricular Septal Defect (VSD)  
- VSD closure (surgical or percutaneous)  
- Left‑to‑right shunt  
- Qp:Qs ratio (pulmonary/systemic flow ratio)  
- Pulmonary Arterial Hypertension (PAH)  
- Pulmonary Vascular Resistance (PVR) – Wood units  
- Eisenmenger physiology / Eisenmenger syndrome  
- Left‑ventricular volume overload  
- Left‑ventricular dilatation / hypertrophy  
- Left‑ventricular dysfunction  
- Right‑ventricular dysfunction  
- Pulmonary hypertension (general)  
- Arrhythmia (including complete heart block)  
- Heart failure  
- Infective endocarditis  
- Conduction system disease  
- Transthoracic echocardiography (TTE)  
- Transesophageal echocardiography (TEE)  
- Transcatheter (catheter‑based) closure devices  
- Surgical closure procedures  
- Percutaneous closure procedures  
- Aortic insufficiency / aortic valve disease  
- Prolapse of the right coronary cusp (aortic valve)  
- Sinus of Valsalva aneurysm / prolapse  
- Double‑chambered right ventricle (DCRV)  
- Pulmonary hypertension therapies (pharmacologic)  
- Acute reversibility studies during cardiac catheterization  
- Pulmonary hypertension specialist care  
- Risk stratification for PAH  
- Late post‑closure PAH  
- Residual shunt  
- Complete heart block risk (perimembranous VSD)  
- Wood units (measure of pulmonary vascular resistance)  
- Restrictive VSDs (pressure‑ and/or volume‑restrictive)  
- Non‑restrictive VSDs (large, associated with Eisenmenger)  

Feel free to add any additional terms that you find relevant to your clinical context.

Page 41 Extracted Terms:
- aortic insufficiency  
- sinus of Valsalva aneurysm  
- aortic valve cusp prolapse  
- ventricular septal defect (VSD)  
- aortic regurgitation  
- early aortic valve replacement  
- aortic valve repair  
- Eisenmenger syndrome  
- AR (aortic regurgitation abbreviation)  
- LV (left ventricular)  
- PVR (pulmonary vascular resistance)  
- Qp:Qs (pulmonary‑to‑systemic blood flow ratio)  
- Wood units  
- preventive surgery  
- conservative approach (treatment strategy)

Page 42 Extracted Terms:
- Ventricular septal defect (VSD)  
- Aortic valve replacement  
- Infective endocarditis  
- Pulmonary arterial hypertension (PAH)  
- Pulmonary vascular resistance (PVR)  
- Eisenmenger syndrome  
- Atrioventricular septal defect (AVSD)  
- Left‑ventricular outflow tract obstruction (LVOT obstruction)  
- Left‑ventricular systolic dysfunction  
- Left‑ventricular ejection fraction (LVEF)  
- Cardiopulmonary bypass  
- Pre‑operative PAH therapy  
- Peri‑operative risk  
- Right‑ventricular failure  
- Septic emboli to the lungs  
- Cerebral abscesses  
- Cerebrovascular events  
- Antibiotic prophylaxis  
- Percutaneous closure  
- Surgical closure  
- Right‑heart decompression  
- Atrial fenestration  
- Right‑ventricular volume overload  
- Left‑ventricular volume overload  
- Pulmonary hypertension management  
- Hemodynamic shunt assessment (Qp:Qs)  
- Long‑term PAH therapy  
- Right‑heart monitoring  
- Follow‑up echocardiography  
- Electrocardiogram monitoring  
- Functional status improvement  
- Risk stratification for ACHD patients  
- Adult congenital heart disease (ACHD)  
- Severe PAH with shunt reversal  
- Non‑restrictive VSD  
- Restrictive VSD  
- Unrepaired VSD  
- Residual shunts after repair  
- Ventricular septal defect closure strategy  
- Cardiovascular outcomes in ACHD  
- Complication risk with VSD repair  

These terms capture the core concepts, conditions, interventions, and complications discussed in the provided guideline excerpt.

Page 43 Extracted Terms:
- Atrioventricular septal defect (AVSD)  
- Atrioventricular canal  
- Endocardial cushion defect  
- Partial AVSD (incomplete atrioventricular canal / primum ASD)  
- Complete AVSD (complete atrioventricular canal)  
- Transitional AVSD (transitional atrioventricular canal)  
- Atrioventricular valve regurgitation  
- Left atrioventricular valve regurgitation  
- Left‑ventricular dilation  
- Left‑ventricular systolic dysfunction  
- Left‑ventricular ejection fraction  
- Left‑to‑right shunt (Qp:Qs)  
- Pulmonary arterial hypertension (PAH)  
- Pulmonary vascular resistance (PVR)  
- Eisenmenger physiology  
- Shunt closure  
- Residual shunts  
- Ventricular function  
- Surgical repair (of AVSD, shunt, valve, or LVOT)  
- Reoperation  
- Arrhythmias  
- Conduction abnormalities  
- Complete heart block  
- Electrocardiogram (ECG)  
- Transthoracic echocardiogram (TTE)  
- Cardiac catheterization  
- Adult congenital heart disease (ACHD)  
- Congenital heart defect / disease  
- Pulmonary hypertension  
- Subaortic stenosis  
- Valvular aortic stenosis  
- Left‑ventricular outflow tract (LVOT) obstruction  
- LVOT gradient (peak ≥50 mm Hg, mean ≥40 mm Hg)  
- LV function  
- Atrioventricular node displacement  
- His bundle displacement  
- Left‑axis deviation pattern  
- Late‑onset complete heart block  
- Routine follow‑up / monitoring  
- Pulmonary arterial hypertension guidelines (PAH guidelines)

Page 44 Extracted Terms:
**Key heart‑disease terms extracted from the text**

- Adult Congenital Heart Disease (ACHD)  
- Atrioventricular Canal Defect (AVSD) – partial and complete  
- Left Ventricular Outflow Tract (LVOT) obstruction  
- Mitral (left atrioventricular) valve regurgitation  
- Left Ventricular (LV) dysfunction  
- LV dilation / end‑systolic diameter >40 mm  
- Atrial septal defect (ASD)  
- Ventricular septal defect (VSD)  
- Pulmonary hypertension (PAH)  
- Eisenmenger physiology / syndrome  
- Pulmonary vascular disease  
- Pulmonary outflow tract obstruction (PVR)  
- Anomalous Pulmonary Venous Connections (APVC)  
- Shunt (left‑to‑right, Qp:Qs)  
- Right ventricular (RV) size and function  
- Peak Doppler gradients (≥ 50 mm Hg)  
- Echocardiography / Doppler imaging  
- Cardiovascular magnetic resonance (CMR) imaging  
- Computed tomography (CT) angiography  
- Cardiac catheterization  
- Surgical repair / primary repair / reoperation  
- Reintervention rates  
- Operative mortality / operative risk  
- Residual lesions / residual shunt  
- Symptomatic vs asymptomatic presentation  
- Functional capacity / dyspnea on exertion  
- Surgical indications and guidelines for chronic mitral regurgitation  
- Congenital heart surgeon expertise  
- Long‑term survival rates (e.g., 91–94 % at 15–30 years)  
- Reoperation risk (reoperation frequency, freedom from reoperation)  
- Heart failure as a risk factor for death  

These terms capture the principal clinical concepts, anatomical structures, diagnostic modalities, and outcome metrics related to heart disease discussed in the guideline excerpt.

Page 45 Extracted Terms:
- Adult congenital heart disease (ACHD)  
- Anomalous pulmonary venous connections (APVC)  
- Atrial septal defect (ASD)  
- Right ventricle (RV)  
- Pulmonary arterial hypertension (PAH)  
- Qp:Qs ratio (pulmonary to systemic flow)  
- Cardiac symptoms  
- Reduced functional capacity  
- Surgical repair (pulmonary vein repair)  
- Left‑to‑right shunting (shunts)  
- RV volume overload  
- RV systolic function  
- Invasive measurement (of PAH)  
- Objective exercise intolerance  
- Cardiothoracic surgery (as treatment option)  
- Shunt magnitude  
- Diastolic compliance  
- Pulmonary vein stenosis  
- Warden procedure (repair method)  
- Scimitar vein (variant of APVC)  
- Pulmonary sequestration  
- Patent foramen ovale (implied in shunting context)  
- PA hypoplasia  
- Aortopulmonary collaterals  
- Thrombosis (post‑repair risk)  
- 3‑dimensional cardiovascular magnetic resonance (CMR) imaging  
- Echocardiography (transthoracic and electrocardiogram)  
- Cardiac catheterization angiography  
- Computed tomography (CT) angiography  
- Electrocardiogram (ECG)  
- Transthoracic echocardiogram (TTE)

Page 46 Extracted Terms:
- Atrial partial pulmonary venous connection (APVC)  
- Right ventricle (RV) size  
- Right ventricular function / RV systolic dysfunction  
- Pulmonary arterial hypertension (PAH)  
- Pulmonary hypertension (PH)  
- Pulmonary vein stenosis / baffle stenosis  
- Warden procedure  
- Superior vena cava obstruction  
- Echocardiography (2‑D and Doppler)  
- Cardiovascular magnetic resonance (CMR)  
- Cardiac CT angiography  
- Invasive hemodynamics  
- Cardiac catheterization  
- Left‑to‑right shunt  
- Qp:Qs ratio  
- Pulmonary vascular resistance (PVR)  
- Pulmonary blood flow  
- Cardiopulmonary exercise testing (CPET)  
- Functional capacity  
- Congenital heart disease (CHD) surgeons / congenital heart surgeons  
- Patent ductus arteriosus (PDA)  
- Adult congenital heart disease (ACHD) specialist  
- Pulmonary artery (PA)  
- Right‑ventricular dilation  
- Surgical repair / baffle rerouting  
- Obstructive sleep apnea (risk factor for PH)  
- Intracardiac shunts (other than APVC)  
- Connective tissue disease (cause of PH)  
- Portal hypertension (cause of PH)  
- Age (risk factor for complications)  
- Scimitar syndrome (scimitar vein repair)  

These terms capture the key concepts and clinical factors related to heart disease discussed in the guideline excerpt.

Page 47 Extracted Terms:
- Patent ductus arteriosus (PDA)  
- Pulmonary arterial hypertension (PAH)  
- Pulmonary vascular resistance (PVR)  
- Left ventricular (LV) function  
- Left‑sided chamber size  
- Echocardiography  
- Cardiac magnetic resonance imaging (CMR)  
- Balloon test occlusion  
- Left‑to‑right shunt  
- Right‑to‑left shunt  
- Eisenmenger syndrome  
- Pulmonary hypertension (PH)  
- Pulmonary vasodilators  
- Electrocardiogram (ECG)  
- Transthoracic echocardiogram (TTE)  
- Cardiac catheterization  
- Oxygen saturation measurement (oximetry)  
- Hemodynamic assessment  
- Clinical outcomes (morbidity/mortality)  
- Left heart enlargement / dilation  
- Ventricular dilation / dysfunction  
- Chamber dilation  
- Pulmonary overcirculation  
- Systemic resistance  
- Pulmonary capillary wedge pressure (PCWP)  
- Mean pulmonary artery pressure (mPAP)  
- Wood units  
- Device closure (PDA closure)  
- Unrepaired PDA  
- Adult congenital heart disease (ACHD)

Page 48 Extracted Terms:
- Adult congenital heart disease (ACHD)  
- Patent ductus arteriosus (PDA)  
- Echocardiography  
- Cardiac magnetic resonance imaging (CMR)  
- Flow assessment (Qp:Qs)  
- Left ventricular (LV) volume  
- LV function  
- Ductal anatomy  
- LV remodeling  
- LV dysfunction  
- Pulmonary hypertension (PH)  
- Pulmonary arterial hypertension (PAH)  
- Transcatheter device closure  
- Cardiac computed tomography (CT)  
- Aortic arch  
- Pulmonary vascular resistance (PVR)  
- Wood units (WU)

Page 49 Extracted Terms:
- Pulmonary arterial saturation  
- PDA insertion point  
- Pulmonary blood flow  
- Pulmonary vascular resistance (PVR)  
- Pulmonary arterial hypertension (PAH)  
- Catheter‑based calculation  
- Transpulmonary gradient  
- Hybrid techniques  
- Cardiac magnetic resonance imaging (CMR)  
- Balloon test occlusion  
- Ductus closure tolerability  
- Pulmonary arterial pressure  
- Aortic pressure  
- Left ventricular enlargement  
- Left ventricular dysfunction  
- Endarteritis  
- Percutaneous closure  
- Surgical closure  
- Net left‑to‑right shunt  
- Net right‑to‑left shunt  
- Pulmonary hypertension expertise  
- PVR Wood units (e.g., 2–5, <5, <10, >8, >10)  
- Pulmonary systolic pressure  
- Left atrial hypertension  
- Cor triatriatum sinister  
- Transesophageal echocardiography  
- Cross‑sectional imaging  
- Membrane orifice  
- Pulmonary vein stenosis  
- Atrial fibrillation  
- Atrial flutter  
- Left atrial thrombus  
- Stroke  
- Chronic anticoagulation  
- Congenital cardiac defects  
- Volume overload  
- Hemodynamically insignificant shunt  
- Mortality and morbidity risks  
- Progressive LV enlargement  
- PAH progression  
- Transpulmonary gradient measurement  
- Pulmonary blood flow measurement

Page 50 Extracted Terms:
- Cor triatriatum sinister  
- Congenital heart disease  
- Adult congenital heart disease (ACHD)  
- Unrepaired cor triatriatum sinister  
- Cor triatriatum membrane  
- Fenestrated fibromuscular membrane  
- Left atrial hypertension  
- Left atrial appendage  
- Mitral valve  
- Mitral stenosis (shared pathophysiology)  
- Mitral regurgitation (progression)  
- Atrial fibrillation  
- Atrial flutter  
- Atrial septal defect (ASD)  
- Persistent left superior vena cava  
- Partial anomalous pulmonary venous return (PAPVR)  
- Pulmonary vein stenosis  
- Pulmonary hypertension  
- Pulmonary arterial wedge pressure  
- Left ventricular diastolic pressure  
- Heart failure (gradual onset)  
- Dyspnea on exertion  
- Orthopnea  
- Palpitations  
- Systemic thromboembolism  
- Cardioembolic events  
- Surgical membrane resection  
- Catheter‑based intervention (bridge to surgery)  
- Rhythm control strategy  
- Chronic anticoagulation  
- Transesophageal echocardiography (TEE)  
- Transthoracic echocardiography (TTE)  
- Three‑dimensional echocardiography (3‑DE)  
- Cardiac magnetic resonance imaging (CMR)  
- Computed tomography angiography (CTA)  
- Cardiac catheterization  
- Fibrotic degeneration of the cor membrane  
- Calcification of the cor membrane  
- Fenestrated/obstructive membrane orifice  
- Clinical sequelae of left atrial hypertension  
- Residual anatomical abnormalities post‑repair  
- Intracardiac repair of congenital defects  
- Multimodality imaging for cor triatriatum sinister  
- Routine follow‑up (physiological stages A–D)  
- Electrocardiogram (ECG) monitoring  
- Transthoracic echocardiogram (TTE) follow‑up  
- 3‑D imaging of atrial chambers  
- Clinical decompensation  

(*Terms are extracted to highlight key heart‑disease concepts and related clinical interventions, diagnoses, imaging modalities, and complications discussed in the guideline text.*)

Page 51 Extracted Terms:
- **Cor triatriatum sinister**  
- **Left atrial membrane**  
- **Systemic thromboembolism**  
- **Paradoxical embolism**  
- **Atrial fibrillation**  
- **Pulmonary hypertension (PAH)**  
- **Mitral stenosis**  
- **Congenital mitral stenosis**  
- **Parachute mitral valve**  
- **Supravalvar mitral ring**  
- **Double‑orifice mitral valve**  
- **Shone complex**  
- **Atrial septal defect (ASD)**  
- **Pulmonary venous stasis**  
- **Chronic anticoagulation**  
- **Warfarin**  
- **Direct oral anticoagulants (DOACs)**  
- **Intravenous anticoagulation**  
- **Surgical resection**  
- **Transcatheter ablation**  
- **Maze operation**  
- **Cardiopulmonary bypass**  
- **Heart failure**  
- **Pulmonary edema**  
- **Pregnancy‑associated cardiac risk**  
- **Postpartum cardiac decompensation**  
- **Percutaneous balloon dilatation**  
- **Atrial septal dilation**  
- **Mitral valve injury**  
- **Cardiac perforation**  
- **Left‑heart obstructive lesions**  
- **Invasive hemodynamic assessment**  
- **Pulmonary over‑pressure**  
- **Cor triatriatum membrane regrowth**  
- **Hemodynamically severe obstruction** (≥15 mm Hg gradient)  
- **Noninvasive Doppler interrogation**  
- **Intracardiac repair**  
- **Congenital heart disease (ACHD)**  
- **Maternal and fetal cardiac risk**  
- **Acute pulmonary hypertension**  
- **Cardiac operative risk**

Page 52 Extracted Terms:
- Adult Congenital Heart Disease (ACHD)  
- Congenital mitral valve disease  
- Mitral valve prolapse  
- Balloon mitral valvuloplasty  
- Mitral stenosis  
- Atrioventricular septal defect (AVSD)  
- Left atrioventricular valve regurgitation  
- Shone complex  
- Pulmonary hypertension  
- Pre‑capillary pulmonary hypertension  
- Post‑capillary pulmonary hypertension  
- Right heart catheterization  
- Subaortic stenosis  
- Exercise stress testing  
- Surgical repair (membrane resection, myectomy)  
- Left ventricular (LV) dysfunction  
- LV hypertrophy  
- Aortic regurgitation  
- Aortic valve stenosis  
- Membranous obstruction (subaortic obstruction)  
- Mitral valve attachments  
- Endocardial cushion tissue  
- Hypertrophic cardiomyopathy  
- Heart block  
- Reoperation (surgical recurrence)  
- Echocardiogram / Transthoracic echocardiogram  
- Electrocardiogram (ECG)  
- ACHD cardiologist (clinical follow‑up)

Page 53 Extracted Terms:
**Key terms related to heart disease**

- Subaortic stenosis  
- Aortic stenosis  
- Congenital left ventricular outflow tract (LVOT) obstruction  
- LVOT gradient  
- Left ventricular outflow tract (LVOT)  
- Left ventricular hypertrophy (LVH)  
- Left ventricular dysfunction (LVD)  
- Left ventricular remodeling  
- Aortic regurgitation (AR)  
- Bicuspid aortic valve (BAV)  
- Coarctation of the aorta (COA)  
- Aortic aneurysm  
- Aortic dissection  
- Valve replacement  
- Transcatheter aortic valve replacement (TAVR)  
- Adult congenital heart disease (ACHD)  
- Exercise stress testing  
- Exercise stress echocardiography  
- Electrocardiogram (ECG)  
- Transthoracic echocardiogram (TTE)  
- Doppler echocardiography  
- Peak gradient  
- Threshold gradient (e.g., ≥ 50 mm Hg, ≥ 80 mm Hg)  
- Surgical repair of subaortic stenosis  
- Prophylactic surgery  
- Survival rate  
- Intervention‑free survival  
- Risk factor for aortic dissection  
- Surveillance for thoracic aortic disease  
- Physiological stages (A, B, C, D) in ACHD follow‑up  
- Follow‑up intervals (outpatient, ECG, TTE)  
- Screening for congenital aortic valve abnormalities  
- Shared decision‑making for valve therapy  

These terms capture the primary disease entities, diagnostic and therapeutic modalities, risk stratification concepts, and guideline‑specific recommendations discussed in the text.

Page 54 Extracted Terms:
- Bicuspid aortic valve (BAV)
- Congenital aortic valve stenosis
- Aortic regurgitation
- Balloon valvuloplasty
- Aortic valve surgery
- Aortic valve replacement
- Transcatheter aortic valve replacement (TAVR)
- Aortic dissection
- Aortic dilation / aortic enlargement
- Aortic root dilatation
- Coarctation of the aorta (COA)
- Root phenotype aortopathy
- Left ventricular (LV) remodeling
- Left ventricular ejection fraction (LVEF)
- Hypoplastic left heart syndrome (HLHS)
- Truncus arteriosus
- Turner syndrome
- Shone complex
- NOTCH1 gene mutation
- ADAMTS19 gene mutation
- SMAD6 gene mutation
- ROBO4 gene mutation
- NT-proBNP (biomarker)
- Echocardiography
- Cardiac‑gated CT angiography
- Magnetic resonance angiography (MRA)
- Cardiovascular magnetic resonance (CMR)
- Thoracic aortic disease
- Aortic valve disease
- Aortic annulus
- Aortic arch
- Aortic valve imaging intervals
- Aortic valve surgical planning
- Familial inheritance (autosomal dominant pattern)
- Variable penetrance
- Aortic valve repair
- Aortic valve replacement criteria
- Aortic valve hemodynamics (Vmax, ΔP)
- Aortic diameter thresholds (4–5 cm)
- Aortic growth rate ≥ 0.3 cm/year
- Family history of aortic dissection
- Family history of thoracic aortic disease
- History of COA (coarctation of the aorta)
- Periodic imaging surveillance
- Aortic valve surgical durability in young patients
- Aortic valve intervention age considerations
- Coronary artery disease (implicit in cardiovascular context)

Page 55 Extracted Terms:
**Key terms related to heart disease (from the provided guideline excerpt)**  

- Bicuspid aortic valve (BAV)  
- Thoracic aortic disease  
- Aortic valve abnormality  
- Aortic valve interventions  
- Valve repair  
- Ross operation  
- Bioprosthetic valve replacement  
- Mechanical valve replacement  
- Transcatheter aortic valve replacement (TAVR)  
- Congenital heart disease (CHD)  
- Aortic valve replacement (AVR)  
- Aortic valve stenosis  
- Aortic valve regurgitation  
- Calcified aortic valve stenosis  
- Balloon valvuloplasty / balloon dilation of the aortic valve  
- Supravalvar aortic stenosis (SVAS)  
- Williams syndrome  
- Coronary ostial stenosis  
- Coronary artery revascularization  
- Left ventricular (LV) systolic function / LV dysfunction  
- Ventricular function (general)  
- Left ventricular outflow tract (LVOT) obstruction  
- Baseline aortic imaging  
- Baseline coronary imaging  
- Transthoracic echocardiography (TTE) with Doppler  
- Peak and mean pressure gradients across aortic stenosis  
- Surgical repair of SVAS or valve  
- Redo sternotomies  
- Transplantation (cardiac transplant)  
- Reproductive issues & pregnancy considerations in valve disease  
- Sports participation & lifestyle changes in cardiac patients  
- Sudden cardiac death (SCD) risk assessment  
- Clinical decision‑making & shared decision‑making processes in cardiac care  

These terms capture the primary disease processes, diagnostic modalities, therapeutic interventions, and clinical considerations discussed in the guideline text.

Page 56 Extracted Terms:
- Supravalvar aortic stenosis  
- Adult congenital heart disease (ACHD)  
- Williams syndrome  
- Coronary ostial stenosis  
- Coronary artery dilation  
- Coronary artery obstruction  
- Coronary artery anomalies  
- Coronary artery abnormalities (diffuse stenosis, obstruction)  
- Coronary ischemia  
- Ischemic heart disease  
- Arrhythmia  
- Heart failure  
- Left ventricular systolic dysfunction  
- Left ventricular dysfunction  
- LVOT (left ventricular outflow tract) obstruction  
- Aortic valve stenosis  
- Sinotubular junction  
- Aortic valve leaflet adhesion  
- Fibrotic thickening around coronary ostia  
- Coronary revascularization  
- Surgical repair (aortic or coronary)  
- Transesophageal echocardiography  
- Transthoracic echocardiography  
- Cardiovascular magnetic resonance (CMR)  
- MR angiography  
- CT angiography  
- Electrocardiography (ECG)  
- Exercise stress testing  
- Electrocardiogram‑gated coronary CT angiography  
- Invasive coronary angiography  
- Cardiologist follow‑up (ACHD cardiologist)  
- Screening for coronary artery anomalies  
- ELN gene (elastin) – elastin arteriopathy  
- Reintervention rates  
- Long‑term ventricular function  
- Coronary perfusion impairment  
- Coronary artery stenosis (ostial)  
- Coronary artery diastolic filling  
- Coronary artery systolic pressure exposure  
- Anatomic variability  
- Cardiovascular imaging  
- Clinical guidelines  

These terms capture the key heart‑disease concepts referenced in the guideline text.

Page 57 Extracted Terms:
**Key terms related to heart disease in the guideline**

- Coarctation of the Aorta (COA)  
- Unrepaired COA  
- Repaired COA  
- Aortic isthmus stenosis  
- Aortic arch hypoplasia  
- Bicuspid aortic valve (BAV)  
- Left ventricular outflow tract (LVOT) disease  
- Subaortic stenosis  
- Supra‑valvar aortic stenosis  
- Supra‑valvar mitral stenosis  
- Parachute mitral valve  
- Endothelial dysfunction  
- Abnormal smooth‑muscle reactivity  
- Sympathetic hyperactivity  
- Left ventricular (LV) pressure overload  
- LV remodeling (hypertrophy, fibrosis, impaired relaxation, impaired compliance, impaired contractility)  
- Hypertension  
- Blood pressure measurement (upper vs lower extremities)  
- Ambulatory blood pressure monitoring  
- Exercise testing (exercise‑induced hypertension)  
- Coronary artery disease  
- Intracranial aneurysms (brain MRI/CT angiography)  
- Echocardiography – transthoracic Doppler mean gradient  
- Cardiac catheterization (COA peak‑to‑peak gradient)  
- Transcatheter stent therapy  
- Surgical repair/stent therapy  
- Guideline‑directed medical therapy (GDMT) for hypertension  
- Electrocardiogram (ECG)  
- Cardiovascular magnetic resonance (CMR)  
- Computed tomography (CT) angiography (CTA)  
- Magnetic resonance angiography (MRA)  
- Diagnostic indices:  
  - Upper‑to‑lower extremity systolic BP gradient >20 mm Hg  
  - Doppler mean gradient >20 mm Hg  
  - Corrected COA gradient >20 mm Hg  
  - COA peak‑to‑peak gradient >20 mm Hg  
  - Aortic isthmus ratio <0.5–0.7  
  - Collateral arteries  
- Angiogram (plain imaging of aorta)  
- Physiological stages of follow‑up (Stages A–D)  
- ACHD (Adult Congenital Heart Disease)  
- LV dysfunction from chronic pressure overload  
- Aortic root/ascending aorta aneurysms  
- Focal aortic aneurysm, pseudoaneurysm, dissection  
- Stent fracture  
- Upper‑lower extremity systolic blood pressure gradient  
- Diastolic tail in descending aorta  
- Diastolic forward flow in abdominal aorta  

These terms capture the core clinical aspects, diagnostic modalities, and management strategies discussed in the text.

Page 58 Extracted Terms:
- Aortic coarctation (COA)  
- Aortic arch anatomy  
- Ascending aorta dimensions  
- Left ventricular (LV) remodeling  
- LV diastolic dysfunction  
- LV systolic dysfunction  
- Left atrial dysfunction  
- Heart failure with preserved ejection fraction (HFpEF)  
- Pulmonary hypertension  
- Atrial fibrillation  
- Premature coronary artery disease  
- Stroke  
- Re‑coarctation (restenosis of aortic isthmus)  
- Aortic aneurysm  
- Pseudoaneurysm  
- Aortic dissection  
- Systemic hypertension  
- Hypertension screening (office, home, ambulatory)  
- LV hypertrophy (cardiomyocyte hyperplasia)  
- LV pressure overload  
- Myocardial ischemia  
- Replacement fibrosis  
- Exercise‑induced hypertension  
- CPET (cardiopulmonary exercise testing)  
- Exercise‑induced arrhythmias  
- Vascular complications (wall injury, remodeling)  
- Longitudinal imaging surveillance (transthoracic echocardiography, CMR, CT angiography)

Page 59 Extracted Terms:
- Coarctation of the aorta (COA)  
- Hypertension (systemic and exercise‑induced)  
- Antihypertensive therapy  
- Ambulatory blood pressure monitoring  
- Exercise testing  
- Coronary artery disease (CAD)  
- Myocardial infarction  
- Atherosclerotic cardiovascular disease  
- Hyperlipidemia  
- Type 2 diabetes mellitus  
- Angina  
- Exertional dyspnea  
- Intracranial aneurysm  
- Magnetic resonance imaging (MRI) of the brain  
- Computed tomography angiography (CTA) of the brain  
- Surgical repair of COA  
- Transcatheter COA repair / stent therapy  
- COA pressure gradient  
- Aortic isthmus ratio (CMR/CT angiography)  
- Cardiac magnetic resonance (CMR) imaging  
- Left ventricular hypertrophy (LVH)  
- Left ventricular dysfunction  
- Left ventricular reverse remodeling  
- Cardiovascular events  
- Ebstein anomaly  
- Electrophysiological study  
- Arrhythmia  
- Electrophysiological ablation  
- Ventricular preexcitation  
- Right ventricular (RV) dimensions  
- Right ventricular systolic function  
- Stent fracture  
- Restenosis  
- Aneurysm/pseudoaneurysm  
- Reintervention risk  
- Institutional expertise in congenital heart disease (CHD)  
- Cardiovascular surgery  
- Interventionist procedures for CHD  

(Each item is a key term or concept related to heart disease extracted from the provided guideline text.)

Page 60 Extracted Terms:
- Ebstein anomaly  
- Tricuspid valve morphology & function  
- Tricuspid regurgitation  
- Right ventricular (RV) dysfunction  
- RV systolic dysfunction  
- Cardiac output  
- Heart failure  
- Exercise capacity (functional status)  
- Atrial tachyarrhythmias  
- Ventricular tachyarrhythmias  
- Accessory pathways (pre‑excitation)  
- Sudden cardiac death (SCD)  
- Catheter ablation  
- Electrophysiological (EP) study  
- Tricuspid valve surgery  
- Bidirectional superior cavopulmonary (Glenn) anastomosis  
- Atrial septal defect (ASD)/Patent foramen ovale (PFO)  
- Cyanosis  
- Paradoxical embolism  
- Right‑to‑left atrial shunt  
- Multimodality imaging  
- Transthoracic echocardiography (TTE)  
- Transesophageal echocardiography (TEE)  
- Cardiovascular magnetic resonance (CMR)  
- Electrocardiogram (ECG)  
- Pulmonary stenosis (associated defect)  
- Ventricular pre‑excitation  
- Adult congenital heart disease (ACHD)  
- Congenitally corrected transposition of the great arteries (CCTGA)  

These terms capture the central heart‑disease concepts referenced in the guideline text.

Page 61 Extracted Terms:
- Ebstein anomaly  
- Right atrial enlargement  
- Right ventricular (RV) dysfunction  
- Tricuspid regurgitation (TR)  
- Preexcitation  
- Accessory pathways (concealed and manifest)  
- Supraventricular tachycardia (SVT)  
- Ventricular tachycardia (VT)  
- Sudden cardiac death (SCD)  
- Cardiopulmonary exercise testing (CPET)  
- Cardiovascular magnetic resonance (CMR)  
- Transthoracic echocardiography (TTE)  
- Transesophageal echocardiography (TEE)  
- 3‑dimensional echo imaging  
- Cone procedure (tricuspid valve repair)  
- Bidirectional superior cavopulmonary (Glenn) shunt  
- Cardiac computed tomography (CT)  
- Catheter ablation (electrophysiologic testing)  
- Arrhythmia surgery  
- Atrial septal defect (ASD) closure  
- Patent foramen ovale (PFO) closure  
- Left ventricular hypertrophy (LVH)  
- Diastolic dysfunction  
- Pulmonary arterial hypertension  
- Hemodynamic assessment  
- RV volume loading  
- Myopathic process in Ebstein anomaly  
- Pre‑operative catheterization for shunt feasibility  
- Reverse remodeling after surgical repair  
- Risk stratification  
- Surgical repair of tricuspid valve (repair versus replacement)  
- Valve‑in‑valve catheter intervention  
- Proactive intervention strategy  

These terms capture the key cardiovascular disorders, diagnostic modalities, and therapeutic interventions discussed in the guideline text.

Page 62 Extracted Terms:
- Ebstein anomaly  
- Ventricular pre‑excitation  
- Accessory pathways  
- High‑risk pathways  
- Sudden cardiac death (SCD)  
- Catheter ablation  
- Surgical interruption of accessory pathways  
- Atrial arrhythmias  
- Systemic desaturation  
- Tricuspid regurgitation (TR)  
- Right‑ventricular (RV) dysfunction  
- Tricuspid valve surgery  
- Atrial septal defect (ASD) closure  
- Patent foramen ovale (PFO) closure  
- Arrhythmia surgery (e.g., Maze procedures)  
- Right‑atrial Maze procedure  
- Left‑atrial Cox Maze III procedure  
- Balloon valvuloplasty (pulmonary)  
- Pulmonary valve replacement (PVR)  
- Valvular pulmonary stenosis (PS)  
- Pulmonary valve intervention  
- Pulmonary stenosis severity (moderate/severe)  
- RV pressure overload  
- Cyanosis  
- Paradoxical embolism  
- Hemodynamics (intracardiac pressures, cardiac output)  
- Cardiac transplantation  
- Bidirectional cavopulmonary shunt (Glenn shunt)  
- Multidisciplinary team evaluation  
- Genetic syndromes (e.g., Noonan syndrome)  
- Dilated main pulmonary artery (PA)  
- Dysplastic pulmonary valve cusps  
- Symptomatic vs. asymptomatic pulmonary stenosis  
- Percutaneous device closure  
- Ventricular arrhythmias  
- Atrial fibrillation  
- Stroke volume support by RV  
- Pediatric vs. adult surgical indications  
- Interventional cardiology techniques  
- Surgical risk assessment  
- Valve anatomy (favorable/unfavorable)  
- Suboptimal valvuloplasty results  

These are the principal terms related to heart disease extracted from the guideline text.

Page 63 Extracted Terms:
**Key heart‑disease terms extracted from the guideline text**

- Pulmonary valve stenosis  
- Pulmonary valve regurgitation  
- Pulmonary balloon valvuloplasty  
- Valvuloplasty (general)  
- Surgical pulmonary valvotomy  
- Pulmonary valve replacement  
- Tricuspid valve regurgitation / insufficiency  
- Right‑to‑left shunt  
- Right ventricular outflow tract dysfunction  
- RV systolic dysfunction  
- Exercise‑induced hypoxemia  
- Objective exercise capacity  
- Cyanosis  
- Symptomatic vs. asymptomatic patients  
- Annular hypoplasia  
- Valvular dysplasia  
- Adult congenital heart disease (ACHD)  
- Routine follow‑up for valvular pulmonary stenosis  
- Electrocardiogram (ECG)  
- Transthoracic echocardiogram  
- Cardiovascular magnetic resonance (CMR) imaging  
- Doppler velocity and gradient across the right ventricular outflow tract  
- Peak gradient (mm Hg, m/s)  
- Mean gradient  
- Regurgitant fraction  
- Regurgitant volume  
- Vena contracta  
- Pressure half‑time  
- PR index (pulmonary regurgitation index)  
- Echocardiographic features of pulmonary regurgitation  
- Doppler spectral signal characteristics  
- Exercise capacity decline  
- Follow‑up intervals (physiological stages A–D)  

These terms collectively capture the key anatomical, physiological, diagnostic, and interventional concepts relevant to heart disease discussed in the guideline.

Page 64 Extracted Terms:
- Pulmonary Regurgitation  
- Pulmonary Stenosis  
- Isolated Pulmonary Regurgitation  
- Isolated Pulmonary Stenosis  
- Pulmonary Valve Replacement  
- Transcatheter Pulmonary Valve Implantation  
- Surgical Valvotomy  
- Balloon Valvuloplasty  
- Right Ventricular (RV) Systolic Dysfunction  
- RV Dilation  
- RV Enlargement  
- Right Ventricular (RV) Systolic Function  
- RV Volumes  
- Right Heart Anatomy  
- Cardiac MRI (CMR)  
- Echocardiography  
- Tricuspid Regurgitation  
- Symptoms of Heart Failure  
- Infective Endocarditis  
- Tetralogy of Fallot (TOF)  
- Congenital Heart Disease (CHD)  
- Chronic Pulmonary Regurgitation  
- Pulmonary Valve Insufficiency  
- Right Ventricular Remodeling  
- Reverse Remodeling  
- Pulmonary Valve Gradients  
- Exercise Capacity  
- Late Intervention  
- Early Intervention  
- Surveillance CMR  
- Pulmonary Valve Function  

Page 65 Extracted Terms:
**Key heart‑disease terms extracted from the guideline text**

- Double‑Chambered Right Ventricle (DCRV)  
- DCRV (abbreviation)  
- Right ventricular (RV) dysfunction  
- Right ventricular outflow tract (RVOT) obstruction  
- Cardiac catheterization  
- Cardiovascular magnetic resonance (CMR)  
- Cardiac CT  
- Surgical repair (of DCRV)  
- Heart failure  
- Cyanosis  
- Exercise limitation / intolerance  
- Asymptomatic adult with DCRV  
- Severe RVOT obstruction  
- Right ventricular remodeling  
- Hypertrophied muscle bundles  
- Right ventricular cavity  
- Ventricular septal defect (VSD)  
- Restrictive VSD  
- High‑pressure inlet chamber (RV)  
- Low‑pressure outlet chamber (RV outflow)  
- Intravenous pressure gradient (within RV)  
- Pulmonary regurgitation (PR)  
- Pulmonary stenosis (PS)  
- Tricuspid regurgitation (TR)  
- Dyspnea  
- Chest pain  
- Exercise intolerance attributable to PR or other causes  
- Pulmonary regurgitation after repair of pulmonary stenosis  

These terms capture the core cardiac conditions, diagnostic tools, interventions, and clinical manifestations discussed in the guideline excerpt.

Page 66 Extracted Terms:
- Double‑Chambered Right Ventricle (DCRV)  
- Ventricular Septal Defect (VSD)  
- Right Ventricular Outflow Tract (RVOT)  
- Subpulmonary Stenosis  
- Mid‑RV Obstruction  
- Intramyocardial Muscle Bundles  
- Pressure Gradient (RVOT)  
- Right‑to‑Left Shunting  
- Left‑to‑Right Shunting  
- Echocardiography (Transthoracic)  
- Cardiac Computed Tomography (CT)  
- Cardiovascular Magnetic Resonance (CMR)  
- Cross‑Sectional Imaging  
- Electrocardiogram (ECG)  
- Adult Congenital Heart Disease (ACHD)  
- Pulmonary Artery (PA) Stenosis  
- Peripheral Pulmonary Artery Stenosis  
- Tricuspid Regurgitation  
- Pulmonary Regurgitation  
- Right Ventriculotomy  
- Right Ventricular Dysfunction  
- Ventricular Arrhythmias  
- Surgical Repair (Resection of Obstructive Muscle Bundles)  
- Recurrent DCRV  
- Postoperative Outcomes.

Page 67 Extracted Terms:
- Pulmonary branch stenosis  
- Peripheral pulmonary artery stenosis  
- Right ventricular (RV) hypertension  
- RV dysfunction  
- Tricuspid regurgitation  
- Pulmonary hypertension  
- Right heart failure  
- Cyanosis (atrial‑level right‑to‑left shunting)  
- Balloon angioplasty (pulmonary)  
- Stent implantation (pulmonary)  
- Pulmonary perfusion testing  
- Transthoracic echocardiography  
- Computed tomography (CT)  
- Cardiac magnetic resonance (CMR)  
- Right ventricular pressure  
- Pulmonary blood flow  
- Right ventricular filling pressure  
- Exercise intolerance / exercise tolerance  
- Ventilatory efficiency  
- Pulmonary artery pressure gradient  
- Restenosis  
- Surveillance imaging  
- Adult congenital heart disease (ACHD)  
- Noonan syndrome  
- Alagille syndrome  
- Williams syndrome  
- Maternal rubella exposure  
- Echocardiographic imaging  
- Cross‑sectional imaging  
- Cardiovascular intervention  
- ACHD interventional cardiologist  
- Cardiac surgery (ACHD expertise)  
- Follow‑up intervals for isolated branch pulmonary artery stenosis  

Page 68 Extracted Terms:
- Tetralogy of Fallot (TOF)  
- Repaired Tetralogy of Fallot  
- Pulmonary valve dysfunction (moderate PR, PR >25% by CMR)  
- Pulmonary regurgitation  
- Pulmonary stenosis  
- Right ventricular outflow tract (RVOT) dysfunction  
- Residual ventricular septal defects (VSDs)  
- Tricuspid valve dysfunction / tricuspid regurgitation  
- Right atrial size  
- Right ventricular (RV) size and function  
- Left ventricular (LV) size and function  
- Right ventricular systolic pressure (RVSP)  
- Right ventricular end‑systolic volume index (RVESVI)  
- Right ventricular end‑diastolic volume (RVEDV)  
- Left ventricular ejection fraction (LVEF)  
- Right ventricular ejection fraction (RVEF)  
- Ventricular tachycardia (VT)  
- Ventricular arrhythmia / tachyarrhythmia  
- Sudden cardiac death (SCD)  
- Implantable cardioverter‑defibrillator (ICD)  
- Electrophysiology evaluation  
- Catheter ablation  
- Anti‑arrhythmic therapy (class I/III agents, amiodarone)  
- Electrical cardioversion  
- Defibrillation / ICD shock  
- Pace termination  
- Pulmonary valve replacement (surgical or transcatheter)  
- Transcatheter pulmonary valve placement (balloon‑expandable platform)  
- Pulmonary valve conduit stenting  
- Cardiac catheterization with angiography  
- Echocardiography (including assessment of pulmonary and tricuspid valves, RVOT, etc.)  
- Cardiovascular magnetic resonance (CMR) imaging  
- Cardiac computed tomography (CT) angiography  
- 12‑lead electrocardiography  
- Contrast‑enhanced MR imaging  
- CT angiography  
- Surgical repair of TOF (initial surgery)  
- RVOT anatomy (native vs conduit)  
- Branch pulmonary artery size and flow  
- Aortopulmonary collateral flow  
- Myocardial fibrosis assessment (CMR)  
- Functional tricuspid regurgitation  
- Exercise capacity  

These terms capture the core concepts related to heart disease management and surveillance in adults with repaired Tetralogy of Fallot.

Page 69 Extracted Terms:
- Adult congenital heart disease (ACHD)  
- Tetralogy of Fallot (TOF)  
- Right ventricular (RV)  
- Right ventricular outflow tract (RVOT)  
- Pulmonary valve  
- RV‑to‑PA conduit  
- RVOT dysfunction  
- Branch pulmonary artery stenosis  
- Pulmonary valve dysfunction  
- Primary regurgitation  
- Primary stenosis  
- Mixed pulmonary valve disease  
- Moderate pulmonary regurgitation  
- CMR‑measured regurgitant fraction  
- RV pressure  
- RV systolic pressure  
- Monomorphic ventricular tachycardia (VT)  
- Sudden cardiac death (SCD)  
- QRS duration ≥180 ms  
- QRS fragmentation  
- Inducible sustained ventricular arrhythmia  
- Electrophysiology study  
- Surgical era (pre‑1980 vs. ≥1980)  
- Coronary artery disease  
- Left ventricular ejection fraction (LVEF)  
- LV dysfunction  
- Right ventricular ejection fraction (RVEF)  
- RV volume  
- RV pressure  
- Late gadolinium enhancement (LGE)  
- LV LGE extent  
- RV LGE present  
- NYHA II‑III symptoms / NYHA class  
- Supraventricular tachycardia  
- Systemic EF <40 %  
- Subpulmonary EF <40 %  
- QRS duration ≥120 ms  
- QT dispersion ≥70 ms  
- Shunt pre‑repair  
- Age at repair <6.5 years  
- Peak VO₂ ≤17 mL/kg/m²  
- B‑type natriuretic peptide (BNP) ≥127 ng/L  
- Akinetic RVOT length ≥55 mm  
- RVOT pressure ≥47 mm Hg  
- Implantable cardioverter‑defibrillator (ICD)  
- Ventriculotomy  
- Infundibulotomy  
- Transannular patch  
- RV free wall  
- Fibrosis  
- Scar tissue  
- Aneurysmal area  
- Dyskinetic area  
- Pulmonary valve atresia  
- RVOT obstruction  
- RVOT resection  
- Conduit replacement  
- Pulmonary regurgitation  
- Pulmonary stenosis  
- Ventricular fibrillation (VF)  
- ECG (electrocardiogram)  
- Electrophysiology  
- PREVENTION‑ACHD risk score  
- Brompton risk score  
- PACES risk score

Page 70 Extracted Terms:
- Tetralogy of Fallot (TOF)  
- Repaired TOF  
- Right Ventricular Outflow Tract (RVOT) obstruction  
- Right ventricular (RV) function  
- Pulmonary regurgitation (PR)  
- RV dilation  
- RV dysfunction  
- Tricuspid valve regurgitation (TR)  
- Left ventricular (LV) dysfunction  
- Aortic root dilation  
- Atrial arrhythmias (atrial flutter, atrial fibrillation)  
- Ventricular arrhythmias  
- Monomorphic ventricular tachycardia  
- Sudden cardiac death (SCD)  
- Pulmonary valve replacement  
- Right ventricular systolic pressure (RVSP)  
- Regurgitant fraction (RF)  
- Cardiovascular magnetic resonance (CMR) imaging  
- End‑systolic volume index (ESVi)  
- Left ventricular end‑diastolic volume (LVEDV)  
- Left ventricular ejection fraction (LVEF)  
- Right ventricular end‑diastolic volume (RVEDV)  
- Right ventricular ejection fraction (RVEF)

Page 71 Extracted Terms:
**Key heart‑disease terms extracted from the guideline text**

- Tetralogy of Fallot (TOF)  
- Repaired Tetralogy of Fallot  
- Unrepaired Tetralogy of Fallot  
- Pulmonary atresia  
- Ventricular tachycardia (VT)  
- Sustained monomorphic ventricular tachycardia  
- Ventricular fibrillation (VF)  
- Sudden cardiac death (SCD)  
- Implantable cardioverter‑defibrillator (ICD)  
- Catheter‑based ablation  
- Right ventricular outflow tract (RVOT)  
- Pulmonary valve replacement (PVR)  
- Transcatheter pulmonary valve replacement  
- Balloon‑expandable pulmonary valve  
- Self‑expanding pulmonary valve  
- Coronary artery anomaly (e.g., anomalous LAD from RCA)  
- Coronary artery compression  
- Aortography  
- Coronary angiography  
- Cardiac computed tomography (CT)  
- Cardiovascular magnetic resonance (CMR)  
- Echocardiography (2‑D, 3‑D, M‑mode, strain imaging, Doppler)  
- QRS duration > 180 ms  
- QRS fragmentation  
- Late gadolinium‑enhancement CMR  
- Risk stratification for VT/SCD  
- Electrocardiogram (ECG)  
- Transthoracic echocardiogram  
- Pulmonary regurgitation  
- Ventricular dysfunction (right or left)  
- Symptomatic nonsustained ventricular tachycardia  
- Left ventricular (LV) dysfunction  
- Pulmonary hypertension  
- Cardiac chamber size and function  
- Adult congenital heart disease (ACHD)  

These terms capture the primary clinical entities, imaging modalities, procedural interventions, and risk‑assessment factors discussed in the guideline excerpt.

Page 72 Extracted Terms:
Tetralogy of Fallot (TOF) – repaired TOF  
Pulmonary valve replacement (surgical & transcatheter)  
Pulmonary regurgitation  
Right ventricular dilation / enlargement  
Right ventricular hypertrophy  
Right ventricular dysfunction  
Ventricular tachycardia (VT) – monomorphic, sustained, reentrant  
Sudden cardiac death (SCD)  
Pulmonary artery (PA) pressure  
Pulmonary vascular resistance (PVR)  
Cardiac catheterization  
Echocardiography – diastolic dysfunction  
Electrophysiology study (EPS) – programmed ventricular stimulation  
Catheter ablation – VT substrate ablation, cryoablation  
Electrocardiogram (ECG) – QRS duration, fragmentation, isthmus conduction  
Contrast‑enhanced cardiac magnetic resonance imaging (CMR) – signal intensity, ventricular volume  
Multidetector computed tomography (CT) angiography – wall thickness, coronary anatomy  
Right ventricular end‑diastolic volume (RVEDV) – indexed RVEDV (RVEDVi)  
Right ventricular end‑systolic volume index (RVESVi)  
Right ventricular ejection fraction (RVEF) – threshold <46 %  
Left ventricular ejection fraction (LVEF) – threshold <50 %  
Cardiopulmonary exercise testing (CPET) – functional capacity, exercise tolerance  
Risk stratification scores – conventional risk‑factor analysis, clinical risk scores  
Thresholds for pulmonary valve replacement (RVEDV >80 mL/m², RVEDV ≥2× LVEDV)  
Arrhythmia substrate identification – conduction isthmuses, QRS morphology  
Functional class improvement post‑pulmonary valve replacement.

Page 73 Extracted Terms:
- Tetralogy of Fallot (TOF)  
- Pulmonary valve replacement  
- Right ventricular (RV) dysfunction / dilatation  
- Left ventricular (LV) dysfunction  
- Ventricular tachycardia (monomorphic)  
- Sudden cardiac death (SCD)  
- Implantable cardioverter‑defibrillator (ICD) placement  
- Catheter ablation  
- Cardiac magnetic resonance imaging (CMR) / MRI  
- QRS duration and fragmentation  
- Myocardial scarring  
- Tricuspid regurgitation  
- Heart failure  
- Coronary artery disease  
- Reverse Bernheim effect (ventricular‑ventricular interaction)  
- Ventricular‑ventricular interaction  
- Risk stratification scores  
- Indexed right ventricular end‑diastolic volume (RVEDV)  
- Indexed right ventricular end‑systolic volume (RVESV)  
- Biventricular global function index  
- Heart transplantation  
- Mechanical circulatory support (MCS)  
- Ventricular dysfunction (general)  
- Cardiac arrhythmia  
- Systolic dysfunction  
- Diastolic dysfunction  
- Electrophysiology study / invasive electrophysiology  
- Ventricular remodeling  
- Pulmonary valve dysfunction  
- Tricuspid valve intervention  
- Endocarditis  
- Device lead implantation  
- Annular dilation  
- Ventricular systolic function  
- Ventricular diastolic volume  
- Ventricular end‑systolic volume  
- Ventricular end‑diastolic volume



Page 74 Extracted Terms:
- Tetralogy of Fallot (TOF)  
- Pulmonary regurgitation  
- Ventricular tachycardia  
- Arrhythmia management  
- Pulmonary valve replacement (surgical)  
- Pulmonary valve replacement (transcatheter)  
- Implantable cardioverter‑defibrillator (ICD)  
- Catheter ablation of ventricular tachycardia  
- Pulmonary Atresia with Intact Ventricular Septum (PA‑IVS)  
- Right Ventricular Outflow Tract (RVOT)  
- Tricuspid valve hypoplasia  
- Right ventricular (RV) pressure overload  
- Coronary circulation  
- Coronary sinusoids  
- Coronary fistulas  
- RV‑dependent coronary circulation  
- Biventricular repair  
- 1½ ventricular repair  
- Fontan procedure  
- Cardiac transplantation  
- Shunt palliation  
- Atrial arrhythmias  
- Restrictive RV physiology  
- Ventricular fibrosis  
- Sudden cardiac death (SCD)  
- Heart failure  
- Right atrial function  
- Right atrial strain  
- Hepatorenal dysfunction  
- Cardiovascular death  
- RV‑to‑Pulmonary Artery (RV‑to‑PA) conduit  
- Conduit stent implantation  
- Coronary artery compression  
- Conduit dysfunction  
- Stent fracture  
- Pulmonary stenosis  
- Pulmonary regurgitation (conduit related)  
- Infective endocarditis  
- Thrombus  
- Cardiac catheterization  
- Hemodynamics of RV‑to‑PA conduit  
- Clinical heart failure in PA‑IVS  
- ICD therapies reduction  
- Conduit fracture imaging  
- Conduit dysfunction evaluation  
- Unanticipated conduit dysfunction  
- SCD risk reduction via ablation  
- SCD rate increase with RV‑dependent circulation  
- Management of right atrial strain  
- Clinical outcomes of functional status  
- Management of RV‑to‑PA conduit failure


Page 75 Extracted Terms:
- RV‑to‑PA conduit  
- Transcatheter intervention  
- Coronary CT  
- Conduit calcification  
- Anatomical characteristics  
- Coronary artery proximity  
- Procedural planning  
- Severe stenosis  
- Severe regurgitation  
- Moderate stenosis  
- Moderate regurgitation  
- Sustained arrhythmia  
- Cardiovascular status  
- Tetralogy of Fallot (TOF)  
- Pulmonary atresia  
- Truncus arteriosus  
- Aortic stenosis  
- Transposition of the great arteries (TGA)  
- Ross procedure  
- Rastelli procedure  
- Congenitally corrected transposition of the great arteries (CCTGA)  
- Sano shunt  
- Homograft (aortic or pulmonary)  
- Xenograft  
- Bioprosthetic valve  
- Progressive stenosis  
- Valvular regurgitation  
- Coronary artery compression  
- Coronary compression testing  
- Balloon‑expanded stent  
- Stent fracture  
- Stent fracture‑related stenosis  
- Pulmonary regurgitation  
- Infective endocarditis  
- Transcatheter pulmonary valve (MPV)  
- Routine follow‑up  
- Adult congenital heart disease (ACHD)  
- Electrocardiogram (ECG)  
- Transthoracic echocardiogram (TTE)

Page 76 Extracted Terms:
- Infective endocarditis  
- Cardiac valve implantation  
- RV‑to‑PA conduit  
- Pulmonary stenosis  
- Pulmonary regurgitation  
- Bioprosthetic valve thrombosis  
- Conduit dysfunction  
- Conduit stenosis  
- Conduit regurgitation  
- Stent implantation  
- Transcatheter valve placement  
- Cardiac catheterization  
- Echocardiography  
- Cardiovascular magnetic resonance (CMR) imaging  
- Coronary computed‑tomography (CT) angiography  
- Pulmonary arterial hypertension  
- Right ventricular dysfunction  
- Right ventricular dilation  
- Exercise capacity  
- Arrhythmias (atrial and ventricular)  
- Tricuspid regurgitation  
- Thrombus formation (subclinical)  
- Aspirin therapy  
- Surgical valve replacement  
- Transcatheter valve replacement  
- Hemodynamic assessment  
- Pulmonary arterial pressures  
- Cardiac output  
- Volume status  
- Pulmonary arterial resistance  
- Periprocedural complications  
- Long‑term outcomes  

Page 77 Extracted Terms:
- Dextro‑Transposition of the Great Arteries (d‑TGA)  
- Atrial switch (Surgically induced)
- Systemic right ventricle  
- Tricuspid valve (systemic AV valve)  
- Heart failure  
- Exercise intolerance  
- Pulmonary hypertension  
- Baffle leak  
- Baffle obstruction  
- Ventricular tachyarrhythmia  
- Supraventricular tachyarrhythmia (atrial arrhythmias)  
- Sustained ventricular tachyarrhythmia  
- Sudden cardiac death (SCD)  
- Implantable cardioverter‑defibrillator (ICD)  
- Pacemaker (permanent)  
- Cardiac resynchronization therapy (CRT)  
- Guideline‑directed medical therapy (GDMT) for HFrEF  
- Anticoagulation (oral)  
- Transcatheter valve placement  
- Balloon‑expandable percutaneous valves  
- Self‑expanding valve technologies  
- Conduit intervention  
- Complex congenital lesions  
- Right ventricular ejection fraction (RVEF)  
- Systemic venous pathway stenosis  
- Pulmonary venous pathway stenosis  
- Exercise capacity improvement  
- Transthoracic echocardiography (TTE)  
- Cardiac magnetic resonance imaging (CMR)  
- Cardiopulmonary exercise testing (CPET)  
- Invasive hemodynamic assessment  
- Electrocardiogram (ECG)  
- Ambulatory rhythm monitoring  
- Catheter‑based interventions for residual lesions  
- Risk score application for ventricular arrhythmia & SCD  
- Mechanical circulatory support (MCS)  
- Transplantation (heart‑lung, heart).

Page 78 Extracted Terms:
- Regurgitation (moderate or severe)  
- Exercise intolerance  
- Heart failure  
- Ventricular dysfunction  
- Valve dysfunction  
- Chronotropic incompetence  
- Pathway obstruction  
- Baffle leaks  
- Arrhythmia (atrial, ventricular)  
- Pulmonary arterial hypertension (PAH)  
- Pulmonary hypertension (post‑capillary, pre‑capillary, combined)  
- Stenosis of pulmonary and systemic venous pathways  
- Pulmonary or systemic venous congestion  
- Left‑to‑right shunting  
- Ventricular overload  
- Bidirectional shunting  
- Cyanosis  
- Paradoxical emboli  
- Atrial arrhythmias (28.9% prevalence)  
- Ventricular arrhythmias (5.8% prevalence)  
- Sudden death  
- Loss of sinus rhythm  
- Permanent pacing / pacemaker  
- Transthoracic echocardiography (TTE)  
- Cardiovascular magnetic resonance (CMR)  
- Late gadolinium enhancement (LGE)  
- Myocardial scar  
- Cardiac catheterization  
- Electrocardiogram (ECG) / Holter monitoring  
- Peak oxygen consumption (VO₂)  
- Ventilation to CO₂ output slope  
- CPET (cardiopulmonary exercise testing)  
- Exercise‑induced cyanosis  
- Tachyarrhythmias  
- Bradyarrhythmias  
- Pulmonary venous pathways  
- d‑TGA (dextro‑transposition of the great arteries)  
- ACHD (adult congenital heart disease)  
- Atrial switch operation  
- Systemic right ventricle (RV) function  
- Tricuspid regurgitation  
- Venous return pathways  
- Stent or closure device (artifact in imaging)  

These terms capture the cardiovascular conditions, diagnostic modalities, and relevant clinical considerations presented in the guideline excerpt.

Page 79 Extracted Terms:
**Key heart‑disease terms extracted from the text**

- Pulmonary hypertension  
- Advanced heart failure  
- Heart–lung transplantation  
- Permanent pacemaker (PPM)  
- Implantable cardioverter‑defibrillator (ICD)  
- Transvenous pacing leads  
- Subcutaneous ICD  
- Cardiac resynchronization therapy (CRT)  
- d‑Transposition of the great arteries (d‑TGA)  
- Atrial switch (Senning/Mustard procedures)  
- Superior vena cava (SVC) pathway  
- Azygos vein (off‑loading pathway)  
- Baffle leak (intratrial)  
- Thromboembolic complications (related to baffle leaks)  
- Ventricular arrhythmia  
- Atrial arrhythmia  
- Supraventricular arrhythmia  
- Left ventricular (LV) dysfunction  
- Right ventricular (RV) dysfunction  
- Severe tricuspid regurgitation  
- Sudden cardiac death (SCD)  
- Malignant arrhythmias (e.g., sustained ventricular tachycardia)  
- ICD therapy (appropriate shocks)  
- Holter monitoring  
- Implantable loop recorder  
- Intra‑atrial reentrant tachycardia (IART)  
- Electrical cardioversion  
- Antiarrhythmic drug therapy  
- Catheter ablation (including 3‑D imaging, mapping, robotic magnetic navigation)  
- Baffle‑leak intervention (e.g., closure procedures)  
- Left‑to‑right shunt (clinical significance)  
- QRS duration (≥120 ms)  
- LVOT obstruction  
- Risk stratification for mortality and major events  

These terms capture the major cardiovascular conditions, interventions, and risk‑assessment elements discussed in the guideline excerpt.

Page 80 Extracted Terms:
**Key heart‑disease terms extracted from the guideline text**

- Left‑ventricular (LV) volume overload  
- Right‑to‑left shunting  
- Cyanosis at rest or with exercise  
- Paradoxical emboli  
- Baffle leak  
- Pulmonary congestion  
- Systemic right‑ventricle (RV) dysfunction  
- Tricuspid regurgitation (TR)  
- Systemic venous pathway stenosis  
- Superior vena cava (SVC) stenosis  
- Inferior vena cava (IVC) stenosis  
- De‑xtro‑transposition of the great arteries (d‑TGA)  
- Atrial switch repair  
- Progressive systemic RV dysfunction  
- Heart failure (HF)  
- Refractory arrhythmias  
- Cardiac transplantation  
- Mechanical circulatory support (MCS)  
- Intravenous diuretics  
- Pulmonary vascular resistance (PVR)  
- Tricuspid valve repair / replacement  
- Permanent pacemaker implantation  
- Implantable cardioverter‑defibrillator (ICD) implantation  
- CHA₂DS₂‑VASc score  
- Anticoagulation (vitamin K antagonists, direct oral anticoagulants)  
- Echocardiography (transthoracic, transesophageal, agitated saline test)  
- Cardiac resynchronization therapy (CRT)  
- Renin–angiotensin–aldosterone system (RAAS) inhibitors  
- Beta‑blockers  
- Phosphodiesterase‑5 inhibitor (tadalafil)  
- Sacubitril/valsartan  
- Dapagliflozin.

Page 81 Extracted Terms:
- Adult congenital heart disease (ACHD)  
- Arterial switch operation  
- d‑TGA (dextro‑transposition of the great arteries)  
- Neoaortic size/diameter  
- Neoaortic root dilation  
- Neoaortic regurgitation (insufficiency)  
- Neoaortic valve stenosis  
- Neoaortic valvular dysfunction  
- Neoaortic root replacement  
- Supravalvar pulmonary artery stenosis  
- Branch pulmonary artery stenosis  
- Coronary artery anatomy  
- Coronary obstruction  
- Coronary angiography  
- Coronary revascularization  
- Myocardial ischemia  
- Echocardiography  
- Cardiovascular magnetic resonance (CMR)  
- Cardiac computed tomography (CT)  
- Right ventricular hypertension  
- Right ventricular dysfunction  
- Tricuspid regurgitation  
- Exercise capacity  
- Aortic valve disease  
- Late postoperative complications  
- Routine follow‑up intervals  
- Monitoring of pulmonary artery anatomy  
- Monitoring of ventricular function  
- Monitoring of valve function  
- Monitoring of coronary artery patency  

Page 82 Extracted Terms:
- Neoaortic diameter  
- Branch pulmonary artery (PA) stenosis  
- Cardiac Magnetic Resonance Imaging (CMR)  
- Cardiac Computed Tomography (CT)  
- Regadenoson stress CMR perfusion  
- Arterial switch operation  
- Coronary artery assessment  
- Coronary reintervention  
- Ventricular tachycardia (VT)  
- Sudden cardiac death (SCD)  
- Intra‑mural course  
- Acute angulation of the left coronary artery  
- Clockwise rotation of the left coronary ostium  
- Distance between left coronary ostium and neopulmonary artery  
- Lecompte maneuver  
- Aortic dilation/enlargement  
- Right ventricular (RV) pressure load  
- Neoaortic root intervention  
- Neoaortic insufficiency (regurgitation)  
- Neoaortic regurgitation  
- Root diameter  
- Aortic dissection  
- Bicuspid aortic valve (BAV)  
- Connective tissue disease  
- Valve‑sparing aortic root replacement  
- Cardiac catheterization  
- Dynamic obstruction  
- Perfusion imaging  
- Pulmonary valve stenosis  
- Transcatheter intervention  
- Aortopulmonary fistula  
- Exercise capacity  
- Functional status  
- Symptomatic ischemia  
- Exertional dyspnea  
- Interventional cardiology  
- Heart disease imaging modalities  

Page 83 Extracted Terms:
- Adult Congenital Heart Disease (ACHD)  
- Dextro‑Transposition of the Great Arteries (d‑TGA)  
- Rastelli Repair/Operation  
- Ventricular Septal Defect (VSD)  
- Right Ventricular–to‑Pulmonary Artery (RV‑to‑PA) Conduit  
- Left Ventricular Outflow Tract (LVOT) Obstruction  
- Right Ventricular (RV) Dysfunction (systolic and diastolic)  
- Aortic Dissection  
- Neo‑aortic Root Diameter  
- Prophylactic Root Replacement  
- Thoracic Aortic Disease  
- Arrhythmia  
- Heart Failure  
- Right Ventricular Outflow Tract (RVOT) Obstruction  
- Pulmonary Regurgitation (pulmonary insufficiency)  
- Neo‑aortic Insufficiency  
- Coronary Artery Stenosis  
- Infective Endocarditis  
- Conduit Stenosis  
- Conduit Insufficiency / Calcification  
- Residual VSD  
- RV Pressure/Volume Overload  
- Tricuspid Regurgitation Velocity  
- RV Hypertrophy  
- RV Dilatation  
- Transthoracic Echocardiography (Echo)  
- Cardiac Magnetic Resonance Imaging (CMR)  
- Cardiac Computed Tomography Angiography (CT angiography)  
- Electrocardiogram (ECG)

Page 84 Extracted Terms:
- Congenitally Corrected Transposition of the Great Arteries (CCTGA)  
- Atrioventricular (AV) block  
- Systemic tricuspid valve dysfunction / regurgitation  
- Systemic ventricular dysfunction (right‑ventricular systolic dysfunction)  
- Subpulmonic left‑ventricular dysfunction  
- Left‑ventricular outflow tract (LVOT) stenosis / obstruction  
- Right‑ventricular systolic dysfunction  
- Right‑ventricular systolic dysfunction prevalence (50–80%)  
- Left‑ventricular systolic dysfunction prevalence (11–40%)  
- Ventricular arrhythmias (atrial and ventricular)  
- Cardiac remodeling  
- Heart failure (HF) with RV dysfunction  
- Cardiovascular mortality  
- Structural heart lesions (tricuspid valve dysplasia, Ebstein‑like anomaly, VSD, LVOT obstruction)  
- Atrial septal defects (ASD)  
- Ventricular septal defect (VSD)  
- Congenital valve dysplasia  
- Cardiovascular magnetic resonance (CMR)  
- Computed tomography (CT)  
- Transthoracic echocardiography (TTE)  
- Electrocardiogram (ECG)  
- Ambulatory rhythm monitoring  
- Cardiac pacing (physiological pacing, CRT, conduction‑system pacing)  
- Global‑dose management therapy (GDMT) for heart failure  
- Atrial–ventricular conduction system  
- Atrial switch operation  
- Arterial switch operation  
- Physiological repair (surgical or transcatheter)  
- Cardiopulmonary exercise testing (CPET)  
- Biomarker assay (NT‑proBNP)  
- ACHD (adult congenital heart disease)  
- Cardiac imaging  
- Systemic ventricular volume measurement  
- Rhythm abnormalities  
- Exercise training  
- Vascular remodeling  

These are the core heart‑disease–related terms and concepts extracted from the guideline text.

Page 85 Extracted Terms:
- Atrioventricular block  
- Atrial arrhythmias  
- Biatrial remodeling  
- Cardiac pacing (including LV pacing, CRT, conduction‑system pacing)  
- Cardiac electrophysiology evaluation (ambulatory rhythm monitoring)  
- Cardiac valve disease (tricuspid valve dysplasia, mitral‑like valve anomalies)  
- Cardiac valve replacement/repair (mechanical prosthesis, bioprosthesis)  
- Cardiac valve surgery (tricuspid valve surgery, valve replacement)  
- Cardiac imaging (trans‑thoracic echocardiography, 2‑D Doppler, speckle tracking, CMR, CT)  
- Chronic heart failure symptoms  
- Congenital corrected transposition of the great arteries (CCTGA)  
- Coronary artery relationship to heart structures (anatomical assessment)  
- Diagnostic monitoring (electrophysiologist’s evaluation, ambulatory rhythm monitoring)  
- End‑organ dysfunction (right‑ventricular systolic dysfunction, left‑ventricular systolic dysfunction)  
- Ejection fraction (right‑ventricular, left‑ventricular)  
- Electro‑cardiographic abnormalities (high‑grade atrioventricular block)  
- Generalized ventricular dysfunction (progressive systemic RV dysfunction)  
- Heart failure management (GDMT, angiotensin‑receptor neprilysin inhibitor)  
- Hemodynamic evaluation (LVOT stenosis – valvular and subvalvular)  
- Hemodynamic burden (chronic heart failure, RV dysfunction)  
- Impaired chronotropic response (chronotropic incompetence)  
- Imaging frequency guidelines (CMR imaging every 1–5 years)  
- Interventional therapy (surgical or transcatheter LVOT stenosis relief)  
- Long‑term outcomes (mechanical prosthesis durability, valve repair durability)  
- Management of anticoagulation (vitamin K antagonist)  
- Advanced heart failure therapies (intra‑pump or transplant referral)  
- Neurohormonal activation (targeted by neprilysin inhibitor)  
- Structural lesion (LVOT stenosis, tricuspid regurgitation)  
- Systemic ventricular dysfunction (post‑pacing, post‑surgery)  
- Symptom‑driven pacing indications (symptomatic bradycardia, heart failure symptoms)  
- Systemic tricuspid regurgitation severity (mild vs. severe, progressive disease)  
- Ventricular systolic dysfunction (moderate vs. severe, residual dysfunction post‑repair)

Page 86 Extracted Terms:
**Key Terms Related to Heart Disease**

- LVOT stenosis  
- LVOT obstruction  
- Tricuspid regurgitation  
- Ventricular septal geometry  
- Truncus arteriosus  
- Cyanotic cardiac defect  
- Pulmonary hypertension  
- Pulmonary vascular obstructive disease  
- Pulmonary arterial trunk  
- VSD (ventricular septal defect)  
- VSD closure  
- Neoaortic insufficiency  
- Neoaortic dilation  
- Double‑outlet right ventricle (DORV)  
- Mitral‑aortic discontinuity  
- Tetralogy of Fallot (TOF)  
- d‑Transposition of the great arteries (d‑TGA)  
- Rastelli repair  
- Left ventricle‑to‑aorta baffle  
- RV‑to‑PA conduit  
- Arterial switch operation  
- Fontan palliation  
- Single‑ventricle physiology  
- Hypoplastic right or left ventricle  
- Atrial isomerism  
- AVSD (atrioventricular septal defect)  
- Straddling atrioventricular valves  
- Major pulmonary artery anomalies  
- Reintervention (RV‑to‑PA reoperation)  
- Reoperation for LVOT obstruction  
- Patch leaks (VSD repair)  
- ACHD (adult congenital heart disease)  
- Electocardiogram  
- Transthoracic echocardiogram  
- Routine follow‑up intervals (physical, electrocardiogram, echocardiogram)

Page 87 Extracted Terms:
- Fontan circulation  
- single‑ventricle physiology  
- Fontan palliation  
- Fontan circulatory failure  
- heart failure  
- heart transplantation  
- Fontan‑associated liver disease (FALD)  
- hepatocellular carcinoma  
- liver fibrosis / cirrhosis  
- hepatic testing  
- portal hypertension  
- liver biopsy  
- cardiac catheterization  
- atrial tachyarrhythmias  
- atrial flutter  
- atrial fibrillation  
- supraventricular tachycardia  
- thrombus  
- thromboembolism  
- Fontan‑pathway thrombosis  
- pulmonary vasculature  
- CT angiography  
- MR imaging  
- transesophageal echocardiography  
- hypoxemia  
- systemic ventricular overload  
- aortopulmonary collaterals  
- pulmonary vasodilators  
- pulmonary hypertension  
- ventricular pacing  
- pacemaker implantation  
- atrioventricular block  
- exercise program  
- cardiac rehabilitation  
- catheter ablation  
- Fontan stenosis  
- Fontan pressure  
- Fontan conversion surgery  
- transplant‑free survival  
- anticoagulation therapy  
- aspirin therapy  
- multidisciplinary transplant committee  
- non‑cardiac organ dysfunction  
- functional capacity improvement  
- heart‑related morbidity and mortality

Page 88 Extracted Terms:
- Fontan circulation  
- Fontan procedure  
- Fontan palliation  
- Fontan circulatory failure  
- Single‑ventricle congenital heart disease  
- Systemic venous hypertension  
- Low cardiac output  
- Multi‑system disease  
- Liver cirrhosis  
- Hepatocellular carcinoma  
- Hepatic screening  
- Multidisciplinary team  
- ACHD (adult congenital heart disease) cardiologist  
- Electrocardiogram  
- Transthoracic echocardiogram  
- Cardiovascular magnetic resonance (CMR) imaging  
- Cardiac transplantation  
- Cardiac failure/heart failure  
- Advanced cardiac therapies  
- Arrhythmia  
- Thrombo‑prophylaxis  
- Structured exercise program  
- Catheter‑based interventions  
- Organ dysfunction (renal, hepatic, lymphatic)  
- Ventricular dysfunction  
- Transplant listing and timing  
- Multiorgan dysfunction  
- Obesity, social obstacles, substance use (barriers to transplant)

Page 89 Extracted Terms:
- Fontan circulation  
- Fontan pathway  
- Single‑ventricle  
- Hemodynamic assessment  
- Pulmonary circulation  
- Pulmonary pressures  
- Ventricular pressures  
- Systemic vascular resistance  
- Pulmonary vascular resistance  
- Atrial arrhythmias  
- Atrial tachyarrhythmias  
- Tachyarrhythmias  
- Ventricular dysfunction  
- Valvular disease  
- Outflow tract obstruction  
- Thrombotic complications  
- Endothelial dysfunction  
- Venous stasis  
- Clotting mechanisms  
- Hepatic dysfunction (Fontan‑associated)  
- Stroke  
- Neurocognitive decline  
- Arteriovenous malformations  
- Veno‑venous collaterals  
- Aortopulmonary collaterals  
- Shunting  
- Cardiac CT angiography  
- Cardiac MRI (CMR)  
- Transthoracic echocardiography  
- Transesophageal echocardiography  
- Single‑ventricle congenital heart disease  
- Fontan completion  
- Fontan revision  
- Fontan circulatory failure  
- Cardiac function  
- Cardiopulmonary assessment  
- Pulmonary hypertension  
- Structural heart disease  
- Hemodynamic abnormalities  
- Congenital heart disease  
- Cardiac imaging  
- Cardiac hemodynamics

Page 90 Extracted Terms:
**Key heart‑disease related terms extracted from the guideline text**

- Fontan circulation
- Fontan-associated thrombus
- Fontan-associated liver disease (FALD)
- Fontan circulatory failure
- Thrombocytopenia
- Erythrocytosis
- Lymphopenia
- Chronic hypoxemia
- Protein‑losing enteropathy
- NT‑proBNP
- Albumin
- 24‑hour stool α‑1 antitrypsin clearance
- Iron studies (serum iron, total iron‑binding capacity, ferritin)
- Fontan‑related portal hypertension
- Combined heart–liver transplantation
- Liver fibrosis (assessment via biopsy)
- Trans‑esophageal echocardiography (TEE)
- CT angiography
- Cardiac magnetic resonance (CMR)
- Sustained atrial flutter/fibrillation (>30 s)
- Thromboembolic disease
- Cerebrovascular accident (stroke)
- Atriopulmonary Fontan
- Anticoagulation (warfarin, non‑vitamin K oral anticoagulants)
- Antithrombotic prophylaxis
- Antiplatelet agents
- Bleeding contraindications
- Right‑to‑left shunting
- Kawashima procedure
- Transvenous pacemaker system
- Ventricular pacing
- Sinus node dysfunction
- Loss of atrial rhythm
- Chronotropic incompetence
- Tachy‑brady syndromes
- Bradycardia
- Functional status (decreased)
- Ventricular dysfunction
- Pulmonary venous flow reversal
- Adverse outcomes
- Hemodynamic alterations

These terms capture the diseases, complications, diagnostic markers, imaging modalities, and therapeutic strategies highlighted in the guideline.

Page 91 Extracted Terms:
- Fontan circulation  
- Atrioventricular valve function  
- Ventricular relaxation  
- Sinus node dysfunction  
- Electrophysiologist  
- Device therapy (permanent device)  
- Lead placement  
- Atrial pacing  
- Ventricular pacing  
- Atrial arrhythmias  
- Atrial flutter  
- Intra‑atrial re‑entrant tachycardia  
- Atrial fibrillation  
- Acute cardioversion  
- Ventricular dysfunction  
- Fontan circulatory failure  
- Antiarrhythmic medication  
- Thrombosis risk (Fontan population)  
- Transesophageal echocardiography  
- Anticoagulation (post‑cardioversion)  
- Heart transplantation  
- Cardiac transplantation in adult congenital heart disease (ACHD)  
- Multidisciplinary transplant team  
- ACHD (adult congenital heart disease) specialists  
- Heart failure/transplantation team  
- Congenital heart disease surgery  
- Transplant surgery  
- Cardiac imaging  
- Hepatology (transplant hepatology)  
- Psychiatry  
- Combined heart‑liver transplantation  
- Fontan‑associated liver disease (FALD)  
- Portal hypertension  
- Ascites  
- Varices  
- Splenomegaly  
- Epicardial apical site pacing  
- Ventricular synchrony  
- Exercise training (for Fontan adults)  
- Peak VO₂  
- Quality of life (cardiac context)  
- Skeletal muscle mass  
- Adiposity  
- Resistance training  
- Catheter ablation (atrial arrhythmias)  
- Atrial arrhythmia burden  
- Intra‑atrial re‑entrant tachycardia (Scar‑mediated)  
- Focal atrial tachycardias  
- Antiarrhythmic medical therapy (general)  
- Pacing (general term for cardiac pacing)

Page 92 Extracted Terms:
Fontan circulation  
Fontan pathway stenosis  
Fontan pathway conduit (extracardiac conduit)  
Fontan pressure  
Fontan obstruction  
Fontan conversion (total cavopulmonary Fontan)  
Aortopulmonary collaterals  
Pulmonary vasodilators  
Pulmonary vascular resistance (PVR)  
Ventricular preload  
Exercise performance (anaerobic threshold)  
Fenestration‑associated liver disease (FALD)  
Atrial arrhythmias (recurrent atrial arrhythmias)  
Atrial scarring  
Conduction system injury  
Electrophysiology ablation  
Stenting of Fontan pathway  
Ventricular end‑diastolic pressure  
Atrial‑ventricular valve dysfunction  
Common atrioventricular valve  
Morphologic tricuspid valve  
Protein‑losing enteropathy  
Hypoplastic left heart syndrome (HLHS)  
Norwood repair (HLHS/Norwood)  
3‑dimensional imaging of the neoaorta  
Transplantation (cardiac transplantation)  
Multidisciplinary cardiac surgical procedures (non‑transplant)  
Atrial maze procedure (modified Maze)  
Venous hypertension (elevated Fontan pressure)  
Pulmonary artery pressure  
Catheterization in adults with Fontan circulation  
Ventricular enlargement  
End‑diastolic pressure  
Aortic‑pulmonary collaterals (aortopulmonary collaterals)  
Pulmonary artery (PA)  
Cardiac output  
Conventional catheter ablation.

Page 93 Extracted Terms:
**Key Heart‑Disease Related Terms Extracted**

- HLHS (Hypoplastic Left Heart Syndrome)  
- Single‑ventricle congenital heart disease  
- Left ventricle  
- Aortic valve  
- Ascending aorta  
- Fontan physiology  
- Fontan failure  
- Norwood repair (stage 1)  
- Distal main pulmonary artery (PA)  
- Hypoplastic aorta  
- Pulmonary stump  
- Blalock‑Taussig‑Thomas shunt  
- RV‑to‑PA shunt  
- Neoaorta  
- Neoaortic dilation  
- Neoaortic obstruction  
- Neoaortic‑root pathology  
- Hypoplastic aortic root  
- Coronary ischemia  
- Ventricular dysfunction  
- Atrioventricular valve dysfunction  
- Neurocognitive dysfunction  
- Periodic imaging  
- MR angiography  
- CT angiography  
- Echocardiography  
- Cardiac transplantation  
- Eisenmenger syndrome  
- Right‑to‑left shunting  
- Pulmonary arterial hypertension (PAH)  
- Invasive hemodynamic assessment  
- PAH‑directed therapy  
- Endothelin receptor antagonist  
- Phosphodiesterase‑5 inhibitor  
- Prostacyclin therapy (inhaled/subcutaneous)  
- Anticoagulation therapy  
- Thromboembolic complications  
- Pulmonary arterial thrombosis  
- Atrial arrhythmias  
- Intracardiac shunt  
- Permanent pacing  
- Implantable cardioverter–defibrillator (ICD)  
- Endocardial leads  
- Cyanosis  
- Hyperviscosity  
- Iron supplementation  
- 6‑minute walk distance  
- Tricuspid annular plane systolic excursion (TAPSE)  
- NT‑proBNP  
- World Health Organization (WHO) functional class  
- Left ventricular ejection fraction (LV EF)  
- High bleeding risk  
- Perioperative risk  
- Morbidity and mortality  
- Clinical surveillance protocol  
- Advanced cardiac therapies  

These terms capture the principal diseases, anatomical and physiological concepts, diagnostic methods, therapeutic approaches, and risk factors discussed in the guideline text.

Page 94 Extracted Terms:
**Key terms related to heart disease**

- Eisenmenger syndrome  
- Pulmonary arterial hypertension (PAH)  
- Congenital heart disease (CHD) / ACHD  
- Left‑to‑right shunt defects  
- Right‑to‑left shunt / bidirectional shunting  
- High pulmonary vascular resistance (PVR)  
- Chronic cyanosis  
- Diastolic dysfunction  
- Systolic dysfunction  
- Arrhythmias  
- Sudden cardiac death (SCD)  
- Down syndrome  
- Obstructive sleep apnea  
- Thyroid dysfunction  
- 6‑minute walk distance (6MWD)  
- Supplemental oxygen therapy  
- High‑altitude exposure  
- Pregnancy in CHD patients  
- Nephrotoxic exposure  
- Mechanical circulatory support  
- Pulmonary circulatory support  
- Lung transplantation (with cardiac repair)  
- Heart‑lung transplantation  
- Endothelin‑receptor antagonists  
- Bosentan  
- Macitentan  
- Phosphodiesterase‑5 (PDE5) inhibitors  
- Sildenafil (example PDE5 inhibitor)  
- Soluble guanylate cyclase stimulator (riociguat)  
- Prostacyclin analogs / receptor agonists  
- Inhaled iloprost  
- Selexipag (oral prostacyclin receptor agonist)  
- Activin signaling inhibitor (sotatercept)  
- B‑type natriuretic peptide (BNP)  
- N‑terminal proBNP (NT‑proBNP)  
- World Health Organization (WHO) functional class  
- Systemic vascular resistance (SVR)  
- Risk‑assessment tools (e.g., 6MWD, hemodynamic parameters)  

These terms encompass diseases, clinical features, risk factors, diagnostic markers, and therapeutic modalities relevant to heart disease, particularly in the context of Eisenmenger syndrome and associated congenital heart conditions.

Page 95 Extracted Terms:
- Eisenmenger syndrome  
- Pulmonary arterial hypertension (PAH)  
- Bidirectional shunting  
- Large septal defects  
- Pulmonary vascular resistance (PVR)  
- Postcapillary pulmonary hypertension  
- Valvular regurgitant lesion  
- Right‑ventricular (RV) pressure overload  
- Mechanical circulatory support (MCS)  
- Transplantation (cardiac/heart‑lung)  
- Brain natriuretic peptide (BNP)  
- N‑terminal pro‑BNP (NT‑proBNP)  
- Six‑minute walk distance  
- Functional class assessment  
- Risk stratification models  
- Down syndrome  
- Pretricuspid shunt  
- Age (advanced patient age)  
- Hypoxemia  
- Glomerular filtration rate (GFR)  
- Echocardiographic indices of RV dysfunction  
- Systemic vascular resistance  
- Volume overload  
- Univentricular hearts  
- Pregnancy in PAH  
- Right‑to‑left shunting  
- Spontaneous miscarriages  
- PAH crises (post‑partum)  
- Thromboembolic events  
- Paradoxical embolism  
- World Health Organization (WHO) class IV  
- Maternal and fetal morbidity/mortality  
- Multidisciplinary cardio‑obstetrics team  
- Adult congenital heart disease (ACHD) specialists  
- Pulmonary hypertension specialists  
- Obstetric anesthesia  
- Endothelin receptor antagonist therapy  
- Macitentan (endothelin‑1 receptor antagonist)  
- Bosentan (endothelin receptor antagonist)  
- Phosphodiesterase‑5 inhibitors (PDE‑5i)  
- Electrocardiogram (ECG)  
- Transthoracic echocardiogram (TTE)  
- ACHD cardiologist  

(This list captures the key heart‑disease terms and concepts mentioned in the guideline excerpt.)

Page 96 Extracted Terms:
- Eisenmenger syndrome  
- Pulmonary arterial hypertension (PAH)  
- Adult congenital heart disease (ACHD)  
- Systemic vascular resistance  
- Oxygen saturations  
- Phosphodiesterase‑5 inhibitor therapy  
- 6‑minute walk distance  
- Hemodynamics  
- Adult with Eisenmenger syndrome clinical characteristics  
- Upfront combination PAH therapy  
- Monotherapy in PAH  
- Sildenafil (PDE5 inhibitor)  
- Ambrisentan (endothelin receptor antagonist)  
- New York Heart Association (NYHA) functional class  
- Pulmonary pressures (mean pulmonary artery pressure, systolic, diastolic)  
- NT‑proBNP levels  
- Pulmonary vascular resistance (PVR)  
- Qp:Qs (pulmonary to systemic flow ratio)  
- Triple vasodilator therapy  
- Subcutaneous treprostinil  
- Inhaled iloprost  
- Oral prostacyclin analog selexipag  
- Intravenous prostacyclin  
- Paradoxical embolization  
- Arrhythmias (atrial, ventricular)  
- Morbidity and mortality in Eisenmenger syndrome  
- Hemodynamic stability  
- Cardiac anesthesia support  
- Cardioversion for atrial arrhythmias  
- Mild‑to‑moderate intensity exercise  
- World Health Organization (WHO) functional class  
- Home‑based exercise training program  
- Competitive sports and extreme isometric exercise (to be avoided)  
- PAH‑directed medications  
- Prostacyclin therapy (inhaled, subcutaneous, intravenous)  
- Small prospective trial of inhaled prostacyclin in Eisenmenger patients with normal LV function  
- Right ventricular (RV) function  
- Left ventricular (LV) function  
- Clinical trials of PAH‑directed therapy in Eisenmenger syndrome  
- Riociguat (sGC stimulator)  
- Thrombosis in Eisenmenger syndrome  
- Dilated pulmonary arteries (PAs)  
- Dilated or dysfunctional cardiac chambers  
- Intracardiac prosthetic materials (pacemaker leads)  
- Laminated (in‑situ) thrombi  
- Aneurysmal pulmonary arteries  
- Cerebrovascular events (stroke, silent infarcts)  
- Systemic arterial and venous thromboembolic events  
- Systemic anticoagulation treatment  
- Pulmonary hypertension management strategies.

Page 97 Extracted Terms:
- Atrial fibrillation  
- Atrial flutter  
- CHA₂DS₂‑VASc score  
- HAS‑BLED score  
- Anticoagulation  
- Vitamin K antagonists  
- Low‑molecular‑weight heparin  
- Direct oral anticoagulants  
- Eisenmenger syndrome  
- Bleeding risk (↓ factor II, V, VII, IX, X, ↓ von Willebrand factor)  
- Hemoptysis  
- Intrapulmonary hemorrhage  
- Bronchial artery erosion  
- Pulmonary vascular disease  
- Bidirectional shunt  
- Right‑ventricular (RV) strain  
- Intracardiac shunts  
- Transvenous pacemaker leads  
- Epicardial pacemaker leads  
- Subcutaneous implantable cardioverter‑defibrillator (ICD)  
- Systemic thromboembolism  
- Coronary artery anomalies  
- Anomalous aortic origin of a coronary artery (AAOCA)  
- Coronary CT angiography  
- MR angiography  
- Myocardial ischemia attributable to AAOCA  
- Surgical repair (coronary revascularization)  
- High‑risk anatomy (ostial/proximal stenosis, slit‑like orifice, acute angle of takeoff, intramural course)  
- Sudden cardiac death (SCD)  
- Coronary fistula

Page 98 Extracted Terms:
- Anomalous Aortic Origin of the Coronary Artery (AAOCA)  
- Coronary CT angiography  
- Cardiac Magnetic Resonance (CMR) angiography  
- Invasive coronary angiography  
- Intravascular ultrasound (IVUS)  
- Fractional flow reserve (FFR)  
- Coronary artery stenosis  
- Cardiovascular risk stratification  
- Shared decision‑making  
- Serial cardiac imaging  
- Exercise stress testing  
- Coronary artery disease (CAD)  
- Coronary artery bypass graft (CABG)  
- Coronary unroofing (surgery)  
- Osteoplasty (surgical technique)  
- Coronary reimplantation (surgical technique)  
- Pulmonary translocation (surgical technique)  
- Intramural coronary course  
- Fibrosis imaging (via CMR)  
- Shunt assessment  
- Hemodynamic evaluation (for shunts)

Page 99 Extracted Terms:
- Anomalous aortic origin of a coronary artery (AAOCA)  
- Anomalous right coronary artery (ARCA)  
- Anomalous left coronary artery (ALCA)  
- Anomalous left coronary artery arising from the pulmonary artery (ALCAPA)  
- Anomalous right coronary artery arising from the pulmonary artery (ARCAPA)  
- Sudden cardiac death (SCD)  
- Myocardial ischemia / ischemic changes  
- Wall‑motion abnormalities  
- Fractional flow reserve (FFR)  
- Coronary unroofing  
- Osteoplasty (coronary)  
- Coronary reimplantation  
- Pulmonary translocation  
- Coronary artery bypass graft (CABG)  
- Ventricular arrhythmias  
- Exercise stress testing  
- Dobutamine stress testing  
- Stress electrocardiogram (ECG)  
- Echocardiography (transthoracic, Doppler)  
- Nuclear imaging (myocardial perfusion)  
- Cardiac magnetic resonance (CMR) imaging  
- Cardiac function (ejection fraction, systolic function)  
- Cardiac dysfunction  
- Risk stratification  
- Physiological impact / assessment  
- Intramural coronary course  
- Hypoplasia of the proximal segment  
- Ostial stenosis  
- Slit‑like orifice  
- Acute angle of takeoff  
- High‑risk features  
- Shared decision‑making  
- Watchful waiting  
- Adult congenital heart disease (ACHD)  
- Computed tomography (CT) angiography  
- Magnetic resonance (MR) angiography  
- Electrocardiogram (ECG) follow‑up  
- Transthoracic echocardiogram follow‑up  

Page 100 Extracted Terms:
- Anomalous right coronary artery (ARCA) from the pulmonary artery  
- Anomalous left coronary artery (ALCA) from the pulmonary artery  
- Coronary artery fistula  
- Coronary steal phenomenon  
- Coronary artery bypass grafting (CABG)  
- Takeuchi repair  
- Coronary artery reimplantation  
- Ligation/closure of coronary artery at the pulmonary artery level  
- Ventricular dysfunction  
- Myocardial ischemia  
- Angina pectoris  
- Dyspnea  
- Heart failure  
- Myocardial infarction  
- Vascular ring  
- Pulmonary artery sling  
- Vascular ring repair  
- Pulmonary artery sling repair  
- Cross‑sectional imaging of aortic arch and pulmonary arteries  
- Airway compression symptoms (e.g., stridor, wheezing)  
- Esophageal compression symptoms (e.g., dysphagia)  
- Congenital heart disease (CHD)  
- Ventricular septal defect (VSD) as a common comorbidity  
- Right internal mammary artery (RIMA) graft  
- Left internal mammary artery (LIMA) graft  
- Coronary artery interposition graft  
- Sudden cardiac death (SCD) related to coronary anomalies  
- Coronary fistula closure (surgical or catheter‑based)

Page 101 Extracted Terms:
**Key Heart‑Disease Terms Extracted**

1. Adults with Congenital Heart Disease (ACHD)  
2. TOF (Tetralogy of Fallot)  
3. Vascular ring  
4. Pulmonary artery (PA) sling  
5. Pulmonary valve replacement  
6. Pulmonary stenosis  
7. Pulmonary regurgitation  
8. RV‑to‑PA conduit stenosis  
9. RV‑to‑PA conduit regurgitation  
10. Systemic right ventricle  
11. Pacing strategies  
12. Arrhythmia strategies  
13. Endocarditis risk in prosthetic valves (transcatheter or surgical)  
14. Transcatheter or surgical prosthetic valves  
15. Cardiac rehabilitation  
16. Exercise testing for clinical outcomes  
17. Genetic screening for ACHD  
18. Neurocognitive screening in ACHD  
19. Mental‑health screening in ACHD clinics  
20. Hormone replacement therapy in ACHD patients  
21. Gender‑affirming therapies in ACHD  
22. Pulmonary function testing  
23. Barium swallow testing  
24. Cardiac magnetic resonance imaging (CMR)  
25. Computed tomography (CT) angiography  
26. Tracheal compression  
27. Tracheomalacia  
28. Post‑operative imaging for vascular ring/PA sling  
29. Multidisciplinary subspecialties (pulmonary medicine, gastroenterology)  
30. Surgical repair of vascular ring/PA sling  
31. Asymptomatic vs symptomatic vascular ring/PA sling  
32. Vascular ring anatomical classifications (complete, incomplete, double aortic arch, etc.)

Page 102 Extracted Terms:
- Adult Congenital Heart Disease (ACHD)  
- Artificial Intelligence–ECG (AI‑ECG)  
- Guideline‑Directed Medical Therapy (GDMT)  
- Failing Right Ventricle  
- Failing Left Ventricle  
- Heart Failure  
- Heart Transplantation  
- Heart‑Versus‑Liver Transplantation (in Fontan patients)  
- Cardiac Transplantation Criteria (Fontan circulation)  
- Sudden Cardiac Death (SCD)  
- Primary‑Prevention Implantable Cardioverter‑Defibrillator (ICD)  
- Shunt Lesions (e.g., ASD, VSD, patent ductus)  
- Shunt Repair / Closure  
- Pulmonary Arterial Hypertension (PAH)  
- Coarctation of the Aorta (COA)  
- Resting, Exercise, and Ambulatory Hypertension  
- Exercise‑Induced Hypertension  
- Re‑Coarctation  
- Ebstein Anomaly  
- Glenn Shunt (Bidirectional Cavopulmonary Anastomosis)  
- Tetralogy of Fallot (TOF)  
- Pulmonary Valve Replacement (in TOF)  
- Left Ventricular (LV) Dysfunction (post‑TOF)  
- Systemic Right Ventricle  
- Tricuspid Valve Replacement (systemic right ventricle)  
- Cardiac Resynchronization Therapy (CRT)  
- Congenitally Corrected Transposition of the Great Arteries (CCTGA)  
- Ventricular Septal Defect (VSD)  
- Double‑Switch Operation  
- Arterial Switch Operation (d‑TGA)  
- Coronary Disease, Ostial Compression, Ischemia  
- Aortic Root Dilation  
- Antiplatelet Therapy  
- Anticoagulation Therapy  
- Pulmonary Vasodilators  
- Fontan‑Associated Liver Disease (FALD)  
- Protein‑Losing Enteropathy (PLE)  
- Lymphatic Abnormalities (Fontan)  
- Hypoplastic Left Heart Syndrome (HLHS)  
- Single‑Ventricle Physiology  
- Fontan Circulation  

(Each entry represents a key heart‑disease term or concept from the guideline text.)

Page 103 Extracted Terms:
- Double‑chamber right ventricle  
- Subaortic obstruction  
- Aortic dilation  
- Tetralogy of Fallot (TOF)  
- Dextrotransposition of the great arteries (d‑TGA)  
- Arterial switch operation  
- Single‑ventricle physiology  
- Fontan circulation  
- Ross procedure  
- Coronary arteries  
- Premature coronary artery disease  
- Obstruction (clinical threshold for intervention)  
- Stenosis (clinical threshold for intervention)  
- Congenital heart disease (CHD)  
- Intervention criteria in congenital heart conditions  
- Coronary artery disease (CAD) for congenital heart disease patients  

Page 104 Extracted Terms:
- Adult Congenital Heart Disease  
- Congenital Heart Disease  
- Valvular Heart Disease  
- Aortic Disease  
- Coronary Artery Disease  
- Chronic Coronary Disease  
- Heart Failure  
- Atrial Fibrillation  
- Arrhythmias  
- Tetralogy of Fallot (repaired)  
- Heart‑Kidney Transplantation  
- Heart‑Liver Transplantation  
- Multimodality Cardiovascular Imaging  
- Transition to Adulthood (for congenital heart disease)  
- Genetic Basis of Congenital Heart Disease  
- Psychological Outcomes in Congenital Heart Disease  
- Neurodevelopmental Outcomes in Congenital Heart Disease  
- Cardiac Nomenclature (International Pediatric and Congenital Cardiac Code)  
- Cardiovascular Catheterisation (Procedural and Complication Nomenclature)  
- Cardiovascular Complications (in interventional cardiology)

Page 105 Extracted Terms:
- Adult congenital heart disease (ACHD)  
- Congenital heart disease (CHD)  
- Anatomic‑physiologic classification system  
- Risk stratification / mortality prediction models  
- ACHD mortality score  
- Ebstein anomaly  
- Tetralogy of Fallot  
- Fontan procedure / Fontan circulation  
- Valvular heart disease (VHD)  
- Heart failure (HF)  
- Pulmonary hypertension (PH)  
- Infective endocarditis (IE)  
- Arrhythmia burden  
- Implantable cardioverter‑defibrillator (ICD)  
- Cardio‑pulmonary exercise testing (CPET)  
- N‑terminal pro‑brain natriuretic peptide (NT‑proBNP)  
- N‑terminal pro‑B‑type natriuretic peptide (NT‑proBNP)  
- Troponin‑T  
- Growth‑differentiation factor‑15 (GDF‑15)  
- Peak oxygen uptake (VO₂ peak)  
- Ventilatory efficiency (VE/VCO₂ slope)  
- QRS duration  
- Hospitalization trends & health‑resource utilization  
- Transition readiness & education programs  
- Barriers to care & access to specialty services  
- Functional indices (e.g., New York Heart Association class)  
- Clinical outcomes & morbidity‑mortality predictors

Page 106 Extracted Terms:
**Key Terms Related to Heart Disease**

1. Congenital heart disease  
2. Adult congenital heart disease (ACHD)  
3. Transition (care/education)  
4. Gaps in care  
5. Morbidity  
6. Mortality  
7. Specialist care  
8. Telemedicine / digital health technology  
9. Social determinants of health  
10. Distance to care / travel distance  
11. Rural dwelling status / urban‑rural disparities  
12. Access to care  
13. Delivery of care  
14. Knowledge of lifelong cardiac care  
15. Transition education programs (e.g., STEPSTONES, TRANSITION‑CHD)  
16. SCAI position statement on ACHD interventional training  
17. ESC guidelines for ACHD management  
18. AHA/ACC guideline for ACHD  
19. Catheter ablation in ACHD  
20. Heart transplantation in ACHD  
21. Clinical trials / randomized controlled trials  
22. Clinical statements / scientific statements  
23. Risk factors for loss to follow‑up  
24. Quality of care  
25. Policy impact on mortality and outcomes  
26. Patient education and readiness  
27. Healthcare transition for youth with heart disease  

(Note: Each term represents a concept, intervention, outcome, or structural factor repeatedly mentioned in the provided guideline text.)

Page 107 Extracted Terms:
**Key heart‑disease–related terms extracted from the text**

- Adult congenital heart disease (ACHD)  
- Congenital heart disease (CHD)  
- Fontan physiology / Fontan palliation / Fontan circulation  
- Eisenmenger syndrome  
- Atrial septal defect (ASD)  
- Perioperative morbidity and mortality  
- Perioperative outcomes  
- Perioperative cardio‑vascular evaluation and management  
- Perioperative considerations/management for non‑cardiac surgery  
- Non‑cardiac surgery  
- Perioperative events  
- Anesthesia (and anesthetic management)  
- Frailty in ACHD  
- Cognitive function / neurocognitive impairment / neurocognitive dysfunction  
- Neurodevelopmental outcomes  
- Depression in ACHD  
- Anxiety in ACHD  
- Post‑traumatic stress disorder (PTSD) in ACHD  
- Mental health screening (PHQ‑4, etc.)  
- Health‑care utilization in ACHD  
- Stroke risk (ischemic stroke) in the peri‑operative period  
- Clinical practice guidelines (ACC/AHA Task Force)  
- Clinical statements & scientific statements (American Heart Association)  
- Clinical trial / randomized controlled trial (RCT)  
- Prospective and retrospective cohort studies on ACHD outcomes  

These terms capture the primary concepts relating to heart disease and its peri‑operative, anesthetic, and psychosocial aspects that appear throughout the document.

Page 108 Extracted Terms:
**Key heart‑disease related terms extracted from the text**

- Congenital heart disease (CHD)  
- Cyanotic congenital heart disease  
- Eisenmenger syndrome  
- Unoperated single ventricle  
- Heart failure  
- Cardiac resynchronization therapy (CRT)  
- Single‑ventricle repair  
- Cardiac surgery / cardiac operative procedures  
- Perioperative mortality risk  
- Cyanosis management  
- Iron deficiency therapy  
- Exercise capacity / exercise intolerance  
- Quality of life  
- Cerebrovascular events (stroke)  
- Brain abscess  
- Stroke risk in cyanotic disease  
- Pregnancy outcomes in women with heart disease  
- Hormonal contraception & risk of venous thromboembolism  
- Pheochromocytoma / paraganglioma  
- Hyperuricemia  
- Serum uric acid in Eisenmenger syndrome  
- Oxygen therapy effect on exercise performance  
- Hemoglobin & oxygen saturation dynamics  
- Blood viscosity  
- Iron metabolism & homocysteine levels  
- Hematocrit & haemostasis  
- Platelet microparticles  
- Thrombogenesis / hypercoagulability  
- Pulmonary artery thrombosis  
- Anticoagulation in Eisenmenger syndrome  
- Long‑term survival / prognosis  
- Pulmonary arterial hypertension (PAH)  
- Lung function & gas exchange in PAH/Eisenmenger  
- Pulmonary hypertension in CHD  
- Neurodevelopmental evaluation in CHD  
- Restrictive lung disease in CHD  
- Abnormal lung function in adult CHD  
- Cardiac catheter intervention safety  
- Operative volume & surgical learning curve  
- Reoperative cardiac surgery outcomes  
- Clinical management guidelines for adult congenital heart disease  
- Practice patterns for adult congenital heart disease management  

These terms encapsulate the clinical concepts, patient populations, interventions, complications, and outcomes addressed throughout the cited guidelines and literature.

Page 109 Extracted Terms:
- Congenital heart disease (CHD)  
- Adult congenital heart disease (ACHD)  
- Heart failure (HF)  
- Universal definition and classification of heart failure  
- Cardiac resynchronisation therapy (CRT)  
- Cardiac resynchronisation therapy (CRT‑D)  
- Implantable cardioverter‑defibrillator (ICD)  
- Implantable cardioverter‑defibrillator (ICD) in ACHD  
- Sodium‑glucose cotransporter‑2 (SGLT‑2) inhibitors in ACHD  
- Angiotensin‑receptor neprilysin inhibitor (ARNI) in ACHD  
- Sacubitril/valsartan (ARNI) in adult complex CHD  
- Ventricular assist device (VAD) / durable VAD  
- Mechanical circulatory support (MCS)  
- Mechanical circulatory support (MCS) in ACHD (INTERMACS, UNOS)  
- Heart transplantation in ACHD  
- Heart–lung transplantation in ACHD  
- Combined heart–liver transplantation in the failing Fontan  
- Multi‑organ transplantation in ACHD  
- Fontan circulation / Fontan surgery  
- Fontan‑adult Brompton clinical score  
- Mustard operation (surgical correction of transposition of great arteries)  
- Transposition of the great arteries (TGA) with systemic right ventricle  
- Ebstein anomaly  
- Tetralogy of Fallot (TOF)  
- Sudden cardiac death (SCD) in ACHD  
- Ventricular arrhythmias in ACHD  
- PRospEctiVE study (PREVENTION‑ACHD)  
- PREVENTION‑ACHD acronym (ICB‑VSD)  
- Heart‑failure Society of America (HFSA) consensus  
- American Heart Association (AHA) 2022 Heart Failure Guideline  
- Cardiac‑electrophysiology guidelines for pediatric and congenital heart disease  
- European Society of Cardiology (ESC) heart‑failure definition  
- INTERMACS registry for adult CHD patients on MCS  
- German National Register for Congenital Heart Defects (GNHFD)  
- Clinical outcomes and survival metrics in ACHD  
- Post‑operative arrhythmias after Fontan operation  
- Arrhythmic risk scores in systemic right ventricle  
- Implantable cardioverter‑defibrillator shock appropriateness in repaired TOF  
- Long‑term survival, mortality, and morbidity after heart transplantation in CHD  
- Acute and chronic heart failure in congenital heart disease (ACC/AHA statement)  

(These terms capture the key entities, therapies, devices, scores, and clinical contexts discussed in the guidelines and studies.)

Page 110 Extracted Terms:
- Congenital heart disease  
- Adult congenital heart disease  
- Heart transplantation  
- Heart‑lung transplantation  
- Combined heart‑liver transplantation  
- Mechanical circulatory support  
- Ventricular assist device (VAD)  
- Continuous‑flow ventricular assist device  
- INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support)  
- Fontan circulation  
- Eisenmenger syndrome  
- Tetralogy of Fallot  
- Pulmonary atresia  
- Single ventricle (univentricular)  
- Biventricular condition  
- Heterotaxy syndrome  
- Left ventricular systolic dysfunction  
- Heart failure  
- Heart failure hospitalization  
- Peak oxygen consumption  
- Anti‑human leukocyte antigen (anti‑HLA) antibodies  
- Allograft tissue exposure  
- Allograft cryopreservation  
- Right ventricular failure (implied in Fontan context)  
- 22q11.2 deletion syndrome  
- Chromosomal abnormalities  
- Copy‑number variant / de novo mutation  

(Note: Terms are derived directly from the guideline titles, study descriptions, and clinical focuses within the provided text.)

Page 111 Extracted Terms:
- Congenital heart disease  
- Pulmonary atresia  
- Ventricular septal defect  
- Conotruncal defects  
- 22q11.2 deletion (DiGeorge syndrome)  
- Noonan syndrome  
- Williams‑Beuren syndrome  
- Down syndrome  
- Holt‑Oram syndrome  
- Klinefelter syndrome  
- Turner syndrome  
- NKX2‑5 mutation  
- QTc interval prolongation  
- Cardiac repolarization abnormalities  
- Sudden cardiac death  
- Cardiomyopathy  
- Heart failure  
- Peripartum cardiomyopathy  
- Valvular heart disease  
- Coronary artery dissection  
- Pregnancy outcomes in heart disease  
- Cardiac morbidity during pregnancy  
- Hormonal contraception cardiovascular risk  
- Cardiac risk assessment  
- Echocardiographic screening  
- Cardio‑obstetrics program  
- Multidisciplinary cardiac care  
- Reproductive health in congenital heart disease  
- Cardiac risk stratification  
- Congenital cardiovascular malformations  
- Genetic counselling for congenital heart disease  
- Cardiac phenotypic spectrum  

Page 112 Extracted Terms:
Congenital heart disease  
Congenital heart defects  
Tetralogy of Fallot  
Fontan physiology / Fontan patients  
Eisenmenger syndrome  
Transposition of the great arteries  
Ebstein anomaly  
Coarctation of the aorta  
Pulmonary arterial hypertension  
Pulmonary valve replacement  
Cardiac catheterization  
Cardiac procedures  
Cardiac surgery  
Cardiac radiation exposure  
Ionizing radiation exposure  
Heart failure  
Cardiopulmonary exercise testing  
Exercise capacity  
Exercise intolerance  
New York Heart Association (NYHA) functional class  
NT‑proBNP  
Cardiac biomarkers  
Mortality risk  
Prognosis  
Clinical outcomes  
Multidisciplinary heart team  
Pregnancy heart team  
Maternal heart disease  
Cardiovascular disease during pregnancy  
Reproductive health in congenital heart disease  
Preconception counseling  
Fertility  
Sexual health  
Assisted reproductive technology  
Contraception  
Cumulative radiation exposure  
Long‑term chromosomal damage  
Pharmacological management for exercise capacity  
Cardiac imaging parameters  
Spirometry as a predictive tool  

Page 113 Extracted Terms:
**Key heart‑disease related terms extracted from the guidelines text**

- Adult congenital heart disease  
- Eisenmenger syndrome  
- Pulmonary arterial hypertension (PAH)  
- Pulmonary hypertension  
- Atrial septal defect (ASD)  
- Shunt lesions  
- Fontan circulation / univentricular physiology  
- Pulmonary arterial hypertension related to congenital heart disease  
- 6‑minute walk test  
- Resting oxygen saturation  
- Functional class (NYHA/WHO)  
- Cardiopulmonary capacity  
- Cardiorespiratory fitness  
- Inspiratory muscle training  
- Cardiac rehabilitation (center‑based, home‑based, virtual)  
- Exercise training (continuous, interval, home‑based, pulmonary rehab)  
- Exercise capacity  
- Functional capacity  
- B‑type natriuretic peptide (BNP)  
- C‑reactive protein (CRP)  
- Renal dysfunction (kidney disease)  
- Bosentan therapy  
- Treat‑to‑close strategy  
- Treat‑close‑treat strategy  
- Treat‑and‑repair strategy  
- Competitive sports participation guidelines for athletes with cardiovascular abnormalities  
- European Society of Cardiology / European Respiratory Society guidelines for pulmonary hypertension  
- Refined European guidelines instrument for risk prediction in PAH  
- Arrhythmias during exercise testing

These terms capture the principal diseases, diagnostic measures, therapeutic strategies, and contexts discussed in the clinical statements and guidelines.

Page 114 Extracted Terms:
Eisenmenger syndrome  
Pulmonary arterial hypertension  
Atrial septal defect  
Ventricular septal defect  
Partial anomalous pulmonary venous drainage  
Partial anomalous pulmonary venous connection  
Patent foramen ovale  
Superior sinus venosus defect  
Secundum atrial septal defect  
Tricuspid regurgitation  
Pulmonary hypertension  
Bosentan therapy  
Macitentan therapy  
Tadalafil therapy  
Iloprost therapy  
Epoprostenol therapy  
Prostaglandin therapy  
Sildenafil citrate therapy  
Selexipag therapy  
Sotatercept therapy  
Transcatheter closure  
Covered stent exclusion  
Balloon occlusion test  
Surgical repair  
ESC/ERS guideline for pulmonary hypertension  
AHA/ACC guideline for adult congenital heart disease  
CHEST guideline for pulmonary arterial hypertension  
Electrocardiography (implied by diagnostic context)  
Echocardiography (including transesophageal)  
Magnetic resonance imaging (four‑dimensional)  
Computed tomography scanning  
Hemodynamic assessment (catheterization)  
Right ventricular function evaluation  
Left ventricular diastolic dysfunction assessment  

These terms capture the key heart‑related conditions, therapies, interventions, diagnostic modalities, and guideline references present in the text.

Page 115 Extracted Terms:
- Pulmonary arterial hypertension  
- Pulmonary hypertension  
- Congenital heart disease  
- Ventricular septal defect (VSD)  
- Isolated ventricular septal defect  
- Supracristal ventricular septal defect  
- Perimembranous ventricular septal defect  
- Non‑restrictive ventricular septal defect  
- Double‑chambered right ventricle  
- Aortic regurgitation  
- Aortic cusp prolapse  
- Infective endocarditis  
- Left‑to‑right shunt  
- Right ventricular dysfunction  
- Left ventricular dysfunction  
- Pulmonary vascular resistance  
- Pulmonary hypertensive crisis  
- Transcatheter device closure  
- Surgical closure of VSD  
- Percutaneous device closure of VSD  
- Treat‑and‑repair strategy  
- Perioperative management of pulmonary hypertension  
- Sildenafil therapy for pulmonary hypertension  
- Selexipag therapy for pulmonary hypertension  
- Macitentan therapy for pulmonary hypertension  
- Inhaled nitric oxide (pre‑operative test)  
- Ventricular septal defect repair techniques (patch, valve‑patch, double‑patch)  
- Natural history of congenital ventricular septal defect  
- Long‑term outcomes of VSD repair  
- Survival of patients with congenital VSD  
- Infection prevention guidelines for infective endocarditis  
- Catheterization in congenital heart disease  
- Lung biopsy utility in congenital heart disease management  
- Clinical guidelines for infective endocarditis  
- Clinical outcomes of pulmonary arterial hypertension in congenital heart disease.

Page 116 Extracted Terms:
**Key terms related to heart disease**

- Congenital heart disease (CHD)  
- Atrioventricular (AV) septal defect (AVSD)  
  - Complete AV septal defect  
  - Partial/transition AV septal defect  
- Ventricular septal defect (VSD)  
- Pulmonary arterial hypertension (PAH)  
- Partial anomalous pulmonary venous return (PAPVR)  
- Scimitar syndrome  
- Patent ductus arteriosus (PDA)  
- Left ventricular outflow tract (LVOT) obstruction  
- Atrial septal defect (ASD)  
  - Secundum ASD  
  - Sinus venosus ASD  
  - Ostium primum ASD  
- Pulmonary hypertension (PH)  
- Left-valvar morphology (mitral)  
- Heart block (conduction disturbances)  
- Left ventricular remodeling / reverse remodeling  
- Device closure (transcatheter)  
- Surgical closure / repair of congenital lesions  
- Magnetic resonance imaging (MRI) in cardiac imaging  
- Transcatheter pulmonary arterial hypertension therapy  
- Targeted pulmonary hypertension therapy  
- Clinical practice guideline (AHA/ACC, ACC/AHA, ESC/ERS)  
- Scientific statement (American Heart Association)  
- Operability assessment in adult congenital heart disease  
- Prognostic factors for residual lesions after surgery  
- Outcomes after specialty care for PAH  
- Late results of VSD closure (30–35 years)  
- Right atrial involvement in AVSD  
- Superior QRS axis in ostium primum ASD  
- Indications for surgery based on lung biopsy in VSD/PDA with severe PH  
- Long‑term outcomes of unrepaired PAPVR with intact atrial septum  

These terms capture the principal heart‑disease concepts, conditions, interventions, and guideline references highlighted in the provided text.

Page 117 Extracted Terms:
**Key terms related to heart disease extracted from the text**

- Cor triatriatum sinister / sinistrum  
- Congenital heart disease  
- Pulmonary hypertension  
- Pulmonary vascular resistance  
- Left ventricular dysfunction  
- Patent ductus arteriosus closure (surgical & transcatheter)  
- Cardiovascular magnetic resonance  
- Surgical repair of cor triatriatum  
- Transcatheter balloon dilatation of cor triatriatum  
- Inoue balloon‑dilation method  
- Radiofrequency perforation & balloon decompression  
- Aortic dissection  
- Mitral insufficiency  
- Mitral stenosis  
- Congenital mitral stenosis (parachute mitral valve)  
- Shone complex  
- Subaortic stenosis (discrete subaortic stenosis)  
- Cardioembolic stroke  
- Thrombogenesis & arrhythmogenesis in left atrium  
- Partial anomalous pulmonary venous return  
- Ventricular inflow obstruction (pulmonary venous & systemic)  
- Atrial fibrillation in adult congenital heart disease  
- Catheter ablation for atrial fibrillation  
- Cardiopulmonary exercise testing  
- Pulmonary edema (postpartum, labor, pregnancy)  
- Maternal cor triatriatum management during pregnancy  
- Anesthetic management for cardiac surgery in pregnancy  
- Cardiopulmonary bypass in pregnancy  
- 3‑D echocardiographic‑guided surgical repair  
- 2018 AHA/ACC guideline (adults with congenital heart disease)  
- 2020 ACC/AHA guideline (valvular heart disease)  
- 2018 AHA/ACC guideline (adults with congenital heart disease)  
- 2020 ACC/AHA guidline (valvular heart disease)  
- Early‑age percutaneous balloon dilatation  
- Percutaneous balloon dilatation vs. surgical correction  

These terms capture the primary heart‑related concepts, conditions, interventions, and guideline references presented in the document.

Page 118 Extracted Terms:
**Heart‑Disease Related Terms Extracted from the Text**

1. Hypertrophic cardiomyopathy  
2. Aortic regurgitation  
3. Subaortic stenosis (including discrete subvalvular aortic stenosis)  
4. Bicuspid aortic valve  
5. Aortic aneurysm (ascending aortic aneurysm, thoracic aortic aneurysm)  
6. Aortic stenosis (including supravalvular aortic stenosis and congenital aortic valve stenosis)  
7. Transcatheter aortic valve replacement (TAVR)  
8. Balloon aortic valvuloplasty  
9. Supravalvar aortic stenosis  
10. Williams syndrome (elastin‑associated arteriopathy)  
11. Elastin arteriopathy  
12. Left ventricular remodeling  
13. Post‑operative heart failure  
14. Aortic valve dysfunction  
15. Aortic valve replacement (surgical AVR)  
16. Aortic events (e.g., dissection, rupture)  
17. Aortic disease (diagnosis & management)  
18. Congenital heart disease (adult congenital)  
19. Bicuspid vs tricuspid aortic valve outcomes  
20. Aortic dilatation / aortic root dilation  
21. Coronary artery stenosis (ostial)  
22. Coronary artery aneurysm  
23. Valvular heart disease (management)  
24. Risk stratification by exercise testing  
25. Doppler echocardiography (surgical timing)  
26. Multidetector CT angiography (imaging of aortic stenosis)  
27. Cardiac outcomes (adult survivors of supravalvar aortic stenosis)  
28. Surgical repair (coronary ostial stenosis, supravalvar aortic stenosis)  
29. Decision aids for prosthetic valve selection  
30. Family screening for bicuspid aortic valve and aortic aneurysm  
31. Aortic valve pathology (diffuse variant, elastin deficiency)  
32. Aortic valve molecular genetics  
33. Decision‑making in valvular heart disease (shared decision‑making)  
34. Pediatric subvalvular aortic stenosis risk factors  
35. Adult congenital aortic valve interventions  
36. Aortic valve replacement outcomes in congenital versus native valve disease  
37. Aortic stenosis in heterozygous/homozygous familial hypercholesterolemia  
38. Aortic valve complications (e.g., restenosis, prosthetic valve dysfunction)  
39. Aortic valve hemodynamics (flow velocity, gradient)  
40. Aortic valve surgical indications and timing  

These terms capture the key clinical entities, procedural approaches, imaging modalities, risk factors, and guideline‑specific concepts related to heart disease in the provided citations.

Page 119 Extracted Terms:
- Williams syndrome  
- Williams‑Beuren syndrome  
- Congenital heart disease  
- Supravalvular aortic stenosis  
- Coarctation of the aorta  
- Aortic coarctation (native and repaired)  
- Left ventricular ejection fraction  
- Left ventricular hypertrophy  
- Left ventricle strain imaging  
- Coronary artery stenosis  
- Coronary artery disease  
- Myocardial ischemia  
- Pulmonary hypertension  
- Exercise‑induced hypertension  
- Ambulatory blood pressure monitoring  
- Endothelial dysfunction  
- Conduit artery dysfunction  
- Left atrial dysfunction  
- Right heart dysfunction  
- Intraventricular myocardial stiffness  
- Cardiac remodeling  
- Cardiovascular mortality  
- Cardiac surgery (repair, stenting, transcatheter intervention)  
- Systolic blood pressure control  
- Hypertension management (restenosis‑free)  
- Intracranial aneurysms screening  
- Clinical risk stratification in congenital heart disease  
- Prevention of sudden death in Williams‑Beuren syndrome  
- Left ventricular mass and geometry assessment  
- Prognostic impact of LV function in aortic stenosis  
- Screening for intracranial aneurysms in coarctation of the aorta  
- Pediatric and adult outcomes after coarctation repair  
- Percutaneous intervention outcomes for coarctation  
- Diagnostic imaging for coronary and cerebral circulation in coarctation  
- Heart failure with preserved ejection fraction (HFpEF) in coarctation patients  

Page 120 Extracted Terms:
- Coarctation of the aorta  
- Endovascular treatment  
- Stent trials  
- Transcatheter interventions  
- Left ventricular reverse remodeling  
- Left ventricular remodeling  
- Cardiovascular burden  
- Congenital heart disease (CHD)  
- Ebstein’s anomaly  
- Accessory pathway ablation  
- Wolff‑Parkinson‑White syndrome  
- Echocardiography  
- Cardiac magnetic resonance imaging (CMR)  
- Cone operation (cone reconstruction)  
- Biventricular function  
- Catheter ablation of ventricular arrhythmia  
- Electrophysiologic studies (EPS)  
- Tricuspid valve imaging  
- Right ventricular unloading  
- Bi‑directional cavo‑pulmonary shunt  
- Surgical intervention timing  
- Hemodynamic determinants of aerobic capacity  
- Supraventricular arrhythmias  
- Percutaneous atrial septal defect (ASD) closure  
- Mortality in Ebstein’s anomaly  
- Occult left ventricular dysfunction  
- Atrial fibrillation (AF)  
- Arrhythmia management in adult CHD  
- Cardiopulmonary exercise testing  
- Pulmonary stenosis  
- Percutaneous balloon valvuloplasty (balloon pulmonary valvuloplasty)  
- Pulmonary valve replacement (PVR)  
- Pulmonary regurgitation  
- Tricuspid valve intervention  
- Birth prevalence of congenital heart defects  
- Semilunar valve interventions  
- Long‑term outcomes (up to 25–40 years)  
- Exercise capacity  
- Ventricular volume and function  
- Aortic coarctation gradients  
- Left ventricular function  
- Aortic stenosis (implicitly via aortic coarctation)  
- Ventricular tachycardia (VT)  
- Ventricular arrhythmia  
- Aortic balloon valvuloplasty  
- Cardiovascular magnetic resonance (CMR) imaging terms (e.g., dyssynchrony, remodeling, cone reconstruction feasibility)  
- Heart failure related to Ebstein malformation  
- Right ventricular function  

(Note: The list compiles key heart‑disease concepts, conditions, interventions, and clinical outcomes presented in the provided text.)

Page 121 Extracted Terms:
- Pulmonary valve replacement  
- Transcatheter pulmonary valve replacement  
- Tricuspid regurgitation  
- Right ventricular volume/pressure overload  
- Pulmonary valve stenosis  
- Repaired tetralogy of Fallot  
- Pulmonary regurgitation  
- Right‑ventricular (RV) remodeling  
- Right‑ventricular outflow tract (RVOT)  
- Ventricular septal defect (VSD)  
- Double‑chambered right ventricle (DCRV)  
- Branch pulmonary artery stenosis  
- Balloon angioplasty  
- Stenting  
- Cardiac magnetic resonance imaging (CMR)  
- Multimodality imaging (echocardiography, CMR, CT, scintigraphy)  
- SAPIEN S3 transcatheter heart valve  
- 2018 AHA/ACC guideline for adults with congenital heart disease  
- Appropriate use criteria for multimodality imaging in congenital heart disease  
- Congenital heart disease (CHD)  
- Pulmonary valve dysfunction  
- Right‑ventricular ejection fraction (RVEF)  
- Right‑ventricular strain and deformation  
- Hemodynamically significant pulmonary regurgitation  
- Pressure half‑time (PHT)  
- Exertional performance / exercise capacity  
- Imaging assessment of pulmonary stenosis and regurgitation  
- Surgical outcomes and repair of DCRV  
- Post‑operative outcomes of pulmonary valve replacement  
- Long‑term natural history of pulmonary stenosis after surgical repair  
- Clinical practice guidelines for management of pulmonary valve disease  
- Complications of pulmonary artery interventions (adverse events, procedural characteristics)

Page 122 Extracted Terms:
Tetralogy of Fallot  
Pulmonary valve replacement (PVR)  
Pulmonary valve implantation  
Ventri­cular tachycardia (VT)  
Implantable cardioverter‑defibrillator (ICD)  
Arrhythmogenic substrate  
Right ventricular outflow tract (RVOT)  
Conduit  
Bioprosthetic valve  
Pulmonary artery stenosis (PAS)  
Peripheral pulmonary artery stenosis  
Transcatheter pulmonary valve implantation  
Transcatheter pulmonary valve replacement  
Pulmonary regurgitation  
Right ventricular dysfunction  
Right ventricular volume overload  
Tricuspid regurgitation  
Right ventricular activation  
Left ventricular diastolic function  
Left ventricular systolic dysfunction  
Left ventricular longitudinal strain  
QRS fragmentation  
QRS duration  
Cardiac magnetic resonance (CMR)  
Multidetector computed tomography (MDCT)  
Computed tomography angiography (CTA)  
Electrocardiogram (ECG)  
Electroanatomical mapping  
Ventricular arrhythmia  
Sudden cardiac death  
Arrhythmic risk stratification  
Ventricular tachycardia isthmus  
Electrophysiologic study  
Ablation therapy  
Ventricular tachycardia substrate  
Ventricular tachycardia‑related anatomical isthmuses  
Ventricular tachycardia substrate characteristics  
Ventricular tachycardia risk  
Ventricular arrhythmia burden  
Post‑operative survival  
Long‑term outcomes  
Pulmonary valve dysfunction  
Pulmonary valve stenosis  
Right ventricular remodeling  
Cardiac conduction system  
Cardiac arrhythmia  
Right ventricular size  
Right ventricular function  
Congenital heart disease (CHD)  
Adult congenital heart disease (ACHD)  
AHA/ACC clinical practice guideline  
ACHD guideline

Page 123 Extracted Terms:
- Tetralogy of Fallot  
- Repaired tetralogy of Fallot  
- Pulmonary valve replacement  
- Pulmonary regurgitation  
- Pulmonary valve insufficiency  
- Right ventricular dilation  
- Right ventricular systolic function  
- Right ventricular free‑wall strain  
- Right ventricular volume / left ventricular volume ratio  
- Biventricular interaction  
- Biventricular global‑function index  
- Ventricular tachycardia  
- Ventricular arrhythmia  
- Ventricular fibrosis  
- Fragmented QRS complex  
- QRS duration  
- Slow‑conducting electroanatomic isthmus  
- Late gadolinium enhancement  
- Cardiac magnetic resonance (CMR)  
- Cardiac MRI  
- Echocardiography  
- Speckle‑tracking echocardiography  
- Multimodality imaging  
- Cardiac computed tomography (CT) angiography  
- Cardiopulmonary exercise testing  
- Non‑sustained ventricular tachycardia  
- Implantable cardioverter‑defibrillator (ICD)  
- ICD shocks (inappropriate)  
- Sudden cardiac death  
- Mortality risk score  
- Cardiac risk score  
- Right atrial area  
- Right ventricular outflow‑tract dysfunction / akinetic length  
- Electroanatomic mapping  
- Catheter ablation of ventricular tachycardia  
- Surgical ablation of ventricular tachycardia  
- Ventricular tachycardia inducibility  
- ECG algorithm (R'' wave in V1 & terminal QRS vector in aVF)  
- Clinical practice guidelines  
- Adult congenital heart disease (ACHD)  
- Congenital heart disease (CHD)  
- Pulmonary valve replacement timing  
- Preoperative predictors of death  
- Post‑operative outcomes  
- Ventricular tachycardia substrate characterization  
- Pulmonary valve regurgitation quantification  
- Cardiac output  
- Left ventricular ejection fraction  
- Cost of treating ICD patients  
- Quality of life in ICD patients  
- Psychological functioning in ICD patients

Page 124 Extracted Terms:
Tetralogy of Fallot  
Pulmonary valve replacement  
Right ventricular volume  
Right ventricular function  
Pulmonary regurgitation  
Left ventricular cardiomyopathy  
Tricuspid regurgitation  
Tricuspid repair  
Right ventricular outflow tract (RVOT)  
Conduit  
Monomorphic ventricular tachycardia  
Ventricular tachycardia  
Adult congenital heart disease  
Pulmonary atresia  
Intact ventricular septum  
Biventricular repair  
Right ventricular fibrosis  
Single‑ventricle palliation  
Fontan procedure  
Late myocardial ischemia  
Systemic venous hypertension  
Low output  
Right atrial dysfunction  
Transcatheter pulmonary valve implantation (Melody valve)  
Endocarditis  
Infective endocarditis  
Bioprosthetic valve  
Bioprosthetic valve thrombosis  
Echocardiography  
Cardiac magnetic resonance imaging  
Computed tomography angiography  
Coronary artery compression  
Stent fracture  
Valve dysfunction  
RVOT obstruction  
Pressure gradient  
RVOT reintervention  
Congenital heart defect  
Right ventricular remodeling  
Right ventricular loading  
Aortic‑pulmonary transposition  
Systemic right ventricle  
Endovascular stenting  
Catheterization  
Functional outcome  
Long‑term outcomes  
Acute outcomes  
Midterm outcomes

Page 125 Extracted Terms:
- Adult congenital heart disease  
- Transposition of the great arteries (dextro‑TGA)  
- Atrial switch operation (Mustard, Senning)  
- Systemic right ventricle  
- Pulmonary valve dysfunction  
- Transcatheter pulmonary valve replacement  
- SAPIEN 3 transcatheter heart valve  
- Balloon‑expandable valve  
- Baffle leak / baffle obstruction  
- Ventricular arrhythmias  
- Sudden cardiac death  
- Mechanical circulatory support (bridge to transplant, LVAD)  
- Heart failure with systemic right ventricular failure  
- Cardiac resynchronization therapy  
- Anticoagulation (NOACs) for systemic right ventricle  
- Dapagliflozin therapy (heart failure)  
- Sacubitril/valsartan therapy (heart failure)  
- Myocardial work analysis (biventricular performance)  
- Risk scoring for major clinical events (post‑atrial switch)  
- Ventricular arrhythmia risk score  
- Cardiac MRI predictors of adverse outcomes  
- Ventricular size and function (subpulmonary left ventricle)  
- Cardiopulmonary exercise testing (ventilatory efficiency, aerobic capacity)  
- Cyanosis‑associated exercise response  
- Magnetic navigation & robotic ablation (atrial tachyarrhythmias)  
- Stent placement (intra‑vascular, baffle)  
- Catheter‑based interventions for baffle repair  
- Exercise capacity guidelines for congenital heart disease athletes  
- Competitive sport participation recommendations (CHD)  
- Multimodality imaging guidelines (echocardiography, CMR, CT)  
- Machine‑learning assessment of systemic right ventricle  
- Non‑invasive respiratory monitoring for congenital heart disease.

Page 126 Extracted Terms:
- Congenital heart disease  
- Transposition of the great arteries  
- Arterial switch operation  
- Atrial switch operation (Senning/Mustard)  
- Systemic right ventricle  
- Transcatheter pacing leads  
- Implantable cardioverter‑defibrillator (ICD)  
- Implantable loop recorder  
- Late gadolinium enhancement cardiovascular magnetic resonance  
- Pulmonary stenosis  
- Neo‑aortic regurgitation  
- Neo‑aortic root growth  
- Aortic root dilatation  
- Aortic valve regurgitation  
- Coronary artery complications  
- Coro​nary events  
- Coro​nary artery bypass grafting (bypass)  
- Mechanical circulatory support (LVAD, VAD)  
- Heart failure (advanced)  
- Thromboprophylaxis for atrial arrhythmias  
- Tricuspid valve replacement  
- Tricuspid valve repair  
- Cardiac resynchronization therapy  
- Angiotensin receptor blockers (e.g., valsartan, losartan)  
- Phosphodiesterase‑5 inhibitors (e.g., sildenafil)  
- Sacubitril‑valsartan (ARNI)  
- Exercise capacity reduction  
- Arrhythmia detection  
- Coronary artery compression  
- Coronary artery graft failure  
- Pulmonary artery evaluation  
- Four‑dimensional flow magnetic resonance imaging  
- Myocardial stress perfusion MRI (regadenoson)  
- Echocardiography (transthoracic, transesophageal)  
- Afterload reduction therapy  
- Ventricular deformation imaging  
- Medical therapy for systemic right ventricle  
- Cardiac transplant outcomes  
- Cardiac transplant bridge (mechanical assist device)  
- Transplantation referral for thoracic organ disease  
- Renal dysfunction in advanced heart failure  
- Patient‑reported health status  
- Long‑term survival after arterial switch  
- Long‑term survival after atrial switch / arterial switch  
- Cardiac surgical outcomes in d‑transposition of the great arteries  
- Neonatal and pediatric outcomes after arterial switch  
- Late coronary artery complications post‑arterial switch  
- Pulmonary artery stenosis after arterial switch  
- Long‑term prognosis of neo‑aortic root  
- Coronary artery anatomy post‑arterial switch  
- Left ventricular assist device support in transposition of the great arteries  
- Mechanical ventricular assist device  
- Cardiac surgery for d‑transposition of the great arteries.

Page 127 Extracted Terms:
- D‑transposition of the great arteries (D‑TGA)  
- Transposition of the great arteries (TGA)  
- Arterial switch operation (Jatene procedure)  
- Rastelli repair  
- Nikaidoh procedure  
- Reverse‑edge ventricular outflow tract (REV) procedure  
- Double‑outlet right ventricle (DORV)  
- Ventricular septal defect (VSD)  
- Pulmonary valve stenosis (PVS)  
- Pulmonary arteriovenous malformation  
- Pulmonary artery stenosis (PAS)  
- Branch pulmonary artery stenosis  
- Right ventricular dysfunction / failure  
- Left ventricular outflow tract obstruction (LVOTO)  
- Pulmonary outflow tract obstruction (POTO)  
- Biventricular outflow tract reconstruction  
- Aortic translocation  
- Aortic valve–sparing root replacement  
- Bentall procedure  
- Congenital heart disease (CHD)  
- Complex congenital heart disease  
- Chronic coronary disease / coronary artery disease (CAD)  
- Aortic disease (including aortic dissection and aneurysm)  
- Infective endocarditis (post‑valve or post‑repair)  
- Transcatheter pulmonary valve replacement  
- Melody valve  
- Branch pulmonary artery reintervention  
- Pulmonary artery gradient  
- Coronary artery anatomy (specifically coronary pattern post‑arterial switch)  
- Residual coronary/arterial gradients  
- Right ventricular to pulmonary arterial coupling  
- Biventricular surgical strategy  
- Coronary artery reintervention  
- Exercise capacity metrics (e.g., VO₂ max)  
- Multimodality imaging guidelines (Echocardiography, MRI, CT)  
- 4‑D flow MRI  
- 3‑D magnetic resonance imaging of coronary arteries  
- Echocardiography  
- Cardiothoracic magnetic resonance imaging (CMR)  
- Cardiac computed tomography (CCT)  
- Congenital heart disease management guidelines (ACC/AHA, AHA/ACC, etc.)  
- 2020 ACC/AHA guideline for valvular heart disease  
- 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for chronic coronary disease  
- 2022 ACC/AHA guideline for aortic disease  
- 2019 AHA/ACC guideline for adults with congenital heart disease  
- 2018 AHA/ACC guideline for management of adults with congenital heart disease (Task Force)  
- 2025 ACHD guideline  
- Outcomes studies of arterial switch operation  
- Outcomes studies of Rastelli repair  
- Outcomes studies of Nikaidoh/REV procedures  
- Outcomes studies of double‑root translocation  
- Outcomes studies of pulmonary‑to‑pulmonary conduits  
- Outcomes studies of biventricular right‑ventricle–pulmonary‑artery conduits  
- Neurocognitive and psychological outcomes in adults with corrected D‑TGA  
- Quality‑of‑life outcomes after neonatal arterial switch operation  
- Long‑term myocardial infarction outcomes in adults with congenital heart disease  
- Age‑ and lesion‑related comorbidity burden in congenital heart disease  
- Long‑term survival and freedom from coronary artery reintervention post‑arrest  
- Impact of coronary artery anatomy on surgical outcomes  
- Imaging assessment of neopulmonary outflow tract obstruction  
- Coronary artery obstruction surveillance post‑arterial switch  
- Pulmonary valve replacement risks and complications  
- Surgical repair of pulmonary valve atresia with coronary‑pulmonary artery fistula  
- Surgical repair of transposition with VSD and subpulmonary stenosis  
- Surgical repair strategies for complex transposition (double‑root, Rastelli, Nikaidoh, REV, etc.)  
- Arrhythmias in adults after Rastelli surgery  
- Long‑term follow‑up of patients undergoing pulmonary‑ventricle to pulmonary artery conduits  
- Surgical outcomes of double‑root translocation for TGA with pulmonary stenosis  

(These are the primary terms extracted from the provided clinical statements and guidelines that relate to heart disease.)

Page 128 Extracted Terms:
- Congenital heart disease (CHD)  
- Congenitally corrected transposition of the great arteries (CCTGA)  
- Systemic right ventricle (SRV)  
- Truncus arteriosus  
- Double‑outlet right ventricle (DORV)  
- Fontan palliation / Fontan circulation  
- Single ventricle (functional single‑ventricle heart)  
- Atrioventricular valve surgery (e.g., systemic AV valve repair)  
- Tricuspid valve replacement / tricuspid regurgitation  
- Systemic ventricular dysfunction / SRV failure  
- Arrhythmia (atrial & ventricular)  
- Arrhythmia burden, atrial arrhythmia, atrial switch operation  
- Cardiac resynchronization therapy (CRT)  
- Cardiac remodeling  
- Echocardiography (including 3‑D, transesophageal, and imaging for ventricular strain)  
- Longitudinal strain of the systemic right ventricle  
- Exercise capacity / aerobic capacity / exercise tolerance  
- Cardiac output augmentation  
- Angiotensin‑receptor neprilysin inhibitor (ARNI) therapy  
- Sacubitril/valsartan use in systemic RV failure  
- Thrombotic/embolic complications (atrial thrombosis, emboli)  
- Thromboprophylaxis (including direct oral anticoagulants)  
- Pacemaker implantation / ventricular pacing effects  
- Mortality / morbidity in adult Fontan patients  
- Hepatocellular carcinoma & liver cirrhosis (in Fontan patients)  
- Pulmonary valve and aortic root translocation / en‑bloc rotation procedures  
- Virtual surgical planning / 3‑D modelling of intracardiac baffles (DORV)  
- Exercise training / resistance training in Fontan and single‑ventricle patients  
- Post‑operative outcomes for repair of truncus arteriosus, DORV, and Fontan surgeries  
- Chromosome 22q11 deletion in truncus arteriosus patients.

Page 129 Extracted Terms:
Fontan operation  
Fontan circulation  
Fontan physiology  
Fontan failure  
Fontan-associated complications  
Fontan-associated liver disease  
Fontan-associated thrombosis  
Fontan thrombus  
Fontan conversion surgery  
Fontan procedure  
Fontan patient  
Fontan surgery outcomes  
Single ventricle physiology  
Ventricular physiology after Fontan  
Supraventricular tachyarrhythmia  
Atrial arrhythmia  
Atrial tachyarrhythmia  
Supraventricular tachycardia  
Atrial flutter  
Atrial fibrillation  
Cardiac arrhythmias  
Arrhythmias post‑Fontan  
Thromboembolism  
Thromboembolic complications  
Thrombosis  
Thrombus formation  
Intracardiac thrombus  
Intracardiac thrombi  
Anticoagulant therapy  
Antiplatelet therapy  
Warfarin  
Aspirin  
Non‑vitamin K antagonist oral anticoagulants  
Thromboprophylaxis  
Antithrombotic regimens  
Anticoagulation  
Hemodynamic monitoring  
Hemodynamics  
Cardiac pacing  
Ventricular pacing  
Atrial pacing  
Pacemaker lead  
Pacing complications  
Heart transplant  
Advanced heart failure  
Heart failure consultation  
Liver fibrosis  
Transjugular liver biopsy  
Magnetic resonance elastography  
Peak oxygen consumption  
Exercise capacity  
Iron deficiency  
Creatinine  
Cystatin C  
Glomerular filtration rate  
Thrombotic complications  
Portal hypertension  
Hepatocellular carcinoma  
Liver cancer  
Liver nodules  
Liver disease  
Aortopulmonary shunt  
Cavopulmonary shunt  
Extracardiac conduit  
Intracardiac conduit  
Azygous continuation of inferior vena cava  
Computed tomography angiography  
CT angiography  
Echocardiography  
Transesophageal echocardiography  
Transthoracic echocardiography  
Magnetic resonance imaging  
Cardiothoracic imaging  
Cardiac MRI  
Cardiac CT  
Clinical phenotypes  
Clinical outcomes  
Survival  
Mortality  
Late mortality  
Predictors of mortality  
Outcomes of pacing  
Cardiac complications  
Late death  
Late complications  
Early thrombosis  
Thromboembolic events  
Thrombotic events  
Hemodynamic study

Page 130 Extracted Terms:
- Fontan physiology  
- Fontan circulation  
- Fontan procedure  
- Fontan conversion  
- Fontan pathway  
- Fontan conduit stent‑angioplasty  
- Single‑ventricle physiology  
- Atrioventricular valve failure  
- Atrioventricular valve replacement  
- Heart‑liver transplantation  
- Dual‑site ventricular pacing  
- Heart block  
- Atrial arrhythmias  
- Late atrial tachycardia  
- Cryoablation  
- Pacemaker therapy  
- Arrhythmia surgery  
- Extracardiac Fontan conversion  
- Amiodarone therapy  
- Ambrisentan therapy  
- Sildenafil therapy  
- Pulmonary arterial hypertension (PAH)  
- Pulmonary hypertension in congenital heart disease  
- Eisenmenger syndrome  
- Bosentan therapy  
- Tadalafil therapy  
- Phosphodiesterase‑5 inhibitors  
- Pulmonary vasodilators  
- Pulmonary vascular resistance  
- Aortopulmonary collaterals  
- Systemic‑to‑pulmonary arterial collaterals  
- Superior caval‑pulmonary connections  
- Aortopulmonary shunt closure  
- Congenital heart disease (CHD) – adult population  
- Shunt closure complications  
- Hypoplastic left heart syndrome (HLHS) – Norwood repair  
- Early developmental outcome in single‑ventricle reconstruction  
- Pregnancy outcomes in Eisenmenger syndrome  
- Maternal outcomes in congenital heart disease‑associated pulmonary hypertension  
- Exercise tolerance in Fontan patients  
- Central venous pressure prediction  
- Stenosis of Fontan connection  
- Stroke prevention in atrial arrhythmias  
- Hemodynamics of Fontan failure  
- Exercise capacity after heart transplantation  
- Long‑term survival after Fontan procedure  
- Peri‑operative morbidity in Fontan surgery  
- Surgical conversion strategies for Fontan patients  
- Outcome of atrioventricular valve surgery post‑Fontan  
- Outcomes of atrial tachycardia ablation in Fontan patients  
- Long‑term outcome after atrioventricular valve surgery following modified Fontan operation  
- Atrial fibrillation and atrial flutter in congenital heart disease  
- Heart transplantation for complex congenital heart disease  
- Fontan‑associated liver disease  
- Stent placement in Fontan pathway  
- Pulmonary vasodilatory therapy efficacy  
- Pulmonary arterial hypertension guidelines for adults  
- CHEST guideline on pulmonary arterial hypertension  
- AHA/ACC guideline for adults with congenital heart disease  
- Cardiac rehabilitation in congenital heart disease  
- Arrhythmia management in adult congenital heart disease  

These terms capture the key heart‑disease concepts, interventions, and related conditions addressed in the guideline excerpts.

Page 131 Extracted Terms:
Eisenmenger syndrome  
Pulmonary arterial hypertension  
Congenital heart disease  
Eisenmenger physiology  
Pulmonary hypertension  
Right ventricular function  
Left ventricular function  
Biventricular dysfunction  
Ventricular septal defect  
Arrhythmias  
Atrial fibrillation  
Anticoagulation therapy  
Thromboprophylaxis  
Prostacyclin therapy  
Bosentan  
Sildenafil  
Ambrisentan  
Iloprost  
Riociguat  
Triple vasodilator therapy  
Leadless pacemaker implantation  
Leadless atrioventricular synchronous pacing  
Exercise training  
Exercise limitations  
Physical functioning  
Quality of life  
Oxygen saturation  
Pulmonary vascular resistance  
Pulmonary arterial thrombosis  
B‑type natriuretic peptide  
Cardiopulmonary magnetic resonance  
Thromboembolic events  
Cardiovascular complications in pregnancy  
Tachyarrhythmia management  
Transvenous pacing leads  
Surgical correction of left‑to‑right shunts  
Anomalous aortic origin of a coronary artery  
Anomalous coronary artery  
MRI angiography (non‑contrast, free‑breathing)  
Coronary CTA (computed tomography angiography)

Page 132 Extracted Terms:
- Anomalous coronary artery  
- Anomalous coronary artery origin  
- Anomalous aortic origin of the coronary artery  
- Anomalous right coronary artery from the left sinus of Valsalva  
- Anomalous left coronary artery from the pulmonary artery  
- Coronary artery reimplantation (correction of anomalous origin)  
- Coronary artery fistula  
- Vascular ring  
- Pulmonary artery sling  
- Congenital heart disease (adult)  
- Sudden cardiac death (associated with coronary anomalies)  
- Ischemia (identified by myocardial perfusion imaging)  
- Coronary artery disease (obstructive disease in congenital anomalies)  
- Fractional flow reserve (assessment of haemodynamic significance)  
- Stress cardiac magnetic resonance imaging (dobutamine or other)  
- Positron emission tomography myocardial perfusion imaging  
- Coronary angiography (used to evaluate anomalies)  
- Transcatheter fistula closure (management of coronary artery fistula)  
- Surgical correction of anomalous coronary artery origins.

Page 133 Extracted Terms:
- Adults With Congenital Heart Disease  
- Congenital Heart Disease  
- Adult Congenital Heart Disease Fellowship  
- Adult Congenital Heart Program  
- Congenital Cardiothoracic Surgery  
- Cardiovascular Medicine  
- Cardiology

Page 134 Extracted Terms:
**Key heart‑disease related terms extracted from the text**

- Adult Congenital Heart Disease  
- Congenital Heart Disease  
- Cardiology  
- Pediatric Cardiology  
- Cardiovascular Medicine  
- Heart Transplantation  
- Advanced Congenital Cardiac Therapies  
- Adult Single Ventricle Clinic  
- Heart Institute  
- Heart Center  
- Cardiac Therapies  
- Electrophysiology  
- Heart Failure  
- ISACHD (International Society for Adult Congenital Heart Disease)  
- ACHD (Adult Congenital Heart Disease)  
- Heart Disease  
- Heart Transplant  
- Heart Institute (dual reference)

Page 135 Extracted Terms:
- Adult Congenital Heart Disease  
- Congenital Heart Disease  
- Cardiovascular Disease  
- Aortic Valve Replacement  
- Transcatheter Aortic Valve Replacement  
- Cardiology  
- Cardiac  
- Myocardial Infarction  
- Heart Disease  
- Heart Rhythm  
- Pregnancy and Cardiovascular Disease Program  
- Adult Congenital Cardiac Clinic  
- American Heart Association (AHA)  
- American College of Cardiology (ACC)  
- International Society for Adult Congenital Heart Disease (ISACHD)  
- Heart Rhythm Society (HRS)  
- Society for Cardiovascular Angiography and Intervention (SCAI)  
- National Heart, Lung, and Blood Institute (NHLBI)  
- National Institutes of Health (NIH)

Page 136 Extracted Terms:
**Key terms related to heart disease extracted from the text**

- Adult Congenital Heart Disease (ACHD)  
- Congenital Heart Disease  
- Congenital cardiac conditions  
- Congenital heart surgery  
- Adult congenital heart disease management  
- Cardiology  
- Cardiology practice  
- Cardiologist  
- Pediatric cardiology / Paediatric cardiology  
- Congenital heart surgeon  
- ACHD Program  
- Adult Congenital Heart Association (ACHA)  
- American Heart Association (AHA)  
- American College of Cardiology (ACC)  
- Heart Rhythm Society (HRS)  
- International Society for the Advancement of Cardiovascular Surgery (ISACHD)  
- Society for Cardiovascular Angiography and Interventions (SCAI)  
- Clinical guideline for ACHD  
- Guideline peer‑review committee  
- Interventional cardiac systems  
- Cardiovascular devices  
- Life‑sciences technology  
- Medical devices for heart disease  
- Cardiac clinical education / training  
- Cardiac surgery education  

These terms capture the primary heart‑disease concepts and specialties referenced in the guideline text.

Page 137 Extracted Terms:
Adult Congenital Heart Disease (ACHD)  
Congenital Heart Disease (CHD)  
Fontan Procedure / Fontan Outcomes Network  
International Society for Adult Congenital Heart Disease (ISACHD)  
American Heart Association (AHA)  
American College of Cardiology (ACC)  
Adult Congenital Heart Association (ACHA)  
Alliance for Adult Research in Congenital Cardiology (AARCC)  
Heart Rhythm Society (HRS)  
National Heart, Lung, and Blood Institute (NHLBI)  
Society for Cardiovascular Angiography & Interventions (SCAI)  
Cardiologist  
Interventional Cardiologist  
Cardiovascular Medicine  
Pediatric Cardiology  
Medtronic (cardiovascular devices)  
Abbott Laboratories  
B Braun Medical  
Biosense Webster  
Occlutech  
Edward Life‑sciences  
Quidel (diagnostics)



Page 1 Extracted Terms:
- Heart Failure  
- Heart disease  
- Cardiovascular disease  
- AHA (American Heart Association)  
- ACC (American College of Cardiology)  
- HFSA (Heart Failure Society of America)  
- American Heart Association/American College of Cardiology/Heart Failure Society of America (AHA/ACC/HFSA)  
- 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure  
- 2013 ACCF/AHA Guideline for the Management of Heart Failure  
- 2017 ACC/AHA/HFSA Focused Update of the 2013 Guideline  
- Clinical Practice Guidelines  
- Evidence‑based recommendations  
- Patient‑centric recommendations  
- Prevention of heart failure  
- Diagnosis of heart failure  
- Management of heart failure  
- Morbidity and mortality related to heart failure  
- Quality of care in heart failure  
- Economic analysis of heart failure treatments  
- Clinical trials and research studies in heart failure  




Page 2 Extracted Terms:
- heart failure  
- heart failure with reduced ejection fraction (HFrEF)  
- heart failure with preserved ejection fraction (HFpEF)  
- heart failure with mildly reduced ejection fraction (HFmrEF)  
- systolic heart failure  
- chronic heart failure  
- acute decompensated heart failure  
- cardiogenic shock  
- cardiac failure  
- heart failure rehabilitation  
- beta blockers  
- mineralocorticoid receptor antagonists (MRAs)  
- ACE inhibitors (ACEi)  
- angiotensin receptor blockers (ARBs)  
- angiotensin‑neprilysin receptor antagonist (ARNi)  
- sacubitril/valsartan  
- sodium‑glucose cotransporter‑2 inhibitors (SGLT2i)  
- cardiac amyloidosis  
- atrial fibrillation  
- congestive heart failure  
- guideline‑directed medical therapy (GDMT)  
- cardiomyopathy  
- valvular heart disease  
- mitral regurgitation  
- cardiac imaging (echocardiography, MRI, CT, etc.)  
- invasive cardiac evaluation (catheterization)  
- biomarkers for heart failure (BNP, NT‑proBNP)  
- diuretics and decongestion strategies  
- hydralazine and isosorbide dinitrate  
- ivabradine  
- digoxin  
- soluble guanylyl‑cyclase stimulators  
- implantable cardioverter‑defibrillators (ICDs)  
- cardiac resynchronization therapy (CRTs)  
- revascularization for coronary artery disease (CAD)  
- right‑heart pressure assessment  
- exercise and functional capacity testing (6‑minute walk, CPET)  
- cardiac rehabilitation  
- dietary sodium restriction  
- self‑care support in heart failure  
- Stage A (at‑risk) heart failure  
- Stage B (pre‑clinical HF)  
- Stage C (symptomatic HF)  
- heart failure with mildly reduced ejection fraction (HFmrEF)  
- heart failure with improved ejection fraction (HFimpHF)  
- HF risk scoring  
- wearable and remote monitoring technologies  
- wearables, telemonitoring, device monitoring  
- cardiogenic shock management  
- cardiac amyloidosis management  
- cardio‑oncology considerations  
- social determinants of health (contextual factor)  
- palliative care for advanced heart failure  



Page 3 Extracted Terms:
**Key heart‑disease terms identified in the guideline excerpt**

- Heart failure (HF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Heart failure with preserved ejection fraction (HFpEF)  
- Heart failure with mildly reduced ejection fraction (HFmrEF)  
- Preserved EF (HFpEF)  
- Ejection fraction (EF)  
- Systolic/diastolic function  
- Cardiac amyloidosis (amyloid heart disease)  
- Screening for serum and urine monoclonal light chains  
- Bone scintigraphy (for amyloidosis)  
- Genetic sequencing (for amyloidosis)  
- Tetramer stabilizer therapy (for amyloidosis)  
- Anticoagulation (for amyloidosis)  
- Sodium‑glucose cotransporter‑2 inhibitors (SGLT2i)  
- ARA–neprilysin inhibitor (ARNi)  
- Angiotensin‑converting enzyme inhibitor (ACEi)  
- Angiotensin receptor blocker (ARB)  
- Mineralocorticoid receptor antagonist (MRA)  
- β‑blockers  
- Nitrates (routine use contraindicated, class III)  
- Phosphodiesterase‑5 inhibitors (class III)  
- Natriuretic peptides (BNP, NT‑proBNP)  
- Hemodynamic measurement (invasive filling pressures)  
- Non‑invasive filling pressure assessment (diastolic imaging)  
- Advanced HF (Stage D)  
- Mechanical circulatory support (e.g., LVAD)  
- Inotropic support (e.g., dobutamine, milrinone)  
- Cardiac transplantation  
- Cardiogenic shock  
- Venous thromboembolism (VTE) prophylaxis  
- Atrial fibrillation (AF) management  
- Cardio‑oncology (cancer therapy‑related cardiac disease)  
- Heart failure during pregnancy  
- Palliative and supportive care (advanced HF)  
- Primary prevention for HF stages A/B  
- Quality metrics and patient‑reported outcomes  
- Evidence gaps and future research directions  

These terms encompass the diagnostic, therapeutic, and management concepts related to heart disease outlined in the provided guideline text.

Page 4 Extracted Terms:
- Heart Failure (HF)  
- “At risk” for HF (Stage A)  
- Pre‑HF (Stage B)  
- Iron deficiency  
- Anemia  
- Hypertension  
- Sleep disorders  
- Type 2 diabetes  
- Atrial fibrillation  
- Coronary artery disease  
- Malignancy  
- Cardiovascular disease (CVD)  
- AHA/ACC/HFSA Heart Failure Guideline  
- Clinical practice guidelines  
- Cardiovascular health  
- Shared decision‑making  
- Patient engagement  
- Evidence‑based methodologies  
- Value assessment of drug/device/intervention  

Page 5 Extracted Terms:
**Key heart‑disease terms extracted from the guideline text**

- Heart failure  
- Heart failure with reduced ejection fraction (HFrEF)  
- Heart failure with preserved ejection fraction (HFpEF)  
- Heart failure with mildly reduced ejection fraction  
- Systolic heart failure  
- Diastolic (preserved‑ejection) heart failure  
- Chronic heart failure  
- Acute decompensated heart failure  
- Cardiogenic shock  
- Cardiac amyloidosis  
- Valvular heart disease  
- Mitral regurgitation  
- Cardiomyopathy (general)  
- Cardiomyopathy in pregnancy  
- Right‑heart pressure / right‑ventricular dysfunction  
- Atrial fibrillation  
- Congestive heart failure  
- Reduced ejection fraction  
- Guideline‑directed medical therapy (GDMT)  
- Beta‑blockers  
- Mineralocorticoid‑receptor antagonists  
- ACE‑inhibitors  
- Angiotensin‑and‑neprilysin receptor antagonist (sacubitril/valsartan)  
- Angiotensin‑receptor antagonist  
- Sodium‑glucose co‑transporter‑2 (SGLT2) inhibitors  
- Diabetes mellitus (as a comorbid condition in heart disease)  
- Palliative care (in the context of advanced heart failure)

These terms capture the principal cardiac conditions, therapeutic categories, and relevant comorbidities highlighted in the guideline excerpt.

Page 6 Extracted Terms:
- Heart Failure (HF)  
- Stage C heart failure  
- Stage D heart failure  
- Prevention of heart failure  
- New heart failure treatment strategies (SGLT2 inhibitors, ARNI)  
- Atrial fibrillation (AF)  
- Mitral regurgitation (MR)  
- Mitral valve (MV) clipping  
- MV transcatheter edge‑to‑edge repair  
- Cardiac amyloidosis  
- Cardio‑oncology  
- Implantable devices  
- Left ventricular assist device (LVAD)  
- Angiotensin‑converting enzyme inhibitor (ACEi)  
- Acute coronary syndrome (ACS)  
- Angiotensin‑receptor neprilysin inhibitor (ARNI)  
- Angiotensin (II) receptor blocker (ARB)  
- Amyloid cardiomyopathy (AL‑CM)  
- Transthyretin amyloid cardiomyopathy (ATTR‑CM)  
- Variant transthyretin amyloidosis (ATTRv)  
- Wild‑type transthyretin amyloidosis (ATTRwt)  
- B‑type natriuretic peptide (BNP)  
- Coronary artery bypass graft (CABG)  
- Coronary artery disease (CAD)  
- Cardiac contractility modulation (CCM)  
- Congestive heart failure (CHF)  
- Cardiovascular magnetic resonance (CMR)  
- Cardiopulmonary exercise test (CPET)  
- Cardiac resynchronization therapy (CRT)  
- CRT‑D (CRT with defibrillation)  
- CRT‑P (CRT with pacemaker)  
- Central venous pressure (CVP)  
- Direct‑acting oral anticoagulants (DOAC)  
- Electrocardiogram (ECG)  
- Ejection fraction (EF)  
- Heart failure with improved ejection fraction (HFimpEF)  
- Heart failure with mildly reduced ejection fraction (HFmrEF)  
- Heart failure with preserved ejection fraction (HFpEF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Implantable cardioverter‑defibrillator (ICD)  
- Left bundle branch block (LBBB)  
- Left ventricle (LV)  
- Left ventricular assist device (LVAD)  
- Left ventricular end‑diastolic volume (LVEDV)  
- Left ventricular ejection fraction (LVEF)  
- Left ventricular hypertrophy (LVH)  
- Guideline‑directed medical therapy (GDMT)

Page 7 Extracted Terms:
- Heart Failure (HF)  
- Structural heart disease  
- Cardiomyopathies  
- Stages of HF (Stage A, Stage B, Stage C, Stage D)  
- ACC/AHA stages of HF  
- New York Heart Association (NYHA) Classification  
- NYHA functional classes (I, II, III, IV)  
- Left Ventricular Ejection Fraction (LVEF)  
- HF with reduced ejection fraction (HFrEF)  
- HF with preserved ejection fraction (HFpEF)  
- Biomarkers (e.g., NT‑proBNP, other natriuretic peptides)  
- Elevated filling pressures  
- Mechanical circulatory support (MCS)  
- Myocardial infarction (MI)  
- Mitral regurgitation (MR)  
- Mitral valve (MV)  
- Mineralocorticoid receptor antagonist (MRA)  
- Non‑steroidal anti‑inflammatory drug (NSAID)  
- Nonsustained ventricular tachycardia (NSVT)  
- Renin‑angiotensin‑aldosterone system (RAAS)  
- RAAS inhibitors (RAASi)  
- Sodium‑glucose cotransporter‑2 inhibitors (SGLT2i)  
- Transcatheter mitral edge‑to‑edge repair (TEER)  
- Transthoracic echocardiogram (TTE)  
- Ventricular arrhythmia (VA)  
- Ventricular fibrillation (VF)  
- Ventricular tachycardia (VT)  
- Valvular heart disease (VHD)  
- Right atrial (RA)  
- Right ventricular (RV)  
- Pulmonary artery (PA)  
- Pulmonary capillary wedge pressure (PCWP)  
- Oxygen consumption/oxygen uptake (VO₂)  
- Sudden cardiac death (SCD)  
- Quality‑adjusted life year (QALY)  
- Quality of life (QOL)  
- Randomized controlled trial (RCT)  
- Single photon emission CT (SPECT)  
- Positron emission tomography (PET)  
- Technetium‑pyrophosphate (¹⁰¹⁹Tc‑PYP)  
- Peroxisome proliferator‑activated receptor γ (PPAR‑γ)  
- Polyunsaturated fatty acid (PUFA)

Page 8 Extracted Terms:
- Coronary Artery Bypass Graft Surgery  
- Coronary Artery Revascularization  
- Percutaneous Coronary Intervention  
- Valvular Heart Disease  
- Hypertrophic Cardiomyopathy  
- Cardiovascular Disease  
- Atrial Fibrillation  
- High Blood Pressure (Hypertension)  
- Heart Failure  
- New Pharmacological Therapy for Heart Failure  
- Stable Ischemic Heart Disease  
- Atherosclerotic Cardiovascular Risk  
- Blood Cholesterol  
- Lifestyle Management to Reduce Cardiovascular Risk  
- Overweight and Obesity in Adults  
- Management of Blood Cholesterol  
- Assessment of Cardiovascular Risk  
- ST‑Elevation Myocardial Infarction  
- Device‑Based Therapy of Cardiac Rhythm Abnormalities  
- Cardiac Amyloidosis  
- Chest Pain  
- Primary Prevention of Cardiovascular Diseases  
- Diabetes Mellitus (cardiovascular risk)  
- Post–Cardiac Arrest Care  

Page 9 Extracted Terms:
- Heart failure (HF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Heart failure with preserved ejection fraction (HFpEF)  
- Heart failure with mid‑range ejection fraction (HFmrEF)  
- Left ventricular ejection fraction (LVEF)  
- Natriuretic peptide  
- LV (left ventricular) filling pressures  
- Cardiac dysfunction  
- Clinical signs and symptoms of heart failure  
- Diagnostic specificity  
- Objective measures of cardiac dysfunction  
- Elevated natriuretic peptide levels  
- Exercise‑provoked (fluid‑challenge) LV pressure assessment  

Page 10 Extracted Terms:
- Heart failure (HF)  
- Heart failure with preserved ejection fraction (HFpEF)  
- Heart failure with mildly reduced ejection fraction (HFmrEF)  
- Heart failure – recovered ejection fraction (HF‑recovered EF)  
- Ejection fraction (EF) / Left ventricular ejection fraction (LVEF)  
- B-type natriuretic peptide (BNP) / Natriuretic peptides  
- Cardiac troponin (cardiac biomarkers of injury)  
- Left ventricular (LV) chamber dilatation  
- Ventricular systolic function  
- Ventricular diastolic function  
- Ventricular hypertrophy  
- Chamber enlargement  
- Wall motion abnormalities  
- Valvular heart disease  
- Structural heart disease  
- Increased filling pressures  
- Invasive hemodynamic measurements  
- Noninvasive imaging (e.g., Doppler echocardiography)  
- Doppler echocardiography  
- Guideline‑directed medical therapy (GDMT)  
- American College of Cardiology (ACC) – Heart failure stages  
- American Heart Association (AHA) – Heart failure stages  
- ACC/AHA stages of HF (Stages A, B, C, D)  
- Stage A: At risk for HF (risk factors, no symptoms)  
- Stage B: Pre‑HF (evidence of structural or functional abnormality without symptoms)  
- Stage C: Symptomatic HF (symptoms plus structural disease)  
- Stage D: Advanced HF (marked symptoms, recurrent hospitalizations)  
- Risk factors for HF  
- Hypertension  
- Atherosclerotic cardiovascular disease (CVD)  
- Diabetes mellitus  
- Metabolic syndrome  
- Obesity  
- Exposure to cardiotoxic agents  
- Genetic variants for cardiomyopathy  
- Positive family history of cardiomyopathy  
- Cardiac biomarkers of stretch or injury  
- Chronic kidney disease (CKD)  
- Pulmonary embolism (PE)  
- Myopericarditis  

These terms capture the key concepts, classifications, diagnostic measures, risk factors, and therapeutic categories related to heart disease as presented in the guideline text.

Page 11 Extracted Terms:
**Key terms related to heart disease**

- Heart failure (HF)  
- Left ventricular ejection fraction (LVEF)  
- HF with reduced EF (HFrEF)  
- HF with mildly reduced EF (HFmrEF)  
- HF with preserved EF (HFpEF)  
- HF with improved EF (HFimpEF)  
- Guideline‑directed medical therapy (GDMT)  
- Natriuretic peptides  
- E/e′ ratio (diastolic function parameter)  
- Left atrial size / left atrial volume index  
- Left ventricular (LV) mass / LV mass index  
- Pulmonary capillary wedge pressure  
- LV end‑diastolic pressure  
- Pulmonary artery (PA) pressures  
- Stroke volume  
- Cardiac output  
- H₂FPEF score (diagnostic composite score for HFpEF)  
- Obesity (as a risk factor)  
- Atrial fibrillation (AF)  
- Age >60 years  
- Antihypertensive medication burden (≥2 drugs)  
- PA systolic pressure >35 mm Hg  
- Diagnostic algorithm for HF classification  
- Structural heart disease  
- Diastolic dysfunction  
- Exercise stress testing (echocardiographic evaluation)  
- Invasive hemodynamic measurement (rest or exercise)  
- Stage C heart failure  
- Heart failure remission  
- Left ventricular (LV) structural/functional alterations  
- Echocardiographic diastolic parameters  
- Pulmonary artery systolic pressure  
- H₂FPEF score components (obesity, AF, age, antihypertensive meds, E/e′, PA pressure)

Page 12 Extracted Terms:
- Heart failure (HF)  
- Heart failure with preserved ejection fraction (HFpEF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Heart failure with mildly reduced ejection fraction (HFmrEF)  
- Heart failure with improved ejection fraction (HFimpEF)  
- H2FPEF score  
- Left ventricular ejection fraction (LVEF)  
- Echocardiography / exercise echocardiogram  
- Cardiac catheterization  
- Dyspnea / exertional dyspnea  
- AHA/ACC/HFSA Heart Failure Guideline  
- European Society of Cardiology diagnostic algorithm  
- Obesity  
- Hypertension  
- Diabetes  
- Atrial fibrillation (AF)  
- Cardiac ischemia  
- Heart valve disease  
- Biomarker domain  
- Functional domain  
- Morphological domain  
- Diagnostic laboratory tests  
- Electrocardiogram (ECG)  
- Mortality from heart failure  
- Hospitalization for heart failure

Page 13 Extracted Terms:
- Heart failure (HF)  
- HFrEF (heart failure with reduced ejection fraction)  
- HFpEF (heart failure with preserved ejection fraction)  
- HFmrEF (heart failure with mildly reduced ejection fraction)  
- Ejection fraction (EF)  
- Left ventricular ejection fraction (LVEF)  
- B‑type natriuretic peptide (BNP)  
- N‑terminal pro‑B natriuretic peptide (NT‑proBNP)  
- Cardiomyopathy / cardiomyopathies  
- Cardiotoxicity  
- Hypertension  
- Obesity  
- Prediabetes  
- Diabetes  
- Atherosclerotic cardiovascular disease (CVD)  
- Mortality rate (age‑adjusted death rate)  
- Hospitalization rate (HF hospitalizations)  
- Incidence of heart failure  
- Diagnostic algorithm for HF  
- Electrocardiogram (ECG)  
- Racial/ethnic disparities in heart‑failure outcomes (e.g., non‑Hispanic Black, non‑Hispanic White, Hispanic, Asian/Pacific Islander)

Page 14 Extracted Terms:
- Heart failure (HF)  
- Stage A HF  
- Stage B HF  
- Ischemic heart disease  
- Myocardial infarction (MI)  
- Hypertension  
- Valvular heart disease (VHD)  
- Familial cardiomyopathies  
- Genetic cardiomyopathies  
- Amyloidosis  
- Cardiotoxicity (e.g., chemotherapy, cancer treatment)  
- Alcohol abuse  
- Cocaine abuse  
- Methamphetamine abuse  
- Tachycardia  
- Right‑ventricular (RV) pacing  
- Stress‑induced cardiomyopathy (Takotsubo)  
- Peripartum cardiomyopathy  
- Myocarditis  
- Autoimmune causes (e.g., rheumatologic disease)  
- Sarcoidosis  
- Iron overload  
- Hemochromatosis  
- Thyroid disease  
- Endocrine/metabolic conditions (diabetes, obesity, acromegaly, pheochromocytoma)  
- COVID‑19‑related myocardial injury  
- Cardiac imaging  
- Cardiac biomarkers  
- Myocardial injury  
- Cardiac maladaptive structural changes  
- Advanced HF  
- Clinical congestion  
- Jugular venous pressure (JVP)  
- Ejection fraction (EF)  
- HF staging  
- Cardiac rhythm‑related causes (tachycardia, premature ventricular contractions)  
- Chemotherapy cardiotoxicity  
- Rheumatologic or autoimmune disease  
- Infiltrative cardiac disease (amyloid, sarcoid, hemochromatosis)

Page 15 Extracted Terms:
- Heart Failure (HF)  
- Heart Failure with Reduced Ejection Fraction (HFrEF)  
- Distention  
- Orthopnea  
- Bendopnea  
- Square‑wave response to the Valsalva maneuver  
- Leg edema  
- Clinical congestion  
- Diuretics (titration)  
- PARADIGM‑HF trial  
- LCZ696 (Sacubitril/Valsartan)  
- Enalapril  
- Kansas City Cardiomyopathy Questionnaire (KCCQ)  
- Natriuretic peptides  
- MAGGIC risk score  
- Mechanical Circulatory Support (MCS)  
- Cardiac transplantation  
- Advanced heart failure  
- Familial cardiomyopathy  
- Idiopathic dilated cardiomyopathy (DCM)  
- Genetic basis of cardiomyopathy  
- Muscular dystrophy  
- Pacemaker  
- Defibrillator  
- Heart transplant list  
- 3‑generation family pedigree  
- Gadolinium enhancement (cardiac MRI)  
- Major adverse cardiac events (MACE)  
- Cascade screening  
- Guideline‑directed medical therapy (GDMT)  
- Amyloid heart disease  
- Transthyretin amyloidosis  
- Light chain (AL) amyloidosis  
- Sarcoidosis‑related HF  
- Hemochromatosis‑related HF  
- Hypothyroidism‑related HF  
- Hyperthyroidism‑related HF  
- Acromegaly‑related HF  
- Connective tissue disease‑related HF  
- Tachycardia‑induced cardiomyopathy  
- High‑output heart failure  
- Arteriovenous fistula‑related HF  
- Myocardial ischemia  
- Pulmonary embolism  
- Systemic infection  
- Nonsteroidal anti‑inflammatory drugs (NSAIDs)  
- Chronic right‑ventricular (RV) pacing  
- Amiodarone (bradycardia, RV pacing)  
- Social determinants of health (housing stability, food security, transportation)

Page 16 Extracted Terms:
**Heart‑disease related terms extracted from the text**

- Heart failure (HF)  
- Ischemic cardiomyopathy  
- Cardiac amyloidosis  
- Sarcoidosis  
- Hemochromatosis  
- HIV‑associated cardiac disease  
- COVID‑19 related cardiac involvement  
- Chagas disease (cardiac form)  
- Hypothyroidism (cardiac effects)  
- Hyperthyroidism (cardiac effects)  
- Acromegaly (cardiac effects)  
- Connective‑tissue disorders (e.g., systemic sclerosis, systemic lupus)  
- Tachycardia‑induced cardiomyopathy  
- Takotsubo (stress‑induced) cardiomyopathy  
- Peripartum cardiomyopathy  
- Cancer‑therapy–related cardiotoxicity  
- Substance‑abuse–related cardiomyopathy  
- Atrial fibrillation (AF)  
- Acute coronary syndromes (ACS)  
- Valvular heart disease (VHD)  
- Left ventricular hypertrophy (LVH)  
- Right‑ventricular heart failure (RV HF)  
- Pulmonary embolism (pulmonary embolic–related cardiac strain)  
- Pulmonary arterial hypertension (pulmonary hypertension)  
- Obstructive sleep apnea (pulmonary/ cardiac impact)  
- Severe pneumonia (cardiovascular comorbidity)  
- Bacterial sepsis (cardiovascular impact)  
- Severe burns (cardiovascular impact)  
- Renal failure (cardiovascular comorbidity)  
- Anemia (cardiovascular impact)  
- Elevated natriuretic peptides (BNP/NT‑proBNP)

These terms encompass the principal cardiac conditions, comorbidities, and disease‑related syndromes referenced in the guideline text.

Page 17 Extracted Terms:
- B‑type natriuretic peptide (BNP)  
- N‑terminal prohormone of B‑type natriuretic peptide (NT‑proBNP)  
- Heart failure (HF)  
- Chronic heart failure  
- Hospitalized heart failure  
- Risk stratification in heart failure  
- Prognosis of heart failure  
- Left ventricular (LV) dysfunction  
- New‑onset heart failure  
- Predictive biomarkers for heart failure  
- Natriuretic peptide biomarkers  
- Cardiovascular disease (CVD)  
- Cardiovascular specialist  
- Team‑based heart‑failure care  
- Prevention of heart failure  
- Screening for heart failure (STOP‑HF)  
- Renin‑angiotensin‑aldosterone system (RAAS) antagonists  
- Beta blockers  
- Acute decompensated heart failure  
- Cardiac events  
- All‑cause mortality (in heart failure context)  
- Cardiovascular death  
- Major cardiovascular events  
- Post‑discharge prognosis  
- Readmission for heart failure  
- Echocardiography (for LV assessment)  
- Healthy lifestyle behaviors (in heart‑failure management)  
- Glycemic control (in diabetic patients with elevated NT‑proBNP)  
- Blood pressure/Hypertension (risk factor for HF)  
- Diabetes mellitus (risk factor for HF)  
- Vascular disease (risk factor for HF)  
- Obesity (reduces BNP/NT‑proBNP levels, impacting HF diagnosis)  
- Oxidative stress biomarkers (related to heart failure prognosis)  
- Inflammation biomarkers (related to heart failure prognosis)  
- Matrix remodeling biomarkers (related to heart failure prognosis)  

*(All terms are extracted or inferred from the guideline text and are central to heart‑disease evaluation, diagnosis, risk stratification, and management.)*

Page 18 Extracted Terms:
**Key heart‑disease terms extracted from the guideline text**

1. BNP  
2. NT‑proBNP  
3. Heart failure (HF)  
4. Genetic cardiomyopathy  
5. Inherited cardiomyopathies  
6. Dilated cardiomyopathy (DCM)  
7. Left ventricular (LV) hypertrophy  
8. LV non‑compaction  
9. Right ventricular (RV) thinning/fatty replacement  
10. 12‑lead ECG findings (high/low voltage, conduction abnormalities, repolarization changes)  
11. Long QT syndrome  
12. Brugada syndrome  
13. Nonsustained ventricular tachycardia (NSVT)  
14. Premature ventricular contraction (PVC)  
15. Sustained ventricular tachycardia/fibrillation  
16. Implantable cardioverter‑defibrillator (ICD)  
17. Sudden death (primary prevention)  
18. Atrial fibrillation (AF) – early‑onset, “lone” AF  
19. Conduction disease (early onset)  
20. Pacemaker implantation (before age 65)  
21. Coronary artery disease (CAD)  
22. Genetic screening / testing  
23. Genetic counseling  
24. Guideline‑directed medical therapy (GDMT)  
25. Exercise limitation (for hypertrophic cardiomyopathy)  
26. Skeletal myopathy  
27. Neuropathy  
28. Cutaneous stigmata  
29. Dysmorphic features  
30. Mental retardation  
31. Congenital deafness  
32. Neurofibromatosis  
33. Renal failure with neuropathy  
34. Systemic syndromes associated with cardiomyopathy (e.g., limb‑girdle dystrophy, Duchenne/Becker muscular dystrophy, Emory‑Dreifuss)  
35. Cardiac morphology  
36. Family history (3‑generation pedigree)  
37. ECG conduction and repolarization abnormalities  
38. Defibrillator for primary prevention of sudden death  
39. Periodic echocardiographic and electrocardiographic screening for relatives  
40. Phenotype–genotype correlation in cardiomyopathy  

These terms capture the primary heart‑disease concepts, diagnostic markers, therapeutic interventions, and genetic considerations discussed in the guideline excerpt.

Page 19 Extracted Terms:
**Key terms related to heart disease**

- Heart failure (HF)  
- Acute decompensated heart failure  
- New‑onset heart failure  
- Dilated cardiomyopathy (DCM)  
- Restrictive cardiomyopathy  
- Hypertrophic cardiomyopathy  
- Peripartum cardiomyopathy  
- Alcoholic cardiomyopathy  
- Arrhythmogenic cardiomyopathy  
- Arrhythmogenic right‑ventricular cardiomyopathy (ARVC)  
- Conduction block  
- Atrial arrhythmias (e.g., atrial fibrillation)  
- Ventricular arrhythmias  
- Sudden cardiac death  
- Implantable cardioverter‑defibrillator (ICD)  
- Left ventricular ejection fraction (LVEF)  
- Transthoracic echocardiography (TTE)  
- Cardiac magnetic resonance imaging (CMR)  
- Cardiac computed tomography (CT)  
- Radionuclide imaging  
- Single‑photon emission computed tomography (SPECT)  
- Positron emission tomography (PET)  
- Coronary artery disease (CAD)  
- Coronary revascularization (PCI/CABG)  
- Non‑invasive stress imaging  
- Ischemic heart disease  
- Left ventricular remodeling  
- Clinical guideline‑recommended therapy (GDMT)  
- Chest X‑ray (cardiac size, pulmonary congestion)  
- Cardiac imaging (diagnostic and serial assessment)  
- Genetic variants in titin (TTN)  
- Genetic variants in lamin A/C  
- Desmosomal protein mutations (e.g., PKP2, DSG2)  
- Filamin‑C mutations  
- Fabry’s disease cardiomyopathy  
- Enzyme replacement therapy (agalsidase β)  
- Migalastat (small‑molecule therapy for Fabry)  
- Primary prevention ICD criteria (LVEF > 0.35, <3 months of GDMT)  
- Exercise restriction in desmosomal cardiomyopathy  
- Ventricular remodeling acceleration (due to exercise)  
- Genetic confirmation of cardiomyopathy  
- Structural remodeling assessment  
- Valvular function evaluation  
- Echocardiogram adequacy  
- Functional and structural cardiac assessment  
- LVEF measurement in various modalities (echo, CMR, CT, radionuclide)

Page 20 Extracted Terms:
**Key terms related to heart disease**

- Heart Failure (HF)  
- Chest X‑ray  
- Cardiomegaly  
- Pulmonary venous congestion  
- Interstitial edema  
- Alveolar edema  
- Transthoracic Echocardiography (TTE)  
- Echocardiography  
- Myocardium (myocardial structure/function)  
- Heart valves  
- Pericardium  
- Left Ventricular Ejection Fraction (LVEF)  
- Ventricular dimensions  
- Ventricular volumes  
- Chamber geometry  
- Regional wall motion  
- Right Ventricular (RV) size  
- Right Ventricular function  
- Atrial size  
- Diastolic function  
- Left Ventricular filling  
- Left atrial pressure  
- Tricuspid valve regurgitant gradient  
- Inferior vena cava (IVC) diameter  
- Systolic pulmonary artery pressure (PA pressure)  
- Central venous pressure (CVP)  
- Global longitudinal strain (GLS)  
- Subclinical LV systolic dysfunction  
- Point‑of‑care cardiac ultrasound  
- Serial echocardiograms  
- Structural remodeling  
- Valvular function  
- Revascularization  
- Device therapies (e.g., pacemakers, ICD, CRT)  
- Implantable Cardioverter‑Defibrillator (ICD)  
- Cardiac Resynchronization Therapy (CRT)  
- Left Ventricular (LV) systolic dysfunction  
- Chronic tachycardia  
- Thyroid disease (as HF precipitant)  
- Dilated cardiomyopathy  
- Peripartum cardiomyopathy  
- Myocarditis  
- Systemic inflammatory responses  
- Chemotherapy‑associated cardiotoxicity  
- Cardiac Magnetic Resonance (CMR)  
- Left ventricular mass  
- Cardiac volumes  
- Electrocardiographic‑gated cardiac CT  
- Radionuclide ventriculography (RVG)  
- Late Gadolinium Enhancement (LGE)  
- Myocardial fibrosis  
- Acute Myocardial Infarction (MI)  
- Chronic Myocardial Infarction (MI)  
- Coronary Artery Disease (CAD)  
- Infiltrative cardiomyopathies  
- Sarcoidosis  
- Fabry disease  
- Chagas disease  
- Noncompaction cardiomyopathy  
- Iron overload  
- Amyloidosis  
- T1 mapping  
- T2 mapping  
- Myocardial strain imaging  


Page 21 Extracted Terms:
Heart failure (HF)  
Coronary artery disease (CAD)  
Myocardial ischemia  
Revascularization, coronary revascularization  
Endomyocardial biopsy  
Right heart catheterization  
Invasive hemodynamic monitoring  
Noninvasive stress imaging  
Echocardiography  
Nuclear scintigraphy  
SPECT (single‑photon emission computed tomography)  
CMR (cardiac magnetic resonance imaging)  
PET (positron emission tomography)  
Viability imaging  
Myocardial viability  
STICH trial (Surgical Treatment for Ischemic Heart Failure)  
Cardiogenic shock  
Nonischemic cardiomyopathy  
Ischemic cardiomyopathy  
Obstructive CAD  
Amyloidosis  
Light‑chain (AL) amyloidosis  
Transthyretin amyloidosis (ATTR)  
Myocarditis  
Giant cell myocarditis  
Cardiac rejection  
Interstitial space characteristics  
Extracellular volume fraction  
Delayed hyperenhancement  
Cardiac infiltration (myocardial)

Page 22 Extracted Terms:
- Heart Failure (HF)  
- Acute heart failure (acute HF)  
- Right‑heart catheterization  
- Pulmonary artery (PA) catheterization  
- PA catheter monitoring  
- Hemodynamic evaluation/monitoring  
- ESCAPE trial  
- NYHA class III heart failure  
- NYHA class II–IV heart failure  
- Natriuretic peptide levels  
- Guideline‑directed medical therapy (GDMT)  
- CardioMEMS implantable PA pressure sensor  
- CHAMPION trial  
- GUIDE‑HF study  
- Implanted electronic devices (ICDs, CRT‑Ds)  
- Remote monitoring / telemonitoring  
- Wearables (remote monitoring devices)  
- Cardiac tamponade  
- Perforation (of myocardium)  
- Thrombus formation  
- Fluid status  
- Perfusion  
- Pulmonary vascular resistance  
- Systemic vascular resistance  
- Systolic blood pressure (SBP)  
- Renal function  
- Pulmonary capillary wedge pressure  
- Left ventricular ejection fraction (LVEF)  
- Beta‑blockers  
- Angiotensin‑converting enzyme inhibitors (ACEi)  
- Angiotensin receptor blockers (ARBs)  
- Vasoactive agents  
- Invasive hemodynamic measurements  
- Endomyocardial biopsy (risk)  
- Clinical guidelines (AHA/ACC/HFSA)

Page 23 Extracted Terms:
- Heart failure (HF)  
- CardioMEMS device  
- CardioMEMS implantation and monitoring  
- Cardiopulmonary exercise testing (CPET)  
- NYHA functional classification (I–IV)  
- Left ventricular assist device (LVAD)  
- Heart transplantation  
- Dysphnea (dyspnea)  
- 6‑minute walk test  
- Peak VO₂ (peak oxygen consumption/uptake)  
- Peak VO₂ ≤ 14 mL/kg/min (transplant cutoff)  
- Peak VO₂ ≤ 12 mL/kg/min with beta‑blocker therapy (transplant cutoff)  
- Beta‑blockers  
- Survival (mortality, 1‑ and 2‑year survival)  
- Quality‑adjusted life year (QALY)  
- Cost‑effectiveness  
- Economic value of CardioMEMS  
- Cost estimates  
- Model duration  
- Quality of life (QOL) data  
- GUIDE‑HF trial  
- American Heart Association (AHA)  
- American College of Cardiology (ACC)  
- Heart Failure Society of America (HFSA)  
- Clinical benefit  
- Exercise intolerance  
- Functional capacity  
- Advanced treatments (e.g., LVAD, heart transplant)  
- Prognosis in HF  
- Clinical guidelines  
- Functional impairment  
- Exercise testing as a standardized, reliable measure  
- Clinical documentation of NYHA class  
- Candidate selection for drug/device therapy  
- Treatment eligibility criteria  
- Functional limitation grading  
- Reproducibility issues with NYHA classification  
- Risk stratification using CPET variables  

These terms capture the key heart‑disease–related concepts, diagnostics, therapies, and outcomes discussed in the guideline excerpt.

Page 24 Extracted Terms:
- AHA/ACC/HFSA Heart Failure Guideline  
- NYHA class III  
- NYHA class IV  
- 3‑year survival free of heart transplant  
- Dyspnea  
- Cardiopulmonary Exercise Test (CPET)  
- Treadmill exercise test  
- Stationary bicycle exercise test  
- Ventilatory gas exchange measurements  
- Oxygen uptake (VO₂)  
- Carbon dioxide output  
- Ventilation  
- Exercise capacity  
- Cardiopulmonary responses  
- Metabolic abnormalities  
- Deconditioning  
- HF Risk Scoring  
- Multivariable risk scores  
- Mortality  
- Hospitalization  
- Readmission for heart failure  
- Incident heart failure (HF)  
- Advanced heart failure therapies  
- Biomarker testing  
- Risk stratification  
- Seattle Heart Failure Model  
- Heart Failure Survival Score  
- MAGGIC (Meta‑analysis Global Group in Chronic Heart Failure)  
- CHARM Risk Score (Candesartan in Heart failure‑Assessed Reduction in Mortality and Morbidity)  
- CORONA Risk Score (Controlled Rosuvastatin Multinational Trial in Heart Failure)  
- PARADIGM‑HF  
- HF‑ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training)  
- GUIDE‑IT (Guiding Evidence‑Based Therapy Using Biomarker‑Intensified Treatment)  
- I‑PRESERVE Score (Irbesartan in Heart Failure with Preserved Ejection Fraction Study)  
- TOPCAT (Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist)  
- ADHERE Classification (Acute Decompensated Heart Failure National Registry)  
- Regression Tree (CART) Model  
- AHA Get With The Guidelines Score  
- EFFECT Risk Score (Enhanced Feedback for Effective Cardiac Treatment)  
- ESCAPE Risk Model (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness)  
- AHA (American Heart Association)  
- ACC (American College of Cardiology)  
- HFSA (Heart Failure Society of America)  
- HF (heart failure)  
- HFpEF (heart failure with preserved ejection fraction)  
- HFrEF (heart failure with reduced ejection fraction)  
- ARIC (Atherosclerosis Risk in Communities)  

These terms capture the key concepts related to heart disease as presented in the excerpt.

Page 25 Extracted Terms:
- Heart failure (HF)  
- Systolic heart failure (HFrEF)  
- Diastolic heart failure (HFpEF)  
- Ejection fraction (EF)  
- Left ventricular (LV) dysfunction  
- LV systolic dysfunction  
- LV diastolic dysfunction  
- Seattle Heart Failure Model  
- Heart Failure Survival Score  
- MAGGIC score  
- Multivariate risk scores  
- Natriuretic peptide biomarker  
- B-type natriuretic peptide (BNP)  
- N-terminal pro-BNP (NT‑proBNP)  
- Sodium‑glucose co‑transporter‑2 inhibitors (SGLT2i)  
- Hypertension  
- Blood pressure (BP)  
- Systolic blood pressure (SBP)  
- Diastolic blood pressure (DBP)  
- Type 2 diabetes mellitus (T2DM)  
- Cardiovascular disease (CVD)  
- High cardiovascular risk  
- Smoking cessation  
- Obesity / weight control  
- Regular physical activity  
- Healthy dietary patterns  
- Lifestyle modifications  
- Primary prevention  
- Secondary prevention  
- Guideline‑directed medical therapy (GDMT)  
- AHA/ACC heart failure guideline  
- HFSA (Heart Failure Society of America)  
- Clinical risk prediction models  
- Collaborative care / team‑based care  
- Cardiovascular specialist  
- SPRINT trial  


Page 26 Extracted Terms:
- Heart Failure (HF)  
- Left Ventricular Systolic Dysfunction  
- Left Ventricular Ejection Fraction (LVEF)  
- B-type Natriuretic Peptide (BNP) Testing  
- St Vincent’s Screening to Prevent Heart Failure (STOP-HF)  
- Angiotensin‑Converting Enzyme Inhibitor (ACEi)  
- Angiotensin Receptor Blocker (ARB)  
- Sodium‑Glucose Cotransporter‑2 Inhibitor (SGLT2i)  
- Implantable Cardioverter‑Defibrillator (ICD)  
- Myocardial Infarction (MI)  
- Cardiovascular Disease (CVD)  
- Hypertension  
- Diabetes  
- Vascular Disease  
- Pre‑HF (Stage B)  
- Risk Stage A (Patients at Risk of HF)  
- Blood Pressure (BP)  
- Mediterranean Diet  
- DASH Diet (Dietary Approaches to Stop Hypertension)  
- Plant‑Based Diet  
- Whole‑Grain Diet  
- AHA/ACC/HFSA Heart Failure Guideline  
- Class of Recommendation (COR)  
- Composite Endpoint  
- Asymptomatic LV Dysfunction  
- Healthy Dietary Patterns  

Page 27 Extracted Terms:
- Heart failure (HF)  
- Stage A HF  
- Stage B HF (pre‑HF)  
- Symptomatic HF  
- Asymptomatic LV systolic dysfunction  
- Asymptomatic LV diastolic dysfunction  
- Left ventricular ejection fraction (LVEF)  
- LVEF ≤ 40 %  
- LVEF ≤ 30 %  
- LVEF < 50 %  
- New‑onset myocardial infarction (MI)  
- Acute coronary syndrome (ACS)  
- NT‑proBNP  
- Renin–angiotensin–aldosterone system (RAAS) antagonists  
- Angiotensin‑converting enzyme inhibitors (ACEi)  
- Angiotensin II receptor blockers (ARB)  
- Beta‑blockers  
- Guideline‑directed medical therapy (GDMT)  
- Statins  
- Implantable cardioverter‑defibrillator (ICD)  
- Sudden cardiac death (SCD)  
- NYHA class I  
- Thiazolidinediones  
- Nondihydropyridine calcium‑channel blockers  
- QRS duration  
- Diabetes mellitus  
- Obesity  
- Hypertension  
- Framingham Heart Failure Risk Score  
- Health ABC Heart Failure Score  
- ARIC Risk Score (Atherosclerosis Risk in Communities)  
- PCP‑HF (Pooled Cohort Equations to Prevent HF)  
- Electronic health records (EHR)  
- Machine learning in risk prediction  
- Cardiovascular events  
- Mortality reduction  
- Risk prediction models  
- Population‑based cohorts  
- Clinical practice guidelines (AHA/ACC/HFSA)

Page 28 Extracted Terms:
- Heart failure (HF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Stage B heart failure  
- Myocardial infarction (MI)  
- Acute MI / acute myocardial infarction  
- ST‑elevation myocardial infarction (STEMI)  
- Non–ST‑elevation acute coronary syndrome (NST‑ACS) / acute coronary syndrome (ACS)  
- Left ventricular ejection fraction (LVEF)  
- Left ventricular dysfunction / LV dysfunction / left ventricular systolic dysfunction  
- Maladaptive cardiac remodeling  
- Pulmonary congestion  
- Mineralocorticoid receptor antagonist (MRA)  
- Angiotensin‑receptor‑neprilysin inhibitor (ARNi) – e.g., sacubitril/valsartan  
- Angiotensin‑converting enzyme inhibitor (ACEi) – e.g., ramipril, enalapril, captopril  
- Angiotensin‑II receptor blocker (ARB) – e.g., valsartan, losartan  
- Beta‑blocker – e.g., carvedilol, other β‑adrenergic antagonists  
- Statin therapy / statins  
- Guideline‑directed medical therapy (GDMT)  
- Coronary revascularization (percutaneous coronary intervention, PCI)  
- Coronary artery bypass graft surgery (CABG)  
- Valvular heart disease – valve replacement or repair for significant stenosis or regurgitation  
- Congenital heart disease (CHD)  
- Clinical trials / randomized controlled trials (RCTs) – e.g., SOLVD, VALIANT, OPTIMAAL, PARADISE‑MI  
- Guidelines – AHA/ACC/HFSA, ACCF/AHA, ACC/AHA/SCAI, ACC/AHA/STI, etc.  
- Cardiovascular disease (CVD) / cardiovascular risk  
- Angioedema (as a drug‑related adverse effect)

Page 29 Extracted Terms:
- Framingham studies  
- Left ventricular ejection fraction (LVEF)  
- Heart failure (HF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Sudden cardiac death (SCD)  
- Myocardial infarction (MI)  
- Implantable cardioverter‑defibrillator (ICD)  
- Beta‑blockers  
- Angiotensin‑converting‑enzyme inhibitor (enalapril)  
- Thiazolidinediones (pioglitazone, rosiglitazone)  
- Fluid retention / edema  
- New York Heart Association (NYHA) class I‑II  
- Nondihydropyridine calcium‑channel blockers (diltiazem, verapamil)  
- Non‑pharmacologic interventions  
- Self‑care support for heart failure  
- Multidisciplinary care teams  
- Guideline‑directed medical therapy (GDMT)  
- Vaccination against respiratory illnesses  
- Depression (as a risk factor for poor self‑care)  
- Social isolation (as a risk factor for poor self‑care)  
- Frailty (as a risk factor for poor self‑care)  
- Low health literacy (as a risk factor for poor self‑care)

Page 30 Extracted Terms:
Heart failure (HF)  
Heart failure with reduced ejection fraction (HFrEF)  
HF hospitalization  
All‑cause mortality  
All‑cause readmission  
Cardiac death  
Self‑care  
Multidisciplinary team follow‑up  
Case management  
Pharmacist involvement  
Multidisciplinary interventions  
Medication adherence  
Structured telephone support  
Mobile‑health–delivered educational interventions  
Transitional‑care services program  
Angiotensin‑converting enzyme inhibitor (ACEi)  
Angiotensin receptor blocker (ARB)  
Angiotensin receptor‑neprilysin inhibitor (ARNi)  
Cardiac resynchronization therapy (CRT)  
Guideline‑directed medical therapy (GDMT)  
Implantable cardioverter‑defibrillator (ICD)  
Hydralazine and isosorbide dinitrate (hydral‑nitrates)  
Mechanical circulatory support (MCS)  
Left ventricular ejection fraction (LVEF)  
Mineralocorticoid receptor antagonist (MRA)  
Normal sinus rhythm (NSR)  
New York Heart Association (NYHA)  
Sodium‑glucose cotransporter‑2 inhibitor (SGLT2i)  
Left bundle branch block (LBBB)

Page 31 Extracted Terms:
**Key terms related to heart disease**

- Heart Failure (HF)  
- HFrEF (Heart Failure with reduced Ejection Fraction)  
- HFpEF (Heart Failure with preserved Ejection Fraction)  
- NYHA functional class  
- Constrictive/Constricted symptoms (symptoms of congestion)  
- Sodium restriction / Dietary sodium restriction  
- DASH diet (Dietary Approaches to Stop Hypertension)  
- Leg edema  
- Weight/fluid overload  
- Congestion  
- Diuretic use  
- Hospitalization / Hospitalisations  
- Rehospitalization  
- Mortality  
- All‑cause mortality  
- Cardiovascular mortality  
- Adverse cardiovascular events  
- Influenza vaccination  
- Pneumococcal vaccination  
- COVID‑19 vaccination (SARS‑CoV‑2)  
- Self‑care education / Self‑care  
- Depression (as a risk factor)  
- Social isolation  
- Frailty  
- Health literacy / Health numeracy  
- Nutritional adequacy  
- Macronutrient intake  
- Micronutrient intake  
- Iron supplementation  
- Thiamine supplementation  
- Zinc supplementation  
- Vitamin D supplementation  
- Multivitamin supplementation  
- Registered dietitian / Nurse‑coached dietetic intervention  
- Clinical outcomes  
- Clinical benefit / Clinical stability  
- Prospective Comparison of ARNi with ACEi to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM‑HF)  
- Cardiovascular Health Study  
- Composite of mortality and cardiovascular hospitalizations  

(Note: The list prioritizes terminology directly associated with heart disease, its management, outcomes, and related interventions.)

Page 32 Extracted Terms:
- Heart Failure (HF)  
- Stage C Heart Failure  
- Cardiac Rehabilitation  
- Exercise Training / Exercise Prescription  
- Physical Activity  
- Functional Status  
- Exercise Performance  
- Quality of Life (QOL)  
- B‑type Natriuretic Peptide (BNP)  
- Sodium Intake / Dietary Sodium  
- Urinary Sodium  
- HF Self‑Care  
- AHA/ACC/HFSA Heart Failure Guideline (contextual reference)

Page 33 Extracted Terms:
- Heart Failure (HF)  
- Heart Failure with Reduced Ejection Fraction (HFrEF)  
- Heart Failure with Preserved Ejection Fraction (HFpEF)  
- Cardiac Rehabilitation  
- Exercise Training (supervised, graded)  
- Functional Capacity  
- Exercise Performance / Tolerance  
- Quality of Life (QoL)  
- Cardiovascular (CVD) Mortality  
- Hospitalization (all‑cause, HF‑specific)  
- NYHA Class II & III  
- Left Ventricular Ejection Fraction (LVEF) ≤ 35%  
- Diuretics  
  - Loop Diuretics (bumetanide, furosemide, torsemide)  
  - Thiazide Diuretics (metolazone, chlorthalidone, hydrochlorothiazide)  
  - Potassium‑sparing Diuretics (spironolactone)  
- Congestion  
- Fluid Retention / Edema  
- Electrolyte Abnormalities  
- Endothelial Function  
- Catecholamine Spillover  
- Peripheral Oxygen Extraction  
- Peak Oxygen Consumption (VO₂ peak)  
- Guideline‑Directed Medical Therapy (GDMT)  
- Mineralocorticoid Receptor Antagonists (MRAs)  
- Vasopressin Antagonists  
- Hyponatremia  
- Loop of Henle  
- Distal Convoluting Tubule  
- Collecting Duct  
- Clinical Evidence of Fluid Retention  
- Euvolemia


Page 34 Extracted Terms:
**Key heart‑disease terms identified in the text**

- Heart failure (HF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- New York Heart Association (NYHA) class II–III  
- Congestion / volume overload  
- Serum sodium  
- Urinary sodium excretion  
- Physical signs of fluid retention  
- Quality of life (QOL)  
- Exercise tolerance  
- Hospitalization for HF  
- All‑cause 30‑day mortality  
- Diuretics  
- Loop diuretics  
- Furosemide  
- Bumetanide  
- Torsemide  
- Metolazone (thiazide‑like diuretic)  
- Thiazide diuretics (chlorthiazide, chlorthalidone, hydrochlorothiazide, indapamide)  
- Diuretic resistance  
- Intravenous diuretics (bolus or continuous infusion)  
- Combination diuretic therapy  
- Renin–angiotensin system inhibition  
- Angiotensin‑converting‑enzyme inhibitor (ACEi)  
- Angiotensin‑II receptor blocker (ARB)  
- Angiotensin‑receptor neprilysin inhibitor (ARNi)  
- DOSE trial (Diuretic Optimization Strategies Evaluation)  
- OPTIMIZE‑HF registry  
- Oral bioavailability  
- Hypokalemia  
- Hyponatremia  
- Worsening renal function  
- Cough (ACEi side effect)  
- Angioedema (contraindication to ACEi/ARNi)  
- High‐value economic therapy  
- Safety and harm statements (e.g., ARNi/ACEi overlap within 36 h)

Page 35 Extracted Terms:
**Key heart‑disease terms extracted from the guideline text**

- Heart Failure (HF)  
- Heart Failure with Reduced Ejection Fraction (HFrEF)  
- New York Heart Association (NYHA) Class II symptoms  
- New York Heart Association (NYHA) Class III symptoms  
- Angiotensin‑Converting Enzyme Inhibitor (ACEi)  
- Angiotensin‑Receptor Blocker (ARB)  
- Angiotensin‑Receptor Neprilysin Inhibitor (ARNi)  
- Sacubitril–valsartan (ARNi)  
- Enalapril (ACEi)  
- Natriuretic peptides (e.g., BNP, NT‑proBNP)  
- Bradykinin  
- Adrenomedullin  
- Vasoactive peptides  
- LV remodeling (left‑ventricular remodeling)  
- NT‑proBNP (biomarker)  
- Hypotension (symptomatic)  
- Angioedema  
- Renal function (renal insufficiency)  
- Hyperkalemia (serum potassium >5.0 mEq/L)  
- Hospitalization for heart failure  
- Acute decompensated heart failure  
- Chronic symptomatic heart failure  
- PIONEER‑HF trial  
- TRANSITION trial  
- PARADIGM‑HF trial  
- PARADISE‑MI trial  
- Cardiac death (cardiovascular death)  
- HF hospitalization (re‑hospitalization)  
- LVEF ≤ 40 % (left‑ventricular ejection fraction)  
- Pulmonary congestion  
- Coronary artery disease (CAD)  
- Diabetes mellitus (as a risk factor)  
- Myocardial infarction (MI)  
- Early post‑MI period  
- Hemodynamics  
- Mortality reduction  
- Morbidity reduction  
- Clinical deterioration (after abrupt ACEi withdrawal)  
- Symptomatic improvement  
- Clinical deterioration (after abrupt ACE inhibition withdrawal)  
- Symptom‑guided titration  
- Maximally tolerated doses (of ACEi/ARB/ARNi)  
- Clinical guidelines (AHA/ACC/HFSA)  
- Guideline‑specific trial endpoints  
- Prospective Randomized Controlled Trial (RCT)  
- Composite endpoint (cardiovascular death or HF hospitalization)  

These terms collectively capture the clinical entities, pharmacologic agents, biomarkers, therapeutic goals, and key trials referenced in the guideline excerpt.

Page 36 Extracted Terms:
- AHA/ACC/HFSA Heart Failure Guideline  
- Heart Failure (HF)  
- Heart Failure with reduced ejection fraction (HFrEF)  
- Chronic heart failure (HF)  
- Neurohormonal  
- Renin‑angiotensin system  
- Angiotensin‑converting enzyme inhibitor (ACEi)  
- Angiotensin‑receptor blocker (ARB)  
- Angiotensin‑receptor neprilysin inhibitor (ARNi)  
- Enalapril  
- Sacubitril‑valsartan (valsartan‑based ARNi)  
- Valsartan  
- Val-HeFT (Valsartan Heart Failure Trial)  
- ELITE (Evaluation of Losartan in the Elderly) study  
- SOLVD (Studies of Left Ventricular Dysfunction)  
- PARADIGM‑HF (Prospective Comparison of ARNI with ACE inhibitor in Heart Failure)  
- PIONEER‑HF (Prospective Study of ARNI in Acute Heart Failure)  
- Omapatrilat (neprilysin inhibitor/ACEi combination)  
- Neprilysin inhibitor  
- Bradykinin  
- Angioedema  
- Hypertension (arterial hypertension)  
- Low systemic blood pressure  
- Renal insufficiency  
- Serum potassium (hyper‑kalaemia)  
- LV dysfunction  
- LV remodeling  
- Hospitalization  
- Mortality  
- Cost‑effectiveness analysis  
- Quality‑adjusted life year (QALY)  
- Clinical trial outcomes  
- Economic value  
- Treatment cost per QALY  
- Guideline benchmarks (value thresholds)

Page 37 Extracted Terms:
- Heart failure with reduced ejection fraction (HFrEF)  
- Heart failure (HF)  
- β‑blockers  
- Bisoprolol  
- Carvedilol  
- Sustained‑release metoprolol succinate  
- Mortality  
- Hospitalization  
- Left ventricular ejection fraction (LVEF)  
- Coronary artery disease (CAD)  
- Diabetes mellitus  
- Atrial fibrillation (AF)  
- Major cardiovascular events  
- β‑blocker dosing, sequencing, and uptitration  
- Mineralocorticoid receptor antagonists (MRAs)  
- Spironolactone  
- Eplerenone  
- Hyperkalemia  
- Life‑threatening hyperkalemia  
- Renal insufficiency  
- Estimated glomerular filtration rate (eGFR)  
- Serum potassium  
- NYHA class II‑IV symptoms  
- Sudden cardiac death (SCD)  
- Angiotensin‑converting enzyme inhibitors (ACEi)  
- Angiotensin receptor blockers (ARB)  
- Bradykinin  
- Angioedema  



Page 38 Extracted Terms:
- Heart failure (HF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Left ventricular ejection fraction (LVEF)  
- Mineralocorticoid receptor antagonist (MRA)  
- Eplerenone  
- Spironolactone  
- Randomized Aldactone Evaluation Study (RALES)  
- Eplerenone Post‑Acute Myocardial Infarction Heart Failure Evaluation Study (EPHESUS)  
- Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS‑HF)  
- Sodium‑glucose cotransporter‑2 inhibitors (SGLT2i)  
- Dapagliflozin  
- Empagliflozin  
- DAPA‑HF trial (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure)  
- EMPEROR‑Reduced trial (EMPagliflozin Outcomes Trial in Patients With Chronic Heart Failure With Reduced Ejection Fraction)  
- Hyperkalemia  
- Estimated glomerular filtration rate (eGFR)  
- Angiotensin‑converting enzyme inhibitor (ACEi)  
- Angiotensin receptor blocker (ARB)  
- Angiotensin receptor‑neprilysin inhibitor (ARNi)  
- PARADIGM‑HF trial (Prospective Comparison of Angiotensin II Antagonist–Drug Interventions in the Management of Heart Failure)  
- PIONEER‑HF trial (Phase II/III study evaluating novel therapies in decompensated heart failure)  
- Potassium binders (patiromer, sodium zirconium cyclosilicate)  
- Cardiovascular mortality  
- Hospitalization for heart failure  
- Acute myocardial infarction (MI)  
- Type 2 diabetes mellitus  
- Quality‑adjusted life year (QALY)  
- Economic value of therapy  
- AHA/ACC/HFSA Heart Failure Guideline  

These terms capture the key concepts, therapies, trials, and clinical outcomes discussed in the guideline excerpt.

Page 39 Extracted Terms:
- Heart Failure with Reduced Ejection Fraction (HFrEF)
- Left Ventricle Ejection Fraction (LVEF ≤ 40%)
- New York Heart Association (NYHA) Functional Class II, III, IV
- Natriuretic peptides (BNP/NT‑proBNP)
- SGLT2 inhibitors (SGLT2i)
- Dapagliflozin
- Empagliflozin
- Sotagliflozin
- Hydralazine
- Isosorbide dinitrate
- Composite endpoint of cardiovascular death or heart‑failure hospitalization
- Cardiovascular death
- All‑cause mortality
- Heart‑failure (HF) hospitalization
- eGFR (estimated glomerular filtration rate)
- Chronic kidney disease (CKD) / renal insufficiency
- Euglycemic ketoacidosis
- Genital infections
- Soft‑tissue infections
- Volume depletion
- DAPA‑HF trial
- EMPEROR‑Reduced trial
- SOLOIST‑WHF trial
- V‑HeFT I (Vasodilator Heart Failure Trial)
- A‑HeFT (African‑American Heart Failure Trial)
- Guideline‑Directed Medical Therapy (GDMT)
- Angiotensin‑converting enzyme inhibitor (ACEi)
- Angiotensin receptor blocker (ARB)
- Beta‑blocker
- Mineralocorticoid receptor antagonist (MRA)
- Angiotensin receptor‑neprilysin inhibitor (ARNi)
- Quality‑Adjusted Life Year (QALY)
- Cost‑effectiveness analysis
- African American population (race‑specific therapy)
- Heart‑failure biomarker (Natriuretic peptides)
- Heart‑failure morbidity and mortality
- Heart‑failure symptom improvement



Page 40 Extracted Terms:
- Heart failure (HF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Left ventricular ejection fraction (LVEF)  
- Vasodilator therapy (hydralazine)  
- Isosorbide dinitrate (ISO)  
- Hydralazine‑isosorbide dinitrate combination  
- Angiotensin‑converting enzyme inhibitor (ACEi)  
- Angiotensin receptor blocker (ARB)  
- Angiotensin receptor‑neprilysin inhibitor (ARNi)  
- Beta‑blocker  
- Mineralocorticoid receptor antagonist (MRA)  
- Renin‑angiotensin‑aldosterone system inhibitor (RAASi)  
- Digoxin  
- Diuretic  
- Renal insufficiency (as risk factor for HF)  
- Hyperkalemia (serum potassium ≥ 5.5 mEq/L)  
- Potassium binders (patiromer, sodium zirconium cyclosilicate)  
- Omega‑3 polyunsaturated fatty acids (omega‑3 PUFA)  
- Eicosapentaenoic acid (EPA)  
- Docosahexaenoic acid (DHA)  
- GISSI‑HF trial  
- REDUCE‑IT trial  
- Mortality (all‑cause, cardiovascular, sudden cardiac death)  
- Cardiovascular events (fatal and non‑fatal, hospitalizations)  
- Cardiovascular disease (CVD)  
- Heart failure class II‑IV symptoms  
- Cardiovascular hospitalization  

These terms represent the core heart‑disease concepts discussed in the guideline text.

Page 41 Extracted Terms:
- Heart Failure (HF)  
- Heart Failure with Reduced Ejection Fraction (HFrEF)  
- Chronic Heart Failure (CHF)  
- Hyperkalemia  
- Renin‑Angiotensin‑Aldosterone System Inhibitors (RAASi)  
- Patiromer (potassium binder)  
- Sodium Zirconium Cyclosilicate (SZC)  
- PEARL‑HF trial  
- HARMONIZE trial  
- Warfarin  
- Aspirin  
- Clopidogrel  
- Rivaroxaban  
- Antithrombotic therapy  
- Anticoagulation  
- Thromboembolic events  
- Venous Thromboembolism (VTE)  
- Atrial Fibrillation (AF)  
- Cardioembolic source  
- Myocardial Infarction (MI)  
- Stroke (ischemic, intracerebral hemorrhage)  
- Non‑fatal MI  
- Non‑fatal stroke  
- Coronary revascularization  
- Unstable Angina  
- Omega‑3 Polyunsaturated Fatty Acids (PUFA)  
- Eicosapentaenoic Acid (EPA)  
- Dipeptidyl Peptidase‑4 (DPP‑4) Inhibitors (saxagliptin, alogliptin)  
- Thiazolidinediones (TZDs)  
- Calcium Channel Blockers (dihydropyridine, nondihydropyridine)  
- Class IC Antiarrhythmic Medications  
- Dronedarone  
- Non‑steroidal Anti‑Inflammatory Drugs (NSAIDs)  
- Vitamins and Nutritional Supplements  
- Hormonal Therapy  
- Ventricular Arrhythmias  
- Mortality  
- Cardiovascular Death  
- Cardio‑renal Benefit  
- Fecal Excretion (potassium)

Page 42 Extracted Terms:
- Heart failure (HF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Nonischemic cardiomyopathy  
- LV afterload  
- Calcium channel blockers  
- Second‑generation dihydropyridine calcium channel blockers  
- Amlodipine  
- Felodipine  
- Diltiazem (nondihydropyridine calcium channel blocker)  
- Verapamil (nondihydropyridine calcium channel blocker)  
- PRAISE‑1 (Prospective Randomized Amlodipine Survival Evaluation‑1)  
- PRAISE‑2 (Prospective Randomized Amlodipine Survival Evaluation‑2)  
- Coenzyme Q₁₀  
- Q‑SYMBIO (Coenzyme Q₁₀ as adjunctive treatment of chronic heart failure)  
- NYHA functional classification  
- Major adverse cardiovascular events (MACE)  
- Brain‑natriuretic peptide (BNP)  
- Guideline‑directed medical therapy (GDMT)  
- Vitamin D  
- Thiamine  
- Carnitine  
- Taurine  
- Vitamin E  
- Testosterone therapy  
- Growth hormone therapy  
- Thyroid hormone therapy  
- Non‑steroidal anti‑inflammatory drugs (NSAIDs)  
- Cyclo‑oxygenase (COX) inhibitors  
- COX‑2 selective inhibitors  
- Thiazolidinediones  
- Saxagliptin  
- Alogliptin  
- Flecainide  
- Disopyramide  
- Sotalol  
- Dronedarone  
- Alpha‑1 adrenergic blockers  
- Doxazosin  
- Nifedipine  

Page 43 Extracted Terms:
**Key Terms Related to Heart Disease**

- Heart failure (HF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Cardiomyopathy  
- Acute myocardial infarction (MI)  
- Recurrent heart failure  
- Structural heart disease  
- Ventricular arrhythmias  
- Atrial‑ventricular arrhythmias (refractory)  
- Guideline‑directed medical therapy (GDMT)  
- Anti‑arrhythmic drug classes  
- Class IC anti‑arrhythmics (e.g., encainide, flecainide)  
- Class III anti‑arrhythmics (e.g., dronedarone, sotalol)  
- Class IA anti‑arrhythmics (e.g., quinidine)  
- Class IB anti‑arrhythmics (e.g., mexiletine)  
- Specific anti‑arrhythmic agents  
  - Diltiazem  
  - Encainide  
  - Flecainide  
  - Dronedarone  
  - Sotalol  
  - Amiodarone  
  - Dofetilide  
  - Quinidine  
  - Mexiletine  
- Systolic heart failure trials  
  - CAST (Cardiac Arrhythmia Suppression Trial)  
  - ANDROMEDA (Anti‑arrhythmic Trial with Dronedarone)  
  - SWORD (Survival With Oral D‑sotalol)  
- Thiazolidinediones (e.g., rosiglitazone, pioglitazone)  
- Peroxisome proliferator‑activated receptor‑γ (PPAR‑γ)  
- Sodium‑water retention in heart failure  
- Nitro‑sodic‑acid‑dependent peptides (DPP‑4) inhibitors  
  - Saxagliptin  
  - Alogliptin  
  - Sitagliptin  
  - Linagliptin  
- Non‑steroidal anti‑inflammatory drugs (NSAIDs)  
- Implantable cardioverter‑defibrillators (ICDs)  
- Hospitalization for heart failure  
- Cardiovascular mortality  
- All‑cause mortality reduction with GDMT  
- ACE inhibitors (ACEi)  
- Angiotensin receptor blockers (ARB)  
- Angiotensin receptor‑neprilysin inhibitors (ARNi)  
- β‑blockers  
- Diuretic therapy and sodium‑resorption suppression  
- Glycemic control agents affecting HF risk (metformin, insulin, sulfonylureas)  
- Fluid‑retention risk factors in diabetes treatment  
- Titration and uptitration of guideline‑directed therapy  

---

Page 44 Extracted Terms:
- Heart failure (HF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Ejection fraction (EF)  
- Angiotensin‑converting enzyme inhibitor (ACEi) – e.g., captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril  
- Angiotensin‑receptor blocker (ARB) – e.g., candesartan, losartan, valsartan  
- Angiotensin‑receptor neprilysin inhibitor (ARNi) – sacubitril‑valsartan  
- Beta‑blocker – e.g., bisoprolol, carvedilol, metoprolol succinate (CR/XL)  
- Mineralocorticoid‑receptor antagonist – e.g., spironolactone, eplerenone  
- Sodium‑glucose cotransporter‑2 inhibitor (SGLT2i) – e.g., dapagliflozin, empagliflozin  
- Isosorbide dinitrate  
- Hydralazine  
- Isosorbide dinitrate plus hydralazine (fixed‑dose combination)  
- Ivabradine (I‑channel inhibitor)  
- Vericiguat (soluble guanylate cyclase stimulator)  
- Digoxin (cardiac glycoside)  
- Clinical benefit / dose‑response relationship in heart failure therapies  
- Target dose vs. lower dose of HFrEF medications  



Page 45 Extracted Terms:
- Heart Failure with Reduced Ejection Fraction (HFrEF)  
- Stage C Heart Failure  
- New York Heart Association (NYHA) Class II–III  
- Left Ventricular Ejection Fraction (LVEF) ≤ 35 %  
- Guideline‑Directed Medical Therapy (GDMT)  
- β‑blockers  
- Angiotensin‑Converting Enzyme Inhibitors (ACEi)  
- Angiotensin Receptor Blockers (ARB)  
- Angiotensin Receptor Neprilysin Inhibitors (ARNi)  
- Sodium‑Glucose Cotransporter‑2 Inhibitors (SGLT2i)  
- Mineralocorticoid Receptor Antagonists (MRA)  
- Ivabradine  
- Hydralazine + Nitrate therapy  
- Cardiac Resynchronization Therapy (CRT)  
- Implantable Cardioverter‑Defibrillator (ICD)  
- Heart Rate (≥ 70 bpm at rest)  
- Sinus Rhythm  
- Blood Pressure monitoring  
- Electrolyte monitoring  
- Renal function monitoring  
- Cardiovascular death  
- Heart Failure hospitalization  
- Relative Risk Reduction (RRR)  
- Number Needed to Treat (NNT)

Page 46 Extracted Terms:
**Key Heart Disease–Related Terms Extracted**

- Heart failure (HF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Left ventricular ejection fraction (LVEF) ≤ 35%  
- New York Heart Association (NYHA) class II–III  
- Hospitalization (HF hospitalization, HFH)  
- Cardiovascular death  
- Guideline‑directed medical therapy (GDMT)  
- Beta‑blocker therapy (optimal doses, uptitration)  
- Ivabradine therapy (targeting heart rate ≥ 70 bpm)  
- Digoxin (low dose initiation, serum concentration monitoring)  
- Renin‑angiotensin‑aldosterone system inhibitors (RAASi)  
- Mitral valve regurgitation (MR)  
- Normal sinus rhythm (NSR)  
- Shift trial (SHIFT) – a clinical trial on HFrEF  
- AHA/ACC/HFSA Heart Failure Guideline  
- Clinical outcomes: mortality, morbidity, QOL, exercise tolerance  
- Biomarkers: natriuretic peptide (NP)  
- Cardiac imaging metrics: left ventricular end‑systolic dimension (LVESD)  

These terms capture the most clinically and guideline‑relevant concepts related to heart disease found in the provided text.

Page 47 Extracted Terms:
- **Heart Failure (HF)**
- **Heart Failure with Reduced Ejection Fraction (HFrEF)**
- **Vericiguat**
- **Soluble Guanylate Cyclase (sGC) Stimulator**
- **Soluble Guanylyl Cyclase Stimulator**
- **GDMT (Guideline‑Directed Medical Therapy)**
- **Digoxin**
- **LVEF (Left Ventricular Ejection Fraction)**
- **NYHA Class (New York Heart Association Functional Classification)**
- **BNP (Brain Natriuretic Peptide)**
- **NT‑proBNP (N‑terminal pro B‑type Natriuretic Peptide)**
- **VICTORIA Trial**
- **ICD (Implantable Cardioverter‑Defibrillator)**
- **CRT (Cardiac Resynchronization Therapy)**
- **DCM (Dilated Cardiomyopathy)**
- **MI (Myocardial Infarction)**
- **SCD (Sudden Cardiac Death)**
- **LBBB (Left Bundle Branch Block)**
- **QRS duration**
- **Non‑LBBB pattern**
- **NT‑proBNP level ≥ 5314 pg/mL (high‑risk subgroup)**
- **SBP < 100 mm Hg (systolic blood pressure)**
- **eGFR < 15 mL/min/1.73 m² (estimated glomerular filtration rate)**
- **High‑value clinical interventions**

Page 48 Extracted Terms:
- LVEF  
- sinus rhythm  
- left bundle branch block (LBBB)  
- QRS duration  
- NYHA class  
- guideline‑directed medical therapy (GDMT)  
- cardiac resynchronization therapy (CRT)  
- atrial fibrillation (AF)  
- ventricular pacing  
- implantable cardioverter‑defibrillator (ICD)  
- sudden cardiac death (SCD)  
- ischemic cardiomyopathy  
- non‑ischemic cardiomyopathy  
- arrhythmogenic cardiomyopathy  
- heart failure (HF)  
- mortality  
- hospitalizations  
- quality of life (QOL)  
- non‑LBBB pattern  
- QRS duration <120 ms  
- QRS duration <150 ms  
- frailty (impacting survival <1 year)  
- resuscitated cardiac arrest  
- antiarrhythmics  
- defibrillators  
- trial names and acronyms:  
  - AVID (Antiarrhythmics versus Implantable Defibrillators trial)  
  - CASH (Cardiac Arrest Study Hamburg)  
  - CIDS (Canadian Implantable Defibrillator Studies)  
  - MADIT (Multicenter Automated Defibrillator Implantation Trial)  
  - MADIT‑II (Multicenter Automatic Defibrillator Implantation Trial II)  
  - MUSTT (Multicenter UnSustained Tachycardia Trial)  
  - DEFINT (Defibrillators in Non‑Ischemic Cardiomyopathy Treatment Evaluation)  
  - SCD‑HEFT (Sudden Cardiac Death in Heart Failure Trial)  
  - DANISH (Defibrillator Implantation in Patients with Non‑ischemic Systolic Heart Failure)  
- ICD implantation for primary prevention  
- CRT‑D (CRT with defibrillation)  
- ICD and CRT indications  
- survival benefit / cost‑effectiveness ratios (e.g., <$60,000 per year of life added)  
- life expectancy increase (>1.4 years)  
- coronary artery bypass graft (CABG) Patch trial (contrast with ICD benefit)

Page 49 Extracted Terms:
- Heart Failure (HF)  
- Congestive Heart Failure (CHF)  
- Left Ventricular Ejection Fraction (LVEF)  
- New York Heart Association (NYHA) class I–IV  
- Implantable Cardioverter‑Defibrillator (ICD)  
- Cardiac Resynchronization Therapy (CRT)  
- CRT‑D (CRT with defibrillator)  
- CRT‑P (CRT pacemaker)  
- MADIT‑II trial  
- MADIT‑CRT trial  
- COMPANION trial  
- CARE‑HF trial  
- REVERSE trial  
- RAFT trial  
- HFrEF (Heart Failure with reduced Ejection Fraction)  
- Cardiomyopathy  
- Left Bundle Branch Block (LBBB / LBBB)  
- Right Ventricular (RV)  
- Left Ventricular (LV)  
- QRS duration  
- Atrial Fibrillation (AF)  
- Guideline‑Directed Medical Therapy (GDMT)  
- 6‑minute walk test  
- Quality of Life (QOL)  
- Primary endpoint of death or hospitalization  
- Composite HF endpoint

Page 50 Extracted Terms:
- Cardiac Resynchronization Therapy (CRT)  
- Left Bundle Branch Block (LBBB)  
- Non‑Left Bundle Branch Block (non‑LBBB)  
- QRS duration & QRS width (>130 ms, >150 ms)  
- Left Ventricular Ejection Fraction (LVEF)  
- Biventricular pacing  
- Right Ventricular (RV) pacing  
- Ventricular pacing burden (>40 %)  
- Chronic heart failure (HF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- New York Heart Association (NYHA) functional classes I–IV  
- Atrial fibrillation (AF)  
- Implantable cardioverter‑defibrillator (ICD)  
- Guideline‑directed medical therapy (GDMT)  
- Ischemic heart disease  
- Non‑ischemic cardiomyopathy  
- Cardiomyopathy (general)  
- Sudden cardiac death  
- Cardiac transplantation  
- Natriuretic peptide (NP)  
- Mitral valve (MV)  
- Mitral regurgitation (MR)  
- Pulmonary artery systolic pressure (PASP)  
- Normal sinus rhythm (NSR)  
- 6‑minute walk test  
- Left Ventricular End‑Systolic Dimension (LVESD)  
- Key CRT trials: COMPANION, MADIT‑CRT, REVERSE, BLOCK‑HF, CARE‑HF, RAFT, MUSTIC‑AF, SPARE, PAVE  
- Economic value indicators: cost per QALY, incremental cost‑effectiveness ratio (ICER)

Page 51 Extracted Terms:
- Heart Failure (HF)  
- HFrEF (Heart Failure with reduced Ejection Fraction)  
- HFpEF (Heart Failure with preserved Ejection Fraction)  
- Left Ventricular Ejection Fraction (LVEF)  
- New York Heart Association (NYHA) functional class III/IV  
- QRS duration (narrow QRS, <120 ms; 120–130 ms; non‑LBBB 120–149 ms)  
- Cardiac Resynchronization Therapy (CRT)  
- Implantable Cardioverter‑Defibrillator (ICD)  
- Baroreceptor Stimulation (carotid artery)  
- Vagus Nerve Stimulation (VNS)  
- Spinal Cord Stimulation (SCS)  
- Left Bundle Branch Block (LBBB) pacing  
- His Bundle pacing  
- Cardiac Contractility Modulation (CCM)  
- Coronary Artery Disease (CAD)  
- Revascularization  
- Coronary Artery Bypass Grafting (CABG)  
- Percutaneous Coronary Intervention (PCI)  
- Guideline‑Directed Medical Therapy (GDMT)  
- Left Ventricular (LV) dysfunction  
- Mechanical dyssynchrony (detected by echocardiography)  
- Mortality (all‑cause, cardiovascular, HF‑specific)  
- Hospitalization (all‑cause, cardiovascular, HF)  
- Quality of Life (QOL)  
- NT‑proBNP (biomarker for HF severity)

Page 52 Extracted Terms:
- Heart Failure (HF)  
- Heart Failure with Reduced Ejection Fraction (HFrEF)  
- Left Ventricular (LV) Dysfunction  
- Left Ventricular Ejection Fraction (EF)  
- Ischemic Cardiomyopathy  
- Coronary Artery Bypass Grafting (CABG)  
- Guideline‑Directed Medical Therapy (GDMT)  
- Left Ventricular End‑Systolic Dimension (LVESD)  
- Pulmonary Artery Systolic Pressure  
- Right Ventricular (RV) Failure  
- Pulmonary Hypertension  
- Valvular Heart Disease (VHD)  
- Severe Aortic Stenosis  
- Aortic Regurgitation  
- Mitral Regurgitation (MR) – secondary  
- Tricuspid Regurgitation (TR) – secondary  
- Transcatheter Aortic Valve Implantation (TAVI)  
- Transcatheter Aortic Valve Replacement (TAVR)  
- TAVR UNLOAD Trial  
- Transcatheter Mitral Valve Edge‑to‑Edge Repair (TEER) – MitraClip  
- COAPT Trial  
- MITRA‑FR Trial  
- Surgical Ventricular Remodeling  
- LV Remodeling (proportionate vs. disproportionate MR)  
- Multidisciplinary Heart Failure Team  
- Cardiac Imaging (including transesophageal echocardiography)

Page 53 Extracted Terms:
- Heart failure (HF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Secondary mitral regurgitation (MR)  
- Guideline‑directed medical therapy (GDMT)  
- Renin–angiotensin‑aldosterone system (RAAS) inhibition  
- Beta‑blockers  
- Biventricular pacing (cardiac resynchronization therapy)  
- Sacubitril‑valsartan  
- Effective regurgitant area (ERO)  
- Regurgitant volume (RVol)  
- Regurgitant fraction (RF)  
- Transcatheter edge‑to‑edge repair (TEER)  
- Left ventricular ejection fraction (LVEF)  
- Left ventricular end‑systolic diameter (LVESD)  
- Pulmonary artery systolic pressure (PASP)  
- Atrial fibrillation (AF)  
- Coronary artery bypass graft (CABG)  
- New York Heart Association (NYHA) class  
- COAPT trial  
- Mitral valve (MV)  
- Left ventricle (LV)  
- Mitral valve replacement (MV replacement)  
- Annuloplasty repair  
- Cardiology (expertise in heart failure management)  
- Shared decision‑making (for valve intervention)

Page 54 Extracted Terms:
- Heart failure (HF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Heart failure with mildly reduced ejection fraction (HFmrEF)  
- Left ventricular ejection fraction (LVEF)  
- Sodium‑glucose cotransporter‑2 inhibitors (SGLT2i)  
- Empagliflozin  
- β‑blockers (beta blockers)  
- Angiotensin‑converting enzyme inhibitors (ACEi)  
- Angiotensin receptor blockers (ARB)  
- Angiotensin receptor‑neprilysin inhibitors (ARNi)  
- Mineralocorticoid receptor antagonists (MRAs)  
- Spironolactone  
- Natriuretic peptides (BNP, NT‑proBNP)  
- Cardio‑vascular mortality  
- Heart‑failure hospitalization  
- EmpEROR‑Preserved study  
- PARAGON‑HF study  
- BBmeta‑HF (beta‑blockers meta‑analysis)  
- eGFR (estimated glomerular filtration rate)  
- Quality of life (QOL)  
- Symptomatic heart failure  
- Post‑hoc analyses  
- Subgroup analyses  
- Composite endpoint (HF hospitalization or cardiovascular death)

Page 55 Extracted Terms:
**Key heart‑disease terms extracted from the text**

1. Heart failure (HF)  
2. Heart failure with reduced ejection fraction (HFrEF)  
3. Heart failure with mid‑range ejection fraction (HFmrEF)  
4. Heart failure with preserved ejection fraction (HFpEF)  
5. Left ventricular ejection fraction (LVEF)  
6. Left ventricular end‑diastolic volume (LVEDV)  
7. Natriuretic peptides (BNP, NT‑proBNP)  
8. Global cardiovascular health management therapy (GDMT)  
9. Candesartan (anthro‑study CHARM)  
10. Spirontolactone (TOPCAT)  
11. Aldosterone antagonist therapy  
12. Sodium–glucose cotransporter‑2 inhibitors (SGLT2i)  
13. Mineralocorticoid receptor antagonists (MRAs)  
14. Angiotensin‑receptor blocker (ARB)  
15. Angiotensin‑receptor neprilysin inhibitor (ARNi)  
16. Nitrates (pharmacologic therapy)  
17. Phosphodiesterase‑5 inhibitors  
18. Atrial fibrillation (AF) management  
19. Diuretics and decongestion strategies  
20. Coronary artery disease (CAD)  
21. Sarcoidosis  
22. Amyloidosis  
23. Kansas City Cardiomyopathy Questionnaire (KCCQ)  
24. Cardiocardiomyopathy relapse  
25. Cardiovascular death, cardiovascular mortality  
26. Heart‑failure hospitalization  
27. Reduced mortality in heart failure trials (CHA‑RM, TOPCAT)  
28. LVEF trajectories and monitoring  
29. Structural heart disease (Stage C HF)  
30. Relapse/recurrence of heart failure  
31. Blood pressure targets/management in HF  
32. Hypertension in HFpEF  

These terms capture the main cardiovascular conditions, therapeutic agents, clinical measures, and relevant research references discussed in the guideline excerpt.

Page 56 Extracted Terms:
- Heart failure (HF)  
- Heart failure with preserved ejection fraction (HFpEF)  
- Left ventricular ejection fraction (LVEF)  
- Natriuretic peptides (BNP, NT‑proBNP)  
- Diuretics  
- Amyloidosis (cardiac)  
- Hypertension  
- Diabetes mellitus  
- Obesity  
- Coronary artery disease (CAD)  
- Chronic kidney disease (CKD)  
- Atrial fibrillation (AF)  
- Blood pressure control / management  
- Renin–angiotensin–aldosterone system (RAAS) antagonists  
  - Angiotensin‑converting enzyme inhibitors (ACEi)  
  - Angiotensin receptor blockers (ARB)  
  - Mineralocorticoid receptor antagonists (MRA)  
  - Angiotensin receptor‑neprilysin inhibitors (ARNi)  
- β‑blockers  
- Sodium‑glucose cotransporter‑2 inhibitors (SGLT2i)  
  - Empagliflozin (EMPEROR‑Preserved trial)  
- Empa‑Cardio (context of SGLT2i trials)  
- SPRINT (Systolic Blood Pressure Intervention) trial  
- AHA/ACC/HFSA Heart Failure Guideline (2022)  
- Heart failure mortality  
- Heart failure hospitalizations  
- Quality of life (QOL)  
- Estimated glomerular filtration rate (eGFR)  
- Chronic heart failure  
- Cardiovascular events  
- Rhythm and rate control in AF  
- Clinical practice guideline for hypertension  
- Comprehensive AF care in HFpEF  
- Coronary artery disease management in HFpEF  
- Exercise intolerance (chronotropic incompetence)  

These are the principal terms related to heart disease that appear in the provided guideline excerpt.

Page 57 Extracted Terms:
- Heart failure (HF)  
- Heart failure with preserved ejection fraction (HFpEF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Atrial fibrillation (AF)  
- β‑blockers (e.g., bisoprolol)  
- Digoxin  
- Mineralocorticoid receptor antagonists (MRAs) – spironolactone  
- N‑terminal pro–brain natriuretic peptide (NT‑proBNP)  
- Hyperkalemia  
- Renal function / creatinine  
- Estimated glomerular filtration rate (eGFR)  
- Potassium levels  
- Renin–angiotensin–aldosterone system (RAAS) inhibition  
- Angiotensin receptor blockers (ARBs) – candesartan, valsartan  
- Angiotensin receptor neprilysin inhibitor (ARNi) – sacubitril‑valsartan  
- TOPCAT trial  
- CHARM‑Preserved trial  
- PARAMOUNT‑HF trial  
- PARAGON‑HF trial  
- Left‑ventricular ejection fraction (LVEF)  
- Diastolic function  
- Pulmonary congestion  
- Exercise tolerance  
- Nitrate therapy  
- Cardiovascular death  
- Heart‑failure hospitalization  
- Composite endpoints (e.g., cardiovascular death or HF hospitalization)

Page 58 Extracted Terms:
- Heart failure with preserved ejection fraction (HFpEF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Nitrates (e.g., isosorbide mononitrate)  
- Phosphodiesterase‑5 inhibition (e.g., sildenafil)  
- NT‑proBNP  
- Cardiac amyloidosis  
- Transthyretin amyloidosis (ATTR)  
- ATTR wt (wild‑type ATTR)  
- ATTR v (variant ATTR)  
- Light‑chain amyloidosis (AL‑CM)  
- Serum monoclonal light chains  
- Serum free light chains (FLC)  
- Immunofixation electrophoresis (IFE)  
- Bone scintigraphy  
- 99mTc‑PYP scan (technetium‑99m pyrophosphate)  
- LV wall thickness ≥ 14 mm  
- Electrocardiogram QRS voltage  
- Apical sparing of LV longitudinal strain  
- LV longitudinal strain  
- Late gadolinium enhancement on cardiac MRI  
- Cardiac MRI  
- Aortic stenosis  
- Carpal tunnel syndrome  
- Lumbar spinal stenosis  
- Autonomic neuropathy  
- Sensory polyneuropathy  
- Peak VO₂  
- Exercise tolerance  
- Oxygen consumption  
- Dyspnea  
- Fatigue  
- Chest pain  
- Quality of life (QOL)  
- NEAT‑HFpEF trial  
- RELAX trial  

Page 59 Extracted Terms:
**Key heart‑disease related terms extracted**

- ATTR-CM (transthyretin amyloid cardiomyopathy)  
- ATTRv (variant transthyretin amyloidosis)  
- ATTRwt (wild‑type transthyretin amyloidosis)  
- Amyloid cardiomyopathy (AL‑CM)  
- Atrial fibrillation (AF)  
- Congestive heart failure (CHF)  
- Hypertension  
- Diabetes mellitus  
- Stroke  
- Transient ischemic attack (TIA)  
- Vascular disease  
- Sex category (as part of CHA2DS2‑VASc score)  
- ECG (electrocardiogram)  
- H/CL (heart to contralateral chest ratio)  
- HFrEF (heart failure with reduced ejection fraction)  
- IFE (immunofixation electrophoresis)  
- MRI (magnetic resonance imaging)  
- NYHA (New York Heart Association) classification  
- PYP (pyrophosphate) scintigraphy  
- Tc (technetium) labeling  
- TTR (transthyretin protein)  
- Genetic sequencing of the TTR gene  
- Genetic counseling  
- Family screening  
- Inotersen (drug for ATTRv)  
- Patisiran (drug for ATTRv)  
- AHA/ACC/HFSA Heart Failure Guideline 2022  

These terms capture the central clinical concepts, diagnostic methods, therapeutic agents, and guideline frameworks discussed in the text.

Page 60 Extracted Terms:
- Cardiac amyloidosis  
- ATTR‑CM (transthyretin cardiac amyloidosis)  
- Wild‑type transthyretin (ATTRwt)  
- Variant transthyretin (ATTRv)  
- Transthyretin tetramer stabilizer  
- Tafamidis  
- New‑tarry “high‑value” cardiac therapeutic economics (QALY)  
- Heart failure (HF)  
- New York Heart Association (NYHA) class I–III symptoms  
- G‑protein‑coupled receptor blockers (ARNi)  
- Angiotensin‑converting enzyme inhibitor (ACEi)  
- Angiotensin‑receptor blocker (ARB)  
- β‑blocker  
- Implantable cardio‑defibrillator (ICD)  
- Cardiac resynchronization therapy (CRT)  
- Autonomic dysfunction in amyloidosis  
- Disease‑modifying therapies for ATTR – TTR silencers (inotersen, patisiran)  
- Disease‑modifying therapies – TTR stabilizers (diflunisal, tafamidis)  
- Disease‑modifying therapies – TTR disruptors (doxycycline, tauroursodeoxycholic acid [TUDCA], epigallocatechin‑3‑galate [EGCG])  
- Light‑chain (AL) amyloidosis  
- Cardiac involvement in AL amyloidosis  
- Intracardiac thrombosis  
- Atrial fibrillation (AF)  
- Anticoagulation (direct oral anticoagulants [DOACs])  
- CHA₂DS₂‑VASc score  
- Left ventricular (LV) mass  
- End‑stage renal function (eGFR < 25 mL/min/1.73 m²)  
- Cardiovascular morbidity and mortality  
- Cardiovascular‑related hospitalization  
- Economic value of cardiovascular therapies (cost per QALY)

Page 61 Extracted Terms:
- Heart Failure (HF)  
- Advanced Heart Failure (Stage D)  
- LVAD (left ventricular assist device)  
- Cardiac transplantation  
- Palliative care  
- Inotropes (intravenous)  
- NYHA (New York Heart Association) class  
- Natriuretic peptides (BNP/NT‑proBNP)  
- End‑organ dysfunction  
- Ejection fraction (EF / LVEF)  
- Low EF threshold (≤35 %, ≤30 % in ESC criteria)  
- High EF with diastolic dysfunction (≥40 %)  
- Hospitalization for HF  
- Edema despite diuretics  
- Low systolic blood pressure (≤90 mm Hg)  
- Elevated heart rate  
- Prognostic medications (GDMT)  
- GDMT (guideline‑directed medical therapy)  
- INTERMACS profiles  
- ESC (European Society of Cardiology)  
- ATTR‑CM (transthyretin amyloid cardiomyopathy)  
- Atrial fibrillation (AF)  
- Warfarin  
- Left atrial appendage closure devices  
- Bleeding risk in HF patients  
- AL amyloidosis  
- Hemostatic abnormalities (coagulation factor deficiencies, hyperfibrinolysis, platelet dysfunction)  
- TTR amyloidosis (transthyretin)  
- Cardiogenic shock  
- Malignant arrhythmias  
- 6‑minute walk test distance  
- Peak VO₂ (cardiac exercise capacity)

Page 62 Extracted Terms:
**Key heart‑disease terms extracted from the text**

- Heart failure (HF)  
- Advanced heart failure (Adv. HF)  
- Hyponatremia  
- Fluid restriction  
- Congestive symptoms  
- Diuretic‑refractory congestion  
- New York Heart Association (NYHA) functional classification  
- HFrEF – Heart Failure with reduced ejection fraction  
- HFpEF – Heart Failure with preserved ejection fraction  
- Quality of life (QOL)  
- INTERMACS profiles (cardiogenic shock, inotropic dependence, etc.)  
- Cardiogenic shock  
- Inotropic/pressor support  
- Orthopnea  
- Shortness of breath / dyspnea  
- Ascites  
- Lower extremity edema  
- Implantable cardioverter‑defibrillator (ICD)  
- Intravenous diuretics  
- Ultrafiltration  
- Mechanical circulatory support (e.g., temporary circulatory support devices)  
- Arrhythmia (ventricular tachyarrhythmia, ICD shock)  
- Clinical outcomes  
- Patient‑reported outcomes  
- Nutritional counseling (cachexia, malnutrition)  
- Sodium restriction  
- Decompensated heart failure  
- Hospitalization & mortality rates (related to HF management)

Page 63 Extracted Terms:
**Key heart‑disease terms extracted from the guideline text**

- Heart Failure (HF)  
- Advanced (Stage D) HF  
- Guideline‑Directed Medical Therapy (GDMT)  
- Mechanical Circulatory Support (MCS)  
- Cardiac transplantation  
- Inotropic support / inotropes  
- Continuous intravenous inotropic therapy  
- Palliative inotropic therapy  
- Phosphodiesterase inhibition  
- Adrenergic receptor stimulation  
- Dopaminergic receptor stimulation  
- Calcium sensitization  
- End‑organ hypoperfusion  
- Systolic dysfunction  
- Low blood pressure (SBP ≤ 90 mm Hg)  
- Low cardiac index  
- New York Heart Association (NYHA) functional class III–IV  
- Peak VO₂ (< 14 mL/kg/min or < 50 % predicted)  
- 6‑minute walk test distance (< 300 m or inability to walk 1 block)  
- Renin–Angiotensin–Aldosterone System inhibitors (RAASi)  
- Beta‑blockers  
- Diuretics (furosemide, metolazone)  
- Diuretic escalation (> 160 mg/day furosemide equivalent)  
- Ventricular arrhythmias / ICD shocks  
- Cardiac cachexia  
- Hyponatremia (serum sodium < 134 mEq/L)  
- Declining renal function  
- Declining hepatic function  
- Pulmonary hypertension / right HF  
- Predicted 1‑year mortality (> 20 %)  
- MAGGIC (Meta‑analysis Global Group in Chronic Heart Failure)  
- SHFM (Seattle Heart Failure Model)  
- Cardiac Resynchronization Therapy (CRT)  
- Inotrope dependence  
- Low peak VO₂ (< 14–16 mL/kg/min)  
- End‑organ dysfunction due to low cardiac output  
- Irreversible hepatic disease  
- Irreversible renal disease  
- Irreversible neurological disease  
- Age > 80 years (destination therapy)  
- Peripheral vascular disease (PVD)  
- Neurohormonal antagonists  
- Social / psychosocial limitations  
- Medication non‑adherence  
- Active systemic infection  
- Malnutrition / obesity  
- Musculoskeletal limitations  
- Active malignancy  
- Substance abuse  
- Cognitive / psychiatric impairment  
- Lack of social support  
- Implantable cardioverter‑defibrillator (ICD)  

These terms capture the key concepts and clinical markers related to heart disease discussed in the guideline excerpt.

Page 64 Extracted Terms:
- Heart Failure (HF)  
- Heart Failure with Reduced Ejection Fraction (HFrEF)  
- Advanced HFrEF  
- NYHA Class IV  
- Inotropes  
- Bridge Therapy  
- Heart Transplantation  
- Mechanical Circulatory Support (MCS)  
- Durable LVAD  
- Durable MCS  
- Temporary MCS  
- Percutaneous Ventricular Assist Devices (VAD)  
- Extracorporeal Ventricular Assist Devices  
- Bridge to Recovery  
- Bridge to Decision  
- Palliation  
- Arrhythmias  
- Inappropriate Shocks  
- ICD (Implantable Cardioverter‑Defibrillator)  
- Beta Blockers  
- Myocardial Oxygen Demand  
- Pulmonary Hypertension  
- End‑Organ Perfusion  
- Mortality  
- Survival  
- Quality of Life (QOL)  
- Functional Status  
- GDMT (Guideline‑Directed Medical Therapy)  
- Hemodynamic Compromise  
- Shock  
- Intravenous Inotropic Agents  
- Dopamine  
- Dobutamine  
- Milrinone  
- Epinephrine  
- Norepinephrine  
- Adrenergic Agonists  
- Phosphodiesterase 3 Inhibitors (PDE3)  
- Vasopressors  
- Monoamine Oxidase Inhibitor (MAO‑I)

Page 65 Extracted Terms:
- Heart failure (HF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Pump mechanisms (mechanically assisted circulatory support)  
- Ventricular assist devices (VADs) – specifically Left Ventricular Assist Devices (LVADs)  
- Mechanical circulatory support (MCS)  
- Durable MCS / Destination therapy  
- Temporary MCS / Bridge therapy  
- Inotropic therapy (intravenous inotropes)  
- N-terminal pro–B-type natriuretic peptide (NT‑proBNP) – (implicit in HF assessment)  
- New York Heart Association (NYHA) class IV  
- INTERMACS profiles (1–7, Interagency Registry for Mechanically Assisted Circulatory Support)  
- Pulmonary hypertension  
- Central venous pressure  
- Coagulopathy / anticoagulation management  
- Pump thrombosis  
- Hemolysis  
- Ischemic neurologic events  
- Anticoagulation monitoring (INR levels)  
- Glycemic‑diabetes‑management therapy (GDMT) – (implicit in HF treatment)  
- Cardiogenic shock  
- Cardiac transplantation  
- Bridge‑to‑transplant (BTT)  
- Destination therapy (DT)  
- Quality‑adjusted life‑year (QALY)  
- Cost‑effectiveness / incremental cost‑effectiveness ratio (ICER)  
- Hospital readmission / re‑hospitalization  
- Percutaneous lead & external power supplies (device complications)  
- Multidisciplinary heart‑failure team (cardiologist, surgeon, nurse, pharmacist, dietitian, palliative specialist, social worker)

Page 66 Extracted Terms:
**Key Terms Related to Heart Disease**

- Advanced heart failure (HF)  
- Guideline‑Directed Medical Therapy (GDMT)  
- Cardiac transplantation  
- Left Ventricular Assist Device (LVAD)  
- Mechanical Circulatory Support (MCS)  
- Stage D heart failure  
- Survival benefit  
- Quality of life (QOL)  
- Donor allocation policy  
- Waitlist mortality  
- Temporary circulatory support devices  
- Multiorgan transplantation  
- Congestion assessment  
- Perfusion adequacy  
- Cardiopulmonary exercise testing (CPET)  
- Pulmonary hypertension  
- Congenital heart disease  
- Hypertrophic cardiomyopathy  
- Muscular dystrophy (cardiac involvement)  
- Sarcoidosis (cardiac involvement)  
- Amyloidosis (cardiac involvement)  
- Inotrope‑dependent advanced HF  
- Cost‑effectiveness analysis  
- Bridge‑to‑transplant strategy  
- Bridge‑to‑decision strategy  
- Destination therapy strategy  
- Reversible factor management  
- Volume status optimization  
- Functional status improvement  
- Health‑related quality of life  
- Refractory heart failure  
- Post‑transplant outcomes  

These terms encompass the principal clinical conditions, therapeutic modalities, assessment tools, and outcome measures discussed in the guideline excerpts.

Page 67 Extracted Terms:
- Cardiogenic shock  
- Heart failure (HF)  
- Acute coronary syndrome (ACS)  
- Revascularization  
- Ischemia  
- Arrhythmia / ventricular arrhythmia  
- Tricuspid regurgitation (TR)  
- Preserved left ventricular ejection fraction (LVEF)  
- Reduced EF / HFrEF  
- HFpEF (heart failure with preserved ejection fraction)  
- Pulmonary edema  
- Hypertension / uncontrolled hypertension  
- Right‑sided filling pressures  
- Left‑sided filling pressures  
- Natriuretic peptides (e.g., BNP, NT‑proBNP)  
- Congestion / decongestion  
- Hypoperfusion (resting, low pulse pressure)  
- Neurohormonal antagonists (e.g., ACEi, ARBs, beta‑blockers, MRAs)  
- Diuretic therapy  
- Guideline‑directed medical therapy (GDMT)  
- Cardiac resynchronization therapy (CRT)  
- Implantable cardioverter‑defibrillator (ICD)  
- Anticoagulation for atrial fibrillation (AF)  
- Anemia  
- Hyper‑ or hypothyroidism  
- Non‑steroidal anti‑inflammatory drug (NSAID) use  
- Medications with negative inotropic effect (e.g., verapamil)  
- Pulmonary or urinary tract infections (as precipitants of HF)  
- Social determinants of health (impact on HF management)

Page 68 Extracted Terms:
- Heart failure with reduced ejection fraction (HFrEF)  
- Guideline‑Directed Medical Therapy (GDMT)  
- Angiotensin‑converting enzyme inhibitor (ACEi)  
- Angiotensin receptor blocker (ARB)  
- Angiotensin receptor‑neprilysin inhibitor (ARNi)  
- Beta‑blocker (β‑blocker)  
- Mineralocorticoid receptor antagonist (MRA)  
- Diuretic therapy  
- Hospitalization for heart failure  
- Post‑discharge mortality  
- Hospital readmission  
- Renal function (e.g., serum creatinine, eGFR)  
- Systolic blood pressure (SBP)  
- Estimated glomerular filtration rate (eGFR)  
- Acute kidney injury (AKI)  
- Cardiac output  
- Cardiogenic shock  
- Atrioventricular (AV) block  
- Angioedema  
- Oral GDMT  
- Target GDMT dose  
- Clinical stability  
- Optimal dosing  
- Mortality risk  
- Rehospitalization risk  
- OPTIMIZE‑HF study  
- CHAMP‑HF registry  
- PARADIGM‑HF trial  
- SENIORS trial  
- Val‑HeFT trial  
- Carvedilol  
- Nebivolol  
- Spironolactone  
- Sacubitril‑valsartan  
- AHA/ACC/HFSA Heart Failure Guideline  
- Get With The Guidelines–Heart Failure (GWTG‑HF) registry  
- COACH study  
- ARIC study (Atherosclerosis Risk in Communities)  
- AHA (American Heart Association)  
- ACC (American College of Cardiology)  
- HFSA (Heart Failure Society of America)  
- In‑hospital mortality  
- Short‑term mortality  
- Long‑term mortality  
- Volume overload  
- Suboptimal dose of GDMT


Page 69 Extracted Terms:
- AHA/ACC/HFSA Heart Failure Guideline  
- Carvedilol  
- Beta blockers  
- ACEi‑ARB (angiotensin‑converting‑enzyme inhibitor / angiotensin‑II receptor blocker)  
- MRA therapy (mineralocorticoid‑receptor antagonist)  
- Spironolactone  
- ARNi (angiotensin receptor‑neprilysin inhibitor)  
- NT‑proBNP (N‑terminal pro‑B‑type natriuretic peptide)  
- Worsening renal function  
- Hyperkalemia  
- Symptomatic hypotension  
- Angioedema  
- Oral GDMT (guideline‑directed medical therapy)  
- HFrEF (heart failure with reduced ejection fraction)  
- HF readmission / rehospitalization  
- Decongestion strategy  
- Loop diuretics (intravenous)  
- Thiazide diuretic (add‑on)  
- Furosemide (oral loop diuretic)  
- GWTG‑HF (Get With The Guidelines‑Heart Failure)  
- COACH trial  
- PIONEER‑HF trial  
- ARIC study  
- SOLOIST‑WHF trial  
- CHAMP‑HF study  
- 30‑day mortality  
- 1‑year mortality  
- Target doses of beta blockers, ACEi‑ARB, ARNi, MRA  
- Monotherapy, dual therapy, triple therapy (GDMT combinations)  
- Clinical evidence of congestion  
- Symptoms and rehospitalizations (mortality)

Page 70 Extracted Terms:
- Heart failure (HF)
- Heart failure with reduced ejection fraction (HFrEF)
- Congestion
- Decompensated heart failure
- Acute heart failure
- Pulmonary congestion
- Dyspnea
- Right atrial pressure
- Tricuspid regurgitation (TR)
- Elevated filling pressures
- Hypoperfusion
- Renal dysfunction
- Serum electrolytes
- Urea nitrogen
- Creatinine
- Fluid input/output monitoring
- Standing body weight
- Intravenous loop diuretics
- Diuretic dose escalation
- Serial doubling of loop diuretics
- Nephron blockade
- Thiazide diuretic
- Ultrafiltration
- Intravenous nitroglycerin
- Intravenous nitroprusside
- ACE inhibitors (ACEi)
- Angiotensin receptor blockers (ARBs)
- Mineralocorticoid receptor antagonists (MRAs)
- Beta‑blockers
- ARNI (angiotensin receptor‑neprilysin inhibitor)
- SGLT2 inhibitors (SGLT2i)
- Inotropic support
- Cardiogenic shock
- Left ventricular ejection fraction (LVEF)
- Low‑dose dopamine therapy
- Ejection fraction (EF)
- Diuretic optimization
- Hospital readmission
- Mortality
- Clinical signs of congestion
- Hospital discharge criteria
- Continuous infusion vs. bolus diuretic administration
- Fluid removal rate
- Vascular access complications
- Hypotension (systemic and pulmonary)
- Hypotensive management in HF
- Renal impairment monitoring
- Fluid overload
- Diuretic therapy monitoring
- Guideline‑directed medical therapy for HF
- CARRESS trial
- ROSE trial
- DOSE trial
- Parenteral vasodilator therapy
- Inotropic support trials
- Cardiogenic shock management
- Fluid balance management in HF
- Electrolyte monitoring in diuretic therapy

Page 71 Extracted Terms:
- Heart failure (HF)
- Acute decompensated heart failure
- Pulmonary congestion
- Loop diuretics
- Hypertension
- Coronary ischemia
- Mitral regurgitation (MR)
- Intravenous nitroglycerin
- Tachyphylaxis
- Sodium nitroprusside
- Hypotension
- Invasive hemodynamic monitoring
- Arterial line
- Intensive care setting
- Thiocyanate toxicity
- Cyanide toxicity
- Renal insufficiency
- Hepatic disease
- Severe mitral valve (MV) regurgitation
- Left ventricular (LV) dysfunction
- Venous thromboembolism (VTE)
- VTE prophylaxis
- Low‑molecular‑weight heparin
- Unfractionated heparin
- Fondaparinux
- Direct oral anticoagulants (DOACs)
- Enoxaparin
- Rivaroxaban
- Aspirin
- Bleeding complications
- Renal function (creatinine clearance)
- Obesity (dose adjustment)
- Cardiogenic shock
- Intravenous inotropic support
- Systemic perfusion
- End‑organ performance
- Mechanical circulatory support (MCS)
- Multidisciplinary shock team
- Pulmonary artery (PA) line
- Pulmonary artery pressure
- Pulmonary embolism
- Deep vein thrombosis (DVT)
- Antithrombotic drugs
- Acute illnesses
- Severe respiratory diseases  

Page 72 Extracted Terms:
- Cardiogenic shock  
- Cardiac output  
- End‑organ dysfunction  
- Hypotension  
- Systolic blood pressure (SBP)  
- Mean arterial pressure (MAP)  
- End‑organ hypoperfusion  
- Acute decompensation of chronic heart failure (HF)  
- Acute myocardial dysfunction without prior HF  
- Survivors of cardiac arrest  
- Acute myocardial infarction (MI)  
- Revascularization  
- Invasive hemodynamic assessment  
- Mechanical circulatory support (MCS)  
- Pharmacologic therapies  
- Cardiac index  
- Pulmonary capillary wedge pressure (PCW)  
- Pulmonary artery pulse index (PAPi)  
- Central venous pressure (CVP)  
- Cardiac power output (CPO)  
- Shock index (HR/SBP)  
- Right‑ventricular (RV) shock  
- Pulmonary artery systolic pressure (PASP)  
- Pulmonary artery diastolic pressure (PADP)  
- Brain natriuretic peptide (BNP)  
- Lactate (elevated lactate)  
- Urine output (reduced urine output)  
- Mentation (altered mentation)  
- Cold extremities / livedo reticularis  
- Metabolic complications (acidosis, liver function tests)  
- SCAI cardiogenic shock stages (A–E)  
- Hemodynamic criteria for shock (SBP <90 mm Hg, MAP <60 mm Hg, CI <2.2 L/min/m², PCW >15 mm Hg, CPO <0.6 W)  
- Shock index >1.0  
- Pulmonary artery pulsatility index (PAPi) <1.0  
- Right‑ventricular measures (CVP >15 mm Hg, CVP‑PCW >0.6)  
- Cardiogenic shock diagnostic criteria  
- Acute coronary syndrome (ACS)  
- Cardiac arrest 
- Cardiac resuscitation (CPR) 
- Pulseless electrical activity (PEA) 
- Ventricular tachycardia (VT) 
- Ventricular fibrillation (VF)

Page 73 Extracted Terms:
- Cardiogenic shock  
- Heart failure (HF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Inotropic support  
- Mechanical circulatory support (MCS)  
- Invasive hemodynamic monitoring  
- Pulmonary artery catheterization (PA catheter)  
- End‑organ perfusion / end‑organ dysfunction  
- Left ventricular assist device (LVAD)  
- Heart transplant  
- Revascularization (e.g., percutaneous coronary intervention)  
- ST‑elevation myocardial infarction (STEMI)  
- Myocarditis  
- Arrhythmias  
- Vasopressors  
- Shock team  
- Multidisciplinary care teams (HF, critical care, interventional cardiology, cardiac surgery)  
- Palliative care  
- Transitional care / discharge planning  
- Hospitalization / readmission  
- Evidence‑based therapy  
- Clinical guidelines (AHA/ACC/HFSA)  
- Hemodynamic benefits / data  
- Cardiac output  
- Blood pressure  
- Organ hypoperfusion  
- Pharmacologic therapy  
- Mechanical therapy  
- Temporary circulatory support devices  
- Bridge‑to‑decision strategies  
- Durable LVAD or transplant pathways  
- End‑organ malperfusion  
- Risk assessment and therapeutic decision‑making  
- Early follow‑up (within 7 days of discharge)  
- Benchmarking to performance measures  
- Quality of care metrics  
- Cardiovascular disease management programs  
- Clinical statements and recommendations  
- Hemodynamics (hemodynamic monitoring, monitoring of pulmonary pressures, systemic vascular resistance)

Page 74 Extracted Terms:
**Heart‑disease–related terms extracted from the text**

1. Heart failure (HF)  
2. HFrEF (heart‑failure with reduced ejection fraction)  
3. HFpEF (heart‑failure with preserved ejection fraction)  
4. Guideline‑directed medical therapy (GDMT)  
5. Decompensation (HF decompensation)  
6. Readmission / rehospitalization  
7. Multidisciplinary care / team  
8. Case management (case manager, nurse coordinator)  
9. Cardiologists  
10. HF nurses  
11. Primary‑care clinicians  
12. Pharmacists  
13. Dietitians  
14. Social workers  
15. Community health workers  
16. Disease‑management programs  
17. Self‑management  
18. Medication optimization / reconciliation  
19. Device management (pacemakers, defibrillators, etc.)  
20. Weight monitoring  
21. Exercise counseling / rehabilitation  
22. Dietary advice / restrictions  
23. Cardiac rehabilitation  
24. Discharge medications  
25. Follow‑up appointments  
26. Transition of care  
27. Performance‑measure benchmarks (real‑time feedback)  
28. Quality‑improvement programs  
29. Electronic point‑of‑care reminders (for GDMT)  
30. Outpatient follow‑up  
31. Early post‑discharge follow‑up  
32. Diuretics (titration, adjustment)  
33. Electrolytes monitoring  
34. Safety laboratory checks  
35. Renal dysfunction (comorbidity)  
36. Pulmonary disease (comorbidity)  
37. Diabetes (comorbidity)  
38. Mental health (comorbidity)  
39. Substance‑use disorders (comorbidity)  
40. Psychosocial support (limitations)  
41. Health literacy (impaired)  
42. Cognitive impairment  
43. Additional surgical or device therapy  
44. Palliative‑care referral  
45. Hospice enrollment

These are the key terms that relate to heart disease management and care outlined in the provided guideline excerpts.

Page 75 Extracted Terms:
- Heart failure (HF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Neuro‑hormonal guideline‑directed medical therapy (GDMT)  
- Intravenous iron replacement for iron deficiency in HF  
- Erythropoietin‑stimulating agents (contraindicated in HF)  
- Hypertension  
- Ischemic heart disease (IHD)  
- Diabetes mellitus type 2  
- Anemia  
- Chronic kidney disease (CKD)  
- Chronic obstructive pulmonary disease (COPD)  
- Atrial fibrillation (AF)  
- Sleep‑disordered breathing  
- Obstructive sleep apnea (OSA)  
- Central sleep apnea (CSA)  
- Continuous positive airway pressure (CPAP)  
- Adaptive servo‑ventilation (avoided in CSA)  
- Sodium‑glucose co‑transporter‑2 inhibitors (SGLT2i)  
- Telemedicine/virtual visits for chronic HF management  
- Functional status improvement  
- Quality of life (QoL) enhancement  
- Multimorbidity in HF (≥2 chronic conditions)  
- Morbid obesity  
- Frailty  
- Malnutrition  
- Depression (impacting HF prognosis)

Page 76 Extracted Terms:
- Heart Failure (HF)  
- Heart Failure with Reduced Ejection Fraction (HFrEF)  
- Angiotensin‑Converting Enzyme Inhibitors (ACEi)  
- Angiotensin Receptor Blockers (ARB)  
- Sodium‑Glucose Cotransporter‑2 Inhibitors (SGLT2i)  
- Cardiac Resynchronization Therapy (CRT)  
- Valvular Heart Disease (VHD)  
- Atrial Fibrillation (AF)  
- New York Heart Association (NYHA) Classification  
- Left Ventricular Ejection Fraction (LVEF)  
- CHA₂DS₂‑VASc Score (stroke‑risk assessment in AF)  
- Continuous Positive Airway Pressure (CPAP) – for sleep apnea related to HF  
- Ferric Carboxymaltose – iron therapy used in HF with iron deficiency  
- Anemia – frequently present and prognostic in HF  
- Chronic Kidney Disease (CKD) – closely linked comorbidity impacting HF management  

(These terms capture the core heart‑disease concepts, associated therapies, diagnostic metrics, and key comorbidities discussed in the guideline text.)

Page 77 Extracted Terms:
**Key Terms Related to Heart Disease**

- Heart Failure (HF)  
- Chronic Heart Failure  
- Heart Failure with reduced Ejection Fraction (HFrEF)  
- Left Ventricular Ejection Fraction (EF)  
- EF < 50 %  
- EF ≤ 40 %  
- New York Heart Association (NYHA) Class II, III, IV  
- 6‑minute walk test  
- Quality of Life (QOL)  
- Iron Deficiency Anemia  
- Oral iron supplementation  
- Intravenous iron therapy  
- Ferric carboxymaltose  
- IRONOUT HF trial  
- AFFIRM‑AHF trial  
- Cardiovascular death  
- Hospitalization for heart failure  
- Anemia in heart failure  
- Erythropoietin  
- Erythropoietin‑stimulating agents (ESA)  
- Darbepoetin α  
- Thrombotic events (stroke, etc.)  
- Hypertension  
- Systolic blood pressure (SBP) < 120 mm Hg  
- Low blood pressure in HFrEF  
- Antihypertensive therapy  
- Guideline‑directed medical therapy (GDMT)  
- ACC/AHA hypertension guidelines  
- Sleep disorders in heart failure  
- Daytime sleepiness  
- Obstructive sleep apnea (OSA)  
- Central sleep apnea (CSA)  
- Sleep study (polysomnography)  
- Continuous positive airway pressure (CPAP)  
- Nocturnal oxygenation  
- B-type natriuretic peptide (BNP)  
- Adaptive servo‑ventilation  
- Mortality (all‑cause, cardiovascular)  
- Diabetes mellitus  
- Sodium‑glucose cotransporter‑2 inhibitors (SGLT2i)  
- Canagliflozin  
- Dapagliflozin  
- Empagliflozin  
- Sotagliflozin  
- Major adverse cardiovascular events (MACE)  
- DAPA‑HF trial  
- EMPEROR‑Reduced trial  
- All‑cause death  
- Clinical guidelines (AHA/ACC/HFSA Heart Failure Guideline, ACC/AHA hypertension guideline)  
- Clinical trials  
- Meta‑analysis  

These terms capture the principal concepts, conditions, interventions, and outcomes discussed in the text regarding heart disease.

Page 78 Extracted Terms:
- Heart failure  
- HF  
- Chronic heart failure  
- Heart failure with preserved ejection fraction (HFpEF)  
- Left ventricular ejection fraction (LVEF)  
- Atrial fibrillation (AF)  
- Permanent AF  
- Persistent AF  
- Paroxysmal AF  
- AF ablation  
- Antiarrhythmic therapy  
- Amiodarone  
- Atrioventricular nodal ablation  
- Cardiac resynchronization therapy (CRT) device  
- Permanent pacemaker  
- CHA₂DS₂‑VASc score  
- Anticoagulant therapy  
- Direct oral anticoagulants (DOAC)  
- Warfarin  
- Apixaban  
- Rivaroxaban  
- Edoxaban  
- Dabigatran  
- SGLT2 inhibitors (SGLT2i)  
- Dapagliflozin  
- Empagliflozin  
- Hospitalization for heart failure  
- Mortality  
- Stroke prevention  
- Intracranial bleeding  
- Major bleeding  
- Genitourinary infections (risk factor)  
- Renal outcomes  
- NYHA functional class  
- Ventricular rate control  
- Rhythm control strategy  
- Catheter ablation (AF)  
- Cardiology guideline terminology  



Page 79 Extracted Terms:
- Heart Failure (HF)  
- Atrial Fibrillation (AF)  
- Rhythm control strategy  
- Rate control strategy  
- Catheter ablation  
- Implantable Cardioverter‑Defibrillator (ICD)  
- Cardiac Resynchronization Therapy (CRT)  
- Right‑Ventricular (RV) pacing  
- Left‑Ventricular–Based Cardiac Stimulation (PAVE)  
- Biventricular versus Right‑Ventricular Pacing (BLOCK‑HF)  
- Left Ventricular Ejection Fraction (LVEF)  
- New York Heart Association (NYHA) class II‑IV  
- Composite endpoint: death or rehospitalization  
- Hazard ratios and relative risk reductions (e.g., 49%, 56%)  
- CHA₂DS₂‑VASc score  
- Hypercoagulable state in HF  
- Stroke risk  
- Systemic embolism  
- Anticoagulation therapy  
- Clinical trial meta‑analysis of rhythm vs. rate control  
- Clinical statements and guidelines (AHA/ACC/HFSA 2022 HF Guideline)  
- Health disparities / vulnerable populations  
- Social determinants of health  
- Hypertension prevalence in Black patients  
- Polypharmacy, multimorbidity, cognitive decline, frailty  
- Women’s heart failure presentation and outcomes  
- Black patient HF incidence, hospitalization, mortality rates  
- Implicit bias training in healthcare  
- Implicit bias in clinical decision‑making  
- Genotype or race‑based cardiovascular risk  
- Clinical practice monitoring of health disparities  
- Multidisciplinary management strategies for HF  
- GDMT (guideline‑directed medical therapy)  
- Stroke registry data in HF with AF  
- HF as an independent risk factor for stroke, systemic embolism, mortality  

(Note: terms are grouped thematically but all are listed individually.)

Page 80 Extracted Terms:
**Key heart‑disease–related terms extracted from the text**

- Heart Failure (HF)  
- Heart Failure with preserved ejection fraction (HFpEF)  
- Heart Failure with reduced ejection fraction (HFrEF)  
- Guideline‑Directed Medical Therapy (GDMT)  
- Left Ventricular Ejection Fraction (LVEF)  
- Left Ventricular Assist Device (LVAD)  
- Chagas cardiomyopathy  
- Cardiovascular disease (CVD)  
- Transplant wait‑list mortality  
- Age‑adjusted HF mortality  
- Incident HF risk  
- Non‑ischemic HF  
- Ischemic HF  
- Social isolation  
- Caregiver support / caregiver stress  
- Low household income / low socioeconomic status  
- Neighborhood Deprivation Index (ADI)  
- Diabetes mellitus  
- Hypertension  
- Obesity  
- Anxiety  
- Depression  
- Female sex / women (sex‑specific differences)  
- Older adults (≥ 80 years, ≥ 65 years)  
- Low‑income populations  
- Black/African‑American populations  
- Hispanic/Latino populations  
- Asian and Pacific Islander populations  
- Native American and Alaskan Native populations  
- Framingham Heart Study (FHS)  
- Multi‑Ethnic Study of Atherosclerosis (MESA)  
- Get With The Guidelines (GWTG) registry  
- OPTMIZE‑HF registry (Organized Program To Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure)  
- AHA/ACC/HFSA Heart Failure Guideline  
- Hospitalization rates for HF  
- Quality of Life (QOL) measures  
- Mortality (short‑term, 1‑year, 5‑year, overall)  
- Hazard Ratio (HR)  
- Odds Ratio (OR)  
- Predictive value of cardiac biomarkers for incident HF  

These terms encompass the clinical conditions, therapies, risk factors, outcomes, population groups, and research/registry references that are central to heart disease discussion in the provided text.

Page 81 Extracted Terms:
**Key heart‑disease related terms**

- Heart failure (HF)  
- HF incidence  
- HF mortality  
- Heart transplantation  
- Cardiovascular risk factors  
- Cardiovascular complications of cancer therapy  
- Cardiotoxic anticancer therapies  
- Cardio‑oncology (practice of cardiovascular risk stratification in oncology)  
- Cardiomyopathy (including cancer‑therapy–related cardiomyopathy)  
- Left ventricular ejection fraction (LVEF)  
- LV dysfunction  
- Asymptomatic cardiomyopathy (EF < 50 %)  
- Cardiac troponin  
- Progressive heart failure  
- Advanced heart failure therapies  
- Beta‑blockers (β‑blockers)  
- Angiotensin‑converting enzyme inhibitors (ACEi)  
- Angiotensin‑II receptor blockers (ARB)  
- Cardiac function monitoring  
- Cardiac function baseline assessment  
- Cardiogenic shock  
- Primary prevention of drug‑induced cardiomyopathy  
- Early detection of cardiomyopathy  
- Multidisciplinary heart‑failure management  
- CVD (cardiovascular disease)  
- Integrated cardio‑oncology framework  
- Cardio‑vascular risk stratification  
- High‑quality, drug‑specific evidence for cardiotoxicity screening and monitoring  

These terms capture the core concepts and therapies related to heart disease discussed in the provided text.

Page 82 Extracted Terms:
**Key heart‑disease related terms extracted from the text**

- Heart failure (HF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Cardiotoxicity  
- Cancer‑therapy‑related cardiomyopathy  
- Cardiac dysfunction  
- Left ventricular ejection fraction (LVEF)  
- Neurohormonal blockade  
- Guideline‑directed medical therapy (GDMT)  
- Beta‑blockers  
- Angiotensin‑converting enzyme inhibitors (ACEi)  
- Angiotensin‑II receptor blockers (ARBs)  
- Immune‑checkpoint–related myocarditis  
- Anthracyclines  
- Alkylating agents  
- Antimicrotubule agents  
- Antimetabolites  
- Anti‑HER2 agents  
- Tyrosine‑kinase inhibitors  
- Immune‑checkpoint inhibitors  
- Protease inhibitors  
- Endocrine therapy  
- Chimeric antigen receptor (CAR‑T) cell therapy  
- Hematopoietic stem cell transplantation (HSCT)  
- Chest radiation therapy  
- Echocardiography  
- Cardiac monitoring  
- Cardiac imaging  
- Pre‑therapy LVEF assessment  
- Cardiac risk stratification  
- Cardiovascular disease (CVD)  
- Major adverse cardiovascular events (MACE)  
- Cardiac safety assessment  
- Standard heart‑failure therapies (e.g., diuretics, mineralocorticoid antagonists)  


These terms encompass the core concepts and modalities related to heart disease discussions within the provided clinical guideline excerpt.

Page 83 Extracted Terms:
**Key heart‑disease terms extracted**

- Heart failure  
- Cardiomyopathy  
- Cancer therapy‑related cardiomyopathy  
- Left ventricular ejection fraction (LVEF)  
- New York Heart Association (NYHA) class I–II  
- Angiotensin‑converting enzyme inhibitors (ACEi)  
- Angiotensin II receptor blockers (ARB)  
- β‑blockers  
- Spironolactone  
- Carvedilol  
- Nebivolol  
- Anthracyclines  
- Trastuzumab  
- Serial LVEF monitoring  
- Troponin  
- Natriuretic peptides  
- Coronary artery disease (CAD)  
- Hypertension  
- Diabetes mellitus  
- Preexisting cardiomyopathy  
- Previous anthracycline exposure  
- Previous chest radiation  
- Age ≥60 years  
- Black race  
- Elevated pre‑therapy troponin (≥14 ng/L or >0.07 ng/mL)  
- ≥10 % LVEF decline to <50 %  
- LVEF recovery  
- Cardiac events (mortality, heart‑failure hospitalization)  
- Echocardiography  
- Cardiac risk stratification  
- AHA/ACC/HFSA heart‑failure guideline  
- Cancer‑therapy cardiotoxicity  
- Biomarker‑guided therapy  
- Subclinical cardiac injury  
- Temporary/permanent interruption of cardiotoxic agents  

These terms collectively capture the heart‑disease concepts discussed in the guideline excerpt.

Page 84 Extracted Terms:
Heart failure (HF)  
Cardiomyopathy  
Peripartum cardiomyopathy  
Left ventricular ejection fraction (LVEF)  
Left ventricular (LV) dilation  
Left ventricular (LV) dysfunction  
Right ventricular (RV) involvement  
NYHA functional class  
AHA/ACC/HFSA Heart Failure Guideline  
Systolic dysfunction  
Acute HF  
Cardiogenic shock  
Intracardiac thrombus  
Thromboembolic events  
Hypercoagulable state  
Anticoagulation  
Bromocriptine  
Dopamine‑agonist therapy  
GDMT (guideline‑directed medical therapy)  
ACE inhibitor (ACEi)  
Angiotensin receptor blocker (ARB)  
Angiotensin receptor‑neprilysin inhibitor (ARNi)  
Mineralocorticoid receptor antagonist (MRA)  
SGLT2 inhibitor (SGLT2i)  
Ivabradine  
Vericiguat  
Mechanical circulatory support  
Left ventricular assist device (LVAD)  
Heart transplant  
Pregnancy in cardiomyopathy  
Risk factors: maternal age >30 yr, African ancestry, multiparity, multigestation, preeclampsia/eclampsia, anemia, diabetes, obesity, prolonged tocolysis  
ROPAC registry  
CARPREG II score  
Modified WHO risk classification  
World Health Organization (WHO) risk score for pregnancy and cardiac disease

Page 85 Extracted Terms:
- AHA/ACC/HFSA Heart Failure Guideline  
- Heart Failure (HF)  
- Peripartum Cardiomyopathy (PPCM)  
- Left Ventricular Ejection Fraction (LVEF)  
- Right Ventricular (RV)  
- Angiotensin‑converting Enzyme Inhibitor (ACEi)  
- Angiotensin Receptor Blocker (ARB)  
- Angiotensin Receptor‑Neprilysin Inhibitor (ARNi)  
- Mineralocorticoid Receptor Antagonist (MRA)  
- Sodium‑Glucose Cotransporter‑2 Inhibitor (SGLT2i)  
- Beta‑Blocker (e.g., metoprolol, metoprolol succinate)  
- Hydralazine  
- Nitrates (e.g., nitroglycerin)  
- Diuretics (e.g., furosemide)  
- Anticoagulation (prophylactic or therapeutic)  
- Bromocriptine  
- Mechanical Circulatory Support (MCS)  
- Cardiogenic Shock  
- Decompensated Heart Failure  
- Guideline‑Directed Medical Therapy (GDMT)  
- B‑natriuretic Peptide (BNP)  
- N‑terminal pro‑B‑natriuretic Peptide (NT‑proBNP)  
- Echocardiography (cardiac structure & function assessment)  
- Pregnancy Cardiovascular Risk Tools  
- Preconception Genetic Counseling & Testing for Heritable Cardiac Conditions  
- Preeclampsia (shared risk with PPCM)  
- Maternal‑Fetal Medicine Surveillance  
- Breastfeeding‑safe Medications (ACEi, beta‑blockers, diuretics)  
- ESC “BOARD” (Bromocriptine, Oral HF therapy, Anticoagulation, vaso‑Relaxing agents, Diuretics)  
- Randomized Controlled Trial (RCT) evidence on PPCM and bromocriptine  
- Clinical Statements & Guidelines (2022)  
- Perinatal (Pregnancy Continuum) HF Management Strategies  
- Multidisciplinary Collaborative Approach (cardiology, obstetrics, neonatology, genetics)

Page 86 Extracted Terms:
- Heart Failure (HF)  
- Heart Failure with reduced ejection fraction (HFrEF)  
- Heart Failure guidelines (AHA/ACC/HFSA, 2022)  
- Pregnancy and Lactation Labeling Rule  
- Angiotensin‑converting enzyme inhibitors (ACEi) – e.g., enalapril, captopril  
- Angiotensin‑II receptor blockers (ARBs)  
- Angiotensin receptor neprilysin inhibitors (ARNi)  
- Ivabradine  
- Spironolactone  
- Eplerenone  
- Loop diuretic (furosemide)  
- Beta‑blockers (metoprolol, other)  
- Hydralazine  
- Nitrates  
- Peripartum cardiomyopathy  
- Left ventricular recovery (LV recovery)  
- LactMed (Lactation Medications database)  
- Performance measurement / quality metrics in heart failure care  
- Process‑of‑care measures  
- NYHA functional class I and III  
- Patient registries for heart‑failure quality improvement  
- Palliative and supportive care in heart failure  
- Quality of life (QOL)  
- Life‑extending therapies in HF  
- Stage D heart failure  
- Inotropic support  
- Temporary mechanical support  
- Advanced therapies (e.g., transplant, mechanical circulatory support)  
- Multimorbidity, frailty, cognitive impairment in HF patients  
- Shared decision‑making (multidisciplinary)  
- Clinical practice guidelines (ACC/AHA)

Page 87 Extracted Terms:
- Heart Failure (HF)  
- Heart Failure with reduced ejection fraction (HFrEF)  
- Advanced Heart Failure (advanced HF)  
- Left Ventricular Ejection Fraction (LVEF)  
- Beta‑blocker therapy for HFrEF  
- ACE inhibitor (ACEi) therapy for HFrEF  
- Angiotensin‑receptor blocker (ARB) therapy for HFrEF  
- Angiotensin‑receptor neprilysin inhibitor (ARNi) therapy for HFrEF  
- Mineralocorticoid receptor antagonist (MRA) therapy for HFrEF  
- Hydralazine and isosorbide dinitrate therapy for HFrEF in Black or African American patients  
- Guideline‑Directed Medical Therapy (GDMT)  
- Implantable Cardioverter‑Defibrillator (ICD) placement counseling for HFrEF  
- Cardiac Resynchronization Therapy (CRT) implantation for HFrEF  
- Palliative care for patients with HF  
- Advance care planning / advance care directives in HF  
- Hospice referral for advanced HF with <6 month survival  
- Quality of Life (QOL) improvement in HF care  
- Symptom assessment and monitoring in HF  
- Symptom management in HF  
- Patient self‑care education for HF  
- Patient‑reported outcome and health status measurement in HF  
- Exercise training referral for HF (inpatient and outpatient)  
- HF registry participation  
- Performance Measures (PM) for HF  
- Quality Measures (QM) for HF  
- Structural Measures (SM) for HF

Page 88 Extracted Terms:
- Heart Failure (HF)  
- Congestive Heart Failure (CHF)  
- Mechanical Circulatory Support (MCS)  
- Implantable Cardioverter‑Defibrillator (ICD)  
- Intravenous Inotropes  
- Renal Replacement Therapy (used in advanced HF)  
- Life‑sustaining therapies (initiation, continuation, deactivation)  
- Palliative Care in HF  
- Supportive Care in HF  
- Psychological Distress (in the context of HF management)  
- Family Caregiver support (in HF care)

Page 89 Extracted Terms:
- Heart Failure (HF)  
- Guideline‑Directed Medical Therapy (GDMT)  
- Implantable Cardioverter‑Defibrillator (ICD)  
- Left Ventricular Assist Device (LVAD)  
- Deactivation of ICD  
- Palliative Care  
- Hospice Care  
- Advance Care Planning  
- End‑of‑Life Care  
- Symptom Management (dyspnea, fatigue, pain, nausea, depression, anxiety)  
- Shared Decision‑Making  
- High‑Quality Communication  
- Caregiver Support  
- Cardiovascular Mortality/Deaths  
- Prognostic Discussions (“hope for the best, plan for the worst”)  
- Surrogate Decision Maker  
- Life‑Sustaining Treatments (hospitalization, tube feeding, medication)  
- Palliative Care Interventions (e.g., PAL‑HF)  
- Mortality Prediction / Risk Models  
- Terminal Disease/End‑Stage HF  
- Legal and Ethical Considerations (state laws, Medicare eligibility)

Page 90 Extracted Terms:
- Heart failure (HF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Heart failure with preserved ejection fraction (HFpEF)  
- Heart failure with mid‑range ejection fraction (HFmrEF)  
- Heart failure with improved ejection fraction (HFimpEF)  
- Myocarditis  
- Myocardial injury  
- COVID‑19‑associated cardiotoxicity  
- Cardiomyopathies (e.g., peripartum cardiomyopathy, ATTR cardiomyopathy)  
- Right‑ventricular (RV) failure  
- Cardiorenal syndrome  
- Diuretic resistance  
- Precise and individualized HF management  
- Biomarkers in HF therapy optimization  
- Omics and molecular markers for HF diagnosis and prognosis  
- Fluid restriction therapy  
- Sodium restriction (dietary)  
- Cardiac rehabilitation (HFpEF, HFmrEF)  
- Hydralazine‑isosorbide therapy in HF (African American and non‑African American)  
- Vericiguat for HFrEF with high natriuretic peptides  
- Omecamtiv mecarbil for advanced (stage D) HFrEF  
- Sodium‑glucose cotransporter‑2 inhibitors (SGLT2i) in HFpEF, HFmrEF, and HFrEF  
- Dual SGLT2i/SGLT1i therapy in HF  
- Non‑steroidal selective mineralocorticoid receptor antagonists (MRA) in HF  
- Angiotensin receptor–neprilysin inhibition (ARNi) in pre‑HF (stage B) and HFrEF  
- Pulmonary hypertension management (post‑ and precapillary)  
- Fibrosis‑targeted therapies (e.g., pirfenidone) in HFpEF  
- Potassium binders to optimize guideline‑directed medical therapy (GDMT)  
- Blood pressure targets in established HF and hypertension  
- Electrolyte management (hyper‑/hypokalemia) in HF  
- Peripartum cardiomyopathy (cause and targeted therapies)  
- Antioxidants, polyunsaturated fatty acids (PUFA) for atrial fibrillation risk in HF  
- Advanced screening strategies for HF (cost‑effectiveness, risk prediction)  
- Precision medicine/genetic testing in HF management  
- Integrated systems biology models for HF diagnosis, prognosis, and therapy targeting.

Page 91 Extracted Terms:
- Atrial fibrillation (AF)  
- Heart failure (HF)  
- Heart failure with preserved ejection fraction (HFpEF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Heart failure with mildly reduced ejection fraction (HFmrEF)  
- Heart failure with improved ejection fraction (HFimpEF)  
- Ventricular tachyarrhythmias  
- His‑bundle pacing  
- Multisite pacing  
- Cardiac contractility modulation  
- Vagal nerve stimulation  
- Autonomic modulation  
- Renal denervation  
- Splanchnic nerve ablation  
- Interatrial shunt  
- Pericardiectomy  
- Baroreceptor stimulation  
- Neuromodulation  
- Tricuspid regurgitation  
- Mechanical circulatory support (MCS)  
- Cardiac transplantation  
- Percutaneous interventions  
- Transcatheter aortic valve implantation (TAVI)  
- MitraClip (transcatheter mitral valve repair)  
- Tricuspid valve intervention  
- Valvular heart disease (VHD)  
- Chronic kidney disease (CKD)  
- Obesity  
- Diabetes mellitus  
- Depression  
- Cognitive disorders  
- Iron deficiency  
- Pulmonary artery pressure monitoring catheter  
- Remote monitoring  
- Telehealth  
- Digital health  
- Artificial intelligence (AI)  
- Adaptive trials  
- Umbrella trials  
- Basket trials  
- Machine‑learning‑based trials  
- Sodium‑glucose cotransporter‑2 inhibitors (SGLT2i)  
- Sodium‑glucose cotransporter‑1 inhibitors (SGLT1i)  
- Angiotensin receptor‑neprilysin inhibitor (ARNi)  
- Mineralocorticoid receptor antagonist (MRA)  
- Polyunsaturated fatty acids (PUFA)  
- Guideline‑directed medical therapy (GDMT)  
- Patient‑reported outcomes  
- Quality of life (QOL)  
- Left ventricle (LV)  
- Right ventricle (RV)

Page 92 Extracted Terms:
- Heart Failure (HF)  
- Patient‑Reported Outcomes (PROs)  
- Health‑Related Quality of Life (QOL)  
- Kansas City Cardiomyopathy Questionnaire (KCCQ)  
- Minnesota Living with Heart Failure Questionnaire (MLHFQ)  
- PROMIS‑Plus‑HF (Patient‑Reported Outcomes Measurement Information System‑Plus‑Heart Failure)  
- New York Heart Association (NYHA) Functional Classification  
- Cardiopulmonary Exercise Test (CPET)  
- 6‑Minute Walk Test  
- Hospitalization (HF‑related)  
- Mortality (HF‑related)  
- Symptom Burden  
- Prognosis (HF)  
- Diuretic Escalation (HF therapy)  
- Medical Therapy Uptitration (HF)  
- Guideline‑Recommended Therapies (mortality benefit)  
- Population Health Management (HF risk stratification)  
- Routine Patient‑Reported Health Status Assessment  
- Clinical Outcomes (HF)  
- Functional Status (HF)  
- Quality of Treatment Decisions (HF)  
- Healthcare System Data Burden (HF assessment)  
- Evidence Gaps in HF Management  
- Future Research Directions (HF)  
- ACC/AHA/HFSA Heart Failure Guideline (HF)

Page 93 Extracted Terms:
**Key terms related to heart disease extracted from the text**

- Heart failure  
- Cardiovascular disease  
- Primary prevention of cardiovascular disease  
- Valvular heart disease  
- Coronary artery disease  
- Coronary artery revascularization  
- Percutaneous coronary intervention (PCI)  
- Coronary artery bypass graft (CABG) surgery  
- Clinical practice guidelines  
- ACC/AHA guideline  
- AHA/ACC/HFSA Heart Failure Guideline  
- HFSA (Heart Failure Society of America) guideline  
- SCAI (Society for Cardiovascular Angiography and Interventions) guidelines  
- ACCF/AHA guideline  
- Cardiovascular disease management  
- Heart failure management  
- Valvular disease management  
- Coronary disease management  
- Cardiovascular health  
- Heart disease terminology  


These terms capture the main clinical conditions, procedural interventions, and guideline frameworks discussed in the provided excerpt.

Page 94 Extracted Terms:
Heart Failure  
ST‑elevation myocardial infarction (STEMI)  
Myocardial infarction  
Hypertrophic cardiomyopathy  
Atrial fibrillation  
Hypertension / high blood pressure  
Blood cholesterol / dyslipidemia  
Atherosclerotic cardiovascular disease / coronary artery disease  
Stable ischemic heart disease  
Cardiovascular risk assessment  
Cardiac amyloidosis  
Heart rhythm abnormalities (arrhythmia)  
Device‑based cardiac therapy (e.g., pacemaker, ICD)  
Post‑cardiac arrest care  
Cardiopulmonary resuscitation (CPR)  
Emergency cardiovascular care  
Low‑risk chest pain evaluation  
Diabetes‑related cardiovascular prevention  
Secondary prevention in atherosclerotic disease  
Primary prevention of cardiovascular disease  
Cardiovascular functional class (e.g., NYHA)  
New York Heart Association (NYHA) classification  

Page 95 Extracted Terms:
- Heart failure (HF)  
- Left ventricular ejection fraction (LVEF)  
- Heart failure with preserved ejection fraction (HFpEF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Heart failure with recovered left ventricular ejection fraction (HFrecEF)  
- Dilated cardiomyopathy  
- Wild‑type transthyretin cardiac amyloidosis  
- Light‑chain amyloidosis  
- Congestion (clinical congestion, congestion on physical exam)  
- Volume overload  
- Loop diuretic dose  
- Angiotensin‑converting enzyme inhibitors (ACEi)  
- Spironolactone  
- Dobutamine infusion (chronic dobutamine)  
- Milrinone infusion  
- Implantable cardioverter‑defibrillator (ICD) shocks  
- Mortality (all‑cause, HF‑specific, short‑ and long‑term)  
- Hospitalization and readmission (rehospitalization)  
- Physical examination findings (weight change, exam signs of congestion)  
- Exercise echocardiography  
- Cardiac hemodynamics (exercise hemodynamics)  
- H2F‑PEFF model (diagnostic algorithm)  
- HFA‑PEFF diagnostic algorithm (Heart Failure Association – European Society of Cardiology)  
- ESC guidelines (European Society of Cardiology)  
- ACCF/AHA guideline (American College of Cardiology Foundation/American Heart Association)  
- AHA/ACC/HFSA guideline (American Heart Association/American College of Cardiology/Heart Failure Society of America)  
- Heart Failure Society of America (HFSA)  
- Heart Failure Association (HFA) of the European Society of Cardiology (ESC)  
- EU‑FP7 MEDIA study group (diastolic stress tests)  
- American Heart Association (AHA)  
- National trends in HF hospitalization and readmission  
- Temporal trends in HF incidence and mortality  
- Epidemiology of HF, HFrEF, and HFpEF  
- Race and ethnicity in HF outcomes  
- Cardiac‑inherited disease (family history approach)  
- Epidemiological studies (Virani, Heidenreich, Dunlay, etc.)  
- Clinical assessment and prognostic indicators (congestion, weight loss, diuretic dose, ICD shocks)    
- Diagnostic algorithm for HF classification according to LVEF  
- Acute and chronic heart failure diagnosis guidelines  
- Predictive model for HFpEF (e.g., H2F‑PEFF).  

Page 96 Extracted Terms:
- Heart failure  
- Elevated jugular venous pressure  
- Third heart sound (S3)  
- Hemodynamics  
- Advanced heart failure  
- Bendopnea  
- Valsalva maneuver (biomarker)  
- Cardiac amyloidosis  
- Transthyretin cardiac amyloidosis (ATTR)  
- Transthyretin amyloid (ATTR) subtype  
- Dilated cardiomyopathy  
- Restrictive cardiomyopathy  
- Sarcoid cardiomyopathy (cardiac sarcoidosis)  
- Myocarditis  
- Inflammatory cardiomyopathy  
- Peripartum cardiomyopathy  
- Takotsubo (stress) cardiomyopathy  
- Alcohol‑induced cardiac toxicity  
- Cocaine‑associated cardiomyopathy  
- Methamphetamine‑associated cardiomyopathy  
- Anthracycline cardiotoxicity  
- Troponin I (cardiac biomarkers)  
- N‑terminal pro‑B‑type natriuretic peptide (NT‑proBNP)  
- B‑type natriuretic peptide (BNP)  
- Left ventricular dysfunction (ischemic)  
- Ischemic cardiomyopathy  
- Cardiovascular toxicity (due to cancer therapy)  
- Cardiovascular complications of cancer therapy  
- Cardiorheumatology (cardiac involvement in systemic rheumatic disease)  
- Thyroid hormones and cardiovascular disease  
- Heart failure in type 2 diabetes mellitus  
- Pheochromocytoma‑associated cardiomyopathy  
- Acromegaly‑associated heart failure  
- Obesity paradox in heart failure  
- Genotype and phenotype of cardiomyopathies  
- Mechanical circulatory support (bridge‑to‑transplant)  
- Heart transplantation outcomes in cardiomyopathy  
- Acute COVID‑19 cardiovascular syndrome  
- Biomarkers for risk stratification in heart disease  
- Diagnostic and treatment strategies for specific dilated cardiomyopathies  
- Clinical characteristics and management of Chagas cardiomyopathy  
- Current evidence and future directions in myocarditis and inflammatory cardiomyopathy  

(Each term represents a key concept or condition related to heart disease extracted from the guideline text.)

Page 97 Extracted Terms:
- Heart failure  
- Acute heart failure  
- Decompensated heart failure (ADHF)  
- Chronic heart failure  
- Advanced heart failure  
- Reduced ejection fraction (HFrEF)  
- Left ventricular failure (LVF)  
- Natriuretic peptides  
- B‑type natriuretic peptide (BNP)  
- N‑terminus pro‑BNP (NT‑proBNP)  
- Amino‑terminal pro‑BNP (NT‑proBNP)  
- High‑sensitivity troponin T (hs‑TnT)  
- High‑sensitivity cardiac troponin (hs‑cTn)  
- Galectin‑3  
- Soluble ST2 (sST2)  
- Growth differentiation factor‑15 (GDF‑15)  
- Obesity‑related suppression of BNP  
- Atrial fibrillation as a comorbidity in HF  
- Renal dysfunction in heart failure  
- Congestive heart failure  
- Diagnostic accuracy of BNP assays  
- Prognostic value of BNP/NT‑proBNP ratios  
- Biomarker‑guided therapy  
- Rapid bedside BNP testing  
- Emergency department decision‑making in HF  
- Discharge risk scoring models (ELAN‑HF, ESCAPE)  
- Readmission prediction for heart failure  
- Mortality prediction in HF patients  
- Troponin‑based rule‑out of acute cardiac insufficiency (TACIT)

Page 98 Extracted Terms:
- Heart failure  
- Dilated cardiomyopathy  
- Left ventricular dysfunction  
- Right ventricular dysfunction  
- Ventricular remodeling  
- Ischemic heart disease  
- Myocardial infarction  
- Cardiac amyloidosis  
- Anderson‑Fabry disease  
- Arrhythmogenic right ventricular dysplasia/cardiomyopathy  
- Myocardial viability  
- Hibernating myocardium  
- Implantable cardioverter‑defibrillator (ICD)  
- Wearable cardioverter‑defibrillator (WCD)  
- B‑type natriuretic peptide (BNP)  
- NT‑proBNP (N‑terminal pro‑B‑type natriuretic peptide)  
- Echocardiography (2‑D, 3‑D, Doppler)  
- Cardiovascular magnetic resonance (CMR)  
- T1 mapping (non‑contrast)  
- T2* MRI for myocardial iron overload  
- Computed tomography (CT) cardiac imaging  
- Low‑dose dual‑source CT for ventricular function  
- Cardiac CT coronary angiography (CTA)  
- Radionuclide ventriculography  
- Dobutamine stress echocardiography  
- Myocardial perfusion imaging (MPI)  
- Positron emission tomography (PET) with FDG  
- Cardiac structural assessment  
- Cardiac functional assessment  
- Genetic evaluation of cardiomyopathy  
- Family history / pedigree analysis  
- Genetic variation in dilated cardiomyopathy  
- Titin truncations  
- Arrhythmic phenotypes (genetic basis)  
- Non‑invasive global and regional ventricular function  
- Left ventricular ejection fraction (LVEF)  
- Left ventricular volumes  
- Myocardial mass quantification  
- Appropriate use criteria for multimodality imaging (ACC/AHA)  
- Coronary artery disease (CAD) in heart failure  
- Revascularization benefits (PCI, CABG)  
- Myocardial hibernation  
- Myocardial ischemia detection  
- Cardiac mortality assessment  
- Prognostic implications of imaging findings  
- Cardiovascular imaging registry (EuroCMR)  

These terms capture the major concepts related to heart disease discussed throughout the provided guidelines and referenced studies.

Page 99 Extracted Terms:
- Heart Failure  
- Heart Failure with Preserved Ejection Fraction (HFpEF)  
- Heart Failure with Reduced Ejection Fraction (HFrEF)  
- Acute Decompensated Heart Failure  
- Congestive Heart Failure  
- Left Ventricular Dysfunction  
- Left Ventricular Mass  
- Left Ventricular Filling Pressures  
- Systolic Function  
- Diastolic Function  
- Systolic Dysfunction  
- Diastolic Dysfunction  
- Ejection Fraction  
- Left Ventricular Ejection Fraction (LVEF)  
- Left Ventricular Strain  
- Global Longitudinal Strain  
- Left Ventricular Longitudinal Strain  
- Ventricular Volumes  
- Ventricular Size  
- Ventricular Remodeling  
- Ventricular Function  
- Pulmonary Congestion  
- Functional Mitral Regurgitation  
- Myocardial Infarction  
- Coronary Artery Disease  
- Myocardial Scar  
- Dilated Cardiomyopathy  
- Nonischemic Cardiomyopathy  
- Cardiac Sarcoidosis  
- Myocardial Fibrosis  
- Diffuse Myocardial Fibrosis  
- Extracellular Matrix Expansion  
- Late Gadolinium Enhancement (LGE)  
- Cardiac Magnetic Resonance Imaging (CMR)  
- Cardiovascular Magnetic Resonance  
- Delayed‑Enhancement Magnetic Resonance  
- CMR Mapping  
- Cardiac Resynchronization Therapy (CRT)  
- Carvedilol  
- Enalapril  
- Empagliflozin  
- Spironolactone  
- B‑type Natriuretic Peptide (BNP)  
- Hand‑Carried Echocardiography  
- Point‑of‑Care Lung Ultrasound  
- Echocardiographic Diastolic Parameters  
- Cardiac Chamber Quantification  
- SPECT Perfusion Imaging  
- Cardiac Imaging  
- Cardiac Ultrasound  
- Heart Failure Guidelines  
- Left Ventricular Longitudinal Strain (LVLS)  
- Right Ventricular Dysfunction  
- Left Ventricular Function Recovery  
- Ejection Fraction Recovery  
- Cardiovascular Outcomes  
- Prognostic Indicators  
- Myocardial Inflammation  
- Myocardial Fibrosis Assessment  
- Ventricular Scar Detection  
- Cardiomyopathy Etiology  
- Cardiac Magnetic Resonance Contrast  
- Cardiovascular Magnetic Resonance Techniques  
- Cardiac Magnetic Resonance in Acute Heart Failure  
- Cardiac Magnetic Resonance in Chronic Heart Failure  
- Echocardiographic Prognostic Implications  
- Cardiac MRI Myocardial Mapping

These terms capture the key heart‑disease concepts, diagnostic and therapeutic modalities, and prognostic indicators referenced within the provided clinical guideline text.

Page 100 Extracted Terms:
**Key terms related to heart disease**

- Heart failure  
- Chronic heart failure  
- Acute decompensated heart failure  
- Non‑ischemic dilated cardiomyopathy (non‑ischemic heart failure)  
- Ischemic cardiomyopathy / ischemic left‑ventricular dysfunction  
- Left‑ventricular dysfunction / ejection fraction  
- Cardiac amyloidosis / transthyretin amyloid cardiomyopathy  
- Congestive heart failure  
- Coronary artery disease / ischemic heart disease  
- Coronary revascularization / coronary artery bypass grafting  
- Pulmonary artery catheterization / pulmonary artery pressure monitoring  
- Pulmonary hypertension  
- Remote patient monitoring / telemonitoring  
- CardioMEMS implantable pulmonary‑artery pressure sensor  
- Implantable cardioverter‑defibrillators (ICD)  
- Biventricular defibrillators (CRT‑D)  
- Cardiac magnetic resonance (CMR) imaging  
- Late gadolinium enhancement (LGE)  
- Endomyocardial biopsy  
- Cardiovascular imaging / cardiovascular magnetic resonance  
- Appropriate use criteria (AUC) for cardiac imaging and revascularization  
- Randomized controlled trial (RCT)  
- Non‑invasive imaging-assisted management  
- Structured telephone support / telemedicine alerts  
- Cost‑effectiveness analysis  
- Clinical outcomes (mortality, hospitalization)  
- New York Heart Association (NYHA) class  
- Exercise capacity / functional capacity testing  

These terms capture the principal disease entities, diagnostic technologies, therapeutic interventions, and outcome measures discussed in the cited guidelines and studies.

Page 101 Extracted Terms:
**Key terms related to heart disease found in the text**

- Heart failure  
- Systolic heart failure  
- Preserved ejection fraction (HFpEF)  
- Left ventricular dysfunction  
- Cardiopulmonary exercise testing (CPET)  
- Peak oxygen consumption (VO₂ peak)  
- Six‑minute walk test (6MWT)  
- Beta‑blocker therapy  
- Cardiac transplantation  
- Mechanical circulatory support  
- Heart failure risk scoring  
- Seattle Heart Failure Model  
- GWTG‑heart failure risk score  
- MAGGIC (Meta‑analysis Global Group in Chronic Heart Failure) risk calculator  
- ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness) risk model  
- HF‑ACTION predictive risk score  
- GUIDE‑IT predictive model  
- I‑PRESERVE (Irbesartan in Heart Failure with Preserved Ejection Fraction) study  
- Apolipoprotein A‑1  
- High‑sensitivity C‑reactive protein (hs‑CRP)  
- N‑terminal pro‑B‑type natriuretic peptide (NT‑proBNP)  
- New York Heart Association (NYHA) functional classification  
- Functional capacity  
- Mortality  
- Morbidity  
- Readmission  
- Dyspnea  
- Inspiratory muscle strength  
- Blood pressure (hypertension)  
- Coronary artery disease  
- Pulmonary hypertension  
- Sodium‑glucose cotransporter‑2 inhibitors (SGLT2‑i) (mentioned in broader guideline context)

Page 102 Extracted Terms:
- Heart failure  
- Hypertension  
- Blood pressure  
- Left ventricular dysfunction  
- Left ventricular ejection fraction  
- Atherosclerosis  
- Coronary artery disease  
- Myocardial infarction  
- Ischemic heart disease  
- Diabetes mellitus type 2  
- SGLT2 inhibitor  
- ACE inhibitor  
- Angiotensin II receptor blocker  
- Beta blocker  
- Diuretic  
- Statin  
- Antiplatelet therapy  
- Anticoagulant therapy  
- Lifestyle modification  
- Physical activity  
- Sedentary time  
- Mediterranean diet  
- DASH diet  
- Natriuretic peptide  
- NT‑proBNP  
- Risk prediction  
- Framingham risk score  
- ASCVD risk estimate  
- Risk model  
- Heart‑failure prevention  
- Systolic blood pressure  
- Isolated systolic hypertension  
- Heart failure with preserved ejection fraction  
- Heart failure with reduced ejection fraction  
- Left‑ventricular remodeling  
- Cardiovascular death  
- Cardiovascular morbidity  
- Heart‑failure hospitalization  
- Cardiac structure  
- Cardiac function  
- Heart‑failure guidelines  
- AHA/ACC/HFSA guideline  
- ACC/AHA guideline  
- Hypertension guideline  

Page 103 Extracted Terms:
- Atherosclerotic heart disease  
- Aortic stenosis  
- ARNI (angiotensin receptor‑neprilysin inhibitor)  
- Angiotensin‑converting enzyme inhibitor (ACEI)  
- Angiotensin‑II receptor blocker (ARB)  
- Beta‑blocker  
- Blood cholesterol management  
- Cardiac remodeling  
- Cardiomyopathy, idiopathic dilated  
- Cardiovascular mortality  
- Constrictive pericarditis  
- Coronary artery bypass grafting (CABG)  
- Coronary artery disease (CAD)  
- Coronary artery revascularization  
- Diastolic dysfunction  
- Diastolic heart failure (HFpEF)  
- Diastolic dysfunction, asymptomatic  
- Diltiazem, calcium‑channel blocker  
- Drug‑induced heart failure  
- End‑organ damage, cardiac  
- Ejection fraction (EF)  
- Early aldosterone blockade  
- Early eplerenone therapy  
- Heart failure, stage B (pre‑symptomatic)  
- Heart failure, stage C (symptomatic)  
- Heart failure, stage D (advanced)  
- Heart failure, with reduced ejection fraction (HFrEF)  
- Heart failure, with preserved ejection fraction (HFpEF)  
- Heart failure, with mid‑range ejection fraction (HFmrEF)  
- Heart failure, prognostic markers  
- Heart failure, secondary to myocardial infarction  
- Heart failure, type 2 diabetes mellitus  
- Heart function tests  
- Heart transplantation candidates  
- Heart transplant  
- Heterogeneous myocardial infarction outcomes  
- Hemodynamic monitoring  
- Hypertrophic cardiomyopathy  
- Hypertrophic cardiomyopathy  
- Idiopathic dilated cardiomyopathy  
- Left ventricular dysfunction, asymptomatic  
- Left ventricular remodeling  
- Left ventricular strain, speckle‑tracking echocardiography  
- Left ventricular systolic dysfunction  
- Left ventricular diastolic dysfunction  
- Longitudinal strain by echocardiography  
- Major adverse cardiovascular events (MACE)  
- Metabolic syndrome, heart disease risk  
- Myocardial infarction (MI)  
- Myocardial infarction, ST‑elevation (STEMI)  
- Myocardial infarction, non‑ST‑elevation (NSTEMI)  
- Myocardial infarction, acute  
- Myocardial infarction, chronic  
- Myocardial infarction outcome measures  
- Myocardial infarction, evidence‑based interventions  
- Myocardial infarction, revascularization outcomes  
- Multicenter clinical trials (e.g., CAPRICORN, ALBATROSS)  
- New York Heart Association (NYHA) functional classification  
- Non‑ischemic cardiomyopathy  
- Oral glucose‑lowering agents in heart disease  
- Pioglitazone  
- Predictors of heart failure progression  
- Prognostic implications of left‑ventricular strain  
- Prevention of heart failure  
- Primary prophylactic implantable cardio‑electrical defibrillator (ICD) implantation  
- Primary percutaneous coronary intervention (PCI)  
- Prognosis of asymptomatic left‑ventricular dysfunction  
- Prognostic significance of heart failure stages  
- Renin–angiotensin–aldosterone system (RAAS) blockade  
- Risk of progression from left‑ventricular dysfunction to overt heart failure  
- Rosiglitazone  
- Systolic heart failure  
- Tachycardia‑induced cardiomyopathy  
- Thoracic aortic disease  
- Thiazolidinediones (TZDs)  
- Transcatheter aortic valve replacement (TAVR)  
- Treatment guidelines for acute coronary syndromes (ACS)  
- Treatment guidelines for ST‑elevation myocardial infarction (STEMI)  
- Treatment guidelines for non‑ST‑elevation acute coronary syndromes (NST‑ACS)  
- Treatment of asymptomatic left‑ventricular dysfunction  
- Treatment of early post‑myocardial infarction heart failure  
- Treatment of heart failure with preserved ejection fraction (HFpEF)  
- Treatment of heart failure with mid‑range ejection fraction (HFmrEF)  
- Treatment of post‑infarction remodeling  
- Treatment of heart failure, multi‑drug strategies  
- Treatment of diabetes in heart failure  
- Treatment of metabolic disorders in heart disease  
- Time‑to‑event analysis in cardiovascular trials  
- Valvular heart disease, severe aortic stenosis  
- Vasodilator therapy, nitrates  
- Ventricular enlargement after myocardial infarction  
- Ventricular remodeling, left and right  
- Ventricular dysfunction, systolic and diastolic  
- Vascular risk factors in heart disease  
- Vasodilator therapy (e.g., verapamil)  
- Wall‑stress reduction strategies  
- Worsening heart failure symptoms  
- Advanced heart failure interventions  
- Anaphylactic reactions to beta‑blockers  
- Antithrombotic therapy post‑MI  
- Apical aneurysm after MI  
- Arrhythmia management in heart failure  
- Aortic valve repair and replacement  
- Blood pressure control in heart disease  
- Cardiac arrest resuscitation guidelines  
- Cardiac imaging modalities (MRI, CT, PET)  
- Cardiac output monitoring  
- Cardio‑pulmonary exercise testing  
- Cardio‑vascular exercise guidelines  
- Cardio‑vascular disease burden  
- Cardio‑vascular disease epidemiology  
- Cardio‑vascular disease prevention strategies  
- Cardio‑vascular disease risk scores (e.g., Framingham)  
- Cardio‑vascular rehabilitation  
- Cardio‑vascular surgery indications  
- Cardio‑vascular outcomes in diabetes studies  
- Cardio‑vascular outcomes in thiazolidinedione trials  
- Cardio‑vascular outcomes in ACEI/ARB trials  
- Cardio‑vascular outcomes in beta‑blocker trials  
- Cardio‑vascular outcomes in calcium channel blocker trials  

(Feel free to trim or refine the list to your specific focus area.)

Page 104 Extracted Terms:
- Heart failure  
- Stable ischemic heart disease  
- Coronary artery bypass graft surgery  
- Valvular heart disease  
- Congenital heart disease  
- Self‑care support in heart failure  
- Multidisciplinary interventions for heart failure  
- Structured telephone support / telemonitoring  
- Self‑management in heart failure patients  
- Medication adherence interventions  
- Influenza vaccination in heart failure  
- SARS‑CoV‑2 vaccine effectiveness (high‑risk population)  
- Cardiovascular disease / cardio‑vascular outcomes  
- Stroke prevention in cardiovascular disease  
- Depression and heart failure outcomes  
- Social relationships and heart failure survival  
- Frailty in chronic heart failure  
- Health literacy in heart failure patients  
- Team‑based care for cardiac comorbidities  
- Advanced heart failure management  
- mHealth education interventions for heart failure  
- Patient‑centered transitional care for hospitalized heart failure  
- Chronic heart failure (congestive heart failure)  
- Cardiac rehabilitation  
- Heart failure mortality & readmission rates  
- Cardiovascular outcomes in heart failure populations  

Page 105 Extracted Terms:
- Heart failure
- Chronic heart failure
- Decompensated heart failure
- Acute heart failure
- Heart failure with reduced ejection fraction
- Heart failure with preserved ejection fraction
- Cardiac remodeling
- Coronavirus disease‑2019 (COVID‑19)
- Pre‑eclampsia
- Post‑discharge risk
- Cognitive impairment
- Dementia
- Depression
- Substance abuse
- Frailty
- Food insecurity
- Housing insecurity
- Homelessness
- Socioeconomic inequities
- Intimate partner violence
- Elder abuse
- Abuse of vulnerable adults
- Limited English proficiency
- Health literacy
- Social isolation
- Dietary sodium restriction
- Salt restriction
- Fluid restriction
- Low‑sodium diet
- Moderate‑sodium diet
- Mediterranean diet
- Nutritional status
- Micronutrient supplementation
- Iron deficiency
- Oral iron repletion
- Thiamin supplementation
- Zinc deficiency
- Vitamin D supplementation
- Micronutrient deficiency
- Sodium intake
- Sodium‑restricted diet
- Cardiovascular disease
- Cardiometabolic disease
- Coronary artery disease
- Percutaneous coronary intervention
- Cardiac blood flow velocity
- Clinical outcomes
- Readmission burden
- Home‑delivered meals
- Food insecurity screeners
- Cardiovascular health equity
- Primary prevention
- Secondary prevention
- Dietary sodium content
- SODIUM‑HF trial
- Prohibit trial
- MED‑AHF study
- IRONOUT HF trial
- Micronutrient‑deficiency screening
- Fluid and sodium restriction protocols
- Management of heart failure guidelines  


Page 106 Extracted Terms:
- Heart Failure (HF)  
- Chronic Heart Failure  
- Systolic Heart Failure  
- Diastolic Heart Failure  
- Reduced Ejection Fraction (HFrEF)  
- Preserved Ejection Fraction (HFpEF)  
- Cardiac Rehabilitation  
- Exercise Training / Exercise Prescription  
- Aerobic Interval Training  
- Resistance Exercise  
- Exercise Capacity  
- Endurance Exercise  
- Oxygen Uptake / Peak VO₂  
- Quality of Life  
- Diuretic Treatment  
- Loop Diuretics (e.g., Furosemide, Torsemide, Torasemide)  
- Thiazide‑type Diuretics  
- Sodium Retention  
- Diuretic Resistance  
- Cardiorenal Syndrome  
- Diuretic Synergism  
- Renin–Angiotensin–Aldosterone System (RAAS) Inhibition  
- Angiotensin‑Converting Enzyme Inhibitors (ACEi)  
- Angiotensin Receptor Blockers (ARB)  
- Angiotensin Receptor‑Neprilysin Inhibitors (ARNi)  
- Sacubitril/Valsartan (Entresto)  
- Enalapril  
- Aortic Stiffness  
- Endothelial Function  
- Arterial Stiffness  
- Cardiac Reverse Remodeling  
- Diastolic Function  
- Congestive Heart Failure (CHF)  
- Acute Decompensated Heart Failure (ADHF)  
- Hospital Discharge / Early After Discharge Management  
- Bioavailability / Pharmacokinetics / Pharmacodynamics of Diuretics  
- Cardiorespiratory Training  
- Clinical Outcomes  
- Meta‑analysis / Systematic Review  
- Randomized Controlled Trial (RCT)  
- Clinical Guidelines (AHA/ACC/HFSA, Dutch Practice Guideline)  
- Heart Failure-ACTION Study  
- ExTraMATCH Study  
- Ex‑DHF Pilot Study  
- 3T Trial (loop diuretic resistance)  
- TRANSITION Study (sacubitril/valsartan initiation)  
- TORIC Study (torasemide)  
- Cooperative North Scandinavian Enalapril (CONSENSUS) Study  

These terms capture the key heart‑disease concepts and interventions mentioned in the provided guideline excerpt.

Page 107 Extracted Terms:
**Heart‑disease related terms extracted from the text**  

1. Heart failure (congestive heart failure)  
2. Reduced left ventricular ejection fraction  
3. Left ventricular dysfunction  
4. Myocardial infarction  
5. Angiotensin‑converting enzyme (ACE) inhibitor  
6. Enalapril  
7. Lisinopril  
8. Captopril  
9. Ramipril  
10. Trandolapril  
11. Valsartan  
12. Losartan  
13. Telmisartan  
14. ARNI (angiotensin‑receptor‑neprilysin inhibitor)  
15. Sacubitril/valsartan (LCZ‑696, LCZ‑696)  
16. Omapatrilat  
17. β‑blocker (beta‑blocker)  
18. Metoprolol (CR/XL, extended‑release)  
19. Bisoprolol  
20. Carvedilol  
21. Neprilysin inhibitor  
22. Dual‑acting inhibitor of angiotensin II receptor and neprilysin  
23. Angioedema (ACE‑inhibitor‑associated)  
24. Renin‑angiotensin‑aldosterone system (RAAS)  
25. Mortality and morbidity  
26. Clinical outcomes (hospitalisation, survival)  
27. Cost‑effectiveness  
28. Randomised clinical trial  
29. Pharmacologic management of heart failure  
30. Left ventricular systolic dysfunction  
31. Left ventricular mid‑range preserved ejection fraction  
32. Renin‑angiotensin‑inhibitor safety  
33. Blood‑pressure reduction  
34. Antihypertensive therapy  
35. Cardiovascular events  
36. Vascular events  
37. Pharmacogenomics (XPNPEP2 polymorphism)  
38. Acute myocardial infarction with heart failure  
39. Chronic heart failure  
40. Hypertension  

*(List provided as requested format – a simple list of terms.)*

Page 108 Extracted Terms:
- Heart failure  
- Metoprolol CR/XL  
- MERIT‑HF  
- β‑blockers  
- Atrial fibrillation  
- Nebivolol  
- SENIORS  
- Bucindolol  
- Carvedilol  
- Metoprolol  
- COMET  
- Bisoprolol  
- Enalapril  
- CIBIS III  
- Hydrocortisone  
- Spironolactone  
- Mineralocorticoid receptor antagonists (MRAs)  
- Aldactone (spironolactone)  
- Eplerenone  
- Eplerenone Post‑Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS)  
- Angiotensin‑neprilysin inhibition (ARNI)  
- Sacubitril/valsartan  
- RLY5016 (polysorbate potassium binder)  
- Sodium zirconium cyclosilicate (ZS‑9)  
- Sodium‑glucose cotransporter‑2 inhibitors (SGLT2i)  
- Dapagliflozin  
- Empagliflozin  
- Canagliflozin  
- Sotagliflozin  
- DAPA‑HF trial  
- EMPEROR‑Reduced  
- Hydralazine  
- Isosorbide dinitrate  
- Hydralazine‑isosorbide dinitrate (H‑ISDN)  
- Hydralazine‑isosorbide dinitrate for black patients with heart failure  
- n‑3 polyunsaturated fatty acids (omega‑3)  
- GISSI‑HF trial  
- Acute myocardial infarction  
- Left ventricular dysfunction  
- Left ventricular systolic dysfunction  
- Reduced ejection fraction (HFrEF)  
- Chronic congestive heart failure  
- Cardiovascular hospital admission  
- Mortality  
- Hyperkalemia  
- Cost‑effectiveness  
- Veterans Administration Cooperative Study (VACS)  
- Get With The Guidelines‑Heart Failure registry  

*(These terms encompass clinical conditions, pharmacologic agents, therapeutic strategies, trials, and outcome measures relevant to heart disease.)*

Page 109 Extracted Terms:
- Heart Failure  
- Heart Failure with Reduced Ejection Fraction (HFrEF)  
- Congestive Heart Failure (CHF)  
- Left Ventricular Dysfunction  
- Ventricular Dysfunction  
- Myocardial Infarction (MI)  
- Acute Myocardial Infarction  
- Coronary Artery Disease (CAD)  
- Sinus Rhythm  
- Hypertriglyceridemia  
- Hyperkalemia  
- Dyskinesia (mentioned in context of sodium zirconium cyclosilicate)  
- Antithrombotic Therapy  
- Anticoagulation (Warfarin)  
- Aspirin Therapy  
- Clopidogrel Therapy  
- Rivaroxaban Therapy  
- Calcium Channel Blockers (Amlodipine, Verapamil, Diltiazem)  
- Sodium Zirconium Cyclosilicate (ZS‑9)  
- Mineralocorticoid Receptor Antagonists  
- Digoxin  
- Omega‑3 Polyunsaturated Fatty Acids  
- icosapent ethyl  
- Vitamin D Supplementation  
- Vitamin E Supplementation  
- Coenzyme Q10  
- Thiazolidinediones (Rosiglitazone, Pioglitazone, Ipratropium‑related agents)  
- Dipeptidyl Peptidase‑4 (DPP‑4) Inhibitors (Saxagliptin, Alogliptin)  
- Dronedarone  
- Flecainide  
- Encainide  
- D‑sotalol  
- Atrial arrhythmia‑related drugs (noting arrhythmia suppression trials)  
- Cardiac Arrhythmia Suppression Trial (CATS)  
- SWORD (Survival With Oral d‑Sotalol)  
- SAVOR‑TIMI 53 (DPP‑4 inhibitor outcomes)  
- EXAMINE (Alogliptin outcomes)  
- AHA/ACC/HFSA Heart Failure Guideline  
- GISSI‑Prevenzione Trial (n‑3 fatty acids & Vitamin E)  
- REDUCE‑IT Trial (icosapent ethyl)  
- WATCH Trial (Warfarin & antiplatelet therapy)  
- PEARL‑HF Trial (RLY5016 potassium binder)  
- HARMONIZE Trial (Sodium zirconium cyclosilicate)  
- GISSI‑Prevenzione Trial (post‑MI outcomes)  
- VITAL‑Heart Failure Trial (Vitamin D supplementation)  
- Q‑SYMBIO Trial (Coenzyme Q10)  
- Multicenter Diltiazem Post‑Infarction Trial  
- Danish Verapamil Infarction Trial (DAVIT II)  
- GIST (not present in list)  

(Any duplicate or overlapping terms have been merged; the list captures all distinct concepts tied to heart‑disease pathophysiology, risk, or therapy that appear in the provided text.)

Page 110 Extracted Terms:
**Key heart‑disease terms extracted from the guideline text**

- Heart failure (HF)  
- Congestive heart failure (CHF)  
- Chronic heart failure (CHF)  
- Systolic (reduced‑ejection‑fraction) heart failure  
- Diastolic (preserved‑ejection‑fraction) heart failure  
- Left‑ventricular ejection fraction (LVEF)  
- Renin–angiotensin–aldosterone system (RAAS)  
- β‑blockers (e.g., metoprolol, carvedilol, bisoprolol)  
- Angiotensin‑converting‑enzyme inhibitors (ACEi) → enalapril, lisinopril, CIBIS‑II drug  
- Angiotensin‑II receptor blockers (ARBs)  
- Aldosterone antagonists → spironolactone, eplerenone  
- Sodium‑glucose cotransporter‑2 inhibitors (SGLT2i)  
  - Dapagliflozin  
  - Empagliflozin  
- Neurohormonal modulation (GDMT)  
- Combination therapy (isosorbide dinitrate + hydralazine)  
- Anti‑arrhythmic drugs → amiodarone, dofetilide  
- Calcium‑channel blockers → amlodipine  
- Angiotensin‑neprilysin inhibitors (ARNI) → sacubitril/valsartan  
- Thyroid hormone replacement therapy (levothyroxine T4, triiodothyronine T3)  
- Hormonal therapies → growth hormone, testosterone  
- Nutraceuticals / supplements → coenzyme‑Q10, L‑carnitine, taurine, thiamine  
- Cardiac biomarkers → NT‑proBNP, BNP  
- Left‑ventricular dysfunction  
- Myocardial infarction (MI) / acute coronary syndrome (ACS)  
- Ventricular arrhythmias (sudden cardiac death risk)  
- Type 2 diabetes mellitus (T2DM) – interaction with HF medications  
- DPP‑4 inhibitors (saxagliptin, alogliptin, sitagliptin, linagliptin) – HF risk  
- Obesity / cachexia / nutritional status – HF risk factors  

These terms encapsulate the core concepts of cardiovascular pathology, therapeutic targets, and risk factors discussed in the cited clinical statements and guideline references.

Page 111 Extracted Terms:
- Heart failure  
- Chronic heart failure (CHF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Left ventricular dysfunction  
- Left ventricular systolic dysfunction  
- Left ventricular ejection fraction (LVEF)  
- Congestive heart failure (CHF)  
- Atrial fibrillation (AF)  
- Coronary artery disease (CAD)  
- Myocardial infarction (MI)  
- Non‑ischemic cardiomyopathy  
- β‑blocker therapy  
- Carvedilol  
- Captopril  
- Candesartan  
- Enalapril  
- Losartan  
- Valsartan  
- Aldosterone blockade (mineralocorticoid receptor antagonism)  
- Sodium‑glucose cotransporter‑2 inhibitor (SGLT₂‑i) therapy  
- Angiotensin‑converting enzyme inhibitor (ACE‑I)  
- Angiotensin receptor blocker (ARB)  
- Soluble guanylate cyclase stimulators  
- Vericiguat  
- Digoxin  
- Ivabradine  
- Cardiac resynchronization therapy (CRT)  
- Implantable cardioverter‑defibrillator (ICD)  
- Transcatheter mitral‑valve repair (TMVR)  
- Mortality  
- Morbidity  
- Hospitalization  
- Clinical outcome  
- Quality of care  
- Drug‑tolerability  
- Dose‑response  
- Ejection fraction improvement  
- Ventricular remodeling  
- Left ventricular enlargement  
- Heart‑rate control  
- Vasodilator therapy  
- Neurohormonal blockade  
- Antihypertensive therapy  
- Chronic heart‑failure treatment guidelines  
- AHA/ACC/HFSA Heart Failure Guideline  
- DIG trial (Digitalis Investigation Group)  
- SHIFT trial (Ivabradine treatment)  
- BEAUTIFUL trial (Ivabradine in CAD with LV dysfunction)  
- PROVED trial (Digoxin withdrawal in CHF)  
- ATLAS study (Low vs high dose lisinopril)  
- HEAAL study (Losartan dose comparison)  
- SAVE study (Captopril after MI)  
- CHARM‑Overall program (Candesartan in CHF)  
- Valsartan Heart Failure Trial (VHT)  
- Vericiguat trial (Vericiguat in HFrEF)  
- Meta‑analysis studies  
- Randomized controlled trials (RCTs)

These terms capture the primary diseases, therapeutic agents, devices, clinical outcomes, and research/ guideline references discussed in the text.

Page 112 Extracted Terms:
- Heart Failure  
- Congestive Heart Failure  
- Dilated Cardiomyopathy  
- Non‑ischemic Cardiomyopathy  
- Ischemic Cardiomyopathy  
- Myocardial Infarction  
- Coronary Artery Disease  
- Ventricular Arrhythmias  
- Sudden Cardiac Death  
- Implantable Cardioverter‑Defibrillator (ICD)  
- Cardiac Resynchronization Therapy (CRT)  
- Biventricular Pacing / Biventricular Pacemaker  
- Left Ventricular Systolic Dysfunction  
- Left Ventricular Ejection Fraction  
- QRS Morphology (e.g., Right Bundle Branch Block)  
- QRS Duration  
- Left Ventricular Remodeling  
- Right Bundle Branch Block  
- Symptomatic Heart Failure  
- Mild/Moderate Heart Failure  
- Asymptomatic Heart Failure  
- AV Nodal Ablation / Left Ventricular‑Based Cardiac Stimulation  
- Cost‑Effectiveness of Cardiac Devices  
- Genetic Risk in Arrhythmic/Dilated Cardiomyopathy  
- Risk Stratification for Sudden Cardiac Death  
- Multicenter Automatic Defibrillator Implantation Trial (MADIT)  
- Multicenter Un‑sustained Tachycardia Trial (MUST)  
- Sudden Cardiac Death in Heart Failure Trial (SCD‑HeFT)  
- COMPANION Trial  
- REVERSE Study  
- RAFT Study  
- CARE‑HF Trial  
- PAVE Study  
- HRS Expert Consensus on Arrhythmogenic Cardiomyopathy  
- ICD Cost‑Effectiveness  
- CRT Cost‑Effectiveness  
- QRS‑Based Outcome Prediction  
- Cardiovascular Endothelial Nitric Oxide Pathway (includes guanylate cyclase, cGMP)  
- Pharmacologic Antiarrhythmics (e.g., amiodarone, amiodarone vs ICD)  
- Heart‑Failure Pharmacology (implied by trials addressing ICD/CRT in patients with reduced EF)

Page 113 Extracted Terms:
**Key heart‑disease related terms (from the provided guideline text)**  
- AHA/ACC/HFSA Heart Failure Guideline  
- AHA/ACC/HRS guideline for ventricular arrhythmias & prevention of sudden cardiac death  
- Implantable cardioverter‑defibrillator (ICD)  
- Cardiac resynchronization therapy (CRT)  
- Ventricular arrhythmias  
- Sudden cardiac death (SCD)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Neurohormonal activation in heart failure  
- Baroreflex activation therapy (BAT)  
- Vagus nerve stimulation (VNS)  
- His‑bundle pacing (His‑SP) / His‑bundle correction  
- Biventricular (bi‑V) pacing  
- Cardiac contractility modulation (CCM)  
- Revascularization for coronary artery disease (CAD)  
- Coronary artery bypass grafting (CABG)  
- Percutaneous coronary intervention (PCI)  
- Left‑main equivalent coronary artery disease  
- Ischemic cardiomyopathy  
- Left ventricular dysfunction / systolic dysfunction  
- Left ventricular remodeling  
- Mitral regurgitation (functional MR)  
- Valvular heart disease (mitral, aortic)  
- STICH trial (Surgical Treatment for Ischemic Heart Failure)  
- CABG Patch Trial, STICH, REVIVED‑BCIS2, ESH, NARROW‑CRT, LESSER‑EARTH, SPARE, COMPANION, etc. (study identifiers)  
- Cardiovascular outcome studies (e.g., CASS, STICH, REVIVED, ACC/AHA trials)  
- Implantable electrical interventions (e.g., multipoint pacing, non‑excitatory electrical impulses)  
- Coronary revascularization outcomes (e.g., survival advantage, quality‑of‑life, angina relief)  

These terms capture the principal diseases, interventions, therapies, and clinical studies discussed in the excerpt.

Page 114 Extracted Terms:
- Heart failure  
- Heart failure with preserved ejection fraction (HFpEF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Heart failure with mildly reduced ejection fraction (HFmrEF)  
- Heart failure with improved ejection fraction  
- Cardiomyopathy  
- Dilated cardiomyopathy  
- Left ventricular dysfunction  
- Systolic heart failure  
- Left ventricular ejection fraction  
- Left ventricular remodeling  
- Ventricular remodeling  
- Cardiac resynchronization therapy  
- Cardiac contractility modulation  
- β‑blocker therapy / β‑blockade  
- Renin‑angiotensin system inhibitors  
- Angiotensin receptor neprilysin inhibitor (ARNI)  
- Sacubitril/valsartan  
- Empagliflozin  
- Neurohormonal therapy  
- Cardiac rehabilitation  
- High‑intensity exercise‑based cardiac rehabilitation  
- Mitral regurgitation  
- Functional mitral regurgitation  
- Secondary mitral regurgitation  
- Proportionate functional mitral regurgitation  
- Disproportionate functional mitral regurgitation  
- Percutaneous mitral valve repair (TMR)  
- Surgical mitral valve repair  
- Transcatheter aortic valve replacement (TAVR)  
- Transcatheter aortic valve implantation (TAVI)  
- Surgical aortic valve replacement  
- Aortic stenosis  
- Low‑gradient aortic stenosis  
- Low‑flow aortic stenosis  
- Aortic regurgitation  
- Severe aortic regurgitation  
- Valvular heart disease  
- Prosthetic valve  
- Aortic valve intervention  
- Aortic valve surgery  
- Hemodynamic response  
- Cardiac output  
- Pharmacologic treatment  
- Pericardial disease (implicit in heart failure context)

Page 115 Extracted Terms:
**Heart‑disease related terms extracted from the text**

1. Heart failure  
2. Heart failure with preserved ejection fraction (HFpEF)  
3. Heart failure with reduced ejection fraction (HFrEF)  
4. Left‑ventricular ejection fraction (LVEF)  
5. Ejection fraction (EF)  
6. Diastolic dysfunction / diastolic heart failure  
7. Systolic hypertension  
8. Hypertension / high blood pressure  
9. Myocardial infarction  
10. Atrial fibrillation  
11. Coronary artery disease  
12. Revascularisation (PCI/CABG)  
13. Cardiac rehabilitation  
14. β‑blockers (e.g., nebivolol, bisoprolol, digoxin‑related β‑blockade)  
15. Angiotensin‑converting enzyme inhibitors (ACE‑I)  
16. Angiotensin‑II receptor blockers (ARBs)  
17. Aldosterone antagonists (e.g., spironolactone, eplerenone)  
18. Spironolactone  
19. Empagliflozin (SGLT2 inhibitor)  
20. Sacubitril/valsartan (ARNI)  
21. Candesartan (ARB)  
22. Isosorbide mononitrate  
23. Phosphodiesterase‑5 inhibitors (e.g., sildenafil)  
24. Nebivolol  
25. Digoxin  
26. Brain natriuretic peptide (BNP)  
27. N‑terminal pro‑BNP (NT‑proBNP)  
28. Pleural effusion  
29. Clinical trials & studies:  
   - EMPEROR‑Preserved  
   - EMPEROR‑Reduced  
   - TOPCAT  
   - PARADIGM‑HF  
   - SPRINT  
   - CHARM‑Preserved  
   - SPRINT (intensive vs standard BP)  
   - ALLHAT  
   - PEP‑CHF  
   - Packer et al. EMPEROR‑Preserved (2021)  
   - Ather et al. (non‑cardiac comorbidities)  
   - Soloman et al. (PARADIGM‑HF)  
   - Zanchetti et al. (hypertension BP lowering)  
30. Anti‑hypertensive drugs (e.g., diuretics, antihypertensives)  
31. Endothelin system  
32. Renin‑angiotensin system  
33. Myocardial collagen turnover (diastolic HF evidence)  
34. Coronary microvascular endothelial inflammation  
35. Perindopril (in elderly HF)  

*(All terms above are directly referenced or implied within the provided guideline citations and are core concepts in contemporary heart‑disease management.)*

Page 116 Extracted Terms:
**Key heart‑disease terms extracted from the text**

- Heart failure (HF)  
- Preserved ejection fraction (HFpEF)  
- Reduced ejection fraction (HFrEF)  
- Left ventricular ejection fraction (LVEF) – >40 %  
- Beta‑blockers  
- Renin‑angiotensin‑aldosterone system (RAAS) inhibitors  
- Angiotensin receptor neprilysin inhibitor (ARNI)  
- LCZ696 (LCZ)  
- Sacubitril‑valsartan (LCZ‑DPPV)  
- Isosorbide mononitrate  
- Cardiac amyloidosis  
- Transthyretin (TTR) amyloidosis  
- Wild‑type/transthyretin‑derived amyloidosis  
- Light‑chain (AL) amyloidosis  
- Transthyretin‑related amyloidosis (ATTR)  
- Cardiac imaging with planar technetium‑99m pyrophosphate (Tc‑99m‑PYP)  
- Quantitative kappa and lambda free‑light‑chain assays  
- Genetic testing for TTR mutation  
- Tafamidis therapy  
- Inotersen therapy  
- Patisiran therapy (RNA interference)  
- Diflunisal (repurposed)  
- Doxycycline plus ursodeoxycholic acid (TAU)  
- Green tea extract (observational therapy)  
- Intracardiac thrombosis / embolism  
- Anticoagulation therapy (in cardiac amyloidosis)  
- Implantable cardioverter‑defibrillator (ICD) outcomes  
- CHADS‑VASc score in TTR amyloidosis  
- Left atrial appendage thrombus  
- Advanced heart failure (stage D)  
- INTERMACS profiles of advanced HF  
- Specialist clinics for heart failure  
- Medication adherence / non‑adherence in HF  
- AHA/ACC/HFSA heart‑failure guideline statements  
- ACC/AHA/HFSA focused updates (2017, 2013, 2010)  
- Advanced heart‑failure position statements (European Society of Cardiology, American Heart Association)  
- Heart‑failure management in adults (ACC/AHA 2005 updated)  

These terms capture the core clinical conditions, diagnostic modalities, pharmacologic agents, and guideline frameworks discussed in the provided text.

Page 117 Extracted Terms:
- Heart failure  
- Heart failure with reduced ejection fraction (HFrEF)  
- Heart failure with preserved ejection fraction (HFpEF)  
- Left ventricular assist device (LVAD)  
- Heart transplantation  
- Mechanical circulatory support  
- Inotropic therapy  
- Dobutamine  
- Milrinone  
- Pulmonary hypertension  
- Congestion  
- Elevated jugular venous pressure (JVP)  
- Third heart sound (S3)  
- Hyponatremia  
- Sodium restriction  
- Fluid restriction  
- Cachexia  
- Obesity  
- Prognostic risk scores (e.g., Seattle Heart Failure Model, REMATCH, etc.)  
- Acute decompensated heart failure  
- Advanced heart failure (Stage D)  
- Diuretic therapy  
- Angiotensin‑converting‑enzyme inhibitors (ACEi)  
- Angiotensin receptor blockers (ARBs)  
- β‑adrenoceptor antagonists  
- Implantable cardioverter‑defibrillator (ICD)  
- Defibrillator shocks  
- Inotropic infusion  
- Repeated hospitalizations  
- Nutritional management (diet, sodium, fluid)

Page 118 Extracted Terms:
Heart failure  
Severe heart failure  
Acute heart failure  
Chronic heart failure  
Advanced heart failure  
Inotropic therapy  
Dobutamine infusion  
Milrinone infusion  
Levosimendan therapy  
Beta‑blocker therapy  
Calcium upregulation therapy  
Gene therapy (cardiac)  
Vasodilator therapy  
Mechanical circulatory support (MCS)  
Continuous‑flow device  
Magnetically levitated left ventricular assist device (LVAD)  
Heart‑Mate 3  
Heart‑Ware ventricular assist system (HVAD)  
Intrapericardial LVAD  
Cardiogenic shock  
Intra‑aortic balloon pump  
Bridge to transplant  
Bridge to recovery  
Bridge to cure  
Destination therapy  
Pulmonary hypertension (Group 2)  
Pulmonary vascular resistance  
Right ventricular failure  
Pump thrombus  
Antithrombotic therapy  
Neurologic events  
Quality of life  
Functional status  
Cost‑effectiveness analysis  
Frailty assessment  
InterMACS profiling  
INTERMACS profiles  
Heart transplant waiting list  
Survival outcomes  
Long‑term outcomes  
Clinical guidelines (heart failure)

Page 119 Extracted Terms:
- Heart failure  
- Advanced heart failure  
- End‑stage heart failure  
- Left ventricular assist device (LVAD)  
- Ventricular assist device (VAD)  
- Continuous‑flow LVAD  
- Mechanical circulatory support  
- Cardiac transplantation  
- Heart transplant  
- Donor‑recipient size match  
- Donor heart allocation  
- UNOS (United Network for Organ Sharing)  
- INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support)  
- Right heart failure  
- Pulmonary hypertension  
- Congestive heart failure  
- Cardio‑pulmonary exercise testing  
- Peak VO₂ (peak oxygen uptake)  
- VE/VCO₂ slope  
- B‑type natriuretic peptide (BNP)  
- Cardiac output  
- Hemodynamics  
- Cardiogenic shock  
- Hypertrophic cardiomyopathy  
- Transthyretin amyloid cardiomyopathy  
- Cardiac amyloidosis  
- Muscular dystrophy (cardiac involvement)  
- Cardiac sarcoidosis  
- Congenital heart disease (advanced therapies)  
- Cardiac rehabilitation  
- Exercise capacity  
- Ventilatory efficiency  
- Invasive hemodynamics  
- Pre‑operative risk factors  
- Post‑operative risk factors  
- Neuro‑psychological complications  
- Device bridging to transplant  
- LVAD recovery  
- Device indications  
- Heart failure outcomes  
- Quality of life  
- Survival after transplantation  
- Transplant center volume  
- Recipient mortality  
- Clinical guidelines  
- AHA/ACC/HFSA guidelines  
- ESCAPE trial (clinical assessment of hemodynamics)  
- EVEREST trial (congestion in heart failure)  
- PROTECT trial (renal function in acute HF)  
- Cost‑effectiveness  
- Beta‑adrenergic blocker therapy  
- Heart transplant allocation policy changes  
- Left ventricular assist device trends and outcomes  
- Ventricular assist device therapy versus intensive medical therapy  
- Acute decompensated heart failure hospitalizations  
- Predictors of post‑discharge outcomes in acute heart failure  
- Ventricular assist device as a bridge to transplant  
- Donor heart allocation system (2018 revision)  
- Clinical phenotype classification in heart failure  
- Peak exercise oxygen consumption  
- Hemodynamic assessment during heart failure management  
- Cardiac function metrics (EF, stroke volume, etc.)  
- Inpatient monitoring of heart failure  
- Cardiac transplantation in patients with amyloidosis  
- Transplant outcomes in hypertrophic cardiomyopathy  
- Cardiac transplant in muscular dystrophy patients  
- Transplant outcomes in cardiac sarcoidosis  
- Transplant outcomes in congenital heart disease  
- Long‑term outcomes after heart transplantation.

Page 120 Extracted Terms:
- Heart failure  
- Acute heart failure  
- Acute decompensated heart failure  
- Heart failure with reduced ejection fraction (HFrEF)  
- Heart failure with preserved ejection fraction (HFpEF)  
- Fulminant myocarditis  
- Ventricular arrhythmias  
- β‑blocker (beta‑blocker) therapy  
- Angiotensin‑converting enzyme inhibitor (ACE‑I)  
- Angiotensin receptor blocker (ARB)  
- Aldosterone antagonist (mineralocorticoid receptor blocker)  
- Diuretic therapy  
- Loop diuretic  
- Ultrafiltration  
- Guideline‑directed medical therapy (GDMT)  
- Systolic blood pressure  
- Blood pressure management  
- Renal function (worsening renal function, tubule injury)  
- Cardiorenal syndrome  
- Congestion (in‑hospital and residual)  
- Ejection fraction assessment  
- Diuretic strategies (decongestion strategy)  
- Convergent classification of heart failure (ejection fraction categories, clinical presentation)

Page 121 Extracted Terms:
**Key heart‑disease terms identified in the excerpt**

- Heart failure
- Acute decompensated heart failure
- Chronic heart failure
- Ventricular dysfunction (left‑ventricular systolic dysfunction)
- Cardiogenic shock
- Acute myocardial infarction
- Venous thromboembolism (VTE) prophylaxis
- Renal function / creatinine
- Congestion / residual congestion
- Inotropic agents (milrinone, dobutamine, dopamine, epinephrine, norepinephrine)
- Vasodilators (nesiritide, nitroglycerin, nitroprusside, clevidipine)
- Diuretics (furosemide, ultrafiltration, aquapheresis)
- Mechanical circulatory support (Impella, short‑term mechanical support)
- Anticoagulants / thromboprophylaxis (enoxaparin, unfractionated heparin, rivaroxaban, cerotaparin)
- Thrombotic biomarkers
- Left‑ventricle characteristics
- Hemodynamic response / hemodynamics
- Lactate metabolism
- Mortality / survival outcomes
- Rehospitalization
- Prognostic significance
- Aggressive decongestion
- Dose‑response to low‑dose dopamine / nesiritide
- Vascular tolerance (nitrate tolerance)
- Hemodynamic effects of continuous infusion
- Mechanical support utilization trends
- Inotrope strategies
- Pharmacologic therapy in heart failure guidelines
- AHA/ACC/HFSA Heart Failure Guideline
- AHA/ACC/HFSA 2022 Heart Failure Guideline
- Acute heart failure with preserved vs. reduced ejection fraction

These terms capture the clinical concepts, therapeutic agents, interventions, and outcome measures related to heart disease that appear throughout the provided guidelines and study references.

Page 122 Extracted Terms:
- Cardiogenic shock  
- Mechanical circulatory support  
- Intra‑aortic balloon pump (IABP)  
- Impella device  
- Ventricular assist device (VAD)  
- TandemHeart  
- Veno‑arterial extracorporeal membrane oxygenation (VA‑ECMO)  
- Pulmonary artery catheter  
- Acute myocardial infarction  
- Heart failure (HF)  
- Acute heart failure  
- Heart failure with preserved ejection fraction (HFpEF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Cardiac shock care centers  
- Shock team approach  
- Cardiogenic shock protocols / shock protocols  
- Transition / transitional care interventions  
- Discharge education  
- Hospital‑based discharge medication program  
- Heart failure disease management  
- Performance improvement initiative  
- OPTIMIZE‑HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure)  
- Survival after veno‑arterial ECMO (SAVE) score  
- National cardiogenic shock initiative  
- Hemodynamic monitoring & profiling  
- Acute management of cardiogenic shock


Page 123 Extracted Terms:
- Heart failure  
- Acute myocardial infarction  
- Pneumonia  
- Transitions of care  
- Evidence‑based pharmacotherapy  
- 30‑day readmission  
- Continuous positive airway pressure  
- Adaptive servo‑ventilation  
- Central sleep apnea  
- Positive airway pressure therapy  
- Iron deficiency  
- Intravenous iron therapy (ferric carboxymaltose)  
- Anemia  
- Erythropoiesis‑stimulating therapy (darbepoetin alfa, erythropoietin)  
- SGLT2 inhibitors (dapagliflozin, empagliflozin)  
- Blood‑pressure management  
- Intensive blood‑pressure control  
- Depression in heart failure  
- Major depression therapy (escitalopram, sertraline)  
- Kidney disease / chronic kidney disease  
- Polypharmacy  
- Multimorbidity  
- Clinical practice guideline implementation  
- Heart‑failure readmission intervention (e.g., THRIVE, THRIVE)  
- Variable early follow‑up  
- ESCAPE risk model / discharge score  
- Hospital performance metrics (30‑day all‑cause readmission)  
- Management of comorbidities  
- Exercise capacity  
- Mortality risk  
- Pharmacological interventions (e.g., iron, ACE inhibitors, beta‑blockers, ARNI)  
- Clinical outcomes  
- Meta‑analysis  
- Randomized clinical trial  
- Systematic review  
- Evidence‑based interventions  
- Quality improvement initiatives



Page 124 Extracted Terms:
Heart failure  
Reduced ejection fraction heart failure  
Preserved ejection fraction heart failure  
Heart failure with mildly reduced ejection fraction (HFmrEF)  
Systolic heart failure  
Left ventricular systolic dysfunction  
Dilated cardiomyopathy (implied in HF context)  
Atrial fibrillation (AF)  
Paroxysmal atrial fibrillation  
Persistent atrial fibrillation  
Permanent atrial fibrillation  
Valvular atrial fibrillation (non‑valvular)  
Atrial fibrillation‑associated thromboembolism  
Thromboembolic risk  
CHA₂DS₂-VASc score  
Stroke prevention in AF  
Anticoagulation therapy  
Warfarin  
Dabigatran  
Rivaroxaban  
Apixaban  
Edoxaban  
Novel oral anticoagulants (NOACs)  
Anticoagulant therapy in heart failure  
Rate control in AF  
Rhythm control in AF  
Catheter ablation for AF  
Atrioventricular junction ablation  
Cardiac resynchronization therapy (CRT)  
Biventricular pacing  
Right‑ventricular pacing  
Left‑ventricular pacing  
Cardiac pacing after AV nodal ablation  
Cardiac tamponade (implied within HF context)  
Electrical cardioversion  

Blood pressure management  
Hypertension  
Intensive blood pressure lowering  
ACC/AHA guideline for hypertension  

Sleep‑disordered breathing  
Central sleep apnea  
Sleep‑apnea therapy  
Continuous positive airway pressure (CPAP)  
Positive airway pressure therapy  

Diabetes mellitus (type 2)  
Glycemic treatment strategies  
Sodium‑glucose co‑transporter‑2 (SGLT2) inhibitors  
Empagliflozin  
Canagliflozin  
Ipragliflozin  
Sotagliflozin  
Dapagliflozin  

Cardiovascular endpoints  
Mortality  
Hospitalization for heart failure  
Heart failure events  
Morbidity  

Clinical trials related to heart failure  
DELIVER (dapagliflozin trial)  
EMPEROR‑Preserved (empagliflozin trial)  
SAD, etc. (implied in references)  

Guideline documents  
AHA/ACC/HFSA Heart Failure Guideline  
ACC/AHA/NMA/PCNA hypertension guideline  
ESC guideline for atrial fibrillation  
AHA/ACC/HRS guideline for atrial fibrillation  

Key biomarkers  
Brain natriuretic peptide (BNP)  
Natriuretic peptide levels  

Metabolic therapies  
Insulin resistance  
Metformin (implied via glycemic control)

Cardiac imaging (implied)  
Ejection fraction measurement  
Left ventricular dysfunction assessment  

Page 125 Extracted Terms:
Heart failure  
Congestive heart failure  
Heart failure hospitalization  
Heart failure incidence  
Heart failure survival  
Heart failure mortality  
Heart failure management  
Heart failure guidelines  
Heart failure clinics  
Heart failure patients  
Heart failure in older adults  
Heart failure in women  
Heart failure in black patients  
Heart failure in Hispanic/Latino adults  
Heart failure in American Indian/Alaska Native adults  
Heart failure in Asian American/Pacific Islander adults  
Heart failure risk  
Heart failure disparities  
Heart failure referrals  
Heart failure outcomes  
Implantable cardioverter‑defibrillator therapy  
Cardioverter‑defibrillator therapy  
Cardiac surgery  
Cardiac rhythm  
Cardiology  
Cardiologists  
Cardiovascular disease  
Cardiovascular outcomes  
Cardiovascular morbidity  
Cardiovascular mortality  
Cardiovascular health  
Hypertension  
High blood pressure  
Diabetes  
Diabetes in heart failure  
Comorbidities  
Socioeconomic status  
Socioeconomic deprivation  
Neighborhood deprivation  
Racial disparities  
Ethnic disparities  
Sex differences  
Gender disparities  
Structural racism  
Social determinants of health  
Elderly  
Older adults  
Skilled nursing facility care  
Chagas’ disease  
Trypanosoma cruzi infection  
Stroke  
Ischemic stroke  
Stroke in heart failure  
High blood pressure prevention  
Cardiovascular epidemiology  
Cardiovascular epidemiology in diverse populations

Page 126 Extracted Terms:
- Heart disease  
- Cardiovascular disease  
- Heart failure  
- Congestive heart failure  
- Heart failure with reduced ejection fraction (HFrEF)  
- Heart failure with preserved ejection fraction (HFpEF)  
- Left ventricular assist device (LVAD)  
- Heart transplantation / heart transplant  
- Atrial fibrillation  
- Cardiomyopathy  
- Cardiotoxicity  
- Anthracycline‑induced cardiomyopathy  
- Trastuzumab‑related cardiotoxicity  
- Trastuzumab‑associated heart failure  
- Cardiac events  
- Cardiovascular risk factors  
- Ejection fraction  
- Hypertension  
- Stroke  
- Cardiovascular clinical trials  
- Advanced heart failure therapies  
- Cardio‑oncology  
- Chemotherapy‑related cardiac monitoring  
- Cardiac monitoring  
- Cardiovascular health disparities  
- Cardiovascular epidemiology  
- Cardiovascular morbidity  
- Cardiovascular mortality  
- Cardiac outcomes  
- Cardiac monitoring via echocardiography  
- Cardiac tolerance/long‑term cardiac tolerance  
- Cardiovascular disease in specific populations (Hispanic, African American, Asian, South Asian, American Indian)  
- Cardiovascular disease risk statistics  
- Cardio‑oncological chemotherapy agents (anthracyclines, trastuzumab)  
- Cardiac function assessment  
- Cardiac imaging (echocardiography)  
- Cardiac therapy adherence.

Page 127 Extracted Terms:
- Cardiovascular disease  
- Heart failure (HF)  
- Congestive heart failure  
- Left ventricular dysfunction (LVD)  
- Left ventricular ejection fraction (LVEF)  
- Cardiomyopathy (anthracycline‑induced, trastuzumab‑induced, doxorubicin‑related)  
- Trastuzumab cardiotoxicity  
- Anthracycline‑induced cardiotoxicity  
- Chemotherapy‑related cardiotoxicity  
- Immune‑checkpoint‑inhibitor–induced myocarditis  
- Cardiac dysfunction (clinical & subclinical)  
- Cardio‑oncology / cardio‑oncological prevention  
- Cardiac monitoring (baseline, longitudinal)  
- Biochemical cardiac biomarkers  
  - Troponin I  
  - Troponin T  
  - N‑terminal pro‑B type natriuretic peptide (NT‑proBNP)  
- Myocardial performance index (MPI)  
- Neurohormonal therapies for cardioprotection  
  - Beta‑blockers (e.g., carvedilol, metoprolol)  
  - Angiotensin‑converting‑enzyme inhibitors (ACEi, e.g., enalapril, lisinopril)  
  - Angiotensin II receptor blockers (ARBs, e.g., candesartan)  
  - Mineralocorticoid receptor antagonists (spironolactone)  
- Preventive strategies (e.g., ACEi/ARB, β‑blockers, carvedilol, spironolactone)  
- Cardiotoxicity risk stratification  
- Cardiovascular hospitalizations  
- Cardiovascular mortality  
- Cardiac safety monitoring in cancer therapy  
- Clinical guidelines for heart failure (AHA/ACC/HFSA)  

These terms capture the core heart‑related concepts discussed across the cited clinical statements and studies.

Page 128 Extracted Terms:
- Cardiotoxicity  
- Cardiac dysfunction  
- Myocarditis  
- Pericarditis  
- Heart failure  
- Cardiovascular complications  
- Cardiovascular toxicity  
- Cardiac adverse effects  
- Cardiac safety  
- Vascular toxicity  
- Coronary artery stenosis  
- Arrhythmia  
- Cardiovascular events  
- Ventricular dysfunction  
- Left ventricular dysfunction  
- Cardiac injury  
- Myocardial damage  
- Radiotherapy‑associated heart disease  
- Anthracycline‑related cardiotoxicity  
- Tyrosine kinase inhibitor‑associated cardiovascular toxicity  
- BRAF‑inhibitor‑related cardiotoxicity  
- Immune checkpoint‑inhibitor‑associated myocarditis  
- Cardiac mortality  
- Serious cardiac complications during transplantation  
- Short‑term cardiac toxicity (post‑transplant)  
- Long‑term heart failure after radiotherapy


Page 129 Extracted Terms:
- Heart failure  
- Peripartum cardiomyopathy  
- Dilated cardiomyopathy  
- Pregnancy‑associated heart disease  
- Postpartum cardiomyopathy  
- Cardiovascular disease during pregnancy  
- Pre‑pregnancy counseling for heart disease  
- Maternal outcomes  
- Fetal outcomes  
- Maternal‑fetal outcomes  
- Left ventricular ejection fraction  
- Right ventricular dysfunction  
- Cardiogenic shock  
- Bromocriptine therapy  
- Prolactin cleavage (cathepsin‑D cleaved prolactin)  
- Genetic predisposition to cardiomyopathy  
- Titin (TTN) gene mutations  
- PTHLH gene locus (chromosome 12p11.22)  
- Hypertensive diseases of pregnancy  
- Preeclampsia  
- Left ventricular recovery  
- Clinical phenotyping of cardiomyopathy  
- Risk prediction models for peripartum cardiomyopathy  
- Registry data on peripartum cardiomyopathy  
- ESC guidelines for cardiovascular disease in pregnancy  
- AHA/ACC/HFSA heart‑failure guideline  
- JACC state‑of‑the‑art review on cardiovascular drugs in pregnancy  
- Scientific statement on dilated cardiomyopathy diagnostics and treatment  
- Randomized controlled trials of bromocriptine in peripartum cardiomyopathy  
- Meta‑synthesis of women’s experiences with cardiac disease in pregnancy  
- Observational cohort studies on peripartum cardiomyopathy outcomes  
- Clinical characteristics and outcomes in pregnancy‑associated heart failure.

Page 130 Extracted Terms:
peripartum cardiomyopathy  
cardiovascular outcomes  
pregnancy in women with cardiomyopathy  
postpartum cardiovascular outcomes  
inherited cardiomyopathies  
pregnancy with heart failure  
high‑risk cardiac disease in pregnancy  
cardiac risk assessment  
pregnancy outcomes in women with heart disease  
congenital heart disease  
left ventricular assist device  
implantable cardioverter‑defibrillators  
palliative care  
hospice care  
advance care planning  
left ventricular recovery  
cardiomyopathy and preeclampsia  
B‑type natriuretic peptide  
N‑terminal pro‑B‑type natriuretic peptide  
Bromocriptine  
breastfeeding in heart failure  
heart failure  
acute myocardial infarction  
cardiovascular complications  
cardiac disease in pregnancy  
cardiovascular disease

Page 131 Extracted Terms:
**Key heart‑disease terms extracted from the text**

- Heart failure  
- Heart failure with preserved ejection fraction (HFpEF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Congestive heart failure  
- Aortic valve replacement  
- Transcatheter aortic valve replacement (TAVR)  
- Mitral valve repair  
- Left ventricular dysfunction  
- Coronary artery bypass grafting (CABG)  
- Myocardial infarction (AMI)  
- Pulmonary artery hemodynamic monitoring  
- Cardiac resynchronization therapy (CRT)  
- Implantable cardioverter‑defibrillator (ICD)  
- Atrial fibrillation  
- Pulmonary‑vein isolation (for AF)  
- Heart failure registry (e.g., CHAMP‑HF, EVEREST, I‑PRESERVE, SOLVD)  
- Kansas City Cardiomyopathy Questionnaire (KCCQ)  
- Minnesota Living with Heart Failure Questionnaire (MLHFQ)  
- New York Heart Association (NYHA) functional classification  
- Health‑related quality of life (HRQoL)  
- Patient‑reported outcomes (PROs)  
- Hospitalization risk  
- Mortality risk  
- Prognostic biomarkers  
- Symptom burden  
- Palliative care for heart disease  
- Advance care planning  
- End‑of‑life care  
- Cardiovascular mortality  

These terms capture the primary conditions, interventions, measurement tools, outcomes, and care concepts relevant to heart disease that appear throughout the referenced guideline and study citations.

Page 132 Extracted Terms:
- Heart Failure  
- Heart Failure Guideline (AHA/ACC/HFSA)  
- Advanced Heart Failure  
- Heart Transplant  
- Mechanical Circulatory Support (MCS)  
- Cardiology  
- Cardiovascular Medicine  
- Heart Failure Society of America (HFSA)  
- American Heart Association (AHA)  
- American College of Cardiology (ACC)

Page 133 Extracted Terms:
- Heart Failure  
- HF  
- Heart Disease  
- Cardiovascular  
- Cardiology  
- Cardiac  
- Cardiac Electrophysiology  
- Advanced Heart Failure  
- Heart Failure Guideline  
- Heart Failure Society of America (HFSA)  
- Transplantation  
- HFSA Heart Failure Guideline  
- Cardiovascular Medicine  
- Heart Failure Management  
- Cardiology Department  
- Cardiac Care

Page 134 Extracted Terms:
**Key heart‑disease related terms extracted from the text**

1. Heart Failure  
2. Heart Disease  
3. Cardiovascular Disease  
4. Cardiovascular Medicine  
5. Cardiology  
6. Cardiomyopathy  
7. 2022 AHA/ACC/HFSA Heart Failure Guideline  
8. American Heart Association (AHA)  
9. American College of Cardiology (ACC)  
10. Heart Failure Society of America (HFSA)  
11. Clinical Statements  
12. Guideline Advisor  
13. Committee Member  
14. Clinical Trial Enroller  
15. Device (as used in cardiac therapy)  
16. Drug (as used in cardiac therapy)  
17. Heart Failure Management  
18. Cardiac Diagnostics  
19. Cardiac Interventions  
20. AHA/ACC/HFSA Guideline  

*(The list captures the central cardiovascular topics, organizations, and clinical concepts referenced in the document.)*

Page 135 Extracted Terms:
- Heart failure  
- Heart failure management  
- Heart failure guideline  
- AHA (American Heart Association)  
- ACC (American College of Cardiology)  
- HFSA (Heart Failure Society of America)  
- Cardiovascular disease  
- Cardiology  
- Pulmonary hypertension  
- Circulation (journal)  
- Clinical practice guidelines  
- Clinical statements  
- Management of heart failure  
- Heart disease  

These terms capture the primary concepts related to heart disease discussed in the provided guideline excerpt.

Page 136 Extracted Terms:
- Heart Failure  
- AHA (American Heart Association)  
- ACC (American College of Cardiology)  
- HFSA (Heart Failure Society of America)  
- AHA/ACC/HFSA Heart Failure Guideline  
- Circulation (cardiology journal)  
- Heartflow (cardiovascular imaging/diagnostics platform)  
- Medtronic (cardiovascular device manufacturer)  
- NuPulse CV (cardiovascular technology)  
- CVRx (cardiovascular research/therapy company)  
- Cardiovascular  
- Cardiovascular & Risk Reduction Center  
- JAMA (medical journal covering cardiovascular topics)  
- NIH (National Institutes of Health, many cardiovascular research programs)

Page 137 Extracted Terms:
**Key Terms Related to Heart Disease**

- Heart failure  
- HFSA (Heart Failure Society of America)  
- AHA/ACC/HFSA Heart Failure Guideline  
- AHA (American Heart Association)  
- ACC (American College of Cardiology)  
- Cardiology / Cardiovascular health  
- Pulmonary hypertension  
- Pulmonary Hypertension Association  
- Cardiology Fellowship Program  
- US Food and Drug Administration (FDA)  
- Centers for Medicare & Medicaid Services (CMS)  
- Medical device manufacturers related to cardiac care:  
  - Abbott  
  - Medtronic  
  - Boston Scientific  
  - Cardiora  
  - CVRx  
- Pharmaceutical companies with cardiac indications:  
  - AbbVie (Bristol Myers Squibb)  
  - Amgen  
  - AstraZeneca Pharmaceuticals*  
  - Bayer  
  - Boehringer Ingelheim  
  - GlaxoSmithKline  
  - Eli Lilly  
  - Merck  
  - Pfizer  
  - Sanofi  
  - Novartis*  
  - Novo Nordisk  
  - United Therapeutics (Pulmonary Hypertension Association)  
  - Janssen Pharmaceuticals  
  - Myokardia  
  - Ionis  
  - Prothena  
  - Regeneron  
  - Shifamed  
  - Tenax  
  - Ironwood  
  - Cytokinetics  
  - Vascular/heart‑related biotech: Cytokinetics, CVRx, Cyclerion, etc.  
- Regulatory/industry advisory organizations:  
  - National Institutes of Health (NIH)  
  - Clinical Practice Guidelines (Joint Committee)  
- Specialty hospitals and academic centers in cardiology:  
  - St. Vincent Hospital  
  - Northwestern University  
  - Yale University  
  - University of Pennsylvania  
  - University of North Carolina  
  - University of Arizona  
  - Mount Sinai  

These terms encompass cardiovascular conditions, professional societies, regulatory bodies, medical device and pharmaceutical companies, and academic institutions that are directly relevant to the field of heart disease.

Page 138 Extracted Terms:
- Heart failure (HF)  
- Structural heart disease  
- Increased filling pressures  
- Left atrial volume index (LAVI)  
- Left ventricular mass index (LVMI)  
- Relative wall thickness (RWT)  
- Left ventricular wall thickness  
- Left ventricular ejection fraction (LVEF)  
- Global longitudinal strain (GLS)  
- E/e′ ratio  
- Septal e′ velocity  
- Lateral e′ velocity  
- Tricuspid regurgitation (TR) velocity  
- Pulmonary artery systolic pressure (PASP)  
- Brain natriuretic peptide (BNP)  
- N‑terminal proBNP (NT‑proBNP)  
- Atrial fibrillation (AF)  
- Chronic kidney disease (CKD)  
- Diagnostic biomarkers for heart failure  
- Echocardiographic assessment (echo)  
- Ventricular systolic function  
- Ventricular diastolic function  
- Diastolic dysfunction  
- Thrombolysis in Myocardial Infarction (TIMI)  
- Pulmonary Embolism Response Team (PERT)  

These terms capture the key concepts and measurements relevant to heart disease discussed in the provided guideline excerpt.



Page 1 Extracted Terms:
- Hypertrophic cardiomyopathy  
- Left ventricular outflow tract obstruction  
- Septal reduction therapy  
- Septal alcohol ablation  
- Implantable cardioverter‑defibrillator  
- Cardiac myosin inhibitors  
- Diastolic dysfunction  
- Systolic dysfunction  
- Ventricular arrhythmias  
- Atrial fibrillation  
- Family screening  
- Genetics  
- Sarcomeric genes  
- Risk stratification  
- Sports  
- Sudden cardiac death  
- Exercise stress testing  
- Rhythm monitoring  
- Shared decision‑making  
- Pregnancy  
- Cardiovascular magnetic resonance imaging  
- Echocardiography  
- Athlete  
- Physical activity  
- Occupation  

Page 2 Extracted Terms:
- Hypertrophic Cardiomyopathy (HCM)  
- Left Ventricular Outflow Tract (LVOT) Obstruction  
- Diastolic Dysfunction  
- Mitral Regurgitation  
- Myocardial Ischemia  
- Autonomic Dysfunction  
- Sudden Cardiac Death (SCD)  
- Implantable Cardioverter‑Defibrillator (ICD)  
- Pharmacologic Management of Symptomatic Patients with Obstructive HCM  
- Invasive Treatment for Obstructive HCM (e.g., surgical myectomy, alcohol septal ablation)  
- Nonobstructive HCM with Preserved Ejection Fraction (EF)  
- HCM and Advanced Heart Failure (HF)  
- HCM and Atrial Fibrillation (AF)  
- HCM and Ventricular Arrhythmias  
- Echocardiography (ECHO)  
- Cardiovascular Magnetic Resonance (CMR) Imaging  
- Cardiac Computed Tomography (CT)  
- Heart Rhythm Assessment (electrocardiography, Holter, event monitoring)  
- Angiography and Invasive Hemodynamic Assessment  
- Exercise Stress Testing (treadmill, bicycle)  
- Genetics and Family Screening for HCM  
- Genotype‑Positive, Phenotype‑Negative Individuals  
- SCD Risk Assessment in Adults with HCM  
- SCD Risk Assessment in Children/Adolescents with HCM  
- Patient Selection for ICD Placement  
- Device Selection Considerations (ICD, CRT‑D, pacemaker)  
- Lifestyle Considerations for HCM (Recreational Physical Activity, Competitive Sports)  
- Occupational Considerations for Patients with HCM  
- Pregnancy Management in HCM  
- Management of Comorbidities in HCM  
- Evidence Gaps and Future Directions (e.g., refining diagnosis, new therapies, risk stratification, arrhythmia management, genetic architecture)

Page 3 Extracted Terms:
- Hypertrophic Cardiomyopathy (HCM)  
- Atrial fibrillation (AF)  
- Implantable cardioverter‑defibrillator (ICD)  
- Sudden cardiac death (SCD)  
- Left ventricular ejection fraction (LVEF)  
- Left ventricular outflow tract obstruction (LVOTO)  
- Obstructive HCM  
- Non‑obstructive HCM  
- Exercise stress testing  
- Septal reduction therapy (SRT)  
- Myosin inhibitor (e.g., mavacamten)  
- Disopyramide  
- β‑blocker  
- Nondihydropyridine calcium channel blocker  
- Anticoagulation  
- Valsartan  
- NYHA functional class III–IV  
- Risk score / risk factors  
- Systolic dysfunction (LVEF < 50 %)  
- Pregnancy (in HCM)  
- Recreational physical activity  
- Competitive sports



Page 4 Extracted Terms:
- Hypertrophic cardiomyopathy  
- Left ventricular outflow tract obstruction  
- Sudden cardiac death  
- Implantable cardioverter‑defibrillator (ICD)  
- Cardiac myosin inhibitors  
- Mavacamten  
- Septal myectomy  
- Alcohol septal ablation  
- Atrial fibrillation  
- Oral anticoagulation  
- Direct‑acting oral anticoagulants (DOACs)  
- Warfarin  
- CHA₂DS₂‑VASc score  
- Exercise stress testing  
- Exercise tolerance  
- Genetic testing (HCM‑associated variants)  
- Family screening (first‑degree relatives)  
- Risk stratification (pediatric and adult)  
- Pediatric risk calculator  
- Ventricular arrhythmia  
- Stroke risk (HCM patients)  
- Ambulatory telemetry  
- Metabolic equivalents of task (METs)  
- Cardiac contractility  
- Actin‑myosin interaction inhibition  
- Cardiac imaging (serial imaging for HCM)

Page 5 Extracted Terms:
**Key terms related to heart disease**

- Hypertrophic Cardiomyopathy  
- Cardiovascular disease  
- Cardiovascular health  
- Cardiovascular care  

These terms are central to the discussion of heart disease in the provided text.

Page 6 Extracted Terms:
**Key heart‑disease terms extracted from the guideline text**

- Hypertrophic cardiomyopathy (HCM)  
- Left ventricular hypertrophy  
- Subvalvular stenosis  
- Coronary ischemia  
- Atrial fibrillation  
- Stroke volume  
- Sudden cardiac death  
- Cardiac transplant  
- Diagnostic imaging  
- Echocardiography  
- Magnetic resonance imaging (MRI)  
- Nuclear magnetic resonance imaging (NMRI)  
- Computed tomographic angiography (CTA)  
- Genetic testing for cardiac conditions  
- Guideline‑directed management and therapy (GDMT)  
- Cardiac drugs (pharmacological treatment regimens)  
- Cardiac devices (implantable devices)  
- Procedural treatments (surgical or interventional procedures)  
- Clinical evaluation of cardiac patients  
- Dosage and medication interactions  
- Contraindications in cardiovascular therapy  

These terms capture the core cardiovascular concepts and clinical focus discussed in the guideline.

Page 7 Extracted Terms:
**Heart‑disease–related terms extracted from the text**

- Hypertrophic cardiomyopathy (HCM)  
- Heart failure (HF)  
- Atrial fibrillation (AF)  
- Coronary artery disease (CAD)  
- Sudden cardiac death (SCD)  
- Ventricular tachycardia (VT)  
- Ventricular fibrillation (VF)  
- Implantable cardioverter‑defibrillator (ICD)  
- Cardiac resynchronization therapy (CRT)  
- Left ventricular hypertrophy (LVH)  
- Left ventricular outflow tract obstruction (LVOTO)  
- Left ventricular assist device (LVAD)  
- Mitral regurgitation (MR)  
- Systolic anterior motion (SAM)  
- Subclinical atrial fibrillation (SCAF)  
- Nonsustained ventricular tachycardia (NSVT)  
- Left bundle branch block (LBBB)  
- Late gadolinium enhancement (LGE)  
- Ejection fraction (EF / LVEF)  
- Cardiovascular magnetic resonance (CMR)  
- Cardiopulmonary exercise test (CPET)  
- Transesophageal echocardiogram (TEE)  
- Transthoracic echocardiogram (TTE)  
- Guideline‑directed medical therapy (GDMT)  
- Extended septal myectomy (ESM)  
- Septal reduction therapy (SRT)  
- Metabolic equivalent (MET)  
- Direct‑acting oral anticoagulants (DOAC)  
- Right ventricular (RV)  
- Left ventricular (LV)  
- New York Heart Association (NYHA)

Page 8 Extracted Terms:
- Hypertrophic Cardiomyopathy (HCM)  
- Idiopathic hypertrophic subaortic stenosis  
- Hypertrophic obstructive cardiomyopathy  
- Left ventricular (LV) outflow tract obstruction (LVOTO)  
- Left ventricular (LV)  
- Heart failure (HF)  
- Genetic testing for HCM  
- Racial and ethnic disparities in HCM prevalence  
- Female under‑diagnosis of HCM  
- Social determinants of health influencing cardiac disease  
- Structural inequities in access to cardiac specialists  
- Diagnostic testing for HCM  
- Clinical strategies and interventions for cardiac disease  
- Class of Recommendation (clinical guideline classification)  
- Level of Evidence (clinical research grading)

Page 9 Extracted Terms:
- Hypertrophic Cardiomyopathy (HCM)  
- Left Ventricular Hypertrophy (LVH)  
- Left Ventricular (LV) wall thickness  
- RASopathies  
- Mitochondrial myopathies  
- Glycogen storage disease  
- Lysosomal storage disease  
- Fabry disease  
- Amyloidosis  
- Sarcoid (sarcoidosis)  
- Danon cardiomyopathy  
- Athlete’s heart  
- Hypertensive cardiomyopathy  
- Left‑sided obstructive lesions  
- Valvular stenosis  
- Subvalvular stenosis  
- Antero‑apical infarction  
- Stress cardiomyopathy  
- 2‑D echocardiography  
- Cardiovascular magnetic resonance (CMR)  
- Wall thickness ≥15 mm  
- Body surface area–adjusted z‑score  
- Standard deviations above the mean  
- Sarcomere gene  
- Pathogenic variant  
- Likely pathogenic variant  
- Basal anterior septum  
- Anterior free wall  
- Systolic anterior motion (SAM)  
- Hypertrophied papillary muscles  
- Apically displaced papillary muscles  
- Myocardial crypts  
- Anomalous insertion of papillary muscles  
- Elongated mitral valve leaflets  
- Myocardial bridging  
- Right ventricular hypertrophy  
- Sarcomere proteins  
- Abnormal electrocardiogram (ECG)  
- Phenotype  
- Genotype‑positive / phenotype‑negative  
- Diagnostic challenges  
- Pathophysiologic mechanisms  
- Natural history  
- Treatment strategies

Page 10 Extracted Terms:
- Hypertrophic cardiomyopathy (HCM)  
- Left ventricular hypertrophy (LVH)  
- Left ventricular ejection fraction (LVEF)  
- Myocardial fibrosis  
- Diastolic dysfunction  
- Systolic dysfunction  
- Sudden cardiac death (SCD)  
- Implantable cardioverter‑defibrillator (ICD)  
- Ventricular arrhythmia  
- Atrial fibrillation (AF)  
- Thromboembolic stroke  
- Heart failure (HF)  
- Myocardial ischemia  
- Left ventricular outflow tract obstruction (LVOTO)  
- Mitral regurgitation (MR)  
- Small vessel ischemia  
- Intramural coronary artery abnormalities  
- Elongated mitral valve leaflets  
- Congenital anomalies of the submitral valve apparatus  
- Cardiac sarcomere genes  
- Sarcomere‑related structures  
- Beta‑myosin heavy chain 7 (MYH7)  
- Myosin‑binding protein C3 (MYBPC3)  
- TNNI3 (troponin I type 3)  
- TNNT2 (troponin T type 2)  
- TPM1 (tropomyosin 1)  
- MYL2 (myosin light chain 2)  
- MYL3 (myosin light chain 3)  
- ACTC1 (alpha‑actin 1)  
- Pathogenic sarcomeric variant  
- Likely pathogenic variant  
- Nonfamilial HCM  
- Monogenic disease  
- Polygenic susceptibility  
- Genetics‑mediated risk stratification  
- Noninvasive risk markers  
- Cardiometabolic risk factors  
- Obesity  
- Hypertension  
- Diabetes mellitus  
- Obstructive sleep apnea  
- Lifestyle modification (risk factor reduction)  
- Cardiovascular therapies  
- Interventional procedures (e.g., septal reduction)  
- Clinical guidelines for HCM management  
- Outcome prediction in HCM patients  
- Adverse event risk (mortality, HF, stroke, arrhythmia)  
- Disease‑related morbidity and mortality in adults  
- Dynamic LVOTO  
- Autonomic dysfunction  
- Metabolic and energetic abnormalities in HCM.

Page 11 Extracted Terms:
- Hypertrophic Cardiomyopathy (HCM)  
- Left Ventricular Outflow Tract Obstruction (LVOTO)  
- Subaortic Membrane (SAM) of the mitral valve  
- Peak LVOT gradient  
- Intracavitary pressure  
- Diastolic dysfunction  
- LV compliance  
- Microvascular ischemia  
- Sarcomere gene variant carriers  
- Restrictive physiology  
- Atrial fibrillation (AF)  
- Mitral regurgitation (MR)  
- Leaflet abnormalities (excessive leaflet length, anomalous papillary muscle insertion)  
- Mid‑to‑late systolic jets  
- Central and anterior jets  
- Septal reduction therapy (SRT)  
- Intrinsic coronary flow reserve (CRF)  
- Coronary atherosclerosis  
- LV apical aneurysm  
- Heart failure (HF)  
- Stroke  
- Ventricular arrhythmias  
- Myocardial bridging  
- Autonomic dysfunction  
- Heart rate recovery  
- Inappropriate vasodilatation  
- Blood pressure response to exercise  
- Epicardial coronary artery compression  
- Intramural arterioles (density)  
- Myocardial oxygen supply‑demand mismatch  
- Systolic dysfunction  
- Ventricular preload, afterload, contractility  
- Valsalva maneuver  
- Dobutamine stress testing  
- Echocardiographic assessment  
- Invasive LVOT gradient measurement.

Page 12 Extracted Terms:
- Hypertrophic Cardiomyopathy (HCM)  
- HCM  
- Left Ventricular Outflow Tract Obstruction (LVOTO)  
- Septal Reduction Therapy (SRT)  
- Invasive SRT  
- Implantable Cardioverter‑Defibrillator (ICD) implantation  
- Genetic testing  
- Genetic counseling  
- Shared decision‑making  
- Multidisciplinary HCM centers  
- Comprehensive HCM centers  
- Primary HCM centers  
- Advanced therapies for relief of LVOTO  
- High‑intensity or competitive exercise  
- Mitral valve replacement  
- Morbidity  
- Mortality  
- Clinical outcomes  
- Risk assessment  
- Benefit assessment  
- Diagnostic testing  
- Surveillance testing  
- Care coordination  
- Patient and caregiver goals  
- Lifestyle and activity modification  
- Referral pathways  
- Cardiac management decisions  

Page 13 Extracted Terms:
- Hypertrophic Cardiomyopathy (HCM)  
- Comprehensive HCM center  
- Primary HCM center  
- Septal reduction therapy (SRT)  
- Invasive SRTs (myectomy, alcohol septal ablation)  
- Catheter ablation  
- Ventricular tachyarrhythmias  
- Atrial tachyarrhythmias  
- Advanced heart failure (HF) therapies  
- Heart transplant  
- Implantable cardioverter‑defibrillator (ICD)  
- Genetic counseling  
- Sports participation counseling  
- Clinical diagnosis of HCM  
- Physical examination  
- Family history (3‑generation)  
- Cardiac murmur  
- Transthoracic echocardiography (TTE)  
- Advanced echocardiographic imaging  
- Left ventricular outflow tract obstruction (LVOTO)  
- Latent LVOTO detection  
- Echocardiography‑guided SRT  
- Cardiovascular magnetic resonance (CMR) imaging  
- Invasive LVOTO evaluation  
- Coronary angiography  
- Stress testing for LVOTO or advanced HF consideration  
- Risk stratification for sudden cardiac death (SCD)  
- Adult ICD decision‑making (COR 1 & 2a)  
- Pediatric ICD decision‑making (COR 2b)  
- ICD implantation in adults and children  
- Atrial fibrillation (AF) management  
- Stroke prevention in AF  
- AF catheter ablation  
- Heart failure with reduced ejection fraction (HFrEF)  
- Heart failure with preserved ejection fraction (HFpEF)  
- Cardiac resynchronization therapy (CRT)  
- Pharmacologic therapy for HCM  
- Invasive management of obstructive HCM  
- Mitral valve replacement (within 1 year of procedure)  
- Residual mitral regurgitation (moderate or greater)  
- Repeat procedure rate for SRTs  
- Symptomatic improvement (≥1 NYHA functional class)  
- Rest or provoked left ventricular outflow tract (LVOT) gradient <50 mm Hg  
- Left anterior descending (LAD) artery  
- Pacemaker implantation for post‑operative complete heart block  
- NYHA functional class (I–IV)

Page 14 Extracted Terms:
- Hypertrophic cardiomyopathy (HCM)  
- Left ventricular hypertrophy (LVH)  
- Mitral valve systolic anterior motion (SAM)  
- Left ventricular outflow tract obstruction (LVOTO)  
- Mitral regurgitation (MR)  
- Fourth heart sound  
- Systolic murmur (harsh crescendo‑decrescendo)  
- Apical point of maximal impulse  
- Abnormal carotid pulse  
- Valsalva maneuver  
- Squat‑to‑stand maneuver  
- Passive leg‑raising maneuver  
- Walking test (provocative maneuver)  
- 12‑lead electrocardiogram (ECG)  
- Echocardiography (2‑D echo)  
- Comprehensive cardiac history  
- Family history (3 generations)  
- Genotype‑positive screening family member  
- Phenocopy (mimic) of HCM  
- RASopathies (e.g., neurofibromatosis, Noonan syndrome)  
- Glycogen storage diseases  
- Mitochondrial disorders  
- Anderson–Fabry disease  
- Amyloidosis (infiltrative cardiomyopathy)  
- Friedreich’s ataxia  
- Danon disease  
- Renal dysfunction  
- Infiltrative disorders  
- Metabolic acidosis  
- Newborn metabolic screening  
- Specific metabolic assays  
- Biochemical screening  
- Genetic testing  
- Neuromuscular assessment  
- Infant of mother with gestational diabetes  
- Chest pain (symptom)  
- Dyspnea (symptom)  
- Palpitations (symptom)  
- Syncope (symptom)  
- Screening intervals:  
  - Every 1–2 years (pediatric, genotype‑positive)  
  - Every 2–3 years (all other children/adolescents)  
  - Every 3–5 years (adults)  
- Screening for asymptomatic first‑degree relatives  
- Early childhood cognitive and sensory impairments (associated with phenocopies)  
- Skeletal muscle weakness or movement disorder (associated with phenocopies)  
- Peripheral neuropathy (associated with phenocopies)

Page 15 Extracted Terms:
- Hypertrophic Cardiomyopathy (HCM)  
- Transthoracic Echocardiogram (TTE)  
- Transesophageal Echocardiogram (TEE)  
- Left Ventricular Outflow Tract (LVOT) Gradient  
- Dynamic LVOT Obstruction (LVOTO)  
- Mitral Regurgitation (MR)  
- Myocardial Hypertrophy  
- Systolic Dysfunction  
- Diastolic Dysfunction  
- Valvular Heart Disease (VHD)  
- Mitral Valve Anatomy and Function  
- Echocardiographic Screening in First‑Degree Relatives  
- Genotype‑Positive/Phenotype‑Negative Screening  
- Cardiac Magnetic Resonance (CMR) Imaging  
- Left Ventricular Apical Aneurysm  
- Provocative Maneuvers (Valsalva, squat‑to‑stand, standing)  
- Exercise TTE  
- Surgical Septal Myectomy  
- Alcohol Septal Ablation  
- Intracoronary Ultrasound‑Enhancing Contrast  
- Septal Perforator Injection  
- Septal Radiofrequency Therapy (SRT)  
- Wall Thickness Measurement  
- Chamber Dimension Assessment  
- Resting Peak LVOT Gradient < 50 mm Hg  
- Dynamic LVOTO Detection and Quantification  
- Phenotype Severity Assessment  
- Sudden Cardiac Death (SCD) Risk Stratification  
- Serial Follow‑up Echocardiography (every 1–2 years)  
- Non‑conclusive TTE → TEE or CMR  
- Imaging Modality for Myocardial Hypertrophy Pattern (apical, atypical, etc.)  
- Ultrasound‑Enhancing Agent Use (intravenous, intracardiac)  
- Structural Cardiac Abnormalities (mitral valve apparatus, subaortic membrane)  
- Concomitant Cardiac Abnormalities (systolic, diastolic, valvular)

Page 16 Extracted Terms:
- Hypertrophic Cardiomyopathy (HCM)  
- Left ventricular outflow tract obstruction (LVOTO)  
- LVOT gradient  
- Valsalva maneuver  
- Stress echocardiography  
- Postprandial exercise  
- Exercise testing  
- Intraoperative transesophageal echocardiography (TEE)  
- Surgical myectomy  
- Mitral valve abnormalities  
- Mitral regurgitation (MR)  
- Septal hypertrophy  
- Systolic anterior motion (SAM)  
- Ventricular septal defect (VSD)  
- Aortic insufficiency (AI)  
- Left ventricular (LV) systolic function  
- LV diastolic function  
- LV strain (speckle‑track)  
- Left ventricular hypertrophy (LVH)  
- Apical hypertrophy  
- Aneurysm (LV)  
- Thrombus (LV)  
- Alcohol septal ablation  
- Transthoracic echocardiography (TTE)  
- Cardiac magnetic resonance imaging (CMR)  
- Ultrasound‑enhancing agents  
- Family screening (first‑degree relatives)  
- Genotype‑positive, phenotype‑negative status  
- Penetrance  
- Sudden cardiac death (SCD)  
- Implantable cardioverter‑defibrillator (ICD)  
- Cardiac intervention (e.g., myectomy, ICD placement)  
- Hydration status  
- Diuretics  
- Vasodilators  
- Hypertension  
- Septal reduction therapy (SRT)  
- LVOT gradient reduction post‑ablation  
- Residual SAM post‑myectomy or ablation  

Page 17 Extracted Terms:
- Hypertrophic Cardiomyopathy (HCM)  
- CMR Imaging (Cardiac Magnetic Resonance Imaging)  
- LVH (Left Ventricular Hypertrophy)  
- LGE (Late Gadolinium Enhancement)  
- SCD (Sudden Cardiac Death)  
- ICD (Implantable Cardioverter‑Defibrillator)  
- LV wall thickness  
- EF (Ejection Fraction)  
- LV apical aneurysm  
- Myocardial replacement fibrosis  
- LV mass  
- LVOT (Left Ventricular Outflow Tract) obstruction  
- LV cavity dimensions  
- Pressure overload (hypertension, athletic conditioning)  
- Infiltrative cardiomyopathies (e.g., amyloid)  
- Lysosomal storage diseases  
- Glycogen storage diseases  
- Echocardiography  
- ECG (12‑lead electrocardiogram)  
- Cardiac symptoms  
- Inherited heart disease  
- Systolic dysfunction (EF < 50%)  
- Ventricular tachyarrhythmias  
- Ventricular dysfunction  
- Heart failure (HF) symptoms  
- Mitral valve structural abnormalities  
- Subvalvular apparatus abnormalities  
- Noninvasive risk markers  
- LV remodeling (ventricular cavity enlargement, wall thinning)  
- LV segment involvement  
- Quantification of LGE (≥ 15 % LV mass)  
- Diagnostic clarification  
- Risk stratification  
- Preprocedural planning for surgical or catheter‑based interventions (SRT)

Page 18 Extracted Terms:
- Hypertrophic Cardiomyopathy (HCM)  
- Left Ventricular Outflow Tract (LVOT)  
- Septal myectomy  
- Percutaneous alcohol ablation  
- Cardiac Magnetic Resonance (CMR) imaging  
- Echocardiography  
- Late Gadolinium Enhancement (LGE)  
- Sudden Cardiac Death (SCD)  
- Implantable Cardioverter-Defibrillator (ICD) therapy  
- Left Ventricular Hypertrophy (LVH)  
- Systolic dysfunction  
- Systolic Anterior Motion (SAM)  
- Subvalvular apparatus  
- Papillary muscles (abnormal positioning, insertion)  
- Accessory muscle bundles  
- Chordal connections  
- Apical aneurysm  
- Myocardial fibrosis  
- Cardiac Computed Tomography (CT)  
- CT angiography  
- Coronary anatomy  
- Coronary stenosis  
- Anomalous origin of coronary arteries  
- Radiation exposure (CT)  
- Heart rhythm assessment  
- 12‑lead Electrocardiogram (ECG)  
- Ambulatory ECG monitoring (24–48 h)  
- Extended (>24 h) ECG monitoring  
- Event recording (for palpitations/light‑headedness)  
- Atrial fibrillation (AF)  
- Anticoagulation  
- Risk score for AF  
- First‑degree relatives (screening)  
- Risk factors (e.g., for AF, SCD)  
- Periodic longitudinal evaluation (CMR)  
- LV wall‑thickness measurement  
- Subaortic membrane  
- Intracardiac thrombus  

Page 19 Extracted Terms:
- 12‑lead ECG  
- LVH (left ventricular hypertrophy)  
- Repolarization changes  
- Wolff‑Parkinson‑White pattern  
- Phenocopies of hypertrophic cardiomyopathy (HCM)  
- Amyloidosis  
- Low‑voltage ECG findings  
- Conduction delays  
- Pseudo‑myocardial‑infarction pattern  
- HCM screening (family screening)  
- Pre‑participation athletic screening  
- Ambulatory electrocardiographic monitoring  
- Ventricular tachyarrhythmias  
- Non‑sustained ventricular tachycardia (NSVT)  
- Sudden cardiac death (SCD)  
- Implantable cardioverter‑defibrillator (ICD)  
- Arrhythmias (general)  
- Atrial fibrillation (AF)  
- Stroke (as an AF complication)  
- Left atrial dilatation  
- NYHA functional class III–IV heart failure  
- HCM‑AF risk score  
- Angiography (coronary)  
- Coronary atherosclerosis  
- Surgical myectomy  
- Invasive hemodynamic assessment (cardiac catheterization)  
- LVOTO (left ventricular outflow tract obstruction)  
- Myocardial ischemia  
- Gene carriers (HCM genetics)  
- Echocardiography (screening modality)

Page 20 Extracted Terms:
- Hypertrophic cardiomyopathy (HCM)  
- Echocardiography (transthoracic echocardiography, TTE)  
- Left‑ventricular outflow tract obstruction (LVOTO)  
- LVOT gradient / LVOT peak gradient  
- Invasive hemodynamic assessment  
- Coronary artery disease (CAD)  
- Coronary angiography  
- Atherosclerosis / atherosclerotic risk factors  
- Myocardial bridging  
- Alcohol septal ablation  
- Exercise stress testing / exercise TTE  
- Cardiopulmonary exercise testing  
- Heart failure (HF)  
- New York Heart Association (NYHA) functional classes II–IV, III–IV, IV  
- Valsalva maneuver  
- Premature ventricular contraction (PVC)  
- Brockenbrough‑Braunwald‑Morrow sign  
- End‑hole pigtail catheter  
- Halo catheter  
- Left‑ventricular function / cardiac output  
- Filling pressures (e.g., left‑systolic filling pressure)  
- Pulmonary hypertension  
- Concomitant valve disease  
- Mechanical circulatory support (e.g., LVAD)  
- Heart transplantation  
- LVOT peak gradient ≥ 50 mm Hg  
- Dynamic LVOTO detection and quantification  
- Provocative maneuvers for LVOT gradient assessment  
- Epicardial CAD assessment  
- Non‑invasive testing (nuclear imaging, stress echo)  
- Exercise TTE for functional capacity and prognostic information  

Page 21 Extracted Terms:
- Hypertrophic cardiomyopathy (HCM)  
- Heart failure (HF)  
- Ventricular arrhythmias  
- Sudden cardiac death (SCD)  
- Cardiopulmonary exercise test (CPET)  
- Cardiovascular exercise capacity  
- Myocardial ischemia  
- Resting electrocardiogram (ECG)  
- Wall motion abnormalities  
- Myocardial perfusion imaging  
- Single‑photon emission computed tomography (SPECT)  
- Positron emission tomography (PET)  
- Epicardial coronary artery disease (CAD)  
- Coronary angiography (CT or invasive)  
- Dobutamine stress testing  
- Intracavitary gradients  
- Left ventricular outflow tract (LVOT) obstruction (LVOTO)  
- LVOT gradients  
- Transthoracic echocardiography (TTE)  
- Valsalva maneuver  
- Stress echocardiography  
- Postprandial exercise stress testing  
- Pediatric exercise testing (≥ 7–8 years old)  
- Cardiac transplantation evaluation  
- Abnormal blood pressure response to exercise  
- Transplant‑free survival  
- Exercise‑induced ischemic electrocardiographic changes  
- Chronotropic incompetence  
- Heart rate reserve  
- Peak oxygen consumption (peak VO₂)  
- Peak VO₂ pre‑operative  
- Peak VO₂ post‑operative  
- Ventilatory efficiency  
- Anaerobic threshold  
- Advanced heart failure progression  
- Septal myectomy  
- Functional limitation (provocable LVOTO, abnormal BP response, arrhythmias, etc.)  
- Functional capacity (age‑ and sex‑adjusted)  
- Advanced therapies for LVOTO  
- 3‑generation family history screening  
- Genetic testing for HCM and HCM phenocopies  
- Cascade genetic testing for family members  
- Genetic counseling in cardiovascular disease.

Page 22 Extracted Terms:
- Hypertrophic cardiomyopathy (HCM)  
- Genetic testing  
- Cascade genetic testing  
- Sudden unexplained death (SCD)  
- Electrocardiogram (ECG)  
- Two‑dimensional echocardiogram  
- Postmortem genetic testing  
- Variant reclassification  
- Variant of uncertain significance (VUS)  
- Genotype‑positive / genotype‑negative  
- Sarcomere genes  
- MYH7  
- MYBPC3  
- TNNI3  
- TNNT2  
- TPM1  
- MYL2  
- MYL3  
- ACTC1  
- PRKAG2 (glycogen‑storage disease)  
- LAMP2 (Danon disease)  
- GLA (Fabry disease)  
- Transthyretin amyloid cardiomyopathy  
- RASopathies  
- Enzyme replacement therapy  
- Pretest genetic counseling  
- Posttest genetic counseling  

These terms encapsulate the major heart‑disease concepts discussed in the guideline excerpt.

Page 23 Extracted Terms:
- Hypertrophic Cardiomyopathy (HCM)  
- Sarcomere variant  
- Pathogenic variant  
- Likely pathogenic variant  
- Variant of Uncertain Significance (VUS)  
- Cascade genetic testing  
- Penetrance  
- Sudden Cardiac Death (SCD)  
- Implantable Cardioverter‑Defibrillator (ICD)  
- Atrial Fibrillation (AF)  
- Ventricular arrhythmias  
- Heart Failure (HF)  
- Genetic testing (including exome sequencing, targeted gene panel)  
- Postmortem testing / Molecular autopsy  
- Family screening / clinical surveillance  
- Autosomal dominant inheritance  
- Prenatal genetic counseling  
- In vitro fertilization with preimplantation genetic diagnosis (PGD)  
- Phenotypic heterogeneity

These terms capture the core disease concepts, genetic considerations, diagnostic methods, and clinical interventions discussed in the guideline excerpt.

Page 24 Extracted Terms:
- **Hypertrophic Cardiomyopathy (HCM)**  
- **Atrial Fibrillation (AF)**  
- **Cardiovascular Magnetic Resonance (CMR)**  
- **Cardiopulmonary Exercise Test (CPET)**  
- **Electrocardiography / Electrocardiogram (ECG)**  
- **Echocardiography / Echocardiogram (Echo)**  
- **Heart Failure (HF)**  
- **Implantable Cardioverter‑Defibrillator (ICD)**  
- **Left Ventricular Outflow Tract Obstruction (LVOTO)**  
- **Sudden Cardiac Death (SCD)**  
- **Variant of Unknown Significance (VUS)**  
- **Clinical Screening / Surveillance**

Page 25 Extracted Terms:
- Hypertrophic cardiomyopathy (HCM)  
- Genotype‑positive, phenotype‑negative individuals  
- Preclinical HCM  
- Left ventricular hypertrophy (LVH)  
- Myocardial strain abnormalities  
- Left ventricular relaxation abnormalities  
- Myocardial crypts  
- Mitral valve leaflet abnormalities  
- Abnormal trabeculae  
- Myocardial scarring  
- Electrocardiographic (ECG) abnormalities  
- Serum NT‑proBNP concentrations  
- Implantable cardioverter‑defibrillator (ICD)  
- Primary prevention  
- Cardiac imaging  
- Serial clinical assessment  
- Electrocardiography  
- Cardiac surveillance  
- Competitive sports participation  
- Pathogenic variant  
- Likely pathogenic variant  
- Variant of unknown significance (VUS)

Page 26 Extracted Terms:
**Key terms related to heart disease**

- Hypertrophic cardiomyopathy (HCM)  
- Genotype‑positive, phenotype‑negative individuals  
- Sudden cardiac death (SCD)  
- Implantable cardioverter‑defibrillator (ICD)  
- Medical therapy (e.g., diltiazem)  
- Surgical therapy  
- Device therapy  
- Clinical HCM onset  
- Phenotype conversion  
- Screening (genotype‑positive family members)  
- Age‑related risk (≤18 years, >18 years, mid‑life ≈ 50 years)  
- Family history of SCD  
- Competitive sports participation  
- Ambulatory electrocardiography (AECG)  
- Exercise stress testing  
- Non‑invasive SCD risk assessment  
- Personal history of cardiac arrest or sustained ventricular arrhythmias  
- Personal history of arrhythmic syncope  
- Family history of premature HCM‑related sudden death, cardiac arrest, or sustained ventricular arrhythmias  
- Maximal left ventricular (LV) wall thickness  
- Left ventricular ejection fraction (EF)  
- LV apical aneurysm  
- Nonsustained ventricular tachycardia (NSVT) episodes  
- Cardiac magnetic resonance (CMR) imaging  
- Late gadolinium enhancement (LGE)  
- Echocardiographic parameters: left atrial diameter, LV outflow tract (LVOT) gradient  
- Estimated 5‑year sudden death risk  
- Risk stratification for ICD placement  
- Shared decision‑making  
- SCD risk markers (clinical, imaging, electrophysiologic)  
- Disease penetrance  
- Age‑specific risk prediction models  
- Clinical screening intervals (1–2 years)  

These terms capture the central concepts, risk factors, diagnostic tools, treatment options, and patient management strategies discussed in the guideline excerpt.

Page 27 Extracted Terms:
**Key Heart‑Disease Terms (from the HCM guideline excerpt)**  

- Hypertrophic Cardiomyopathy (HCM)  
- Sudden Cardiac Death (SCD)  
- Implantable Cardioverter‑Defibrillator (ICD)  
- Ventricular tachyarrhythmias  
- Nonsustained Ventricular Tachycardia (NSVT)  
- Ventricular Tachycardia (VT)  
- Left Ventricular (LV) wall thickness  
- Left Ventricular Hypertrophy (LVH)  
- Left Ventricular ejection fraction (EF)  
- Late Gadolinium Enhancement (LGE)  
- Cardiovascular Magnetic Resonance (CMR) imaging  
- LV apical aneurysm  
- LV systolic dysfunction (EF < 50 %)  
- Family history of sudden death from HCM  
- Syncope (unexplained, arrhythmia‑related)  
- Genetic testing / genotype status (pathogenic/likely pathogenic variants)  
- Predictive risk scores (5‑year SCD risk)  
- Risk stratification (for ICD decision‐making)  
- Ambulatory electrocardiographic monitoring (24‑48 h)  
- Cardiac imaging (for maximal LV thickness, wall thickness, EF, LGE)  
- Transmural scar (identified by LGE)  
- Left Ventricular Outflow Tract Obstruction (LVOTO)  
- Periodic reassessment of SCD risk  
- Longitudinal evaluation of HCM patients  
- Myocardial replacement fibrosis  
- Extensive LGE (≥ 15 % LV mass)  
- Pediatric HCM risk indicators (e.g., maximal wall thickness z‑score ≥ 20, age ≤ 50 yr for family history)

Page 28 Extracted Terms:
- Hypertrophic Cardiomyopathy (HCM)  
- Sudden Cardiac Death (SCD)  
- Estimated 5‑year SCD risk  
- Echocardiographic left atrial diameter  
- Maximal instantaneous LVOT gradient  
- Continuous‑wave Doppler technique  
- Systolic dysfunction (EF < 50%)  
- Ejection fraction (EF)  
- Apical aneurysm  
- Late Gadolinium Enhancement (LGE)  
- Left ventricular (LV) wall thickness  
- Left ventricular outflow tract (LVOT)  
- LV posterior wall thickness  
- Non‑sustained ventricular tachycardia (NSVT)  
- Ambulatory electrocardiographic monitoring  
- Non‑invasive SCD risk assessment  
- Implantable cardioverter‑defibrillator (ICD)  
- Cardiac magnetic resonance (CMR) imaging  
- Myocardial fibrosis  
- Myocardial replacement fibrosis  
- Genotype / genetic variants  
- Syncope  
- Family history of premature HCM‑related sudden death  
- Personal history of cardiac arrest or sustained ventricular arrhythmias  
- Body surface area–adjusted z‑score for LV wall thickness  
- Risk prediction models for children with HCM  
- Shared decision‑making for ICD placement  
- Psychological impact of ICD implantation  
- Inappropriate ICD shock  
- Contrast‑enhanced CMR  
- 24‑ to 48‑hour monitoring  
- 5‑year risk estimate calculation  
- Interventricular septal thickness in diastole  
- LV wall thickness measurement in any segment  
- Presence of apical aneurysm on imaging  
- Extent of late gadolinium enhancement (LGE) on CMR  
- Pediatric‑specific risk markers  
- Clinical evaluation of risk factors (Figures 1, 3; Table 8)

Page 29 Extracted Terms:
**Key heart‑disease terms extracted from the guideline text**

- Hypertrophic Cardiomyopathy (HCM)  
- Implantable Cardioverter‑Defibrillator (ICD)  
- Sudden Cardiac Death (SCD)  
- Left Ventricular Outflow Tract (LVOT) gradient  
- Non‑Sustained Ventricular Tachycardia (NSVT)  
- Late Gadolinium Enhancement (LGE)  
- Left Ventricular Hypertrophy (LVH)  
- Apical aneurysm (LV apical aneurysm)  
- Left Ventricular ejection fraction (EF)  
- Systolic dysfunction (EF < 50 %)  
- Transmural scar  
- Massive LVH (≥ 30 mm in any LV segment)  
- Unexplained syncope  
- Exercise‑induced ischemia  
- Family history of early HCM‑related SCD  
- Cardiac arrest (documented)  
- Sustained ventricular tachycardia (VT)  
- Ventricular tachyarrhythmias (VT/VF)  
- Contrast‑enhanced Cardiac Magnetic Resonance (CMR) imaging  
- Ambulatory monitoring (for NSVT)  
- Competitive athletics (as a clinical consideration)  
- Risk stratification  
- Shared decision‑making (in ICD placement)  
- Risk‑estimate calculator (5‑year SCD risk)  
- SCD risk markers (e.g., LV apical aneurysm, LGE, EF < 50 %)  

These terms capture the main clinical entities, diagnostic measures, risk factors, and therapeutic considerations discussed in the guideline.

Page 30 Extracted Terms:
- Hypertrophic cardiomyopathy (HCM)  
- Sudden cardiac death (SCD)  
- Implantable cardioverter‑defibrillator (ICD)  
- Ventricular tachycardia (VT)  
- Ventricular fibrillation (VF)  
- Non‑sustained ventricular tachycardia (NSVT)  
- Late gadolinium enhancement (LGE)  
- Left ventricular systolic dysfunction (EF < 50 %)  
- Left ventricular apical aneurysm  
- Risk stratification  
- Risk‑factor algorithm  
- Primary‑prevention ICD  
- Secondary‑prevention ICD  
- Pediatric HCM  
- Age‑appropriate risk factors  
- Genotype status  
- Left atrial diameter z‑score  
- Ambulatory (Holter) monitoring  
- SCD risk calculator  
- Shared‑decision making  
- Long‑term complications of ICD therapy

Page 31 Extracted Terms:
**Key heart‑disease terms extracted from the guideline text**

- Hypertrophic Cardiomyopathy (HCM)  
- Implantable Cardioverter‑Defibrillator (ICD)  
- Transvenous ICD  
- Subcutaneous ICD  
- Single‑chamber ICD  
- Dual‑chamber ICD  
- Single‑coil ICD leads  
- Dual‑coil ICD leads  
- Defibrillation threshold  
- Ventricular tachycardia (VT)  
- Ventricular fibrillation (VF)  
- Atrial tachycardia  
- Atrial fibrillation (AF)  
- Obstructive HCM  
- Non‑obstructive HCM  
- Cardiac resynchronization therapy (CRT)  
- Left bundle branch block (LBBB)  
- Left ventricular ejection fraction (LVEF)  
- New York Heart Association (NYHA) class  
- Nonsustained ventricular tachycardia (NSVT)  
- Sudden cardiac death (SCD)  
- Late gadolinium enhancement (LGE)  
- Left ventricular hypertrophy (LVH)  
- Bradycardia  
- Conduction abnormalities  
- Pediatric ICD implantation  
- Epicardial leads  
- Family history of HCM  
- Massive LVH  
- Unexplained syncope  
- Cardiovascular magnetic resonance (CMR)  
- Shared decision‑making (as a key process in risk assessment)

Page 32 Extracted Terms:
- Hypertrophic cardiomyopathy (HCM)  
- Implantable cardioverter‑defibrillator (ICD)  
- Transvenous ICD  
- Subcutaneous ICD  
- ICD lead failure / lead infection  
- Oversensing (post‑exercise)  
- Inappropriate shock  
- Bradycardia pacing  
- Ventricular tachycardia (VT)  
- Defibrillation threshold / testing  
- Single‑coil ICD lead  
- Dual‑coil ICD lead  
- Left‑sided ICD implant  
- Right‑sided ICD implant  
- Epicardial ICD system  
- Left ventricular outflow tract (LVOT)  
- LVOT gradient (≥30 mm Hg)  
- Dual‑chamber pacing system  
- RV apical pacing  
- Cardiac resynchronization therapy (CRT)  
- CRT‑defibrillator  
- Left ventricular assist device (LVAD)  
- Heart transplantation  
- New York Heart Association (NYHA) functional class  
- Left ventricular ejection fraction (LVEF)  
- QRS duration  
- Left bundle branch block (LBBB)  
- Beta blockers (non‑vasodilating)  
- LVOT obstruction (LVOTO)  
- Pharmacologic management of obstructive HCM  
- AHA/ACC/HFSA guideline  
- AHA/ACC/HRS guideline  
- Atrial lead  
- Supraventricular arrhythmia  
- Ventricular arrhythmia  
- Pediatric atrial tachyarrhythmia  

These are the principal heart‑disease related terms extracted from the guideline text.

Page 33 Extracted Terms:
- Hypertrophic cardiomyopathy (HCM)  
- Obstructive HCM  
- Left ventricular outflow tract obstruction (LVOTO)  
- Beta blockers  
- Nondihydropyridine calcium channel blockers  
- Verapamil  
- Diltiazem  
- Myosin inhibitor  
- Mavacamten  
- Disopyramide  
- Septal reduction therapy (SRT)  
- Phenylephrine  
- Vasoconstrictors (non‑inotropic)  
- Fluid administration  
- Diuretics  
- Low‑dose oral diuretics  
- High‑dose diuretics  
- Left‑sided filling pressures  
- Volume overload  
- Dyspnea  
- Hypotension  
- Acute hypotension  
- Angiotensin‑converting enzyme inhibitors (ACE inhibitors)  
- Angiotensin receptor blockers (ARBs)  
- Dihydropyridine calcium channel blockers  
- Digoxin  
- Left ventricular ejection fraction (LVEF)  
- Outflow tract gradient  
- Dynamic LV obstruction  
- Pharmacologic therapy  
- Symptom relief  
- Risk evaluation and mitigation strategy  
- Comprehensive HCM centers  
- Midventricular obstruction

Page 34 Extracted Terms:
- Hypertrophic Cardiomyopathy (HCM)  
- Left Ventricular Outflow Tract Obstruction (LVOTO)  
- LVOT gradient  
- Septal Reduction Therapy (SRT)  
- Alcohol Septal Ablation  
- Surgical Myectomy  
- Mitral Valve Replacement  
- Atrioventricular Node  
- Atrial Fibrillation (AF)  
- β‑Blocker  
- Verapamil  
- Diltiazem  
- Disopyramide  
- Phenylephrine (intravenous vasoconstrictor)  
- Diuretics  
- Vasoconstrictors  
- Vasodilators  
- Inotropic agents  
- Guideline‑Directed Medical Therapy (GDMT)  
- New‑Guideline Recommendations (NG)  
- Acute Hypotension  
- Preload  
- Afterload  
- Contractility  
- Heart Rate  
- Supraventricular Tachycardia  
- Congestive Heart Failure (HF)  
- Pulmonary Hypertension  
- Left Atrial Enlargement (LAE)  
- Systolic Anterior Motion (SAM)  
- Anomalous Papillary Muscle  
- Elongated Anterior Mitral Leaflet  
- Intrinsic Mitral Valve Disease  
- Multivessel Coronary Artery Disease (CAD)  
- Aortic Stenosis  
- NYHA Functional Class  
- Dynamic LVOT Gradient at Rest or Provocation  
- Targeted Anterior Septal Thickness  
- Comprehensive HCM Centers  
- Symptom‑relief of LVOTO  
- Hemodynamic Parameters (gradient ≥ 50 mm Hg)  
- Clinical Eligibility Criteria  
- Early Surgical Intervention (NYHA II)  
- Risk Stratification (Serious Comorbidities, Advanced Age)  
- Shared Decision‑Making in Treatment Choices  
- Contraindication: High‑Dose Diuretics  
- Contraindication: Pure Vasodilators  
- Contraindication: Positive Inotropes  
- Conduction System Modulation  
- Pre‑operative Functional Capacity Assessment  
- Treadmill Exercise Testing  
- SRT Not Recommended in Asymptomatic Patients  
- Mitral Regurgitation (MR) Associated with LVOTO  
- SRT in Pediatric and Young Adult Patients (> 100 mm Hg gradient)  
- Use of β‑Blockade with Vasoconstrictor to Reduce Heart Rate and Contractility  
- Low‑Dose Diuretics for Congestion in HCM  
- Aggressive Diuresis Leading to LVOTO Amplification  
- High-Grade LVOT Gradients (80–100 mm Hg)  
- Life‑threatening Bradycardia with Verapamil in Neonates  
- Clinical Outcomes for SRT and Surgical Myectomy  
- Safety Profile of Verapamil and Diltiazem in HCM  
- Post-Treatment Surveillance of LVOT Gradients  
- Role of Primary HCM Centers in Procedural Excellence  
- Management of Concomitant Cardiac Conditions in HCM  
- Use of Vasodilators in Hypertension and Renal Protection  
- Treatment of Concomitant Coronary Artery Disease in HCM patients  
- Pharmacologic Modulation of Preload and Afterload in HCM Therapy.

Page 35 Extracted Terms:
- Hypertrophic Cardiomyopathy (HCM)  
- Left Ventricular Outflow Tract Obstruction (LVOTO)  
- Septal Myectomy (surgical)  
- Transaortic Septal Myectomy / Extended Septal Myectomy (ESM)  
- Alcohol Septal Ablation  
- Septal Reduction Therapy (SRT)  
- Atrial Fibrillation (AF) / Paroxysmal AF  
- Pulmonary Vein Isolation  
- Maze Procedure  
- Anomalous Papillary Muscle  
- Elongated Anterior Mitral Leaflet  
- Mitral Regurgitation (MR)  
- Coronary Artery Disease (CAD)  
- Aortic Stenosis  
- Left Ventricular Hypertrophy  
- Pulmonary Hypertension  
- Left Atrial Enlargement  
- Arrhythmia (atrial, ventricular)  
- Permanent Pacemaker  
- New‑Onset AF Burden  
- NYHA Functional Class  
- HCM Center / Comprehensive Center  
- Modified Konno Procedure  
- Transapical Approach  
- Combined Transaortic & Transapical Approach  
- Gradient Relief (LVOT gradient)  
- Post‑operative Hemodynamic Instability  
- Recurrent Outflow Tract Obstruction  
- Systolic Anterior Motion (SAM)  
- Clinical Success Rate  
- Operative Mortality Rate  
- Pacemaker Implantation Risk  
- Repeat Intervention Risk  
- Surgical Myectomy Benefit (e.g., improvement in pulmonary hypertension, exercise tolerance, reverse atrial enlargement)

Page 36 Extracted Terms:
- Hypertrophic Cardiomyopathy (HCM)  
- Nonobstructive HCM  
- Obstructive HCM  
- Septal myectomy  
- Septal reduction therapy (SRT)  
- Systolic anterior motion (SAM)  
- Mitral regurgitation (MR)  
- Mitral valve replacement  
- Mitral valve repair  
- NYHA functional class  
- Angina  
- Dyspnea  
- Heart failure (HF)  
- Left ventricular (LV) dysfunction  
- LV wall thickness  
- LV end‑diastolic volume  
- LV stroke volume  
- Diastolic dysfunction  
- Restrictive physiology  
- Coronary artery disease (CAD)  
- Beta blockers  
- Nondihydropyridine calcium channel blockers (e.g., verapamil, diltiazem)  
- Oral diuretics  
- Angiotensin‑converting enzyme inhibitors (ACEi)  
- Angiotensin receptor blockers (ARBs)  
- Valsartan  
- Procedural mortality  
- Hospital morbidity/mortality  
- Length of hospitalization  
- Shared decision‑making  
- Exercise tolerance  
- Ventricular remodeling  
- Pathogenic cardiac sarcomere genetic variant  
- Implantable cardioverter‑defibrillator (ICD)  
- Hypertension  
- Diabetes  
- Obesity  
- Obstructive sleep apnea  
- Physical inactivity

Page 37 Extracted Terms:
- Hypertrophic cardiomyopathy (HCM)  
- Obstructive HCM  
- Non‑obstructive HCM  
- LV outflow tract obstruction (LVOTO)  
- Left ventricular ejection fraction (LVEF)  
- Systolic dysfunction  
- Diastolic dysfunction  
- LV mass  
- LV wall thickness  
- LV end‑diastolic volume  
- LV stroke volume  
- LV end‑diastolic pressure  
- Left atrial size  
- Diastolic parameters  
- Left ventricle (LV)  
- Myocardial fibrosis  
- Heart failure (HF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- NYHA functional class I–IV  
- NYHA class III–IV  
- Guideline‑directed medical therapy (GDMT)  
- Beta blockers  
- Nondihydropyridine calcium‑channel blockers  
- Verapamil  
- Diltiazem  
- Loop diuretics  
- Thiazide diuretics  
- Aldosterone antagonists  
- Angiotensin‑converting enzyme inhibitors (ACEi)  
- Angiotensin receptor blockers (ARBs)  
- Losartan  
- Valsartan  
- Sarcomeric genetic variants  
- Angina  
- Refractory angina  
- Dyspnea  
- Ventricular arrhythmias  
- Transapical myectomy  
- Heart transplantation  
- Mechanical circulatory support  
- Cardiopulmonary exercise testing (CPET)  
- Implantable cardioverter‑defibrillator (ICD)  
- ICD shocks (appropriate ICD shocks)  
- Chronotropic incompetence  
- Ambulatory ECG  
- Stress test (exercise test)  
- Bradycardia  
- Atrioventricular conduction block  
- LV end‑diastolic volume <50 mL/m² (small cavity definition)  
- LV stroke volume <30 mL/m² (small cavity definition)

Page 38 Extracted Terms:
- Hypertrophic Cardiomyopathy (HCM)  
- Heart Failure (HF)  
- Nonobstructive HCM  
- Obstructive HCM / LVOTO (left ventricular outflow tract obstruction)  
- New York Heart Association (NYHA) functional classes I–IV  
- Left Ventricular Ejection Fraction (LVEF)  
- Reduced LVEF (<50%)  
- Severely reduced LVEF (<35%)  
- Generalized Disease‑Managing Therapy (GDMT)  
- Cardiac resynchronization therapy (CRT)  
- Implantable Cardioverter‑Defibrillator (ICD)  
- Left Ventricular Assist Device (LVAD)  
- Continuous‑flow LVAD  
- Heart transplantation / transplant evaluation  
- Life‑threatening ventricular arrhythmias  
- Sudden Cardiac Death (SCD)  
- Ventricular tachycardia/fibrillation (VT/VF)  
- Ventricular arrhythmia monitoring  
- Cardiopulmonary exercise testing (CPET)  
- Peak oxygen consumption (VO₂ peak)  
- Minute ventilation to CO₂ production (VE/VCO₂)  
- Ventilatory anaerobic threshold  
- Cardiac myosin inhibitors (e.g., mavacamten)  
- Negative inotropes (verapamil, diltiazem, disopyramide)  
- Restrictive physiology / restrictive cardiomyopathy phenotype  
- Left Ventricular (LV) dilation / chamber size  
- Coronary Artery Disease (CAD)  
- Valvular heart disease  
- Metabolic disorders affecting the heart  
- AHA/ACC/HFSA heart failure guideline  
- United Network for Organ Sharing (UNOS) heart transplant allocation policy  
- Heart transplant listing criteria for HCM  
- Mechanical circulatory support (MCS)  
- Advanced heart failure therapies  
- Clinical guideline classification (e.g., B‑NR, B‑R, C‑EO, C‑LD)  
- Prognostic risk stratification tools  

These terms capture the key concepts, diagnoses, therapeutic interventions, risk factors, diagnostic tools, and guideline references relevant to heart disease as discussed in the provided text.

Page 39 Extracted Terms:
- Hypertrophic Cardiomyopathy (HCM)  
- Cardiomyopathy  
- Myocardial contractility  
- Left Ventricular Ejection Fraction (LVEF)  
- Mavacamten (myosin‑inhibitor drug)  
- Heart transplantation  
- Management of symptoms in HCM  
- Clinical guideline (2024 Hypertrophic Cardiomyopathy Guideline)

Page 40 Extracted Terms:
- Hypertrophic cardiomyopathy (HCM)  
- Heart failure algorithm  
- Cardiac myosin inhibitor  
- Left ventricular ejection fraction (LVEF) / ejection fraction (EF)  
- Cardiac resynchronization therapy (CRT)  
- Guideline‑directed medical therapy (GDMT)  
- Implantable cardioverter‑defibrillator (ICD)  
- Left ventricular assist device (LVAD)  
- Left bundle branch block (LBBB)  
- New York Heart Association (NYHA) classification  

Page 41 Extracted Terms:
- Hypertrophic Cardiomyopathy (HCM)  
- Left ventricular ejection fraction (LVEF)  
- Systolic dysfunction  
- Heart failure (HF)  
- LVAD (left ventricular assist device)  
- ICD (implantable cardioverter‑defibrillator)  
- Cardiac resynchronization therapy (CRT)  
- Atrial fibrillation (AF)  
- Direct‑acting oral anticoagulants (DOACs)  
- Vitamin K antagonists (e.g., warfarin)  
- Beta‑blockers  
- Verapamil  
- Diltiazem  
- Disopyramide  
- Temporary mechanical circulatory support (e.g., biventricular support)  
- Ventricular arrhythmias / malignant arrhythmias  
- LV cavity size / dimensions (e.g., ≥46‑50 mm)  
- QRS duration (≥150 ms)  
- Left bundle branch block (LBBB)  
- Malignant arrhythmia risk stratification (SHaRe score)  
- Sudden cardiac death (SCD)  
- AF burden / episode duration (>24 h or >5 min)  
- Cardioversion and rhythm‑control strategies  
- Catheter ablation for AF  
- Surgical myectomy with concomitant AF ablation  
- HF hospitalizations  
- Survival outcomes in HF/HCM patients  
- Anticoagulation strategy independent of CHA₂DS₂‑VASc score  
- Systolic EF thresholds (≤35%, 35‑50%, ≤50%)  

These terms capture the major heart‑disease concepts referenced in the guideline excerpts.

Page 42 Extracted Terms:
- Hypertrophic Cardiomyopathy (HCM)  
- Atrial fibrillation (AF)  
- Clinically evident AF  
- Asymptomatic/Subclinical AF (SCAF)  
- Atrial flutter  
- Thromboembolic events / thromboembolism  
- Stroke risk / systemic embolization  
- Anticoagulation therapy  
- Vitamin K antagonists (e.g., warfarin)  
- Direct oral anticoagulants (DOACs)  
- Left atrial appendage occlusion devices  
- CHA₂DS₂‑VASc score  
- Rhythm‑control strategy  
- Rate‑control strategy  
- Antiarrhythmic drugs  
- Catheter ablation  
- Surgical atrial fibrillation ablation  
- Myectomy (surgical myectomy)  
- Supraventricular arrhythmias  
- Cardiac devices / implantable devices  
- Device‑detected AF  
- Intracardiac electrocardiograms (ECGs)  
- Cardiac imaging for monitoring AF burden  
- Left ventricular outflow tract obstruction (LVOTO)  
- Nondihydropyridine calcium channel blockers  
- Beta‑blockers  
- Digoxin  
- Verapamil  
- Atrioventricular node ablation  
- Pacemaker implantation  
- Stroke prevention measures  
- Antithrombotic therapy effectiveness  
- AF duration thresholds  
- AF burden metrics  
- Thromboembolism incidence in HCM  
- Anticoagulation risk-benefit assessment in HCM.

Page 43 Extracted Terms:
- Hypertrophic cardiomyopathy (HCM)  
- Atrial fibrillation (AF)  
- Stroke  
- CHADS2 score  
- NYHA functional class  
- Left atrial diameter  
- Vascular disease  
- Left ventricular (LV) wall thickness  
- LV outflow tract obstruction (LVOTO)  
- Diastolic dysfunction / impairment  
- Mitral regurgitation (MR)  
- Antiarrhythmic drugs  
  - Amiodarone  
  - Disopyramide  
  - Flecainide  
  - Propafenone  
  - Sotalol  
  - Dofetilide  
  - Dronedarone  
- Implantable cardioverter‑defibrillator (ICD)  
- Catheter ablation  
- Electrophysiologic remodeling  
- Structural remodeling  
- Atrial remodeling  
- Torsades de pointes (TdP)  
- Prolonged QTc  
- Proarrhythmia  
- Bradycardia  
- Fatigue  
- Headache  
- Hepatic toxicity (liver)  
- Pulmonary toxicity (lung)  
- Endocrine toxicity (thyroid)  
- Dermatologic toxicity (skin)  
- Neurologic toxicity (neurologic)

Page 44 Extracted Terms:
Hypertrophic Cardiomyopathy (HCM)  
HCM  
Atrial fibrillation (AF)  
AF  
Catheter ablation  
Surgical AF ablation  
Open heart surgery  
Myectomy  
Left ventricular outflow tract (LVOT) gradient  
LVOT gradient  
Mitral regurgitation (MR)  
MR  
Negative atrial remodeling  
Atrial remodeling  
Ventricular arrhythmias  
Ventricular tachyarrhythmias  
Life‑threatening ventricular tachyarrhythmia  
Heart transplantation  
Transplant assessment  
Implantable cardioverter‑defibrillator (ICD)  
ICD  
Antiarrhythmic drug therapy  
Amiodarone  
Dofetilide  
Mexiletine  
Sotalol  
Beta‑blockers  
Propafenone  
Flecainide  
Antitachycardia pacing  
Programming antitachycardia pacing  
Sustained monomorphic VT  
Ventricular flutter  
ICD shocks  
ICD programming  
Arrhythmia burden  
Left atrial size  
AF recurrence  
AF burden  
Quality of life  
Overall survival  
Transplant referral  
OPTIC trial (Optimal Pharmacological Therapy in Cardioverter Defibrillator Patients)  
Heart failure (HF)  
Advanced heart failure  
Restrictive physiology  
Intracardiac arrhythmias

Page 45 Extracted Terms:
**Key terms related to heart disease (as extracted from the provided text)**

- Hypertrophic cardiomyopathy (HCM)  
- Implantable cardioverter‑defibrillator (ICD)  
- Sudden cardiac death (SCD)  
- Ventricular fibrillation (VF)  
- Ventricular tachycardia (VT)  
- Ventricular flutter  
- Anti‑arrhythmic agents / therapy  
- Anti‑tachycardia pacing (ATP)  
- Catheter ablation  
- Epicardial ablation  
- Endocardial ablation  
- Combined epicardial‑endocardial ablation  
- Apical aneurysm  
- Aneurysmectomy (surgical aneurysmectomy)  
- Sympathetic denervation  
- Left cardiac sympathetic denervation (LCS)  
- Proarrhythmia (drug‑induced arrhythmia)  
- ICD shocks (appropriate and inappropriate)  
- Recurrent ventricular arrhythmias  
- Pharmacologic therapy (beta‑blockers, etc.)  
- Psychological trauma related to ICD shocks  
- Cardiorespiratory fitness  
- Physical performance / endurance  
- Recreational physical activity (moderate–vigorous intensity)  
- Competitive sports participation  
- Metabolic equivalents (METs) – light, moderate, vigorous  
- Borg scale of perceived exertion  
- Phenotype‑negative / genotype‑positive status for HCM  
- Shared decision‑making (SDM) in sports/physical activity  
- Comprehensive cardiac evaluation (annual reassessment)  
- ICD placement for sports participation (contraindicated)  
- Cardiac risk stratification for HCM patients  

These terms capture the principal clinical concepts, interventions, and lifestyle considerations pertaining to heart disease as described in the guideline excerpt.

Page 46 Extracted Terms:
- Hypertrophic cardiomyopathy  
- HCM  
- Sudden cardiac death (SCD)  
- Genotype‑positive, phenotype‑negative status  
- Ventricular arrhythmias  
- Arrhythmic events  
- Exercise intensity  
- METs (metabolic equivalents)  
- Moderate‑intensity exercise  
- Vigorous‑intensity exercise  
- Peak oxygen consumption  
- Nonlethal arrhythmias  
- Risk prediction models for SCD  
- Family history of SCD  
- NYHA functional class I‑II  
- Cardiovascular mortality  
- Obstructive physiology  
- Ambulatory electrocardiography  
- Exercise stress testing  
- Physical activity guidelines for adults and children  
- Aerobic exercise  
- Competitive sports participation  
- Exercise training compliance  
- Electrocardiographic monitoring (ECG)

Page 47 Extracted Terms:
- Hypertrophic Cardiomyopathy (HCM)  
- Implantable Cardioverter‑Defibrillator (ICD)  
- Sudden Cardiac Death (SCD)  
- Guideline‑Directed Medical Therapy (GDMT)  
- Ventricular arrhythmias  
- Competitive athletics / sports participation  
- Arrhythmic events  
- Arrhythmic risk  
- ICD shock rates  
- ICD utilization  
- Risk stratification for SCD  
- SCD risk assessment  
- Low‑molecular‑weight heparin (anticoagulation)  
- Vitamin K antagonists (anticoagulation)  
- Federal Motor Carrier Safety Administration (FMCSA) guidelines  
- Federal Aviation Administration (FAA) guidelines  
- Clinical evaluation of occupational risk  
- Shared decision‑making  
- Commercial driving (occupational consideration)  
- Piloting an aircraft (occupational consideration)  
- Manual labor / heavy lifting occupational consideration  
- High physical performance occupations (law enforcement, firefighters)  

Page 48 Extracted Terms:
- Hypertrophic Cardiomyopathy (HCM)  
- Left ventricular outflow tract obstruction (LVOTO)  
- Beta‑blockers (e.g., metoprolol, bisoprolol, labetalol, pindolol, propranolol, atenolol)  
- Arrhythmias (atrial fibrillation, ventricular arrhythmias)  
- Cardioversion (for new or recurrent AF)  
- General or epidural anesthesia (used during delivery)  
- Echocardiography (serial maternal and fetal imaging)  
- Fetal echocardiography (for diagnosis of fetal HCM)  
- Maternal‑fetal medicine (specialist care coordination)  
- Anticoagulation therapy  
  - Low‑molecular‑weight heparin  
  - Warfarin  
  - Direct oral anticoagulants (DOACs)  
- Stroke risk in HCM patients with AF  
- Maternal mortality in HCM pregnancy (very low)  
- Heart failure (HF) in the context of HCM  
- Mavacamten (contraindicated in pregnancy)  
- Guideline‑directed medical therapy (GDMT)  
- Implantable cardioverter‑defibrillator (ICD)  
- Surgical relief therapy (SRT) for refractory LVOTO  
- Advanced heart failure therapies (considered pre‑conception)  
- Valsalva maneuver (during labor)  
- Vaginal delivery (preferred first‑choice delivery option)  
- Cesarean section (reserved for obstetric or emergency cardiac indications)  
- Pregnancy counseling  
  - Preconceptional genetic counseling  
  - Prenatal genetic counseling  
  - Preimplantation genetic testing  
  - Fetal screening  
  - Postnatal genetic testing  
- Maternal/fetal risk assessment  
- Reproductive options (informed decision‑making)

Page 49 Extracted Terms:
- Hypertrophic Cardiomyopathy (HCM)  
- Left Ventricular Outflow Tract Obstruction (LVOTO)  
- Left Ventricular Hypertrophy (LVH)  
- Heart Failure (HF)  
- Atrial Fibrillation (AF)  
- Ventricular Arrhythmias  
- Stroke  
- Beta‑blockers  
- Non‑dihydropyridine Calcium Channel Blockers  
- Diuretics  
- Vasodilators  
- Anticoagulation  
- Thromboembolism  
- Cardioversion  
- Sleep‑Disordered Breathing  
- Obesity  
- Hypertension  
- Primary Prevention  
- Myosin Inhibitors  
- Fetal Echocardiography  
- Echocardiography  
- Pregnancy (obstetric considerations for HCM)  
- Anesthesia (epidural, general)  
- Gene Variant Carriers  
- Sarcomere Gene Variant.

Page 50 Extracted Terms:
- Hypertrophic Cardiomyopathy (HCM)  
- Non‑obstructive HCM  
- Obstructive HCM  
- Sleep‑disordered breathing  
- Obstructive sleep apnea  
- Atrial fibrillation (AF)  
- Non‑sustained ventricular tachycardia (NSVT)  
- Left ventricular (LV) wall thickness  
- Left ventricular hypertrophy (LVH)  
- Diastolic abnormalities  
- Restrictive physiology  
- Myocardial energetics  
- Cardiac myosin inhibitors  
- Sodium‑glucose cotransporter‑2 inhibitors (SGLT2i)  
- Mineralocorticoid receptor antagonists  
- Heart failure with preserved ejection fraction (HF‑PEF)  
- Implantable cardioverter‑defibrillator (ICD)  
- Sudden cardiac death (SCD)  
- Risk stratification  
- Late gadolinium enhancement (LGE)  
- 3‑dimensional strain (3D strain)  
- Cardiac magnetic resonance (CMR)  
- Troponin  
- Genetic sarcomere variant  
- Hypertension  
- Valsartan  
- Gene‑based therapy  
- Cardiopulmonary rehabilitation  
- Artificial intelligence (risk prediction)  
- Arrhythmia management  
- Thromboembolic complications  
- Ablation therapy  
- Left ventricular function  
- Clinical guidelines  
- Diagnostic criteria  
- Phenotype  
- Pathophysiology  
- Molecular diagnosis  
- Pathogenesis  
- Predictors of disease progression  
- Biomarkers

Page 51 Extracted Terms:
- Hypertrophic cardiomyopathy (HCM)  
- Cardiac genetics  
- Genetic evaluation  
- Genetic counseling  
- Genetic testing  
- Variant of uncertain significance  
- ClinGen (Clinical Genome Resource)  
- National Institutes of Health (NIH)  
- Polygenic risk scores  
- Genotype‑phenotype correlation  
- Clinical outcomes  
- Family management of heart disease  
- Tailored therapies  
- Gene‑specific therapeutics  
- Cardiomyopathy (general)  
- Heart disease (general)  
- Longitudinal cardiac screening  
- Environmental factors influencing cardiomyopathy  
- Precision medicine in cardiology  
- Screening stratification risk prediction  

Page 52 Extracted Terms:
**Key heart‑disease terms mentioned in the text**

- Hypertrophic Cardiomyopathy  
- Atrial Fibrillation  
- Heart Failure  
- Cardiovascular Disease (and primary prevention)  
- Cardiac Rhythm Abnormalities  
- Device‑Based Therapy of Cardiac Rhythm Abnormalities  

These terms capture the primary disease entities and therapeutic focus areas highlighted in the clinical guideline references.

Page 53 Extracted Terms:
- Hypertrophic cardiomyopathy  
- Ventricular arrhythmias  
- Sudden cardiac death  
- Left ventricular outflow tract obstruction  
- Bradycardia  
- Cardiac conduction delay  
- Coronary artery disease  
- Atherosclerotic vascular disease  
- Valvular heart disease  
- Hypertension  
- Genetic cardiomyopathy  
- Phenotype  
- Genotype  
- Cardiovascular risk factors  
- Atrial fibrillation  
- Ischemic heart disease  
- Heart failure  
- Cardiac catheterization  
- Echocardiography  
- Exercise stress echocardiography  
- Dobutamine stress echocardiography  
- Valsalva maneuver  
- Amyl nitrite  
- Post‑prandial hemodynamics  
- Respiratory‑related fluctuations  
- Dynamic obstruction  
- Genetic pathways  
- Clinical guidelines  
- Clinical practice guidelines  
- AHA/ACC/HRS  
- ACCF/AHA  
- ESC  
- Clinical diagnosis  
- Cardiac risk assessment  
- Secondary prevention  
- Risk reduction therapy  
- Obstructive physiology  
- Intraventricular gradients  
- Takotsubo syndrome  
- Obstructive cardiomyopathy  
- Dynamic intraventricular obstruction  
- Exercise‑induced gradient  
- Obliquely arranged myocytes  
- Genotype‑based burden of disease  
- Cardiovascular mortality  
- Asymptomatic adult cardiac risk assessment  
- Prevention of cardiovascular disease in women  
- Genetic screening for cardiomyopathy  
- Cardiac imaging  
- Multimodal imaging  
- Clinical course of hypertrophic cardiomyopathy  
- Exercise echocardiography  
- Stress‑induced gradient  
- Genetic testing  
- Clinical phenotype in hypertrophic cardiomyopathy  
- Cardiac genetics  
- Cardiovascular surveillance  
- Prognosis of hypertrophic cardiomyopathy  

(Note: Each line represents a distinct heart‑disease‑related term extracted from the source text.)

Page 54 Extracted Terms:
- Hypertrophic cardiomyopathy (HCM)  
- Diastolic dysfunction  
- Left ventricular (LV) outflow tract obstruction  
- Mitral regurgitation  
- Myocardial ischemia  
- Autonomic dysfunction  
- Ventricular tachycardia  
- Myocardial bridging  
- Epicardial coronary artery disease  
- Small vessel (intramural) coronary disease  
- Myocardial stiffness  
- Echocardiographic strain imaging  
- Cardiac magnetic resonance imaging (CMR)  
- Left ventricular systolic‑diastolic coupling  
- Septal myectomy  
- Alcohol septal ablation  
- Risk stratification for sudden cardiac death  
- Heart rate recovery (post‑exercise)  
- Blood pressure response during exercise  
- Left ventricular hypertrophy (interventricular septum)  
- Left atrial enlargement  
- Valvular heart disease (mitral, aortic)  
- Apical aneurysm  
- Valve surgery (repair/replacement)  
- Catheter ablation (ventricular tachycardia)  
- Shared decision‑making in HCM management  
- Multidisciplinary HCM centers  
- Vascular dilator reserve impairment  
- Coronary perfusion deficit  
- Myocardial energy impairment during exercise  

These terms capture the key cardiovascular disease concepts referenced in the provided clinical guideline excerpts.

Page 55 Extracted Terms:
- Hypertrophic cardiomyopathy  
- Left ventricular hypertrophy  
- Left ventricular outflow tract obstruction  
- Septal myectomy  
- Mitral valve replacement  
- Valvular heart disease  
- Advanced heart failure  
- Advanced therapies (e.g., surgical, mechanical support)  
- Heart transplant  
- Myocardial fibrosis  
- Cardiac magnetic resonance imaging  
- Doppler echocardiography  
- Transesophageal echocardiography  
- Two‑dimensional echocardiography  
- Three‑dimensional echodoppler imaging  
- Multimodality cardiovascular imaging  
- Systolic impairment  
- Left ventricular remodeling  
- Cardiac genetics  
- Family screening for cardiomyopathy  
- Genetic counseling  
- Sudden cardiac death risk stratification  
- Implantable cardioverter‑defibrillator (ICD)  
- Lethal arrhythmic events  
- Valsalva maneuver (echo provocation)  
- Amyl nitrite provocation  
- Exercise echocardiography  
- Upright treadmill exercise testing  
- Semi‑supine bicycle exercise testing  
- Appropriate use criteria for echocardiography  
- Intraoperative echocardiographic guidance  
- Intraoperative decision making  
- Clinical staging of hypertrophic cardiomyopathy  
- Clinical diagnosis and imaging protocols  
- Cardiac catheterization (pressure measurement)  
- ESC, ACC, AHA, AATS/ACC/ASE/SCAI/STS guidelines and consensus documents  

---

Page 56 Extracted Terms:
- Hypertrophic cardiomyopathy  
- Hypertrophic obstructive cardiomyopathy  
- Apical hypertrophic cardiomyopathy  
- Left ventricular outflow tract obstruction  
- Transluminal septal ablation  
- Alcohol septal ablation  
- Transcoronary ablation of septal hypertrophy (TASH)  
- Intraprocedural myocardial contrast echocardiography  
- Echocardiographic monitoring  
- Cardiovascular magnetic resonance imaging (CMR)  
- Late gadolinium enhancement (LGE)  
- Myocardial strain imaging  
- Tissue Doppler imaging  
- Diastolic dysfunction  
- Myocardial necrosis  
- Septal myectomy  
- Aneurysm (left ventricular apical aneurysm)  
- Mitral valve abnormalities  
- Papillary muscle morphology  
- Left ventricular wall thickness measurement  
- Left ventricular remodeling  
- Genetic counselling  
- Genetic testing  
- Family screening for hypertrophic cardiomyopathy  
- Penetrance of hypertrophic cardiomyopathy  
- Risk stratification of sudden cardiac death  
- Ventricular septal thickness  
- Intraprocedural echocardiography  
- Ultrasound enhancing agents  
- Post‑prandial upright exercise echocardiography  
- Contrast‑enhanced cardiovascular magnetic resonance  
- Subclinical hypertrophic cardiomyopathy  
- Dilated cardiomyopathy (in genetic context)  
- Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C)  

Page 57 Extracted Terms:
**Key Heart‑Disease–Related Terms Extracted**

- Hypertrophic cardiomyopathy  
- Left ventricular outflow tract obstruction  
- Papillary muscle insertion (antero‑mitral leaflet)  
- Myocardial fibrosis  
- Late gadolinium enhancement  
- Cardiac magnetic resonance imaging (CMR)  
- Cardiac computed tomography (CT)  
- Electrocardiogram (ECG)  
- Ambulatory ECG monitoring (Holter)  
- Atrial fibrillation (subclinical, device‑detected, silent episodes)  
- Ventricular tachycardia / non‑sustained ventricular tachycardia  
- Sudden cardiac death risk  
- Coronary artery disease / epicardial coronary disease  
- Left ventricular hypertrophy (LVH)  
- Left ventricular filling pressures  
- Isoproterenol challenge  
- Doppler echocardiography (rest, exercise, upright)  
- Valsalva maneuver / amyl nitrite provocation  
- Cardiopulmonary exercise testing (CPET)  
- Cardiac catheterization (direct pressure measurement, left atrial pressure)  
- Surgical myectomy / papillary muscle surgical management  
- Diagnostic predictive models (e.g., HCM‑AF Score)  
- Exercise‑induced LV outflow tract gradient  
- Heart‑rate reserve during exercise  
- Pre‑operative coronary angiography assessment  
- Athlete’s heart differential diagnosis  
- Competitive athlete eligibility/disqualification criteria  
- Heart‑failure progression in HCM  
- Prognostic implications of arrhythmias  
- Outflow tract gradient variability  
- Late/ delayed myocardial enhancement quantification  
- Echocardiographic assessment of obstruction severity  
- Cardiometabolic stress testing (treadmill, semi‑supine bicycle)  

These terms capture the major clinical entities, diagnostic modalities, physiological assessments, and therapeutic contexts discussed in the guideline excerpts.

Page 58 Extracted Terms:
- Hypertrophic cardiomyopathy  
- Left ventricular outflow tract obstruction  
- Left ventricular outflow tract gradient  
- Amyl nitrite provocation  
- Cardiopulmonary exercise test  
- Exercise testing  
- Septal myectomy  
- Surgical myectomy  
- Post‑prandial upright exercise echocardiography  
- Long‑term survival  
- Imaging phenotype  
- Phenotypic expression  
- Cardiac genotype  
- LAMP2 cardiomyopathy  
- Pediatric cardiomyopathy  
- Family screening  
- Cardiovascular genetics  
- Genetic counselling  
- Genetic testing  
- Pathogenic variants  
- Variant pathogenicity  
- Clinically actionable variants  
- Penetrance  
- Sudden cardiac death  
- Cardiomyopathy (general)  
- Clinical outcome  
- Prognostic relevance  
- Risk stratification  
- Clinical validity of genetic tests  
- Variant interpretation  
- Whole genome sequencing  
- Genetic misdiagnosis  
- Health disparities  
- Compound and double mutations  
- Non‑familial hypertrophic cardiomyopathy  
- Disease burden  
- Prevalence  
- Anderson‑Fabry disease (in hypertrophic cardiomyopathy)  
- Molecular autopsy  
- Arrhythmias  
- Psychosocial care for inherited cardiovascular disease  
- Left ventricular hypertrophy  
- Cardiovascular disease  
- Clinical screening  
- Clinical yield  
- Cardiovascular genetics programs  
- Risk of cardiomyopathy with family history  
- Pediatric risk assessment  
- Genetic testing outcomes  
- Clinical screening for hypertrophic cardiomyopathy in first‑degree relatives  
- Genetic counseling and testing guidelines  
- Genetic counseling services  
- Clinical screening paradigms  
- Cardiovascular genetics consensus recommendations  
- Clinical screening strategies  
- Clinical testing in children and adolescents  
- Molecular autopsy for sudden death  
- Cardiovascular screening guidelines  
- Cardio‑respirology exercise diagnostics  
- Cardiovascular phenotyping  
- Clinical predictors of genetic testing outcomes  
- Genetic variant re‑analysis  
- Genetic variant re‑contact guidelines  
- Clinical outcome and phenotypic expression in LAMP2 cardiomyopathy  
- Clinical outcome after septal myectomy  
- Clinical outcome after surgical myectomy  
- Clinical outcome in hypertrophic cardiomyopathy patients  
- Clinical outcome of exercise capacity post‑septal myectomy

Page 59 Extracted Terms:
- Hypertrophic cardiomyopathy  
- Left ventricular hypertrophy  
- Left ventricular wall thickness  
- Left ventricular outflow obstruction  
- Left ventricular apical aneurysm  
- Apical hypertrophic cardiomyopathy  
- Left ventricular remodeling  
- Ventricular tachycardia  
- Non‑sustained ventricular tachycardia  
- Sudden cardiac death  
- Implantable cardioverter‑defibrillator  
- Implantable defibrillator therapy  
- Cardiac magnetic resonance imaging  
- Late gadolinium enhancement  
- Magnetic resonance imaging (MRI)  
- Transthoracic echocardiography  
- Echocardiography  
- Sarcomere mutation  
- Genotype positive  
- Phenotype negative  
- Family history of sudden death  
- Risk stratification  
- Risk prediction model  
- HCM Risk‑SCD model  
- HCM Risk‑Kids model  
- Prognosis  
- Prognostic value  
- Clinical risk prediction  
- Cardiovascular mortality  
- Mortality rates  
- Vigorous exercise  
- Clinical outcomes  
- Left ventricular systolic dysfunction  
- Pediatric hypertrophic cardiomyopathy  
- Adult‑onset hypertrophic cardiomyopathy  
- Ventricular fibrillation (implied)  
- Apical outpouching  
- Left ventricular strain  
- Sarcomere mutation carriers.

Page 60 Extracted Terms:
- Hypertrophic cardiomyopathy  
- Left ventricular diastolic function  
- Tissue Doppler imaging  
- Clinical status  
- Childhood / pediatric heart disease  
- Adolescents / young adults  
- Sudden cardiac death (SCD)  
- Implantable cardioverter‑defibrillator (ICD)  
- Risk stratification  
- HCM Risk‑Kids model  
- Genetic risk factors  
- Late gadolinium enhancement (LGE)  
- Cardiovascular magnetic resonance (CMR)  
- Echocardiography  
- Left ventricular wall thickness  
- Left ventricular apical aneurysm  
- Massive left ventricular hypertrophy  
- Arrhythmic events  
- Epidemiology of hypertrophic cardiomyopathy  
- Clinical outcomes  
- Prognostic value of CMR  
- Exercise test abnormalities  
- Contemporary management strategies  
- Mortality and survival analysis  
- Clinical features and outcomes, population‑based study  

These are the key heart‑disease–related terms that emerge from the cited clinical guidelines and studies.

Page 61 Extracted Terms:
- Hypertrophic cardiomyopathy (HCM)  
- Sudden cardiac death (SCD)  
- Left ventricular hypertrophy (LVH)  
- Left ventricular systolic dysfunction (LVSD)  
- Left ventricular remodeling  
- End‑stage hypertrophic cardiomyopathy  
- Implantable cardioverter‑defibrillator (ICD)  
- Non‑sustained ventricular tachycardia (NSVT)  
- Syncope  
- Exercise test abnormalities  
- Family history of sudden death  
- Risk stratification  
- Prognostic implications  
- Late gadolinium enhancement (LGE)  
- Cardiovascular magnetic resonance (CMR)  
- Left ventricular apical aneurysm  
- Left ventricular outflow obstruction  
- Preventive ICD therapy  
- Pediatric hypertrophic cardiomyopathy  
- HCM Risk-SCD model  
- HCM Risk‑Kids model  
- Sudden death risk prediction  
- Implantable defibrillator complications  
- Adult HCM management strategies  
- Pediatric HCM management strategies  
- Pediatric arrhythmic events  
- Clinical risk factors  
- Echocardiographic assessment  
- Electrocardiographic identification  
- Contemporary management strategies  
- Long‑term follow‑up outcomes  
- Prognostic determinants  
- Ventricular tachycardia outcomes  

Page 62 Extracted Terms:
- Hypertrophic cardiomyopathy (HCM)  
- Obstructive hypertrophic cardiomyopathy  
- Non‑obstructive hypertrophic cardiomyopathy  
- End‑stage hypertrophic cardiomyopathy  
- Dilated‑phase hypertrophic cardiomyopathy  
- Hypertrophic subaortic stenosis  
- Sudden death risk  
- Sudden cardiac death  
- Left ventricular outflow tract gradients  
- Angina pectoris  
- Late gadolinium enhancement (LGE)  
- LGE‑CMR (late gadolinium‑enhanced cardiovascular magnetic resonance)  
- Implantable cardioverter‑defibrillator (ICD)  
- Subcutaneous ICD (S‑ICD)  
- Dual‑chamber ICD  
- Single‑chamber ICD  
- Defibrillation threshold  
- Dual‑chamber pacing  
- Single‑coil defibrillator lead  
- Cardiac resynchronization therapy (CRT)  
- Biventricular pacing  
- Cardiac remodeling  
- Bradycardia  
- Cardiac conduction delay  
- Tachyarrhythmia detection algorithms  
- Inappropriate ICD shock  
- Beta‑adrenergic blockade (beta‑blockers)

Page 63 Extracted Terms:
- Hypertrophic cardiomyopathy (HCM)  
- Obstructive hypertrophic cardiomyopathy  
- Hypertrophic subaortic stenosis (SAS)  
- Left ventricular outflow tract obstruction (LVOTO)  
- Surgical septal myectomy  
- Alcohol septal ablation (ASA)  
- Verapamil therapy  
- Diltiazem therapy  
- Propranolol therapy  
- Disopyramide therapy  
- Mavacamten (myosin inhibitor)  
- β‑blocker therapy  
- Pulmonary hypertension  
- Mitral valve abnormalities (mitral regurgitation, papillary muscle insertion)  
- Implantable cardioverter‑defibrillator (ICD)  
- Sudden cardiac death risk  
- Resting LVOT gradient  
- Exercise echocardiography  
- Left atrial remodeling / enlargement  
- Conduction abnormalities  
- Acquired von Willebrand syndrome  
- Transaortic myectomy  
- Aortic valve replacement (SAVR) with concomitant septal myectomy  
- Hospital volume outcomes  
- Surgical management of LVOT obstruction  
- Constrictive left ventricular hypertrophy  
- Symptom status (NYHA class)  
- Gradient resistant to first‑line therapy  
- Vascular dysfunction (von Willebrand factor activity)  
- Cardiac magnetic resonance imaging (MRI) for LVOT evaluation  
- Percutaneous intervention in HCM  
- Long‑term survival in HCM  
- Guideline‑based referral for septal reduction therapy.

Page 64 Extracted Terms:
**Key terms related to heart disease**

- Hypertrophic cardiomyopathy (HCM)  
- Obstructive hypertrophic cardiomyopathy  
- Non‑obstructive hypertrophic cardiomyopathy  
- Ventricular septal myectomy  
- Transaortic approach to septal myectomy  
- Transapical approach to septal myectomy  
- Apical myectomy  
- Alcohol septal ablation (ASA)  
- Mitral valve plication  
- Anterior mitral leaflet extension  
- Subvalvular mitral apparatus reconstruction  
- Mitral valve abnormalities  
- Papillary muscle abnormalities  
- Papillary muscle morphology  
- Left ventricular hypertrophy (LVH)  
- Left ventricular outflow tract (LVOT) obstruction  
- Pulmonary hypertension  
- Atrial fibrillation (AF)  
- Residual gradients  
- Recurrent gradients  
- Hemodynamic function  
- Myocardial perfusion  
- Left ventricular relaxation  
- Prognosis  
- Genotype (sarcomeric HCM)  
- Sarcomeric human cardiomyopathy registry (SHaRE)  
- Epicardial coronary artery disease  
- Pharmacologic treatment options  
- Beta‑blockers (e.g., propranolol, nadolol)  
- Calcium‑channel blockers (e.g., verapamil, diltiazem)  
- Angiotensin II receptor blocker (losartan)  
- Angiotensin receptor blocker (valsartan)  
- Echocardiography  
- Doppler echocardiography  
- Cardiac catheterization  
- Catheter cardiovascular intervention  
- AHA/ACC/HFSA guideline for heart failure management  
- Heart failure with preserved ejection fraction (HFpEF)  
- Modified Konno procedure (high‑risk children)  
- Ventricular septal defect (VSD)  
- Myocardial metabolism  
- Randomized clinical trials  
- Meta‑analysis  
- Systematic review  
- Clinical outcomes  
- Long‑term follow‑up  
- Survival analysis  
- Risk factors  
- Prognostic predictors  
- Surgical outcomes  
- Reoperation outcomes  
- Myectomy outcomes  
- Alcohol septal ablation outcomes  

Page 65 Extracted Terms:
Hypertrophic cardiomyopathy (HCM)  
End‑stage hypertrophic cardiomyopathy  
Dilated phase of hypertrophic cardiomyopathy  
Hypokinetic hypertrophic cardiomyopathy  
Restrictive cardiomyopathy  
Heart failure  
Advanced heart failure  
Left ventricular remodeling  
Left ventricular systolic dysfunction  
Cardiopulmonary exercise testing  
Cardiac resynchronization therapy (CRT)  
Biventricular pacing  
Left ventricular assist device (LVAD)  
Mechanical circulatory support device  
Heart transplantation  
Orthotopic heart transplantation  
International Society for Heart Lung Transplantation (ISHLT) listing criteria  
Mavacamten  
Angiotensin II receptor blocker losartan  
Spironolactone  
Non‑vitamin K antagonist oral anticoagulants (NOACs)  
Anticoagulation  
Atrial fibrillation (AF)  
Thromboembolism  
Stroke  
Late gadolinium enhancement (LGE)  
Cardiovascular magnetic resonance (CMR)  
CMR assessment  
CMR risk stratification  
Molecular profiling  
Single‑nucleus profiling  
Clinical phenotype  
Prognosis  
Risk factors  
Genetics  
Cardiovascular imaging  
Ventricular remodeling  
INTERMACS  
Berlin Heart EXCOR  
COMPANION trial  
Defibrillation  
Implantable cardioverter‑defibrillator (ICD)  
Management of HCM and AF  
Stroke risk  
Anticoagulation strategies  
Clinical guidelines  
2024 Hypertrophic Cardiomyopathy Guideline  
Survival after transplantation  
Waitlist outcomes  
Cardiac outcomes  
End‑stage heart disease

Page 66 Extracted Terms:
- Hypertrophic cardiomyopathy (HCM)  
- Atrial fibrillation (AF)  
- Subclinical atrial fibrillation  
- Device‑detected atrial fibrillation  
- Ventricular tachycardia (VT)  
- Ventricular arrhythmia  
- Implantable cardioverter‑defibrillator (ICD)  
- ICD shock  
- Catheter ablation  
- Radiofrequency ablation  
- Surgical ablation of atrial fibrillation  
- Septal myectomy  
- Heart transplant  
- Beta‑blocker therapy  
- Amiodarone  
- Sotalol  
- Disopyramide  
- Dofetilide  
- Mexiletine  
- Encainide  
- Flecainide  
- Non‑vitamin K antagonist oral anticoagulant (NOAC)  
- Warfarin  
- Anticoagulation for atrial fibrillation  
- Thromboembolic risk  
- Stroke risk  
- Ventricular tachycardia suppression  
- HCM risk calculators (e.g., HCM‑Risk‑CVA)  
- Sudden cardiac death (SCD)  
- Atrial tachyarrhythmia  
- Rhythm‑control strategies  
- Device‑detected arrhythmia duration  
- Implantable cardioverter‑defibrillator programming and testing  
- Ventricular tachycardia triggers  
- Pre‑operative arrhythmia management  
- Advanced heart failure with preserved ejection fraction (HFpEF) in HCM  
- Congestive heart failure outcomes  

These terms capture the principal heart‑disease entities, arrhythmias, therapies, and risk factors referenced in the provided guideline excerpts.

Page 67 Extracted Terms:
- Hypertrophic cardiomyopathy (HCM)  
- Ventricular arrhythmia  
- Ventricular tachycardia  
- Sudden cardiac death (SCD)  
- Implantable cardioverter‑defibrillator (ICD)  
- Radiofrequency catheter ablation  
- Exercise training (structured)  
- Physical activity (moderate‑intensity, vigorous)  
- Competitive sports participation  
- Genetically inherited heart diseases  
- Long QT syndrome  
- Risk factors for sudden death  
- Cardiac arrest (sudden cardiac arrest, SCA)  
- Cardiac screening (genetic testing, imaging)  
- Cardiopulmonary exercise testing  
- Exercise intensity (MET values)  
- Exercise-induced arrhythmia  
- Cardiac rehabilitation  
- Electrophysiology interventions  
- AHA/ACC guideline for HCM  
- ESC guideline for HCM  
- Aeronautical medical certification for heart disease  
- Physical activity guidelines for Americans  
- Shared decision‑making in HCM care  
- Return‑to‑play protocols for athletes with heart disease  
- Sports‑related sudden death epidemiology  
- Structural heart disease (apical aneurysm, mid‑ventricular obstruction)  
- Inherited channelopathies (e.g., Brugada, catecholaminergic polymorphic ventricular tachycardia)  
- Cardiac genetics and mutation carriers  
- Barriers to physical activity in HCM patients  
- Emergency action plans for sudden cardiac arrest in sport.

Page 68 Extracted Terms:
- Hypertrophic Cardiomyopathy (HCM)  
- Pregnancy‑related cardiac risk in HCM  
- Atrial fibrillation  
- Thromboembolism  
- Stroke  
- Mechanical heart valves  
- Anticoagulation therapy (including DOACs)  
- Valvular heart disease  
- ACC/AHA clinical practice guidelines  
- ESC guidelines for cardiovascular diseases in pregnancy  
- Obesity & cardiac remodeling in HCM  
- Exercise tolerance / capacity  
- Left ventricular morphology / wall thickness  
- Sleep‑disordered breathing (obstructive sleep apnea)  
- Nocturnal oximetry abnormalities  
- Ventricular tachycardia (nonsustained)  
- Myocardial fibrosis  
- Cardiac magnetic resonance imaging (CMR)  
- Implantable cardioverter‑defibrillators (ICDs)  
- Sudden cardiac death (SCD) prevention  
- Genotype‑based risk stratification in HCM  
- Phenotype‑specific risk algorithms  
- Valsartan (Angiotensin II receptor blocker) for early HCM  
- Mavacamten (myosin inhibitor) for obstructive HCM  
- Aficamten (myosin inhibitor) clinical trials  
- Sarcomere contractility inhibitors  
- Early‑stage HCM biomarkers  
- Maximal left‑ventricular wall‑thickness measurement  
- HCM risk score (eg., HCM Risk‑CVA, HCM Risk‑SCD)  
- Obstructive vs. non‑obstructive HCM classification  
- Cardiogenic risk in primary prevention of cardiovascular disease  
- Sleep‑disordered breathing interaction with atrial fibrillation  
- Pregnancy‑focused obstetric–cardiologic outcomes  
- Registry data (e.g., ROPAC, SHaRE) in HCM research  
- Clinical trial design for HCM therapeutics  
- Cardio‑thoracic surgery considerations in HCM  
- Left‑ventricular hypertrophy pathophysiology  
- Genetic mutations in MYL2, sarcomeric proteins, and HCM susceptibility  

These terms capture the core heart‑disease concepts highlighted in the provided guideline excerpts.

Page 69 Extracted Terms:
Hypertrophic Cardiomyopathy  
Atrial Fibrillation  
Arrhythmia Management  
Catheter Ablation  
Pulmonary Vein Isolation  
Pulsed Field Ablation  
Genetic Variants in Cardiomyopathy  
MYH7 Gene  
Dilated Cardiomyopathy  
Late Gadolinium Enhancement  
Myocardial Scar  
Radiomics  
3‑Dimensional Strain Analysis  
Cardiac Imaging  
Electrophysiology  
Heart Failure  
Cardiomyopathy  
Cardiac Rhythm Disorders  
Ventricular Tachycardia  
Ventricular Fibrillation  
Dofetilide Therapy  
Rhythm Control  
Heart Rate Management  
Cardiovascular Genetics  
Inheritable Cardiomyopathies  
ACMG/AMP Variant Classification  
National Heart, Lung, and Blood Institute (NHLBI)  
Heart and Lung Institute (HCI)  
Hypertrophic Cardiomyopathy Registry (HCMR)  
Clinical Guidelines for HCM  
Heart and Blood Vessel Disease  
Cardiac Electrophysiology  
Catheter‑Based Ablation of Atrial Fibrillation  
Pulmonary Vein Isolation Techniques  
Myocardial Scar Heterogeneity  
Genetic Architecture of HCM  
Cardiovascular Institute  
Pediatric Electrophysiology  
Translational Research in Cardiovascular Medicine  
Cardiovascular Clinic  
Genetic Pathways in Cardiac Disease  
Cardiovascular Research Institution  
Evidence‑Based Management of HCM  
Efficacy of Rhythm‑Control Medications  
Outcomes of Ablation in HCM Patients  
Predictors of Major AF Endpoints  
Systolic Dysfunction  
Cardiac Structural Assessment  
Biomarker Analysis  
Clinical Decision Support in Cardiomyopathy  
Pharmacologic Management of Atrial Fibrillation  
Heart‑Disease Risk Factors  
Family Screening for Cardiomyopathy  
Myocardial Strain Imaging  
Late Gadolinium Enhancement Imaging  
Radiomics in Cardiac Imaging  
Heart‑Disease Genetic Counseling  
Heart‑Disease Clinical Trials  
Heart‑Disease Registry Data  
Heart‑Disease Pathophysiology  
Heart‑Disease Prognosis  
Heart‑Disease Management Strategies

Page 70 Extracted Terms:
- Hypertrophic Cardiomyopathy
- Congenital Heart Surgery
- Cardiovascular Imaging
- Clinical Cardiac Electrophysiology
- Heart Failure
- Transplantation
- Cardiovascular Medicine
- Radiology
- Pacing
- Pediatric Cardiology
- Sports Cardiology
- Cardiomyopathy Program
- Cardiovascular Research
- Heart Function
- Heart Function and Transplant Program
- Heart Failure Research
- Heart Failure and Transplantation
- Cardiovascular Research
- Cardiovascular 
- Cardiac 
- Heart Failure Programme (if inferred)

Page 71 Extracted Terms:
- Hypertrophic Cardiomyopathy  
- HCM (Hypertrophic Cardiomyopathy)  
- Cardiology  
- Cardiovascular medicine  
- Heart  
- Cardiac cath labs (cardiac catheterization)  
- Heart rhythm  
- Heart disease management  
- Clinical guidelines for heart disease  
- Clinical trial enrolment in cardiac research  
- Cardiovascular research  
- Cardiovascular magnetic resonance (JCMR reference)  
- Heart rhythm society (HRS)  
- Pediatric & congenital electrophysiology (PACES) – related to cardiac conduction  
- National Heart, Lung, and Blood Institute (NHLBI) – heart disease funding  
- Heart disease disclosure policies (ACC/AHA)  

Page 72 Extracted Terms:
- Hypertrophic Cardiomyopathy  
- Heart Disease  
- Heart Failure  
- Chest Pain  
- Heart Rhythm Disorders  
- Cardiomyopathy  
- Cardiac  
- Heart  
- HCM (Hypertrophic Cardiomyopathy)  
- HRS (Heart Rhythm Society)  
- HFSA (Heart Failure Society of America)  
- AHA/ACC (American Heart Association / American College of Cardiology)  
- AMSSM (American Society of Sports Medicine)  
- NIH (National Institutes of Health)  
- Heart Hospital  
- Heart Centre  
- Heart Rhythm Institute  
- National Center for Catastrophic Sports Injury Research  
- Medtronic (device manufacturer for heart conditions)  
- Abbott (device manufacturer for heart conditions)  
- Biosense Webster (device manufacturer for cardiac rhythm management)

Page 73 Extracted Terms:
- Hypertrophic Cardiomyopathy  
- Cardiomyopathy  
- Heart Failure  
- Heart Rhythm  
- HCM Guidelines (Hypertrophic Cardiomyopathy Guideline)  
- AHA (American Heart Association)  
- ACC (American College of Cardiology)  
- HFSA (Heart Failure Society of America)  
- HRS (Heart Rhythm Society)



Page 1 Extracted Terms:
**Key heart‑disease–related terms extracted**

- Lower extremity peripheral artery disease  
- Peripheral artery disease  
- Asymptomatic peripheral artery disease  
- Chronic symptomatic peripheral artery disease  
- Chronic limb‑threatening ischemia  
- Acute limb ischemia  
- Vascular disease  
- Cardiovascular  
- Endovascular surgery  
- Interventional radiology  
- Angiography  
- Vascular surgery  
- Vascular nursing  
- Clinical practice guidelines  
- ACC (American College of Cardiology)  
- AHA (American Heart Association)  
- AACVPR (American Association of Cardiovascular and Pulmonary Rehabilitation)  
- APMA (American Podiatric Medical Association)  
- ABC (Association of Black Cardiologists)  
- SCAI (Society for Cardiovascular Angiography and Interventions)  
- SVM (Society for Vascular Medicine)  
- SVN (Society for Vascular Nursing)  
- SVS (Society for Vascular Surgery)  
- SIR (Society of Interventional Radiology)  
- VESS (Vascular & Endovascular Surgery Society)  
- Guideline  
- Evidence  
- Literature review  
- PubMed  
- EMBASE  
- Cochrane Library  
- CINHL Complete  

These terms capture the primary clinical, procedural, and organizational concepts related to heart and vascular disease present in the provided guideline text.

Page 2 Extracted Terms:
**Key terms related to heart disease extracted from the guideline text**

- Atherosclerosis  
- Antiplatelet therapy  
- Anticoagulation therapy  
- Antithrombotic therapy  
- Lipid‑lowering therapy  
- Antihypertensive therapy  
- Statin therapy  
- Cardiovascular risk reduction  
- Diabetes management (as a key cardiovascular risk factor)  
- Smoking cessation  
- Acute limb ischemia (a manifestation of systemic arterial occlusion)  
- Chronic limb‑threatening ischemia (CLTI, indicating severe systemic atherosclerosis)  
- Peripheral arterial disease (PAD) – the overarching vascular disorder linked to coronary disease  
- Ischemia (general term encompassing myocardial, limb, and other tissue ischemia)  
- Revascularization (both endovascular and open surgical)  
- Endovascular therapy  
- Bypass grafting / vascular surgery  
- Stenting  
- Thrombolysis  
- Blood pressure lowering  
- Cardiovascular risk amplifiers (e.g., older age, sex, comorbidities)  

These terms capture the core cardiovascular components addressed in the guideline, even though the primary focus is on peripheral vascular disease.

Page 3 Extracted Terms:
- Peripheral artery disease (PAD)  
- Cardiovascular disease (CVD)  
- Myocardial infarction  
- Stroke  
- Ankle‑brachial index  
- Antiplatelet therapy  
- Antithrombotic therapy  
- Lipid‑lowering therapy  
- High‑intensity statin  
- Antihypertensive therapy  
- Diabetes management  
- Smoking cessation  
- Rivaroxaban  
- Aspirin  
- Structured exercise therapy  
- Endovascular revascularization  
- Surgical revascularization  
- Hybrid revascularization  
- Limb loss (prevention)  
- Foot care (preventive and advanced)  
- Wound‑healing therapies  
- Foot surgery  
- Multispecialty care team  
- American College of Cardiology (ACC)  
- American Heart Association (AHA)

Page 4 Extracted Terms:
**Key Heart‑Disease Related Terms Extracted**

- Peripheral Artery Disease (PAD)  
- Cardiovascular disease  
- Heart disease  
- American Heart Association (AHA)  
- American College of Cardiology (ACC)  
- AHA/ACC Joint Committee on Clinical Practice Guidelines  
- Guideline‑directed management and therapy (GDMT)  
- Clinical evaluation  
- Diagnostic testing  
- Pharmacological treatments  
- Procedural treatments  
- Drug treatment regimens  
- Devices (cardiovascular devices)  
- Benefit‑risk assessment  
- Evidence‑based methodology  
- Randomized controlled trials (RCTs)  
- Non‑randomized comparative studies  
- Cohort studies  
- Registries  
- Systematic reviews  
- Evidence review committee  
- Patient engagement  
- Comorbidities  
- Cost–value considerations  
- Clinical practice settings  
- Modularity in guideline presentation (knowledge chunk format)  
- Peer review  
- Regulatory compliance (US approval status)

Page 5 Extracted Terms:
**Key terms related to heart disease extracted from the guideline text**

- Cardiovascular disease (CVD)  
- Peripheral artery disease (PAD)  
- Atherosclerotic disease  
- Thrombotic disease  
- Lower‑extremity arteries  
- Angioplasty  
- Bypass grafting / open bypass surgery  
- Stenting  
- Thrombolysis  
- Statin therapy  
- Antiplatelet therapy  
- Antithrombotic therapy  
- Lipid‑lowering therapy  
- Blood‑pressure‑lowering therapy  
- Diabetes (as a cardiovascular risk factor)  
- Ankle‑brachial index (diagnostic test)  
- Endovascular therapy  
- Hybrid approach (combining endovascular and open methods)  
- Exercise rehabilitation / exercise therapy / exercise training (cardiovascular rehab)  
- Smoking cessation (cardiovascular risk modification)  
- Diagnostic testing (imaging, functional testing)  
- Clinical practice guidelines (ACC, AHA, etc.)

Page 6 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Aortoiliac arterial segment  
- Femoropopliteal arterial segment  
- Infrapopliteal arterial segment  
- Vasculitis (as a cause of lower‑extremity arterial disease)  
- Fibromuscular dysplasia  
- Cystic adventitial disease  
- Perioperative cardiovascular evaluation and management  
- Dual antiplatelet therapy in coronary artery disease  
- Coronary artery disease (CAD)  
- High blood pressure / hypertension in adults  
- Blood cholesterol management  
- Stroke prevention in patients with prior stroke or transient ischemic attack  
- Chronic coronary disease management  
- Influenza vaccination as secondary prevention for cardiovascular disease  
- Cardiovascular disease (CVD) in general  
- Ankle‑brachial index measurement and interpretation  
- Aorto‑iliac arterial intervention (appropriate use)  
- Lower extremity threatened limb classification system  
- Atherosclerotic occlusive disease of the lower extremities (asymptomatic disease and claudication)  
- Claudication (intermittent claudication)  
- Diabetes type 2 – prevention of cardiovascular disease  
- Tobacco cessation treatment for cardiovascular risk reduction  
- Exercise programs for patients with PAD  
- Chronic limb‑threatening ischemia (CLTI) management  
- Critical limb ischemia (CLI) perfusion assessment  
- Peripheral artery intervention (endovascular)  
- Device selection in aorto‑iliac arterial interventions  
- Lower‑extremity amputations – reduction strategies  
- Telehealth in cardiovascular disease management  
- Diabetes management – standards of care  
- Endovascular specialist competencies for CLTI care  
- Health disparities in peripheral artery disease  
- Peripheral artery disease quality‑of‑care improvement and patient‑reported outcomes  
- Intermittent claudication management  
- Limb‑ischaemia evaluation and device deployment  
- Cardiovascular rehabilitation (ACVPR, AHA)   
- Cardiovascular and pulmonary rehabilitation (AACVPR)  
- Cardiovascular disease prevention strategies (e.g., lifestyle, pharmacologic)

Page 7 Extracted Terms:
- MACE (major adverse cardiovascular events)
- MI (myocardial infarction)
- Acute coronary syndrome (including acute MI, unstable angina)
- Stroke
- Heart failure
- Death (all‑cause or cardiovascular)
- Rehospitalization for cardiovascular causes
- Cardiovascular (as an endpoint or cause)

Page 8 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Lower Extremity Peripheral Artery Disease  
- ACC (American College of Cardiology)  
- AHA (American Heart Association)  
- AACVPR (American Association of Cardiovascular and Pulmonary Rehabilitation)  
- APMA (American Pulmonary & Medical Association)  
- ABC (American Board of Cardiology)  
- SCAI (Society for Cardiovascular Angiography & Interventions)  
- SVM (Society of Vascular Medicine)  
- SVN (Society for Vascular Nursing)  
- SVS (Society of Vascular Surgery)  
- SIR (Society of Interventional Radiology)  
- VESS (Venous and Vascular Surgery Society)  
- Management of Lower Extremity PAD  
- Class of Recommendation (COR)  
- Level of Evidence (LOE)  
- Clinical Trials  
- Interventions  
- Treatments  
- Diagnostic Testing  
- Patient Care (in the context of cardiovascular practice)

Page 9 Extracted Terms:
- Peripheral Artery Disease  
- Coronary Artery Disease  
- Cardiovascular Disease  
- Myocardial Infarction  
- Major Adverse Cardiovascular Events  
- Angiotensin‑converting Enzyme  
- Angiotensin‑converting Enzyme Inhibitor  
- Low‑Density Lipoprotein Cholesterol  
- Guideline‑Directed Medical Therapy  
- Systolic Blood Pressure  
- 6‑Minute Walk Test  
- Ankle‑Brachial Index  
- Computed Tomography Angiography  
- Magnetic Resonance Angiography  

(Note: Terms directly related to heart disease are highlighted, with related diagnostic and therapeutic concepts included.)

Page 10 Extracted Terms:
- Peripheral arterial disease (PAD)  
- Asymptomatic PAD  
- Claudication  
- Chronic symptomatic PAD  
- Chronic limb‑threatening ischemia (CLTI)  
- Acute limb ischemia (ALI)  
- Major adverse cardiovascular events (MACE)  
- Mortality  
- Atrial fibrillation  
- Revascularization  
- Fontaine classification  
- Rutherford classification  
- WIfI classification (Wound, Ischemia, Foot Infection)  
- Ischemic rest pain  

---

Page 11 Extracted Terms:
**Key terms related to heart disease**

- Peripheral Artery Disease (PAD)  
- Atherosclerotic Vascular Disease  
- Cardiovascular Risk Factors  
- Atherosclerosis  
- Coronary Artery Disease (CAD)  
- Carotid Artery Disease  
- Subclavian Artery Disease  
- Renal Artery Stenosis  
- Mesenteric Artery Stenosis  
- Abdominal Aortic Aneurysm (AAA)  
- Major Adverse Cardiovascular Events (MACE)  
- Major Adverse Limb Events (MALE)  
- Claudication  
- Walking Impairment  
- Ankle‑Brachial Index (ABI)  
- Low/Reduced ABI  
- Lower Extremity Pulse Assessment (Femoral, Popliteal, Dorsalis Pedis, Posterior Tibial)  
- Pulse Deficits (absent, diminished, normal, bounding)  
- Vascular Bruit (epigastric, periumbilical, groin)  
- Foot Inspection & Foot Care for PAD  
- Non‑healing Lower Extremity Wound  
- Lower Extremity Gangrene  
- Peripheral Neuropathy (in patients with diabetes)  
- Erectile Dysfunction (as a PAD risk marker)  

These terms capture the cardiovascular disease concepts, risk factors, diagnostic measures, and clinical features discussed in the guideline.

Page 12 Extracted Terms:
**Key terms related to heart (cardiovascular) disease in the guideline text**

- Peripheral arterial disease (PAD)  
- Ankle‑brachial index (ABI)  
- Resting ABI  
- Exercise treadmill ABI  
- Abnormal ABI (≤ 0.90)  
- Borderline ABI (0.91–0.99)  
- Normal ABI (1.00–1.40)  
- Noncompressible ABI (> 1.40)  
- Toe‑brachial index (TBI)  
- Toe pressure  
- Transcutaneous oxygen pressure (TcPO₂)  
- Skin perfusion pressure (SPP)  
- Segmental leg pressures  
- Doppler waveforms  
- Ankle pulse volume recordings (PVR)  
- Angiography (invasive imaging)  
- Revascularization  
- Chronic limb‑threatening ischemia (CLTI)  
- Chronic symptomatic PAD  
- Exertional (claudication) pain  
- Rest pain  
- Leg ischemia  
- Risk factors for PAD (e.g., diabetes, smoking, hyperlipidemia)  
- Screening for PAD  
- Diagnostic testing for PAD  
- Clinical guideline statement  
- Evidence‑based recommendation  
- Cardiovascular disease (general term encompassing PAD)  
- Atherosclerosis (underlying pathology)  
- Ischemia (limb and systemic)  
- Peripheral vascular disease (broader term)  

These terms capture the cardiovascular/heart‑related concepts embedded in the PAD guideline narrative.

Page 13 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Chronic Limb-Threatening Ischemia (CLTI)  
- Critical Limb Ischemia (CLI)  
- Acute Limb Ischemia (ALI)  
- Ankle‑Brachial Index (ABI)  
- Toe‑Brachial Index (TBI)  
- Toe pressure  
- Transcutaneous partial pressure of oxygen (TcPO₂)  
- Skin perfusion pressure (SPP)  
- Doppler waveforms (continuous‑wave Doppler)  
- Plethysmographic pulse volume recording (PVR)  
- Segmental pressures  
- Leg pressure monitoring  
- Noncompressible vessels  
- Diabetes mellitus (as a modifier of PAD severity)  
- Chronic kidney disease (CKD)  
- Cardiovascular morbidity  
- Cardiovascular mortality  
- Atherosclerosis  
- Coronary artery disease (implied in GDMT)  
- Cardiac monitoring  
- Coronary calcium computed tomography (CT)  
- Abdominal aortic aneurysm (AAA) screening  
- Structured exercise programs for PAD  
- Guideline‑directed medical therapy (GDMT) for PAD  
- Vascular screening programs  
- Symptom‑free (asymptomatic) PAD  
- Functional status decline in PAD  
- Vascular laboratory assessment  
- Office‑based ABI measurement  
- Perfusion imaging techniques

(These terms capture the core heart‑and‑vascular‑related concepts presented in the guideline excerpt.)

Page 14 Extracted Terms:
- Ankle‑Brachial Index (ABI)  
- Toe‑Brachial Index (TBI)  
- Peripheral Artery Disease (PAD)  
- Chronic Limb‑Threatening Ischemia (CLTI)  
- Computed Tomography Angiography (CTA)  
- Magnetic Resonance Angiography (MRA)  
- Guideline‑Directed Management and Therapy (GDMT)  
- Pulse Volume Recording (PVR)  
- Skin Perfusion Pressure (SPP)  
- Transcutaneous Oxygen Pressure (TcPO₂)  
- Exercise Treadmill ABI  
- Doppler Device  
- Blood Pressure Cuff  
- Digital Arteries  
- Diabetic Neuropathy (implied comorbidity)  
- Chronic Kidney Disease (CKD, implied comorbidity)

Page 15 Extracted Terms:
**Key heart‑disease related terms extracted from the guideline text**

- Peripheral Artery Disease (PAD)  
- Chronic Limb‑Threatening Ischemia (CLTI)  
- Ankle‑Brachial Index (ABI)  
- Toe pressure / Toe‑Brachial Index (TBI)  
- Exercise ABI testing  
- Treadmill exercise ABI  
- Walking performance metrics (time to onset of symptoms, maximal walking time)  
- Post‑exercise ABI  
- Medical therapy (for PAD)  
- Structured exercise therapy (for PAD)  
- Revascularization (for PAD)  
- Randomized Controlled Trials (RCTs) in PAD therapy evaluation  
- Segmental limb pressure measurements  
- Peripheral Vascular Resistance (PVR)  
- Doppler waveforms (lower extremity arterial)  
- Aortoiliac arterial disease  
- Femoropopliteal arterial disease  
- Infrapopliteal arterial disease  
- Imaging for PAD (angiography, duplex ultrasound, etc.)  
- Lower‑extremity arterial waveform nomenclature  
- Vascular laboratory setting  
- Blood pressure gradients between cuffs (leg to ankle)  
- Peripheral vascular disease (general term)  
- Atherosclerotic cardiovascular disease (broader context)  
- American Heart Association (organizational reference)  
- American College of Cardiology Foundation (organizational reference)

Page 16 Extracted Terms:
- Peripheral Arterial Disease (PAD)  
- Critical Limb Ischemia (CLTI)  
- Ankle‑Brachial Index (ABI)  
- Toe‑Brachial Index (TBI)  
- Skin Perfusion Pressure (SPP)  
- Transcutaneous Oxygen Tension (TcPO₂)  
- Guideline‑Directed Medical Therapy (GDMT)  
- Duplex ultrasound  
- Computed Tomography Angiography (CTA)  
- Magnetic Resonance Angiography (MRA)  
- Catheter angiography  
- Claudication  
- Ischemia  
- Amputation  
- Wound healing  
- Perfusion assessment  
- Revascularization strategy  
- Vascular access  
- Contrast media  
- Radiation exposure  
- Laser Doppler flowmetry  
- Laser speckle imaging  
- Pedal acceleration time  
- Spatial frequency domain imaging  
- Toe pressures  
- Continuous‑wave Doppler waveform  
- Photoplethysmographic waveform  
- Abnormal ABI/TBI values  
- Major amputation  
- Non‑healing lower‑extremity wounds  
- Structural exercise (as part of GDMT)  
- Anatomic assessment of disease severity  
- Vascular imaging modalities  
- Diagnostic imaging for PAD  
- Ankle‑brachial index assessment  
- Functional limitation of claudication  
- Revascularization planning  
- Clinical suspicion of PAD  
- Unconclusive ABI and physiological testing.

Page 17 Extracted Terms:
- Cardiovascular  
- Major adverse cardiovascular events (MACE)  
- Major adverse limb events (MALE)  
- Revascularization  
- Guideline‑directed medical therapy (GDMT)  
- Catheter angiography  
- Computed tomography angiography (CTA)  
- Magnetic resonance angiography (MRA)

Page 18 Extracted Terms:
**Key terms related to heart disease extracted from the text**

- Peripheral artery disease (PAD)  
- Major adverse cardiovascular events (MACE)  
- Major adverse limb events (MALE)  
- Chronic limb‑threatening ischemia (CLTI)  
- Chronic kidney disease (CKD)  
- End‑stage kidney disease (ESKD)  
- Diabetes mellitus  
- Smoking (current/ongoing smoking)  
- Hypertension  
- Polyvascular disease  
- Atherosclerosis (atherosclerotic disease)  
- Inflammation  
- Oxidative stress  
- Microvascular disease  
- Retinopathy  
- Neuropathy  
- Nephropathy  
- Guideline‑directed medical therapy (GDMT)  
- Antihypertensive therapy  

Page 19 Extracted Terms:
Peripheral Artery Disease (PAD)  
Myocardial Infarction (MI)  
Coronary Artery Disease (CAD)  
Cardiovascular Death  
Major Adverse Cardiac Events (MACE)  
Major Adverse Limb Events (MALE)  
Critical Limb Ischemia (CLTI/CLI)  
Endovascular Revascularization  
Lower‑Extremity Bypass Revascularization  
Polyvascular Disease  
Microvascular Disease  
Chronic Kidney Disease (CKD)  
End‑Stage Kidney Disease (ESKD)  
Diabetes Mellitus  
Smoking/Tobacco Use  
Atherosclerosis  
Ischemic Stroke  
Vascular Events (general)

Page 20 Extracted Terms:
**Key heart‑disease‑related terms extracted from the guideline text**

- Peripheral Artery Disease (PAD)  
- Myocardial Infarction (MI)  
- Stroke  
- Polyvascular disease  
- Major Adverse Cardiovascular Events (MACE)  
- Major Adverse Limb Events (MALE)  
- Chronic Limb‑Threatening Ischemia (CLTI)  
- Coronary Artery Disease (CAD)  
- Ankle‑Brachial Index (ABI)  
- Acute Limb Ischemia (ALI)  
- Chronic Kidney Disease (CKD)  
- End‑Stage Renal Disease (ESRD / ESKD)  
- Diabetes mellitus  
- Smoking (tobacco use)  
- Depression (ICD‑9/ICD codes)  
- Geriatric Depression Scale (GDS) – GDS ≥ 6  
- Patient Health Questionnaire – PHQ‑9 / PHQ‑8  
- Stress, Anxiety, and depressive symptoms  
- Social determinants of health (racial/ethnic disparities, socioeconomic status, rural residence)  
- Structural racism / chronic stress (“weathering”)  
- Health disparities in diagnosis, treatment, and outcomes  
- Risk‑amplifying comorbidities  
- Medical therapy: Guideline‑Directed Medical Therapy (GDMT)  
- Longitudinal follow‑up for PAD  
- Vascular Outcomes Study of ASA (VOYAGER PAD)  
- COMPASS study (cardiovascular outcomes for people using anticoagulation strategies)  
- EUCLID trial (examining ticagrelor in PAD)  
- Hazard Ratio (HR)  
- Odds Ratio (OR)  
- International Classification of Diseases (ICD)  

These terms capture the primary cardiovascular conditions, outcomes, risk factors, comorbidities, and key studies/metrics discussed within the clinical guideline text.

Page 21 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Cardiovascular Disease (CVD)  
- Major Adverse Limb Events (MALE)  
- Critical Limb‑Threatening Ischemia (CLTI)  
- Major Limb Amputation (MLA)  
- Major Adverse Cardiovascular Events (MACE)  
- Guideline‑Directed Medical Therapy (GDMT)  
- Antiplatelet therapy  
- Statin therapy  
- Supervised exercise therapy  
- Revascularization  
- Systemic hypertension  
- Diabetes mellitus  
- Chronic Kidney Disease (CKD)  
- Stroke  
- Health disparities  
- Uninterrupted health insurance coverage  
- Tobacco product regulation  
- Clinical decision support for PAD care  
- Quality measures for PAD care  
- Policy recommendations for PAD  
- Physical exam of pulses  
- Functional decline  
- Limb‑salvage procedures

Page 22 Extracted Terms:
**Key heart‑disease–related terms extracted from the text**

- Peripheral Artery Disease (PAD)  
- Critical Limb Ischemia (CLTI)  
- Ankle‑Brachial Index (ABI)  
- Major Adverse Cardiac Events (MACE)  
- Major Adverse Limb Events (MALE)  
- Revascularization  
  - Endovascular revascularization  
  - Surgical revascularization  
- Amputation (above‑knee, below‑knee)  
- Geriatric syndromes  
  - Frailty  
  - Sarcopenia  
  - Malnutrition  
  - Mobility impairment  
- Racial and ethnic disparities (Hispanic, Black, White, American Indian)  
- Socioeconomic status (income, education, Distressed Communities Index)  
- Geographic disparities (urban vs rural, geographic isolation, clinician shortages)  
- Atherosclerotic cardiovascular disease (CVD)  
- Comorbidities (e.g., smoking, diabetes)  

These terms capture the core clinical concepts, risk factors, interventions, and demographic factors relevant to heart disease discussion in the supplied text.

Page 23 Extracted Terms:
Peripheral artery disease (PAD)  
Chronic limb‑threatening ischemia (CLTI)  
Major adverse cardiovascular events (MACE)  
Major adverse limb events (MALE)  
Guideline‑directed medical therapy (GDMT)  
Angiotensin‑converting enzyme (ACE) inhibitor  
Angiotensin‑receptor blocker (ARB)  
Statin therapy  
Antiplatelet therapy  
Quality of life (QOL)  
Revascularization (endovascular, surgical, infrainguinal bypass)  
Amputation  
30‑day mortality  
2‑year survival  
5‑year survival  
5‑year amputation‑free survival  
Clinical frailty scale  
Modified frailty index  
Risk Analysis Index  
Geriatric Nutritional Risk Index (GNRI)  
Polypharmacy  
Frailty  
Sarcopenia  
Malnutrition  
Mobility impairment  
Functional status  
Life‑space mobility  
Multimorbidity  
Predicted survival  
Invasive treatment decisions (revascularization, amputation)

Page 24 Extracted Terms:
**Key Heart‑Disease–Related Terms**

1. Peripheral Artery Disease (PAD)  
2. Revascularization  
3. Endovascular revascularization  
4. Surgical revascularization  
5. Hybrid revascularization  
6. Major Adverse Limb Events (MALE)  
7. Major Adverse Cardiac Events (MACE)  
8. Myocardial Infarction (MI)  
9. Stroke (ischemic)  
10. Antiplatelet therapy  
11. Aspirin  
12. Clopidogrel  
13. Rivaroxaban (low‑dose)  
14. Low‑dose aspirin (aspirin + rivaroxaban)  
15. Dual antiplatelet therapy (DAPT)  
16. P2Y12 antagonist  
17. Vorapaxar  
18. Full‑intensity oral anticoagulation  
19. Atrial fibrillation (AF)  
20. Clinical Atherosclerosis (i.e., CAD, cerebrovascular disease)  
21. GMDT (Guideline‑Directed Medical Therapy) for PAD  
22. Foot care / preventive foot care  
23. Ulceration / Critical Limb‑Threatening Ischemia (CLTI)  
24. Quality of Life (QOL)  
25. Bleeding risk (major bleeding)  
26. Cardiovascular and limb events  
27. Residual cardiovascular risk  
28. Prothesis graft (surgical context)

These terms capture the central concepts, interventions, outcomes, and related conditions discussed in the guideline excerpt.

Page 25 Extracted Terms:
Peripheral Artery Disease (PAD)  
Atherosclerosis  
Atrial fibrillation  
Coronary artery disease (CAD)  
Carotid disease  
Ankle‑brachial index (ABI)  
Endovascular revascularization  
Surgical revascularization  
Percutaneous coronary intervention (PCI)  
Drug‑eluting stents (DES)  
Drug‑coated balloons (DCB)  
Paclitaxel‑coated devices  
Antiplatelet therapy  
Antithrombotic therapy  
Dual antiplatelet therapy (DAPT)  
Single antiplatelet therapy (SAPT)  
Triple therapy (full‑intensity anticoagulation + DAPT)  
Low‑dose rivaroxaban  
Low‑dose aspirin  
Rivaroxaban (full‑dose)  
Aspirin (acetylsalicylic acid)  
Clopidogrel (P2Y12 inhibitor)  
Ticagrelor (P2Y12 inhibitor)  
P2Y12 receptor antagonists  
Major Adverse Cardiac Events (MACE)  
Major Adverse Limb Events (MALE)  
Acute limb ischemia (ALI)  
Major bleeding  
Intracranial hemorrhage  
Intra‑cranial tumor / vascular abnormality  
Gastrointestinal bleeding  
VOYAGER PAD trial  
COMPASS trial (Cardiovascular Outcomes for People Using Anticoagulation Strategies)  
CAPRIE trial (Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events)  
EUCLID trial (Examining Use of Ticagrelor in Peripheral Artery Disease)  

These terms encapsulate the principal concepts and therapeutic strategies related to heart disease addressed in the provided guideline excerpt.

Page 26 Extracted Terms:
- Peripheral artery disease (PAD)  
- Antiplatelet therapy  
- Aspirin  
- Dual antiplatelet therapy (DAPT)  
- Single antiplatelet therapy (SAPT)  
- Oral anticoagulation  
- Atrial fibrillation (Afib)  
- Venous thromboembolism (VTE)  
- Chronic limb‑threatening ischemia (CLTI)  
- Major adverse cardiovascular events (MACE)  
- Major adverse limb events (MALE)  
- Ankle‑brachial index (ABI)  
- Toe‑brachial index (TBI)  
- Percutaneous coronary intervention (PCI)  
- Endovascular revascularization  
- Symptomatic vs. asymptomatic PAD  
- Aspirin for Asymptomatic Atherosclerosis (AAA) trial  
- Prevention of Progression of Arterial Disease and Diabetes (POPADAD) trial  
- Critical Leg Ischemia Prevention (CLIPS) trial  

These terms capture the key cardiovascular and heart‑related concepts discussed in the guideline excerpt.

Page 27 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Coronary Artery Disease (CAD)  
- Myocardial Infarction (MI)  
- Major Adverse Cardiac Events (MACE)  
- Major Adverse Limb Events (MALE)  
- Antiplatelet therapy  
- Dual antiplatelet therapy  
- Aspirin  
- Clopidogrel  
- Ticagrelor  
- Vorapaxar (thrombin receptor antagonist)  
- Warfarin  
- Rivaroxaban  
- Low‑dose aspirin  
- High‑intensity statin therapy  
- PCSK9 inhibitor therapy  
- Ezetimibe therapy  
- Ankle‑Brachial Index (ABI)  
- Asymptomatic PAD  
- Symptomatic PAD  
- Lower extremity bypass grafting  
- Intracranial hemorrhage  
- Bleeding risk (moderate‑to‑severe)  
- PEGASUS‑TIMI 54 trial  
- CHARISMA trial  
- TRA 2P‑TIMI 50 trial  
- CASPAR trial  
- WAVE trial  
- Atrial fibrillation (AF)  
- Venous thromboembolism (VTE)

Page 28 Extracted Terms:
**Key heart‑disease terms extracted from the text**

- Peripheral Artery Disease (PAD)  
- Low‑density lipoprotein cholesterol (LDL‑C)  
- High‑intensity statin therapy  
- Statin initiation / continuation  
- Atherosclerotic cardiovascular disease (CVD)  
- Major adverse cardiovascular events (MACE)  
- Major adverse limb events (MALE)  
- Critical limb‑threatening ischemia (CLTI)  
- Endovascular revascularization  
- Surgical revascularization  
- Limb amputation  
- PCSK9 inhibitor  
- Alirocumab  
- Evolocumab  
- FOURIER study (Clinical trial)  
- ODYSSEY OUTCOMES study (Clinical trial)  
- IMPROVE‑IT study (Clinical trial)  
- Atorvastatin (40–80 mg)  
- Rosuvastatin (20–40 mg)  
- Simvastatin (20–40 mg)  
- Pravastatin (40–80 mg)  
- Lovastatin (40–80 mg)  
- Fluvastatin XL (80 mg)  
- Pitavastatin (1–4 mg)  
- Dyslipidemia  
- Primary hypercholesterolemia  
- Mixed dyslipidemia  
- Myopathy (muscle disease)  
- Rhabdomyolysis  
- Acute coronary syndrome (ACS)  
- Vascular Outcomes Study (VOYAGER PAD)  
- Aspirin (acetylsalicylic acid)  
- Rivaroxaban (anticoagulant drug)  

*(All terms are directly related to cardiovascular/heart disease context within the provided guideline text.)

Page 29 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Atherosclerotic arterial disease  
- Major Adverse Cardiovascular Events (MACE)  
- Major Coronary Event  
- Ischemic Stroke  
- Major Adverse Limb Events (MALE)  
- Low‑density lipoprotein (LDL) target <70 mg/dL  
- American Heart Association / American College of Cardiology (AHA/ACC) cholesterol guideline  
- Antihypertensive therapy  
- Systolic blood pressure (SBP)  
- Diastolic blood pressure (DBP)  
- Target blood‑pressure goal <130/80 mm Hg (or <120/80 mm Hg in some trials)  
- Angiotensin‑converting enzyme inhibitors (ACE‑I)  
- Angiotensin‑receptor blockers (ARBs)  
- Hypertension as a cardiovascular risk factor  
- Ankle‑brachial index (ABI)  
- Systolic Blood Pressure Intervention Trial (SPRINT)  
- ABCD (Appropriate Blood Pressure Control in Diabetes) study  
- INVEST (International Verapamil‑SRV Trandolapril) study  
- ALLHAT (Antihypertensive and Lipid‑Lowering Treatment to Prevent Heart Attack Trial)  
- EUCLID trial  
- Heart Outcomes Prevention Evaluation (HOPE) trial  
- Ramipril  
- ONTARGET (Telmisartan Alone and in Combination with Ramipril)  
- Telmisartan  
- Coronary artery disease (CAD)  
- Myocardial infarction (MI)  
- Heart failure (HF)  
- Left ventricular systolic dysfunction  
- Revascularization procedures  
- Clinical atherosclerotic cardiovascular disease (CVD)  

These terms capture the heart‑disease‑related concepts highlighted in the guideline excerpts.

Page 30 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Cardiovascular disease (CVD)  
- Coronary Artery Disease (CAD)  
- Hypertension  
- Angiotensin‑converting enzyme (ACE) inhibitors  
- Angiotensin‑receptor blockers (ARBs)  
- Major Adverse Cardiovascular Events (MACE)  
- Major Adverse Limb Events (MALE)  
- Stroke  
- Vascular risk factors (e.g., smoking, secondhand smoke)  
- Nicotine replacement therapy  
- Varenicline  
- Bupropion  
- Electronic nicotine delivery systems (e‑cigarettes)  
- Tobacco use/cessation interventions  
- Vascular health outcomes (e.g., limb‑related events, mortality)

Page 31 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Chronic Limb‑Threatening Ischemia (CLTI)  
- Major Adverse Limb Events (MALE)  
- Major Adverse Cardiovascular Events (MACE)  
- Myocardial Infarction (MI)  
- Stroke (non‑fatal)  
- Cardiovascular death  
- Hospitalization for heart failure  
- Glucagon‑like peptide‑1 (GLP‑1) agonists  
- Liraglutide  
- Semaglutide  
- Tirzepatide  
- Sodium‑glucose cotransporter‑2 (SGLT‑2) inhibitors  
- Canagliflozin  
- Dapagliflozin  
- Empagliflozin  
- Ertugliflozin  
- EMPA‑REG OUTCOME trial  
- CANVAS trial  
- DECLARE‑TIMI 58 trial  
- SUSTAIN‑6 trial  
- LEADER trial  
- Cardiovascular outcomes  
- Non‑fatal MI  
- Non‑fatal stroke  
- Type 2 diabetes  
- Glycemic control  
- Weight management (pharmacologic and non‑pharmacologic therapies for cardiovascular risk)

Page 32 Extracted Terms:
**Key terms related to heart disease extracted from the text**

- Peripheral Artery Disease (PAD)  
- Critical Limb Threatening Ischemia (CLTI)  
- Major Adverse Cardiovascular Events (MACE)  
- Major Adverse Limb Events (MALE)  
- canagliflozin  
- empagliflozin  
- SGLT2 inhibitors  
- type 2 diabetes mellitus  
- diabetes mellitus (general)  
- hemoglobin A1c  
- glycemic control  
- cardiovascular risk  
- heart failure  
- revascularization (endovascular/surgical)  
- infra‑popliteal procedures  
- diabetic foot ulcer  
- diabetic neuropathy  
- preprocedural glycemic control  
- ischemic limb outcomes  
- vaccine‑associated vascular complications (influenza, SARS‑CoV‑2)  
- clinical trials: CANVAS, CREDENCE, EMPA‑REG OUTCOME, EUCLID, Strong Heart study  

These terms capture the cardiovascular conditions, risk factors, therapeutic agents, and clinical studies highlighted in the guidelines.

Page 33 Extracted Terms:
Peripheral Artery Disease (PAD)  
Coronary Artery Disease (CAD)  
Cardiovascular Disease (CVD)  
Major Adverse Cardiovascular Events (MACE)  
Influenza vaccination  
SARS‑CoV‑2 vaccination  
Antiplatelet therapy  
Antithrombotic therapy  
Lipid‑lowering therapy  
Antihypertensive therapy  
Smoking cessation  
Diabetes management  
Healthy diet  
Mediterranean diet  
DASH (Dietary Approaches to Stop Hypertension) diet  
PREDIMED study  
Lyon Diet Heart Study  
Vitamin B‑complex supplementation  
Vitamin D supplementation  
Homocysteine  
Chelation therapy  
HOPE‑2 trial (Heart Outcomes Prevention Evaluation‑2)  
TACT trial (Trial to Assess Chelation Therapy)  
Stroke  
Myocardial infarction (MI)  
Recurrent cardiovascular events  
Secondary prevention  
Primary prevention  
Atherosclerotic cardiovascular disease  
Blood pressure  
Sodium reduction  
Blood pressure reduction  
Cardiovascular risk reduction  
Clinical outcomes  

Page 34 Extracted Terms:
**Key heart‑disease related terms identified in the text**

- Peripheral Artery Disease (PAD)  
- Claudication  
- Cilostazol  
- Pentoxifylline  
- Chelation therapy  
- Congestive heart failure (CHF) (any severity)  
- Re‑stenosis (post‑interventional)  
- Endovascular therapy  
- Femoropopliteal disease  
- In‑stent re‑stenosis  
- Bare‑metal femoropopliteal stent  
- Paclitaxel‑eluting stent  
- Major adverse limb event (MALE)  
- Major amputation  
- Major Adverse Cardiac Events (MACE)  
- All‑cause mortality  
- Cardiovascular deaths  
- Cardiovascular disease (CVD)  
- Vitamin D deficiency / hypovitaminosis D  
- Vitamin D supplementation  
- Phosphodiesterase III inhibitor  
- Milrinone (phosphodiesterase inhibitor)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Heart failure with preserved ejection fraction (HFpEF)  
- Cardiovascular risk/vascular risk  
- ABI (ankle‑brachial index) – vascular health indicator  
- PAQ (Peripheral Artery Questionnaire) – assessment of limb function  
- QOL (quality of life) – health outcome metric  
- Walking distance / maximal walking distance – functional capacity metric

Page 35 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Cardiovascular Disease (CVD)  
- Coronary Artery Disease (CAD)  
- Heart Failure  
- Cerebrovascular Disease  
- Chronic Limb‑Threatening Ischemia (CLTI)  
- Endovascular revascularization  
- Surgical revascularization  
- Vascular specialists  
- Claudication (leg pain on walking)  
- Rest pain (ischemic pain at rest)  
- Clotting or thrombosis of peripheral arteries (implied by PAD discussion)  
- Chronic Kidney Disease (CKD) – a major cardiovascular comorbidity  
- End‑Stage Kidney Disease (ESKD) – an extreme CKD stage linked to vascular disease  
- Diabetes with poor glycemic control – a key modifiable risk factor for cardiovascular disease  
- Peripheral neuropathy – a neurological complication often secondary to vascular disease  
- Charcot foot deformity – a severe complication of PAD with cardiovascular implications  
- Foot ulceration and amputation – sequelae of advanced peripheral arterial disease and systemic vascular compromise  
- Therapeutic footwear – a preventive strategy to reduce cardiovascular‑related foot ulceration risk  
- Foot self‑care education – a non‑pharmacologic intervention to mitigate cardiovascular complications associated with PAD  

(Note: All terms are derived directly from the text and pertain to heart or cardiovascular disease concepts.)

Page 36 Extracted Terms:
**Key terms related to heart disease (and vascular complications) in the guideline:**

- Peripheral Artery Disease (PAD)  
- Foot ulcers  
- Foot care / self‑foot care  
- Foot inspection / foot surveillance  
- Foot deformities (e.g., bunions/hallux valgus, hammertoe, claw toe, flatfoot/pes planus, severe high‑arch foot/pes cavus, Charcot foot, arthritic foot)  
- Protective footwear / therapeutic footwear  
- Podiatry / podiatrist  
- Revascularization  
- Multispecialty care team  
- Exercise therapy for PAD  
- Lower extremity amputation  
- Walking performance / functional status  
- Diabetes‑associated neuropathy  
- Foot temperature monitoring  
- Foot education resources (American Diabetes Association, CDC, NIDDK)  
- Risk‑based foot screening intervals (annual, every 3–6 months, every 1–3 months)  

These terms capture the primary concepts, interventions, and complications discussed in the guideline that relate to vascular health and, by extension, heart‑related disease processes.

Page 37 Extracted Terms:
- Peripheral artery disease (PAD)  
- Claudication  
- Revascularization  
- Supervised Exercise Therapy (SET)  
- Structured community‑based exercise program  
- Home‑based exercise program  
- Walking performance  
- Functional status  
- Quality of life (QOL)  
- Endothelial function  
- Endothelial dysfunction  
- Angiogenesis  
- Microvascular blood flow  
- Macrovascular blood flow  
- Ischemia‑reperfusion injury  
- Intermittent walking  
- Treadmill training  
- Stationary bicycle training  
- Arm ergometry  
- Recumbent stepping  
- Behavioral change techniques  
- Activity monitors  
- Clinical exercise physiologists  
- Nurses with exercise training experience  
- Cardiac rehabilitation  
- Medicare coverage of exercise therapy  
- Commercial insurance coverage of exercise therapy  
- Muscle fiber adaptations  
- Mitochondrial density and activity  
- Skeletal muscle strength and endurance  
- Blood distribution efficiency  
- Local inflammatory response  
- Ischemic symptoms (moderate‑to‑severe claudication pain)  
- Pain‑induced rest periods  
- Incremental increases in walking intensity  
- Progressive training to 30‑45 min of active walking  
- Exercise session duration (30‑45 min per 60‑min session)  
- Exercise session frequency (≥3 sessions per week)  
- Minimum training duration (≥12 weeks)  
- Walking distance and speed progression  
- Exercise prescription alterations  
- Monitoring of exercise progress  
- Patient counseling and education  
- Behavioral coaching (in‑person or virtual)  
- Home or community setting for exercise  
- Hospital or outpatient facility setting for exercise  
- Structured exercise program classification  
- Exercise adherence and adherence strategies  
- Cardiovascular health interventions  
- Physical activity promotion  
- Exercise therapy for cardiovascular disease management

Page 38 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Claudication  
- Supervised Exercise Therapy (SET)  
- Structured community‑based exercise programs  
- Revascularization  
- Treadmill walking  
- 6‑Minute Walk Test (6MWT)  
- Walking performance  
- Functional status  
- Quality of Life (QOL)  
- Cardiac rehabilitation  
- Exercise‑limiting cardiovascular disease (CVD)  
- Amputation  
- Wheelchair confinement  
- Diabetes (as a PAD comorbidity)  
- Home‑based exercise programs  
- Virtual coaching  
- Activity tracking  
- Behavioral change techniques  
- Health coaching  
- LITE (Low Intensity Exercise Intervention in PAD) trial  
- GOALS (Group Oriented Arterial Leg Study)  
- Medicare coverage of SET  
- Insurance reimbursement for exercise therapy  
- Exercise prescription parameters (treadmill walking parameters, 6MWT)  
- Evidence‑based risk–benefit ratio for SET in PAD  

Page 39 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Intermittent Claudication  
- Supervised Exercise Therapy (SET)  
- Structured Exercise Programs  
- Community‑Based Exercise  
- Home‑Based Walking Program  
- 6‑Minute Walk Test (6MWT)  
- Quality of Life (QOL)  
- Percutaneous Transluminal Angioplasty (PTA)  
- Endovascular Revascularization  
- Endoluminal Revascularization  
- Femoropopliteal Disease  
- Aortoiliac PAD  
- Revascularization + SET Combination Therapy  
- Alternative Exercise Modalities (cycling, recumbent stepping, resistance training)  
- Treadmill Walking (low‑intensity vs. moderate/high‑intensity)  
- Functional Status Improvement  
- Pain Levels (moderate to severe claudication pain)  
- Structured Community‑Based Exercise Programs (including home‑based)  
- Unstructured Exercise (self‑directed walking)  
- Exercise‑Induced Ischemic Symptoms  

(Note: These terms represent the primary disease‑condition, therapeutic modalities, outcome measures, and exercise strategies mentioned in the text.)

Page 40 Extracted Terms:
**Key terms related to heart disease**

- Peripheral Artery Disease (PAD)  
- Asymptomatic PAD  
- Chronic Limb‑Threatening Ischemia (CLTI)  
- Acute Limb Ischemia (ALI)  
- Claudication  
- Endovascular revascularization procedures  
- Surgical revascularization procedures  
- Transfemoral aortic valve replacement  
- Mechanical circulatory support  
- Endovascular aortic aneurysm repair  
- Endovascular stenting  
- Endoconduit creation  
- Iliac artery conduit  
- Iliofemoral bypass  
- Catheter‑based cardiac procedures  
- Catheter insertion and removal  
- Safety of sheath insertion  
- Major Adverse Limb Events (MALE)  
- Vascular complications  
- Cardiovascular Angiography and Interventions (SCAI)  
- Vascular Quality Initiative (VQI)  
- National Cardiovascular Data Registry (NCDR)  
- Society of Interventional Radiology (SIR)  
- PVI Registry (Peripheral Vascular Intervention)  
- VIRTEX Registry  
- Endovascular therapies (general)  
- Conduit placement (general)

Page 41 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Chronic Symptomatic PAD  
- Claudication (exertional leg symptoms)  
- Rest pain  
- Critical Limb-threatening Ischemia (CLTI)  
- Revascularization (endovascular, surgical, hybrid)  
- Guideline‑Directed Medical Therapy (GDMT)  
- Quality of Life (QOL)  
- Foot care  
- Exercise therapy for PAD  
- Patient outcomes  
- Local quality improvement initiatives  
- Benchmarking across centers  
- Revascularization procedures  
- Tracking of revascularization procedures  
- Professional societies (guideline authors)

Page 42 Extracted Terms:
**Key terms related to heart disease / cardiovascular care:**

- Peripheral arterial disease (PAD)
- Claudication
- Revascularization
- Endovascular revascularization
- Surgical revascularization
- Aortoiliac disease
- Femoro‑popliteal disease
- Common femoral artery disease
- Infrapopliteal disease
- Hemodynamically significant lesion
- Glucose‑lowering medical therapy (GDMT) – often including antihypertensive, lipid‑lowering, antiplatelet agents
- Structured exercise therapy
- Quality of life (QOL)
- Walking performance / functional status
- Major adverse cardiovascular events (MACE)
- Bleeding
- Infection
- Perioperative risk
- Endovascular techniques:
  - Percutaneous transluminal angioplasty (PTA / balloon angioplasty)
  - Drug‑coated balloon angioplasty
  - Bare‑metal stents
  - Drug‑eluting stents
  - Covered stents
  - Lithotripsy (intravascular lithotripsy)
  - Atherectomy
- Intravascular pressure measurements
- Resting vs. provoked pressure gradients
- Anatomical evaluation of disease
- Longitudinal follow‑up
- Diagnostic testing for PAD
- Patient‑centered decision making
- Patient engagement
- Smoking cessation
- Medication adherence

These terms capture the cardiovascular concepts, therapeutic options, outcomes, and patient‑care considerations present in the guideline excerpt.

Page 43 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Claudication  
- Surgical revascularization  
- Endarterectomy  
- Bypass (vascular bypass)  
- Endovascular treatment  
- Hybrid approaches (combined surgical/endovascular)  
- Guideline‑Directed Medical Therapy (GDMT)  
- Structured exercise (SET)  
- Pain‑free walking distance  
- Total walking distance  
- Quality of Life (QOL)  
- Diabetes mellitus  
- End‑stage kidney disease (ESKD)  
- Obesity  
- Frailty  
- Functional status  
- Major adverse limb events (MALE)  
- Restenosis  
- Acute limb ischemia (ALI)  
- Critical limb‑threatening ischemia (CLTI)  
- Anterior aortoiliac disease  
- Femoropopliteal disease  
- Critical limb ischemia (CLI)  
- Long‑term durability of revascularization  
- Reintervention risk  
- Readmission risk  
- Randomized controlled trials (RCTs)  
- Network meta‑analysis  

These terms capture the major concepts and clinical factors related to heart (cardiovascular) disease discussed in the provided guideline excerpt.

Page 44 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Endovascular Treatment  
- Endovascular Revascularization  
- Endovascular Therapy  
- Endovascular Intervention  
- Claudication  
- Supervised Exercise Therapy (SET)  
- Walking Performance  
- Walking Distance  
- Quality of Life (QOL)  
- Vessel Patency  
- Primary Patency  
- Secondary Patency  
- Aortoiliac Segment  
- Femoropopliteal Segment  
- Aortoiliac Disease  
- Femoropopliteal Disease  
- Occlusion  
- Stenosis  
- Lesion Length  
- Multiple Lesions  
- Diffuse Lesions  
- Poor-Quality Runoff  
- Diabetes Mellitus  
- Chronic Kidney Disease (CKD)  
- Renal Failure  
- Smoking  
- Guideline-Directed Medical Therapy (GDMT)  
- Medical Therapy  
- Medications Alone  
- Surgical Revascularization  
- Endarterectomy  
- Common Femoral Endarterectomy  
- Perioperative Risk  
- Major Adverse Cardiovascular Events (MACE)  
- Reintervention  
- Restenosis  
- Durability  
- Patency Rates  
- Complications  
- Wound Infection  
- Lymphatic Fistula  



Page 45 Extracted Terms:
- Peripheral arterial disease (PAD)  
- Claudication  
- Critical limb ischemia (CLTI)  
- Endovascular revascularization  
- Open surgical revascularization  
- Endarterectomy  
- Autogenous vein graft (e.g., great saphenous vein)  
- Prosthetic conduit (prosthetic graft material)  
- Femoropopliteal bypass  
- Popliteal artery  
- Common femoral artery  
- Aorto‑iliac lesions  
- Infra‑popliteal disease  
- Bypass graft patency  
- Multispecialty, team‑based care for PAD  
- Revascularization as standard therapy for CLTI  
- Wound care, infection management, and pressure off‑loading as adjuncts  
- Structured exercise (comparative treatment option)  

These terms capture the core cardiovascular concepts discussed in the guideline excerpt.

Page 46 Extracted Terms:
- Chronic limb‑threatening ischemia (CLTI)  
- Peripheral artery disease (PAD)  
- Multi‑specialty care team  
- Revascularization techniques  
- Vascular care  
- Wound‑healing therapies  
- Podiatry  
- Foot surgery  
- Guideline‑directed medical therapy (GDMT)  
- Quality of life (QOL)  
- Comprehensive care  
- Wound healing  
- Prevention of amputation  
- Tissue loss  
- Ambulatory status  
- Multidisciplinary approaches  
- Vascular revascularization  
- Patient‑centered care  

Page 47 Extracted Terms:
- Chronic Limb-Threatening Ischemia (CLTI)  
- Peripheral Artery Disease (PAD)  
- Revascularization  
- Surgical revascularization  
- Endovascular revascularization  
- Hybrid revascularization  
- Bypass  
- Autogenous vein  
- Great saphenous vein  
- Ultrasound mapping  
- Prosthetic graft  
- Cadaveric graft  
- Popliteal artery  
- Infrapopliteal arteries (tibial, pedal)  
- Inflow disease  
- Outflow disease  
- In-line blood flow  
- Perfusion  
- Tissue loss  
- Wound healing  
- Nonhealing wounds  
- Gangrene  
- Ischemic rest pain  
- Limb‑threatening infection  
- Amputation  
- Multispecialty care team  
- Vascular medicine  
- Vascular surgery  
- Vascular interventional radiology  
- Interventional cardiology  
- Endovascular specialist  
- Surgical specialist  
- Nurse practitioner / physician assistant  
- Nurse  
- Podiatrist  
- Orthopedic surgeon  
- Foot surgeon  
- Wound‑care specialist  
- Endocrinologist  
- Internal medicine specialist  
- Infectious disease specialist  
- Diagnostic radiologist  
- Vascular imaging specialist  
- Pharmacist  
- Physical medicine and rehabilitation clinician  
- Occupational therapist  
- Physical therapist  
- Clinical exercise physiologist  
- Nutritionist / dietitian  
- Social worker  
- Patients and family members (care coordination)

Page 48 Extracted Terms:
**Key heart‑disease related terms**

- Peripheral Artery Disease (PAD)  
- Chronic Limb‑Threatening Ischemia (CLTI)  
- Revascularization  
- Endovascular therapy  
- Surgical revascularization  
- Hybrid revascularization  
- Bypass surgery  
- Angioplasty  
- Endarterectomy  
- Autogenous vein conduit  
- Saphenous vein  
- Coronary artery bypass surgery  
- Coronary ischemia  
- Cardiomyopathy  
- Heart failure  
- Major adverse cardiac events (MACE)  
- BEST‑CLI (trial)  
- BASIL‑2 (trial)  

These terms capture the cardiovascular interventions, conditions, and trial identifiers that are central to the guideline’s discussion of heart‑related disease.

Page 49 Extracted Terms:
1. Revascularization  
2. Endovascular intervention  
3. Surgical bypass  
4. Critical Limb Ischemia (CLTI)  
5. Peripheral Artery Disease (PAD)  
6. Autogenous vein  
7. Great saphenous vein  
8. Small saphenous vein  
9. Basilic vein  
10. Cephalic vein  
11. Composite bypass conduit  
12. Popliteal artery  
13. Infrapopliteal disease  
14. BASIL‑2 trial (Bypass versus Angioplasty for Severe Ischaemia of the Leg)  
15. BEST‑CLI trial (Best-CLI)  
16. Global Limb Anatomic Staging System (GLASS)  
17. Major Adverse Limb Events (MALE)  
18. Major amputation  
19. Graft thrombectomy  
20. Graft revision  
21. Thrombolysis  
22. Patency  
23. Duplex ultrasound  
24. Vein mapping  
25. Vascular laboratory  
26. Preoperative assessment of vein adequacy  
27. Vein conduit suitability  
28. Anatomic pattern of disease  
29. Multidisciplinary care team  
30. Risk‑benefit calculation.

Page 50 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Chronic Limb‑Threatening Ischemia (CLTI)  
- Revascularization  
- Inflow lesions  
- Outflow lesions  
- Autogenous vein graft  
- Prosthetic bypass graft  
- Saphenous vein (autogenous conduit)  
- Cadaveric vein graft  
- Endovascular intervention  
- Endovascular therapy  
- Surgical bypass  
- Angiosome (direct pulsatile flow)  
- Collateral circulation  
- Limb salvage  
- Wound healing  
- Ischemic rest pain  
- Multilevel disease  
- Pressure offloading  
- Diabetic foot ulcer  
- Customized footwear (pressure‑offloading)  
- Duplex ultrasound (vascular laboratory)  
- Point‑of‑care ultrasound  
- Vascular laboratory  
- Vascular conduit  
- Hemodynamic blood flow to foot  
- Perfusion to the wound bed  
- Pulse flow (direct revascularization)  
- Vascular laboratory‑based duplex ultrasound  

(These terms capture the key cardiovascular and vascular concepts discussed in the guideline excerpt.)

Page 51 Extracted Terms:
**Key heart‑vascular terms extracted from the text**

- Peripheral Artery Disease (PAD)  
- Chronic Limb‑Threatening Ischemia (CLTI)  
- Revascularization  
- Pressure offloading devices (non‑removable vs removable)  
- Hyperbaric oxygen therapy  
- Negative pressure wound therapy (NPWT)  
- Minor and major amputation (foot, digit)  
- Surgical debridement (for foot infections/gangrene)  
- Foot ulcer management (including diabetic foot ulcers)  
- Antimicrobial therapy for foot infections  
- Multidisciplinary wound‑care team (for CLTI)  

These terms capture the cardiovascular and peripheral‑vascular focus of the guideline text.

Page 52 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Chronic Limb‑Threatening Ischemia (CLTI)  
- Endovascular revascularization  
- Limb salvage  
- Venous arterialization  
- Arterial intermittent pneumatic compression devices  
- Prostanoids (in the context of CLTI)  
- Ischemia  
- Revascularization (when not an option)  
- Hyperbaric oxygen therapy  
- Cardiovascular risk factor modification  
- Wound healing in PAD/CLTI  
- Pressure offloading  
- Pain control (for ischemic rest pain)  
- Smoking cessation  
- Glycemic control (diabetes management)  
- Multispecialty care team (vascular, wound care, cardiology)  
- Endovascular therapy for PAD  
- Ankle‑Brachial Index (ABI) <0.80  
- Toe‑Brachial Index (TBI) <0.70  
- Limb‑preservation strategies  
- Tissue growth optimization  
- Edema control  
- Infection management in PAD patients

Page 53 Extracted Terms:
**Key Heart‑Disease–Related Terms Extracted**

- Cardiovascular mortality  
- Vascular endothelial cytoprotection  
- Vasodilation  
- Platelet aggregation inhibition  
- Nitric‑oxide release  
- Prostanoids (prostacyclin, iloprost)  
- Endovascular revascularization  
- Intermittent pneumatic compression device (arterial pump)  
- Arteriovenous pressure gradient  
- Reversal of vasomotor paralysis  
- Chronic limb‑threatening ischemia (CLTI)  
- Peripheral artery disease (PAD)  
- Limb salvage rate  
- Wound healing (vascular component)  
- Anatomic classification of limb ischemia (GLASS/WIfI)

Page 54 Extracted Terms:
**Key Heart‑Disease–Related Terms Extracted**

1. Peripheral Artery Disease (PAD)  
2. Critical Limb Ischemia / Critical Limb Threatening Ischemia (CLTI)  
3. Ischemia  
4. Revascularization  
5. Venous Arterialization  
6. Percutaneous Deep Vein Arterialization (pDVA)  
7. Hybrid techniques (open, percutaneous, or combined)  
8. Limb salvage  
9. Amputation‑free survival  
10. Major amputation  
11. Minor amputation (inframalleolar level)  
12. Wound healing / complete wound healing  
13. Infection (advanced or bone/soft‑tissue involvement)  
14. Inflammation / metabolic derangement  
15. Prosthetic rehabilitation / ambulation  
16. Quality of Life (QOL) outcomes in limb loss  
17. Multispecialty care team / team‑based care for CLTI  
18. Objective limb‑threat classification tools  
19. AHA (American Heart Association) non‑traumatic amputation reduction goal  
20. Cardiovascular risk factors implied by “ischemia” and “revascularization”  

These terms capture the cardiovascular‑focused concepts presented in the guideline excerpt.

Page 55 Extracted Terms:
**Key heart‑disease related terms extracted from the text**

- Peripheral Artery Disease (PAD)  
- Critical Limb‑Threatening Ischemia (CLTI)  
- Cardiovascular Disease (CVD)  
- Revascularization (interventional/surgical)  
- Ischemia (vascular‑related tissue hypoxia)  
- WIfI (Wound‑Ischemia‑Foot‑Infection) classification tool  
- GLASS (Global Limb Anatomic Staging System) classification tool  
- Advanced CVD (as a reference to severe cardiovascular disease)

Page 56 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Acute Limb Ischemia (ALI)  
- Chronic Limb‑Threatening Ischemia (CLTI)  
- Revascularization (endovascular or surgical)  
- Coronary Artery Bypass Grafting (CABG)  
- Valve Surgery  
- Percutaneous Coronary Intervention (PCI)  
- Myocardial Infarction (MI)  
- WIfI classification (Wound, Ischemia, foot Infection)  
- GLASS classification (Global Limb Ankle and Foot Severity Score)  
- Vascular Quality Initiative (VQI)  
- National Cardiovascular Data Registry (NCDR) – PVI Registry  
- Society of Interventional Radiology VIRTEX registry  
- Society of Thoracic Surgery (STS) reporting  
- Limb Viability  
- Limb Salvage  
- Ischemia  
- Endovascular Procedures  
- Duplex Ultrasound  
- Computed Tomography Angiography (CTA)  
- Magnetic Resonance Angiography (MRA)  
- Continuous Wave Doppler (limb assessment)

Page 57 Extracted Terms:
**Key heart‑disease related terms**

- Peripheral artery disease (PAD)  
- Acute limb ischemia (ALI)  
- Revascularization (surgical or endovascular)  
- Cardiovascular (CV)  
- Aortic dissection  
- Bypass graft  
- Stent (endovascular stenting)  
- Ischemia  
- Thrombosis  
- Embolus  
- Duplex ultrasound  
- Computed tomography angiography (CTA)  
- Magnetic resonance angiography (MRA)  
- Doppler ultrasonography (continuous‑wave Doppler)  
- Electrocardiogram (ECG)  
- Morbidity and mortality (cardiovascular outcomes)

Page 58 Extracted Terms:
**Key terms related to heart disease (vascular/ischemic disease) extracted from the guideline text**

- Acute Limb Ischemia (ALI)  
- Salvageable limb  
- Non‑salvageable limb  
- Revascularization  
- Endovascular revascularization  
- Surgical revascularization  
- Catheter‑directed thrombolysis  
- Catheter‑based thrombolysis  
- Ultrasound‑accelerated thrombolysis  
- Pharmacomechanical thrombectomy  
- Vacuum‑assisted percutaneous mechanical thrombectomy  
- Endovascular thromboembolectomy  
- Surgical thromboembolectomy (e.g., Fogarty catheter)  
- Bypass graft occlusion  
- Retained valves  
- Neointimal hyperplasia  
- Diffuse atherosclerotic lesions  
- Focal atherosclerotic lesions  
- Patch angioplasty  
- Jump extension grafts  
- Interposition grafts  
- Endarterectomy  
- Percutaneous transluminal angioplasty (PTA)  
- Stenting (endovascular stent)  
- Compartment syndrome  
- Reperfusion injury  
- Limb salvage  
- Major amputation  
- Mortality (high rates of mortality associated with ALI)  
- Limb loss  
- Chemotherapeutic‑induced prothrombotic viral states  
- Catheter‑based mechanical thrombectomy  
- Lytic agent (used in thrombolysis)  
- Revascularization strategy  
- Culprit lesion  
- Catheter‑directed thrombolysis efficacy vs. open surgery  
- Revascularization planning strategy  
- Adjuvant (adjunctive) revascularization procedures  
- Revascularization indications (categories I, IIa, IIb)  

These terms capture the key clinical concepts, procedures, and risk factors discussed in the guideline excerpt.

Page 59 Extracted Terms:
- Acute limb ischemia (ALI)  
- Peripheral artery disease (PAD)  
- Thrombolysis  
- Revascularization (endovascular or surgical)  
- Catheter‑directed thrombolysis  
- Anticoagulation  
- Unfractionated heparin  
- Thrombotic events  
- Tyrosine kinase inhibitors  
- Cancer chemotherapy (platinum‑based agents)  
- Prothrombotic states  
- Systemic proinflammatory states  
- COVID‑19 / SARS‑CoV‑2 infection  
- Multiorgan failure  
- Cardiovascular collapse  
- Ischemia (irreversible, prolonged)  
- Reperfusion injury  
- Oxygen‑free radicals  
- Compartment syndrome  
- Compartment pressures  
- Creatine kinase elevation  
- Collateral circulation  
- Limb loss  
- Amputation  
- Prophylactic fasciotomy  
- Reperfusion metabolites  
- Endovascular techniques  
- Surgical bypass  
- Clinical stability and comorbidities  
- Multidisciplinary discussion (treatment approach)

Page 60 Extracted Terms:
- Coronary artery disease (CAD)  
- Heart failure  
- Aortic dissection  
- Cardiac thromboembolism (cardiovascular cause of thromboembolism)  
- Ischemia (e.g., myocardial or limb ischemia)  
- Reperfusion syndrome  
- Reperfusion injury  
- Anticoagulation therapy  
- Unfractionated heparin  
- Direct thrombin inhibitor  
- Thrombus  
- Embolism  
- Revascularization procedures  
- Vascular (cardiovascular) disease  
- Compartment syndrome (associated with ischemic injury)

Page 61 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Acute Limb Ischemia (ALI)  
- Atrial fibrillation  
- Myocardial infarction (MI)  
- Cardiomyopathy  
- Valvular heart disease  
- Mitral stenosis  
- Left atrial thrombus / left atrial appendage thrombus  
- Left ventricular thrombus  
- Infective endocarditis (valvular vegetation)  
- Intracardiac shunt (e.g., patent foramen ovale)  
- Intracardiac mural thrombi  
- Transient ischemic attack / stroke (as a cardiac embolic event)  
- Heart rhythm disturbances (irregular rhythm, arrhythmia)  
- Palpitations  
- Tachycardia  
- Chest pain (cardiac origin)  
- Congestive heart failure  
- Cardiac murmur  
- Electrocardiography (ECG)  
- Cardiac rhythm monitoring (e.g., Holter, event recorder)  
- Echocardiography (transthoracic / transesophageal)  
- Cardiac embolization mechanisms  
- Anticoagulation therapy for atrial fibrillation  
- Anticoagulation monitoring (last dose, INR, etc.)  
- Cardiac causes of thromboembolic disease (e.g., left atrial thrombus, valvular vegetations, intracardiac shunts)  
- Cardiac-related pulmonary symptoms (e.g., dyspnea, pulmonary edema)  
- Cardiac evaluation in acute limb ischemia management

These terms represent the primary concepts in the source text that are associated with heart disease.

Page 62 Extracted Terms:
- Atrial fibrillation  
- Valvular disease  
- Intracardiac thrombus  
- Mitral stenosis  
- Cardioembolic cause (e.g., AF, stenosis, thrombus)  
- Thrombus (aortic)  
- Aortic aneurysm (imaging of the aorta)  
- Hypercoagulable states  
- Major adverse cardiovascular events (MACE)  
- Myocardial infarction (MI)  
- Stroke  
- Death  
- Guideline‑directed medical therapy (GDMT)  
- Cardiovascular risk factors  
- Cardiovascular and limb risk reduction efforts  

Page 63 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Critical Limb Ischemia (CLTI)  
- Major Adverse Cardiovascular Events (MACE)  
- Myocardial Infarction (MI)  
- Ischemic Stroke  
- Guideline‑Directed Medical Therapy (GDMT)  
- Lipid‑lowering therapy  
- Statin therapy  
- Antiplatelet therapy  
- Antithrombotic therapy  
- Low‑Density Lipoprotein Cholesterol (LDL‑C)  
- Blood‑pressure control  
- Diabetes mellitus  
- Hypertension  
- Dyslipidemia  
- Smoking cessation  
- Cardiovascular risk factors  
- Ankle‑Brachial Index (ABI)  

Page 64 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Restenosis  
- Revascularization (endovascular and surgical)  
- Duplex ultrasound surveillance  
- Infrainguinal autogenous vein bypass grafts  
- Prosthetic bypass grafts  
- Low flow (graft compromise indicator)  
- Stenosis (severe)  
- Aortoiliac, femoropopliteal, infrapopliteal vessel segments  
- Critical Limb-Threatening Ischemia (CLTI)  
- Acute Limb Ischemia (ALI)  
- Telehealth (virtual visits for vascular care)  
- Symptomatic PAD (claudication, ischemia-related exertional symptoms)  
- Asymptomatic PAD screening  
- Cardiovascular risk reduction therapies  
- Major Adverse Cardiovascular Events (MACE)  
- Major Adverse Limb Events (MALE)  
- Antiplatelet and antithrombotic regimens  
- Supervised Exercise Training (SET)  
- Functional status / walking performance metrics  
- Endovascular devices: balloon angioplasty, drug-coated balloon angioplasty, atherectomy  
- Shared decision‑making strategies in PAD management  
- Wound healing and limb salvage strategies for CLTI  
- Comparative effectiveness studies of revascularization strategies.

Page 65 Extracted Terms:
Peripheral Artery Disease (PAD)  
Chronic Limb‑Threatening Ischemia (CLTI)  
Cardiovascular Disease (CVD)  
Coronary Artery Disease (CAD)  
Revascularization  
Guideline‑Directed Medical Therapy (GDMT)  
Structured Exercise Training (SET)  
Telehealth  
Remote Patient‑Monitoring Devices (wearables, smart devices)  
Nontraumatic Lower Extremity Amputation  
Limb Outcomes  
Cardiovascular Outcomes  
Risk Factor Modification  
Smoking Cessation  
Detection  
Diagnosis  
Clinical Outcomes  
Readmissions  
Hybrid Programs (facility‑based & community/home‑based)  
National Registry of Nontraumatic Amputations  
PAD National Action Plan  
AHA Get With The Guidelines  
Multispecialty / Multisocietal Collaboration  
Advocacy Priorities  
Disparities (in care, outcomes, access)  
Prevention  
Telemedicine  
Wearable Technology  
Smart Devices  
Peripheral Vascular Surveillance Testing  
Quality Outcomes  
Access to Care  
Affordability  
Telehealth Implementation  
Remote Monitoring  
Risk Factor Identification  
Clinical Surveillance  
Regulatory Support  
Public Health Initiative  
Evidence‑Based Interventions  
Healthcare Disparity Gap  
Medical Therapy Optimization  
Lifestyle Modification  
Outpatient Follow‑up  
Revascularization Readmissions  
Clinical Surveillance Programs  
Patient‑Engagement Tools  
Digital Health Platforms  
Population‑Based Data Collection  
Registry‑Based Research  
Outcome Tracking  
Policy Development  
Care Coordination  
Data‑Driven Quality Improvement.

Page 66 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Lower extremity peripheral artery disease  
- Cardiovascular disease (CVD)  
- Cardio‑vascular disease and comorbid conditions  
- Coronary artery disease (inferred from dual antiplatelet therapy context)  
- Dual antiplatelet therapy  
- Perioperative cardiovascular evaluation  
- Non‑cardiac surgery (perioperative context)  
- Heart disease (general term)  
- Stroke (as a major cardiovascular comorbidity)

Page 67 Extracted Terms:
- Peripheral Artery Disease  
- Cardiovascular disease  
- Heart disease  
- Chronic coronary disease  
- Stroke  
- Hypertension  
- Blood cholesterol  
- Atherosclerosis  
- Atherosclerotic occlusive disease  
- Chronic limb‑threatening ischemia  
- Critical limb ischemia  
- Lower extremity ischemia  
- Aorto‑iliac arterial intervention  
- Ankle‑brachial index  
- Claudication  
- Endovascular intervention  
- Ischemia  
- Diabetes mellitus  
- Smoking cessation  
- Atherosclerotic vascular disease  
- Wound, Ischemia, and Foot Infection (WIfI) classification  
- Lower extremity threatened limb  
- Angiosomes  
- Lower extremity  
- Coronary disease  
- Cardiovascular disease prevention  
- Telehealth in cardiovascular disease  
- Acute limb ischemia

Page 68 Extracted Terms:
- Peripheral Artery Disease (PAD)    
- Lower‑Extremity Arterial Disease    
- Ankle‑Brachial Index (ABI)    
- Intermittent Claudication    
- Chronic Limb‑Threatening Ischemia    
- Critical Limb Ischemia    
- Lower‑Extremity Ischemia    
- Wound, Ischemia, and Foot Infection (WIfI) Classification    
- Atherosclerosis    
- Coronary Artery Disease    
- Vascular Morbidity    
- Vascular Mortality    
- Non‑invasive Testing (e.g., Doppler, Ultrasound)    
- Resting ABI    
- Endovascular Therapy    
- Surgical Revascularisation    
- Amputation    
- Physical Examination (pulse palpation)    
- Pulse Palpation    
- Family History (of peripheral artery disease)    
- Risk Stratification    
- Clinical Data Standards (for peripheral atherosclerotic disease)    
- American Heart Association (AHA) Guidelines    
- American College of Cardiology (ACC) Guidelines

Page 69 Extracted Terms:
- Peripheral Arterial Disease (PAD)  
- Ankle‑Brachial Index (ABI)  
- Toe‑Brachial Index (TBI)  
- Critical Limb Ischemia (CLI)  
- Carotid Atherosclerosis  
- Cerebrovascular Accident (Stroke)  
- Transient Ischemic Attack (TIA)  
- Cardiovascular Disease (CVD)  
- Coronary Heart Disease  
- Atherosclerotic Disease  
- Exercise Treadmill Test  
- 6‑Minute Walk Test  
- Non‑Invasive Vascular Assessment  
- Transcutaneous Oxygen Pressure (TcPO₂)  
- Skin Perfusion Pressure (SPP)  
- Continuous‑Wave Doppler  
- Photoplethysmography  
- Risk Assessment  
- Framingham Risk Score  
- Chronic Kidney Disease (CKD)  
- Diabetes Mellitus  
- Vascular Events  
- Major Amputation  
- Revascularization  
- Endovascular Intervention  
- Clinical Outcomes  
- Functional Status  
- Systolic Blood Pressure  
- Segmental Systolic Pressures  
- Peripheral Occlusive Disease  
- Wound, Ischemia, Foot Infection (WIfI) Classification  
- Arterial Stenosis  
- Arterial Occlusion  
- Ischemic Limb  
- Peripheral Vascular Disease  
- Cardiovascular Events  
- Angiography  
- Duplex Ultrasound  
- Vascular Screening  
- Risk Stratification  
- Pulse Wave Analysis  

Page 70 Extracted Terms:
**Key heart‑/vascular‑disease terms extracted from the guideline text**

- Peripheral artery disease (PAD)  
- Ankle‑brachial index (ABI)  
- Cardiovascular disease (CVD)  
- Endovascular revascularization  
- Critical limb ischemia (CLI)  
- Lower extremity arterial disease  
- Vascular assessment (photoplethysmography, laser Doppler flowmetry, duplex ultrasonography, CT angiography, MR angiography, angiography)  
- Antiplatelet therapy  
- Lipid‑lowering therapy  
- Tobacco use / cessation  
- Diabetes mellitus (type 1 & type 2)  
- Diabetic foot ulcer (DFU)  
- Amputation risk  
- Renal insufficiency / chronic kidney disease (CKD)  
- Contrast‑induced nephropathy  
- Nephrogenic systemic fibrosis (NSF)  
- Gadolinium‑based contrast agents  
- Iodinated contrast media  
- Radiographic contrast media safety  
- Stroke risk (via PAD as a marker)  
- Mortality risk in PAD patients  
- Endovascular disease progression  
- Lower limb wound healing  

These terms capture the cardiovascular, diagnostic, therapeutic, and risk‑factor elements relevant to heart disease discussed in the guideline.

Page 71 Extracted Terms:
- Peripheral artery disease  
- Coronary artery disease  
- Atherosclerosis  
- Myocardial infarction  
- Stroke  
- Cerebrovascular disease  
- Acute coronary syndromes  
- Polyvascular disease  
- Cardiovascular risk factors  
- Atherosclerotic cardiovascular disease  
- Cardiovascular events  
- Cardiovascular outcomes  
- Cardiovascular morbidity  
- Cardiovascular mortality  
- Cardiovascular and limb outcomes  
- Heart disease  
- Critical limb ischemia  
- Microvascular disease

Page 72 Extracted Terms:
**Key terms related to heart disease**

- Peripheral artery disease  
- Lower‑extremity peripheral artery disease  
- Nontraumatic lower‑extremity amputation  
- Racial disparities in peripheral artery disease  
- Socioeconomic status  
- Ankle‑brachial index  
- Coronary heart disease  
- Vascular disease  
- Structural heart disease  
- Congenital heart disease  
- Cardiovascular health  
- Cardio‑vascular outcomes  
- Revascularization  
- Amputation  
- Diabetes mellitus  
- Risk factors for peripheral artery disease  
- Sex differences in peripheral artery disease  
- Female‑sex cardiovascular risk  
- Disparities in care  
- Allostatic load  
- Health disparities  
- Public policy for cardiovascular disease  
- American Heart Association guidelines  
- Scientific statement  
- Policy statement  
- Epidemiology  
- Clinical characteristics  
- Leg symptoms  
- Lower extremity functioning  
- Supervised exercise therapy  
- Medicare beneficiaries  
- Amputation rates  
- Racial and ethnic disparities in cardiovascular risk  
- Structural racism  
- Minority communities  
- Amputation prevention  
- Nontraumatic amputation  
- Treatment of vascular disease

Page 73 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Cardiovascular Disease (CVD)  
- Cardiovascular Events  
- Myocardial Infarction (MI)  
- Stroke  
- Antiplatelet Therapy  
- Antithrombotic Therapy  
- Aspirin (ASA)  
- Clotting / Thrombosis  
- Atherosclerosis  
- Chronic Limb‑Threatening Ischemia  
- Critical Limb Ischemia (CLI)  
- Lower Extremity Amputation (Amputation, Major Amputation)  
- Bypass Grafting (Open Bypass Surgery)  
- Endovascular Therapy (Endovascular Revascularization)  
- Ankle‑Brachial Index (ABI)  
- Angiography / Vascular Imaging  
- Lipid Management / Statins  
- Blood Pressure Management (Hypertension)  
- Diabetes‑Related Vascular Disease  
- Socioeconomic Deprivation / Rurality Impact on CVD  
- Frailty and Sarcopenia (muscle loss)  
- Functional Status / Mobility Limitations  
- Mortality (Short‑ and Long‑Term)  
- Revascularization (Surgical & Endovascular)  
- Antiplatelet Agents (Clopidogrel, Ticagrelor, etc.)  
- Anticoagulation (Heparin, Warfarin, DOACs)  
- Cardiovascular Prevention Guideline (ACC/AHA, ESC)  
- Clinical Outcomes (Major Adverse Cardiovascular Events – MACE)  
- Lifestyle Modifications (Smoking Cessation, Physical Activity)  
- Nutritional Status / Malnutrition in PAD patients  

(Each item represents a key heart‑disease–related concept or outcome referenced in the provided clinical statements and guideline citations.)

Page 74 Extracted Terms:
- Peripheral artery disease (PAD)  
- Atherosclerosis  
- Atherosclerotic cardiovascular disease (ASCVD)  
- Coronary artery disease (CAD)  
- Myocardial infarction (MI)  
- Acute coronary syndrome (ACS)  
- Stroke  
- Transient ischemic attack (TIA)  
- Venous thromboembolism (VTE)  
- Atrial fibrillation (AF)  
- Vascular morbidity  
- Mortality  
- Ankle‑brachial index (ABI)  
- Endovascular femoropopliteal intervention  
- Paclitaxel‑eluting stent  
- Rivaroxaban  
- Aspirin  
- Clopidogrel  
- Ticagrelor  
- Vorapaxar  
- Antiplatelet therapy  
- Antithrombotic therapy  
- Anticoagulation therapy  
- Revascularization  
- Bypass surgery  
- Statins (incl. high‑intensity statin therapy)  
- Lipid‑lowering therapy  
- Low‑density lipoprotein cholesterol (LDL‑C)  
- High‑density lipoprotein cholesterol (HDL‑C)  
- PCSK9 inhibitors  
- Evolocumab  
- Alirocumab  
- Lipoprotein(a) (Lp(a))  
- Polyvascular disease  
- Peripheral arterial occlusive disease  
- Symptomatic PAD  
- Asymptomatic PAD  
- Major adverse limb events (MALE)  
- Long‑term survival  
- Clinical guidelines (e.g., ACC/AHA, AHA/ACC/ACE)

Page 75 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Critical Limb Ischemia  
- Statin Therapy  
- High‑Intensity Statin Therapy  
- Antihypertensive Therapy  
- Intensive Blood‑Pressure Control  
- Nebivolol  
- Hydrochlorothiazide  
- β‑Blockers  
- Angiotensin‑Converting Enzyme (ACE) Inhibitors  
- Angiotensin Receptor Blockers (ARBs)  
- Renin–Angiotensin–Aldosterone System (RAAS) Drugs  
- Telmisartan  
- Ramipril  
- Lipoprotein (LDL) Cholesterol  
- Ankle‑Brachial Index  
- Cardiovascular Events  
- Amputation‑Free Survival  
- Mortality  
- Smoking Cessation  
- Varenicline (Nicotine Replacement)  
- Bupropion (Nicotinic Antagonist)  
- Electronic Cigarettes / Vaping  
- Water‑Pipe (Hookah) Smoking  
- Secondhand Smoke Exposure  
- Cardiovascular Disease  
- Atherosclerotic Disease  
- Coronary Artery Disease  
- Hypertension  
- Hyperlipidemia  
- Lifestyle Management (Diet, Exercise)  
- Vascular Operations  
- HOPE Study (Heart Outcomes Prevention Evaluation)  
- EUCLID Trial (Peripheral Artery Disease)

Page 76 Extracted Terms:
**Key heart‑disease terms extracted from the text**

1. Peripheral Artery Disease  
2. Cardiovascular outcomes  
3. Coronary artery disease  
4. Acute coronary syndrome  
5. Myocardial infarction  
6. Heart failure  
7. Atherosclerotic cardiovascular disease  
8. Sodium‑glucose cotransporter 2 (SGLT2) inhibitors (empagliflozin, dapagliflozin, canagliflozin)  
9. Glucagon‑like peptide‑1 (GLP‑1) receptor agonists (liraglutide, semaglutide, exenatide, lixisenatide, tirzepatide)  
10. Diabetes management  
11. Glycemic control  
12. HbA1c variability  
13. Lower‑extremity amputations  
14. Diabetic foot ulcers  
15. Smoking cessation  
16. Electronic cigarettes  
17. Nicotine‑replacement therapy  
18. Influenza vaccination  
19. Dietary sodium reduction  
20. DASH diet (Dietary Approaches to Stop Hypertension)  
21. Mediterranean diet  
22. Hypertension  
23. Endothelial dysfunction  
24. Atherosclerosis  
25. Cardiometabolic health  
26. Cardiovascular ageing  
27. Coronary interventions (percutaneous coronary intervention)  
28. Microvascular complications  
29. Peripheral arterial disease severity  

These terms capture the core clinical concepts, therapies, and preventative strategies discussed in the provided guideline excerpts.

Page 77 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Intermittent Claudication  
- Myocardial Infarction  
- Atherosclerotic Cardiovascular Disease  
- Endovascular Revascularization  
- Restenosis (stent restenosis)  
- Chronic Heart Failure  
- Milrinone (oral)  
- Cilostazol  
- Pentoxifylline  
- Clopidogrel  
- Ticagrelor  
- Rivaroxaban  
- Homocysteine‑lowering therapy (folic acid & B‑vitamins)  
- Vitamin D supplementation (serum 25‑hydroxyvitamin D)  
- Chelation therapy (EDTA‑based, EDTA‑chelating agents)  
- Mediter­rainian dietary pattern (high‑score Mediterranean diet)  
- COVID‑19 cardiovascular comorbidities / outcomes  
- Femoropopliteal lesions  
- Endothelial dysfunction (implied by PAD and atherosclerosis)

Page 78 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Peripheral Arterial Disease  
- Intermittent Claudication  
- Exercise Therapy (supervised)  
- Exercise Therapy (home‑based)  
- Supervised Exercise Training  
- Home‑Based Walking Exercise  
- Walking Exercise Therapy  
- Endovascular Revascularization  
- Percutaneous Transluminal Angioplasty  
- Revascularization (vascular)  
- Vascular Function  
- Vascular Guidelines  
- Endovascular Treatment  
- Angioplasty  
- Claudication  
- Cardiovascular Disease  
- Heart Disease  
- Peripheral Vascular Disease (PVD)

Page 79 Extracted Terms:
Peripheral artery disease (PAD)  
Intermittent claudication  
Endovascular revascularisation  
Conservative management  
Resistance training  
Treadmill exercise training  
Supervised exercise therapy (SET)  
Upper‑limb aerobic exercise  
Lower‑limb aerobic exercise  
Walking distance  
Endothelial function  
Aortic endografting  
Large sheath access  
Lithotripsy for calcified iliacs  
Iliac artery recanalization  
Chronic occlusion  
Aorto‑iliac arterial intervention  
Transcatheter aortic valve replacement (TAVR)  
Femoral access vs non‑femoral access  
Transcarotid access  
Subclavian/axillary access  
Catheter‑based limb angioplasty  
Bypass graft  
Limb‑threatening ischemia  
Acute limb ischemia  
Embolisation  
Complications of percutaneous transluminal angioplasty  
Natural history of arteriosclerosis  
Risk factors for claudication  
Atherosclerosis of lower extremities  
Disease progression  
Cardiovascular events  
Guideline‑recommended therapy  
American Heart Association (AHA)  
American College of Cardiology (ACC)  
Society for Cardiovascular Angiography and Interventions (SCAI)  
Society of Interventional Radiology (SIR)  
Society of Vascular Medicine (SVM)

Page 80 Extracted Terms:
Peripheral artery disease  
Intermittent claudication  
Revascularization  
Endovascular revascularization  
Angioplasty  
Percutaneous transluminal angioplasty (PTA)  
Stenting  
Atherectomy  
Bypass surgery  
Lower extremity bypass  
Common femoral artery disease  
Femoropopliteal disease  
Aortoiliac occlusive disease  
Supervised exercise therapy  
Exercise training  
Endarterectomy  
Thromboendarterectomy  
Restenosis  
Chronic limb‑threatening ischemia  
Surgical versus endovascular comparison  
Invasive versus non‑invasive treatment strategy  
Clinical effectiveness  
Randomized controlled trial  
Meta‑analysis  
Clinical guideline  
SCAI device‑selection guideline  
SVS Vascular Quality Initiative  
SIR data registry  
Reintervention outcomes  
30‑day unplanned readmission  
Quality of life outcomes  
Symptomatic peripheral artery disease  
Peri‑operative outcomes  
Multicenter study  
Prospective randomized trial  
Open repair versus endovascular repair  
Routine versus selective stenting  
Bifurcation lesion management  
Procoagulant and hypofibrinolytic state  
Patient‑reported outcomes  
Health‑related quality of life  
Endovascular versus surgical management  
Percutaneous transluminal balloon angioplasty  
Endovascular treatment of common femoral artery stenosis  
Endovascular intervention in symptomatic peripheral arterial disease  
Clinical registry outcomes.

Page 81 Extracted Terms:
- Peripheral Artery Disease  
- Critical Limb Ischemia  
- Intermittent Claudication  
- Endovascular Revascularization  
- Femoro‑Popliteal Angioplasty  
- Femoro‑Popliteal Bypass  
- Stent Placement (Common Femoral, Iliac)  
- Endarterectomy (Common Femoral)  
- Hybrid Surgery (Endovascular + Open)  
- Aorto‑Iliac Disease  
- Vascular Surgery (Open Reconstruction)  
- Cardiovascular Disease  
- Cardiovascular Interventions  
- ACC/AHA Appropriate Use Criteria  
- SCAI Guidelines (Device Selection, Endovascular Specialists)  
- Percutaneous Translational Angioplasty  
- Bio‑absorbable Stent Implantation  
- Vein Graft vs. PTFE Graft (Bypass)  
- Multidisciplinary/Team‑Based Care for Chronic Limb‑Threatening Ischemia  
- Perioperative Cardiovascular Evaluation and Management (ACC/AHA 2014)  
- Vascular Quality Initiative (Clinical Outcomes Database)  
- Angiographic Criteria/Pressure Measurements (Hemodynamic Significance)  
- Long‑Term Patency / Long‑Term Success (Angioplasty/Bypass)  
- Surgical vs. Endovascular Therapy for Chronic Limb‑Threatening Ischemia  
- Wound Healing / Amputation‑Free Survival in CLTI  
- Clinical Practice Guidelines (AHA/ACC, SCAI, SVS, etc.)

Page 82 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Chronic Limb‑Threatening Ischemia (CLTI) / Critical Limb Ischemia (CLI)  
- Femoropopliteal Bypass  
- Iliac Artery Stenting  
- Femoral Endarterectomy  
- Hybrid Procedure (combination of open and endovascular)  
- Endovascular Intervention (angioplasty, stenting)  
- Angiosome‑Targeted Revascularization  
- Composite Vein Bypass  
- Saphenous Vein Graft (great, small, or femoral)  
- Polytetrafluoroethylene (PTFE) Prosthetic Graft  
- Autologous Vein Graft  
- Limb Salvage  
- Graft Patency  
- Antithrombotic Therapy  
- Bypass versus Angioplasty (BASIL) Trial  
- Open Infrainguinal Bypass  
- Aortoiliac Occlusive Disease  
- Aortoiliac‑Femoral Occlusive Disease  
- Infrapopliteal Intervention  
- Infrapopliteal Bypass  
- Vascular Quality Initiative (VQI) Database  
- Clinical Outcomes & Registry Data (e.g., CRITISCH, SPINACH, BASIL, BASIL‑2)  
- Graft Failure and Technical Factors  
- Spliced Arm Vein Graft  
- Pre‑cuffed PTFE vs. Vein‑cuffed PTFE Graft  
- Surgical Reconstruction vs. Endovascular Placement  
- Perioperative Outcomes  
- Meta‑analysis of PAD interventions  
- Graft Type Comparison (prosthetic vs. autogenous)  
- Infragenicular Arterial Bypass  
- Endovascular Era Outcomes  
- Critical Limb Ischemia Management Guidelines  
- Composite vs. Conventional Vein Conduit  
- Direct vs. Indirect Angiosomal Revascularization  
- Angioplasty‑First vs. Bypass‑First Strategy  

*(All terms directly relate to cardiovascular (heart and peripheral vascular) disease and its interventional management.)*

Page 83 Extracted Terms:
- Peripheral arterial disease (PAD)  
- Critical limb ischemia (CLI/CLTI)  
- Lower‑extremity ischemia  
- Vascular disease  
- Angiosome  
- PTFE bypass (peripheral bypass)  
- Endovascular therapy  
- Collateral vessels  
- Hemodynamic effects  
- Prostanoids (pharmacologic agents in arterial disease)  
- Intermittent pneumatic compression  
- Sequential pneumatic compression  
- Revascularization  
- Angiology (clinical specialty)  
- Vascular surgery (procedural specialty)

Page 84 Extracted Terms:
- Peripheral arterial disease  
- Chronic limb‑threatening ischemia (CLTI)  
- Critical limb ischemia (CLI)  
- Lower‑extremity amputation  
- Wound, Ischemia, Foot Infection (WIfI) classification  
- Vascular surgery / endovascular intervention  
- Revascularization  
- Deep venous arterialization  
- Cardiovascular events (e.g., myocardial infarction, stroke)  
- Smoking cessation pharmacotherapies  
- American Heart Association policy statements  
- National Cardiovascular Data Registry (NCDR)  
- Society of Thoracic Surgeons (STS) national database  
- Global vascular guidelines on chronic limb‑threatening ischemia  
- Health‑related quality of life after vascular procedures  
- Multidisciplinary vascular care teams  
- Non‑reconstructable peripheral arterial disease  
- Ischemic foot ulcer in diabetic patients  

*(All terms extracted directly from the provided guideline references.)*

Page 85 Extracted Terms:
**Key heart‑disease related terms extracted from the text**

1. Acute limb ischemia  
2. Peripheral artery disease  
3. Peripheral atherosclerotic vascular disease  
4. Lower extremity ischemia  
5. Acute lower extremity ischemia  
6. Arterial thrombosis  
7. Arterial embolism  
8. Arterial thromboembolism  
9. Vascular occlusion  
10. Thrombolysis  
11. Catheter‑directed thrombolysis  
12. Ultrasound‑accelerated thrombolysis  
13. Percutaneous mechanical thrombectomy  
14. Endovascular revascularization  
15. Surgical revascularization  
16. Bypass graft  
17. Vascular graft  
18. Lower extremity bypass  
19. Vascular complications of cancer treatments (vascular‑related heart disease)

Page 86 Extracted Terms:
- Peripheral Arterial Disease (PAD)  
- Acute Limb Ischemia (ALI)  
- Acute Lower‑Limb Ischemia  
- Lower‑Extremity Thrombosis  
- Thrombolysis (intra‑arterial, catheter‑directed)  
- Heparin‑Induced Thrombocytopenia (HIT)  
- Anticoagulation Therapy  
- Antiplatelet Therapy  
- Rivaroxaban  
- Vorapaxar  
- Aspirin  
- Statin Therapy (e.g., simvastatin)  
- Hypercoagulable Syndromes  
- Antiphospholipid Antibody Syndrome  
- Atrial Fibrillation (non‑valvular)  
- Cardiogenic Limb Emboli  
- Aortic Dissection (type B)  
- Aortic Aneurysm (infra‑inguinal, popliteal)  
- Popliteal Entrapment/ Aneurysm  
- COVID‑19–Associated Thrombosis  
- Carotid Artery Disease  
- Ischemia (general)  
- Compartment Syndrome (acute extremity)  
- Fasciotomy (therapeutic)  
- Quality of Life in Peripheral Vascular Disease  
- Major Cardiovascular Events (stroke, myocardial infarction, heart failure)

Page 87 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Lower extremity ischemia  
- Critical limb ischemia  
- Limb‑threatening ischemia  
- Revascularization (endovascular, surgical)  
- Bypass graft failure  
- Infrainguinal bypass graft  
- Prosthetic bypass graft  
- Dual‑antiplatelet therapy  
- Antiplatelet agents (aspirin, clopidogrel, ticagrelor)  
- Antithrombotic agents (rivaroxaban, rivaroxaban + aspirin)  
- Anticoagulation therapy  
- Statin therapy  
- LDL‑cholesterol lowering  
- PCSK9 inhibition (evolocumab)  
- Glycemic control  
- Diabetes mellitus type 2  
- Hemoglobin A1c  
- Foot ulcer  
- Lower‑extremity amputation  
- Patency (vascular graft patency)  
- Cardiovascular events (myocardial infarction, stroke)  
- Cardiovascular risk  
- Cardiovascular outcomes  
- Vascular imaging (duplex ultrasound, duplex surveillance)  
- Ultrasound surveillance  
- Endovascular injury  
- Neo‑intimal hyperplasia  
- Telehealth for PAD management  
- Digital health monitoring  
- Electronic consults  
- Multidisciplinary vascular team  
- Patient‑reported outcomes  
- Depression (co‑morbid psychological factors)  
- American Heart Association guidelines  
- Atherosclerosis  
- Atherosclerotic cardiovascular disease  
- Vascular surgery follow‑up  
- Peripheral vascular disease  
- Chronic limb‑threatening ischemia guidelines  
- LDL‑lowering therapy guidelines  
- Antiplatelet therapy guidelines  
- Glycemic control guidelines  
- Lipid‑lowering therapy guidelines.

Page 88 Extracted Terms:
- Peripheral Artery Disease  
- Lower Extremity Peripheral Artery Disease  
- Heart  
- Heart & Vascular Institute  
- Vascular Center  
- Vascular Medicine  
- Vascular Surgery  
- Anticoagulation Forum  
- ACC/AHA Guidelines (Cardiology)  
- Circulation (journal)

Page 89 Extracted Terms:
**Key heart‑disease related terms extracted from the text**

- Peripheral Artery Disease  
- Cardiovascular  
- Heart  
- Cardiac  
- Vascular  
- AHA/ACC (American Heart Association / American College of Cardiology)  
- Heart Center  
- Cardiovascular Medicine  
- Cardiovascular Systems  
- Cardiology (implied from “Cardiovascular”)  
- Heart Center Director of Education  
- Cardiovascular Medicine  
- New Cardiovascular Horizons  
- Cardiovascular (implied in multiple references)  

**Relevant industry / technology terms (often linked to heart disease management)**  

- Abbott  
- Medtronic  
- Boston Scientific  
- Cordis / Cardinal Health  
- Amgen  
- Janssen Pharmaceuticals  
- Nuvasive  
- Penumbra  
- Shockwave Medical  
- W.L. Gore (Surgical/medical devices)  
- Silk Road Medical  
- Cardiovascular Systems (company name)  
- Cardiac (brand of products implied)  

These items capture the primary cardiovascular or heart‑related concepts, roles, and vendor references appearing in the provided guideline excerpt.

Page 90 Extracted Terms:
- Peripheral Artery Disease  
- Cardiovascular  
- Cardiology  
- Cardiac Catheterization Laboratory  
- Vascular Surgery  
- Vascular Medicine  
- Arteriopathy Clinic  
- Heart Hospital  

Page 91 Extracted Terms:
- Peripheral Artery Disease  
- Acute limb ischemia  
- Women’s Heart Clinic  
- Comprehensive Cardiology Clinic  
- Cardiology  
- Vascular Surgery  
- Vascular Intervention  
- Interventional Radiology  
- Endovascular  
- Angiodynamics  
- Vascular Surgery Fellowship  
- Vascular Surgery Residency

Page 92 Extracted Terms:
- Peripheral Artery Disease  
- Cardiovascular  
- Vascular  
- Heart  
- Cardiovascular Medicine  
- Cardiovascular Interventional  
- Cardiovascular Interventional Fellows  
- Heart and Vascular Institute  
- Cardiovascular device manufacturers  
  - Abbott  
  - Boston Scientific  
  - Medtronic  
  - Philips  
  - Terumo  
  - Inari Medical  
  - Trireme Medical

Page 93 Extracted Terms:
- ACS (Acute Coronary Syndrome)  
- Peripheral Artery Disease  
- Heart & Vascular Center  
- Interventional and Cardiovascular Programs  
- Cardiovascular  
- Cardiology  
- ACC (American College of Cardiology)  
- AHA (American Heart Association)

Page 94 Extracted Terms:
- Peripheral Artery Disease  
- Cardiovascular  
- Chest Pain Centers  
- Invasive Cardiology  
- Myocardial  
- Ischemia  
- Vascular  
- Endo‑tronic (endovascular)  
- MyoKardia (myocardial therapy)  
- Ischemix (ischemic vascular therapy)

Page 95 Extracted Terms:
**Key terms related to heart disease extracted from the text**

- Peripheral Artery Disease (PAD)  
- Lower‑Extremity Peripheral Artery Disease  
- Spontaneous Coronary Artery Dissection (SCAD)  
- Cardiovascular  
- Cardiovascular Disease  
- Cardiac / Heart  
- Vascular  
- Vascular Disease  
- Endovascular  
- Cardiovascular Angiography  
- Cardiovascular Interventions  
- American College of Cardiology (ACC) – major cardiovascular body  
- American Heart Association (AHA) – major cardiovascular body  
- National Heart, Lung, and Blood Institute (NHLBI) – key cardiovascular research institute  
- Society for Cardiovascular Angiography and Interventions (SCAI)  
- Society for Vascular Medicine (SVM)  
- Society for Vascular Surgery (SVS)  
- Society for Interventional Radiology (SIR)  
- Academy of Cardiovascular & Pulmonary Rehabilitation (AACVPR)  

These terms capture the primary disease concepts, related specialties, and major professional organizations discussed in the guideline excerpt.

Page 96 Extracted Terms:
- Peripheral Artery Disease  
- PAD  
- ACC/AHA PAD Guideline  
- AHA (American Heart Association)  
- Heartflow  
- Cardiovascular Research Group  
- Thrombosis Research Institute  
- Heart disease  
- Cardiovascular  
- Heart  
- Vascular  



Page 97 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- ACC/AHA PAD Guideline  
- American Heart Association (AHA)  
- American Society of Echocardiography (ASE)  
- Society for Vascular Surgery (SVS)  
- National Heart, Lung, and Blood Institute (NHLBI)  
- Cardio‑vascular  
- Heartflow  
- Hurst’s The Heart Online  
- Circulation (peer‑reviewed cardiovascular journal)

Page 98 Extracted Terms:
- Peripheral Artery Disease (PAD)
- Cardiovascular
- Vascular
- Heart disease
- Cardiovascular disease
- Cardiovascular angiography
- Cardiovascular interventions
- Cardiovascular rehabilitation
- Cardiovascular & pulmonary rehabilitation
- Echocardiography
- Cardiovascular imaging
- American College of Cardiology (ACC)
- American Heart Association (AHA)
- National Heart, Lung, and Blood Institute (NHLBI)
- Society for Vascular Medicine (SVM)
- Society for Vascular Nursing (SVN)
- Society for Vascular Surgery (SVS)
- Society for Cardiovascular Angiography & Interventions (SCAI)
- American Association of Cardiovascular and Pulmonary Rehabilitation (AACVPR)
- American Association of Black Cardiologists (ABC)
- Association of Podiatric Medical Association (APMA)
- National Institutes of Health (NIH)
- Patient-Centered Outcomes Research Institute (PCORI)
- Duke Clinical Research Institute (DCRI)
- Medtronic (device manufacturer relevant to cardiovascular therapy)



Page 1 Extracted Terms:
- ACC/AHA (American College of Cardiology / American Heart Association)  
- Peripheral artery disease (PAD)  
- Cardiovascular disease  
- Heart disease  
- AHA Scientific Statements  
- Clinical performance measures  
- Performance measures  
- Quality indicators  
- Quality measures  
- Joint Committee on Performance Measures  
- Cardiovascular Angiography  
- Interventional Radiology  
- Cardiovascular and Pulmonary Rehabilitation  
- Vascular Medicine  
- Vascular Nursing  
- Vascular Surgery  
- Association of Black Cardiologists  
- American College of Cardiology (ACC)  
- American Heart Association (AHA)  
- Evidence‑based care  
- Medication management for PAD  
- Diagnostic testing for PAD  
- Treatment decisions  
- Follow‑up assessment  
- Patient‑centered care

Page 2 Extracted Terms:
**Key terms related to heart disease (primarily peripheral artery disease)**  

- Peripheral Artery Disease (PAD)  
- Lower‑extremity peripheral artery disease  
- Chronic limb‑threatening ischemia (CLTI)  
- Blood pressure management / Target BP for PAD (PM‑1)  
- Use of ACE inhibitors or ARBs for PAD (PM‑2)  
- Diabetes management in PAD (PM‑3)  
- Antithrombotic therapy for symptomatic PAD (PM‑4)  
- Lipid‑lowering therapy for PAD (high‑intensity statins) (PM‑5)  
- Novel lipid‑lowering drugs for PAD (QM‑4)  
- Tobacco use screening and counseling (PM‑6)  
- Structured exercise / community‑based exercise therapy (PM‑7)  
- Vascular review of systems for lower‑extremity PAD (QM‑1)  
- Pulse examination for PAD “at risk” patients (QM‑2)  
- Preventive foot care for PAD (QM‑3)  
- Identification of health disparities in PAD (QM‑5)  
- Saphenous vein assessment before leg revascularization (QM‑6)  
- Lower‑extremity surveillance after revascularization (QM‑7)  
- Multidisciplinary team evaluation for CLTI patients (QM‑8)  
- ACC/AHA peripheral artery disease guidelines  
- Class I (strong) recommendations  
- Public reporting of performance measures  
- Pay‑for‑performance (P4P) programs  
- Performance measures (PM‑1 to PM‑7)  
- Quality measures (QM‑1 to QM‑8)

Page 3 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Lower Extremity Peripheral Artery Disease  
- Atherosclerosis (peripheral arteries)  
- Claudication  
- Exertional leg disorders  
- Acute Limb Ischemia  
- Chronic Limb‑Threatening Ischemia  
- Cardiovascular Care  
- Cardiovascular Services  
- Performance Measures  
- Quality Measures  
- American College of Cardiology (ACC)  
- American Heart Association (AHA)  
- ACC/AHA Clinical Practice Guidelines  
- Class 1 Recommendations (Strong)  
- Class 2 Recommendations (Moderate)  
- Class 3 Recommendations (No benefit)  
- Level of Evidence (e.g., Class 1, 2, 3)  
- Performance Attribution  
- Pay‑for‑Performance Programs  
- Public Reporting  
- Multidisciplinary Care Team  
- Patient‑Centeredness  
- Timeliness, Safety, Effectiveness, Efficiency, Equity (quality domains)

Page 4 Extracted Terms:
- Peripheral Artery Disease  
- American College of Cardiology (ACC)  
- American Heart Association (AHA)  
- Class of Recommendation  
- Level of Evidence  
- Clinical Strategies  
- Interventions  
- Treatments  
- Diagnostic Testing  

Page 5 Extracted Terms:
**Key heart‑disease–related terms**

- ACC (American College of Cardiology)  
- AHA (American Heart Association)  
- ACE (Angiotensin‑Converting Enzyme)  
- ACE inhibitors  
- ARB (Angiotensin‑Receptor Blocker)  
- Blood pressure – BP  
- Peripheral artery disease – PAD  
- Chronic limb‑threatening ischemia – CLTI  
- Lipid‑lowering therapy (high‑intensity statins)  
- Statins  
- Antithrombotic therapy  
- Supervised exercise therapy – SET  
- Structured community‑based exercise therapy  
- Tobacco use screening and counseling  
- Diabetes management (in PAD)  
- Preventive foot care (in PAD)  
- Vascular review of systems (for PAD)  
- PAD “At‑Risk” pulse examination  
- Novel lipid‑lowering drugs (for PAD)  
- Saphenous vein assessment before leg revascularization  
- Lower extremity surveillance after revascularization  
- Multidisciplinary team evaluation (for CLTI)  
- Cost‑effectiveness evaluation  
- Guideline recommendations (Class 1, Class 2)  
- Performance measure (PM)  
- Quality measure (QM)

Page 6 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Lower‑extremity PAD  
- Atherosclerosis  
- Aortic disease  
- Major arterial branches  
- Catheter‑based treatment  
- Amputation risk  
- Preventive medical therapy  
- Risk‑factor modification  
- Smoking cessation  
- Procedural aspects of PAD care  
- Vascular medicine  
- Vascular nursing  
- Vascular surgery  
- Interventional radiology  
- Vascular and Endovascular Surgery Society (VESS)  
- Cardiovascular rehabilitation  
- High blood pressure (Hypertension)  
- ACC/AHA guideline for PAD management  
- AHA/ACC performance measures for adults with PAD  
- AHA/ACC guideline on lower‑extremity PAD  
- ACCF/AHA/ACR/SCAI performance measures for PAD  
- Cardiovascular disease (general term)

Page 7 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- ACC/AHA Peripheral Artery Disease Measure Set  
- ACCF/AHA Peripheral Artery Disease performance measures  
- Performance measures (class I recommendations)  
- Quality measures (clinical practice guideline‑based)  
- Evidence‑based medicine  
- Clinical practice guidelines  
- Class I recommendation  
- Patient outcomes  
- Structural measures  
- Process measures  
- Outcome measures  
- High‑impact area (improving patient outcomes)  
- Care setting (inpatient, outpatient)  
- Measurement attributes (evidence‑based, reliability, validity, feasibility)  
- Gap in care  
- American College of Cardiology (ACC)  
- American Heart Association (AHA)

Page 8 Extracted Terms:
**Key terms related to heart disease (from the provided text)**  

- Peripheral Artery Disease (PAD)  
- Blood pressure medications  
- Diabetes care  
- Antithrombotic therapies  
- Lipid‑lowering therapy  
- Statin therapy (high‑intensity statin)  
- LDL‑C (low‑density lipoprotein cholesterol)  
- Cholesterol‑lowering medications  
- Smoking cessation / tobacco use  
- Supervised exercise  
- Community‑based exercise therapy  
- Lower extremity vein bypass graft surveillance  
- Vascular review of systems for lower extremity PAD  
- PAD “At Risk” population pulse examination  
- Wound care  
- Vascular testing interventions  
- Smartphone‑based tools leveraging artificial intelligence  
- AI‑powered imaging analysis for early PAD detection  
- Wearable sensors for PAD‑related physiologic changes  
- Health care access & treatment adherence  
- Health services research  
- Implementation science  
- Social determinants of health  
- Health disparities affecting PAD care  
- Continuous real‑time monitoring of disease progression  
- Clinical trial evidence for medical therapies  
- Post‑procedure combination therapies  
- Novel agents for diabetes, obesity, and hyperlipidemia  
- Risk amplifiers for PAD (guideline‑defined)  
- Cardiovascular outcomes & limb‑related events  
- Patient‑centered treatments  
- Cost‑effective medical management strategies.

Page 9 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Chronic Limb‑Threatening Ischemia (CLTI)  
- Major Adverse Cardiovascular Events (MACE)  
- Major Adverse Limb Events (MALE)  
- Angiotensin‑Converting Enzyme Inhibitors (ACEi)  
- Angiotensin‑Receptor Blockers (ARB)  
- Blood Pressure (BP)  
- Glucagon‑Like Peptide‑1 (GLP‑1) Agonists  
- Sodium‑Glucose Cotransporter‑2 (SGLT‑2) Inhibitors  
- Lipid‑Lowering Therapy  
- Statins (High‑Intensity Statins)  
- PCSK9 Inhibitors  
- Ezetimibe  
- Low‑Density Lipoprotein Cholesterol (LDL‑C)  
- Antithrombotic Therapy  
- Diabetes Management (Type 2 Diabetes)  
- Preventive Foot Care  
- Saphenous Vein Assessment  
- Multidisciplinary Team Evaluation  
- Guideline Class 1 Recommendation (2024 PAD Guideline)  
- Guideline Class 2 Recommendation (PCSK9, Ezetimibe)  
- Performance Measures (PM‑1 to PM‑6)  
- Quality Measures (QM‑3 to QM‑8)  
- American College of Cardiology (ACC)  
- American Heart Association (AHA)  
- Electronic Health Record (EHR)  
- Chronic Limb‑Threatening Ischemia (CLTI)  
- Health Disparities in PAD  
- Peripheral Artery Disease Risk Factors (Hypertension, Diabetes, Dyslipidemia)

Page 10 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- ACC/AHA Peripheral Artery Disease Measures  
- American College of Cardiology (ACC)  
- American Heart Association (AHA)  
- Cardiovascular  
- Vascular  
- Cardiovascular Angiography and Interventions  
- Interventional Cardiovascular Procedures  
- Cardiovascular and Pulmonary Rehabilitation  
- Vascular Medicine  
- Vascular Nursing  
- Vascular Surgery  
- Endovascular Surgery  
- Clinical Practice Guidelines  
- Guideline Science and Methodology  
- Scientific Statements  
- Systematic Reviews  
- Performance Measures (cardiovascular performance metrics)  
- Current Procedural Terminology (CPT) codes (used in cardiovascular coding)  
- Quality & Health IT (related to cardiovascular care)  
- Clinical Policy and Guidelines (cardiovascular)  

These terms capture the key concepts related to heart disease and cardiovascular care that appear in the provided text.

Page 11 Extracted Terms:
- Peripheral artery disease  
- Peripheral vascular disease  
- Critical limb ischemia  
- Hypertension (high blood pressure)  
- Blood‑pressure control  
- Intensive blood‑pressure control  
- Heart failure  
- Acute coronary syndrome  
- Coronary artery disease  
- Major adverse cardiovascular events (MACE)  
- Cardiovascular outcomes  
- Vascular events  
- Lower‑extremity amputation  
- Foot ulcer / diabetic foot ulcer  
- Revascularization  
- Beta‑blockers  
- Angiotensin‑converting enzyme inhibitors (ACEi)  
- Angiotensin‑receptor blockers (ARBs)  
- Sodium‑glucose cotransporter‑2 (SGLT2) inhibitors  
- Canagliflozin (Invokana)  
- Empagliflozin  
- Dapagliflozin  
- Ertugliflozin  
- Glucagon‑like peptide‑1 (GLP‑1) receptor agonists  
- Liraglutide  
- Semaglutide  
- Exenatide  
- Dulaglutide  
- Cardiovascular‑glycemic management (e.g., GLP‑1 and SGLT2 agents)  
- Diabetes‑related cardiovascular risk  
- Clinical performance measures for cardiovascular care  
- Guideline‑based clinical practice for heart disease  

(Each line represents a distinct term or concept relevant to heart disease as derived from the provided text.)

Page 12 Extracted Terms:
Peripheral Artery Disease  
Major Adverse Limb Events  
Cardiovascular Disease  
Rivaroxaban  
Aspirin  
Warfarin  
Oral Anticoagulant Therapy  
Cholesterol  
Low‑Density Lipoprotein (LDL)  
Simvastatin  
Statin Therapy  
PCSK9 Inhibitors  
Evolocumab  
Alirocumab  
Lipoprotein(a)  
Smoking Cessation  
Tobacco Cessation  
Electronic Cigarettes  
Vaping Products  
Endovascular Revascularization  
Claudication  
Supervised Exercise  
Home‑Based Walking Exercise  
Stent Revascularization  
Angioplasty  
Infrapopliteal Balloon Angioplasty  
Critical Limb Ischemia  
Peripheral Arterial Bypass  
Revascularization  
Lifestyle Management  
Atherosclerotic Risk  
Diabetes  
Glycemic Control  
Antiplatelet Therapy  
Thromboembolic Events  
High‑Risk Conditions  
Medication Adherence  
Cardiopulmonary Impact  
Cardiovascular Events  
Mortality  
Risk Factors  
Guideline Recommendations  
Clinical Trial  
Randomized Controlled Trial  
Meta‑Analysis  
Systematic Review  
Cohort Study  
Population‑Based Study  
Health Outcomes  

Page 13 Extracted Terms:
- Peripheral artery disease (PAD)  
- Intermittent claudication  
- Endovascular revascularization  
- Percutaneous transluminal angioplasty (PTA)  
- Endovascular treatment (ET)  
- Supervised exercise therapy (SET)  
- Home‑based walking exercise  
- Treadmill training  
- Arm‑ergometer exercise  
- Resistance training  
- Functional status  
- Walking capacity / walking distance  
- Endothelial function  
- Quality of life (QOL)  
- Functional impairment  
- Clinical outcomes  
- Cardiovascular / vascular function  
- Pulmonary/renal comorbidity (e.g., renal insufficiency)  
- Prevalence of peripheral arterial disease  
- Diagnosis / detection of PAD  
- Awareness of PAD  
- Management of PAD  
- Treatment options for PAD  
- Exercise prescription for PAD  
- Leg ischemia  
- Symptomatic peripheral arterial disease  
- Atherosclerosis  
- Coronary artery disease (referenced in broader context)  
- Atherosclerotic disease risk  
- Lower extremity manifestations of PAD  
- Peripheral arterial disease epidemiology  
- Gaps in management of PAD  
- Future directions in PAD treatment  

These terms capture the key cardiovascular and peripheral arterial disease concepts discussed in the provided text.

Page 14 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Lower‑extremity peripheral arterial disease  
- Ankle‑Brachial Index (ABI)  
- Chronic limb‑threatening ischemia  
- Revascularization  
- Endovascular therapy  
- Vein bypass graft  
- Vein graft failure  
- Neointimal hyperplasia  
- Diabetic foot ulcer  
- Foot ulceration and amputation  
- Peripheral vascular disease (PVD)  
- Vascular assessment  
- Vascular surgery  
- Vascular risk  
- Cardiovascular risk factors  
- Cardiovascular morbidity  
- Cardiovascular mortality  
- Major cardiovascular events  
- Sex‑specific cardiovascular risk  
- Racial disparities in cardiovascular care  
- Socioeconomic deprivation and vascular health  
- Rural health disparities in vascular care  
- Peripheral Artery Questionnaire (PAQ)  
- Vascular quality‑of‑life questionnaire  
- PAD‑specific quality of life (PADQOL)  
- ACC/AHA Peripheral Artery Disease Measures  
- BASIL‑2 trial  
- PREVENT III study  
- PED-FOG (edifoligide prevention study)  
- PORTRAIT PAD Registry  
- REACH registry  
- Community‑based screening for PAD  
- Clinical guidelines on PAD care  
- Vascular follow‑up guidelines (Surgery & Endovascular)

Page 15 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Critical Limb Ischemia  
- Limb‑threatening Ischemia  
- Infrainguinal Bypass Graft  
- Endovascular Revascularization  
- Duplex Ultrasound Surveillance  
- Prosthetic Bypass Failure  
- Warfarin Therapy (in the context of graft patency)  
- Graft Surveillance  
- Lower Extremity Arterial Revascularization  
- Post‑Therapy Imaging  
- Appropriate Use Criteria (for vascular diagnostics)  
- Multidisciplinary Care in Vascular Disease  
- Wound Healing in Peripheral Artery Disease  
- Diabetic Foot Ulcer  
- Neuroischemic Wounds  
- Vascular Imaging  
- Peripheral Vascular Ultrasound  
- Hemodynamic Assessment (arterial ultrasound)  
- Cardiovascular Outcomes in Peripheral Disease  
- Vascular Ultrasound Screening (for PAD)  
- Vascular Guidelines for Chronic Limb‑Threatening Ischemia  
- Vascular Surveillance Protocols (duplex)  
- Atherosclerotic Vascular Disease  
- Lower Extremity Arterial Disease  

Page 16 Extracted Terms:
**Key heart‑disease related terms**

- Peripheral Artery Disease (PAD)  
- Hypertension / High Blood Pressure (HBP)  
- Blood Pressure (BP)  
- Systolic Blood Pressure (SBP)  
- Diastolic Blood Pressure (DBP)  
- Antihypertensive therapy  
- Major Adverse Cardiovascular Events (MACE)  
- Chronic Kidney Disease (CKD)  
- End‑Stage Kidney Disease (ESKD)  
- Ankle‑Brachial Index (ABI)  
- Cardiovascular (clinical) guidelines (ACC/AHA)  
- Cardiovascular risk factor  
- Vascular disease  
- BP control / BP goal (<130/<80 mm Hg)  
- BP measurement (home, office, electronic)  
- MACE risk reduction  
- Cardiovascular event prevention  
- Cardiovascular performance metrics  
- Cardiovascular outcome (MACE, CKD progression, decline in ABI)  

These terms capture the core heart‑disease concepts presented in the guideline summary.

Page 17 Extracted Terms:
**Key heart‑disease–related terms**

- Angiotensin‑converting enzyme (ACE) inhibitor  
- Angiotensin‑receptor blocker (ARB)  
- Angiotensin‑receptor‑neprilysin inhibitor (ARN)  
- Peripheral arterial disease (PAD)  
- Hypertension  
- Ankle‑brachial index (ABI)  
- Chronic limb‑threatening ischemia (CLTI)  
- Myocardial infarction (MI)  
- Stroke  
- Vascular death  
- Major adverse cardiovascular events (MACE)  
- Ramipril  
- Telmisartan  
- Cardiomyopathy  
- Heart Outcomes Prevention (HOPE) trial  
- ONTARGET (Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial)  
- Blood pressure (BP) — systolic (SBP) and diastolic (DBP)  
- End‑stage kidney disease (ESKD)  

These terms capture the core medical concepts related to cardiovascular disease and its management within the provided text.

Page 18 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Type 2 Diabetes Mellitus  
- Glucagon‑like peptide‑1 (GLP‑1) agonists  
- Sodium‑glucose cotransporter‑2 (SGLT‑2) inhibitors  
- Major Adverse Cardiovascular Events (MACE)  
- Heart Failure  
- Empagliflozin  
- Canagliflozin  
- Dapagliflozin  
- Liraglutide  
- Semaglutide  
- Limb survival  
- Amputation  
- Cardiovascular Outcomes Trial  
- Vascular disease  

Page 19 Extracted Terms:
**Key Terms Related to Heart Disease**

- Peripheral Artery Disease (PAD)  
- Symptomatic PAD  
- Chronic Limb‑Threatening Ischemia (CLTI)  
- Myocardial Infarction (MI)  
- Stroke  
- Cardiovascular death  
- Major Adverse Cardiovascular Events (MACE)  
- Major Adverse Limb Events (MALE)  
- Coronary Artery Disease (CAD)  
- Carotid disease  
- Ankle‑Brachial Index (ABI)  
- Acute Coronary Syndrome (ACS)  
- Revascularization (endovascular or surgical)  
- Endovascular limb revascularization  
- Surgical limb revascularization  
- Bypass surgery  
- Percutaneous intervention  
- Antithrombotic therapy  
- Low‑dose rivaroxaban  
- Low‑dose aspirin  
- Dual antiplatelet therapy  
- Full‑intensity anticoagulation  
- Vitamin K antagonists (VKA)  
- Direct oral anticoagulants (DOAC)  
- Bleeding risk (associated with anticoagulation)  
- COMPASS trial (cardiovascular outcomes)  
- VOYAGER trial (anticoagulation with aspirin)  

These terms capture the core concepts, conditions, treatments, and clinical trial references pertinent to heart disease described in the text.

Page 20 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- High‑Intensity Statin Therapy  
- Atorvastatin (≥ 40 mg)  
- Rosuvastatin (≥ 20 mg)  
- Low‑Density Lipoprotein Cholesterol (LDL‑C)  
- Dyslipidemia  
- Cholesterol‑lowering therapy  
- Statins (hydroxymethylglutaryl‑Coenzyme A reductase inhibitors)  
- Atherosclerosis / Plaque  
- Major Adverse Cardiac Events (MACE)  
- Major Adverse Limb Events (MALE)  
- Myocardial Infarction (MI)  
- Stroke  
- Coronary Artery Disease (CAD)  
- Cardiovascular Death  
- Risk reduction of cardiovascular events  
- Heart Protection Study (HPS)  

These terms capture the key heart‑disease concepts discussed in the guideline text.

Page 21 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Major Adverse Limb Events (MALE)  
- Major Adverse Cardiovascular Events (MACE)  
- Tobacco use  
- Smoking cessation  
- Electronic Nicotine Delivery Systems (ENDS)  
- Second‑hand smoke  
- Varenicline (treatment)  
- Bupropion (treatment)  
- Nicotine Replacement Therapy (NRT)  
- Cessation counseling  
- Lower‑extremity peripheral artery disease  
- ACC/AHA guidelines for PAD  
- ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline  
- American College of Cardiology (ACC)  
- American Heart Association (AHA)  
- American Association of Cardiovascular and Pulmonary Rehabilitation (AACVPR)  
- Association of Black Cardiologists (ABC)  
- Society for Cardiovascular Angiography and Interventions (SCAI)  
- Society of Interventional Radiology (SIR)  
- Society for Vascular Medicine (SVM)  
- Society for Vascular Nursing (SVN)  
- Society for Vascular Surgery (SVS)  
- Vascular and Endovascular Surgery Society (VESS)  
- Electronic Health Record (EHR)  
- Digital health solutions  
- Group therapy models  
- Cardiovascular disease  
- Stroke (as a related outcome)

Page 22 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Chronic symptomatic PAD  
- Claudication (intermittent claudication)  
- Chronic limb‑threatening ischemia (CLTI)  
- Ischemic rest pain  
- Non‑healing ischemic ulcers  
- Gangrene  
- Unstable angina  
- Myocardial infarction (MI)  
- Decompensated heart failure  
- Uncontrolled cardiac arrhythmias  
- Severe or symptomatic valvular disease  
- Revascularization (e.g., endovascular or surgical)  
- Supervised Exercise Therapy (SET)  
- Structured Community‑Based Exercise Therapy  
- Walking performance (functional outcome)  
- Functional status (exercise tolerance)  
- Quality of Life (QOL)  
- Alternative non‑walking exercise (arm ergometry, stationary cycling)  

These terms capture the primary heart‑vascular conditions, relevant complications, and key therapeutic concepts discussed in the text.

Page 23 Extracted Terms:
**Key heart‑disease related terms extracted from the text**

- Peripheral Artery Disease (PAD)  
- Lower Extremity PAD  
- Vascular Review of Systems (vascular review)  
- Walking impairment / Claudication  
- Ischemic rest pain  
- Lower extremity non‑healing wounds  
- Exertional leg symptoms  
- Ischemic skin changes  
- Atherosclerosis  
- Coronary artery disease  
- Cerebrovascular disease  
- Polyvascular disease  
- Microvascular disease  
- Retinopathy  
- Neuropathy  
- Nephropathy  
- Chronic Kidney Disease (CKD)  
- End‑Stage Kidney Disease (ESKD)  
- Estimated Glomerular Filtration Rate (eGFR) <60 mL/min/1.73 m²  
- Diabetes Mellitus  
- Smoking / Tobacco use (including other forms of tobacco)  
- Older age (≥ 75 years)  
- Frailty  
- Mobility impairment  
- Depression  
- Risk amplifiers (≥ 1 of the above factors)  
- Clinical assessment for PAD  
- Diagnostic testing for PAD  
- Vascular examination of legs and feet  
- Vascular inspection of lower extremities  
- ACC/AHA Peripheral Artery Disease Measures (QM-1)  
- Electronic Health Record (EHR) – data source for cardiovascular assessment  
- Administrative data/claims – data source for cardiovascular measurement  
- Inpatient care setting – cardiovascular care context  
- Outpatient care setting – cardiovascular care context  

These terms capture the core cardiovascular concepts, risk factors, diagnostic elements, and quality‑measurement language present in the provided guidelines.

Page 24 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Atherosclerosis  
- Cardiovascular risk factors  
- Atherosclerotic vascular disease  
- Coronary artery disease  
- Cerebrovascular disease  
- Polyvascular disease (disease in ≥2 arterial beds)  
- Microvascular disease (retinopathy, neuropathy, nephropathy)  
- Diabetes mellitus  
- Smoking / tobacco use  
- Chronic Kidney Disease (CKD)  
- End‑Stage Kidney Disease (ESKD / dialysis dependence)  
- Estimated Glomerular Filtration Rate (eGFR)  
- Older age (≥75 years)  
- Geriatric syndromes (frailty, mobility impairment)  
- Depression (as a risk amplifier)  
- Lower‑extremity pulse examination  
- Femoral pulse  
- Popliteal pulse  
- Dorsalis pedis pulse  
- Posterior tibial pulse  
- Exertional leg symptoms  
- Lower‑extremity rest pain  
- Ischemic skin changes (wounds, ulceration)  
- Vascular examination of legs and feet  
- Clinical assessment / risk assessment  
- Risk amplifiers (clinical definitions for PAD)

Page 25 Extracted Terms:
- Peripheral artery disease (PAD)  
- Cardiovascular disease (CVD)  
- Coronary artery disease (CAD)  
- Heart failure  
- Cerebrovascular disease  
- Chronic limb‑threatening ischemia (CLTI)  
- Lower extremity revascularization  
- Tobacco use  
- Diabetes mellitus  
- Chronic kidney disease (CKD)

Page 26 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Lipid‑Lowering Therapy  
- Statin therapy  
- High‑intensity statin therapy  
- Maximum tolerated statin  
- PCSK9 inhibitors  
- Ezetimibe  
- Low‑density lipoprotein cholesterol (LDL‑C)  
- LDL‑C target ≤ 70 mg/dL  
- Major Adverse Cardiac Events (MACE)  
- Major Adverse Limb Events (MALE)  
- Myocardial infarction (MI)  
- Stroke  
- Cardiovascular death  
- Chronic limb‑threatening ischemia (CLTI)  
- Clinical measures (QM‑4)  
- Randomized controlled trial (RCT)  
- IMPROVE‑IT Trial  
- FOURIER Study  
- ODYSSEY OUTCOMES Trial  
- Hazard Ratio (HR)  
- ACC/AHA guidelines  
- ACC  
- AHA  
- AACVPR  
- APMA  
- ABC  
- SCAI  
- SIR  
- VESS  
- SVM  
- SVN  
- SVS  
- EHR (electronic health record)  

Page 27 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Lower extremity PAD  
- Peripheral vascular disease  
- Lower extremity amputation  
- Revascularization procedures (e.g., angioplasty, bypass, endovascular therapy)  
- Evidence‑based therapies  
- Statins  
- Antiplatelet agents (e.g., aspirin, clopidogrel)  
- Dual antiplatelet therapy  
- Diagnostic testing for PAD  
- Screening and referral processes  
- Atherosclerosis  
- Critical limb ischemia  
- Cardiovascular disease  
- Diabetes mellitus (risk factor)  
- Hypertension (risk factor)  
- Dyslipidemia / hyperlipidemia  
- Smoking (risk factor)  
- Obesity (risk factor)  
- Racial disparities  
- Ethnic disparities  
- Sex disparities  
- Gender‑identity disparities  
- Socioeconomic status (SES)  
- Income level  
- Educational status  
- Housing stability  
- Housing status  
- Transportation access  
- Rurality / geographic remoteness  
- Social determinants of health  
- Intersectionality (combined risk factor impact)  
- Health disparities in diagnosis, treatment, and outcomes  
- Morbidity and mortality associated with PAD  
- Access to specialized vascular care  
- Virtual or home‑based care delivery.

Page 28 Extracted Terms:
- American College of Cardiology (ACC)  
- American Heart Association (AHA)  
- Peripheral Artery Disease (PAD)  
- Chronic Limb‑Threatening Ischemia (CLTI)  
- Saphenous Vein (Great Saphenous Vein)  
- Revascularization (surgical bypass, endovascular)  
- Ultrasound Mapping  
- Surgical Bypass Surgery  
- Endovascular Therapy  
- BEST‑CLI Trial  
- Class I Clinical Recommendation  
- Level of Evidence: B‑R  
- Society for Cardiovascular Angiography and Interventions (SCAI)  
- Society of Interventional Radiology (SIR)  
- Society for Vascular Medicine (SVM)  
- Society for Vascular Nursing (SVN)  
- Society for Vascular Surgery (SVS)  
- Vascular and Endovascular Surgery Society (VESS)

Page 29 Extracted Terms:
**Key terms related to heart disease (peripheral artery disease & related care):**

- Peripheral artery disease (PAD)
- Ankle‑brachial index (ABI)
- Duplex ultrasound surveillance (DUS)
- Autogenous vein bypass graft (AVBG)
- Autogenous vein bypass graft surgery
- Lower extremity revascularization
- Infrainguinal bypass graft
- Prosthetic bypass graft
- Endovascular procedure
- Graft failure
- Stenotic lesions
- Lower extremity ischemia
- Graft patency (primary, assisted primary, secondary)
- Longitudinal follow‑up
- Clinical evaluation (pulse, foot assessment)
- Functional status
- Quality of life (QOL)
- Risk factor management
- Surveillance protocols
- Clinical recommendation
- Class 1/2a/2b recommendations
- Level of evidence (C‑EO, B‑NR, C‑LD, B‑R, C‑LD)
- Quality measure (QM‑7)
- Circ Pulm Health Outcomes (journal)
- ACC/AHA peripheral artery disease guideline
- AACVPR (American Association of Cardiovascular and Pulmonary Rehabilitation)
- AHA (American Heart Association)
- ACC (American College of Cardiology)
- APMA (American Podiatric Medical Association)
- ABC (Association of Black Cardiologists)
- SCAI (Society for Cardiovascular Angiography and Interventions)
- SVS (Society for Vascular Surgery)
- SIR (Society of Interventional Radiology)
- SVM (Society for Vascular Medicine)
- SVN (Society for Vascular Nursing)
- VESS (Vascular and Endovascular Surgery Society)
- Electronic health record (EHR)
- Administrative data / claims
- Imaging laboratory records
- Outpatient care setting
- 12‑month measurement period
- Lower extremity surveillance procedure
- ABI and arterial DUS screening interval (1–3 months, 6 months, 12 months, annual)

Page 30 Extracted Terms:
- ACC (American College of Cardiology)  
- AHA (American Heart Association)  
- Cardiac (related to heart)  
- Cardiovascular  
- Peripheral Artery Disease (PAD)  
- Chronic Limb‑Threatening Ischemia (CLTI)  
- Revascularization (endovascular or surgical)  
- Multidisciplinary Team (MDT) evaluation  
- Wound healing  
- Offloading  
- Infection management  
- Palliative care (limb)  
- Limb preservation/limb salvage  
- Amputation (most distal level)  
- Endovascular revascularization  
- Surgical revascularization  
- Wound‑healing therapies  
- Foot surgery  
- Vascular surgery  
- Orthopedics  
- Podiatry  
- Plastic surgery  
- Rehabilitation  
- Diabetes management  
- Orthotics  
- Prosthetics  
- Case conferences  
- Morbidity and mortality discussions  
- Shared decision‑making  
- Quality measure (QM‑8)  
- Class I recommendation (Class 1)  
- Level of Evidence (B‑NR, C‑EO, etc.)  
- PAD guideline (2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS)  
- Endovascular therapy  
- Surgical therapy  
- Multispecialty care team  

*(These terms capture the cardiovascular/heart‑related concepts, clinical processes, and guideline terminology referenced in the text.)*

Page 31 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Vascular Surgery  
- Cardiovascular Medicine  
- Interventional Cardiologist  
- American Heart Association (AHA)  
- American College of Cardiology (ACC)  
- AHA/ACC (combined AHA‑ACC entity)  
- ACC/AHA Peripheral Artery Disease Measures  
- Clinical Performance and Quality Measures for Patients With Peripheral Artery Disease  
- Society for Cardiovascular Angiography and Interventions (SCAI)  
- Society for Vascular Surgery (SVS)  
- AHA/ACC Guideline Liaison  
- Performance Measures (cardiovascular/vascular)  
- Vascular Health Institute (vascular‑medicine focus)

Page 32 Extracted Terms:
**Key heart‑disease related terms extracted from the text**

- Peripheral Artery Disease (PAD)  
- ACC/AHA Peripheral Artery Disease Measures  
- Cardiovascular Medicine  
- Interventional Cardiologist  
- Cardiovascular Surgery  
- Cardiology / Cardiac  
- Heart (as part of institution name)  
- AHA (American Heart Association)  
- NIH (National Institutes of Health)  
- Abiomed  
- Chiesi USA  
- Idorsia  
- SIR (Society for Interventional Radiology)  
- Vascular Surgery  
- Vascular (as a related medical specialty)

Page 33 Extracted Terms:
- Cardiovascular  
- Cardiovascular medicine  
- Cardiology  
- Heart  
- Heart disease  
- Peripheral artery disease (PAD)  
- Vascular  
- Vascular medicine  
- Vascular surgery  
- Cardiovascular and pulmonary rehabilitation  
- ACC (American College of Cardiology)  
- AHA (American Heart Association)

Page 34 Extracted Terms:
- Peripheral Artery Disease  
- Cardiovascular — Cardiology, Cardiovascular Research, Cardiovascular Innovations Foundation  
- Cardiac Rehabilitation  
- Cardiac Exercise Physiologist  
- Cardiologist  
- Lipid Clinic (Cardiovascular Disease Prevention)  
- Rasmussen Cardiovascular Disease Prevention Center  
- Clinical Performance and Quality Measures for Patients With Peripheral Artery Disease  
- ACC/AHA (American College of Cardiology/American Heart Association)  
- SVS (Society of Vascular Surgeons)  
- JCPM (Joint Commission on Practice‑Mediated)  
- AACVPR (American Association of Cardiovascular & Pulmonary Rehabilitation)  
- APMA (American Physical Medicine & Rehabilitation)  
- Endowed Chair in Cardiology  
- Peripheral Artery Disease Measures  
- Cardio‑vascular Innovations Foundation  
- AngioSafe  
- Kaneka Pharma America LLC  
- Elsevier (clinical research)  
- GE Healthcare (cardiovascular imaging)  
- Novartis (cardiovascular therapeutics)  
- Inari Medical (vascular interventions)  
- Pfizer (cardiovascular drugs)  
- Amgen (cardiovascular biologics)  
- Arrowhead Pharmaceuticals (cardiovascular therapeutics)  
- NHLBI (National Heart, Lung, and Blood Institute)  
- Cook Medical (vascular and cardiovascular products)

Page 35 Extracted Terms:
- ACC (American College of Cardiology)  
- AHA (American Heart Association)  
- ACC/AHA (American College of Cardiology / American Heart Association)  
- Cardiologist  
- Cardiology  
- Cardiovascular  
- Cardiovascular and Pulmonary Rehabilitation  
- Heart  
- Heart and Vascular Center  
- Peripheral Artery Disease  
- Vascular Medicine  
- Vascular Medicine Outcomes Program (VAMOS)  
- Vascular Surgery  
- Vascular Surgeon  
- National Heart, Lung, and Blood Institute (NHLBI)  
- National Lipid Association (NLA)  
- Society for Cardiovascular Angiography and Interventions (SCAI)  
- Society of Interventional Radiology (SIR)  
- Society for Vascular Medicine (SVM)  



Page 1 Extracted Terms:
- AHA Scientific Statements  
- guidelines  
- antihypertensive agents  
- aspirin  
- atherosclerosis  
- atherosclerotic cardiovascular disease  
- atrial fibrillation  
- behavior modification  
- behavior therapy  
- blood cholesterol  
- blood pressure  
- body mass index  
- cardiovascular team‑based care  
- cardiovascular  
- cardiovascular disease  
- cholesterol  
- chronic kidney disease  
- coronary artery calcium score  
- coronary disease  
- coronary heart disease  
- cost  
- diet  
- dietary patterns  
- dietary fats  
- dietary sodium  
- dyslipidemia  
- e‑cigarettes  
- exercise  
- healthcare disparities  
- health services accessibility  
- heart failure  
- hypertension  
- LDL cholesterol  
- diabetes mellitus  
- lifestyle  
- lipids  
- measurement  
- myocardial infarction  
- nicotine  
- nonpharmacological treatment  
- nutrition  
- physical activity  
- prejudice  
- primary prevention  
- psychosocial deprivation  
- public health  
- quality indicators  
- quality measurement  
- risk assessment  
- risk-enhancing factors  
- risk factors  
- risk reduction  
- risk reduction discussion  
- risk treatment discussion  
- secondhand smoke  
- sleep  
- smoking  
- smoking cessation  
- social determinants of health  
- socioeconomic factors  
- statin therapy  
- systems of care  
- tobacco  
- tobacco smoke pollution  
- treatment adherence  
- treatment outcomes  
- type 2 diabetes mellitus  
- waist circumference  
- weight loss

Page 2 Extracted Terms:
Atherosclerotic cardiovascular disease (ASCVD)  
Heart failure  
Atrial fibrillation  
Statin therapy  
Aspirin use  
Antihypertensive therapy  
Low‑density lipoprotein cholesterol (LDL‑C)  
High‑density lipoprotein cholesterol (HDL‑C)  
Coronary artery calcium (CAC) scanning  
Blood pressure  
Hypertension  
Type 2 diabetes mellitus  
Metformin (first‑line therapy for diabetes)  
Sodium‑glucose cotransporter‑2 (SGLT2) inhibitor  
Glucagon‑like peptide‑1 (GLP‑1) receptor agonist  
Tobacco use (risk factor)  
Risk‑estimation for ASCVD (10‑year ASCVD risk score)  
Lifestyle modifications (diet, exercise)

Page 3 Extracted Terms:
- Atherosclerotic cardiovascular disease (ASCVD)  
- Cardiovascular disease (CVD)  
- Myocardial infarction (MI)  
- Heart failure  
- Atrial fibrillation  
- Blood pressure (BP)  
- Lipid‑lowering medication  
- Diabetes medication  
- Aspirin therapy  
- Exercise / physical activity  
- Tobacco use / smoking cessation  
- Secondhand smoke exposure  
- Life’s Simple 7 (ideal cardiovascular health metrics)  
- Lifestyle optimization (diet, activity, tobacco avoidance)  
- Primary prevention of ASCVD  
- Risk factor optimization  
- Shared decision‑making  
- Team‑based care  
- Social determinants of health  
- Clinical guideline‑directed management  
- Diagnostic testing for cardiovascular disease  
- Pharmacological therapy for cardiovascular risk reduction  
- ACC/AHA primary‑prevention guidelines  
- Cardiovascular risk assessment  
- Lifestyle goal setting (dietary modification, exercise plans)  
- Healthcare cost burden of cardiovascular disease (>$200 billion US annually)

Page 4 Extracted Terms:
- Cardiovascular disease (CVD)  
- Atherosclerotic cardiovascular disease (ASCVD)  
- Primary prevention of CVD/ASCVD  
- ACC/AHA guideline (for cardiovascular prevention)  
- Risk assessment (for cardiovascular risk)  
- Diet (as a cardiovascular risk factor)  
- Exercise / physical activity (cardiovascular health)  
- Obesity  
- Weight loss  
- Type 2 diabetes mellitus (T2DM)  
- Blood cholesterol / lipid levels  
- Hypertension / high blood pressure (BP)  
- Smoking cessation  
- Aspirin use (for cardiovascular prevention)  
- Cardiovascular risk  
- Heart disease (general term)

Page 5 Extracted Terms:
- Cardiovascular disease (CVD)  
- Myocardial infarction (MI)  
- Stable angina  
- Unstable angina  
- Arterial revascularization  
- Stroke  
- Transient ischemic attack (TIA)  
- Peripheral arterial disease  
- Heart failure  
- Atrial fibrillation  
- Lifestyle factors: diet, exercise, physical activity  
- Obesity  
- Diabetes  
- Blood cholesterol  
- High blood pressure (BP)  
- Smoking  
- Aspirin use  
- Team‑based care  
- Shared decision‑making  
- Social determinants of health  
- Primary prevention  
- Cost and value of prevention  
- Class of Recommendation (COR)  
- Level of Evidence (LOE)

Page 6 Extracted Terms:
**Key heart‑disease related terms extracted**

- Atherosclerotic cardiovascular disease (ASCVD)  
- Coronary heart disease (CHD)  
- Cardiovascular disease (CVD)  
- Myocardial infarction (MI)  
- Hypertension (high blood pressure) – includes systolic BP (SBP), diastolic BP (DBP)  
- Diabetes mellitus (DM, specifically type 2 DM – T2DM)  
- Hyperlipidemia (high LDL‑C, low HDL‑C)  
- Pooled cohort equations (PCE) – ASCVD risk estimation  
- Glucagon‑like peptide‑1 receptor (GLP‑1R) agonists – cardiovascular benefit agents  
- Sodium‑glucose cotransporter‑2 (SGLT‑2) inhibitors – cardiovascular benefit agents  
- Urinalysis markers: hemoglobin A1c (HbA1c) (used in diabetes control)  
- Agatston units (AU) – coronary calcium scoring  
- Risk‑factor control/optimization: lifestyle modification, pharmacologic therapy (statins, antihypertensives, antidiabetic drugs)  
- Team‑based care / multidisciplinary care (clinical strategy for ASCVD prevention)  
- Shared decision‑making (clinical decision process for preventive therapy)  

These terms capture the core disease entities, risk factors, biomarkers, therapeutic targets, and recommended clinical approaches discussed in the guideline.

Page 7 Extracted Terms:
- Atherosclerotic cardiovascular disease (ASCVD)  
- Cardiovascular risk assessment  
- Pooled Cohort Equations (PCE)  
- 10‑year ASCVD risk  
- Borderline risk (5 %–<7.5 %)  
- Intermediate risk (≥7.5 %–<20 %)  
- Risk‑enhancing factors  
- Statin therapy (primary prevention)  
- Coronary artery calcium (CAC) score  
- Traditional cardiovascular risk factors (e.g., age, sex, LDL‑C, HDL‑C, systolic BP, smoking)  
- Blood pressure (BP) / hypertension  
- Lipids / dyslipidemia  
- High blood pressure / hypertension management  
- Obesity / overweight  
- Weight loss / weight maintenance  
- Body‑size perception  
- Diabetes mellitus type 2  
- Glycemic control (HbA1c)  
- Lifestyle counseling (diet, exercise)  
- Diet modifications (low‑sodium, heart‑healthy)  
- Food access / food security  
- Physical activity / exercise prescription  
- Neighborhood environment / access to facilities  
- Sleep hygiene / short sleep duration (<6 h)  
- Tobacco use / tobacco treatment  
- Psychosocial stressors  
- Social support (individual and group)  
- Health literacy assessment  
- Socioeconomic status (SES)  
- Housing instability  
- Food insecurity  
- Transportation difficulties  
- Utility assistance needs  
- Interpersonal safety  
- Mental illness (comorbid)  
- Financial strain  
- Inadequate housing conditions  
- Inadequate social support  
- Exposure to adversity (violence, trauma)  
- Advanced age (≥75 y)  
- Racial/ethnic disparities in cardiovascular outcomes  
- Primary prevention of ASCVD  
- Cardiovascular outcomes  
- Social determinants of health (SDOH)  

These terms capture the key heart‑disease concepts, risk factors, interventions, and social determinants discussed in the guideline excerpt.

Page 8 Extracted Terms:
- ASCVD risk  
- Lifetime ASCVD risk  
- 10‑year ASCVD risk  
- 30‑year ASCVD risk  
- Primary prevention of cardiovascular disease  
- Lipid management  
- Blood‑pressure (BP) management  
- Stage 1 hypertension (BP 130–139/80–89 mm Hg)  
- Coronary artery calcium (CAC) score  
- Risk‑enhancing factors  
- Risk calculators (e.g., PCE, Framingham, Reynolds, SCORE, QRISK/JBS3)  
- PCE (Pooled Cohort Equations)  
- Framingham CVD risk score  
- Reynolds risk score  
- SCORE (Systematic Coronary Risk Evaluation)  
- QRISK / JBS3  
- Clinical decision support tools  
- Risk thresholds (low < 5 %, borderline 5 %–< 7.5 %, intermediate ≥ 7.5 %–< 20 %, high ≥ 20 %)  
- Statin therapy (e.g., for elevated ASCVD risk or familial hypercholesterolemia)  
- Familial hypercholesterolemia  
- Traditional cardiovascular risk factors  
- Race‑specific risk estimation (non‑Hispanic White, non‑Hispanic Black, other ethnic groups)  
- Age‑specific risk assessment (20–39 yrs, 40–59 yrs, 60–75 yrs, > 75 yrs)  
- Risk assessment frequency (every 4–6 years)  
- Lifestyle interventions (heart‑healthy lifestyle, diet, exercise)  
- Comorbidities (e.g., chronic inflammatory conditions, autoimmune disease, HIV infection, socioeconomic disadvantage)  
- Over‑ or underestimation of risk by PCE  
- Life expectancy considerations  
- Shared decision‑making in cardiovascular prevention



Page 9 Extracted Terms:
**Key terms related to heart disease**

- Atherosclerotic cardiovascular disease (ASCVD)  
- Cardiovascular disease (CVD)  
- Coronary artery calcium (CAC)  
- Coronary artery calcium score  
- Coronary atherosclerosis  
- Coronary artery calcium measurement  
- Coronary artery calcium score in Agatston units (AU)  
- Pooled Cohort Equation (PCE)  
- Risk calculators  
- Risk‑enhancing factors  
- Risk reclassification  
- Cardiovascular risk estimation  
- Cardiovascular risk stratification  
- Primary hypercholesterolemia  
- LDL‑cholesterol (LDL‑C)  
- HDL‑cholesterol (HDL‑C)  
- Non‑HDL‑cholesterol  
- Lipoprotein(a) [Lp(a)]  
- Apolipoprotein B (apoB)  
- High‑sensitivity C‑reactive protein (hs‑CRP)  
- Chronic kidney disease (CKD)  
- Chronic inflammatory disease  
- Rheumatoid arthritis (RA)  
- Systemic lupus erythematosus (lupus)  
- Human immunodeficiency virus (HIV)  
- Metabolic syndrome  
- Elevated triglycerides  
- Elevated blood pressure  
- Elevated glucose  
- Low HDL‑cholesterol  
- Diabetes mellitus  
- Ankle‑brachial index (ABI)  
- South Asian ancestry (high‑risk race/ethnicity)  
- Preeclampsia  
- Premature menopause (before age 40)  
- Early menopause (before age 55 in men, before age 65 in women)  
- Erectile dysfunction  
- Statin therapy  
- Aspirin (antiplatelet)  

These terms capture the principal concepts and risk‑enhancing factors discussed in the provided guideline excerpt.

Page 10 Extracted Terms:
**Key Heart‑Disease–Related Terms Extracted from the Text**

- Atherosclerotic cardiovascular disease (ASCVD)  
- Coronary artery calcium (CAC) score / measurement  
- Coronary heart disease (CHD)  
- Statin therapy / statins  
- Cholesterol (dietary & blood)  
- Lipid lowering therapy  
- Risk estimation tools (e.g., ASCVD Risk Estimator, PCE, 30‑year/lifetime risk estimator)  
- Risk reclassification & discrimination  
- Non‑calcified plaque  
- Lifetime ASCVD risk  
- 30‑year ASCVD risk  
- Cardiovascular mortality / deaths  
- Obesity epidemic  
- Diabetes mellitus  
- Hypertension  
- Lifestyle factors impacting cardiovascular risk  
- Nutrition and diet (heart‑healthy diet)  
- Vegetables, fruits, legumes, nuts, whole grains, fish  
- Saturated fat  
- Monounsaturated fat  
- Polyunsaturated fat  
- Trans fats  
- Dietary cholesterol  
- Sodium  
- Processed meats (e.g., bacon, salami, ham, hot dogs, sausage)  
- Refined carbohydrates  
- Sweetened beverages  
- Sugar and high‑carbohydrate diets  
- Low‑carbohydrate diets  
- Mediterranean diet  
- Plant‑based diet  

These terms encapsulate the primary concepts related to heart disease prevention, risk assessment, treatment, and lifestyle recommendations presented in the guideline excerpt.

Page 11 Extracted Terms:
- Cardiovascular disease (CVD)  
- Atherosclerotic cardiovascular disease (ASCVD)  
- Myocardial infarction (MI)  
- Stroke  
- Cardiovascular mortality / death  
- Heart disease  
- Coronary events / coronary artery disease  
- Blood pressure (BP) / Hypertension  
- Dietary sodium  
- Trans fatty acids  
- Saturated fatty acids  
- Unsaturated fatty acids  
- Dietary fats  
- Plant protein  
- Animal protein  
- Red meat  
- Processed red meat  
- Poultry  
- Fish  
- Dairy products  
- Eggs  
- Nuts and seeds  
- Mediterranean diet  
- DASH diet (Dietary Approaches to Stop Hypertension)  
- PREDIMED trial  
- PURE study (Prospective Urban Rural Epidemiology)  
- REGARDS study (REasons for Geographic and Racial Differences in Stroke)  
- ARIC study (Atherosclerosis Risk in Communities)  
- Type 2 diabetes mellitus (T2DM)  
- Sugar‑sweetened beverages  
- Artificially sweetened beverages  
- Added sugar  
- Low‑carbohydrate diet  
- Refined carbohydrates  
- Fried foods  
- Added fats  
- Organ meats  
- Low‑calorie sweetened beverages  

Page 12 Extracted Terms:
- ASCVD (Atherosclerotic Cardiovascular Disease)  
- Cardiovascular disease  
- Coronary heart disease  
- Myocardial infarction (MI)  
- Stroke  
- Endothelial dysfunction  
- Insulin resistance  
- Inflammation  
- Arrhythmias  
- Blood pressure (BP)  
- Hypertension  
- Lipids  
- Lipoproteins  
- LDL cholesterol  
- HDL cholesterol  
- Total cholesterol  
- Trans fat  
- Partially hydrogenated oils  
- High‑carbohydrate diet  
- Low‑carbohydrate diet  
- Animal protein (e.g., lamb, beef, pork, chicken)  
- Plant protein (e.g., nuts, whole‑grain breads)  
- Dietary fat  
- Dietary carbohydrate  
- Cardiovascular risk  
- Risk factors  
- Physical activity  
- Moderate‑intensity aerobic activity  
- Vigorous‑intensity aerobic activity  
- Sedentary behavior  
- Exercise guidelines (≥150 min/week moderate or ≥75 min/week vigorous)  
- Resistance exercise  
- Glycemic control  
- Diabetes  
- BP lowering  
- Cardiovascular health  
- Mortality rate  
- Mortality risk  
- Lifestyle counseling  
- Physical activity counseling  
- Aerobic exercise safety  
- Dose‑response relationship to ASCVD events and death.

Page 13 Extracted Terms:
ASCVD (atherosclerotic cardiovascular disease)  
Cardiovascular disease  
Heart failure  
Cardiometabolic risk factors  
Physical activity (general)  
Sedentary behavior  
Moderate‑intensity aerobic physical activity  
Vigorous‑intensity aerobic physical activity  
Light‑intensity physical activity  
Moderate‑to‑vigorous physical activity  
Physical activity intensity levels (METs) (e.g., 1.6–2.9 METs for light, 3.0–5.9 METs for moderate, ≥6 METs for vigorous)

Page 14 Extracted Terms:
- Cardiovascular disease  
- Atherosclerotic cardiovascular disease (ASCVD)  
- Heart failure  
- Atrial fibrillation  
- Hypertension (high blood pressure)  
- Blood pressure (BP)  
- Low‑density lipoprotein cholesterol (LDL‑C)  
- Triglycerides  
- Body mass index (BMI)  
- Waist circumference  
- Physical activity (exercise)  
- Weight loss (as prevention strategy)

Page 15 Extracted Terms:
- Cardiovascular disease  
- Atherosclerotic cardiovascular disease (ASCVD)  
- Cardiometabolic risk  
- Metabolic syndrome  
- Obesity  
- Overweight  
- Body mass index (BMI)  
- Waist circumference  
- Waist‑hip ratio  
- Dual‑energy X‑ray absorptiometry (DXA)  
- Bioimpedance  
- Type 2 diabetes mellitus (T2DM)  
- Glycemic control  
- Hemoglobin A1c (HbA1c)  
- Sodium‑glucose cotransporter‑2 (SGLT‑2) inhibitor  
- Glucagon‑like peptide‑1 receptor (GLP‑1R) agonist  
- Heart‑healthy dietary pattern  
- Mediterranean diet  
- DASH diet  
- Vegetarian/vegan diet  
- Physical activity  
- Moderate‑intensity physical activity  
- Vigorous‑intensity physical activity  
- Metformin  
- Cardiovascular risk factors  
- Weight loss  
- Central adiposity  
- ASCVD events  
- Cholesterol management  
- Hypertension  
- Cardiovascular risk factor treatment  
- Lifestyle interventions  
- Bariatric surgery  
- FDA‑approved drugs  
- National Heart, Lung, and Blood Institute (NHLBI)  
- Cardiovascular disease prevention guidelines  

Page 16 Extracted Terms:
- Cardiovascular disease (CVD)  
- Atherosclerotic cardiovascular disease (ASCVD)  
- CVD events  
- CVD death  
- Primary prevention of cardiovascular disease  

Page 17 Extracted Terms:
**Terms related to heart disease extracted from the guideline text**

- ASCVD (atherothrombotic cardiovascular disease)  
- Cardiovascular disease (CVD)  
- Heart failure  
- Myocardial infarction (MI)  
- Coronary artery disease (CAD)  
- Coronary artery calcium score  
- Statin therapy  
- LDL‑C (low‑density lipoprotein cholesterol)  
- HDL‑C (high‑density lipoprotein cholesterol)  
- Total cholesterol  
- Hypercholesterolemia  
- Lipid‑lowering therapy  
- SGLT‑2 inhibitors  
- GLP‑1 receptor agonists  
- Glycemic control (diabetes mellitus) as a risk factor  
- Hypertension / high blood pressure  
- 10‑year ASCVD risk score  
- Primary prevention of CVD  
- Secondary prevention of CVD  
- Risk‑enhancing factors  
- Risk discussion / shared decision making  
- Intensive/statistically significant risk reduction  
- Cholesterol clinical practice guidelines  
- Clinical statements on ASCVD outcomes  
- Coronary artery calcium score thresholds (0, 1‑99, ≥100)  
- Intensive statin intensity (moderate‑intensity, high‑intensity)  
- Maximally tolerated statin therapy  

These terms collectively capture the key cardiovascular disease concepts and therapeutic considerations highlighted in the guideline excerpts.

Page 18 Extracted Terms:
Primary ASCVD prevention  
ASCVD risk factors  
Cholesterol management  
Low‑density lipoprotein cholesterol (LDL‑C)  
Statin treatment  
Statin safety  
Statin‑associated side effects  
Moderate‑intensity statin therapy  
High‑intensity statin therapy  
Randomized controlled trial (RCT)  
Cardiovascular risk factor  
Coronary artery calcium (CAC)  
Ankle‑brachial index (ABI)  
Apolipoprotein B (apoB)  
Lipoprotein(a) (Lp(a))  
High‑sensitivity C‑reactive protein (hs‑CRP)  
Coronary heart disease (CHD)  
Human immunodeficiency virus (HIV)  
Lifetime risk of ASCVD  
10‑year ASCVD risk  
Cardiovascular disease (CVD)  
Primary prevention  
Risk assessment  
Risk discussion  
Clinical trial  
Placebo comparison  
Ethnically and racially diverse population  
Intermediate‑risk patients  
Statin benefit  
Cardiovascular disease prevention policies

(Note: All terms are directly referenced or implied in the guideline text.)

Page 19 Extracted Terms:
**Key heart‑disease–related terms identified in the guideline excerpt**

1. ASCVD (atherosclerotic cardiovascular disease)  
2. Hard ASCVD endpoint  
3. LDL‑C (low‑density lipoprotein cholesterol)  
4. Statin therapy  
5. High‑intensity statin  
6. Moderate‑intensity statin  
7. Rosuvastatin  
8. Pravastatin  
9. JUPITER (Justification for the Use of Statins in Prevention) trial  
10. 10‑year ASCVD risk  
11. 20‑year ASCVD risk  
12. Cardiovascular mortality  
13. Cardiovascular death  
14. Myocardial infarction (MI)  
15. Coronary revascularization  
16. Primary prevention of cardiovascular disease  
17. Diabetes (type 1 and type 2)  
18. Diabetes‑related ASCVD risk  
19. Hypercholesterolemia (primary severe hypercholesterolemia)  
20. LDL‑C ≥ 190 mg/dL (≥ 4.9 mmol/L)  
21. High‑sensitivity C‑reactive protein (hsCRP)  
22. 7.5 % 10‑year risk threshold (PCE ≥ 7.5 %)  
23. High‑sensitivity CRP ≥ 2.0 mg/L  
24. Global risk  
25. Residual risk  
26. Risk‑enhancing factors (family history of premature ASCVD, elevated hsCRP, lipid‑rich environment)  
27. Lipid‑increasing effect of statins (LDL‑C lowering)  
28. Pooled Cohort Equations (PCE)  
29. Coronary event  
30. Cardiovascular event  

These terms capture the core concepts, risk measures, therapeutic strategies, and patient populations discussed in the cited ACC/AHA guideline for primary prevention of cardiovascular disease.

Page 20 Extracted Terms:
- ASCVD (atherosclerotic cardiovascular disease)  
- Cardiovascular disease  
- Heart disease  
- Primary prevention of cardiovascular disease  
- Statin therapy  
- Elevated lifetime ASCVD risk  
- Metabolic syndrome  
- Psoriasis  
- Rheumatoid arthritis  
- HIV  
- Protease inhibitors  
- Lipoprotein (a)  
- Triglycerides  
- Non‑HDL‑C (total cholesterol – HDL‑C)  
- Apolipoprotein B  
- Coronary artery calcium (CAC)  
- Coronary artery calcium score  
- CAC measurement  
- Risk reclassification  
- Low‑density lipoprotein cholesterol (LDL‑C)  
- Pooled Cohort Equations (PCE)  
- Diabetes mellitus (type 1 and type 2)  
- Diabetes‑specific risk enhancers:  
  - Long duration of diabetes (≥10 yr for T2DM; ≥20 yr for type 1)  
  - Albuminuria (≥30 µg albumin/mg creatinine)  
  - Estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m²  
  - Retinopathy  
  - Neuropathy  
  - Ankle‑brachial index (ABI) < 0.9  
- Family history of premature ASCVD  
- Cigarette smoking  
- Chronic inflammatory conditions  
- Statin‑associated symptoms  
- Risk‑enhancing factors (e.g., elevated lipoprotein (a), metabolic syndrome, inflammatory diseases, HIV, protease inhibitors)

Page 21 Extracted Terms:
- Atherosclerotic cardiovascular disease (ASCVD)  
- Hypertension  
- Blood pressure (BP)  
- Systolic blood pressure (SBP)  
- Diastolic blood pressure (DBP)  
- Antihypertensive medications  
- BP‑lowering medication  
- Nonpharmacological interventions  
- Weight loss  
- Heart‑healthy dietary pattern  
- Sodium reduction  
- Dietary potassium supplementation  
- Physical activity  
- Structured exercise program  
- Alcohol consumption  
- Primary prevention of cardiovascular disease  
- Cardiovascular disease (CVD)  
- Coronary heart disease  
- Stroke  
- Heart failure  
- Chronic kidney disease  
- Type 2 diabetes mellitus (T2DM)  
- 10‑year ASCVD risk  
- ACC/AHA pooled cohort equations  
- Meta‑analysis  
- Randomized controlled trials (RCTs)  
- Mortality (death from stroke, heart disease, or other vascular disease)  
- Modifiable risk factors  
- BP target (<130/80 mmHg)  
- ASCVD event risk


Page 22 Extracted Terms:
- Cardiovascular disease (CVD)  
- Atherosclerotic cardiovascular disease (ASCVD)  
- Primary prevention of cardiovascular disease  
- Hypertension  
- Blood pressure (BP)  
- Systolic blood pressure (SBP)  
- Diastolic blood pressure (DBP)  
- BP‑lowering medications  
- Antihypertensive drug treatment  
- Stroke  
- BP thresholds for treatment  
- Class of recommendation (clinical guideline)  
- Nonpharmacological interventions for hypertension  
- Weight loss / weight reduction  
- Healthy diet  
- DASH dietary pattern (Dietary Approaches to Stop Hypertension)  
- Dietary sodium reduction  
- Dietary potassium intake  
- Physical activity  
- Aerobic exercise  
- Dynamic resistance exercise  
- Isometric resistance exercise  
- Moderation of alcohol intake  
- Cardiovascular risk assessment  
- Normotension (normal blood pressure)

Page 23 Extracted Terms:
- Cardiovascular disease (CVD)  
- Atherosclerotic cardiovascular disease (ASCVD)  
- Hypertension  
- Blood pressure (BP)  
- Systolic blood pressure (SBP)  
- Diastolic blood pressure (DBP)  
- Coronary events  
- Stroke  
- Myocardial infarction (MI)  
- Cardiovascular mortality  
- Tobacco use  
- Smoking cessation 

Page 24 Extracted Terms:
- Atherosclerotic cardiovascular disease (ASCVD)  
- Coronary heart disease (CHD)  
- Myocardial infarction (MI)  
- Stroke  
- Cardiovascular disease (CVD)  
- Cardiovascular risk  
- Hypertension  
- Arrhythmias  
- Electronic nicotine delivery systems (ENDS) – cardiovascular risk  
- Cardiovascular and pulmonary diseases (combined term)

Page 25 Extracted Terms:
- Cardiovascular disease  
- Atherosclerotic cardiovascular disease (ASCVD)  
- Heart failure  
- Myocardial infarction (MI)  
- Arrhythmia  
- Angina  
- Primary prevention  
- Cigarette smoking  
- Tobacco cessation  
- Tobacco dependence  
- Chronic disease management  
- Risk factor (tobacco use)  
- Premature death (associated with ASCVD)

Page 26 Extracted Terms:
- Atherosclerotic cardiovascular disease (ASCVD)  
- Primary prevention of ASCVD  
- Secondary prevention of ASCVD  
- Low‑dose aspirin (75–100 mg daily)  
- Aspirin contraindication (increased bleeding risk)  
- Myocardial infarction (MI)  
- Stroke  
- Atherothrombosis  
- Platelet inhibition (irreversible)  
- Gastrointestinal bleeding  
- Peptic ulcer disease  
- Chronic kidney disease (CKD)  
- Thrombocytopenia  
- Coagulopathy  
- Non‑steroidal anti‑inflammatory drugs (NSAIDs)  
- Steroids  
- Direct oral anticoagulants (DOACs)  
- Warfarin  
- Risk estimators (e.g., Pooled Cohort Equations – PCE)  
- 10‑year ASCVD risk threshold  
- Smoking restrictions in homes and vehicles  
- Second‑hand smoke exposure  
- Electronic nicotine delivery systems (ENDS)  
- Hazard–benefit ratio  
- Cardiovascular disease prevention guidelines (ACC/AHA, European guidelines)  
- Elevated ASCVD risk  
- Antithrombotic therapy  
- Coronary heart disease (implied by ASCVD context)

Page 27 Extracted Terms:
- Atherosclerotic Cardiovascular Disease (ASCVD)  
- Myocardial Infarction (MI)  
- Cardiovascular Disease (CVD)  
- Coronary Artery Calcium Score  
- Prophylactic Aspirin (low‑dose/high‑dose)  
- Bleeding Risk (including gastrointestinal bleeding)  
- Peptic Ulcer Disease  
- Thrombocytopenia  
- Coagulopathy  
- Chronic Kidney Disease (CKD)  
- Non‑steroidal Anti‑inflammatory Drugs (NSAIDs)  
- Steroids  
- Direct Oral Anticoagulants (DOACs)  
- Warfarin  
- Lipid Targets (LDL, HDL, triglycerides)  
- Blood‑Pressure (BP) Targets  
- Glucose Targets (HbA1c)  
- Family History of Premature MI  
- Risk‑Enhancing Factors  
- High‑Risk ASCVD  
- Low‑Risk ASCVD  
- Age (≥70 years, <40 years)  
- Body Weight (low‑weight vs high‑weight)  
- Risk‑Benefit Ratio of Aspirin  
- Cost‑Effectiveness / Value in Cardiovascular Care  

These terms capture the primary concepts related to heart disease addressed in the guideline excerpt.

Page 28 Extracted Terms:
- ASCVD (Atherosclerotic Cardiovascular Disease)  
- CVD (Cardiovascular Disease)  
- Coronary artery calcium measurement  
- Antihypertensive therapy  
- Statin therapy (cholesterol‑lowering therapy)  
- Primordial prevention  
- Primary prevention  
- Cardiovascular risk factors  
- Tobacco avoidance  
- Brisk physical activity  
- Healthy dietary pattern  
- Trans fats  
- Added sugars  
- Sugar‑sweetened beverages  
- Red meats  
- Sodium  
- Saturated fats  
- Lipid‑lowering medication  
- Risk‑enhancing factors  
- Quantitative risk estimation  
- Absolute risk of future ASCVD event  
- Cost‑effectiveness analysis  
- Quality‑adjusted life‑years (QALYs)  
- Social determinants of ASCVD risk  
- Health literacy  
- Lifestyle improvements (diet, exercise, smoking cessation)

Page 29 Extracted Terms:
**Key heart‑disease related terms extracted from the text**

- ASCVD (Atherosclerotic cardiovascular disease)
- Atherosclerotic cardiovascular disease prevention
- AHA (American Heart Association)
- ACC (American College of Cardiology)
- American College of Cardiology/American Heart Association (ACC/AHA) Guideline
- American College of Cardiology/American Heart Association Task Force
- Primary prevention of cardiovascular disease
- Cardiovascular disease
- Cardiovascular health
- Coronary heart disease
- Heart disease
- Hypertension
- Blood pressure
- High blood pressure
- Blood cholesterol
- Cholesterol management
- Lipid management
- Ideal cardiovascular health
- Risk factors for cardiovascular disease
- Mortality (cardiovascular mortality)
- Morbidity (cardiovascular morbidity)
- Behavioral risk factors
- Protective factors
- Patient‑centered approaches
- Comprehensive ASCVD prevention
- Team‑based care
- Pharmacist interventions in cardiovascular care
- Diabetes care (as a cardiovascular risk modifier)
- Class of recommendation
- Level of evidence
- Evidence‑based guidelines
- Clinical practice guidelines
- Systematic review
- Meta‑analysis
- Statin therapy (implicitly referenced in cholesterol management)

Page 30 Extracted Terms:
- Cardiovascular disease  
- Heart disease  
- Hypertension  
- Blood pressure  
- Blood pressure control  
- Blood pressure management  
- Atherosclerotic cardiovascular disease  
- Myocardial infarction  
- Stroke  
- Cardiometabolic disease  
- Coronary artery disease  
- Heart failure  
- Lipid management / Dyslipidemia  
- Cholesterol  
- LDL cholesterol  
- HDL cholesterol  
- Triglycerides  
- Hyperlipidemia  
- Prevention of cardiovascular disease  
- Primary prevention of cardiovascular disease  
- Secondary prevention of cardiovascular disease  
- Cardiovascular risk  
- Cardiovascular risk assessment  
- Cardiovascular risk score  
- Atherosclerotic cardiovascular disease risk score  
- Framingham risk score  
- Risk factor modification  
- Lifestyle modification  
- Physical activity  
- Sedentary behavior  
- Dietary patterns  
- Obesity  
- Body mass index (BMI)  
- Overweight  
- Body size misperception  
- Sleep disturbances / sleep deficiency  
- Health literacy  
- Social determinants of health  
- Built environment  
- Neighborhood environment  
- Health disparities / health inequalities  
- Advanced practice providers  
- Team‑based care  
- Shared decision‑making  
- Patient activation  
- Medication adherence  
- Glycemic control (in type 2 diabetes)  
- Preventive cardiology  
- Clinical guidelines on cardiovascular disease  
- Lifestyle interventions for cardiovascular health  
- Cardiovascular disease outcomes  
- Cardiovascular disease prevention strategies  
- Cardiovascular disease risk reduction  

*(Listed as key terms relevant to heart disease extracted from the provided clinical guideline references.)*

Page 31 Extracted Terms:
- ACC/AHA  
- 2019 ACC/AHA Guideline on Primary Prevention of Cardiovascular Disease  
- 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APH/ASPC/NLA/PCNA Guideline on Blood Cholesterol Management  
- 2013 ACC/AHA Guideline on Treatment of Blood Cholesterol  
- ASCVD (Atherosclerotic Cardiovascular Disease)  
- Cardiovascular disease (CVD)  
- Cardiovascular risk assessment  
- Coronary artery calcium (CAC) score  
- Coronary heart disease (CHD)  
- Coronary artery disease (CAD)  
- Myocardial infarction (MI)  
- Angina pectoris  
- Atherosclerosis  
- Chronic disease risk behaviors  
- Lipids (total cholesterol, LDL, HDL, triglycerides)  
- Low‑density lipoprotein (LDL)  
- High‑density lipoprotein (HDL)  
- Non‑HDL cholesterol  
- C‑reactive protein (CRP)  
- Statins (e.g., rosuvastatin, atorvastatin)  
- Statin eligibility  
- Lifespan risk of cardiovascular disease  
- Lifetime risk of cardiovascular disease  
- 10‑year ASCVD risk calculator  
- Multi‑Ethnic Study of Atherosclerosis (MESA)  
- Framingham Risk Score  
- ESC guidelines (European Society of Cardiology)  
- Coronary artery calcium zero (CAC=0) as negative risk marker  
- Traditional cardiovascular risk factors  
- Family history of premature coronary heart disease  
- Pre‑eclampsia  
- Preterm delivery  
- Early menopause  
- Erectile dysfunction as a cardiovascular predictor  
- HIV infection and cardiovascular risk  
- Rheumatoid arthritis and cardiovascular events  
- Systemic lupus erythematosus (SLE) and myocardial infarction  
- Smoking cessation guidelines  
- Diabetes mellitus type 2 and cardiovascular risk  
- Glycaemic control  
- Insomnia and risk of cardiovascular disease  
- Social engagement and chronic disease risk  
- Psychological status and cardiovascular health  
- Multimorbidity  
- Risk prediction functions  
- Coronary artery calcium versus age in older adults  
- Negative risk markers (e.g., CAC=0)  
- Non‑traditional risk markers  
- Risk factor burden at age 50  
- Risk factor burden at age 70  
- Coronary artery calcium imaging  
- Cardiovascular health outcomes in astronauts (AstroCHARM)  
- Guideline‑based statin eligibility evaluation  
- Coronary artery calcium prevalence and prognostic implications  
- BioImage Study (personalized statin allocation)  
- Coronary artery calcium improvement of risk assessment  
- Coronary artery calcium score interpretation  
- Coronary calcification in low‑risk women  
- Coronatory artery calcium as a prognostic tool  
- Coronary calcium scoring in asymptomatic individuals  
- Coronary artery calcium and longevity  
- Coronary artery calcium in African American individuals  
- Coronary artery calcium in Asian Americans  
- Coronary artery calcium in different ethnicities  
- Cardiovascular disease risk calculators  
- ASCVD risk prediction models  
- Coronary artery calcium and statin therapy initiation  
- Coronary artery calcium and lifestyle preventive therapies  
- Coronary artery calcium and statin allocation  
- Coronary artery calcium as a determinant of future cardiovascular events  
- Cardiovascular disease outcomes in the Jackson Heart Study  
- Coronary artery calcium and treatment decisions  
- Cardiovascular health promotion series  
- Coronary artery calcium and clinical decision making.

Page 32 Extracted Terms:
- Cardiovascular disease (CVD)  
- Atherosclerotic cardiovascular disease (ASCVD)  
- Primary prevention of CVD  
- Secondary prevention of CVD  
- Cardiovascular risk prediction / risk assessment  
- Pooled cohort equations (ACC/AHA)  
- Framingham risk score / study  
- Reynolds risk score  
- European Society of Cardiology (ESC/EAS) guidelines  
- American College of Cardiology / American Heart Association (ACC/AHA) guidelines  
- Joint British Societies (JBS3) consensus  
- Canadian Cardiovascular Society dyslipidaemia guidelines  
- US Preventive Services Task Force recommendations (aspirin, statin use)  
- Statin therapy / statin prescribing  
- Aspirin use for primary prevention  
- Dyslipidemia management  
- Lipid goals (LDL‑C, HDL‑C, triglycerides)  
- Coronary artery calcium (CAC) scoring  
- Coronary artery calcium testing guidance  
- Hypertension / blood pressure management  
- Lifestyle modification (diet, exercise, smoking cessation)  
- Mediterranean diet (extra‑virgin olive oil, nuts)  
- Plant‑based diets  
- Diet quality (nutrient composition, fiber)  
- C‑reactive protein (CRP) as a risk marker  
- Risk factor clustering (age, sex, smoking, diabetes, hyperlipidemia, hypertension)  
- Socioeconomic position / social deprivation status  
- Race/ethnicity related risk variation  
- Gender‑specific risk models  
- Revascularization (PCI, CABG)  
- Global cardiovascular risk (e.g., Reynolds score)  
- Risk factor algorithms for specific populations (e.g., Veterans Affairs, Women’s Health Initiative, China‑PAR, Korean risk model)  
- Prevention strategies in specialty populations (rheumatoid arthritis, diabetes)  
- Cardiovascular outcomes (myocardial infarction, stroke, heart failure)  
- Clinical decision tools (e.g., clinical risk calculators, calculators embedded in electronic health records)  
- Risk prediction performance (validity, calibration, discrimination)  
- Risk score recalibration / customization  
- Evidence‑based guideline implementation  
- Prevention of cardiovascular disease in adults  

These terms capture the key concepts related to heart disease and cardiovascular disease prevention and management that are referenced throughout the provided guideline citations.

Page 33 Extracted Terms:
- Heart disease  
- Cardiovascular disease  
- Coronary heart disease  
- Myocardial infarction  
- Stroke  
- Ischemic heart disease  
- Ischemic stroke  
- Cardiovascular mortality  
- Cardiometabolic health  
- Trans fatty acids (risk factor for heart disease)  
- Dietary sodium (risk factor for heart disease)  
- Added sugar (risk factor for heart disease)  
- Red and processed meat (risk factor for heart disease)  
- Long‑chain n‑3 polyunsaturated fatty acids (protective factor for heart disease)  
- Pro‑vegetarian food pattern (protective factor for heart disease)  

Page 34 Extracted Terms:
- Cardiovascular disease  
- Heart disease  
- Cardiovascular disease prevention  
- Coronary heart disease  
- Coronary artery disease  
- Stroke  
- Ischemic heart disease  
- Heart failure  
- Atrial fibrillation  
- Hypertension  
- Type 2 diabetes mellitus  
- Metabolic syndrome  
- Obesity  
- Overweight  
- Central obesity (waist circumference, waist‑hip ratio)  
- Body mass index (BMI)  
- Bariatric surgery (gastric bypass, sleeve gastrectomy, adjustable gastric banding)  
- Intensive lifestyle intervention (diet, exercise)  
- Physical activity  
- Aerobic training  
- Resistance training (strength training)  
- Isometric exercise  
- Sedentary behaviour  
- Subclinical coronary artery disease  
- Acute cardiovascular events  
- Cardiovascular morbidity  
- Cardiovascular mortality  
- Cardiometabolic health  
- Cardiovascular disease risk factors  
- ACC/AHA primary‑prevention guidelines  
- European society of cardiology cardiovascular‑disease‑prevention guidelines  
- American Heart Association/ACC guidelines on obesity and overweight  
- WHO guidelines on body‑mass index for Asian populations  
- American Heart Association scientific statements on physical activity in health care settings  
- American Heart Association Council on nutritional, physical activity, and metabolism  
- American Heart Association Council on clinical cardiology  
- American Heart Association task force on practice guidelines  
- American College of Cardiology/Heart Association task force on obesity  
- American College of Cardiology/Heart Association task force on type 2 diabetes prevention  
- National Physical Activity Plan (American Heart Association)

Page 35 Extracted Terms:
- Cardiovascular disease  
- Coronary artery disease  
- Coronary heart disease  
- Cardiovascular risk  
- Cardiovascular outcomes  
- Heart disease  
- Stroke  
- Acute coronary events  
- Vascular events  
- High blood cholesterol  
- LDL cholesterol  
- Statin therapy  
- Rosuvastatin  
- Lovastatin  
- Simvastatin  
- Ezetimibe  
- Empagliflozin  
- Dapagliflozin  
- Canagliflozin  
- Liraglutide  
- Semaglutide  
- Albiglutide  
- GLP‑1 receptor agonist  
- C‑reactive protein

Page 36 Extracted Terms:
- Coronary artery calcium score  
- Statin therapy  
- Familial hypercholesterolemia  
- Low‑density lipoprotein cholesterol (LDL‑C)  
- High‑density lipoprotein cholesterol (HDL‑C)  
- Apolipoprotein B  
- Lipoprotein(a)  
- Atherosclerotic cardiovascular disease (ASCVD)  
- Coronary heart disease (CHD)  
- Cardiovascular disease (CVD)  
- Primary prevention of cardiovascular disease  
- Cardiovascular risk assessment  
- Cardiovascular risk scores (e.g., Framingham, ACC/AHA)  
- High‑intensity statin therapy  
- Cholesterol‑lowering interventions  
- Metabolic syndrome  
- Type 2 diabetes mellitus  
- Type 1 diabetes mellitus  
- Myocardial infarction (MI)  
- Acute coronary syndrome (ACS)  
- Dyslipidemia  
- Elevated high‑sensitivity C‑reactive protein (hs‑CRP)  
- Psoriasis (as a cardiovascular risk factor)  
- Human immunodeficiency virus (HIV) (as a cardiovascular risk factor)  
- Coronary artery disease (CAD)  
- Coronary artery calcium (CAC) testing  
- Statin eligibility criteria  
- Coronary artery plaque  
- Lipid‑lowering agents (e.g., pravastatin, atorvastatin, rosuvastatin, simvastatin)  
- Coronary artery calcium reclassification  
- Cardiovascular event risk  
- Cardiovascular mortality  
- Risk discrimination  
- Risk calibration  
- Lifestyle preventive therapies  
- Calibrated risk scores  
- Clinical utility of genetic sequencing (e.g., FH genes)  
- Emerging lipid‑lowering therapies  
- Cardiovascular risk stratification in multi‑ethnic cohorts.

Page 37 Extracted Terms:
**Key heart‑disease related terms extracted from the provided text**

- Coronary artery disease  
- Cardiovascular disease (CVD)  
- Atherosclerosis  
- Coronar​ry artery calcium (CAC)  
- CAC score  
- Statin eligibility / statin therapy  
- Cholesterol / dyslipidemia  
- Primary prevention  
- Risk stratification  
- Non‑traditional risk markers  
- C‑reactive protein (CRP)  
- Family history of coronary heart disease  
- Coronary heart disease (CHD)  
- Myocardial infarction (MI)  
- Peripheral arterial disease (PAD)  
- Peripheral neuropathy  
- Diabetic retinopathy  
- Diabetes mellitus (type 2)  
- Albuminuria / renal function as CVD predictors  
- Stroke / cerebrovascular disease  
- Hypertension / high blood pressure  
- Sodium intake / sodium reduction  
- Potassium intake / potassium supplementation  
- DASH diet (Dietary Approaches to Stop Hypertension)  
- Exercise training / aerobic exercise  
- Isometric exercise training  
- Lifestyle modification  
- Weight loss / weight reduction  
- Blood pressure management  
- Clinical guidelines (ACC/AHA, ESC, AHA/ACC)  
- Trial of Hypertension Prevention (THP)  
- PREMIER trial  
- Global sodium consumption  
- Renin‑angiotensin‑aldosterone system (RAS) effects  
- Lipid profile (cholesterol, triglycerides)  

These terms capture the central concepts related to heart disease discussed in the cited guidelines and studies.

Page 38 Extracted Terms:
- Blood pressure  
- Hypertension  
- Systolic blood pressure  
- Diastolic blood pressure  
- Intensive blood pressure lowering  
- Standard blood pressure control  
- Antihypertensive treatment  
- Blood pressure lowering drugs  
- SPRINT study  
- ACC/AHA guideline  
- DASH diet  
- Exercise  
- Resistance training  
- Alcohol consumption  
- Alcohol reduction  
- Chronic kidney disease  
- Renal disease  
- Proteinuria  
- Protein restriction  
- Angiotensin‑converting enzyme inhibition  
- AASK trial  
- REIN‑2 trial  
- Type 2 diabetes mellitus  
- Diabetes  
- Left ventricular hypertrophy  
- Cardiovascular disease  
- Coronary heart disease  
- Cardiovascular risk  
- Metabolic risk  
- Lifestyle interventions  
- Diet  
- Weight loss  
- Metabolic syndrome  
- Hypercholesterolemia  
- Hyperlipidemia  
- Smoking  
- Physical activity  
- Lifestyle factors  
- Markov decision analysis  
- Meta‑analysis  
- Systematic review  
- Randomized controlled trial  
- Prospective study  
- Vascular mortality  
- Risk factor management  
- Blood pressure target  
- Microalbuminuria  
- Macroalbuminuria

Page 39 Extracted Terms:
- Cardiovascular disease  
- Primary prevention of cardiovascular disease  
- Blood pressure  
- Cardiovascular biomarkers  
- Hypertension  
- Cardiovascular risk  
- Cardiovascular risk assessment  
- Myocardial infarction  
- Stroke  
- Diabetes mellitus  
- Cardiovascular events  
- Heart failure  
- Coronary artery disease (implied)  
- Tobacco use  
- Smoking cessation  
- Electronic cigarettes  
- Cardiac sympathetic activity  
- Oxidative stress  
- DASH diet  
- Intensive blood‑pressure control  
- Intensive glucose lowering  
- Intensive blood‑pressure reduction  
- Blood‑pressure trajectories  
- Hypertension definition (Seventh Report/JNC7)  
- Cardiovascular disease prevention  
- Antihypertensive medication treatment  
- Intensive blood‑pressure reduction studies  
- Cardiovascular outcomes in diabetes  
- Cardiovascular risk with second‑hand smoke exposure  
- Cardiovascular risk in smokers  
- Cardiovascular risk in e‑cigarette users  

Page 40 Extracted Terms:
- Cardiovascular disease  
- Primary prevention  
- Aspirin  
- Bleeding risk  
- Coronary circulation  
- Cardiovascular events  
- Atherosclerosis / Atherosclerotic cardiovascular disease  
- Heart failure  
- Stroke  
- Peripheral arterial disease  
- Diabetes mellitus  
- Antithrombotic therapy  
- Low‑dose aspirin  
- High‑dose aspirin  
- Acute coronary events  
- Body weight / dose relationship  
- European Society of Cardiology guidelines  
- American Heart Association statements  
- American Diabetes Association position statement

Page 41 Extracted Terms:
**Key heart‑disease related terms extracted from the text**

- Cardiovascular disease  
- Primary prevention of cardiovascular disease  
- Blood‑pressure control  
- Hypertension (HTN)  
- Intensive blood‑pressure management  
- Statin therapy / statin use  
- Coronary heart disease (CHD)  
- Stroke (cerebrovascular disease)  
- Vascular risk levels  
- Cardiovascular events  
- Lifestyle counseling  
- Behavioral counseling  
- Diet/healthy diet  
- Physical activity/exercise  
- Weight‑loss interventions  
- Obesity  
- Glucose control / abnormal glucose  
- Type 2 diabetes mellitus  
- Tobacco cessation  
- Aspirin (for primary prevention)  

These terms capture the key concepts related to heart disease and its prevention that appear in the provided guideline excerpts.

Page 42 Extracted Terms:
**Key terms related to heart disease extracted from the text**

- Cardiovascular  
- Coronary  
- Heart  
- Myocardial infarction (MI)  
- CVD (Cardiovascular Disease)  
- CHD (Coronary Heart Disease)  
- Cerebrovascular  
- Stroke  
- Microvascular  
- Mortality  
- Prevent*  
- Tobacco Use  
- Smoking / cigarette use  
- Electronic Cigarettes / e‑cigarettes / vape / vaping (ENDS)  
- Aspirin (acetylsalicylic acid)  
- Clopidogrel  
- Diet / Diet Therapy (healthy diet)  
- Obesity / Weight Loss (overweight)  
- Type 2 Diabetes Mellitus (diabetes, prediabetes, impaired glucose tolerance)  

These terms collectively capture disease entities, risk factors, preventive therapies, and related interventions discussed in the guideline.

Page 43 Extracted Terms:
- Cardiovascular disease  
- Primary prevention of cardiovascular disease  
- Coronary heart disease (CHD)  
- Atherosclerosis  
- Acute coronary syndrome (ACS)  
- Angina (stable, unstable)  
- Unstable angina  
- Myocardial infarction (MI)  
- ST‑elevation myocardial infarction (STEMI)  
- Non‑ST‑elevation myocardial infarction (NSTEMI)  
- Cardiogenic shock  
- Myocardial stunning  
- No‑reflow phenomenon  
- Sudden cardiac death  
- Heart arrest  
- Stroke (cerebrovascular, brain infarction, brain‑stem infarction)  
- Cerebrovascular disease  
- Hypertension  
- Lipids  
- Cholesterol (hypercholesterolemia)  
- Diabetes mellitus  
- Obesity  
- Smoking  
- Aspirin (antiplatelet therapy)  
- Waist circumference (obesity marker)  
- Exercise & physical activity (modifiable risk factor)  

These terms capture the core diseases, syndromes, risk factors, and related interventions discussed in the guideline excerpts.

Page 44 Extracted Terms:
**Key terms related to heart disease**

- Cerebral Infarction  
- Myocardial ischemia  
- Dementia multi infarct  
- Infarction anterior cerebral artery  
- Infarction middle cerebral artery  
- Infarction posterior cerebral artery  
- Myocardial revascularization  
- Coronary artery bypass  
- Internal mammary coronary artery anastomosis  
- Angioplasty  
- Angioplasty transluminal percutaneous coronary  
- Heart failure (HF)  
- Hospitalization / rehospitalization  
- Atherectomy coronary  
- Coronary stent  
- CABG (coronary artery bypass graft)  
- Bypass grafts  
- Carotid pathology  
- Non‑coronary revascularization procedure  
- Carotid revascularization  
- Lower extremity revascularization  
- Percutaneous transluminal angioplasty (PTA)  
- Stent placement  
- Abdominal aortic aneurysm repair  
- AAA repair  
- Risk score  
- Coronary risk modification  
- Cardiovascular diseases (CVD)  
- Cardiovascular disease  
- Coronary disease  
- Coronary artery disease (CAD)  
- Myocardial infarction (MI)  
- CHF / CHD  
- Cerebrovascular disorders  
- Dyspnea paroxysmal  
- Edema cardiac  
- Exercise test (Graded exercise test / GXT)  
- Lifestyle / exercise / training / walking  
- VO₂ max / maximal metabolic equivalent (METs)  
- Physical activity  
- Acute Coronary Syndrome (ACS)  
- Acute coronary syndromes  
- Angina unstable  
- Cardiogenic shock (shock)  
- Myocardial stunning  
- No‑reflow phenomenon  
- Cardiac arrest  
- ST‑elevation myocardial infarction (STEMI)  
- Non‑ST‑elevation myocardial infarction (NSTEMI)  
- Death / sudden cardiac arrest  
- Stroke  
- Brain infarction / brain stem infarctions  
- Lateral medullary syndrome  

Page 45 Extracted Terms:
- Cardiovascular diseases
- Cardiovascular OR CVD
- Cardiovascular disease
- Coronary disease
- coronary
- Coronary artery disease
- Myocardial infarction
- Heart failure
- CHF OR CHD
- Cerebrovascular disorders
- “dyspnea paroxysmal”
- “edema cardiac”
- physiopathology
- Non‑coronary revascularization procedure
- Carotid revascularization
- Lower extremity revascularization
- Percutaneous transluminal angioplasty
- Stent placement
- Abdominal aortic aneurysm repair
- AAA repair
- complications
- Event? OR outcome? OR episode?
- Risk score
- Coronary risk modification

Page 46 Extracted Terms:
**Key terms related to heart disease**

- ACC/AHA Guideline  
- Primary Prevention  
- Cardiovascular Disease (CVD)  
- Heart Disease  
- Prevention of Heart Disease  
- Cardiology  
- Preventive Cardiology  
- Cardiologist / Cardiologists  
- Cardiac  
- Cardiac Disease  
- Coronary Artery Disease (CAD)  
- Heart Failure  
- Hypertension  
- Dyslipidemia  
- Diabetes / Diabetes Mellitus  
- Statins  
- Blood Pressure (BP)  
- Lifestyle Modification  
- Physical Activity / Exercise  
- Smoking Cessation  
- Nutrition / Diet  
- Cardiovascular Risk Assessment  
- Risk Factors  
- Framingham Risk Score  
- ASCVD Risk Calculator  
- Lipid Management  
- Lipids  
- LDL‑C / LDL  
- HDL‑C / HDL  
- Triglycerides  
- Atherosclerosis  
- Plaque  
- Endothelial Function  
- Inflammation  
- Biomarkers (e.g., hs‑CRP)  
- Systolic Blood Pressure  
- Diastolic Blood Pressure  
- Blood Glucose / HbA1c  
- Weight Management / Obesity  
- Sleep Apnea  
- Mediterranean Diet  
- DASH Diet  
- Non‑invasive Imaging  
- Stress Test  
- Coronary CT Angiography  
- Echocardiography  
- Cardiac Catheterization  
- Heart Rate Control  
- β‑Blockers  
- ACE Inhibitors  
- Angiotensin‑Receptor Blockers (ARBs)  
- Calcium Channel Blockers  
- Antiplatelet Therapy (e.g., Aspirin, Clopidogrel)  
- PCSK9 Inhibitors  
- Bile Acid Sequestrants  
- Fibrates  
- Niacin  
- Lipoprotein(a) / Lp(a)  
- Apolipoprotein B  
- LDLR  
- Cardiovascular Risk Algorithm  
- Prevention Guidelines  
- Clinical Statements  
- Evidence Grade / Recommendation Level  
- Implementation Strategies  
- Physician Education / Patient Education  
- Shared Decision‑Making  
- Multidisciplinary Care  
- Cardiovascular Institute / Prevention Program  
- Quality Improvement / Performance Measures  
- Health Policy / Quality Metrics  


These terms capture the principal concepts and interventions associated with heart disease prevention and care as referenced throughout the guideline and author affiliations.

Page 47 Extracted Terms:
Cardiovascular disease  
Primary prevention of cardiovascular disease  
Cardiology  
Heart disease  
Cardiovascular risk  
Cardiovascular medications  
Cardiopulmonary arrest  
Out‑of‑hospital cardiovascular event  
ACC/AHA  
AHA  
Cleveland Heart Lab  
Tendyne  
Athersys  
Cardiovascular device  
Cardiovascular therapy  
Coronary artery disease  
Heart failure  
Myocardial infarction  
Arrhythmia  
Stroke  
Percutaneous coronary intervention (PCI)  
Coronary artery bypass grafting (CABG)  
Implantable cardioverter‑defibrillator (ICD)  
Cardiac resynchronization therapy (CRT)  
Transcatheter aortic valve replacement (TAVR)  
Heart valve replacement  
Cardiomyopathy  
Angina  
Hypertension  
Dyslipidemia  
Diabetes mellitus



Page 48 Extracted Terms:
- Cardiovascular Disease  
- Heart Disease  
- Heart Failure  
- Cardiac Electrophysiology  
- Primary Prevention of Cardiovascular Disease  
- Cardiovascular Prevention  
- Cardiology  
- Cardiovascular Medicine  
- ACC/AHA Guideline  
- American Heart Association  
- American College of Cardiology  
- Heart Failure Society of America  
- Cardiovascular Division  
- Cardiovascular Research  
- Cardiovascular Health  
- Cardiovascular Epidemiology  
- Cardiovascular Risk Factors  
- Cardiovascular Outcomes  
- Cardiovascular Management  
- Cardiovascular Screening  

Page 49 Extracted Terms:
- ACC/AHA  
- Primary Prevention  
- Cardiovascular Disease  
- Heart Disease  
- Cardiology  
- Cardiovascular Medicine  
- Cardiac Rehabilitation  
- Nuclear Cardiology  
- American Heart Association  
- American Society of Nuclear Cardiology  
- National Heart, Lung, and Blood Institute (NHLBI)  
- Cardiovascular Research  
- Cardiac Prevention  
- Cardiovascular Disease Prevention  
- Cardiac Rehabilitation and Prevention  
- Cardiovascular Health  
- Heart Failure (inferred from cardiology focus)

Page 50 Extracted Terms:
- Cardiovascular disease  
- Heart disease  
- Primary prevention of cardiovascular disease  
- ACC/AHA guideline  
- Cardiologic / cardiology  
- Cardiovascular disease prevention  
- Lipid disorders  
- LDL‑C (low‑density lipoprotein cholesterol)  
- Atherosclerosis  
- Lipid metabolomics  
- Advanced lipid disorders program  
- Cardiovascular disease fellowship program  
- Cardiovascular disease (in clinical statements and guidelines)

Page 51 Extracted Terms:
- Cardiovascular disease  
- Primary prevention of cardiovascular disease  
- Heart disease  
- Cardiovascular imaging  
- Cardiac computed tomography (Cardiac CT)  
- Preventive cardiology  
- Low‑density lipoprotein cholesterol (LDL‑C)  
- National Heart, Lung, and Blood Institute (NHLBI)  
- American College of Cardiology (ACC)  
- American Heart Association (AHA)  
- ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease  
- Cardiovascular computed tomography  
- Cardiac imaging modalities  
- Clinical statements and guidelines related to cardiovascular disease  
- Cardiovascular disease prevention  

These terms capture the key cardiovascular/heart disease concepts referenced in the provided text.



Page 1 Extracted Terms:
- anticoagulation therapy  
- aortic regurgitation  
- aortic stenosis  
- bicuspid aortic valve  
- cardiac surgery  
- guidelines  
- infective endocarditis  
- mitral regurgitation  
- mitral stenosis  
- mitral transcatheter edge-to-edge repair  
- prosthetic valve  
- pulmonic regurgitation  
- pulmonic stenosis  
- transcatheter aortic valve replacement or implantation  
- tricuspid regurgitation  
- tricuspid stenosis  
- valvular heart disease

Page 2 Extracted Terms:
- Valvular Heart Disease  
- Aortic Stenosis  
- Aortic Regurgitation  
- Bicuspid Aortic Valve  
- Mitral Stenosis  
- Mitral Regurgitation  
- Tricuspid Valve Disease  
- Tricuspid Regurgitation  
- Pulmonic Valve Disease  
- Mixed Valve Disease  
- Prosthetic Valves  
- Antithrombotic Therapy  
- Bridging Therapy  
- Anticoagulation for Atrial Fibrillation in Valve Disease  
- Infective Endocarditis Prophylaxis  
- Valve Prosthesis Selection (Bioprosthetic vs Mechanical)  
- Prosthetic Valve Thrombosis  
- Prosthetic Valve Stenosis  
- Prosthetic Valve Regurgitation  
- Valve Disease Severity Assessment  
- Multidisciplinary Heart Valve Team  
- Diagnostic Testing (e.g., Echocardiography, Cardiac Catheterization)  
- Timing of Valve Intervention  
- Medical Therapy for Valve Disease  
- Secondary Prevention of Rheumatic Fever  
- Acute Mitral Regurgitation  
- Chronic Primary Mitral Regurgitation  
- Chronic Secondary Mitral Regurgitation  
- Acute Aortic Regurgitation  
- Chronic Aortic Regurgitation  
- Rheumatic Mitral Stenosis  
- Nonrheumatic Calcific Mitral Stenosis  
- Surgical and Transcatheter Interventional Risk Evaluation  
- Routine Follow‑Up Imaging after Valve Intervention  

Page 3 Extracted Terms:
- Valvular Heart Disease (VHD)  
- Infective Endocarditis  
- Aortic Stenosis  
- Aortic Regurgitation  
- Mitral Stenosis  
- Mitral Regurgitation  
- Tricuspid Regurgitation  
- Pulmonary Regurgitation (if applicable)  
- Coronary Artery Disease (CAD) in VHD patients  
- Transcatheter Aortic Valve Implantation (TAVI)  
- Surgical valve replacement/repair  
- Valve surgery  
- Atrial Fibrillation (AF) in VHD  
- Oral anticoagulation therapy  
- Vitamin K antagonist (e.g., warfarin)  
- Non‑vitamin K antagonist oral anticoagulants (NOACs)  
- CHA₂DS₂‑VASc score  
- Valve intervention (timing, type, approach)  
- Mechanical prosthetic heart valves  
- Bioprosthetic (tissue) valves  
- Multidisciplinary valve team  
- Primary Valve Center  
- Comprehensive Valve Center  
- Transcatheter edge‑to‑edge mitral repair (MitraClip)  
- Isolated tricuspid regurgitation surgery  
- Pregnancy in VHD (management/anticoagulation)  
- Stages of valve disease (A, B, C, D)  
- Noncardiac surgery in VHD patients  
- Symptomatic vs. asymptomatic patient management  
- Prevention of valve disease  
- Disease progression therapy  
- Optimal timing of intervention  
- Imaging modalities: ECG, chest X‑ray, TTE, CT, CMR, stress testing, TEE, cardiac catheterization  
- Ventricular systolic function assessment  
- Left ventricular volume overload  
- Stroke prevention in AF/VHD  

These terms capture the core concepts and clinical focus areas discussed in the guideline text.

Page 4 Extracted Terms:
- Valvular heart disease  
- Cardiac valve dysfunction  
- Bioprosthetic valve dysfunction  
- Bioprosthetic leaflet degeneration  
- Valve thrombosis  
- Prosthetic valve dysfunction  
- Paravalvular leak  
- Right ventricular dysfunction  
- Cardiovascular disease  
- End‑organ damage (liver and kidney)  
- Cardiovascular health  
- Bioprosthetic valve  
- Valve degeneration  
- Cardiovascular care (clinical context)

Page 5 Extracted Terms:
- Valvular heart disease  
- Aortic stenosis  
- Aortic regurgitation  
- Bicuspid aortic valve  
- Mitral stenosis  
- Mitral regurgitation  
- Tricuspid stenosis  
- Tricuspid regurgitation  
- Pulmonic stenosis  
- Pulmonic regurgitation  
- Prosthetic valves  
- Anticoagulation therapy  
- Infective endocarditis  
- Cardiac surgery  
- Transcatheter aortic valve replacement  
- Transcatheter aortic valve implantation  
- Percutaneous mitral clip  

Page 6 Extracted Terms:
- Valvular Heart Disease  
- Aortic Valve Stenosis (AS)  
- Aortic Regurgitation (AR)  
- Bicuspid Aortic Valve (BAV)  
- Mitral Regurgitation  
- Tricuspid Regurgitation  
- Atrial Fibrillation (AF)  
- Heart Failure (HF)  
- Hypertrophic Cardiomyopathy  
- Infective Endocarditis (IE)  
- Congenital Heart Disease  
- Prosthetic Valve  
- Percutaneous Valve Repair / Replacement  
- Coronary Artery Disease (CAD)  
- Coronary Artery Bypass Graft (CABG)  
- Angiotensin‑Converting Enzyme (ACE) Inhibitors  
- Angiotensin Receptor Blockers (ARB)  
- B‑Type Natriuretic Peptide (BNP)  
- Low‑Molecular‑Weight Heparin (LMWH)  
- International Normalized Ratio (INR)  
- Activated Partial Thromboplastin Time (aPTT)  
- Electrocardiogram (ECG)  
- Computed Tomography (CT)  
- Cardiac Magnetic Resonance Imaging (CMR)  
- Echocardiography (2‑D & 3‑D)  
- Doppler Echocardiography  
- Guideline‑Directed Medical Therapy (GDMT)  

**Key Guideline Terms**  
- ACC/AHA Guideline for the Management of Valvular Heart Disease  
- ACC/AHA/ESC Guidelines for Atrial Fibrillation  
- ACCF/AHA Guideline for the Management of Heart Failure  
- ESC/EACTS Guidelines on Valvular Heart Disease  
- ESC/EAC Guidelines for Congenital Heart Disease  
- ACCP Antithrombotic and Thrombolytic Therapy for Valvular Disease

Page 7 Extracted Terms:
- Valvular heart disease (VHD)  
- Valvular lesions/valve dysfunction  
- Heart murmur  
- Electrocardiogram (ECG)  
- Chest X‑ray  
- Transthoracic echocardiography (TTE)  
- Transesophageal echocardiography (TEE)  
- Computed tomography (CT)  
- Cardiac magnetic resonance (CMR) imaging  
- Positron emission tomography (PET)  
- Holter monitoring  
- Diagnostic hemodynamic cardiac catheterization  
- Transcatheter aortic valve implantation (TAVI)  
- Surgical aortic valve replacement (SAVR)  
- Transcatheter edge‑to‑edge repair (TEER)  
- Valve‑in‑valve (ViV) procedures  
- Mitral regurgitation (MR)  
- Mitral stenosis (MS)  
- Tricuspid regurgitation (TR)  
- Atrial fibrillation (AF)  
- Pulmonary hypertension  
- Stroke (as a VHD‑related complication)  
- Left ventricle (LV)  
- Right ventricle (RV)  
- Left ventricular ejection fraction (LVEF)  
- Left ventricular end‑diastolic dimension (LVEDD)  
- Left ventricular end‑systolic dimension (LVESD)  
- NYHA functional class  
- Non‑vitamin K oral anticoagulant (NOAC)  
- Vitamin K antagonist (VKA)  
- Unfractionated heparin (UFH)  
- Percutaneous coronary intervention (PCI)  
- Percutaneous mitral balloon commissurotomy (PMBC)  
- Randomized controlled trial (RCT)  
- Multidisciplinary team (MDT)  
- Level of Evidence (LOE)  
- Stages A–D of VHD progression  
- Symptom evaluation (e.g., dyspnea, chest pain)  
- Valve anatomy and hemodynamics assessment  
- Ventricular and vascular function impact  
- End‑organ damage criteria  
- Surgical or transcatheter intervention criteria  
- Periodic monitoring and patient education  
- Comorbidities, frailty, patient preferences, and values.

Page 8 Extracted Terms:
- TTE (transthoracic echocardiography)  
- Valve anatomy  
- Valve disease  
- Aortic dilation  
- Left ventricular (LV) anatomy  
- Linear dimensions  
- 2D volumes  
- 3D volumes  
- Ejection fraction (LVEF)  
- Sequential studies  
- Measurement variability  
- Doppler echocardiography  
- Valve hemodynamics  
- Stenotic lesions  
- Maximum velocity  
- Mean gradient  
- Valve area  
- Regurgitant lesions  
- Regurgitant orifice area  
- Regurgitant volume  
- Regurgitant fraction  
- Multiparameter severity grade  
- Color Doppler imaging  
- Continuous‑wave Doppler  
- Pulsed‑wave Doppler  
- Distal flow reversals  
- Pulmonary systolic pressure  
- Right ventricular (RV) size  
- Right ventricular function  
- Stress testing  
- TEE (transesophageal echocardiography)  
- Cardiac catheterization  
- CT imaging  
- CMR imaging  
- Cardiac imaging  
- Hemodynamics  
- Echocardiography (as primary evaluation tool)  
- Valvular heart disease (VHD)  
- ACC/AHA guideline for valvular heart disease  
- Intersocietal Accreditation Commission (IAC) accreditation  
- Class of Recommendation and Level of Evidence (clinical strategies, interventions, treatments, or diagnostic testing)

Page 9 Extracted Terms:
- Valvular Heart Disease (VHD)  
- Transthoracic Echocardiography (TTE)  
- Transesophageal Echocardiography (TEE)  
- Cardiac Magnetic Resonance (CMR)  
- Positron Emission Tomography–Computed Tomography (PET‑CT)  
- Stress Testing (exercise treadmill, stress echo)  
- Cardiac Catheterization  
- Echocardiographic Strain Imaging (TTE strain)  
- Pulmonary Circulation  
- Ventricular Response  
- Left Ventricular Function  
- Heart Failure (HF)  
- Electrocardiogram (ECG)  
- Biomarkers (filling pressures, myocardial damage)  
- Intracardiac Pressures  
- Valve Morphology  
- Valve Severity  
- Valve Deterioration  
- Progressive Valve Dysfunction  
- Volume Overload  
- Pressure Overload  
- Aortic Disease  
- Intracardiac Mass  
- Intracardiac Abscess  
- Left Atrial Thrombus  
- Fibrosis (gadolinium enhancement)  
- Frailty Score  
- Surgical Risk (STS Score)  
- Transcatheter Aortic Valve Implantation (TAVI)  
- Coronary Angiography (CT or invasive)  
- Peripheral Access (CT Peripheral)  
- Cardiac CT (CT Cardiac)  
- Dental Examination (infection source)  
- Chest X‑ray  
- History and Physical Examination  
- Symptom Status  
- Physical Examination  
- Stages C2 and D Disease  
- Interventional Candidates  
- Clinical Follow‑up Schedule  
- Intrinsic Myocardial Performance  
- Prognostic Markers  
- Risk Stratification  
- Timing of Intervention

Page 10 Extracted Terms:
Valvular heart disease (VHD)  
Hemodynamic catheterization  
Transvalvular pressure gradients  
Cardiac output measurement  
Valvular stenosis  
Valve regurgitation  
Doppler beam alignment/velocity jet  
Contrast angiography  
Pulmonary vascular resistance  
Dobutamine infusion (low‑flow states)  
Pulmonary vasodilators  
Pulmonary hypertension  
Exercise hemodynamics  
Exercise stress testing  
Exercise capacity assessment  
Blood pressure response to exercise  
Prognostic value in asymptomatic valve disease  
Standard guideline‑directed medical therapy (GDMT)  
Hypertension  
Diabetes mellitus  
Hyperlipidemia  
Heart‑healthy lifestyle factors  
Aerobic exercise  
Left ventricular (LV) afterload  
Resistive training with light weights  
Risk factors for development of VHD  
Stage A: At risk (risk factors present)  
Stage B: Progressive (mild‑to‑moderate, asymptomatic)  
Stage C1: Asymptomatic severe, LV/RV compensated  
Stage C2: Asymptomatic severe, LV/RV decompensation  
Stage D: Symptomatic severe  
Left ventricle (LV)  
Right ventricle (RV)  
Aortic stenosis (AS)  
Aortic regurgitation (AR)  
Mitral stenosis (MS)  
Mitral regurgitation (MR)  
Maximum velocity (Vmax)  
Mitral valve (MV) area  
Serial echocardiographic surveillance intervals (3–5 y, 1–2 y, 6–12 mo, 1 yr)

Page 11 Extracted Terms:
- Valvular heart disease (VHD)  
- Left ventricular (LV) systolic dysfunction  
- Guideline‑directed medical therapy (GDMT)  
- Diuretics  
- Angiotensin‑converting enzyme (ACE) inhibitors  
- Angiotensin receptor blockers (ARBs)  
- Beta blockers  
- Aldosterone antagonists  
- Sacubitril/valsartan  
- Biventricular pacing  
- Heart failure (HF)  
- Stenotic valve lesions  
- Abrupt lowering of blood pressure  
- Rheumatic fever prophylaxis  
- Infective endocarditis (IE) prophylaxis  
- Oral health maintenance  
- Influenza vaccination  
- Pneumococcal vaccination  
- Atrial fibrillation (AF)  
- Anticoagulation therapy  
- Rheumatic heart disease  
- Strep A pharyngitis (group A streptococcus)  
- Antibiotic prophylaxis  
- Dental procedures (gingival manipulation, periapical manipulation, mucosal perforation)  
- Prosthetic cardiac valves  
- Transcatheter‑implanted prostheses  
- Homografts  
- Prosthetic material for valve repair (annuloplasty rings, chords, clips)  
- Previous infective endocarditis (IE)  
- Unrepaired cyanotic congenital heart disease  
- Repaired congenital heart disease with residual shunts or valvular regurgitation  
- Prosthetic patch or prosthetic device  
- Cardiac transplant with valve regurgitation caused by an abnormal valve  
- Non‑dental invasive procedures (transthoracic/ transesophageal echocardiography, esophagogastroduodenoscopy, colonoscopy, cystoscopy)  
- Penicillin G benzathine (intramuscular)  
- Penicillin V potassium (oral)  
- Sulfadiazine (oral)  
- Macrolide or azalide antibiotics (for penicillin‑allergic patients)  
- Lifelong or extended prophylaxis (≥ 10 years or until 40 years of age)  
- Group A streptococcus exposure risk  
- Clinical or echocardiographic evidence of residual valvular heart disease.

Page 12 Extracted Terms:
- Infective Endocarditis (IE)  
- Prophylactic Antibiotics  
- Prosthetic Valve  
- Prior Infective Endocarditis  
- Congenital Heart Disease (with residual flow disturbances)  
- Transcatheter Aortic Valve Implantation (TAVI)  
- Surgical Aortic Valve Replacement (SAVR)  
- Valve Repair with Prosthetic Material  
- Heart Transplant Recipients  
- Endothelial Disruption  
- High‑Intensity Immunosuppressive Therapy  
- Central Venous Catheter Access  
- Endomyocardial Biopsies  
- Oral Health / Oral Hygiene (brushing teeth, flossing)  
- Transient Bacteremia  
- Clostridium difficile Colitis  
- Anticoagulation for Atrial Fibrillation (AF) in Valvular Heart Disease (VHD)  
- Native Valve Heart Disease (excluding rheumatic mitral stenosis)  
- Rheumatic Mitral Stenosis (MS)  
- Bioprosthetic Valve (≥ 3 months post‑implantation)  
- CHA₂DS₂‑VASc Score  
- Vitamin‑K Antagonist (VKA) Anticoagulation  
- Non‑Vitamin‑K Oral Anticoagulant (NOAC)  
- Mechanical Heart Valves  
- Valve Thrombosis Prevention  
- Atrial Fibrillation (AF)  
- Valvular Heart Disease (VHD)  

Page 13 Extracted Terms:
**Key heart‑disease related terms from the text**

1. Valvular heart disease (VHD)  
2. Bioprosthetic valves  
3. Rheumatic mitral stenosis (MS)  
4. Non‑vitamin K oral anticoagulants (NOACs)  
5. Warfarin  
6. Vitamin K antagonist (VKA)  
7. Mechanical heart valves  
8. Atrial fibrillation (AF)  
9. CHA₂DS₂‑VASc risk score  
10. Thromboembolic events (e.g., stroke)  
11. Post‑operative AF after VHD intervention  
12. Bioprosthesis (bioprosthetic valve prosthesis)  
13. Transcatheter valve implantation  
14. Target international normalized ratio (INR)  
15. Stroke and mortality risks associated with AF/VHD  
16. Phase II RE‑ALIGN study (dabigatran vs. warfarin in valve replacement)  

These terms capture the key clinical concepts and disease entities discussed in the guideline excerpt.

Page 14 Extracted Terms:
Valvular heart disease (VHD)  
Mechanical heart valve  
Bleeding (in anticoagulation)  
Dabigatran  
Non‑vitamin K antagonist oral anticoagulants (NOACs)  
Evaluation of surgical and interventional risk  
Transcatheter aortic valve implantation (TAVI)  
Aortic stenosis (AS)  
Valve durability  
Permanent pacemaker implantation  
Surgical bioprosthesis  
Valve‑in‑valve (ViV) procedure  
Reoperation  
Surgical aortic valve replacement (SAVR)  
Mitral valve repair  
Mitral regurgitation (MR)  
STS risk calculator (STS‑Predicted Risk of Death)  
EuroSCORE II risk calculator  
Frailty assessment (frailty indices)  
Organ system compromise  
Cardiac dysfunction  
Left‑ventricular dysfunction (systolic or diastolic)  
Right‑ventricular dysfunction  
Pulmonary hypertension  
Risk assessment tools  
Shared decision‑making process

Page 15 Extracted Terms:
- Valvular Heart Disease (VHD)  
- Multidisciplinary Heart Valve Team (MDT)  
- Primary or Comprehensive Heart Valve Center  
- Aortic Valve Replacement (AVR)  
- Surgical Aortic Valve Replacement (SAVR)  
- Transcatheter Aortic Valve Implantation (TAVI)  
- Transcatheter Edge‑to‑Edge Repair (TEER)  
- Mitral Valve Repair  
- Mitral Valve Replacement  
- Coronary Artery Bypass Grafting (CABG)  
- Society of Thoracic Surgeons (STS) score  
- Chronic Obstructive Pulmonary Disease (COPD)  
- Pulmonary Hypertension  
- Right Ventricular (RV) Dysfunction  
- Hepatic Dysfunction  
- Frailty (including Katz Activities of Daily Living Score)  
- Life expectancy < 1 year  
- Poor candidate for rehabilitation  
- Multivalve disease  
- Aorto‑iliac occlusive disease (precluding transfemoral approach)  
- Ascending aortic calcification (porcelain aorta)  
- Aortic arch atherosclerosis (protuberant lesions)  
- Severe mitral regurgitation (MR)  
- Severe tricuspid regurgitation (TR)  
- Basal septal hypertrophy  
- Valve morphology (bicuspid, unicuspid, thickening, perforations, clefts, calcification, stenosis)  
- Extensive left‑ventricular outflow tract calcification  
- Prior mediastinal radiation  
- Prior sternotomy  
- Prior mitral valve surgery  
- Risk prediction tools (tool‑specific)  
- Operator/institutional case volume  
- Perioperative mortality rates  
- Surgical procedure‑specific mortality (e.g., AVR, AVR+CABG, mitral repair, etc.)

Page 16 Extracted Terms:
- TAVI (transfemoral)  
- Percutaneous aortic valve balloon dilation  
- TAVI – alternative access (transthoracic, transapical, subclavian, carotid, caval)  
- Valve‑in‑valve procedures  
- TEER (transcatheter edge‑to‑edge repair)  
- Prosthetic valve paravalvular leak closure  
- Percutaneous mitral balloon commissurotomy  
- SAVR (surgical aortic valve replacement)  
- Valve‑sparing aortic root procedures  
- Aortic root procedures for aneurysmal disease  
- Concomitant septal myectomy with AVR  
- Root enlargement with AVR  
- Mitral repair for primary MR (posterior leaflet)  
- Mitral valve replacement  
- Multivalve operations  
- Reoperative valve surgery  
- Isolated or concomitant tricuspid valve repair or replacement  
- Concomitant tricuspid valve repair or replacement with mitral surgery  
- Echocardiographer (valve disease expertise)  
- Expertise in CT (valve assessment and procedural planning)  
- Interventional echocardiographer (imaging guidance)  
- Expertise in cardiac MRI (valve disease assessment)  
- Valve echocardiographer (pre‑ and post‑procedural assessment)  
- Expert in CT (pre‑procedural assessment of valve disease)  
- Interventional echocardiographer (formalized role)  
- Multidisciplinary team (MDT)  
- Valve coordinator (dedicated role)  
- Cardiac anesthesia support  
- Palliative care team  
- Vascular surgery support  
- Neurology stroke team  
- Consultative services with cardiovascular subspecialties  
- Consultative services with other medical and surgical subspecialties  
- Echo 3D TEE (transesophageal echocardiography)  
- Comprehensive TTE (transthoracic echocardiography)  
- Cardiac CT  
- ICU (intensive care unit)

Page 17 Extracted Terms:
- Valvular heart disease (VHD)  
- Heart valve programs  
- Multidisciplinary team (MDT)  
- Cardiologists (including valve disease specialists)  
- Interventional cardiologists  
- Cardiovascular imaging specialists  
- Heart failure (HF) specialist  
- Cardiovascular nurses  
- Cardiovascular anesthesiologists  
- Intensivists  
- Primary clinical cardiologist  
- Secondary mitral regurgitation (MR)  
- Tricuspid regurgitation (TR)  
- Operative mortality  
- Perioperative morbidity  
- Institutional volume  
- Surgical aortic valve replacement (SAVR)  
- Transcatheter aortic valve implantation (TAVI)  
- Mitral valve repair (surgical)  
- Primary/Comprehensive heart valve center  
- Multiple comorbidities  
- Cardiac surgical care  
- Cardiac catheterization laboratory  
- Hybrid catheterization laboratory  
- Hybrid operating room (OR) laboratory  
- Permanent pacemaker (PPM) implantation  
- Implantable cardioverter‑defibrillator (ICD) implantation  
- Temporary mechanical support (e.g., intra‑aortic balloon pump, temporary peripheral ventricular assist device, ECMO)  
- Left‑ventricular assist device (LVAD)  
- Right‑ventricular assist device (RVAD)  
- Intersocietal Accreditation Commission (IAC) echocardiography laboratory accreditation  
- Intensive care unit (ICU) coverage  
- Fixed radiographic imaging system and flat‑panel fluoroscopy  
- Aortic valve replacement (AVR)  
- Computed tomography (CT)  
- Extracorporeal membrane oxygenation (ECMO)  
- Implantable cardioverter defibrillator (ICD)  
- Intersocietal Accreditation Commission (IAC)  
- Intensive care unit (ICU)  
- Multidisciplinary team (MDT)  
- Mitral regurgitation (MR)  
- Magnetic resonance imaging (MRI)  
- Operating room (OR)  
- Permanent pacemaker (PPM)  
- Surgical aortic valve replacement (SAVR)  
- Transcatheter aortic valve implantation (TAVI)  
- Transesophageal echocardiography (TEE)  
- Transcatheter edge‑to‑edge repair (TEER)  
- Transthoracic echocardiography (TTE)  
- Valvular heart disease (VHD)  
- Valve‑in‑valve (ViV) procedures

Page 18 Extracted Terms:
- Valvular heart disease (VHD)  
- Prosthetic valve  
- Valve replacement (surgical & transcatheter)  
- Valve repair (mitral)  
- Aortic valve replacement (AVR)  
- Bicuspid aortic valve disease  
- Mechanical valve (surgical)  
- Bioprosthetic valve (surgical & transcatheter)  
- Atrial fibrillation (post‑operative AF)  
- Pulse‑wave and conduction abnormalities (heart block, permanent pacing)  
- Stroke and embolic events  
- Vascular complications (access‑site, systemic)  
- Bleeding complications  
- Pericarditis  
- Infection (prosthetic valve endocarditis)  
- Endocarditis prophylaxis  
- Antithrombotic therapy for prosthetic valves  
- Valve thrombosis  
- Valve stenosis  
- Valve regurgitation (including paravalvular leak)  
- Residual valve dysfunction  
- Coronary artery disease (CAD) – concurrent with VHD  
- Primary prevention of CAD  
- Secondary prevention of CAD  
- Cardiovascular outcomes and coronary events  
- Heart failure (HF) – symptom management, GDMT  
- Left‑ventricular (LV) systolic dysfunction  
- Left‑ventricular (LV) diastolic dysfunction  
- Right‑ventricular (RV) dysfunction  
- Pulmonary hypertension  
- Renal dysfunction (post‑operative)  
- Transthoracic echocardiography (TTE) – baseline, periodic imaging  
- Timing of periodic imaging (baseline, 1 yr, 5 yr, 10 yr, annual)  
- Valve degeneration (early bioprosthetic degeneration)  
- Risk factors for valve degeneration (younger age, diabetes, renal failure)  
- Hemodynamic monitoring after valve intervention  
- Clinical follow‑up (annual, pregnancy)  
- Primary Valve Center, Comprehensive Valve Center, Valve surveillance programs



Page 19 Extracted Terms:
- Valve intervention  
- Baseline transthoracic echocardiography (TTE)  
- Prosthetic valve  
- Transaortic maximum velocity  
- Mean pressure gradient  
- Low‑flow, low‑gradient severe aortic stenosis (AS)  
- Stage D2 (low LVEF)  
- Stage D3 (normal LVEF)  
- Bicuspid aortic valve (BAV)  
- Doppler echocardiography  
- Transesophageal echocardiography (TEE)  
- Cardiac magnetic resonance (CMR)  
- Cardiac computed tomography (CT)  
- Positron emission tomography (PET)  
- Endocarditis  
- Aortic valve hemodynamics  
- Left ventricular (LV) systolic function  
- LV size  
- Pulmonary systolic pressure  
- Left ventricular ejection fraction (LVEF)  
- Contractile reserve  
- Valve anatomy and motion  
- Valve obstruction  
- Residual valve dysfunction  
- Concurrent cardiac conditions  
- Blood pressure control  
- Low‑dose dobutamine stress testing  
- Valvular heart disease (VHD)  
- Aortic valve calcium score  
- Hemodynamic severity  
- Ventricular size  
- Cardiac catheterization  
- Fluoroscopy  
- Clinical history and physical examination  
- Periodic imaging schedule  
- Valve repair/valve prosthesis type  
- Symptom‑based monitoring  
- Systemic hypertension  
- Blood pressure management  
- Transaortic volume flow rate  
- Stroke volume  
- Systolic function assessment  
- Valve replacement recommendations  
- Valve surveillance guidelines  

Page 20 Extracted Terms:
**Key heart‑disease terms extracted**

- Aortic stenosis (AS)  
- Aortic valve area (AVA)  
- Aortic valve area indexed (AVAi)  
- Aortic valve sclerosis  
- Bicuspid aortic valve (BAV)  
- Aortic regurgitation (AR)  
- Left ventricular ejection fraction (LVEF)  
- Left ventricular hypertrophy (LVH)  
- Left ventricular systolic dysfunction  
- Left ventricular diastolic dysfunction  
- Forward stroke volume  
- Stroke volume index (SVi)  
- Transaortic pressure gradient  
- Mean pressure gradient (ΔP)  
- Maximum velocity (Vmax)  
- Severe AS  
- Low‑gradient AS  
- High‑gradient AS  
- Symptomatic severe AS  
- Asymptomatic severe AS  
- Low‑flow AS  
- Paradoxical low‑flow severe AS  
- Pulmonary hypertension  
- Exercise tolerance  
- Exertional dyspnea  
- Exertional angina  
- Syncope / presyncope  
- Heart failure (HF)  
- Stage A, B, C, D of AS progression  
- Doppler velocity data  
- Invasive pressure measurements  
- Valve anatomy  
- Valve hemodynamics  
- Valve calcification/fibrosis  
- Commissural fusion  
- Stroke‑volume index <35 mL/m²  
- Small left‑ventricular chamber  
- Restrictive diastolic filling  
- Aortic Vmax ≥4 m/s or ≥5 m/s  
- Aortic Vmax <4 m/s or 2.0–2.9 m/s  
- Mean ΔP ≥40 mm Hg or <20 mm Hg  
- Small, low‑flow, low‑gradient AS  
- Symptomatic low‑gradient AS with preserved LVEF.

Page 21 Extracted Terms:
- Valvular heart disease  
- Aortic stenosis (AS)  
- Moderate aortic stenosis  
- Severe aortic stenosis  
- Aortic valve calcification  
- Bicuspid aortic valve (BAV) disease  
- Dobutamine stress echocardiography  
- Aortic velocity  
- Mean pressure gradient  
- Trans‑aortic velocity  
- Valve area (effective orifice area)  
- Valve area measurement by continuity equation  
- Outflow tract‑to‑aortic velocity ratio  
- Lateral velocity ratio threshold (≤0.25)  
- Stroke volume reserve (≥20% increase with dobutamine)  
- Lack of contractile reserve / flow reserve  
- Aortic valve calcium volume (CT imaging)  
- Sex‑specific Agaston unit thresholds (1300 women, 2000 men)  
- Annulus area (CT measurement for TAVI planning)  
- Leaflet length (CT measurement for TAVI planning)  
- Annular‑to‑coronary ostial distance (CT measurement for TAVI planning)  
- Aortic murmur characteristics (loudness, onset, peak, A2 component)  
- Aortic valve stenosis progression metrics (velocity, gradient, area changes)  
- Aortic sclerosis (velocity <2.0 m/s)  
- Transaortic pressure gradient (cardiac catheterization)  
- Left ventricular (LV) outflow tract diameter/area  
- Left ventricular ejection fraction (LVEF)  
- Cardiac output  
- Hemodynamic demands (surgery, pregnancy, infection, anemia, bleeding)  
- Symptom onset in severe AS  
- Event‑free survival percentages for severe AS  
- Follow‑up intervals for asymptomatic severe or moderate AS  
- Diagnostic transthoracic echocardiography (TTE)  
- Doppler echocardiography (velocity, gradient measurement)  
- Non‑invasive imaging limitations (parallel intercept angle, image quality)  
- Angiographic assessment of aortic valve stenosis severity.

Page 22 Extracted Terms:
- Aortic Stenosis (AS)  
- Valvular Heart Disease (VHD)  
- Exercise Testing  
- Exercise‑induced Angina  
- Excessive Dyspnea  
- Syncope  
- Ventricular Tachycardia  
- Asystole  
- Gorlin Formula  
- Fick Method  
- Thermodilution  
- Cardiac Output  
- Aortic Velocity  
- Mean Pressure Gradient  
- Hypertension  
- Hypertensive Therapy  
- Statin Therapy  
- Renin–Angiotensin System Blocker  
- ACE Inhibitor  
- ARB (Angiotensin‑II Receptor Blocker)  
- TAVI (Transcatheter Aortic Valve Implantation)  
- Calcific Aortic Stenosis  
- Disease Staging (Stage A; Stage B; Stage C; Stage D)  
- GDMT (Guideline‑Directed Medical Therapy)  
- Coronary Angiography  
- Hemodynamic Compromise  
- Blood Pressure Monitoring  
- ECG Monitoring  
- Functional Capacity  
- Clinical Outcome  
- Guideline for Management of Valvular Heart Disease  
- ACC/AHA Guideline for Valvular Heart Disease  
- Circulation (journal)  
- Diagnostic Testing  
- Physiological Changes  
- Hemodynamics  
- Complications (e.g., syncope, ventricular tachycardia, death)

Page 23 Extracted Terms:
- Aortic stenosis (AS)  
- Asymptomatic aortic stenosis  
- Severe aortic stenosis  
- Very severe aortic stenosis  
- Aortic valve replacement (AVR)  
- Surgical aortic valve replacement (SAVR)  
- Transcatheter aortic valve implantation (TAVI)  
- Left ventricular ejection fraction (LVEF)  
- Low‑flow, low‑gradient severe AS  
- Low surgical risk  
- High‑gradient severe AS  
- Elevated B‑type natriuretic peptide (BNP)  
- Ischemic cardiovascular events  
- Cardiovascular mortality  
- Hypertension (high blood pressure)  
- Renin–angiotensin system blockers  
- Angiotensin‑converting enzyme (ACE) inhibitors  
- Diuretics  
- LV fibrosis  
- Hypercholesterolemia  
- Coronary artery disease (CAD)  
- Statin therapy  
- Lipid‑lowering therapy  
- Experimental models of calcific AS  
- Randomized controlled trials (RCTs)  
- Observational and registry data  
- Clinical guideline statements (ACC/AHA, 2020)  
- Low‑flow versus high‑flow states in AS  
- Systolic blood pressure fall during exercise  
- Exercise testing (stress test)  
- Progressive decline in LVEF  
- Progressive increase in aortic velocity  
- Aortic valve event rates  
- Perioperative management of AS patients.

Page 24 Extracted Terms:
- Aortic stenosis (AS)  
- Severe high‑gradient AS  
- Low‑gradient AS  
- Symptomatic AS  
- Asymptomatic AS  
- Stage C, Stage D1, D2, D3 (AS staging)  
- Aortic valve replacement (AVR)  
- Surgical aortic valve replacement (SAVR)  
- Transcatheter aortic valve implantation (TAVI/TAVR)  
- Mechanical valve  
- Bioprosthetic valve  
- Left ventricular ejection fraction (LVEF)  
- Left ventricular systolic function  
- Exertional dyspnea  
- Decreased exercise tolerance  
- Heart failure (HF)  
- Syncope  
- Angina  
- Sudden death risk  
- B‑type natriuretic peptide (BNP)  
- Blood pressure (BP)  
- Dobutamine stress echocardiography (DSE)  
- Exercise treadmill test (ETT)  
- Mean systolic pressure gradient (∆Pmean)  
- Stroke volume index (SVI)  
- Aortic valve area (AVA)  
- Aortic valve area index (AVAi)  
- Maximum velocity (Vmax)  
- Afterload mismatch  
- Symptomatic survival benefit of AVR  
- Transcatheter versus surgical AVR choice  
- Palliative care in prohibitive surgical risk patients  
- RCT (randomized controlled trial)  

(Note: All terms are extracted from the guideline excerpt and pertain to heart disease, particularly aortic valve disease and its management.)

Page 25 Extracted Terms:
- Aortic valve replacement (AVR)  
- Transcatheter aortic valve implantation (TAVI)  
- Aortic stenosis (AS)  
- Severe aortic stenosis  
- Very severe aortic stenosis  
- Low‑flow, low‑gradient severe AS  
- High‑gradient AS  
- Mean pressure gradient (mm Hg)  
- Aortic velocity (m s⁻¹)  
- Stroke volume (mL)  
- Stroke volume index (mL m⁻²)  
- Left ventricular ejection fraction (LVEF)  
- Contractile reserve  
- Dobutamine stress testing  
- Echocardiographic assessment of valve stenosis  
- Valve area (cm²)  
- Valve area indexed to body size  
- Valve area index (cm² m⁻²)  
- Aortic valve calcium score (CT)  
- B‑type natriuretic peptide (BNP)  
- Cardiovascular mortality  
- Surgical risk (e.g., low, high)  
- Patient‑prosthesis mismatch  
- Anticoagulation considerations  
- Symptom onset (clinical, exercise‑provoked)  
- Afterload mismatch  
- Left‑ventricular systolic dysfunction  
- Left‑ventricular diastolic dysfunction  
- Hypertension (blood‑pressure control)  
- Doppler imaging  
- Two‑dimensional (2D) imaging  
- Guideline recommendations (ACC/AHA, 2020)  
- Surgical aortic valve replacement (SAVR)  
- Exercise testing (symptom clarification)

Page 26 Extracted Terms:
- BNP (Brain Natriuretic Peptide)  
- Aortic valve stenosis (AS)  
- Aortic valve replacement (AVR)  
- Left ventricular ejection fraction (LVEF)  
- Left‑ventricular systolic function  
- Hemodynamic progression  
- Aortic velocity  
- Mean gradient  
- Valve area  
- Valve calcification  
- Severe AS (asymptomatic or symptomatic)  
- Symptom onset  
- Sudden death  
- All‑cause mortality  
- Cardiovascular mortality  
- Hazard ratio (HR)  
- BNP level >300 pg/mL  
- Mechanical prosthetic valve  
- Bioprosthetic valve  
- Ross procedure (pulmonic autograft)  
- TAVI (transcatheter aortic valve implantation)  
- VKA anticoagulation  
- Anticoagulant therapy  
- Valve reintervention  
- Shared decision‑making  
- Serial imaging studies  
- Valve durability  
- Clinical risk factors (age, comorbid conditions)  

(Note: The list captures key heart‑disease‑related terms from the guideline excerpt.)

Page 27 Extracted Terms:
- Valvular heart disease  
- Aortic valve replacement (AVR)  
- Mitral valve replacement  
- Bioprosthetic valve  
- Mechanical valve prosthesis  
- Transcatheter aortic valve implantation (TAVI)  
- Valve durability  
- Structural valve deterioration (SVD)  
- Reintervention / reoperation  
- Valve prosthesis mismatch  
- Anticoagulation therapy  
- Vitamin K antagonist (VKA)  
- Low‑molecular‑weight heparin (LMWH) – alternative anticoagulant (not directly mentioned but relevant)  
- New‑generation direct oral anticoagulants (DOACs)  
- Thromboembolic events  
- Bleeding risk (intracranial, gastrointestinal)  
- International Normalized Ratio (INR) monitoring  
- Long‑term anticoagulation  
- Age stratification in valve choice (<50, 50–65, >65 years)  
- Patient values and preferences  
- Shared decision‑making process  
- Pregnancy‑related anticoagulation considerations  
- Surgical vs interventional risk  
- Hemodynamics of valve type and size  
- Post‑implant monitoring  
- Implantation‑related complications  
- Structural deterioration probability (15‑year risk %)  
- Survival advantage with mechanical valves  
- Late mortality associated with bioprosthetic valves  

   (All terms are directly related to heart valve disease management and outcomes as described in the guideline excerpt.)

Page 28 Extracted Terms:
**Key heart‑disease terms identified**

- Valvular heart disease  
- VKA therapy  
- Bleeding complications  
- Anticoagulation  
- Bioprosthetic valve  
- Prosthetic heart valve  
- Ross procedure  
- Aortic valve replacement  
- Pulmonary autograft (Ross procedure)  
- Pulmonic homograft  
- Valve degeneration  
- Valve calcification  
- Valve re‑intervention  
- Severe aortic stenosis (AS)  
- Aortic valve (AV)  
- Pulmonary valve (PV)  
- Valve durability  
- Aortic valve (AV) replacement (SAVR)  
- Transcatheter aortic valve implantation (TAVI)  
- Transfemoral TAVI  
- Life expectancy  
- Symptomatic vs. asymptomatic AS  
- LVEF (<50%)  
- BNP  
- Exercise test (exercise‑testing)  
- High or prohibitive surgical risk  
- Palliative care  
- Critical illness  
- Percutaneous aortic balloon dilation  
- Shared decision‑making  
- Comprehensive valve center  
- Valve hemodynamics  
- Valve failure (regurgitation of the neoaortic valve)  
- Valve position (pulmonic, aortic)  
- Valve anatomy  
- Valve durability data (≥10 years)  
- Post‑TAVI survival  
- Post‑SAVR survival  
- Quality of life (QoL)  

These terms capture the major concepts and interventions related to heart valve disease discussed in the provided guideline excerpt.

Page 29 Extracted Terms:
- ACC/AHA Guideline for the Management of Valvular Heart Disease  
- Valvular Heart Disease  
- Surgical Aortic Valve Replacement (SAVR)  
- Transcatheter Aortic Valve Implantation (TAVI)  
- Aortic Valve Replacement (AVR)  
- Aortic Stenosis (AS)  
- Bioprosthetic Valve  
- Mechanical Valve  
- Valve Durability  
- Lifelong Anticoagulation  
- Vitamin K Antagonist (VKA)  
- Transfemoral Delivery  
- Aortic Root Dilation  
- Annulus Size and Shape  
- Leaflet Number  
- Calcification  
- Coronary Ostial Height  
- Left Ventricular Ejection Fraction (LVEF)  
- Quality of Life (QOL)  
- Society of Thoracic Surgeons (STS)  
- ACC Expert Consensus Statement  
- Valvular Anatomy   
- Transcatheter Valve Placement  
- Age-Related Longevity and Valve Selection  
- Vascular Anatomy Compatibility



Page 30 Extracted Terms:
- Valvular Heart Disease  
- Aortic Valve Replacement (AVR)  
- Surgical Aortic Valve Replacement (SAVR)  
- Transcatheter Aortic Valve Implantation (TAVI)  
- Aortic Stenosis (AS)  
- Severe Aortic Stenosis  
- Low‑flow, low‑gradient Severe AS  
- High‑velocity Severe AS (Stage D1)  
- Left Ventricular Ejection Fraction (LVEF)  
- Paravalvular Leak / Regurgitation  
- Valve Durability  
- Transfemoral TAVI Approach  
- Balloon‑Expandable Valve  
- Self‑Expanding Valve  
- Valve‑in‑Valve TAVI  
- Permanent Pacemaker Implantation  
- Vascular Complications  
- Stroke  
- Major Bleeding  
- Atrial Fibrillation (AF)  
- Hospital Length of Stay  
- Post‑operative Pain  
- Symptomatic Patients  
- Surgical Risk (High, Low, Intermediate)  
- Life Expectancy  
- Comorbid Cardiac Conditions  
- Noncardiac Conditions  
- Frailty  
- Dementia  
- Shared Decision‑Making  
- Mortality Risk  
- Paravalvular Leakage  
- Stroke Risk (HR)  
- Bleeding Risk  
- AF Risk  
- Paravalvular Regurgitation  
- Durability Beyond 5–6 Years  
- Age‑Based Recommendations (≤65 yr, 65–80 yr, >80 yr)

Page 31 Extracted Terms:
- Valvular heart disease  
- Aortic stenosis (AS)  
- Severe aortic stenosis  
- Left ventricular ejection fraction (LVEF)  
- Left ventricular systolic dysfunction  
- Transcatheter aortic valve implantation (TAVI)  
- Surgical aortic valve replacement (SAVR)  
- Percutaneous aortic balloon dilation (balloon aortic valvuloplasty)  
- New York Heart Association (NYHA) functional class  
- Stroke  
- Major vascular complications  
- Pulmonary hypertension  
- Anemia  
- Chronic obstructive pulmonary disease (COPD)  
- Liver disease  
- Frailty  
- Porcelain aorta  
- Chest radiation damage  
- Valve reintervention  
- STS (Society of Thoracic Surgeons) surgical risk score

Page 32 Extracted Terms:
- Percutaneous aortic balloon dilation  
- Aortic stenosis (AS)  
- Calcific valve deposits  
- Aortic annulus  
- Valve commissures  
- Hemodynamics  
- Surgical aortic valve replacement (SAVR)  
- Transcatheter aortic valve implantation (TAVI)  
- Aortic valve palliation  
- Bicuspid aortic valve (BAV)  
- Subaortic (LV outflow tract) calcification  
- Rheumatic valve disease  
- Aortic annulus size  
- Calcific AS of a trileaflet valve  
- Mechanical prosthetic valve  
- Bioprosthetic valve  
- Patient–prosthesis mismatch  
- Valve durability  
- Primary mitral regurgitation (MR)  
- Coronary artery disease (CAD)  
- Coronary artery bypass grafting  
- Septal hypertrophy  
- Myectomy  
- Atrial fibrillation (AF)  
- Porcelain aorta  
- Left‑ventricular (LV) systolic dysfunction  
- Severe mitral regurgitation (MR) due to annular calcification  
- Severe lung, liver, or renal disease  
- Mobility issues / procedural risk  
- Severe dementia  
- Frailty  
- Procedural or surgical risk of SAVR/TAVI  
- Vascular access constraints  
- Previous cardiac surgery with at‑risk grafts  
- Previous chest irradiation  
- Goals of care (e.g., symptom relief, quality of life, life prolongation)  
- Permanent pacemaker risk  
- Stroke risk  
- Valve replacement durability data (5‑year TAVI, 20‑year bioprosthetic)  
- Life expectancy / actuarial tables  
- Valve type selection (mechanical vs. bioprosthetic)  
- Valve enlargement procedures  
- Non‑cardiac comorbidities affecting treatment choice.

Page 33 Extracted Terms:
- Aortic valve disease  
- Aortic stenosis (AS)  
- Aortic regurgitation (AR)  
- Transcatheter aortic valve implantation (TAVI)  
- Surgical aortic valve replacement (SAVR / AVR)  
- Percutaneous aortic balloon dilation  
- Acute aortic regurgitation  
- Chronic aortic regurgitation  
- Endocarditis‑related AR  
- Aortic dissection‑related AR  
- Bicuspid aortic valve (BAV) disease  
- Rheumatic heart disease  
- Transcatheter procedures (e.g., transcatheter aortic valve, transcatheter aortic valve replacement)  
- Transcatheter aortic valve replacement (TAVR)  
- Transcatheter aortic valve implantation (TAVI)  
- Valve area (cm²)  
- Transvalvular pressure gradient  
- Left ventricular (LV) volume overload  
- LV chamber dilation  
- LV hypertrophy  
- Pulmonary congestion  
- Pulmonary edema  
- Cardiac output  
- Transthoracic echocardiography (TTE)  
- Transesophageal echocardiography (TEE)  
- Cardiac computed tomography (CT)  
- Cardiac magnetic resonance imaging (MRI)  
- Intra‑aortic balloon counterpulsation  
- Beta blockers (in aortic dissection)  
- Acute severe AR surgical emergency  
- Acute AR diagnosis criteria (deceleration time, pressure half‑time, holodiastolic flow reversal)  
- Aortic root imaging  
- Aortic diastolic pressure equilibration  
- Surgical delay in acute severe AR  
- Acute coronary syndrome (differential diagnosis)

Page 34 Extracted Terms:
- Valvular Heart Disease  
- Aortic Regurgitation (AR)  
- Bicuspid Aortic Valve (BAV)  
- Aortic valve sclerosis  
- Aortic sinuses  
- Ascending aorta  
- Rheumatic fever  
- Rheumatic heart disease  
- Infective endocarditis (IE)  
- Congenital valve anomaly / congenital abnormality  
- Calcific aortic valve disease  
- Left ventricular (LV) systolic function  
- Left ventricular ejection fraction (LVEF)  
- Left ventricular end‑systolic dimension (LVESD)  
- LV dilation / left ventricular dilation  
- LV outflow tract (LVOT)  
- Jet width (percentage of LVOT)  
- Vena contracta (cm)  
- Regurgitant volume (mL/beat)  
- Regurgitant fraction (%)  
- Effective regurgitant orifice (ERO) (cm²)  
- Angiography grade (1–4)  
- Holodiastolic flow reversal in abdominal aorta  
- Exertional dyspnea  
- Angina  
- Heart failure (HF)  
- Mild AR  
- Moderate AR  
- Severe AR  
- Asymptomatic severe AR  
- Symptomatic severe AR  
- Stages of chronic AR (Stage A, B, C, D)  
- LV systolic dysfunction (LVEF ≤ 55%)  
- LV end‑systolic dimension index (mm²/m²)

Page 35 Extracted Terms:
- Chronic aortic regurgitation (AR)  
- Aortic regurgitation severity  
- Valve reparability  
- Transthoracic echocardiography (TTE)  
- Transesophageal echocardiography (TEE)  
- Cardiovascular magnetic resonance (CMR)  
- Cardiac catheterization  
- Aortic angiography  
- Left ventricular (LV) systolic function  
- Left ventricular ejection fraction (LVEF)  
- Fractional shortening  
- LV end‑systolic dimension (LVESD)  
- LV end‑systolic volume (LVESV)  
- LV end‑diastolic dimension/volume (LVEDD/LVEDV)  
- Bicuspid aortic valve (BAV)  
- Aortic sinuses dilation  
- Ascending aorta dilation  
- Symptom staging (Stages B, C, C2, D)  
- Heart failure (HF) symptoms  
- Hypertension (systolic >140 mm Hg)  
- Glycemic‑controlled disease management (GDMT)  
- Angiotensin‑converting enzyme inhibitors (ACE‑I)  
- Angiotensin receptor blockers (ARBs)  
- Sacubitril/valsartan (ARNI)  
- Beta‑blockers  
- Systolic blood pressure (SBP)  
- Diastolic blood pressure (DBP)  
- Pulse pressure  
- Trans‑aortic stroke volume  
- Regurgitant volume  
- Effective regurgitant orifice (ERO) area  
- Regurgitant fraction  
- Aortic valve disease  
- Valve intervention (aortic valve replacement, AVR)  
- Cardiology guidelines  
- Clinical outcomes  
- Survival and functional results  
- Surgical risk assessment  

These terms capture the cardiovascular concepts and therapies discussed in the guideline excerpt.

Page 36 Extracted Terms:
**Key terms related to heart disease extracted from the text**

- Chronic severe aortic regurgitation (AR)  
- Aortic valve surgery / aortic valve replacement (AVR, SAVR)  
- Left ventricular (LV) systolic function  
- Left ventricular ejection fraction (LVEF)  
- LV end‑systolic diameter (LVESD)  
- LV end‑diastolic diameter (LVEDD)  
- LV volume overload / LV volume measurements  
- Mechanical valve (prosthetic)  
- Bioprosthetic valve (prosthetic)  
- Valve‑sparing procedures / valve‑spare surgery  
- Aortic root reconstruction  
- Ascending aorta repair / replacement  
- Transcatheter aortic valve implantation (TAVI)  
- Coronary artery bypass grafting (CABG)  
- Mitral valve surgery  
- Symptomatic patients (with severe AR)  
- Asymptomatic patients (with severe or moderate AR)  
- Severe AR (Stage C1, C2, D)  
- Moderate AR (Stage B)  
- LV systolic dysfunction (LVEF ≤55%)  
- Progressive decline in LVEF (to 55‑60%)  
- Progressive LV dilation (LVEDD >65 mm)  
- Global longitudinal strain (GLS)  
- Circulation biomarkers (e.g., natriuretic peptides)  
- Exercise capacity / exercise testing  
- Survival and functional status after surgery  
- Perioperative period / peri‑operative hemodynamics  
- Mortality rate post‑AVR  
- Clinical evaluation and symptom assessment  
- Risk factors for AVR timing  
- ACC/AHA guideline recommendations  
- Evidence levels (e.g., B‑NR, C‑EO)  
- Clinical outcomes and prognostic markers  
- Imaging modalities: 2‑D echocardiography, 3‑D echocardiography, cardiac MRI (CMR)  
- LVESD index (indexed LVESD, mm/m²)  
- Intervention thresholds (e.g., LVESD >50 mm, indexed >25 mm/m²)  
- Surgical indications: before LVEF falls below 55 %  
- Post‑operative outcomes in asymptomatic patients with LV dysfunction

*(These terms capture the main concepts concerning heart disease, valve pathology, diagnostic imaging, surgical interventions, and guideline‐based recommendations discussed in the text.)*

Page 37 Extracted Terms:
Aortic regurgitation (AR)  
Aortic valve (AV)  
Aortic valve replacement (AVR)  
Valve‑sparing procedure  
Aortic root  
Ascending aorta  
Mitral valve  
Coronary artery bypass grafting (CABG)  
Transcatheter aortic valve implantation (TAVI)  
Left ventricular end‑diastolic dimension (LVEDD)  
Left ventricular end‑systolic dimension (LVESD)  
Left ventricular systolic volume  
Left ventricular ejection fraction (LVEF)  
Effective regurgitant orifice (ERO)  
Regurgitant volume (RVol)  
Regurgitant fraction (RF)  
Vena contracta (VC)  
Cardiac events  
Post‑operative outcomes  
Transcatheter valve migration  
Paravalvular leak  
Transthoracic echocardiography (TTE)  
Transesophageal echocardiography (TEE)  
Cardiac magnetic resonance imaging (CMR)  
Aortic annulus  
Valve calcification  
Valve anatomy  
Aortic root size and shape  
Heart failure (HF)  
Severe regurgitation  
Asymptomatic patients.

Page 38 Extracted Terms:
- Bicuspid aortic valve (BAV)  
- Aortic stenosis (AS)  
- Aortic regurgitation (AR)  
- Aortic aneurysm  
- Aortic dilation  
- Aortopathy  
- Ascending aorta  
- Aortic sinuses (sinuses of Valsalva)  
- Sinotubular junction  
- Aortic coarctation  
- Aortic dissection  
- Transthoracic echocardiography (TTE)  
- Transesophageal echocardiography (TEE)  
- Cardiac magnetic resonance (CMR) angiography  
- Computed tomography (CT) angiography  
- Aortic valve replacement (AVR)  
- Lifelong serial imaging (echocardiography, CMR, CT)  
- Diagnostic imaging of the aorta  
- Screening TTE in first‑degree relatives  
- Genetic inheritance of aortopathy  
- Hemodynamic assessment (Doppler interrogation)  
- Valve morphology evaluation  
- Severity grading of AS and AR  
- Imaging intervals based on aortic size and progression  
- Radiological assessment of aortic annulus, sinuses, and ascending aorta

Page 39 Extracted Terms:
- Bicuspid aortic valve (BAV)  
- Aortic dilation  
- Aortic dissection  
- Aortic grafting  
- Valve surgery / valve replacement  
- Aortic imaging  
- Aortic diameter  
- Aortic sinuses  
- Ascending aorta  
- Surgical intervention  
- Aortic coarctation  
- Aortic growth rate  
- Valvular heart disease  
- Comprehensive Valve Center  
- Computed tomographic angiography (CTA)  
- Cardiac magnetic resonance (CMR)  
- Transthoracic echocardiography (TTE)

Page 40 Extracted Terms:
- BAV (Bicuspid Aortic Valve)  
- SAVR (Surgical Aortic Valve Replacement)  
- TAVI (Transcatheter Aortic Valve Implantation)  
- AVR (Aortic Valve Replacement)  
- AS (Aortic Stenosis)  
- AR (Aortic Regurgitation)  
- Aortic sinuses  
- Ascending aorta  
- Aortic dilation / aortic enlargement  
- Aortic dissection  
- Aortic coarctation  
- Aortic growth rate  
- Valve‑sparing surgery  
- Aortic valve repair  
- Aortic valve reimplantation  
- Comprehensive Valve Center  
- Operative intervention (aortic surgery)  
- Imaging of the aorta (CT, MRI, TEE)  
- Surgical threshold (≥4.5 cm, 5.0–5.5 cm, ≥5.5 cm)  
- Low surgical risk  
- Shared decision‑making  
- Family history of aortic dissection  
- Risk factors for dissection  
- Progressive aortic dilation  
- Retro­active studies on BAV outcomes  
- Aortic valve prosthetic choice (mechanical, bioprosthetic)

Page 41 Extracted Terms:
**Key heart‑disease terms extracted from the text**

- Surgical repair  
- Aortic valve  
- Valve repair  
- Aortic root anatomy  
- Comprehensive Valve Center  
- Transcatheter aortic valve implantation (TAVI)  
- Severe symptomatic aortic stenosis (AS)  
- Bicuspid aortic valve (BAV)  
- Paravalvular leak  
- 30‑day mortality rate  
- 1‑year mortality rate  
- Stroke rate  
- Risk‑benefit ratio (TAVI vs. SAVR)  
- Surgical aortic valve replacement (SAVR)  
- Mitral stenosis (MS)  
- Rheumatic mitral stenosis  
- Female predominance (≈80 % of rheumatic MS cases)  
- Clinical presentation (young age, teenage–30 yr)  
- Aortic replacement intervention  
- Family history of aortic dissection  
- Aortic growth rate (≥ 0.5 cm / year)  
- Aortic coarctation  
- Aortic valve replacement (AVR)  
- Comprehensive Valve Center (CVC)  
- STS/ACC Transcatheter Valve Therapies Registry  

These terms represent the key clinical entities, procedures, outcomes, and populations discussed in the guidelines excerpt.

Page 42 Extracted Terms:
- Mitral stenosis (MS)  
- Rheumatic heart disease  
- Valvular heart disease  
- Commissural fusion  
- Calcific mitral stenosis  
- Mitral valve area  
- Transmitral mean pressure gradient  
- Diastolic pressure half‑time  
- Left atrium (LA)  
- Pulmonary artery systolic pressure (PASP)  
- Pulmonary hypertension  
- Left atrial enlargement  
- Mitral regurgitation (MR)  
- Atherosclerotic disease  
- Hypertension  
- Diastolic dysfunction  
- Transthoracic echocardiography (TTE)  
- Transesophageal echocardiography (TEE)  
- Percutaneous mitral balloon commissurotomy (PMBC)  
- Mitral commissurotomy  
- Valve hemodymamics  
- Valve anatomy  
- Valve obstruction  
- Transvalvular flow rate  
- Heart rate  
- Mitral valve leaflet calcification  
- Mitral valve annulus calcification  
- Continuity equation  
- Gorlin formula  
- Left ventricular (LV) compliance  
- Left atrial (LA) compliance  
- Diastolic filling period  
- LA thrombus  
- Severe MS criteria (≤1.5 cm², >5 mm Hg gradient)  
- Moderate LA enlargement  
- Exertional dyspnea  
- Decreased exercise tolerance

Page 43 Extracted Terms:
**Key terms related to heart disease (valvular and hemodynamic):**

1. Valvular heart disease  
2. Rheumatic mitral stenosis (MS)  
3. Mitral regurgitation (MR)  
4. Percutaneous balloon mitral commissurotomy (PMBC)  
5. Transthoracic echocardiography (TTE)  
6. Transesophageal echocardiography (TEE)  
7. Three‑dimensional echocardiography (3‑D echo)  
8. Doppler echocardiography  
9. Transvalvular gradients  
10. Mean gradient  
11. Mitral valve area  
12. Mitral valve morphology  
13. Commissural fusion  
14. Commissural morphology  
15. Valve thickening  
16. Valve mobility  
17. Valve calcification  
18. Subvalvular chordal fusion  
19. Mitral pressure half‑time  
20. Pulmonary hypertension  
21. Right ventricular (RV) systolic pressure  
22. Tricuspid regurgitation (TR) velocity  
23. Right ventricular enlargement  
24. Left atrial (LA) thrombus  
25. Atrial fibrillation (AF)  
26. Hyperthyroidism  
27. Cardiac catheterization  
28. Left ventricular (LV) diastolic pressure  
29. Pulmonary artery wedge pressure  
30. Gorlin equation (mitral area calculation)  
31. Pulmonary circulation pressure  
32. Hemodynamic load  
33. Exercise hemodynamics  
34. Valve area progression (0.1 cm²/year)  
35. Diastolic dysfunction  
36. LA non‑compliance  
37. Intrinsic pulmonary vascular disease  

These terms capture the primary clinical, diagnostic, and therapeutic concepts discussed in the guideline excerpt.

Page 44 Extracted Terms:
- Rheumatic mitral stenosis (MS)  
- Valvular heart disease  
- Echocardiography  
- Doppler echocardiography  
- Resting echocardiographic findings  
- Exercise testing  
- Treadmill exercise testing  
- Bicycle exercise testing  
- Cardiac catheterization  
- Invasive hemodynamic assessment  
- Mean mitral gradient  
- Pulmonary artery pressure  
- Pulmonary artery wedge pressure  
- Pulmonary artery systolic pressure  
- Valve gradient  
- Diastolic filling period  
- Left atrial (LA) pressure  
- Atrial fibrillation (AF)  
- Rapid ventricular response  
- Sinus tachycardia  
- Anticoagulation  
- Vitamin K antagonist (VKA)  
- Direct oral anticoagulants (DOACs) – noted as “non‑vitamin K oral anticoagulation”  
- Embolic event  
- Left atrial thrombus  
- Beta‑blockers  
- Calcium‑channel blockers  
- Ivabradine  
- Heart rate control  
- Leg‑lift maneuver  
- Sit‑up maneuver  
- Thromboembolic risk  
- Hemodynamic consequences  
- Exercise capacity  
- Symptomatic response  
- Diagnostic testing  
- Clinical statements  
- Guideline recommendations  
- Hemodynamic mismatch (resting vs. clinical symptoms)

Page 45 Extracted Terms:
- Rheumatic mitral stenosis (MS)
- Mitral valve area ≤ 1.5 cm²
- NYHA functional class II–IV
- Pulmonary artery systolic pressure > 50 mm Hg
- Pulmonary artery wedge pressure > 25 mm Hg
- Mean mitral valve gradient > 15 mm Hg during exercise
- Atrial fibrillation (AF)
- Embolic events
- Left atrial (LA) size / thrombus
- Hemodynamic response
- Valve morphology
- Negative dromotropic agents
- Beta blockers
- Ivabradine
- Chronotropic incompetence
- Stroke volume
- Exercise tolerance
- Symptomatic patients
- Asymptomatic patients
- Comprehensive Valve Center
- Percutaneous mitral balloon commissurotomy (PMBC)
- Mitral valve surgery (repair, commissurotomy, replacement)
- Commissurotomy
- Valve replacement
- Mitral regurgitation (MR) ≤ 2 +
- Doppler echocardiography
- Sellar’s criteria
- Interventional procedures
- Diastolic filling period
- Transmitral mean gradient
- Cardiac output
- Fibrosis of the atria
- Fibrosis of internodal/interatrial tracts
- Damage to the sinoatrial node

Page 46 Extracted Terms:
Mitral valve  
Mitral stenosis (MS)  
Mitral regurgitation (MR)  
Percutaneous mitral balloon commissurotomy (PMBC)  
Mitral valve surgery  
Closed commissurotomy  
Open commissurotomy  
Mitral valve replacement  
Tricuspid regurgitation (TR)  
Tricuspid valve repair  
Rheumatic mitral stenosis  
Atrial fibrillation (AF)  
New York Heart Association (NYHA) class  
Pulmonary artery systolic pressure (PASP)  
Pulmonary hypertension (PH)  
Pulmonary artery pressure  
Doppler echocardiography  
Left atrial (LA) thrombus  
Left ventricular (LV) dysfunction  
Left ventricular diastolic dysfunction  
Left atrial noncompliance  
Net atrial‑ventricular compliance  
Mitral valve area (MVA)  
Valve morphology  
Leaflet calcification  
Subvalvular fusion/fibrosis  
Leaflet tethering  
Valve thickening  
Valve commissures  
Balloon catheter  
Surgical backup  
Long‑term follow‑up  
Survival rate  
Valve repair  
Comprehensive Valve Center  
Mitral valve morphology score  
Pulmonary vascular disease  
Pulmonary circulation  
Pulmonary systolic pressure  
Mitral valve area score  
Mitral valve anatomy  
Mitral subvalvular apparatus  
Valve anatomy assessment  
Mitral valve replacement strategy  
Mitral valve stenosis progression  
Valve surgical outcomes  
Valve replacement outcomes  
Valve replacement indications  
Valve repair outcomes  
Valvular thickening.

Page 47 Extracted Terms:
- Valvular heart disease  
- Mitral valve disease  
- Pulmonary arterial resistance  
- Right ventricular dysfunction  
- Tricuspid regurgitation (TR)  
- Pulmonary hypertension  
- Mitral regurgitation (MR)  
- Atrial fibrillation (AF)  
- Rheumatic mitral stenosis (MS)  
- Left atrial (LA) pressure  
- Percutaneous mitral balloon commissurotomy (PMBC)  
- P‑wave dispersion  
- Mitral valve area  
- Mitral valve gradient  
- Exercise testing  
- Pulmonary artery wedge pressure  
- Commissural calcification  
- Wilkins morphology score  
- New‑onset atrial fibrillation  
- NYHA Class III  
- NYHA Class IV  
- Severe mitral stenosis  
- Stage D mitral stenosis  
- Mitral annular calcification  
- Calcific mitral stenosis (calcific MS)  
- Radiation‑induced mitral stenosis  
- Post‑repair mitral stenosis  
- Annuloplasty ring  
- Mitral leaflet‑base calcification  
- Left‑ventricular compliance  
- Right‑ventricular compliance  
- Left‑atrial compliance  
- High procedural risk  
- Advanced age  
- Multiple comorbidities  
- Five‑year survival rate < 50 %  
- Elevated gradient  
- Planimetric area  
- Diastolic filling interval  
- Rapid ventricular response  
- Thromboembolic events  
- Symptom onset  
- Symptomatic patient  
- Hemodynamics  
- High LA pressure  
- Suboptimal valve anatomy  
- High success rate  
- Low risk  
- Periprocedural complications

Page 48 Extracted Terms:
**Key Heart‑Disease Terms Extracted**

1. Valvular heart disease  
2. Mitral regurgitation (MR)  
3. Acute mitral regurgitation  
4. Chronic mitral regurgitation  
5. Primary (degenerative) MR  
6. Secondary (functional) MR  
7. Mitral valve prolapse  
8. Myxomatous degeneration  
9. Barlow’s valve  
10. Fibroelastic deficiency  
11. Chordal rupture  
12. Papillary muscle rupture  
13. Mitral annular calcification  
14. Valve commissurotomy  
15. Prosthetic valve  
16. Intra‑aortic balloon counterpulsation (IABP)  
17. Vasodilator therapy  
18. Sodium nitroprusside  
19. Nicardipine  
20. Percutaneous circulatory assist device  
21. Catheter‑based therapies  
22. Transthoracic echocardiography (TTE)  
23. Transesophageal echocardiography (TEE)  
24. Pulmonary congestion  
25. Pulmonary hypertension  
26. Left ventricular (LV) systolic dysfunction  
27. Left atrial (LA) dilation  
28. ST‑segment‑elevation myocardial infarction (STEMI)  
29. Inferior infarction  
30. Cardiac output  
31. Aortic afterload  
32. Systemic hypotension  
33. Peripheral resistance  
34. Hemodynamic decompensation  
35. Mitral valve surgery / repair  
36. High surgical risk


Page 49 Extracted Terms:
**Key heart‑disease terms extracted from the guideline text**

- Valvular Heart Disease  
- Chronic Primary Mitral Regurgitation (MR)  
- Severe Primary MR  
- Mitral Intervention (repair or replacement)  
- Valve Repair  
- Valve Replacement  
- Mitral Valve Prolapse  
- Infective Endocarditis (IE)  
- Connective Tissue Disorders  
- Rheumatic Heart Disease  
- Cleft Mitral Valve  
- Radiation Heart Disease  
- Heart Failure (HF)  
- Myocardial Damage  
- Left Ventricular (LV) Size  
- Left Ventricular Function  
- LV Ejection Fraction (LVEF)  
- Right Ventricular (RV) Function  
- Left Atrial (LA) Size  
- Pulmonary Artery Pressure  
- Chamber Volumes  
- Volume Overload  
- Regurgitant Volume  
- Regurgitant Fraction  
- Effective Orifice Area  
- Proximal Isovelocity Surface Area (PISA)  
- Color Jet Area  
- Vena Contracta  
- Continuous‑Wave Doppler Intensity  
- Trans‑Mitral Jet Velocity Curve  
- Transthoracic Echocardiography (TTE)  
- Transesophageal Echocardiography (TEE)  
- Three‑Dimensional TEE  
- Cardiac Magnetic Resonance (CMR)  
- Cardiac Catheterization (invasive evaluation)  
- Intraoperative TEE  
- Stages A–D (valvular disease severity/management stages)  
- ACC/AHA Guideline for the Management of Valvular Heart Disease  
- Clinical Statements & Guidelines  

These terms encompass the diseases, anatomical structures, diagnostic modalities, severity indices, and management strategies discussed in the excerpt.

Page 50 Extracted Terms:
- Intraoperative trans‑esophageal echocardiography (TEE)  
- 3‑dimensional TEE (“surgical view”)  
- Mitral regurgitation (MR)  
- Mitral valve anatomy  
- Mitral valve repair  
- Residual MR  
- Reoperation  
- Left ventricle (LV)  
- Systolic anterior leaflet motion  
- Left ventricular outflow tract obstruction  
- Transcatheter edge‑to‑edge repair  
- Primary severe MR  
- High surgical risk  
- Diagnostic testing: changing signs or symptoms  
- Primary MR stages (B–D)  
- Transthoracic echocardiography (TTE)  
- Mitral valve apparatus  
- Left ventricular ejection fraction (LVEF)  
- Left ventricular end‑systolic dimension (LVESD)  
- Left atrial enlargement  
- Pulmonary hypertension  
- Exertional dyspnea  
- Exercise tolerance  
- Effective regurgitant orifice (ERO)  
- Infective endocarditis (IE)  
- Mitral valve prolapse  
- Flail leaflet  
- Rheumatic valve changes  
- Holosystolic eccentric jet MR  
- Central jet MR  
- Vena contracta  
- Regurgitant volume  
- Regurgitant fraction  
- Mild, moderate, and severe MR definitions  
- Valve thickening  
- Leaflet restriction  
- Normal coaptation  
- Loss of coaptation  
- Left atrium (LA)

Page 51 Extracted Terms:
- Severe mitral regurgitation (MR)  
- Mitral valve surgery  
- Mitral valve repair  
- Left ventricular (LV) function  
- Left ventricular ejection fraction (LVEF)  
- Left ventricular end‑diastolic diameter (LVEDD)  
- Left ventricular end‑systolic diameter (LVESD)  
- Global longitudinal strain  
- LV compliance  
- LV dysfunction  
- LV remodeling  
- Pulmonary artery pressure  
- Pulmonary hypertension  
- Right ventricular (RV) function  
- Tricuspid regurgitation (TR)  
- Atrial fibrillation (AF)  
- Orthopnea  
- Dyspnea on exertion  
- Exercise tolerance  
- Symptom onset  
- Asymptomatic patients  
- Stage B / C1 disease (valvular disease stages)  
- Transthoracic echocardiography (TTE)  
- Cardiac catheterization  
- Left ventriculography  
- Hemodynamic measurements  
- Invasive hemodynamic evaluation  
- Serum biomarkers  
- Natriuretic peptides (BNP, NT‑proBNP)  
- Diuretics  
- Comprehensive valve center  
- Chronic primary MR (valvular heart disease)

Page 52 Extracted Terms:
**Key heart‑disease terms extracted from the text**

- Mitral Regurgitation (MR)  
- Primary MR  
- Chronic Primary MR  
- Acute Severe Symptomatic MR  
- Valvular Heart Disease  
- Pulmonary Hypertension  
- Left Atrial (LA) pressure  
- Pulmonary Artery Wedge pressure  
- Transpulmonary gradient  
- Left Ventricular (LV) systolic dysfunction  
- LV systolic dysfunction  
- LV systolic function  
- Heart Failure (HF)  
- Systolic dysfunction  
- Exercise testing  
- Hemodynamic exercise testing  
- Treadmill exercise test  
- Exercise echocardiography  
- Cardiopulmonary exercise testing  
- Cardiac catheterization  
- Echocardiography (including Doppler)  
- Doppler echocardiography  
- Ventriculography  
- Vasodilator therapy  
- Guideline‑Directed Medical Therapy (GDMT)  
- Beta‑adrenergic blockade  
- ACE inhibitors  
- ARBs (angiotensin‑II receptor blockers)  
- Aldosterone antagonists  
- Transcatheter repair  
- Diagnostic testing  
- Guideline stages B, C, D  
- Lung disease (concomitant)  
- Exercise tolerance  
- Oxygen consumption measurements  
- Dyspnea  
- LV filling pressures  
- Afterload reduction  

These items encompass the principal clinical concepts, diagnostic modalities, therapeutic strategies, and disease stages referenced in the guideline excerpt.

Page 53 Extracted Terms:
**Key Heart‑Disease–Related Terms**

- Mitral valve prolapse  
- Mitral regurgitation (MR)  
- Concomitant hypertension  
- Left‑ventricular (LV) systolic pressure  
- Transmitral gradient  
- Chronic primary MR  
- Mitral valve intervention  
- Mitral valve surgery  
- Mitral valve repair  
- Mitral valve replacement  
- Degenerative mitral‑valve disease  
- Left‑ventricular ejection fraction (LVEF)  
- LV systolic dysfunction  
- LV end‑systolic diameter (LVESD)  
- NYHA functional class III/IV  
- Transcatheter edge‑to‑edge repair (TEER)  
- Rheumatic valve disease  
- Posterior leaflet pathology  
- Bileaflet (anterior‑and‑posterior) prolapse/replacement  
- Papillary‑muscle rupture  
- Infective endocarditis (IE)  
- Cleft mitral valve  
- Mechanical mitral‑valve replacement  
- Anticoagulation (post‑replacement)  
- Hospital mortality rate  
- High‑volume valve‑surgery centers  
- Mixed valve disease (combined MR + aortic stenosis)  
- Heart valve team  
- Surgical risk (high or prohibitive)  
- Severity thresholds for MR (e.g., “severe primary MR”)  
- LV functional thresholds (LVEF ≤ 60 %, LVESD ≥ 40 mm)  
- Stage C1, C2, and D (guideline staging).

Page 54 Extracted Terms:
- Valvular Heart Disease  
- Mitral Regurgitation (MR)  
- Left Ventricular Ejection Fraction (LVEF)  
- Left Ventricular End‑Systolic Diameter (LVESD)  
- Left Ventricular (LV) dysfunction  
- Pulmonary hypertension  
- Mitral Valve Repair  
- Mitral Valve Replacement (MVR)  
- Surgical volume (expertise)  
- Operative mortality  
- Long‑term survival  
- Freedom from reoperation  
- Freedom from recurrent moderate/severe MR  
- Effective Regurgitant Orifice (ERO)  
- End‑Systolic Dimension (ESD)  
- Regurgitant Fraction (RF)  
- Regurgitant Volume (RVol)  
- Vena Contracta (VC)  
- Comprehensive Valve Center (CVC)

Page 55 Extracted Terms:
- Valvular Heart Disease  
- Mitral Regurgitation (MR)  
- Primary MR  
- Secondary MR (chronic secondary MR)  
- Ischemic chronic secondary MR  
- Non‑ischemic chronic secondary MR  
- Left Ventricular (LV) dysfunction  
- Left Ventricular End‑Systolic Diameter (LVESD)  
- Left Ventricular Ejection Fraction (LVEF)  
- Heart Failure (HF)  
- Transcatheter Edge‑to‑Edge Repair (TEER)  
- Mitral Valve Repair  
- Mitral Valve Replacement  
- Rheumatic Mitral Valve Disease  
- Degenerative Mitral Disease  
- Coronary Artery Disease (CAD)  
- Atrial Fibrillation (AF)  
- Mitral Annular Dilation  
- Papillary Muscle Displacement  
- Valve apparatus  
- Valve leaflets  
- Valve chords  
- Valve clip (mitral valve clip)  
- Annuloplasty  
- Valve tethering  
- Valve remodeling (LV remodeling)  
- Valve repair durability  
- Valve repair success rate  
- Valve repair freedom from reoperation  
- Valve replacement freedom from recurrence  
- Operative mortality  
- Mechanical prosthesis  
- Biological prosthesis  
- Valve surgery  
- Valve center (comprehensive valve center)  
- Valve lesion  
- Volume overload  
- LV dilation  
- Valve repair vs. replacement strategy  
- Valve disease progression  
- Valve repair indications (≤½ posterior leaflet)  
- Valve repair criteria (LVEF > 64 %, LVESD < 37 mm)  
- Valve repair thresholds (LVESD ≈ 40 mm, LVEF ≈ 60 %)

Page 56 Extracted Terms:
- Valvular heart disease  
- Mitral regurgitation (MR)  
- Primary MR  
- Secondary MR  
- Regurgitant orifice area (ERO)  
- Regurgitant volume  
- Transthoracic echocardiography (TTE)  
- Transesophageal echocardiography (TEE)  
- Stress nuclear/PET imaging  
- Cardiac magnetic resonance (CMR)  
- Coronary CT angiography  
- Coronary arteriography  
- Myocardial viability  
- Transcatheter mitral valve intervention  
- Transcatheter edge‑to‑edge repair (TEER / MitraClip)  
- Mitral valve morphology  
- Coaptation length  
- Leaflet tethering  
- A2/P2 scallops  
- Valve calcification  
- Cleft in A2/P2 scallops  
- Primary/secondary chordal support  
- Left‑ventricular (LV) remodeling (regional/global)  
- LV systolic dysfunction  
- Left ventricular ejection fraction (LVEF)  
- Pulmonary hypertension  
- Ischemic MR  
- Non‑ischemic MR  
- Coronary artery disease (CAD)  
- Percutaneous coronary intervention (PCI)  
- Coronary artery bypass grafting (CABG)  
- Guideline‑directed medical therapy (GDMT)  
- STICH trial  
- COAPT trial  
- EVEREST trial  
- Heart failure (HF)  
- Functional mitral regurgitation  
- Mitral valve leaflet scallops  
- Hibernating myocardium  
- Viable myocardium  
- 10‑year survival rate  
- Moderate MR (ERO ≥ 20 mm²)  
- Severe MR (ERO ≥ 40 mm² or ≥ 0.4 cm²; regurgitant volume ≥ 60 mL)

Page 57 Extracted Terms:
- Heart Failure (HF)  
- Left Ventricular Ejection Fraction (LVEF)  
- Valvular Heart Disease  
- Mitral Regurgitation (MR)  
- Secondary Mitral Regurgitation (secondary MR)  
- Standard Guideline‑Directed Medical Therapy (GDMT) for HF  
- Angiotensin‑Converting Enzyme (ACE) inhibitors  
- Angiotensin II Receptor Blockers (ARBs)  
- β‑Blockers  
- Aldosterone Antagonists  
- Sacubitril/Valsartan  
- Biventricular Pacing (Cardiac Resynchronization Therapy, CRT)  
- Coronary Revascularization  
- Chronic Severe Secondary MR  
- Staging of Secondary MR (Stages A, B, C, D)  
- Valve Anatomy (leaflets, chordae, annulus)  
- Valve Hemodynamics  
- Effective Regurgitant Orifice area (ERO)  
- Regurgitant Volume  
- Regurgitant Fraction  
- Regional Wall Motion Abnormalities  
- Left Ventricular (LV) Dilation  
- LV Systolic Dysfunction  
- Primary Myocardial Disease  
- Left Atrial (LA) Size/volume  
- Exertional Dyspnea  
- Decreased Exercise Tolerance  
- Multidisciplinary Team (MDT)  
- Cardiologist Expert in Heart Failure  

These terms capture the key clinical concepts, therapies, and anatomical/hemodynamic aspects related to heart disease that are referenced in the provided guideline excerpt.

Page 58 Extracted Terms:
- Secondary mitral regurgitation (MR)  
- Chronic severe secondary MR  
- Severe secondary MR  
- Left ventricular (LV) systolic dysfunction  
- Reduced left ventricular ejection fraction (LVEF < 50 %)  
- Preserved LVEF (≥ 50 %)  
- New York Heart Association (NYHA) class II–IV  
- Heart failure (HF)  
- Stage D heart failure  
- Guideline‑directed medical therapy (GDMT)  
- Transcatheter edge‑to‑edge repair (TEER)  
- Transesophageal echocardiography (TEE)  
- LV end‑systolic dimension (LVESD)  
- LV end‑diastolic dimension (LVEDD)  
- Pulmonary artery systolic pressure  
- Mitral valve surgery (repair/replacement)  
- Coronary artery bypass grafting (CABG)  
- Myocardial ischemia  
- Atrial annular dilation  
- Atrial fibrillation (AF)  
- Chordal‑sparing mitral valve replacement  
- Downsized annuloplasty repair  
- COAPT trial  
- MITRA‑FR study  
- STICH trial  
- Hibernating myocardium  
- LV and left atrial (LA) reverse remodeling  
- MitraClip device  
- Ventricular remodeling  
- Clinical guideline (ACC/AHA)  
- Valvular heart disease  
- Surgical correction of MR  
- Revascularization  
- Optimal GDMT  
- Surgical timing for mixed valve disease  
- Mitral valve repair strategies  
- Mitral valve replacement vs repair  
- Symptom‑based indications for intervention  
- LV dysfunction thresholds for TEER  
- Pulmonary hypertension (moderate)  
- Mitral valve anatomy  
- Mitral valve leaflets malcoaptation  
- Restrictive cardiomyopathy  
- Non‑obstructive hypertrophic cardiomyopathy  
- Sinus‑based atrial maze procedure  
- Observation‐based therapeutic strategies  
- Outcome measures: survival, hospitalization, quality of life  
- Trial inclusion criteria (LVESD ≤70 mm)  
- MR severity (effective regurgitant orifice area)  
- Symptom persistence despite medical therapy  

These terms represent the key concepts and entities related to heart disease discussed in the provided guideline text.

Page 59 Extracted Terms:
**Key heart‑disease related terms extracted from the text**

1. Mitral valve repair  
2. Mitral valve replacement  
3. Mitral regurgitation (MR)  
4. Secondary mitral regurgitation  
5. Primary mitral regurgitation  
6. Ischemic mitral regurgitation  
7. Anterior‑posterior (annular) dilation  
8. Atrial fibrillation (AF)  
9. Coronary artery bypass graft (CABG)  
10. Effective regurgitant orifice (ERO)  
11. Regurgitant fraction (RF)  
12. Regurgitant volume (RVol)  
13. Guideline‑directed medical therapy (GDMT)  
14. Heart failure (HF)  
15. Left ventricular ejection fraction (LVEF)  
16. Left ventricular end‑systolic dimension (LVESD)  
17. Pulmonary artery systolic pressure (PASP)  
18. Ventricular dilation  
19. Left ventricular remodeling  
20. Papillary muscle displacement  
21. Peak oxygen consumption  
22. Survival rate  
23. Quality of life  
24. Chamber size  
25. Recurrent mitral regurgitation  
26. Repeat hospitalization  
27. Medications (Rx)  
28. Chronic severe secondary MR  
29. RCT (Randomized Controlled Trial)  
30. Durability of repair/replacement  

These terms capture the clinical concepts, interventions, measurements, and outcomes discussed in the guidelines excerpt.

Page 60 Extracted Terms:
- Valvular heart disease  
- Tricuspid valve disease  
- Tricuspid regurgitation (TR)  
- Classification and stages of TR  
- Trace, mild, significant, worsening TR  
- Primary disorders of the tricuspid apparatus  
- Rheumatic disease  
- Infective endocarditis (IE)  
- Congenital disease (e.g., Ebstein’s anomaly, levo‑transposition of the great arteries)  
- Myxomatous changes  
- Blunt chest trauma  
- Carcinoid syndrome  
- Drug‑induced TR  
- Radiation‑induced TR  
- Iatrogenic etiologies (device leads, endomyocardial biopsy)  
- Secondary TR  
- Tricuspid annular dilation  
- Leaflet tethering  
- Right‑ventricular (RV) remodeling  
- Pressure overload  
- Volume overload  
- Pulmonary hypertension (primary or secondary to left‑sided heart disease)  
- Dilated cardiomyopathy  
- Atrial fibrillation (AF)  
- Isolated TR (associated with AF, preserved LVEF)  
- RV volume overload (shunts/high‑output states)  
- Central venous pressure  
- End‑organ damage (hepatic failure, renal failure)  
- Survival impact of Stage D TR  
- Pulmonary artery systolic pressure (PASP)  
- Cardiac index  
- Right‑sided diastolic pressures  
- Pulmonary vascular resistance  
- Right ventriculography  
- Physical examination findings in TR  
- Transthoracic echocardiography (TTE)  
- Invasive measurements of pulmonary artery pressures  
- Cardiac catheterization  
- Tricuspid annular plane systolic excursion (TAPSE)  
- Tricuspid annular velocity (S′)  
- RV end‑systolic area  
- Fractional area change  
- 3D transesophageal echocardiography (TEE)  
- Magnetic resonance imaging (MRI)  
- Computed tomography (CT) scan  
- Left ventricular ejection fraction (LVEF)

Page 61 Extracted Terms:
- Tricuspid regurgitation (TR)  
- Right‑sided heart failure (HF)  
- Pulmonary hypertension  
- Pulmonary artery pressure  
- Right atrial pressure  
- Right ventricular pressure  
- Pulmonary vasodilators  
- Invasive measurement (direct invasive measurement)  
- Thermodilution cardiac output  
- Fick cardiac output  
- Guideline‑Directed Medical Therapy (GDMT)  
- Heart failure with reduced left ventricular ejection fraction (LVEF)  
- Diuretics (loop diuretics)  
- Aldosterone antagonists  
- Hepatic congestion  
- Secondary hyperaldosteronism  
- Pulmonary vascular resistance  
- Pulmonary vasomodulators  
- Rhythm control of atrial fibrillation (AF)  
- Annular dilation (associated with AF)  
- Low‑salt diet  
- Compression stockings (support stockings)  
- Stages C and D of tricuspid regurgitation  
- Central jet (≥50% right atrial)  
- Vena contracta width (≥0.7 cm)  
- Effective regurgitant orifice (ERO) (≥0.40 cm²)  
- Regurgitant volume (≥45 mL)  
- Dense continuous‑wave signal (triangular shape)  
- Hepatic vein systolic flow reversal  
- Dilated right ventricle (RV)  
- Dilated right atrium (RA)  
- c‑V wave (systolic positive wave)  
- Right‑ventricular afterload (pulmonary vascular resistance)  
- Systemic congestion (peripheral edema, ascites)

Page 62 Extracted Terms:
**Key heart‑disease terms extracted from the guideline**

- Severe tricuspid regurgitation (TR)  
- Primary TR  
- Secondary TR  
- Tricuspid annular dilation  
- Tricuspid annulus end‑diastolic diameter  
- Tricuspid annulus dilation > 4.0 cm (40 mm)  
- Tricuspid annulus dilation > 40 mm or > 21 mm/m² indexed to BSA  
- Tricuspid annulus dilation > 70 mm intra‑operatively  
- Tricuspid valve surgery (repair or replacement)  
- Tricuspid valve repair  
- Tricuspid valve replacement  
- Left‑sided valve surgery (mitral, aortic)  
- Reoperation with isolated tricuspid valve surgery  
- Right‑sided heart failure (HF)  
- Right ventricular (RV) dilation  
- RV systolic dysfunction  
- RV remodeling  
- Leaflet tethering height  
- Pulmonary hypertension (PH)  
- Pulmonary artery hypertension  
- Severe pulmonary hypertension  
- Left‑sided valve disease  
- Right‑sided HF signs and symptoms  
- Stage B, C, D progression (tricuspid regurgitation stages)  
- End‑organ damage/dysfunction (e.g., renal, hepatic)  
- Operative mortality (8–20 %)  
- Perioperative mortality (10–25 %)  
- Catheter‑based therapies for isolated TR  
- Surgical intervention timing  
- Operative risk reduction (advanced surgical techniques)  
- Tricuspid annulus end‑diastolic diameter > 4 cm  
- Atrial fibrillation (AF) (risk factor for TR progression)  
- Intra‑annular RV pacemaker or implantable cardioverter‑defibrillator leads  
- Functional outcome and survival  
- Tricuspid valve repair vs. replacement selection criteria  

These terms capture the clinical concepts, measurements, stages, procedures, and risk factors central to the management of valvular heart disease as discussed in the guideline.

Page 63 Extracted Terms:
- Tricuspid regurgitation (TR)  
- Tricuspid valve repair  
- Tricuspid valve replacement  
- Right‑sided heart failure (HF)  
- Pulmonary hypertension (PH)  
- Right ventricular (RV) dysfunction  
- Atrial fibrillation (AF)  
- Secondary tricuspid regurgitation  
- Annular dilation  
- Leaflet tethering  
- Carcinoid heart disease  
- Flail tricuspid leaflet  
- Guideline‑directed medical therapy (GDMT)  
- Pulmonary artery pressure (PAP)  
- Left‑sided valve disease  
- Surgical intervention  
- Operative mortality  
- Systemic venous congestion  
- Congestive hepatopathy  
- Cirrhosis  
- Stage D heart failure  
- Right ventricular size assessment  

Page 64 Extracted Terms:
**Key Heart‑Disease Terms Identified**

- Valvular Heart Disease (VHD)  
- Aortic valve  
- Mitral valve  
- Tricuspid valve (TR)  
- Pulmonary valve  
- Tricuspid regurgitation (TR)  
- Right‑ventricular (RV) dysfunction  
- Pulmonary hypertension  
- Right‑sided heart failure (HF)  
- Severe tricuspid regurgitation (severe TR)  
- Reoperative tricuspid surgery  
- Left‑sided valve surgery  
- Reoperative mortality  
- Left‑ventricular (LV) dysfunction  
- Hepatic dysfunction (right‑HF‑related)  
- Renal dysfunction (right‑HF‑related)  
- Mixed valve disease  
- Stenosis  
- Regurgitation (valvular)  
- Concentric hypertrophy  
- Eccentric hypertrophy  
- Right‑ventricular (RV) systolic dysfunction  
- Cardiac remodeling  
- Ventricular function  
- Transthoracic echocardiography (TTE)  
- Biomarkers (e.g., BNP)  
- Invasive hemodynamic measurements  
- Filling pressure / filling pressures  
- Doppler hemodynamics  
- Jet velocities  
- Valve areas  
- Regurgitant flow  
- Regurgitant orifice area  
- Catheterization (exercise/at rest)  
- Comprehensive imaging approach  
- Clinical guidelines (ACC/AHA)  
- Management of congenital heart disease  
- Comprehensive Valve Center  

These terms encapsulate the major concepts related to heart disease, valve pathology, diagnostic modalities, and clinical considerations discussed in the provided guideline excerpt.

Page 65 Extracted Terms:
- Valvular Heart Disease (VHD)  
- Mixed aortic stenosis (AS) and aortic regurgitation (AR)  
- Symptomatic patients  
- Peak transvalvular jet velocity  
- Mean transvalvular gradient  
- Aortic valve replacement (AVR)  
- Surgical aortic valve replacement (SAVR)  
- Transcatheter aortic valve implantation (TAVI)  
- Left ventricular ejection fraction (LVEF)  
- Stage B disease (progressive, no therapeutic action)  
- Mixed moderate AS/AR  
- Mixed severe AS and mitral regurgitation (MR)  
- Primary MR (organic mitral valve disease)  
- Secondary MR (LV‑remodeling‑related)  
- Left ventricular dysfunction (LVEF < 50 %)  
- Surgical risk categories: low, intermediate, high, prohibitive  
- Double valve replacement (AVR + mitral valve replacement)  
- Mitral valve surgery (repair or replacement)  
- Mitral transcatheter edge‑to‑edge repair (TEER)  
- Valve replacement strategy (SAVR vs. TAVI)  
- Multidisciplinary team (MDT) involvement  
- Shared decision‑making with patients  
- Pressure gradient across the aortic valve  
- LV remodeling and its effect on MR  
- Clinical statements and guidelines (ACC/AHA)  
- Sequelae of AVR on MR (improvement vs. persistence)  
- Mortality risk associated with moderate mixed disease  
- Natural history of moderate mixed VHD  
- Decision criteria for valve replacement in symptomatic patients  
- Stage B progressive disease definition  
- Mitral valve repair feasibility  
- Post‑TAVI mitral repair potential  
- Outcomes of staged procedures (TAVI → TEER)  
- Evaluation of short‑ and long‑term outcomes in complex valve disease.

Page 66 Extracted Terms:
- Aortic valve replacement (AVR)  
- Surgical aortic valve replacement (SAVR)  
- Transcatheter aortic valve implantation (TAVI)  
- Transcatheter edge‑to‑edge repair (TEER)  
- Mitral regurgitation (MR)  
- Aortic stenosis (AS)  
- Mitral stenosis (MS)  
- Aortic regurgitation (AR)  
- Rheumatic valve disease  
- Mitral annular calcification  
- Left atrial (LA) pressure  
- Pulmonary artery wedge pressure  
- Left ventricle (LV)  
- Transcatheter approach  
- Surgical approach  
- Prosthetic valve  
- Transthoracic echocardiogram (TTE)  
- Transesophageal echocardiogram (TEE)  
- Cardiac computed tomography (CT)  
- Fluoroscopy  
- Valve hemodynamics  
- Valve dysfunction  
- Bioprosthetic surgical valve  
- Bioprosthetic TAVI  
- Mitral valve replacement  
- Mitral valve repair  
- Mixed mitral stenosis and mitral regurgitation (MS‑MR)  
- Mixed mitral stenosis and aortic regurgitation (MS‑AR)  
- Mixed mitral stenosis and aortic stenosis (MS‑AS)  
- LV filling  
- Stroke volume  
- Transvalvular gradient  
- Valve anatomy  
- Valve disease  
- Valve surgery  
- Valve replacement  
- Valve repair

Page 67 Extracted Terms:
- Prosthetic heart valves  
- Repaired native valves  
- Ventricular function  
- Atrial fibrillation (AF)  
- Pulmonary hypertension  
- Coronary artery disease (CAD)  
- Valve‑related complications  
- Endocarditis prophylaxis  
- Anticoagulation therapy  
- Transthoracic echocardiography (TTE)  
- Transesophageal echocardiography (TEE)  
- Cardiac CT imaging  
- Fluoroscopy  
- Transvalvular velocities  
- Transvalvular pressure gradients  
- Transvalvular leak  
- Paravalvular leak  
- Bioprosthetic valve dysfunction  
- Mechanical valve dysfunction  
- Heart failure (HF) symptoms  
- Shock  
- Thromboembolic events  
- Hemolysis  
- INR monitoring  
- Prosthesis‑patient mismatch  
- Functional stenosis  
- Valve area measurement  
- Left ventricular (LV) volumes  
- Left ventricular ejection fraction (LVEF)  
- Pulmonary artery systolic pressure  
- Right heart function  
- Mitral regurgitation (MR)  
- Pannus formation  
- Vegetation  
- Abscess formation  
- Valve obstruction  
- Reduced valve motion due to pannus or thrombus  
- Structural valve deterioration  
- Valve gradient ≥10 mm Hg  
- Transprosthetic regurgitation severity  
- Early postoperative complications  
- Routine follow‑up visits  
- Valve type (aortic, mitral, bioprosthetic)  
- Residual heart disease  
- Surgical aortic valve bioprosthesis  
- Incidence of valve deterioration after 10 years  
- Risk factors: young age (<60 yr), smoking, diabetes mellitus, chronic kidney disease, initial mean gradient ≥15 mm Hg, valve type.

Page 68 Extracted Terms:
- Aortic valve
- Valve dysfunction
- Prosthetic valve
- Bioprosthetic valve (bioprosthesis)
- Mechanical valve
- Valve replacement
- Valve repair
- Transcatheter aortic valve implantation (TAVI)
- Surgical aortic valve replacement (SAVR)
- Mitral valve replacement
- Pulmonic autograft (Ross procedure)
- Anti‑coagulation therapy
- Vitamin K antagonist (VKA) therapy
- Anticoagulant therapy
- Valve reintervention
- Structural valve deterioration (SVD)
- Transesophageal echocardiography (TTE)
- Hemodynamics
- Atrial fibrillation (AF)
- Pulmonary artery pressure
- Left ventricular (LV) function
- Valve choice
- Shared decision‑making
- Valve durability
- Patient‑prosthesis mismatch
- Invasive monitoring
- Long‑term VKA therapy
- Inconvenience of monitoring
- Dietary restrictions
- Medication interactions
- Athletic activity restrictions
- Radiation exposure risks
- Clinical statements
- Guidelines (ACC/AHA)

Page 69 Extracted Terms:
- Valvular heart disease  
- Aortic valve replacement (AVR)  
- Mechanical valve prosthesis  
- Bioprosthetic valve prosthesis  
- Valve durability  
- Valve type and size  
- Valve hemodynamics  
- Structural deterioration of bioprosthesis  
- Reintervention / reoperation  
- Anticoagulation therapy  
- Vitamin K antagonist (VKA)  
- Warfarin  
- International normalized ratio (INR) monitoring  
- Bleeding risk  
- Thromboembolic events  
- Antithrombotic safety in mechanical valves  
- Atrial fibrillation (AF)  
- Transcatheter aortic valve implantation (TAVI)  
- Valve‑in‑valve (ViV) procedure  
- Small aortic root / patient–prosthesis mismatch  
- Surgical vs. interventional risk  
- Age‑dependent valve choice (≤50 y, 50–65 y, >65 y)  
- Pregnancy‑related anticoagulation considerations  
- Long‑term anticoagulation complications  
- Anticoagulation monitoring accessibility  
- High‑risk reintervention (e.g., porcelain aorta, prior radiation)  
- Access to low‑mortality surgical centers  
- Prosthetic valve selection factors (durability, anticoagulation risk, patient preference)

Page 70 Extracted Terms:
- Bioprosthetic valve replacement  
- Mechanical valve replacement  
- Anticoagulation (VKA therapy)  
- Structural valve deterioration  
- Reoperation / repeat intervention  
- Bleeding complications  
- Thromboembolism / stroke risk  
- Aortic valve replacement (AVR)  
- Surgical aortic valve replacement (SAVR)  
- Transcatheter aortic valve implantation (TAVI)  
- Mitral valve replacement  
- Valve durability  
- Life expectancy / longevity  
- Shared decision‑making  
- Transcatheter bioprosthetic valves  
- Valve durability vs age  
- Mortality rate  
- Bioprosthetic mitral valve  
- Mechanical mitral valve  
- Long‑term VKA anticoagulation  
- Valve type selection  
- Valve durability data (20‑year, 5‑year)

Page 71 Extracted Terms:
- Bioprosthetic mitral valve replacement  
- Mechanical prosthetic valve  
- Ross procedure (pulmonary autograft)  
- Pulmonary homograft  
- Valve degeneration  
- Valve regurgitation  
- Antithrombotic therapy  
- Anticoagulation  
- Vitamin K antagonist (VKA)  
- International Normalized Ratio (INR)  
- Atrial fibrillation (AF)  
- Thromboembolism  
- Left ventricular dysfunction  
- Hypercoagulable state  
- Tissue valve (bioprosthetic)  
- Transcatheter aortic valve implantation (TAVI)  
- Surgical aortic valve replacement (SAVR)  
- Low-dose rivaroxaban  
- Dual antiplatelet therapy (aspirin + clopidogrel)  
- Direct thrombin inhibitor (dabigatran)  
- Anti‑Xa direct oral anticoagulants  
- Aspirin 75‑100 mg daily  
- Clopidogrel 75 mg daily  
- Thrombosis prevention in prosthetic valves  
- Bleeding risk management

Page 72 Extracted Terms:
- Mechanical valve prostheses  
- Bioprosthetic valve  
- Anticoagulant therapy  
- Vitamin K antagonist (VKA)  
- International Normalized Ratio (INR)  
- Thromboembolism  
- Valve thrombosis  
- Embolic events  
- Bleeding complications  
- Hemodynamic shear stress  
- Platelet activation  
- Aortic valve replacement (AVR)  
- Mitral valve replacement  
- Transcatheter Aortic Valve Implantation (TAVI)  
- Percutaneous coronary intervention (PCI)  
- Aspirin  
- Clopidogrel  
- Dual‑antiplatelet therapy  
- Antiplatelet therapy  
- Antithrombin agents  
- Anti‑Xa agents  
- Atrial fibrillation (AF)  
- Venous thromboembolic disease  
- Hypercoagulable state  
- Left‑ventricular (LV) dysfunction  
- Ball‑in‑cage valve  
- Low‑intensity anticoagulation  
- High‑intensity anticoagulation  
- INR target ranges  
- Stroke  
- Myocardial infarction  
- Transient ischemic attack (TIA)  
- Major adverse events  
- Mortality / survival rate  
- Coagulopathy  
- Prosthetic heart valve  
- Thromboembolic risk factors  
- Mechanical valve thrombogenicity  
- Embolism prevention  
- Prothrombotic state  
- Hemorrhage  
- Clinical guidelines  
- ACC/AHA  
- Circulation journal  

Page 73 Extracted Terms:
- Valvular Heart Disease  
- Aortic Valve Replacement (AVR)  
- Mitral Valve Replacement (MVR)  
- Bioprosthetic Valve  
- Biological Valve  
- Mechanical Valve  
- Transcatheter Aortic Valve Implantation (TAVI)  
- Anticoagulation  
- Antiplatelet Therapy  
- Dual Antiplatelet Therapy  
- Single-Anticoagulant Therapy  
- Vitamin K Antagonist (VKA)  
- Aspirin  
- Thromboembolism  
- Thromboembolic Events  
- Stroke  
- Ischemic Stroke  
- Myocardial Infarction  
- Major Bleeding  
- Life‑threatening Bleeding  
- Endothelialization  
- International Normalized Ratio (INR)  
- On‑X AVR  
- Hypercoagulable State  
- Left Ventricular (LV) Systolic Dysfunction  
- Sinus Rhythm  
- Atrial Fibrillation (AF)  
- Bioprosthetic Aortic Valve  
- Bioprosthetic Mitral Valve  
- Antithrombotic Therapy  

Page 74 Extracted Terms:
Valvular heart disease  
Bioprosthetic mitral valve replacement  
Bioprosthetic aortic valve replacement (bioprosthetic AVR)  
Mechanical valve prosthesis  
Transcatheter aortic valve implantation (TAVI)  
Valve‑in‑valve TAVI (ViV TAVI)  
Self‑expanding TAVI device  
On‑X aortic valve  
Anticoagulation therapy  
Vitamin K antagonist (VKA)  
Direct oral anticoagulant (DOAC)  
Low‑dose aspirin  
Aspirin 81 mg daily  
Dual‑antiplatelet therapy (e.g., aspirin + clopidogrel)  
International Normalized Ratio (INR)  
INR target ranges (1.5‑2.0, 2.5, 2.0‑3.0)  
Stroke (ischemic)  
Transient ischemic attack (TIA)  
Myocardial infarction  
Major bleeding  
Minor bleeding  
Cerebrovascular events  
Valve leaflet thrombosis  
Valve perforation  
Mean transvalvular gradient >10 mm Hg  
Low‑dose rivaroxaban  
GALILEO trial  
Antithrombotic strategy  
Antiplatelet strategy  
Bleeding risk  
Mortality (all‑cause, cardiovascular)

Page 75 Extracted Terms:
- Valvular heart disease  
- Low‑dose aspirin  
- Clopidogrel  
- Rivaroxaban  
- Warfarin  
- Dabigatran  
- Mechanical valve prosthesis  
- Oral anti‑Xa agents  
- Bridging therapy  
- Oral anticoagulation  
- Prosthetic heart valves  
- Mechanical heart valves  
- Bileaflet mechanical aortic valve replacement (AVR)  
- Vitamin K antagonist (VKA)  
- Therapeutic INR  
- Subtherapeutic INR  
- 4‑factor prothrombin complex concentrate (4‑PCC)  
- Activated prothrombin complex concentrate (aPCC)  
- Embolic events  
- Valve thrombosis  
- Aortic valve replacement (AVR)  
- Mitral valve replacement (MVR)  
- Thromboembolic complications  
- Bleeding complications  
- Minor procedures (e.g., dental extraction, cataract removal)  
- Invasive procedures  
- Non‑cardiac surgery  
- Transesophageal echocardiography (TEE)  
- Transthoracic echocardiography (TTE)  
- Computed tomography (CT)  
- International normalised ratio (INR)

Page 76 Extracted Terms:
- Valvular heart disease  
- Bioprosthetic heart valves  
- Annuloplasty rings  
- Anticoagulation for atrial fibrillation (AF)  
- CHA₂DS₂‑VASc score  
- Mechanical aortic valve replacement (AVR)  
- Mechanical mitral valve replacement  
- Mechanical bileaflet AVR  
- Bridging anticoagulation therapy  
- Invasive procedures  
- Thromboembolic risk factors  
- International Normalized Ratio (INR)  
- Unfractionated heparin (UFH)  
- Low‑molecular‑weight heparin (LMWH)  
- Prothrombin complex concentrate (PCC)  
- Fresh frozen plasma (FFP)  
- Direct oral anticoagulants (NOACs)  
- Warfarin  
- Moderate to severe rheumatic mitral stenosis  
- Bioprosthetic valve replacement or repair  
- Native valve repair  
- Antithrombotic therapy  
- Anticoagulation reversal  
- Vitamin K  
- Bleeding risk  
- Thrombosis risk  
- Prosthetic heart valves  

Page 77 Extracted Terms:
- Valvular Heart Disease  
- Prosthetic Valves  
- Mechanical Valves  
- Bioprosthetic Valves  
- Annuloplasty Rings  
- Direct Oral Anticoagulants (DOACs)  
- Vitamin K Antagonists (VKA)  
- Four‑factor Prothrombin Complex Concentrate (PCC)  
- Activated Prothrombin Complex (aPCC)  
- Idarucizumab (dabigatran antidote)  
- Andexanet Alfa (anti‑Xa antidote)  
- Intravenous Vitamin K  
- International Normalized Ratio (INR)  
- Supratherapeutic INR (>5.0)  
- Inadequate or excessive anticoagulation  
- Bleeding / Hemorrhage (including uncontrolled bleeding, life‑threatening bleeding)  
- Thromboembolism  
- Stroke (cerebrovascular event)  
- Systemic embolic event  
- Low‑dose Aspirin (75–100 mg)  
- Antiplatelet Therapy  
- Mechanical Aortic Valve Replacement (AVR)  
- Mechanical Mitral Valve Replacement  
- Bioprosthetic Surgical or Transcatheter Aortic Valve  
- Bioprosthetic Mitral Valve  
- Anticoagulation Reversal  
- Therapeutic INR range  

These terms capture the key concepts related to heart disease, particularly valvular heart disease and its management with anticoagulation.

Page 78 Extracted Terms:
- Valvular Heart Disease  
- VKA (Vitamin K antagonist) anticoagulation  
- INR (International Normalized Ratio)  
- Therapeutic range  
- Subtherapeutic INR  
- Thromboembolism  
- Infective Endocarditis (IE)  
- Atrial fibrillation (AF) / new‑onset AF  
- Hypercoagulable state  
- Bioprosthetic valve  
- Transcatheter aortic valve (TAVR)  
- Mechanical valve  
- Leaflet thrombosis  
- Pannus formation  
- Bleeding risk  
- Low‑dose aspirin  
- NOAC (Novel Oral Anticoagulant)  
- Stroke  
- Systemic embolic event  
- Transesophageal echocardiography (TEE)  
- Transthoracic echocardiography (TTE)  
- Fluoroscopy  
- Multidetector CT imaging  
- 3‑D CT scanning  
- Valve function assessment  
- Valve leaflet motion  
- Thrombus detection  
- Valve obstruction  
- Transvalvular gradient  
- Pulmonary edema  
- Stenotic murmur  
- Muffled closing clicks  
- Aortic prosthesis  
- Mitral prosthesis  
- Tricuspid prosthesis  
- Left ventricular (LV) size  
- LV systolic function  
- Estimated pulmonary pressures  
- High‑output state  
- Clinical decision‑making  
- Full neurological evaluation 

Page 79 Extracted Terms:
- Mechanical prosthetic valve thrombosis  
- Valve obstruction  
- Fibrinolytic therapy  
- Low‑dose thrombolytic therapy  
- Slow‑infusion thrombolysis  
- Emergency surgery  
- Left‑sided mechanical prosthetic heart valve  
- NYHA class I  
- NYHA class II  
- Hemodynamic success  
- Embolic events  
- Major bleeding  
- Transvalvular velocity  
- Transcatheter aortic valve implantation (TAVI)  
- Bioprosthetic valve thrombosis  
- Leaflet thrombosis  
- 3D transesophageal echocardiography (TEE)  
- 4D computed tomography (CT) imaging  
- Cardiac magnetic resonance (CMR) imaging  
- Hypoattenuation of valve leaflets  
- Oral anticoagulation  
- Vitamin K antagonist (VKA)  
- Anticoagulation therapy  
- Thrombus burden  
- Recurrent valve thrombosis  
- Surgical expertise  
- Valve stent (bioprosthetic valve)  
- Transvalvular gradient  
- Valve function improvement  

Page 80 Extracted Terms:
- Prosthetic Valve Stenosis  
- Mechanical Valve Stenosis  
- Bioprosthetic Valve Stenosis  
- Trans‑Thoracic Echocardiography (TTE)  
- Trans‑Echocardiographic Echocardiography (TEE)  
- Fluoroscopy  
- Cine‑Computed Tomography (cine‑CT)  
- Three‑Dimensional Trans‑Echocardiographic Imaging (3D TEE)  
- Four‑Dimensional CT Imaging (4D CT)  
- Pulmonary Artery Systolic Pressure  
- Ventricular Function  
- Leaflet Mobility  
- Pannus Ingrew  
- Thrombus Formation  
- Structural Valve Deterioration  
- Leaflet Thinning/Calcification/Tear  
- Stent Creep  
- Valve Academic Research Consortium (VARC) Criteria  
- Patient‑Prosthesis Mismatch  
- Transvalvular Gradient  
- Left Ventricular (LV) Hypertrophy  
- Cardiovascular Events  
- NYHA Class (I–IV)  
- Systemic Fibrinolysis  
- Surgical Therapy (Valve Replacement/Repair)  
- Coronary Artery Disease (CAD)  
- LA Thrombus  
- Intra‑operative Imaging  
- Valve Leaflet Opening/Closing Angles  
- Bioprosthetic Valve Degeneration  
- Endocarditis  
- Non‑Laminar Blood Flow  
- Mechanical Valve Leaflet Imaging  
- Cardiac Output Demands  
- Imaging Diagnostic Criteria for Stenosis Severity  
- Valve Implantation Baseline Hemodynamics  
- Imaging Modality for Pannus Detection  
- Left Ventricular Pressure Gradient  

(Note: All items are key heart‑disease‑related terms extracted from the guideline text.)

Page 81 Extracted Terms:
**Key Terms Related to Heart Disease**

- ACC/AHA Guideline for the Management of Valvular Heart Disease  
- Valvular heart disease  
- Valve stenosis  
- Bioprosthesis  
- Structural valve degeneration  
- Pannus formation  
- Thrombus (valve thrombus, subclinical bioprosthetic valve thrombosis)  
- Calcium deposition (paravalvular calcification)  
- CT imaging (4‑D CT)  
- TAVI (Transcatheter Aortic Valve Implantation)  
- 3‑D TEE (Three‑Dimensional Transesophageal Echocardiography)  
- Prosthetic valve stenosis  
- Surgical intervention (reoperative AVR, SAVR)  
- High or prohibitive surgical risk  
- Transcatheter ViV (Valve‑in‑Valve) procedure  
- Comprehensive Valve Center  
- Oral anticoagulation with a VKA (vitamin K antagonist)  
- Cumulative survival rates  
- Patient‑prosthesis mismatch  
- Paravalvular leak  
- Aortic valve gradients  
- VIVID registry (Valve‑in‑Valve International Data)  
- Stroke and bleeding risks  
- Functional status (NYHA class I/II)  
- Reoperative surgery mortality and morbidity  
- Coronary artery obstruction (specific to aortic ViV)  
- Permanent pacemaker implantation  
- Annulus rupture (not reported)  
- LV outflow obstruction (post‑mitral ViV)  
- Mechanical prosthetic valve complications  
- Transvalvular regurgitation (pannus, thrombus, vegetation)  
- Suture line disruption, annular disruption, endocarditis  
- Severe mitral annular calcification (late paravalvular leak risk)  
- Bioprosthetic valve regurgitation (paravalvular)  

These terms capture the principal concepts, procedures, complications, and clinical decision points discussed in the provided guideline excerpt.

Page 82 Extracted Terms:
- Valvular Heart Disease  
- Prosthetic Valve Regurgitation  
- Prosthetic Valve Stenosis  
- Transvalvular Leak  
- Paravalvular Leak  
- Mechanical Valve  
- Bioprosthetic Valve  
- Calcification  
- Leaflet Perforation  
- Leaflet Flail  
- Hemolysis  
- Heart Failure (HF)  
- Pulmonary Artery Systolic Pressure  
- Transthoracic Echocardiography (TTE)  
- Transesophageal Echocardiography (TEE)  
- 3‑Dimensional TEE (3D TEE)  
- 4‑Dimensional Imaging (4D)  
- Computed Tomography (CT)  
- Comprehensive Valve Center (CVC)  
- Valve‑in‑Valve (ViV)  
- Valve Thrombosis  
- Murmur  
- Auscultatory Findings  
- Echocardiographic Definitions  
- Diagnostic Imaging  
- Transcatheter Procedure  
- Hemodynamic Effects  
- Asymptomatic Presentation  
- New‑Onset Heart Failure  
- Unexplained Hemolysis  
- Estimated Pulmonary Pressure  
- Critical Diagnostic Distinction (Transvalvular vs. Paravalvular)  
- Clinical Presentation of Prosthetic Valve Dysfunction  
- Routine Clinical or Imaging Follow‑up  
- Intraprocedural Guidance  
- 3‑Dimensional Guidance for Transcatheter Procedures  

Page 83 Extracted Terms:
**Key Heart‑Disease Related Terms Extracted**

- Echocardiography (TTE, TEE, 3‑D TEE, real‑time 3‑D TEE)  
- Valve Academic Research Consortium (VARC) – 5‑class grading for paravalvular leak severity  
- Prosthetic valve regurgitation (transvalvular & paravalvular)  
- Prosthetic mitral valve; prosthetic aortic valve  
- Valve thrombosis (see Sections 11.6 & 11.8)  
- Prosthetic valve endocarditis (see Section 12.3)  
- Hemolytic anemia / intractable hemolysis  
- Heart failure (HF) – acute or chronic severe regurgitation; NYHA class III/IV symptoms  
- Transcatheter paravalvular leak closure (catheter‑based, percutaneous repair)  
- Comprehensive Valve Center (recommended site for advanced interventions)  
- Transcatheter valve‑in‑valve (ViV) procedure  
- Bioprosthetic valve degeneration (leaflet calcification, non‑coaptation, tear, perforation)  
- Infection (infective endocarditis, IE) – contraindication to transcatheter therapy, requires antibiotics before surgery  
- Surgical risk (high, prohibitive, low)  
- Anemia management (folic acid, iron supplementation, periodic transfusion)  
- Residual regurgitation assessment post‑device placement  
- Acoustic shadowing, paravalvular leak detection challenges (TTE suboptimal posterior, TEE suboptimal anterior)  

These terms capture the primary disease entities, clinical features, imaging modalities, therapeutic strategies, and risk stratification concepts emphasized in the guideline.

Page 84 Extracted Terms:
- Aortic valve replacement (AVR)  
- Reoperative AVR  
- Surgical reoperation  
- Paravalvular leak  
- Aortic valve  
- Mitral valve  
- Valve replacement  
- Prosthetic valve deterioration  
- Regurgitation  
- Leaflet calcification  
- Leaflet degeneration  
- Leaflet tear / perforation  
- Infective Endocarditis (IE)  
- Watchful waiting  
- Comprehensive Heart Valve Center  
- Percutaneous paravalvular leak closure  
- Multidisciplinary team (MDT)  
- Residual regurgitation  
- Heart failure (HF) symptoms  
- Valve‑in‑Valve (ViV)  
- Transcatheter ViV procedure  
- Stroke  
- Functional status  
- Hemodynamic outcomes  
- Reoperative SAVR (surgical aortic valve replacement)  
- All‑cause mortality  
- Low‑risk patients  
- Endocarditis classification  
- Native valve  
- Prosthetic valve  
- Timing of infection after valve intervention.

Page 85 Extracted Terms:
- Infective Endocarditis (IE)  
- Valvular Heart Disease (VHD)  
- Prosthetic heart valve  
- Left‑sided valve regurgitation  
- Congenital or acquired VHD  
- Injection drug use (risk factor for IE)  
- Blood culture  
- Staphylococcus aureus bacteremia  
- Enterococcal infection  
- Fungal infection  
- Modified Duke Criteria  
- Multispecialty Heart Valve Team  
- Cardiologist  
- Cardiac surgeon  
- Cardiac anesthesiologist  
- Neurologist  
- Transthoracic echocardiography (TTE)  
- Transesophageal echocardiography (TEE)  
- Intraoperative TEE  
- Baseline TEE (before oral therapy)  
- Repeat TEE (before completion of oral therapy)  
- Cardiac imaging (CT, CT/PET)  
- 18F‑fluorodeoxyglucose PET/CT  
- Vegetations  
- Hemodynamic severity of valvular lesions  
- Ventricular function  
- Pulmonary pressures  
- Embolism  
- Heart failure (HF)  
- Abscess  
- Atrioventricular heart block  
- Valve surgery for IE  
- Early change to oral antibiotic therapy for stable IE  
- Nosocomial S. aureus bacteremia  
- Paravalvular infection  
- Diagnostic imaging adjuncts (CT, PET/CT)

Page 86 Extracted Terms:
- Valvular Heart Disease  
- Infective Endocarditis (IE)  
- Culture‑negative Endocarditis  
- New or increased left‑sided valve regurgitation  
- Left‑sided valve  
- Valve regurgitation (mitral, aortic, etc.)  
- Prosthetic valve  
- Valve disease / valve lesions  
- Echocardiography (TTE, TEE)  
- Echocardiogram positive for IE  
- Vegetation  
- Oscillating intracardiac mass  
- Intracardiac abscess  
- Structural heart damage  
- Heart failure (HF)  
- Vascular emboli / embolization (including stroke, septic pulmonary infarcts, mycotic aneurysm)  
- Septic pulmonary infarcts  
- Janeway lesions  
- Osler’s nodes  
- Roth’s spots  
- Glomerulonephritis  
- Immunologic phenomena (immune complex deposition, rheumatoid factor)  
- Blood culture (positive, persistently positive, single positive, etc.)  
- Serological evidence of active infection  
- Polymerase chain reaction (PCR)  
- HACEK organisms (Haemophilus spp., Actinobacillus spp., Cardiobacterium hominis, Eikenella spp., Kingella kingae)  
- Viridans streptococci, Streptococcus bovis, Staphylococcus aureus, enterococci  
- Modified Duke Criteria (major and minor criteria for IE diagnosis)  
- Endocardial involvement  
- New partial dehiscence of prosthetic valve  
- Cardiovascular complications (stroke, intracranial hemorrhage, embolic events)  
- Cardiac imaging findings (e.g., oscillating mass, abscess, valve dehiscence)  
- Infection‑related heart disease indicators (fever >38 °C, vascular phenomena, immunologic phenomena)

Page 87 Extracted Terms:
- Valvular Heart Disease  
- Infective Endocarditis (IE)  
- Valve Vegetation  
- Transthoracic Echocardiography (TTE)  
- Transesophageal Echocardiography (TEE)  
- Prosthetic Valve Endocarditis  
- Aortic Regurgitation  
- Paravalvular Leak  
- Ventricular Size and Systolic Function  
- Pulmonary Pressures / Pulmonary Hypertension  
- Aortic Transvalvular Velocity / Gradient  
- Abscess (intracardiac or paravalvular)  
- Pericardial Effusion  
- Valve Perforation  
- Fistulae (paravalvular or intracardiac)  
- Intracardiac Thrombi  
- Heart Failure (HF)  
- Paravalvular Extension  
- Embolic Events (systemic emboli, stroke)  
- Early Surgical Intervention / Valve Surgery  
- Repeat Echocardiography (TTE/TEE)  
- Air Embolism (intraoperative)  
- Comprehensive Valve Center  
- Telemedicine (remote IE management)  
- Heart Valve Multidisciplinary Team (MDT)  
- Intraoperative TEE  
- Partial Oral Treatment of Endocarditis (POET) trial  
- Infectious Disease Specialists (role in IE care)

Page 88 Extracted Terms:
- Infective endocarditis (IE)  
- S.* aureus bacteremia  
- Transesophageal echocardiography (TEE)  
- Transthoracic echocardiography (TTE)  
- Multidetector‑row computed tomography (CT)  
- 18F‑fluorodeoxyglucose PET/CT  
- Prosthetic valve endocarditis  
- Native valve endocarditis  
- Mechanical prosthetic valve  
- Bioprosthetic valve  
- Valve vegetation  
- Valvular perforation  
- Paravalvular abscess  
- Annular abscess  
- Systemic embolization  
- Septic pulmonary infarct  
- Heart failure (HF)  
- Valvular heart disease  
- Aortic valve involvement  
- Coronary artery evaluation in IE  
- Modified Duke Criteria (major and minor criteria)  
- Intravascular catheter–associated bacteremia  
- Right‑sided infective endocarditis  
- Infective material limiting valve occluder motion  
- Thrombus on prosthetic valve  
- Cardiac fluoroscopy (adjunct imaging modality)

Page 89 Extracted Terms:
- Valvular heart disease  
- Infective endocarditis (IE)  
- Left‑sided infective endocarditis  
- Right‑sided infective endocarditis  
- Mechanical heart valve  
- Intracardiac device  
- Anticoagulation  
- Vitamin‑K antagonist (VKA)  
- Intravenous drug use–associated endocarditis  
- Opioid substitution therapy  
- Paravalvular infection  
- Transesophageal echocardiography (TEE)  
- Blood cultures  
- Antibiotic therapy  
- Antibiotic sensitivity data  
- Cerebral embolism  
- Stroke  
- Intracranial bleeding  
- Systemic emboli  
- Mycotic aneurysm  
- Antimicrobial regimens  
- Heart valve team  
- Antithrombotic therapy  
- Antimicrobial stewardship  
- Hemodialysis dependency  
- Spinal infection or non‑vertebral osteomyelitis  
- Infectious disease specialists (MDT)

Page 90 Extracted Terms:
**Key terms related to heart disease found in the text**

- Valvular heart disease  
- Infective endocarditis (IE)  
- Native valve endocarditis (NVE)  
- Prosthetic valve endocarditis (PVE)  
- Prosthetic valve dysfunction  
- Valve dysfunction  
- Ischemia  
- Hemorrhagic transformation (stroke)  
- Stroke  
- Anticoagulant therapy  
- Vitamin K antagonist (VKA)  
- Unfractionated heparin (UFH)  
- Bridging therapy  
- Antiplatelet therapy  
- Transesophageal echocardiography (TEE)  
- Transthoracic echocardiography (TTE)  
- Computed tomography (CT)  
- Positron emission tomography (PET)  
- 18F‑fluorodeoxyglucose (18FDG)  
- POET study (patient outcome evaluation)  
- Intravenous antibiotic treatment  
- Oral antibiotic treatment  
- Blood culture (diagnostic standard for IE)  
- Heart Valve Team  
- Cardiothoracic surgeon  
- Cardiologist  

These terms capture the primary concepts and interventions discussed in the guideline excerpt that pertain to heart disease management.

Page 91 Extracted Terms:
- Infective endocarditis (IE)  
- Prosthetic valve endocarditis  
- Heart valve dysfunction  
- Heart failure (HF)  
- Left‑sided endocarditis  
- S. aureus endocarditis  
- Fungal endocarditis  
- Highly resistant organisms  
- Heart block  
- Annular abscess  
- Aortic abscess  
- Destructive penetrating lesions  
- Persistent infection (bacteremia, fevers >5 days)  
- Pacemaker or defibrillator infection  
- Complete removal of cardiac electronic device  
- Recurrent endocarditis  
- Intravenous drug use–related endocarditis  
- Embolic events (recurrent emboli)  
- Vegetations (mobile >10 mm)  
- Cerebral embolic events  
- Stroke (ischemic and hemorrhagic)  
- Intracranial hemorrhage  
- Extensive neurological damage  
- Heart Valve Multidisciplinary Team (MDT)  
- Cardiology  
- Cardiothoracic surgery  
- Infectious disease  
- Comprehensive Valve Center  
- STS (Society of Thoracic Surgeons) risk‑scoring system for cardiac surgery  
- Surgical risk in infective endocarditis  

These terms capture the key heart‑disease–related concepts discussed in the guideline excerpt.

Page 92 Extracted Terms:
- Valvular heart disease  
- Infective endocarditis (IE)  
- Native valve endocarditis (NVE)  
- Prosthetic valve endocarditis (PVE)  
- Staphylococcus aureus endocarditis  
- Staphylococcal prosthetic valve endocarditis  
- Viridans streptococci endocarditis  
- Enterococcus faecalis (E. faecalis) endocarditis  
- Coagulase‑negative staphylococci endocarditis  
- Left‑sided infective endocarditis  
- Right‑sided infective endocarditis  
- Heart failure (HF)  
- Moderate to severe heart failure  
- Valve surgery  
- Early surgery (during initial hospital course)  
- Severe valvular dysfunction  
- Transesophageal echocardiography (TEE)  
- Transthoracic echocardiography (TTE)  
- Implantable cardioverter‑defibrillator (ICD)  
- Vitamin‑K antagonist (VKA) therapy  
- Embolic event  
- Central nervous system (CNS) event  
- Stroke  
- Intracranial hemorrhage  
- Drug‑use associated endocarditis (DUA)  
- Opioid substitution treatment (OST)

Page 93 Extracted Terms:
- Endocarditis  
- Valvular Heart Disease  
- Native Valve Endocarditis  
- Prosthetic Valve Endocarditis  
- Paravalvular Abscess  
- Annular Abscess  
- Aortic Abscess  
- Heart Block  
- Cardiac Device Endocarditis  
- Device Extraction  
- Parenteral Antibiotics  
- Methicillin‑Resistant *Staphylococcus aureus* (MRSA)  
- Vegetation  
- Vegetation Size >10 mm  
- Vegetation Mobility  
- Embolic Events  
- Septic Embolism  
- Left‑Sided Infective Endocarditis (IE)  
- Right‑Sided IE  
- Mitral Valve Lesions  
- Aortic Valve Lesions  
- Injection Drug Use–Associated IE  
- Blood Culture Negativity  
- Antifungal Therapy  
- Surgical Intervention  
- Operative Survival (5‑year actuarial survival)  
- Mortality Rate  
- Survival Benefit (device removal)  
- PET/CT Imaging  
- Addiction Therapy  
- Recurrent Fever  
- Recurrent IE  
- Paravalvular Invasion  
- Fistula Formation  
- Destructive Penetrating Lesions  
- Extensive Paravalvular Infections  
- Cardiac Tissue Destruction  
- ICU/Multidisciplinary Team (MDT) Involvement  
- Early Surgery  
- Proportional Hazards Regression  
- Incidence of Drug Use–Associated IE  
- Readmission Rates  
- Cost of Care  
- Antimicrobial Therapy Duration 48 hrs - 1 week  
- Long‑Term Outcomes (8‑year freedom from IE)

Page 94 Extracted Terms:
**Key terms related to heart disease**

- Valvular heart disease (VHD)  
- Infective endocarditis (IE)  
- Stroke (ischemic and hemorrhagic)  
- Embolic events  
- Heart failure (HF)  
- Heart block  
- Paravalvular extension  
- Early surgical intervention  
- Conventional treatment  
- All‑cause mortality  
- Perioperative hemorrhagic conversion  
- Surgical timing (>4 weeks after stroke or hemorrhage)  
- Pregnancy in women with severe valve disease  
- Transthoracic echocardiography (TTE)  
- Bicuspid aortic valve  
- Unicuspid aortic valve  
- Aortic sinus dilation  
- Ascending aorta dilation  
- Aortic dissection  
- Valve lesion staging (Stages C, D; Stage C1)  
- Functional capacity assessment  
- Left ventricular (LV) function  
- Right ventricular (RV) function  
- Pulmonary hypertension  
- Heart Valve Team (cardiologists, surgeons, anesthesiologists, maternal‑fetal medicine obstetricians)

Page 95 Extracted Terms:
- Valvular Heart Disease (VHD)  
- Valve replacement  
- Valve repair  
- Percutaneous aortic balloon dilation  
- Percutaneous mitral balloon dilation  
- Rheumatic mitral stenosis (MS)  
- Aortic stenosis (AS)  
- Severe valve disease  
- Cardiac morbidity  
- Cardiac mortality  
- High‑risk cardiac conditions  
- Stage D heart failure  
- Beta‑blocker medications  
- Diuretic medications  
- Angiotensin‑converting enzyme (ACE) inhibitors  
- Angiotensin‑receptor blockers (ARBs)  
- Arrhythmia  
- Atrial fibrillation (AF)  
- Anticoagulation therapy  
- Pregnancy‑related cardiac complications  
- Low birth weight  
- Fetal malformations  
- Fetal growth retardation  
- Maternal cardiac disease  
- Fetal outcome  
- ROPAC registry (Registry On Pregnancy And Cardiac Disease)  
- Exercise testing (for risk assessment)  
- Cardiac monitoring  

These terms capture the key heart‑disease concepts discussed in the guideline excerpt.

Page 96 Extracted Terms:
**Key Terms Related to Heart Disease**

1. Valvular heart disease (VHD)  
2. Mechanical valve  
3. Bioprosthetic valve  
4. Valve thrombosis  
5. Anticoagulation  
6. Warfarin  
7. International Normalized Ratio (INR)  
8. Pulmonary mitral balloon commissurotomy (PMBC)  
9. Rheumatic mitral stenosis (MS)  
10. Aortic stenosis (AS)  
11. Mitral regurgitation (MR)  
12. Valve repair  
13. Ross procedure  
14. Transcatheter aortic valve implantation (TAVI)  
15. Percutaneous aortic balloon dilation  
16. Valve replacement  
17. Valve intervention  
18. Valve morphology  
19. Valve area  
20. Aortic velocity  
21. Pressure gradient  
22. Hemodynamic changes  
23. Heart failure (HF)  
24. Arrhythmias  
25. Maternal adverse outcome  
26. Fetal complications  
27. Maternal death  
28. Excessive bleeding  
29. Preconception evaluation  
30. Serum brain natriuretic peptide (BNP)  
31. Symptom‑based indications  
32. Shared decision‑making  
33. Stage C / Stage C1 (severity classification)  
34. Preoperative trial of anticoagulation  
35. Mechanical vs. bioprosthetic valve durability in young women  

These terms capture the core concepts, procedures, risks, and clinical considerations discussed in the guideline excerpt.

Page 97 Extracted Terms:
**Key heart‑disease terms extracted from the text**

- Valvular Heart Disease (VHD)  
- Aortic Stenosis (AS)  
- Mitral Regurgitation (MR)  
- Left Ventricular (LV) Systolic Function  
- Biomarkers (in the context of LV function)  
- Mechanical Heart Valve  
- Bioprosthetic Valve  
- Valve Regurgitation (general)  
- Heart Failure (HF)  
- Pulmonary Hypertension (PH)  
- Pulmonary Artery Systolic Pressure (≥ 50 mm Hg)  
- Comprehensive Valve Center  
- Mitral Valve Morphology  
- Valve Repair  
- Surgical Risk (valve surgery)  
- Preconception Management of Valvular Disease  
- Native Valve Disease  
- Transthoracic Echocardiography (TTE) – imaging modality for valvular assessment  

Page 98 Extracted Terms:
**Key terms related to heart disease in the text**

- Valvular Heart Disease (VHD)  
- Severe aortic stenosis (AS)  
- Mean pressure gradient ≥ 40 mm Hg  
- Stage D disease  
- NYHA class III and IV heart‑failure (HF) symptoms  
- Rheumatic mitral stenosis (MS)  
- Mitral valve area ≤ 1.5 cm²  
- Pulmonary‑mural balloon commissurotomy (PMBC)  
- Valve regurgitation (severe)  
- Valve surgery (open heart)  
- Percutaneous balloon dilatation of the aortic valve  
- Percutaneous balloon dilation of the mitral valve  
- High‑risk procedures during pregnancy  
- Multidisciplinary team (cardiologists, interventionalists, cardiac anesthesiologists, obstetricians)  
- Prosthetic (mechanical) heart valves  
- Pre‑pregnancy assessment (echocardiography)  
- Mechanical prosthesis monitoring  
- Tertiary‑care center  
- Maternal‑fetal medicine obstetricians  
- Anticoagulation strategy for mechanical valves  
- Transesophageal echocardiography (TEE)  
- Prosthetic valve obstruction  
- Embolic event  
- Maternal mortality risk (~1 %)  
- Pregnancy risk category III (World Health Organization)  
- Valvular thrombosis risk (~5 %)  

These terms capture the primary heart‑disease concepts and clinical considerations discussed in the guideline excerpt.

Page 99 Extracted Terms:
- Valvular heart disease  
- Prosthetic heart valves  
- Mechanical heart valves  
- Valve dysfunction  
- Valve intervention  
- Preconception transthoracic echocardiography (TTE)  
- Transthoracic echocardiography (TTE)  
- Transesophageal echocardiography (TEE)  
- Transvalvular gradients  
- Valve regurgitation  
- Valve thrombosis  
- Embolic event  
- Heart failure (HF)  
- Pulmonary artery systolic pressure  
- Anticoagulation strategy  
- Vitamin K antagonist (VKA)  
- Warfarin  
- Low‑molecular‑weight heparin (LMWH)  
- Unfractionated heparin (UFH)  
- Activated partial thromboplastin time (aPTT)  
- Anti‑Xa level  
- Hypercoagulable state  
- Maternal mortality  
- Miscarriage  
- Fetal death  
- Congenital abnormalities  
- Maternal‑fetal medicine team  
- Heart Valve Team  
- Cesarean section  
- Vaginal delivery  
- First trimester  
- Second trimester  
- Third trimester  
- Therapeutic anticoagulation  
- Maternal and fetal safety  
- Pregnant women with mechanical prostheses  
- Shared decision‑making  
- Embolic risk  
- Thrombus burden  
- Maternal counseling  
- Fetal counseling  
- Clinical deterioration  
- Valve gradients  
- Valve regurgitation  
- Monitoring of anticoagulation  
- Reversal of anticoagulation  
- Anticoagulation titration  
- Gated cardiac CT  
- Fluoroscopy  
- Thrombus visualization  
- Surgical management of valve disease  
- Valve replacement  
- Valve prosthesis maintenance  
- Thrombus surveillance  
- Anticoagulation adjustment  
- Dose‑adjusted LMWH  
- Dose‑adjusted UFH  
- Target anti‑Xa range (0.8–1.2 U/mL)  
- Therapeutic INR  
- Dose‑adjusted warfarin  
- Anticoagulant safety profile  
- Maternal–fetal outcome optimization  

Page 100 Extracted Terms:
- Mechanical heart valves  
- Valvular heart disease  
- Mechanical valve prosthesis  
- Mechanical valve thrombosis  
- Anticoagulation  
- Warfarin  
- Low‑molecular‑weight heparin (LMWH)  
- Unfractionated heparin (UFH)  
- Direct thrombin inhibitor (dabigatran)  
- Direct oral anticoagulants (DOACs)  
- Anti‑Xa levels  
- International Normalized Ratio (INR)  
- Thromboembolism  
- Thrombosis  
- Hemorrhage  
- Fetal intracranial hemorrhage  
- Fetal intracranial bleeding  
- Warfarin embryopathy  
- Maternal morbidity  
- Maternal mortality  
- Fetal outcomes  
- Spontaneous abortion / miscarriage  
- Loss of pregnancy  
- Teratogenicity  
- Placental crossing of medication  
- Sequential therapy (heparin then warfarin)  
- Continuous warfarin therapy  
- Dose‑adjusted anticoagulation  
- Therapeutic anticoagulation  
- Anticoagulation monitoring  
- Antithrombotic therapy  
- Maternal and fetal risk balance

Page 101 Extracted Terms:
- Valvular heart disease  
- Prosthetic mechanical heart valves  
- Anticoagulation  
- Low‑molecular‑weight heparin (LMWH)  
- Unfractionated heparin (UFH)  
- Vitamin K antagonist (VKA)  
- Anti‑Xa levels  
- Activated partial thromboplastin time (aPTT)  
- Dose‑adjusted LMWH dosing  
- Therapeutic range  
- Pregnancy‑specific anticoagulation strategy  

These are the primary heart‑disease–related terms extracted from the text.

Page 102 Extracted Terms:
- Valvular Heart Disease  
- Mechanical heart valve  
- Prosthetic valve  
- Valve thrombosis (incl. mechanical valve thrombosis)  
- Low‑dose warfarin  
- Warfarin embryopathy / teratogenicity  
- Low‑dose LMWH (Low‑molecular‑weight heparin)  
- Unfractionated heparin (UFH)  
- Intravenous heparin infusion (continuous or slow‑infusion)  
- Activated partial thromboplastin time (aPTT)  
- Anti‑factor Xa level monitoring  
- Thrombolysis (tissue‑type plasminogen activator, tPA)  
- Fetal intracranial hemorrhage  
- Fetal loss / embryopathy  
- Anticoagulation management in pregnancy  
- Maternal hemorrhage risk  
- Thrombotic complications (stroke, valve thrombosis)  
- Obstetric anticoagulation strategy (e.g., warfarin shift, LMWH use)  
- Mechanical valve thrombosis management during pregnancy  
- Obstetric and anesthesia coordination for anticoagulation  
- Monitoring of anti‑Xa trough levels >0.6 IU/mL  
- Dose‑adjusted LMWH  
- Continuous UFH infusion for low‑dose warfarin replacement  
- Thrombus size criteria (>10 mm) for mechanical valve thrombosis.

Page 103 Extracted Terms:
- Valvular Heart Disease  
- Low‑dose warfarin  
- Low Molecular Weight Heparin (LMWH)  
- Mechanical heart valves  
- Valve thrombosis  
- Maternal thrombotic complications  
- Low‑dose aspirin (pregnancy safety)  
- Preeclampsia prevention  
- Anti‑Xa activity / anti‑Xa levels  
- Dabigatran (direct thrombin inhibitor)  
- Direct oral anticoagulants (DOACs)  
- Warfarin  
- Coronary Artery Disease (CAD)  
- Transcatheter Aortic Valve Implantation (TAVI)  
- Surgical Aortic Valve Replacement (SAVR)  
- Coronary Artery Bypass Grafting (CABG)  
- Aortic Stenosis (AS)  
- Left main coronary artery disease  
- Proximal coronary artery disease  
- Angina  
- Fractional Flow Reserve (FFR)  
- Instantaneous Wave‑Free Ratio (iFR)  
- SYNTAX Score  
- Cardiac cross‑clamp time  
- Cardiopulmonary bypass time  
- Aortic dilation  
- Mitral valve intervention  
- Aortic valve replacement (AVR)  
- Left ventricular (LV) function  
- Pulmonary hypertension  
- Renal injury (post‑operative)  
- Post‑operative adhesions  
- Medial radiation effects on cardiac surgery  
- Re‑operative cardiac procedures  
- Frailty / fragile tissue integrity  
- Concomitant surgical procedures (e.g., maze procedure for AF)

Page 104 Extracted Terms:
- Severe coronary artery disease (CAD)  
- SYNTAX score  
- Revascularization  
- Transcatheter aortic valve implantation (TAVI)  
- Severe aortic stenosis (AS)  
- Obstructive CAD  
- Coronary angiography  
- Coronary CT angiography  
- Fractional flow reserve (FFR)  
- Instantaneous wave‑free ratio (iFR)  
- Percutaneous coronary intervention (PCI)  
- Dual‑antiplatelet therapy (DAPT)  
- Left main coronary disease  
- Coronary artery bypass graft (CABG)  
- Aortic valve replacement (AVR)  
- Mitral regurgitation (MR)  
- Left ventricular (LV)  
- Computed tomography (CT)  

*(All terms are directly related to heart disease and its management as cited in the text.)*

Page 105 Extracted Terms:
- ACC/AHA Guideline  
- Valvular Heart Disease (VHD)  
- Percutaneous treatment  
- Left main disease  
- SYNTAX score  
- Surgical approach  
- Surgical aortic valve replacement (SAVR)  
- Revascularization  
- Coronary Artery Disease (CAD)  
- Significant CAD (>50% stenosis)  
- Valve surgery  
- Invasive coronary angiography  
- Angina  
- Ischemia  
- Left ventricular (LV) systolic function  
- Coronary risk factors  
- Men >40 years  
- Postmenopausal women  
- Chronic severe secondary mitral regurgitation (MR)  
- Contrast‑enhanced coronary CT angiography  
- Pretest probability of CAD  
- Coronary artery bypass grafting (CABG)  
- Proximal CAD (≥70% luminal diameter reduction)  
- Left main coronary artery CAD (≥50% luminal diameter reduction)  
- Physiologically significant CAD  
- Valve repair  
- Valve replacement  
- Coronary imaging in VHD  
- Secondary MR  
- LV reverse remodeling  
- LV remodeling  
- Periprocedural risk  
- Long‑term outcome  
- Percutaneous intervention  
- Sequential intervention  
- Radiation exposure  
- Renal failure (contrast‑related)  
- Diagnostic sensitivity (>90%)  
- Diagnostic specificity (60–90%)  
- Diagnostic accuracy (>90%)  
- Mitral valve disease  
- Aortic valve disease  
- Aortic valve repair/replacement  
- Coronary CT angiography contraindications (active angina, documented ischemia, prior CAD)  
- Cardiac imaging modalities (invasive vs. non‑invasive)  
- Coronary anatomy status  
- Coronary anatomy contribution to risk stratification  
- Coronary risk stratification.

Page 106 Extracted Terms:
- Valvular Heart Disease  
- Valve surgery  
- Myocardial infarction  
- Left ventricular (LV) systolic dysfunction  
- Operative mortality  
- Coronary artery stenosis  
- Left anterior descending artery  
- Left internal thoracic artery graft  
- Hybrid percutaneous coronary intervention (PCI)  
- Surgical valve repair  
- Surgical valve replacement  
- Atrial fibrillation (AF)  
- Atrial flutter  
- Valvular heart disease with atrial fibrillation  
- Arrhythmia surgery  
- Pulmonary vein isolation (PVI)  
- Maze procedure (atrial maze)  
- Left atrial (LA) appendage ligation  
- LA appendage excision  
- LA appendage occlusion/exclusion/amputation  
- Anticoagulation therapy  
- Thromboembolic events  
- Permanent pacemaker implantation  
- Catheter‑based ablation (including cryoenergy or radiofrequency)  
- Mitral valve repair  
- Mitral valve replacement  
- Aortic valve procedure  
- Tricuspid valve procedure  
- Recurrent atrial fibrillation  
- Catheter ablation (for AF)  
- Thrombogenic endocardial lesions  
- Complete revascularization  
- Incomplete revascularization  
- Perioperative complications  
- Bypass surgery (CABG)

Page 107 Extracted Terms:
**Key heart‑disease terms extracted from the text**

- Valvular heart disease (VHD)  
- Atrial fibrillation (AF)  
- Left atrial (LA)  
- Stroke  
- Catheter ablation  
- Surgical ablation  
- Oral anticoagulation  
- Anticoagulation (general)  
- Vitamin K antagonist (VKA)  
- CHA₂DS₂‑VASc score  
- Periprocedural phase  
- Endocardial healing  
- Bioprosthetic valve  
- LA appendage occlusion / exclusion  
- Valvular stenosis  
- Valvular regurgitation  
- Preoperative echocardiography  
- Non‑cardiac surgery in VHD patients  
- Arrhythmia recurrence  
- Valve repair/replacement  

These terms capture the primary themes related to heart disease and its management in the cited clinical guideline.

Page 108 Extracted Terms:
- Valvular heart disease (VHD)  
- Severity of VHD  
- Symptoms (symptomatic disease)  
- Risk of noncardiac intervention  
- Left ventricular (LV) response to overload  
- Right ventricular (RV) response to overload  
- Pulmonary artery systolic pressure  
- Cardiac intervention  
- Valve intervention (replacement, repair)  
- Heart Team  
- Cardiologist  
- Cardiac anesthesiologist  
- Cardiac surgeons  
- Cardiovascular anesthesiologist  
- Invasive hemodynamic monitoring  
- Transesophageal echocardiography (TEE)  
- Pre‑operative resting 12‑lead ECG  
- Transthoracic echocardiography (TTE)  
- Valve stenosis  
- Valve regurgitation  
- Systolic function  
- Diastolic function  
- Left ventricular (LV) size  
- Myocardial structure  
- Right ventricular (RV) size  
- Pulmonary artery pressure  
- Aortic stenosis (AS)  
- Aortic valve replacement (AVR)  
- Surgical aortic valve replacement (SAVR)  
- Transcatheter aortic valve implantation (TAVI)  
- Balloon aortic valvuloplasty  
- Rheumatic mitral stenosis (MS)  
- Mitral valve surgery (repair, replacement)  
- Aortic valve surgery (repair, replacement)  
- Left‑sided regurgitant lesions (mitral regurgitation, aortic regurgitation)  
- High‑risk non‑cardiac surgery  
- Elective non‑cardiac surgery  
- Elevated‑risk non‑cardiac surgery  
- Hemodynamic instability  
- Cardiac complications (10‑30 % rate in undiagnosed severe AS)  
- Pulmonary hypertension (> 50 mm Hg)  
- Coronary artery disease (CAD)  
- Perioperative risk  
- Non‑cardiac procedures  
- Ventricular function assessment  
- Valve pathology evaluation  
- Pre‑operative cardiac imaging  
- Symptomatic severe VHD  

These terms capture the core concepts and conditions related to heart disease discussed in the guideline excerpt.

Page 109 Extracted Terms:
- Valvular heart disease (VHD)  
- Asymptomatic VHD patient  
- Non‑cardiac surgery  
- Aortic stenosis (AS) – moderate or greater, severe  
- Mitral stenosis (MS) – rheumatic, moderate or greater, pulmonary artery systolic pressure < 50 mm Hg  
- Mitral regurgitation (MR) – moderate or greater, normal LV systolic function, pulmonary artery systolic pressure < 50 mm Hg  
- Aortic regurgitation (AR) – moderate or greater, normal LV systolic function  
- Left ventricular (LV) systolic function / left ventricular ejection fraction (LVEF)  
- Coronary artery disease (CAD)  
- Pulmonary hypertension  
- Peripheral artery disease (PAD)  
- Right ventricular (RV) dysfunction  
- Sinus rhythm  
- Hemodynamic monitoring (invasive)  
- Right‑heart catheterization  
- Transesophageal echocardiography (TEE)  
- Preload optimization  
- Forward cardiac output  
- Pulmonary edema  
- Left atrial (LA) pressure  
- Pulmonary capillary wedge pressure  
- Phenylephrine, norepinephrine (vasopressors)  
- Calcium channel blockers (arterial dilators)  
- Epidural/spinal (neuraxial) anesthesia  
- Neuraxial local anesthetic agents  
- Opioids (adjunct)  
- Hemodynamic stability (blood pressure, intracardiac volume)  
- Cardiac complications (myocardial injury, arrhythmias, ischemia, failure, death)  
- Aortic valve replacement (AVR)  
- Risk‑benefit ratio for intervention  
- CT or angiographic imaging for CAD exclusion.

Page 110 Extracted Terms:
- Valvular heart disease (VHD)  
- Acute pulmonary edema  
- Tachycardia  
- Diastolic left‑ventricular (LV) filling time  
- Stenotic mitral valve  
- Left atrial (LA) pressure  
- Rheumatic mitral stenosis (MS)  
- Pulmonary artery systolic pressure  
- Non‑cardiac surgery  
- Mitral regurgitation (MR)  
- LV systolic function  
- Heart failure (HF)  
- Myocardial infarction  
- Neuraxial local anesthetics  
- Opioids  
- Systemic vasodilation  
- General anesthesia  
- Preload  
- Invasive hemodynamic monitoring  
- Intraoperative transesophageal echocardiography (TEE)  
- Fluid balance  
- Ischemic heart disease  
- Hypertrophic cardiomyopathy  
- Aortic regurgitation (AR)  
- Hypotension  
- Arrhythmias  
- Stroke  
- Prolonged intubation (>24 h)  
- Cardiopulmonary complications  
- Mortality  
- Risk factors for valve disease  
- Rheumatic fever  
- Rheumatic heart disease  
- Calcific aortic stenosis (AS)  
- Bicuspid aortic valve (BAV)  
- Lipoprotein(a)  
- Genetic and pathobiological causes of valve dysfunction  
- Prevention of valve disease  
- Artificial intelligence and machine learning in cardiology  
- Imaging and engineering advances for valve diagnosis and treatment.

Page 111 Extracted Terms:
**Key Terms Related to Heart Disease**

- Valvular Heart Disease (VHD)  
- Stage B (Medical Therapy to Treat or Prevent Disease Progression)  
- Stage C (Optimal Timing of Intervention)  
- Stage D (Better Options for Intervention)  
- Early VHD  
- Calcific disease  
- Myxomatous disease  
- Disease progression  
- Patient monitoring  
- Severe disease  
- Symptoms  
- Abnormal cardiovascular function  
- Advanced imaging markers of disease progression  
- Randomized Controlled Trials (RCTs)  
- Valvular involvement  
- Ventricular involvement  
- Vascular involvement  
- Left‑ventricular (LV) dysfunction  
- Pulmonary hypertension  
- Patient education  
- Shared decision‑making  
- LV volumes  
- Systolic function  
- Diastolic function  
- Myocardial performance  
- LV size  
- Chronic severe aortic regurgitation (AR)  
- Strain imaging  
- Strain‑rate imaging  
- Circulating blood markers  
- Older adults  
- Cognitive function  
- Frailty  
- Mobility challenges  
- Women (gender representation)  
- Minorities (racial/ethnic representation)  
- Severe asymptomatic VHD  
- Severe aortic stenosis (AS)  
- Asymptomatic severe AR with normal LV systolic function  
- Severe primary mitral regurgitation (MR)  
- Valve repair  
- Valve replacement  
- Tricuspid regurgitation (TR)  
- Registries  
- Quality of care  
- Prosthetic valve  
- Life‑time risks of valve therapy  
- Transcatheter valve procedures (TAVR, TTVR, etc.)  
- Valve durability (long‑term, >5 years)  
- Mechanical valve replacement  
- Oral anticoagulation  
- Anticoagulant therapy  
- Nonthrombogenic valve surfaces  
- Hemodynamics of valve function  
- Valve substitutes  
- Epidemiology of moderate to severe VHD  
- Surgical procedures for valve disease  
- Clinical trial representation and inclusivity  
- Prediction of outcomes after valve intervention  
- Early markers of myocardial dysfunction  
- Advanced imaging for LV strain and strain‑rate  
- Risk–benefit balance of intervention timing  
- Quality‑of‑life considerations post‑intervention  

These terms capture the primary clinical concepts, therapeutic strategies, patient characteristics, imaging modalities, and research priorities discussed in the guideline excerpt.

Page 112 Extracted Terms:
- Valvular Heart Disease (VHD)  
- Aortic Stenosis (AS)  
- Mitral Regurgitation (MR)  
- Aortic Valve Replacement (AVR)  
- Surgical Aortic Valve Replacement (SAVR)  
- Transcatheter Aortic Valve Implantation (TAVI)  
- Atrial Fibrillation (AF)  
- Left Ventricular (LV)  
- Vitamin K Antagonist (VKA)  
- Randomized Controlled Trial (RCT)  

**Disease / Pathophysiology Terms**  
- Disease mechanisms  
- Rheumatic heart disease  
- Calcific valve disease  
- Ventricular and vascular interactions  
- Valve disease severity  
- Ventricular anatomy and function  

**Diagnostic / Risk Assessment Terms**  
- Advanced imaging endpoints  
- LV size (volumes vs. dimensions)  
- LV strain (function)  
- Nonimaging parameters (serum markers, novel approaches)  
- Decision aids for shared decision‑making  

**Therapeutic & Management Terms**  
- Medical therapy for progressive valve disease (Stage B)  
- Targeted therapy to slow or reverse disease progression  
- Antithrombotic therapy (post‑TAVI, mechanical valves)  
- Alternatives to VKA anticoagulation  
- Anticoagulation during pregnancy  
- Optimal blood pressure targets after valve intervention  
- Medical therapy after AVR (ventricular and vascular function)  
- Prevention of postoperative atrial fibrillation  
- Prevention of complications (e.g., need for permanent pacing, endocarditis, thromboembolic events)  

**Research / Implementation Terms**  
- Patient‑centered research  
- Inclusion of diverse patient groups  
- Decision algorithms for physicians and Heart Valve Teams  
- Evidence gaps & future directions  
- Equity, disparities, and cost‑effective long‑term management in rural settings  
- Access to therapies for valvular dysfunction  

**Procedural / Device Terms**  
- Durable prosthetic valves (TAVI & surgical)  
- Nonthrombogenic valves  
- Lower procedural risk (surgical morbidity & mortality)  

These terms capture the key concepts related to heart disease discussed in the guideline text.

Page 113 Extracted Terms:
**Key terms related to heart disease extracted from the text**

1. Valvular Heart Disease  
2. Heart Disease  
3. Cardiovascular Disease  
4. Cardiac  
5. Valve  
6. Aortic Valve  
7. Mitral Valve  
8. Valve Replacement  
9. Valve Repair  
10. Heart Failure

Page 114 Extracted Terms:
**Key Terms Related to Heart Disease**

- Valvular heart disease  
- Aortic valve stenosis  
- Mitral valve regurgitation  
- Tricuspid valve regurgitation  
- Bicuspid aortic valve  
- Aortic dilatation / dilation  
- Aortic valve regurgitation  
- Prosthetic valve evaluation  
- Hypertrophic cardiomyopathy  
- Congenital heart disease  
- Atrial fibrillation (AF)  
- Heart failure (HF)  
- Antithrombotic therapy  
- Thrombolytic therapy  
- Echocardiographic assessment  
- 2‑D and 3‑D echocardiography  
- Cardiovascular magnetic resonance imaging (MRI)  
- Non‑invasive evaluation of valvular disease  
- Cardiovascular disease during pregnancy  
- ESC/EACTS guidelines for valvular disease  
- ACC/AHA guidelines for valvular disease  
- ACCF/AHA guidelines for hypertrophic cardiomyopathy  
- ESC guidelines for cardiovascular disease during pregnancy  
- Cardiac imaging Committee (American Heart Association)  
- Society of Cardiovascular Echocardiography recommendations  
- Cardiac evaluation of native versus prosthetic valves  

*(This list captures the primary heart‑disease concepts referenced in the cited clinical guidelines.)*

Page 115 Extracted Terms:
Valvular heart disease  
Aortic stenosis (calcific)  
Aortic regurgitation  
Mitral regurgitation  
Mitral stenosis  
Doppler echocardiography  
Stress echocardiography (exercise Doppler)  
Cardiopulmonary exercise testing  
Exercise tolerance  
Left ventricular ejection fraction  
Left ventricular systolic function  
Hemodynamics (cardiac catheterization)  
Dobutamine challenge (dobutamine stress test)  
Watchful waiting (conservative management)  
Valve surgery (timing of aortic/mitral valve surgery)  
Bacterial endocarditis  
Rheumatic fever  
Endocarditis prophylaxis (antibiotic prophylaxis)  
ACC/AHA guideline (2020 Valvular Heart Disease)  
ESC working group on valvular heart disease  
ACC/AHA/HFSA heart failure guideline (2017)  
Secondary prevention (rheumatic fever, endocarditis)  
Primary prevention (cardiovascular disease)  
Heart failure management  
Valve clinic organization and structure  
Echocardiographic quantification of valve disease  
Low‑output low‑gradient aortic stenosis  
Quantitative exercise Doppler echocardiography  
Prognostic significance of exercise testing  
Left‑ventricular remodeling  
Aortic valve disease (overall)  
Valve pathology and diagnostics.

Page 116 Extracted Terms:
- Valvular heart disease  
- Infective endocarditis  
- Atrial fibrillation  
- Mechanical heart valves  
- Bioprosthetic valves  
- Aortic valve disease / aortic valve replacement  
- Mitral valve disease / mitral valve repair  
- Valve replacement  
- Valve repair  
- Anticoagulation (warfarin, NOACs)  
- Dental-related bacteremia (antibiotic prophylaxis)  
- Heart transplantation (orthotopic)

Page 117 Extracted Terms:
- Valvular heart disease  
- Aortic valve replacement  
- Transcatheter aortic valve replacement (TAVR / TAVI)  
- Transcatheter aortic valve implantation  
- Mitral valve repair  
- Mitral valve replacement  
- Valve bioprosthesis  
- Atrial fibrillation  
- Direct oral anticoagulants (DOACs)  
- Warfarin  
- Rivaroxaban  
- Dabigatran  
- Percutaneous mitral valve repair (e.g., MitraClip)  
- Balloon‑expandable prostheses  
- Mitral stenosis  
- Aortic stenosis  
- Mitral regurgitation  
- Aortic regurgitation  
- Heart failure  
- Pulmonary hypertension  
- Transpulmonary gradient  
- Surgical risk  
- Frailty  
- Procedural volume  
- Hospital volume  
- Surgical mortality  
- Stroke  
- Thromboembolism  
- Anticoagulation  
- Cardiac surgery  
- Cardiac catheterization  
- Valve pathology  
- Valve repair rates  
- Valve replacement outcomes


Page 118 Extracted Terms:
- Valvular Heart Disease  
- Mitral Valve Repair  
- Mitral Valve Surgery  
- Mitral Regurgitation  
- Hospital Procedural Volume  
- Hospital Volume  
- Failure to Rescue  
- Transcatheter Aortic Valve Implantation (TAVR)  
- Coronary Artery Bypass Grafting (CABG)  
- Open Aortic Aneurysm Repair  
- High‑Risk Surgery  
- Cardiovascular Surgery  
- Intensive Care Unit (ICU) Organization  
- Heart Team  
- Management of Patients with VHD  
- Periodic Imaging After Valve Intervention  
- Hemodynamic Valve Deterioration  
- Bioprosthetic Surgical Aortic Valve Replacement  
- Aortic Stenosis  
- Echocardiographic Assessment of Valve Stenosis  
- Cardiac Auscultation  
- Asymptomatic Valvular Heart Disease  
- Low‑Flow Low‑Gradient Aortic Stenosis  
- Systemic Hypertension  
- Systemic Vascular Load  
- Dobutamine Stress Doppler Hemodynamics  
- Low‑Dose Dobutamine Echocardiography  
- TOPAS Study  
- CT Aortic Valve Calcium Scoring  
- Electron‑Beam Computed Tomography  
- Multislice Computed Tomography  
- Doppler Echocardiography  
- Computed Tomography (CT)  
- Magnetic Resonance Imaging (MRI) – (implied by imaging discussions)  
- Valve Area Determination  
- Valve Calcification  
- Aortic Valve Calcium Score  
- Left Ventricular Ejection Fraction (LVEF)  
- Left Ventricular Systolic Function  
- Left Ventricular Diastolic Function  
- Vascular Load  
- Stress Testing (Dobutamine)  
- Doppler‑Catheter Correlation  
- Surgical Outcomes  
- Mortality  
- Survival  
- Prognostic Indicators  
- Risk Stratification  
- Echocardiographic Measures (velocity, pressure gradients)  
- Doppler‑Based Valve Area  
- Doppler Flow Velocity  
- Aortic Valve Area**  
- Valve Gradient**  
- Clinical Decision‑Making in Valve Disease  

(These terms capture key concepts, conditions, procedures, diagnostic methods, and outcome measures relevant to heart disease as extracted from the provided guideline excerpt.)

Page 119 Extracted Terms:
**Key heart‑disease related terms extracted from the text**

- aortic stenosis  
- valvular heart disease  
- left ventricular ejection fraction  
- Doppler echocardiography  
- dobutamine challenge / dobutamine echocardiography  
- transcatheter valve implantation (TAVI)  
- surgical prosthetic valve implantation  
- low‑flow, low‑gradient aortic stenosis  
- bicuspid aortic valve  
- exercise testing / exercise‑stress echocardiography  
- cardiac catheterization / angiocardiography  
- blood pressure (systolic and optimal)  
- lipid‑lowering therapy (statins, ezetimibe, rosuvastatin)  
- renin‑angiotensin system blockade (ACE inhibitors, ARBs)  
- hemodyamics / hemodynamic progression  
- valve area / projected valve area  
- leaflet calcification / aortic‑valve calcium  
- myocardial dysfunction / left‑ventricular dysfunction  
- symptomatic versus asymptomatic aortic stenosis  
- risk stratification / prognostic assessment  
- treatment decision / surgical indication  
- hypertension in aortic stenosis  

This list captures the primary clinical concepts and interventions discussed in the cited guideline and related studies.

Page 120 Extracted Terms:
- Aortic valve stenosis  
- Valvular heart disease  
- Transcatheter aortic valve replacement (TAVR)  
- Aortic valve replacement  
- Low‑flow low‑gradient aortic stenosis  
- Low‑output low‑gradient aortic stenosis  
- Calcific aortic valve disease  
- B‑type natriuretic peptide (BNP)  
- Natriuretic peptides  
- Left ventricular ejection fraction (LVEF)  
- Left ventricular systolic function / depressed left ventricular function  
- Symptomatic aortic stenosis  
- Asymptomatic aortic stenosis  
- Dobutamine stress echocardiography  
- Exercise‑treadmill testing  
- Valve disease progression  

Page 121 Extracted Terms:
**Key heart‑disease terms identified in the guideline text**

- Aortic stenosis  
- Valvular heart disease  
- Aortic valve replacement (AVR)  
- Transcatheter aortic valve implantation (TAVI)  
- Low‑flow, low‑gradient aortic stenosis  
- Severe aortic stenosis  
- Mild to moderate aortic stenosis  
- Left ventricular ejection fraction (LVEF)  
- Left ventricular function (systolic & diastolic)  
- Contractile reserve  
- Hemodynamic measurements  
- Doppler echocardiography  
- Dobutamine echocardiography  
- Exercise testing  
- Quantitative exercise Doppler  
- Velocity pressure gradient (VPG)  
- Valve area  
- Valve area index  
- Transvalvular gradient  
- Coronary artery bypass graft (CABG)  
- Coronary revascularization  
- Mechanical prostheses  
- Bioprosthetic prostheses  
- Prosthetic valve durability  
- Anticoagulation risk  
- Reoperation risk  
- Lipid‑lowering therapy  
- Simvastatin  
- Ezetimibe  
- Rosuvastatin  
- Statin treatment  
- Survival  
- Long‑term outcome  
- Prognostic indicators  
- Risk stratification  
- Clinical outcome  
- Symptom onset  
- Asymptomatic patients  
- Symptomatic patients  
- Mortality  
- Surgical risk models (e.g., Society of Thoracic Surgeons)  
- ESC/EACTS guidelines  
- ACC/AHA guidelines  
- Echocardiographic assessment  
- Small valve area  
- Pressure drop/flow slope  
- Invasive hemodynamic characteristics


Page 122 Extracted Terms:
- Valvular Heart Disease  
- Mitral valve replacement  
- Aortic valve replacement (SAVR)  
- Transcatheter Aortic Valve Replacement (TAVR)  
- Bioprosthetic valve  
- Mechanical valve  
- Ross procedure  
- Valve‑in‑Valve implantation  
- Self‑expanding prosthesis  
- Balloon‑expandable valve  
- Carpentier‑Edwards Pericardial bioprosthesis  
- Perimount bioprosthesis  
- Aortic stenosis  
- Severe aortic stenosis  
- Low‑risk patients  
- Intermediate‑risk patients  
- High‑risk patients  
- Propensity‑matched analysis  
- Long‑term outcomes  
- Late outcomes  
- Hemodynamic stability  
- Post‑operative anticoagulation  
- Shared decision‑making  
- Bioprosthetic aortic valve durability  
- Autograft aortic root replacement  
- Homograft aortic root replacement  
- Thoracic cardiovascular surgery  
- Cardiac surgical outcomes.

Page 123 Extracted Terms:
- Aortic valve  
- Aortic stenosis  
- Severe aortic stenosis  
- Low‑flow, low‑gradient aortic stenosis  
- Aortic regurgitation (aortic insufficiency)  
- Acute aortic regurgitation  
- Chronic aortic regurgitation  
- Native valve endocarditis  
- Acute type‑A aortic dissection  
- Transcatheter aortic valve replacement (TAVR / TAVI)  
- Transcatheter aortic valve implantation  
- Balloon‑expandable valve (e.g., SAPIEN 3)  
- Self‑expandable valve (e.g., Evolut R)  
- Balloon aortic valvuloplasty  
- Valve Academic Research Consortium‑2 (VARC‑2) criteria  
- Structural valve deterioration  
- Hemodynamic durability  
- Left ventricular ejection fraction (LVEF)  
- Left ventricular dysfunction  
- Severe left ventricular dysfunction  
- Heart failure  
- Inoperable severe aortic stenosis  
- Decompensated aortic stenosis (emergency treatment)  
- Intra‑aortic balloon counterpulsation  
- B‑type natriuretic peptide (BNP)  
- Echocardiography (including quantitative Doppler)  
- Cardiovascular magnetic resonance  
- Functional outcomes  
- Survival outcomes  
- Pre‑operative left ventricular function  
- Asymptomatic aortic regurgitation  
- Asymptomatic severe aortic regurgitation  
- Long‑term clinical outcomes  
- Surgical aortic valve replacement  
- Propensity‑matched comparison  
- Valve replacement timing criteria**

Page 124 Extracted Terms:
- Valvular heart disease  
- Aortic regurgitation (aortic insufficiency)  
- Chronic aortic regurgitation  
- Severe aortic regurgitation  
- Asymptomatic aortic regurgitation  
- Aortic valve replacement  
- Left ventricular function  
- Left ventricular ejection fraction  
- Left ventricular dysfunction  
- Left ventricular dilation / dilatation  
- Left ventricular volume  
- Left ventricular systolic function  
- Right ventricular function  
- Exercise capacity (pre‑operative)  
- Hemodynamically significant aortic regurgitation  
- Cardiac magnetic resonance imaging (CMR)  
- Cardiovascular magnetic resonance (CMR)  
- Transthoracic echocardiography (TTE)  
- Doppler echocardiography  
- Continuous‑wave Doppler ultrasound  
- Velocity‑encoded cine MR imaging  
- Cine nuclear magnetic resonance (cMRI)  
- Cardiovascular imaging modalities  
- Renin‑angiotensin‑aldosterone system blockade  
- Vasodilator therapy  
- Nifedipine  
- Enalapril  
- Hydralazine  
- Felodipine  
- Beta‑blocker therapy  
- Guideline‑based indications  
- Timing of intervention (surgery)  
- Surgical correction of aortic regurgitation  
- Post‑operative left ventricular function  
- Long‑term prognosis  
- Survival outcomes  
- Functional outcomes  
- Clinical outcome  
- B‑type natriuretic peptide (BNP)  
- Heart failure  
- Cardiovascular disease  
- Primary prevention of cardiovascular disease  
- ACC/AHA guidelines for valvular heart disease  
- ACC/AHA guidelines for heart failure management  
- ACC/AHA guidelines for primary prevention of cardiovascular disease  
- Aortic valve pathology  
- Mitral regurgitation (in combined valvular studies)  
- Valve lesion  
- Cardiac output  
- Pre‑operative criteria for surgery  
- Symptomatic versus asymptomatic status  
- Post‑operative prognosis  
- Guideline adherence in severe aortic regurgitation.

Page 125 Extracted Terms:
- Valvular heart disease  
- Aortic regurgitation / aortic insufficiency  
- Chronic aortic regurgitation  
- Severe aortic regurgitation (native or bioprosthetic)  
- Bicuspid aortic valve (BAV)  
- Aortic root dilation / aortopathy  
- Valvular replacement  
- Valve repair  
- Valve‑sparing aortic root replacement  
- Transcatheter aortic valve replacement (TAVR)  
- Transcatheter valve implantation  
- Transapical valve implantation  
- Bilateral/bioprosthetic valve replacement  
- Cardiovascular magnetic resonance (CMR) imaging  
- Echocardiography (transthoracic, transesophageal, M‑mode, speckle‑tracking)  
- B‑type natriuretic peptide (BNP)  
- Left ventricular ejection fraction (LVEF)  
- Left ventricular end‑systolic dimension (LVESD)  
- Left ventricular end‑diastolic dimension (LVEDD)  
- Left ventricular global longitudinal strain (GLS)  
- Left ventricular dilatation and remodeling  
- Wall stress and ventricular geometry  
- Volume overload from valve regurgitation  
- Preoperative predictors (e.g., fractional shortening, LV dimensions)  
- Intraoperative transesophageal echocardiography  
- Clinical outcome and long‑term survival  
- Mortality and morbidity in aortic regurgitation  
- Symptom‑based therapeutic strategy  
- Hemodynamic predictors of surgical success  
- Early detection of subclinical myocardial injury  
- Biomarkers in asymptomatic aortic valve disease  
- Follow‑up and monitoring of bicuspid aortic valve  
- Valve disease prognosis and re‑operation risks  
- Surgical outcomes for chronic aortic valvular disease  
- Subclinical myocardial damage strategies  
- Cardiac chamber quantification guidelines  
- Heart valve repair classification systems (e.g., bicommissural repair)  
- Bioprosthetic valve durability  
- Aortic root reconstruction techniques (reimplantation, David procedure)  
- Left ventricular performance post‑surgery  
- Clinical laboratory and imaging surveillance of valvular disease

Page 126 Extracted Terms:
- Bicuspid aortic valve (BAV)  
- Aortic dilatation / aortic enlargement  
- Aortic root dilatation  
- Ascending aortic aneurysm  
- Thoracic aortic aneurysm  
- Aortic aneurysm rupture / dissection  
- Aortic insufficiency (regurgitation)  
- Aortic stenosis  
- Aortic valve replacement  
- Aortic valve repair  
- Aortic valve–sparing operations  
- Transcatheter aortic valve replacement (TAVR)  
- Surgical repair of the ascending aorta  
- Mitral stenosis  
- Left ventricular diastolic dysfunction  
- Bicuspidoid aortic valve phenotyping  
- Proximal aortic dilatation  
- Aortic cross‑sectional area / height ratio  
- Sinuses of Valsalva (non‑replaced) management  
- Coronary aortic valve geometry  
- Thoracic aortic disease management guidelines  
- Aortic valve root remodeling  
- Transcatheter aortic valve implantation (TAVI)  

These terms capture the central concepts related to heart disease described in the provided text.

Page 127 Extracted Terms:
- Valvular heart disease  
- Mitral stenosis (MS)  
- Rheumatic mitral stenosis  
- Mitral valve  
- Mitral annular calcification  
- Calcific mitral stenosis  
- Percutaneous mitral valvuloplasty  
- Transseptal mitral balloon valvuloplasty  
- Commissural calcification  
- Commissural calcium score  
- Mitral valve area  
- Transmitral gradient  
- Left atrial appendage thrombus  
- Atrial thrombi  
- Atrial fibrillation (AF)  
- Direct oral anticoagulants (DOAC)  
- Anticoagulant prophylaxis  
- Heart rate control  
- Dobutamine stress echocardiography  
- Transthoracic echocardiography (TTE)  
- Transesophageal echocardiography (TEE)  
- Doppler echocardiography  
- Exercise stress testing  
- Cardiac catheterization  
- Gorlin formula  
- Mitral valve resistance  
- Left ventricular compliance  
- Left atrial compliance  
- Valve stenosis  
- Valve area  
- Valve pressure half‑time  
- Valve calcification  
- Cardiac output reserve  
- Exercise intolerance  
- Ivabradine  
- Metoprolol  
- Atenolol  
- Embolism  
- Stroke  
- Heart failure

Page 128 Extracted Terms:
- Mitral stenosis  
- Mitral valve (and its components: commissures, leaflets)  
- Valvular heart disease  
- Atrial fibrillation  
- Pulmonary hypertension  
- Right ventricular dysfunction  
- Tricuspid regurgitation  
- Left atrial thrombus  
- Left atrial volume / diameter  
- Net atrioventricular compliance (NAC)  
- Left ventricular diastolic dysfunction  
- Rheumatic mitral stenosis  
- Low‑gradient severe mitral stenosis  
- Hemodynamic profile (including transpulmonary gradient)  
- Wilkins score (echocardiographic scoring system for mitral stenosis)  
- Commissural calcium score / calcification  
- Commissural area ratio  
- Echocardiography (including trans‑esophageal and stress Doppler)  
- P‑wave dispersion  
- Atrial electromechanical delay  
- Pulmonary artery stiffness  
- Percutaneous balloon mitral valvuloplasty (PBMV)  
- Percutaneous mitral commissurotomy (PMC)  
- Percutaneous mitral valve dilatation  
- Open mitral commissurotomy (OC)  
- Closed mitral commissurotomy (CC)  
- Balloon mitral valvotomy (BMV)  
- Surgical mitral valvotomy / valve replacement  
- Cardiovascular death  
- Long‑term outcomes (≤ 50 years)  
- Mid‑term outcomes (10–20 years)  
- Short‑term outcomes (early results, immediate results)  
- Predictive scores (e.g., Wilkins, integrated approach)  
- Revascularization / valve replacement options (mitral valve replacement)  
- Echocardiographic predictors of outcome  
- Clinical characteristics (including baseline pulmonary artery pressure)  
- Stress echocardiography in mitral stenosis  
- Pulmonary artery compliance  

These terms capture the principal diseases, anatomical structures, complications, diagnostic modalities, procedural interventions, and prognostic factors discussed in the cited 2020 ACC/AHA guideline and related studies.

Page 129 Extracted Terms:
- Mitral Stenosis  
- Mitral Annulus Calcification  
- Degenerative Mitral Stenosis  
- Nonrheumatic Calcific Mitral Stenosis  
- Rheumatic Mitral Stenosis  
- Valve Stenosis  
- Mitral Regurgitation  
- Acute Mitral Regurgitation  
- Chronic Primary Mitral Regurgitation  
- Mitral Valve Replacement  
- Transcatheter Mitral Valve Replacement  
- Intraoperative Transesophageal Echocardiography  
- Dobutamine Stress Echocardiography  
- Echocardiographic Assessment (2‑D, 3‑D, Doppler)  
- Color Flow Doppler  
- Left Ventricular Function  
- Pulmonary Edema  
- Chronic Kidney Disease  
- Renal Function (glomerular filtration, kidney disease)  
- Aortic Stenosis  
- Aortic Valve Calcification  
- Papillary Muscle Rupture  
- Infective Endocarditis  
- Traumatic Mitral Valve Injury (blunt chest trauma)  
- Vasodilator Therapy (for MR)  
- Annulus Washer Technique  
- Supra‑Annular Prosthesis Insertion  
- Intraatrial Placement of Mitral Prosthesis  
- Post‑infarction Mitral Regurgitation  
- Mitral Valve Area Measurement  
- Mitral Valve Orifice Geometry  
- Signal Void in MRI (mitral regurgitation)

Page 130 Extracted Terms:
Valvular heart disease  
Mitral regurgitation  
Aortic regurgitation  
Tricuspid regurgitation  
Leaflet prolapse  
Valve repair  
Valve replacement  
Transcatheter interventions  
Transesophageal echocardiography (TEE)  
Transthoracic echocardiography (TTE)  
Magnetic resonance imaging (MRI)  
Cine Magnetic Resonance  
Left atrial signal loss  
Left ventricular dysfunction  
Left ventricular performance  
Left ventricular volume  
Left ventricular ejection fraction (LVEF)  
Left ventricular end‑systolic dimension  
Global longitudinal strain (GLS)  
Diastolic function  
Chamber quantification  
Pulmonary hypertension  
B‑type natriuretic peptide (BNP)  
Brain natriuretic peptide (BNP)  
Symptom assessment  
Surgical timing  
Natural history of mitral regurgitation  
Watchful waiting  
Early surgery  
Multimodality imaging  
Echocardiographic quantitative assessment  
Hemodynamics  
Cardiac catheterization  
Prognostic markers  
Survival outcomes  
Clinical outcome  
Native valvular regurgitation  
Organic mitral regurgitation  
Degenerative mitral regurgitation  
Severe mitral regurgitation  
Chronic mitral regurgitation  
Asymptomatic mitral regurgitation  
Aortic regurgitation indication  
Surgical indication  
Valve disease guidelines  
Endocardial imaging  
Valve pathology  
Valve surgery  
Valve repair outcomes  
Valve regurgitation evaluation  
Left ventricular longitudinal strain  
Serial measurement of natriuretic peptides

Page 131 Extracted Terms:
**Key terms related to heart disease**

- Valvular Heart Disease  
- Mitral Regurgitation  
- Mitral Valve Prolapse  
- Rheumatic Mitral Valve Disease  
- Severe Mitral Regurgitation  
- Chronic Mitral Regurgitation  
- Degenerative Mitral Regurgitation  
- Mitral Valve Surgery  
- Mitral Valve Repair  
- Mitral Valve Replacement  
- Left Ventricular Performance  
- Left Ventricular Function  
- Left Ventricular Ejection Fraction  
- Left Ventricular End‑Systolic Diameter  
- Left Ventricular End‑Systolic Volume  
- Left Ventricular Mass  
- Left Ventricular Volumes  
- Echocardiography  
- Exercise‑Induced Mitral Regurgitation  
- Pulmonary Hypertension  
- β‑1 Receptor Blockade  
- Angiotensin‑Converting Enzyme (ACE) Inhibition  
- Losartan (Angiotensin Receptor Blocker)  
- Enalapril (ACE Inhibitor)  
- Captopril (ACE Inhibitor)  
- Afterload Reduction  
- Preoperative Symptoms  
- Postoperative Outcomes  
- Survival  
- Mortality  
- Watchful Waiting  
- Early Surgery  
- Surgical Indications  
- Guideline‑Based Indications  
- Valve Surgery Volume  
- Repair Quality  
- Perioperative Outcomes  
- Surgical Durability  
- Heart Valve Centers of Excellence  
- Percutaneous Valve Repair  
- Long‑Term Survival  
- Long‑Term Outcomes  
- Cardiovascular Imaging  
- Exercise Testing  
- Clinical Statements  
- Guidelines

Page 132 Extracted Terms:
- Mitral valve  
- Valvular heart disease  
- Minimally invasive approach  
- Mitral valve repair  
- Mitral valve replacement  
- Ischemic mitral regurgitation  
- Secondary mitral regurgitation (MR)  
- Chronic secondary MR  
- Severe ischemic mitral regurgitation  
- Moderate ischemic mitral regurgitation  
- Left ventricular dysfunction  
- Left ventricular ejection fraction  
- Heart failure  
- Chronic heart failure  
- Reduced left‑ventricular systolic function  
- Neuroendocrine activation  
- Enalapril (ACE‑inhibitor)  
- Candesartan (angiotensin‑II receptor blocker)  
- Carvedilol (beta‑blocker)  
- Spironolactone (aldosterone antagonist)  
- Cardiac resynchronization therapy (CRT)  
- Angiotensin‑receptor neprilysin inhibitor (ARNI)  
- Functional mitral regurgitation  
- Coronary artery bypass grafting (CABG)  
- Myocardial viability  
- Ischemic cardiomyopathy  
- Transcatheter valve repair  
- MitraClip therapy  
- Echocardiography  
- Magnetic resonance imaging (MRI)  
- Doppler assessment  
- Valvular regurgitation evaluation  
- SCAI/AATS/ACC/STS operator and institutional requirements  
- STS/ACC TVT registry  
- ACC/AHA heart failure guidelines  
- NECT (N/A)

Page 133 Extracted Terms:
- Valvular heart disease  
- Mitral regurgitation (functional/secondary)  
- Ischaemic mitral regurgitation  
- Primary mitral regurgitation  
- Mitral valve repair  
- Mitral valve replacement  
- Transcatheter mitral valve repair (MitraClip)  
- Percutaneous mitral valve repair  
- Mitral valve annuloplasty  
- Cardiac resynchronization therapy (CRT)  
- Left‑ventricular systolic dysfunction  
- Left‑ventricular remodeling (reverse remodeling)  
- Heart failure (HF)  
- Ischaemic heart failure  
- Surgical treatment of valve disease  
- Coronary artery bypass grafting (CABG)  
- Revascularization  
- Ischaemic cardiomyopathy  
- Atrial fibrillation (AF)  
- Functional tricuspid regurgitation  
- Tricuspid valve repair/annuloplasty  
- Right‑ventricular function (ejection fraction, volumes)  
- Systolic and diastolic RV function  
- Echo‑based assessment of valve function  
- Cardiac magnetic resonance imaging (MRI)  
- Three‑dimensional echocardiography  
- Regurgitant volume  
- Quantitative Doppler assessment  
- Prognostic implications of valvular dysfunction  
- Operative and mortality risk in valve surgery  
- Recurrent or residual functional regurgitation  
- COAPT trial outcomes  
- MITRA‑FR trial outcomes  
- RIME (Randomized Ischemic Mitral Evaluation) trial  
- Pathophysiology of functional MR  
- Hemodynamic assessment of valve disease  
- Quality control in echocardiographic measurement  
- Echocardiographic inter‑observer concordance  
- Right‑ventricular mass, volume and function assessment  
- Long‑term outcomes of valve interventions  
- Acute vs. chronic valve disease  
- Structural valve deterioration  
- Valve‑centric hemodynamic metrics (e.g., effective regurgitant orifice area)  
- Clinical statements/ guidelines for valvular management  
- Intervention thresholds for valve repair/replacement  
- Surgical vs. transcatheter strategies for valve disease  
- Functional vs. structural valve causes  
- Valve‑related morbidity and mortality.

Page 134 Extracted Terms:
- Valvular heart disease  
- Ischemic mitral regurgitation  
- Functional ischemic mitral regurgitation  
- Mitral valve repair  
- Mitral valve replacement  
- MitraClip therapy  
- Reverse remodeling (left ventricular/left atrial)  
- Left ventricular remodeling  
- Left atrial remodeling  
- Atrial functional mitral regurgitation  
- Atrial fibrillation  
- Tricuspid valve disease  
- Tricuspid regurgitation  
- Isolated tricuspid regurgitation  
- Functional tricuspid regurgitation  
- Pulmonary hypertension  
- Right heart failure  
- Heart failure (reduced/ preserved ejection fraction)  
- Mortality risk associated with valvular lesions  
- Cardiac implantable electronic devices (CIED)  
- Pacemaker lead–induced tricuspid regurgitation  
- Implantable cardioverter‑defibrillator lead–induced tricuspid regurgitation  
- Device lead‑related tricuspid valve dysfunction  
- Three‑dimensional echocardiography of tricuspid/mitral valves  
- Doppler echocardiography assessment  
- Hemodynamic evaluation (cardiac catheterization)  
- Pulmonary artery pressure measurement  
- Vena contracta analysis  
- Effective regurgitant orifice area (EROA)  
- Proximal isovelocity surface area (PISA)  
- Regurgitant volume quantification  
- Tricuspid valve grading scheme  
- Tricuspid valve repair (surgical / percutaneous)  
- Tricuspid valve replacement (surgical)  
- Right ventricular dysfunction secondary to tricuspid regurgitation  
- Left ventricular ejection fraction (LVEF)   
- Mitral annular dilation and valve adaptation  
- Severe symptomatic tricuspid regurgitation (e.g., due to device leads)  
- Tricuspid valve dysfunction following pacemaker/ICD implantation  
- Functional tricuspid regurgitation secondary to chronic atrial fibrillation  
- Surgical outcomes of tricuspid valve procedures.

Page 135 Extracted Terms:
Valvular Heart Disease  
Right ventricular size  
Right ventricular systolic function  
Pulmonary hypertension  
Right ventricular dysfunction  
Tricuspid regurgitation  
Right‑sided heart remodeling  
Tricuspid valve surgery  
Isolated tricuspid valve surgery  
Severe tricuspid regurgitation  
Moderate tricuspid regurgitation  
Tricuspid annular dilatation  
Tricuspid annular systolic velocity  
Functional tricuspid regurgitation  
Mitral valve surgery  
Mitral regurgitation  
Atrial fibrillation  
Maze procedure  
Tricuspid annuloplasty  
Tricuspid valve replacement  
Left‑heart valve surgery  
Degenerative leaflet prolapse  
Rheumatic mitral disease  
Carcinoid heart disease  
Congestive heart failure  
Tricuspid valve repair  
Transcatheter tricuspid valve interventions  
Tricuspid valve disease  
Pulmonary valve disease  
Cardiac surgery  
Echocardiographic assessment  
Two‑dimensional echocardiography  
Doppler color flow mapping  
Tricuspid valve closure  
Permanent pacemaker leads  
Implantable cardioverter‑defibrillator leads

Page 136 Extracted Terms:
- Valvular heart disease  
- Mixed valvular disease  
- Multi‑valve disease  
- Aortic stenosis  
- Aortic regurgitation / insufficiency  
- Mitral stenosis  
- Mitral regurgitation  
- Prosthetic valve  
- Prosthetic aortic valve  
- Prosthetic mitral valve  
- Mechanical prosthesis  
- Bioprosthetic valve  
- Transcatheter aortic valve replacement (TAVR)  
- Surgical aortic valve replacement (SAVR)  
- Valve replacement  
- Structural valve degeneration (SVD)  
- Hemodynamic valve deterioration  
- Valve gradients  
- Doppler echocardiography  
- Continuous‑wave Doppler  
- Transesophageal echocardiography (TEE)  
- Real‑time 3‑D TEE  
- Pressure recovery  
- Valve performance  
- Valve hemodynamics  
- Valve imaging  
- Valve evaluation  
- Valve selection  
- Valve obstruction  
- Valve dehiscence  
- Valve degeneration  
- Valve design  
- Valve outcomes  
- ACC/AHA guidelines  
- European Observational Research Programme (EURObservational)

Page 137 Extracted Terms:
- Valvular heart disease  
- Aortic valve replacement  
- Mitral valve replacement  
- Valved prosthesis (mechanical)  
- Valved prosthesis (bioprosthetic)  
- Transcatheter aortic valve implantation (TAVI)  
- Transcatheter aortic valve replacement (TAVR)  
- Valve‑in‑valve procedure  
- Ross procedure (aortic root autograft)  
- Stentless bioprosthesis  
- Carpentier‑Edwards pericardial bioprosthesis  
- Perimount pericardial bioprosthesis  
- Mechanical heart valve (bileaflet)  
- Antithrombotic therapy  
- Oral anticoagulation  
- Low‑intensity anticoagulation  
- Dabigatran vs warfarin trials (RE‑ALIGN, ENGAGE, etc.)  
- Thromboembolic complications  
- Bleeding complications  
- Valve durability  
- Valve degeneration  
- Valve failure  
- Valve‑related complications  
- Hemodynamic stability  
- Survival outcomes  
- Mortality outcomes  
- Stroke risk  
- Valve replacement in high‑risk patients  
- Valve replacement in low‑risk patients  
- Valve prosthesis selection (mechanical vs biological)  
- Valve implantation outcomes  
- Clinical guidelines (ACC/AHA) on valvular heart disease  
- Percutaneous valve therapies  
- Valve repair versus replacement  
- Valve position (aortic, mitral)  
- Anticoagulant management in valve patients



Page 138 Extracted Terms:
- Valvular heart disease  
- Intracardiac thrombosis  
- Anticoagulation (warfarin, direct oral anticoagulants)  
- Antiplatelet therapy (aspirin, clopidogrel, dual antiplatelet therapy)  
- Mechanical aortic valve replacement  
- Bioprosthetic aortic valve replacement  
- Transcatheter aortic valve replacement (TAVR)  
- Prosthetic heart valves  
- Thromboembolic complications  
- Bleeding complications  
- Valve thrombosis (including subclinical leaflet thrombosis)  
- Structural valve deterioration / failure  
- Perioperative bridging anticoagulation  
- Low‑molecular‑weight heparin (enoxaparin, dalteparin)  
- Unfractionated heparin  
- Prothrombin complex concentrate  
- Direct oral anticoagulants (dabigatran, rivaroxaban, apixaban, edoxaban)  
- Atrial fibrillation in valvular heart disease  
- Early anticoagulation strategies (short‑term, long‑term)  
- Bioprosthetic valve thrombosis prevention (aspirin, warfarin, low‑dose warfarin)  
- Mechanical valve thrombosis prevention  
- Guideline references (ACC/AHA, American College of Chest Physicians, AHA/NASPE‑CPT)  
- Clinical management of antithrombotic therapy in valve disease  


Page 139 Extracted Terms:
- Anticoagulation  
- Anticoagulant reversal agents  
- Andexanet alfa  
- Bioprosthetic valve  
- Bleeding complications  
- Catheter‑derived imaging  
- Catheter‑guided thrombolysis  
- Computed tomography (CT)  
- Dabigatran  
- Idarucizumab  
- Mechanical valve  
- Mechanical valve thrombosis  
- Multimodality imaging  
- New‑generation anticoagulants  
- Subclinical leaflet thrombosis  
- Pannus formation  
- Prosthetic valve obstruction  
- Prosthetic valve thrombosis  
- Prosthetic heart valve  
- Transesophageal echocardiography (TEE)  
- Transthoracic echocardiography (TTE)  
- Transcatheter heart valve (THV)  
- Transcatheter valve‑in‑valve procedure  
- Vitamin K antagonists (warfarin)  
- Vitamin K1  
- Warfarin  
- Left‑sided prosthetic valve  
- Right‑sided prosthetic valve  
- Thrombolytic therapy  
- Tissue‑type plasminogen activator (tPA)  
- Thrombus vs. pannus differentiation  
- Valve‑in‑valve implantation  
- Valve‑prosthesis interaction  
- Echocardiographic Doppler assessment  
- Clinical decision pathways for anticoagulation  
- Risk assessment for thrombolysis  
- Low‑dose infusion strategies  
- Rebound anticoagulation after cessation  
- Fresh frozen plasma in over‑anticoagulation  
- Anticoagulation monitoring (INR)  
- Cardiac imaging guideline  
- Thrombotic events associated with prosthetic valves.

Page 140 Extracted Terms:
- Valvular Heart Disease  
- Thrombolytic therapy for mechanical pulmonic/tricuspid valves  
- Prosthetic valve thrombosis  
- Bioprosthetic valve thrombosis  
- Subclinical leaflet thrombosis  
- Transcatheter aortic valve replacement (TAVR)  
- Mechanical prosthetic valves  
- Pannus formation  
- Structural valve degeneration  
- Prosthesis–patient mismatch  
- Redo aortic valve surgery  
- Transcatheter aortic valve‑in‑valve implantation  
- Failed surgical bioprosthetic valves  
- Transcatheter heart valve thrombosis  
- Phenprocoumon anticoagulation  
- Echocardiography and Doppler ultrasound in valve assessment  
- Cardiovascular imaging guidelines (American Society of Echocardiography, European Association of Cardiovascular Imaging, etc.)

Page 141 Extracted Terms:
- Valvular heart disease  
- Valvular degeneration  
- Prosthetic valve  
- Bicuspid aortic valve  
- Tricuspid aortic valve  
- Aortic valve stenosis  
- Aortic valve regurgitation  
- Mitral valve stenosis  
- Mitral valve regurgitation  
- Valve replacement (surgical)  
- Valve replacement (transcatheter)  
- Transcatheter aortic valve implantation (TAVI)  
- Valve‑in‑valve procedure  
- Mechanical valve  
- Bioprosthetic valve  
- Paravalvular leak  
- Periprosthetic leak  
- Prosthetic valve regurgitation  
- Valvular insufficiency  
- Infective endocarditis  
- Duke criteria  
- Diagnostic criteria for endocarditis  
- Culture‑negative endocarditis  
- Echocardiography (2‑D, 3‑D, transesophageal)  
- Doppler ultrasound  
- Real‑time 3‑D transesophageal echocardiography  
- Intracardiac echocardiography  
- STS (Society of Thoracic Surgeons) risk calculator  
- Risk factors for infective endocarditis  
- Structural valve degeneration  
- Prosthetic valve evaluation  
- Valve imaging assessment  
- Transcatheter valve repair  
- Surgical valve repair  
- Cardiac imaging guidelines  
- Perioperative valve outcomes  
- Long‑term valve survival  
- Valve reoperation risk  

Page 142 Extracted Terms:
- Valvular heart disease  
- Infective endocarditis  
- Endocarditis  
- Transesophageal echocardiography  
- Transthoracic echocardiography  
- Valve vegetation  
- Prosthetic valve endocarditis  
- Aortic valve  
- Mitral valve  
- Valve regurgitation  
- Valve stenosis  
- Bacteremia  
- Staphylococcus aureus  
- Methicillin‑resistant Staphylococcus aureus (MRSA)  
- Methicillin‑sensitive Staphylococcus aureus (MSSA)  
- Antibiotic therapy  
- Antibiotic duration  
- Surgical treatment of endocarditis  
- Embolization  
- Pacemaker endocarditis  
- Cardiac implantable electronic devices (CIED)  
- Intraoperative echocardiography  
- Appropriate use criteria for echocardiography  
- Duke criteria  
- Diagnostic criteria for infective endocarditis  
- Valve infection  
- Blood cultures  
- Valve prosthesis infection  
- Endocarditis mortality  
- Endocarditis guidelines (ACC/AHA, ESC)  
- Echocardiographic sensitivity  
- Echocardiographic specificity  
- Clinical presentation of endocarditis  
- Valve perforation  
- Valve abscess  
- Cardiac surgery decision‐making  
- Infective endocarditis risk factors  
- Valvular dysfunction  
- Echocardiographic detection of vegetation size  
- Cardiovascular imaging  
- Intravenous catheter–associated bacteremia.

Page 143 Extracted Terms:
- Endocarditis  
- Infective endocarditis  
- Native valve endocarditis  
- Prosthetic valve endocarditis  
- Valve infection  
- Aortic valve  
- Mechanical heart valve  
- Valve obstruction  
- Valvular dysfunction  
- Valvular heart disease  
- Heart valve disease  
- Heart valve prosthesis  
- Heart valve replacement  
- Heart valve surgery  
- Transesophageal echocardiography (TEE)  
- Transthoracic echocardiography (TTE)  
- Echo (echocardiography)  
- Multislice computed tomography (CT)  
- Cardiac CT  
- Coronary angiography  
- Coronary artery disease (CAD)  
- FDG PET/CT  
- 18F‑fluorodeoxyglucose PET/CT  
- Anticoagulation therapy  
- Anticoagulant therapy (warfarin, others)  
- Antithrombotic therapy  
- Antithrombotic and thrombolytic therapy  
- Intracranial hemorrhage  
- Cerebral hemorrhage  
- Stroke (embolic stroke)  
- Cerebrovascular complications  
- Myocardial infarction / infarction  
- Cardiovascular complications  
- Cardiovascular disease  
- Cardiac valve complications  
- Mechanical disc prosthesis  
- Prosthetic heart valve complications  
- Valve-related bacteremia (e.g., Staphylococcus aureus bacteremia)  
- Valve‑related sepsis / septic shock  
- Valve disease imaging (CT, PET/CT, echocardiography)

Page 144 Extracted Terms:
- Valvular heart disease  
- Infective endocarditis  
- Prosthetic valve endocarditis  
- Native‑valve endocarditis  
- Bicuspid aortic valve disease  
- Aortic valve disease  
- Mitral valve disease  
- Right‑sided Staphylococcus aureus endocarditis  
- Left‑sided endocarditis  
- Valve surgery  
- Mechanical valve implantation  
- Bioprosthetic (biological) valve replacement  
- Antiplatelet therapy (e.g., aspirin)  
- Anticoagulant therapy (e.g., warfarin)  
- Aspirin‑induced hemorrhage  
- Warfarin‑associated intracranial hemorrhage  
- Stroke / cerebral hemorrhage  
- Sepsis / septic shock management  
- Multidisciplinary management team (e‑Team)  
- Early surgical intervention  
- Mortality predictors in endocarditis  
- Risk scoring system for prosthetic valve procedures  
- Fungal prosthetic valve endocarditis  
- Chronic infection of pacemaker leads  
- Antimicrobial therapy (e.g., cloxacillin, gentamicin)  
- Prosthetic valve replacement versus medical therapy  

These terms capture the core concepts of heart disease discussed in the guideline text.

Page 145 Extracted Terms:
- Valvular heart disease  
- Infective endocarditis  
- Aortic valve endocarditis  
- Native valve endocarditis  
- Prosthetic valve endocarditis  
- Paravalvular abscess  
- Perivalvular abscess  
- Mitral valve endocarditis  
- Left‑sided endocarditis  
- Right‑sided endocarditis  
- Cardio‑embolic stroke  
- Heart failure  
- Aortocavitary fistula  
- Transesophageal echocardiography  
- Transthoracic echocardiography  
- Vegetation  
- Vegetation size  
- Surgical timing  
- Early surgery  
- Conventional treatment  
- Valve replacement  
- Valve repair  
- Mechanical prosthesis  
- Bioprosthetic valve  
- Allograft  
- Implantable cardiac devices  
- Pacemaker endocarditis  
- Implantable cardioverter‑defibrillator (ICD) infection  
- Device‑related endocarditis  
- Percutaneous lead extraction  
- Endocarditis diagnosis  
- Cardiovascular implantable electronic device infection  
- Drug‑use‑associated endocarditis  
- Injection drug users (IDU)  
- Opioid‑dependent patients  
- Buprenorphine treatment  
- Mortality risk  
- Embolic risk  
- Prognostic value  
- Echocardiographic features  
- Long‑term outcomes  
- Early clinical course  
- Outcome prediction  
- Risk factors  
- Pulmonary hypertension  
- Aortic stenosis  
- Pregnancy outcomes  
- Valvular heart disease in pregnancy  
- Native valves in pregnancy  
- Periprosthetic leakage  
- Transcatheter closure of paravalvular defects  
- ESC guidelines  
- ROPAC registry (Registry Of Pregnancy And Cardiac disease)  
- ESC registry of pregnancy and cardiac disease  
- Multicenter prospective study  
- Multicenter registry  
- Pregnancy outcomes in women with heart disease

Page 146 Extracted Terms:
- Valvular heart disease (VHD)  
- Aortic stenosis  
- Mitral stenosis  
- Rheumatic mitral stenosis  
- Congenital aortic stenosis  
- Mechanical heart valve  
- Valve replacement (mechanical/electronic)  
- Percutaneous balloon aortic valvuloplasty (PBA)  
- Percutaneous balloon mitral valvuloplasty (PBMV)  
- Balloon mitral commissurotomy  
- Balloon dilatation of the aortic valve  
- Balloon dilatation for severe aortic stenosis  
- Peri‑pregnancy intervention for VHD  
- Pregnancy outcomes in heart disease  
- Pulmonary hypertension  
- Exercise Doppler echocardiography  
- Risk stratification of asymptomatic valvular disease  
- ESC guidelines for cardiovascular disease during pregnancy  
- ACC/AHA guidelines for valvular heart disease  
- AHA/ACC/HRS guidelines for atrial fibrillation  
- Beta‑adrenergic blockade in pregnancy with valvular disease  
- Angiotensin‑II receptor antagonists and fetal toxicity  
- ACE inhibitor exposure in the first trimester  
- Anticoagulation management in mechanical valve pregnancy  
- Cardiac medication during pregnancy (ROPAC data)  
- Mechanical aortic valve replacement in women of childbearing age  
- Early surgery for severe aortic stenosis  
- Prognostic importance of quantitative exercise Doppler  
- Multicenter pregnancy outcome registries (ROPAC, Registry of Pregnancy and Cardiac Disease)  
- Perinatal cardiac outcomes in valvular disease  
- Volume overload impact on pulmonary circulation during pregnancy  
- Fetal growth effects of atenolol in pregnancy with hypertension  

Page 147 Extracted Terms:
- Valvular heart disease  
- Mitral stenosis  
- Balloon mitral valvuloplasty  
- Percutaneous balloon valvuloplasty  
- Percutaneous balloon commissurotomy  
- Cardiovascular surgery  
- Intracardiac surgery  
- Cardiac surgery  
- Cardiopulmonary bypass  
- Prosthetic heart valves  
- Mechanical prosthetic valve  
- Biologic prosthetic valve  
- Homograft valve  
- Valve replacement  
- Valve prosthesis  
- Thrombus  
- Prosthetic valve thrombosis  
- Anticoagulation  
- Warfarin  
- Low‑molecular‑weight heparin  
- Enoxaparin  
- Anti‑Xa monitoring  
- Tissue‑type plasminogen activator  
- Thrombolytic therapy  
- Transesophageal echocardiography  
- Echocardiographic evaluation  
- Hemodynamic changes  
- Hemodynamics  
- Pregnancy outcomes  
- Maternal outcomes  
- Fetal outcomes  
- Obstetric outcomes  
- Thromboprophylaxis  
- Thromboembolism  
- Thrombolysis

Page 148 Extracted Terms:
- Valvular heart disease (VHD)  
- Prosthetic heart valve (PHV)  
- Mechanical heart valve  
- Aortic stenosis  
- Aortic valve replacement (AVR)  
- Transcatheter aortic valve replacement (TAVR) / implantation (TAVI)  
- Coronary artery disease (CAD)  
- Angina pectoris  
- Percutaneous coronary intervention (PCI)  
- Coronary artery bypass grafting (CABG)  
- Coronary angiography  
- Computed tomography coronary angiography (CTCA)  
- Instantaneous wave‑free ratio (iFR)  
- Revascularization  
- Valve surgery  
- Valve replacement  
- Valve‑related complications  
- Anticoagulation therapy  
- Warfarin  
- Direct oral anticoagulants (DOACs)  
- Low‑molecular‑weight heparin (LMWH)  
- Enoxaparin  
- Subcutaneous heparin  
- Antiplatelet therapy  
- Thrombosis  
- Mechanical valve thrombosis  
- Thromboembolic events  
- Thrombolytic therapy  
- Tissue‑type plasminogen activator (tPA)  
- Maternal complications during pregnancy  
- Fetal outcomes in pregnancy with prosthetic valves  
- Pregnancy anticoagulation dilemma  
- Hemodynamics  
- Pressure overload  
- Surgical considerations for CAD in VHD  
- Angiographic severity assessment  
- Stroke risk in valvular disease  
- Long‑term survival of valve‑repair patients  
- Valve durability and degeneration  
- Cardioprotective management strategies  

These terms capture the key concepts related to heart disease and its management discussed in the provided guideline text.

Page 149 Extracted Terms:
- Valvular Heart Disease  
- Aortic Stenosis  
- Aortic Regurgitation  
- Severe Aortic Stenosis  
- Mitral Regurgitation  
- Valvular Regurgitation  
- Coronary Artery Disease  
- Coronary Artery Stenosis  
- Coronary Atherosclerosis  
- Ischemic Mitral Regurgitation  
- Radiation‑induced Heart Disease  
- Atrial Fibrillation  
- Intraoperative Atrial Fibrillation  
- Cox Maze Procedure  
- Surgical Ablation of Atrial Fibrillation  
- Pulmonary Vein Isolation  
- Left Atrial Appendage Occlusion / Closure  
- Stroke (associated with atrial fibrillation)  
- Transcatheter Aortic Valve Implantation (TAVI)  
- Transcatheter Aortic Valve Replacement (TAVR)  
- Valve Replacement Surgery  
- Coronary Computed Tomography Angiography (CTCA)  
- Multidetector Computed Tomography Coronary Angiography  
- Coronary Angiography (invasive)  
- Hybrid Cardiovascular Procedures  
- Coronary Artery Bypass Grafting (CABG)  
- Anticoagulation Therapy  
- Novel Oral Anticoagulants (NOACs)  
- Left Ventricular Function  
- Early and Late Survival after Valve Replacement  
- Transesophageal Echocardiography (TEE) for valve assessment  
- Framingham Risk Score (cardiovascular risk profiling)  
- Diamond‑Forrester Probability model (coronary artery disease assessment)  
- Preoperative Coronary Angiography for Cardiac Surgery  
- Surgical Thrombectomy / Atrial Appendage Exclusion  
- Cardiothoracic Surgery (general scope)

Page 150 Extracted Terms:
- Valvular heart disease  
- Aortic stenosis  
- Aortic valve replacement  
- Transcatheter aortic valve replacement (TAVR)  
- Surgical aortic valve replacement (SAVR)  
- Balloon aortic valvuloplasty (BAV)  
- Mitral regurgitation  
- Pulmonary arterial hypertension (PAH)  
- Pulmonary hypertension  
- Coronary artery disease  
- Intrinsic cardiac risks  
- Perioperative cardiovascular evaluation  
- Preoperative cardiovascular evaluation  
- Non‑cardiac surgery (in the context of cardiac risk)  
- Perioperative risk  
- Valve disease prevention (e.g., systolic blood pressure, calcific aortic stenosis)  
- Clinical outcomes related to valvular disease management  

Page 151 Extracted Terms:
- Valvular Heart Disease  
- Aortic Stenosis  
- Calcific Aortic Valve Stenosis  
- Myxomatous Mitral Valve  
- Valvular Calcification  
- Rheumatic Heart Disease  
- Cardiac Fibrosis  
- Matrix Remodeling  
- TGF‑β Signalling  
- Reactive Oxygen Species  
- Multimodality Imaging  
- Renin‑Angiotensin System Inhibition  
- Transcatheter Aortic Valve Replacement (TAVR)  
- Blood Pressure  
- Arterial Load  
- Genetic Associations  
- Patient‑Centered Research  
- Valve Durability  
- Shared Decision‑Making  
- Valve Interventions  
- Cardiovascular Imaging  
- Heart Disease  
- Stroke Statistics  
- Valve Disease Burden  
- Valve Imaging  
- Valve Disease Management

Page 152 Extracted Terms:
- Valvular Heart Disease  
- Heart Disease  
- Cardiovascular  
- Cardiac  
- Adult Congenital Heart Disease  
- Cardiac Surgery  
- Cardiology  
- Interventional Cardiology  
- Cardiovascular Medicine  
- Corrigan Minehan Heart Center  
- ACC/AHA Guideline for the Management of Valvular Heart Disease  

Page 153 Extracted Terms:
- Valvular Heart Disease  
- Heart Failure  
- Infective Endocarditis  
- Cardiovascular  
- Cardiology  
- Heart Disease  
- ACC/AHA (American College of Cardiology/American Heart Association) Guidelines  
- Heart Failure Society of America  
- Valvular  
- Management of Valvular Heart Disease  
- Clinical Guidelines for Heart Disease  
- Cardiovascular Fellowship Program  
- Heart‑related Clinical Practice Guidelines  

Page 154 Extracted Terms:
- ACC/AHA Guideline for the Management of Valvular Heart Disease  
- Valvular Heart Disease  
- Heart Valve  
- Heart Valve Voice  
- Medtronic (device manufacturer for heart valve procedures)  
- Abbott (cardiovascular devices)  
- Edwards Lifesciences (heart valve technology)  
- NeoChord (transcatheter mitral valve repair system)  
- HeartFlow (non‑invasive coronary artery disease assessment)  
- AHA (American Heart Association)  
- STEMI (ST‑segment elevation myocardial infarction)  
- Cardiology / Cardiovascular (clinical disciplines)

Page 155 Extracted Terms:
- **Valvular Heart Disease**  
- **ACC/AHA Guideline for the Management of Valvular Heart Disease**  
- **Clinical Cardiac Electrophysiology**  
- **Adult Congenital Heart Disease Program**  
- **Pulmonary Hypertension**  
- **Cardiovascular** (as a general domain)  
- **National Minority Cardiovascular Alliance**  
- **Cardiac Phoenix**  
- **Boston Scientific** (heart‑device manufacturer)  
- **Medtronic** (heart‑device manufacturer)  
- **Edwards Lifesciences** (heart‑valve manufacturer)  
- **Abbott Vascular** (vascular‑intervention manufacturer)  
- **Bayer Healthcare Pharmaceuticals** (cardiovascular drug manufacturer)  
- **Philips Healthcare** (cardiac imaging equipment)  
- **Siemens Healthineers** (cardiac imaging equipment)  
- **NaviGate** (cardiac navigation system)  
- **V‑Wave Ltd.** (cardiac imaging/diagnostic firm)  
- **Joint Committee on Clinical Practice Guidelines** (guideline‑development body)  
- **American Heart Association (AHA)**  
- **American College of Cardiology (ACC)**  
- **ACC/AHA** (combined guideline and organization abbreviation)  
- **Circulation Journals** (cardiology journal)  

*(These terms were extracted from the provided text and are directly related to heart disease, cardiac care, and cardiovascular medicine.)*

Page 156 Extracted Terms:
- Valvular Heart Disease  
- Heart Disease  
- Cardiovascular Disease  
- Cardiac  
- Heart  
- Stroke  
- Valves  
- Valve Disease  
- Valvular disease  
- Cardiac valves  
- Heart valve disorders  



